<SEC-DOCUMENT>0000764180-23-000060.txt : 20230427
<SEC-HEADER>0000764180-23-000060.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427071626
ACCESSION NUMBER:		0000764180-23-000060
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTRIA GROUP, INC.
		CENTRAL INDEX KEY:			0000764180
		STANDARD INDUSTRIAL CLASSIFICATION:	CIGARETTES [2111]
		IRS NUMBER:				133260245
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08940
		FILM NUMBER:		23851851

	BUSINESS ADDRESS:	
		STREET 1:		6601 WEST BROAD STREET
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23230
		BUSINESS PHONE:		(804) 274-2200

	MAIL ADDRESS:	
		STREET 1:		6601 WEST BROAD STREET
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALTRIA GROUP INC
		DATE OF NAME CHANGE:	20030127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIP MORRIS COMPANIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mo-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9,d:bb819a612bfb40178ae4eeaeab3ba640--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:mo="http://www.altria.com/20230331" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mo-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8xLTEtMS0xLTIyMzExMA_e79d68b3-6b7d-46d0-96a0-7e4fa0969c9e">false</ix:nonNumeric><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8yLTEtMS0xLTIyMzExMA_f7aa699a-7007-4e6c-a0ef-53f6c6898c36">2023</ix:nonNumeric><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8zLTEtMS0xLTIyMzExMA_d19ef989-194b-4c3b-87b3-5f3c5e2957f2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF80LTEtMS0xLTIyMzExMA_b8cbb5dd-df12-4b5b-bcb3-0aed19cfd9cf">0000764180</ix:nonNumeric><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF81LTEtMS0xLTIyMzExMA_18b5100c-7022-4223-aba4-9a075db3da19">12/31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xNi9mcmFnOjhkZWU2YzBiMGZhMTRhMDliNTk5MmI1MmQ4N2U4YTc2L3RhYmxlOjAyMzU4NGM5MzBmYzQ0ZjFhNDgxODU1ZTgxODMzMTliL3RhYmxlcmFuZ2U6MDIzNTg0YzkzMGZjNDRmMWE0ODE4NTVlODE4MzMxOWJfMi0xLTEtMS0yMjMxMTA_25fcd563-7e7d-425e-9501-9aa6ed895dd2">0.3333</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xNi9mcmFnOjhkZWU2YzBiMGZhMTRhMDliNTk5MmI1MmQ4N2U4YTc2L3RhYmxlOjAyMzU4NGM5MzBmYzQ0ZjFhNDgxODU1ZTgxODMzMTliL3RhYmxlcmFuZ2U6MDIzNTg0YzkzMGZjNDRmMWE0ODE4NTVlODE4MzMxOWJfMi0yLTEtMS0yMjMxMTA_0cc07ac3-bd3d-429b-9eb6-b3875392e13a">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mo-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i000128edea2348af9dda2888d5316af0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock0.3313ParValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock1.700NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfa2174fce6411089552f283d69732e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock2.200NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock3.125NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6b503caf294c76a5e851c01965e8e5_I20230418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i66477b67e5d24411a9b94a8ac9d67205_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i90474c1a016f4bcab8003b2f31a36b35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d809fc7c4b44ba92b401d313ae3b59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bab0db84d941b8ba69763527b90f7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b599b726c57473687e1536cd1d26c41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2469a4bba094953adfa2888c0f55b57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0c6e3ccab347c88032c15fcb532cd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5140f53521445993db0f74aeb56071_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7101ec192394649a415c1b63b908c30_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaaf63c06a1049e695676e0481062f63_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66aa9b4f0ee44019b9de410d7e55ce7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cccb1a7f24445ba8b43e289af3300ec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e819bf5bdd408a959e0b2e4e7b73d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd940594473144c68357ea9c5539af8e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1266b52910409c97c004b5e3046d53_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff121125e516451b955d8e621eab3ca2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1542e02bb1e24adda3f71e99211fc9ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12ef6040ec2418189e3c2572fa81080_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie382e64c844d405d89091642f2a1d28c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e09c734e014d5ea132f83014347e58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af1b2cb80da4571ac97b869fabca161_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0217eb87e2e241b8ad4da3c44ced3300_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5ef2d10e0747f6975b8eaabca090eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42884e66bec24a6fbaa77ec0ef498541_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic85e35b6659d4fc0930167fa4a8a1832_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1532672af67b495ebb54a98924a90df4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e84fb2796b4e21bbb745b3013fe6e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17705bcff8eb49498848597476b6a197_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c63010612240ff9b4601af94a82301_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">mo:HorizonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i916567e93a6f4954aee581f056c6cbac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:JTIUHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">mo:HorizonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad881c7536c4aefb9f8952e60edc5d0_D20230401-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mo:NJOYHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3187e615f5274b95ad68a22a51aec4fb_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mo:NJOYHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf02e4d84bb4fae848037ad768f4bb2_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77cd95d31f3e47db905a2fce488caf88_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee57b9fa9a0c4629ae346c0ca0694281_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31770ac6973b4c46a9b96965f34f8ec4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407056c006d54b6ab8e43c8dd4f712d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70acd0d1a18e45398127bc9cce16307f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f105c2681d04b75b6c055147bbea3bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2317db73d949bf97a1f0ae5666c118_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29d9e6ebe044e90989cf465823a77f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e30dd02c1c94a5b81ccdba16b4c25b1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df9ced5c50845578c7a1d3348b2c11b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b0728e4a964ae7a16912dba9ce4741_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd8e983be5e4bf49bbb82139b8be78f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038f67664cef4a289bd2e7482068a8df_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bf4062eea24ce4a949beb98cf77963_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic849d2926e4e4725b6bfc1d0c4b15363_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18ca113bad9498b8bce774c190943af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917aa76b7c2948a99dfaf25b1ab4249a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64023a55bc9457f9694dec962ce226d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22be6d10e72a4d068a5e2a59f3619789_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractPreemptiveRIghtsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2698ad66ea7145638fbf517179c1ee03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractPreemptiveRIghtsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3ad097e6354edca8d47d2a62d0b590_D20190301-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbdafadb4994369a437f0cb91cd5ebd_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>mo:contract</xbrli:measure></xbrli:unit><xbrli:context id="i1e386c21ead541d7b2b8e375d8f79708_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0ac77709a6467ea112cb5ce9968742_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8891909d58c4512bd26716fe7321214_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bda6f9d3044065b5cb45c86ee040ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieacd8d560cc14bb3888bf0fb293a903f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd124c60d03f419f9b32a50e8d8ad088_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48147e6321604e39a0674a5c9700d5cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8248ed5a8a794be4ae798af164015026_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae16a7ba3e464592bc4e2b2d8cc85d62_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956ac6a83c434b91ad8b518160de9170_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1c9ebd07c34c43a75cc8eb11135003_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e66b45d2fd44569d4910cd6febb6c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3671b5f23c94bf792e7730b318b4f31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bbd214e79b74f2da6764b8726a150ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948ca0a2116f4d7a820721a03a172caa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2fc3fc500643caa6b4bcbcd6531d2a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15be35835b9b4c7ab7cc385c16e9f766_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a21466ce342442f9033dda351c1c76f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd2a3ee32c4c425687e4ad4ff4d1ef09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9842a26a80164a39b9d29efbd4d26e1f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ee296114304714be05372fa2564b28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760729c61bca480fbf703974d16ebff6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff527c2964e844a7aaf7101d9ebd98da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bca93a749545458ae8cdbafd27b08d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7894c01a5bf841ccac16dae6a03a17b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae3d8b4d3ae4b3b8ab5e8ac275cd4b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b93671e6ac4c71b0ea9f09be8c806e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:OralTobaccoSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:OralTobaccoSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonParticipatingManufacturerArbitrationPanelDecisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">mo:NpmAdjustmentToCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4eb1d656b243898b89b6f3008cb4bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde877d815ab4397aee17c08472bdddf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ee8c9fc92344e99ab8d14573f9be5a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598239b5dde34e519bcd01cb3409992e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1290e16c10451aa1fcb7cc789b60b2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mo:InterestAndOtherDebtExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70aedc832b244d9e934f496edc7227c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mo:InterestAndOtherDebtExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008bb3a34d6f4ad1a419dfbe662171e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e38d13df914cd0b952143a1636ff77_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15af32ff38f4d6d8a39d7de79017b26_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:RevolvingCreditFacilityDueAugust2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16749ccbd508483a9f1550c451780fe1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mo:TermSecuredOvernightFinancingRateTermSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:RevolvingCreditFacilityDueAugust2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ca4b2ce75d43c8a23f0e7a04890b95_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:EuroNotes1000MaturingFebruary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:EuroNotes1000MaturingFebruary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ie2f1978595a44dcbb3a13c8eaf072373_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>mo:state</xbrli:measure></xbrli:unit><xbrli:context id="iefc84e48cf0c42249795f0fa77b9ea65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39fde8db86346d7af0960b18bf2989e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea367655f1904de580fbb5fccfbc7804_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:AgreementToResolveShareholderClassActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaacf9fe9d5240a3bd0459f2294eff52_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:AgreementToResolveShareholderClassActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fe928fcc4f4ef5ad3b60f07ca10cc7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:InterestExpenseRelatedToLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2cceb11df14f4cad29de8cb80794bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:InterestExpenseRelatedToLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2004-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2004-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f2eaac69ca4a1e9412b845d82e98f9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658eb60878114979945a034aa6b1706f_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mo:claim</xbrli:measure></xbrli:unit><xbrli:context id="i8f59e571a0db45e8b6ec28bace62543f_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2aadde9431454a847f57038a8a9480_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264d8c165e0f471f82f66d6e65418cff_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a937a6e7e14fdfacea6ad40290a42f_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f461a1aa5d4ee792394582b58b95ac_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ca21fd598f4791b318ee5cabcbed5d_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac90a0bb5f3f4b2f934b8f25141d8e55_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e19c07da3604784b1f61734070f38d0_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a4f7f89b7241328632d436bff2aa5f_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01034fcbdec149c4be2d97e5b30b1d64_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcf35d29f7e417fa73e1d1a62215cc3_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie745a29b163b4a30b640a432516cbc0a_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137abf0db81a4ec799690639f244c055_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42253bd8d894b90ac70f97908963886_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d977c5bff94d44bd1a0a77dfc89b1c_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:ETSSmokingandHealthCaseFlightAttendantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mo:case</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>mo:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i825d494d8ad74328a30cf05aeba68eeb_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingIndividualLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id749f16e66d343708ca58160babcbc3f_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7b74edbd44460c84d012b02edc884a_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:ClassActionLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029cd62ef0e14cf7ba91174c0f57d16d_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1a190fb9ad430bbd01dfd78341ef13_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7914aaf2c23404eaa505be9823413f4_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6905d6541f1a41eaa7e544fdf55f3804_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170c4207fac14878911ccdae6ebe6376_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff416dc4d4943ef96c7732293bcfb55_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471e8ab3decf44de9984da88cabdc693_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56af47d5d86478d9aa935fb4c5fab66_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AK</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48616efb2c747e4ad07dbc20dd6318a_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7915e288e3e547a89d5b90c15b002d85_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7d7842072042029b37c8e58321a790_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1acd96e2d247de8e9ffbda07748403_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00334a51fb834684ac1bef68ec6e4629_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24403f03a804dd3a1742ecde12c32af_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MO</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac4943d0a50142e0a04534ccdc87f14f_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NH</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfafebb53104f778986825aecf004e5_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9b420fbf06470aa983786428710658_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fca4395dd774138b948e3ba799dee3a_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a13caf9c594420a4982e05e5743e96_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf88f4821d864d0eb1215800a0c994a3_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47eb567f9bbe4ee9b586eb7e4364b47d_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:RI</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd612643df6404aa5c549ad46d4bb3f_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83ad46dbea44d23905da42d1ade08e9_D19990101-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-01-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ca3cff2798450a8d43bf076838e36b_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseWoodleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d071c49dafe4c0ab73b29c76d6a6c88_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseMendezMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68023ac01c34100962358f7742dc848_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseMendezMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d5c15b72454fe3ab6a65a94179d459_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseFontaineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4caa1be6dee14b7da122d03361a0b36e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce2ab3da83c4ec2b9d87386b1b038ec_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4312a6e41a645e78741c53abfb9b9b7_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14f18627ded4c498559f94480d4c268_I20000731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1878a54117dd41c49cbfbb12813f60f6_I20000731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-07-01</xbrli:startDate><xbrli:endDate>2006-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99b75df4d1c4a3e929e255970a683a0_I20080131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f5b4ed913b42fe8a04502626591600_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1d211aa1a14a2e8f642c7b33db6494_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plantiff"><xbrli:measure>mo:plantiff</xbrli:measure></xbrli:unit><xbrli:context id="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296abd7b36374cefa6b045a659376f32_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c6d88f04834b87aad507967fe72e0f_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e9bdff03c04990be62bbba97421122_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesPearsonDCohenCollarChaconMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesReiderandBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesWeingartandHancockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019cbbd7765340719c2430dc78519295_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesPollariMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91a4fb22e6f45518c962f7f28ad376f_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGlogerRintoulandDuignamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300ff9979645484a96be74f4cbad94a6_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesFreemanAndHarrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df68acf1505499c841787fe26736dbf_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesR.DouglasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94aba2dfe6f940fdaa35b3888c250151_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHoffmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dccdeba725b4dc78842d507b0a1991f_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHoffmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033be350699e4706b3c6851d29b8b749_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLevineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d488c73bb644d1bc0a479f11fbe8b4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLevineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e721d76a5f489fbcdc920d74435591_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesSchertzerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief95ac0f1b534c56a693a3370c8c913f_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesSchertzerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017bc393a586425685f5c81ac9bbd36a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLippMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6191346a68624c76936656e4f4e55fbe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLippMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd63ebeb9da4c4e80b4d08ae9800f7b_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9ba1b77468485198eac867421125fd_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3adaf5ea11094a4cb8c711a96d4ae229_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesDuignanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02c207b06774fd59c5484ff5302f756_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesDuignanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9461abd7dc04b78b0217e87d27ace97_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMcCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9beea181cf140f9adfcebd371d4abb8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMcCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d98007769944dc9b0168ff938a9dcc1_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesChadwellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11254f9a2eb24f83821b5815368b8e08_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesChadwellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72830ce222554341a4a9785d1ab879bd_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesKaplanMcLauighlinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700cb3ce10984b889870b8488b2700b5_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesKaplanMcLauighlinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc078b33f7684f5296fa7045d4b552eb_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCooperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940de6589e0b4ee69091b883a32e09d1_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCooperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81bb1c5437a44efb6f55698d59aec06_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMillerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f8c13313ac4e01af20b71a719f8da6_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesTuttleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2680e01eb0d943bc86816de660361441_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCuddiheeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fbbab892b44cfeaa59dc1d86841818_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHollimanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6234f79724d344e6bab36b0693d39350_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesD.BrownMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5c8372783a4bf6bc692e11c709e409_I20090630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50f063bff6144ba9d1c3bae28cb30f0_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40081f1b6885464e9d63334981371279_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AR</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b18f9afe75a43fca6bafec8103beadd_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd7051cbe8249a892d2558422f99b31_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0060f473b507459fa695d7f7e862b35c_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2761f6e6a84a72bf9453a2877514c2_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec26b5b167f64b948eb60bda8d571759_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2140db0c9f194d7598ef7666ded56ffc_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f23159f88b43b1ad03568c321c2d5c_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601e952e30854bf9b7959748729929fb_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9739c01de394810956d3ca2bb685830_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc14a32dde064ccdae95f715a64a3ec8_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac1b63e2f934ed9a1ea24d4138a8bc9_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487924c2b1964c8e814c86ad00645620_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ddfa361b0245fc8632a21a5ab861d1_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aeed91145b54f9e84c1ab265089eff6_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41867538a1a4ecaad3784d369bba1cf_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3dd41044494e7fb215da3b8dbf74b3_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c235c89cfaf42189b0ee56ef85f0f77_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OR</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53df00b29f7f48839e6a9318937b699a_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b75c2442dc43c0a7d18a54f55c6e42_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4697be7d479446d97c049ae8736f48f_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfde9de540b4ed0bb63aaf5d758c946_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf123308c49642739be1ff2dfe411383_D19960501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79ec6e4c9a74c19997a9dca74955a22_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mo:BritishColumbiaSaskatchewanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e90104cb10647bb85cd65620e32994c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="manufacture"><xbrli:measure>mo:manufacture</xbrli:measure></xbrli:unit><xbrli:context id="ia6d6d211a38941ea89399fa49afe5f52_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:AltriaGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="ruling"><xbrli:measure>mo:ruling</xbrli:measure></xbrli:unit><xbrli:context id="i93b593a0985a40cc8016f69134a44753_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="id148113ea1ef41e0add7c35363136f03_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:ThreatenedLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75bf439c827a43829f739f2ff5266976_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1998-11-01</xbrli:startDate><xbrli:endDate>1998-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857721e1a42b4c4895342b88f12153b0_I19981130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>1998-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8f32c1fb40455bb5e51678f9f29624_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e854b8d51348db9f3ecb6573a91237_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id147ed05231e49888e6eec1a1de209d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea3aff15c3244e099d22efd00005e87_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2005NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366e41742fe34ddab3a6ac544395ef0a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2006NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06db80a9cb864760a78eb4b727fccc60_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2007NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a39c242a89b45ba8ba9304730ce2c3d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2008NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52cc241f4134704b38b12055f4d1063_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2009NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ab7c86e216435ab8c328cd46889009_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2010NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cce377b1794cafaea3109e44da8255_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2011NPMAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717c1ffac0354612b496c8adfb4066d4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2012NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88aa0ae8b6904cfaa051db486ab28768_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2013NPMAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4feaea05ac4a4fb3a34ec68b4955edbb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2014NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6488ac6ab1d450094cc398cf207f538_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2015NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic812762e464a4962a618c514c4377af3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b42de2c9385496eaa33ccd7de4d5f3a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc3e2cc3c8b46a39dee066c06a6604b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2018NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85efb7c5447949b2a29da6afbe426465_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2019NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0570863d6e264a92a3cae8a3dbab2b48_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2020NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc46289ddf384a55817708ab513cdea2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2021NPMAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2dea1c170648f5a808f3b76a33303a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2022NPMAdjustmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1998-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a0d0e0236740f7be74ed7a98673a30_D19980101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1998-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8944fccf0041b29f69b6e0e45d7eab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8e8c08cbe740d4a306f6bb4a27e669_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5a205e894c47679bfac6bbc2c7d660_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20042021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606794f712334fc29204002ba0d6ccfe_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20192021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b807a28cc05453d86e74e69ed77073d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad95738830284f1496045d0fe44e4fb8_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20042020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb882978d08a4cea900603cee8983240_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf25cd065fb4f47a44575dc187696f9_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2a79113e7f4166b1ad0a873dc2709e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef8738bcb2b4b82b180b4ae7bcb49c2_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a538cd9271c481bbba5add236551969_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7960b6ec146940de9514bbc0a1bf4361_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mo:ArbitrationPeriodAxis">mo:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mo:ArbitrationPeriodAxis">mo:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a7db94469940b0bdf76635504fc1c9_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefcfe5daa12447d29a502f1354cb8786_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherDisputesUndertheStateSettlementAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41840f71688e4157a71edd78b25d1eb2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:ImplementationofCorrectiveCommunicationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16021c6cb2f8452ba899a790b0995281_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingClassActionLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34fa5a79a1854ef28fd89687426e80a7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad77b9a8d6704b7f94cdfd087b33ca00_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d64c409aed469ba2221a94eff7af46_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014aa6b6af9b4df1a19a1a2b7dbfb8f1_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2439b9bbedc04392b00b5bd6ac3cc370_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aaed74306e54c7498a48f427fbc3dde_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0661196cc9c54e3093e2f4c03321a3af_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41dddbdee384487d9fc710339e3a0ccc_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab08827c3eeb4c2ab05097b269497f30_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>mo:complaint</xbrli:measure></xbrli:unit><xbrli:context id="i9557e21fd37641dcb6ef942359171a0b_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b49d8d6c6d47188f21140eb5cf4f0e_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shareholder"><xbrli:measure>mo:shareholder</xbrli:measure></xbrli:unit><xbrli:context id="idb201318b1d042eb85ed1f7dff301941_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5822c95a3a294185ab7547237ec445a4_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9969d54475e54393ac5135266efac3d4_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4d332571e345e6b507f1fb9fb044e9_D20201001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d69782fb04745ccb891419a687d7398_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida796d6b95934fcfb7672d95fd59a0a8_D20210701-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4a22fdfe7e477ebc36bd80a51ce673_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd283ff376a14d0ebdf290fc219fa37b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f175730caa1454986f3279a4dbc1d37_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida05d85a752347c7bc48b2dd64cfe9f5_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:LightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="court"><xbrli:measure>mo:court</xbrli:measure></xbrli:unit><xbrli:context id="i7e11164646c440cdb43d7579fbad7dbe_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:LightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58bffe3b3264449299e2b9f964207eda_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0ed1328f8e4090ade76858a871504d_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingIndividualLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:USTLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i527b47537c2b4bf4a38a2dc591ed5842_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib778b2cd5f1140bcad20a594e44c8b5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000764180</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4 id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3 id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5 id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMDk5_0d963085-be3b-4ea0-90c4-fb8e81c66363">10-Q</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OTk2ZGEwNjYyODk2NDg3MDk4MWE4OThkYjRmYjA3MTkvdGFibGVyYW5nZTo5OTZkYTA2NjI4OTY0ODcwOTgxYTg5OGRiNGZiMDcxOV8wLTAtMS0xLTIyMzExMA_3ba91723-f18e-4070-9712-3bc3efca9ae9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAw_c70984c7-9967-46fa-8a7d-b1ab4c782dc2">March 31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6YTQxNTJiMWQ5NTFhNGIxMDkxOTRmYTY3NGNiM2ExMDMvdGFibGVyYW5nZTphNDE1MmIxZDk1MWE0YjEwOTE5NGZhNjc0Y2IzYTEwM18wLTAtMS0xLTIyMzExMA_f7725f35-99c9-439b-8009-3ede83cd4e74">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAx_5618bb90-989b-486f-8cf4-bba6f224de46">1-08940</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAy_c346ff27-cfdd-4286-8bbd-327443a6e39d">Altria Group, Inc.</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl8xLTAtMS0xLTIyMzExMA_03028537-6f85-469d-aced-dd7d56c4d64f">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl8xLTMtMS0xLTIyMzExMA_bdd82ee2-981c-4567-97ec-f40f50843f24">13-3260245</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTAtMS0xLTIyMzExMA_88d3808a-0a44-4c1f-b407-ea1e5ec97ccc">6601 West Broad Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTEtMS0xLTIyMzExMA_e21652b2-9b9c-428d-b231-9b6d0e7ef440">Richmond,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTItMS0xLTIyMzExMA_bb8c9d34-554e-4fbe-9892-656231633585">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTMtMS0xLTIyMzExMA_58296682-d315-466b-bb9f-d72694ebd7d3">23230</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;(<ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA1_cd7407ad-74f2-4ed8-8acd-8634cd83c329">804</ix:nonNumeric>) <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA2_de6660ca-c18e-4ad9-8c55-68cf064c9f2d">274-2200</ix:nonNumeric>&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Former name, former address and former fiscal year, if changed since last report</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title of each class&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTAtMS0xLTIyMzExMA_a3578dd1-3e04-4689-a865-afff29fbc23c">Common Stock, $0.33 1/3 par value</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTEtMS0xLTIyMzExMA_703c259f-ea0c-49dc-8b19-197dd95c7da8">MO</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTItMS0xLTIyMzExMA_e3a98f9c-44b3-49fe-9788-1dbf345a9379">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTAtMS0xLTIyMzExMA_7a78d0c5-2a5b-466b-9422-1b1faa119d61">1.700% Notes due 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTEtMS0xLTIyMzExMA_76d18f00-107a-4765-9de6-470efa89d8dd">MO25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTItMS0xLTIyMzExMA_9242a73d-04b1-4292-9c68-3d22a7b8a39a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTAtMS0xLTIyMzExMA_aea3e2a3-c6aa-4cf6-9760-bb61e25cde6a">2.200% Notes due 2027</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTEtMS0xLTIyMzExMA_f7264951-c2e6-4666-b868-e0609908b242">MO27</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTItMS0xLTIyMzExMA_01d8bb6d-5c2a-40bf-b0a4-35185ba8a495">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTAtMS0xLTIyMzExMA_e47f6afb-5e89-4818-997d-4af47d09342e">3.125% Notes due 2031</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTEtMS0xLTIyMzExMA_2cd3935a-45c3-4ee4-b1ad-08f4ff3713d2">MO31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTItMS0xLTIyMzExMA_a86ec828-2998-4490-accc-6a093361ddb6">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA3_84e890f1-9703-44b8-be04-45a750e084e0">Yes</ix:nonNumeric>&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; No&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAz_e3ef0694-6388-4acc-bcd6-875da926c017">Yes</ix:nonNumeric>&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:21.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18wLTAtMS0xLTIyMzExMA_4c1035be-0a76-4b01-9967-458817c43719">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18yLTYtMS0xLTIyMzExMA_e1c39d2b-bcaf-4c09-b5dc-c4701e0386a4">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18zLTYtMS0xLTIyMzExMA_781cead4-2c98-4c40-b1e0-887e7b0f492a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160; Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA4_d86078b4-eb9a-4125-9c84-8ccd3fc29760">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At April 18, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i9c6b503caf294c76a5e851c01965e8e5_I20230418" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMDE0_ad88e48b-cc16-48d3-9d9f-be1c492ad6ae">1,785,039,536</ix:nonFraction> shares outstanding of the registrant&#8217;s common stock, par value $0.33 1/3&#160;per share.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALTRIA GROUP, INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I -</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">Condensed Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13"> and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_13">3</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">Condensed Consolidated Statements of Earnings</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19"> for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">Three Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19"> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_19">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">Condensed Consolidated Statements of Comprehensive Earnings</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22"> for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">Three Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_28">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">Condensed Consolidated Statements of Cash Flows for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_31">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_34">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_115">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_115">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_154">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_154">58</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_157">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_157">59</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II -</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_160">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_160">59</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_163">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_163">59</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_166">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_166">60</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_169">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_169">61</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_172">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_172">62</a></span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in millions of dollars) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________________________ </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMi0yLTEtMS0yMjMxMTA_3cf04aca-c950-404c-8c18-6da06a74ae55">3,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMi00LTEtMS0yMjMxMTA_5c5cb04e-3d70-4705-9c0e-d41ea87b5577">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">commercialization rights</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:ReceivableCommercializationRightsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNC0yLTEtMS0yMjM3OTI_ec530d24-0824-45df-b2dc-f1c7b0d91c67">1,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:ReceivableCommercializationRightsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNC00LTEtMS0yMjM3ODM_82f3135c-56df-4225-aa13-af675781d1db">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMy0yLTEtMS0yMjMxMTA_5ce21df0-9371-47d5-b094-4266de3e2663">58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMy00LTEtMS0yMjMxMTA_d320fab4-4a60-4aec-982c-41e4d9e90ec7">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leaf tobacco</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:InventoryRawMaterialsPlantMaterialNetofReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNS0yLTEtMS0yMjMxMTA_3376ec31-b94a-4148-ad5c-3930723c5e4b">664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:InventoryRawMaterialsPlantMaterialNetofReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNS00LTEtMS0yMjMxMTA_9469ef07-f8d2-47d3-8415-b3b3a7fb0d28">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:OtherInventoryRawMaterialsNetofReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNi0yLTEtMS0yMjMxMTA_847436ad-181a-48a3-85c4-c190588952c6">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:OtherInventoryRawMaterialsNetofReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNi00LTEtMS0yMjMxMTA_eab6a51b-cbe8-40eb-8647-766c269f51bf">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNy0yLTEtMS0yMjMxMTA_a2265bce-2dad-4966-8bf4-e4b71cd434fa">30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNy00LTEtMS0yMjMxMTA_90235714-763d-4812-bbf3-62935814d49b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOC0yLTEtMS0yMjMxMTA_6579a1f6-dbd6-4a11-baa7-f7afc182a574">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOC00LTEtMS0yMjMxMTA_e57084e4-1b50-4dfe-8e42-4d8286bcc005">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOS0yLTEtMS0yMjMxMTA_6fa8aaa9-137d-4e90-9868-1d98d227716a">1,252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOS00LTEtMS0yMjMxMTA_8b315544-4ee7-4641-9301-2740cf47d46e">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTMtMi0xLTEtMjIzMTEw_95fb2eb5-b7c6-42ca-b47f-2785dd509495">183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTMtNC0xLTEtMjIzMTEw_d244edda-1d47-45b0-ba44-7bd40543b694">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTQtMi0xLTEtMjIzMTEw_d888cf65-fcd7-43ff-bae8-8ecf84d1da19">7,152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTQtNC0xLTEtMjIzMTEw_e6bad8a3-9cfc-44e8-95cb-e2ca0c886a7b">7,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTUtMi0xLTEtMjIzMTEw_b8ef197a-2f05-4c02-9d8d-705323da2b1f">4,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTUtNC0xLTEtMjIzMTEw_e8c639fc-cc13-4558-a330-47b52c359c5e">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTYtMi0xLTEtMjIzMTEw_0aaaeb4b-b0c7-4b41-a84c-9b1298246246">2,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTYtNC0xLTEtMjIzMTEw_aee80cb4-9ad0-4e43-a670-2300190797b4">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTctMi0xLTEtMjIzMTEw_3b9d929f-9463-4c6e-857c-0231255a2f1c">1,593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTctNC0xLTEtMjIzMTEw_5f4516fe-ff57-4107-b6a7-5cceb6ec3769">1,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTgtMi0xLTEtMjIzMTEw_d391f314-22b6-4177-a8fa-7f106a76d5f3">5,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTgtNC0xLTEtMjIzMTEw_98a221ac-02e4-475b-9476-dcf664751252">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTktMi0xLTEtMjIzMTEw_e000d7e0-53a1-47a3-b332-5481686145c3">12,366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTktNC0xLTEtMjIzMTEw_5a773f6c-74d2-430e-83ee-b18fc476ea5b">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities ($<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MjI4ZTUwNDlmMDA4NGU5MDhkNjlmZmUyNzk4ODdhNDJfMzI5ODUzNDg4MzY0Nw_2611aa4b-e8e7-4069-8f61-7a85fc9d244b">0 million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MjI4ZTUwNDlmMDA4NGU5MDhkNjlmZmUyNzk4ODdhNDJfNDU_e37f8354-edc6-4ed4-b8fe-43285dc3cf68">250</ix:nonFraction> million at March 31, 2023 and December&#160;31, 2022, respectively,  measured at fair value)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMi0xLTEtMjIzMTEw_122d07f3-836c-481a-bd03-9b4dd18ad4bf">9,559</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtNC0xLTEtMjIzMTEw_f8429373-eb21-44dc-b68e-ebb26941d1f8">9,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjItMi0xLTEtMjIzMTEw_5f69022b-830f-45ed-a8f2-fb23ea427b06">979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjItNC0xLTEtMjIzMTEw_fd97436a-80c3-4895-b307-bba0ddcf3cce">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjMtMi0xLTEtMjIzMTEw_a6b335ab-43ce-4b09-9a3a-4c87ff339cd2">36,826</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjMtNC0xLTEtMjIzMTEw_3d2836c0-14cc-4806-8836-4cd6d234f807">36,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions of dollars, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMy0yLTEtMS0yMjMxMTA_0d67b0ab-d4c2-47fd-9f94-db8c8675b11f">1,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMy00LTEtMS0yMjMxMTA_234384d7-1a3e-475d-a73f-1f855a04e65e">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNC0yLTEtMS0yMjMxMTA_090b94c0-bc44-4d4b-a696-7fa47bc5d188">412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNC00LTEtMS0yMjMxMTA_1e6b7e0a-e526-4719-8c6a-c999e70a2603">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:AccruedMarketingCostsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNi0yLTEtMS0yMjMxMTA_9f59c499-f8df-4fcd-ae59-d3b0b48b311e">587</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:AccruedMarketingCostsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNi00LTEtMS0yMjMxMTA_f8f19388-67e6-41b2-861e-ba2790ccaaff">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:AccruedSettlementLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfOS0yLTEtMS0yMjMxMTA_11eee933-4a7c-4c94-a881-2afa6e413dda">3,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:AccruedSettlementLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfOS00LTEtMS0yMjMxMTA_75740422-ccf7-4cec-a1cc-36c4dc76403a">2,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTAtMi0xLTEtMjIzMTEw_e0c2135d-d2c2-401c-a729-dab0ced51776">1,303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTAtNC0xLTEtMjIzMTEw_ea27fcb0-257c-4755-b63a-13e905123f88">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTItMi0xLTEtMjIzMTEw_57d57016-b0d0-4c96-ac56-33b5a2446b12">1,685</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTItNC0xLTEtMjIzMTEw_1b818f2a-3fcc-45ce-80de-2d64c286e347">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTQtMi0xLTEtMjIzMTEw_cec50704-7021-49ff-bb5f-f58d8da45574">9,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTQtNC0xLTEtMjIzMTEw_d2896faa-7b7a-4477-9aba-8774b41ffea0">8,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTUtMi0xLTEtMjIzMTEw_5c6d8c0b-f3a9-4164-82f1-5d81417c63df">24,048</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTUtNC0xLTEtMjIzMTEw_0cf8ae40-dc07-46c1-b789-73f81fca86cf">25,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTYtMi0xLTEtMjIzMTEw_a942de44-8843-4122-b299-2564cd75a431">2,735</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTYtNC0xLTEtMjIzMTEw_abff64de-49d2-4407-8855-e704b39a502f">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued pension costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTctMi0xLTEtMjIzMTEw_b4b71a99-b1ca-4348-bdf2-2fba502f642f">128</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTctNC0xLTEtMjIzMTEw_0c3370cb-d42d-4b2c-abea-362c2d7c0964">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued postretirement health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTgtMi0xLTEtMjIzMTEw_33e462ff-b227-4852-87db-e691cac486ab">1,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTgtNC0xLTEtMjIzMTEw_5804e906-2e37-4712-b073-e52e40ac1cb0">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred gain from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> System commercialization rights</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktMi0xLTEtMjIzODM1_45b904fa-0d00-412b-8f94-9583c1438d2f">2,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktNC0xLTEtMjIzODI5_83a531a4-9278-4be4-b362-43e8e1b2f715">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktMi0xLTEtMjIzMTEw_35393c7c-a1ea-4359-a095-0800e3ad3b9e">809</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktNC0xLTEtMjIzMTEw_1d9341e8-612b-45e1-9d89-686d279854c1">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjAtMi0xLTEtMjIzMTEw_60307d70-aee3-425d-9f92-7b28081e1429">40,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjAtNC0xLTEtMjIzMTEw_c9e3e0f8-7a44-4c86-a13c-5fc4cc03ed8c">40,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjEtMi0xLTEtMjIzMTEw_c1e108de-bebc-4858-b3bb-9f491d0b3063"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjEtNC0xLTEtMjIzMTEw_4ef5120b-77d8-4c01-8214-c5c1be762676"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $0.33 1/3&#160;per share</span></div><div style="padding-left:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246YjhiODdhNzkxMzc1NGFjNzk0MzJiMTk1ZTRkYTIxZGFfNTA_00b1a730-fc25-49d3-ba1e-1b7e89408533"><ix:nonFraction unitRef="shares" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246YjhiODdhNzkxMzc1NGFjNzk0MzJiMTk1ZTRkYTIxZGFfNTA_fdb45978-348f-437d-9cc5-261797dd1b26">2,805,961,317</ix:nonFraction></ix:nonFraction> shares issued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMi0xLTEtMjIzMTEw_f371abda-8318-4b4c-b4cd-26fe0bc2d519">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtNC0xLTEtMjIzMTEw_11f19c07-6cf3-4d3f-a40c-cdf0734aa72d">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjUtMi0xLTEtMjIzMTEw_76714759-a8fb-4c65-a536-385f13e269e6">5,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjUtNC0xLTEtMjIzMTEw_de34a1de-afa9-4ef8-b50f-c6ea3d4d06c3">5,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings reinvested in the business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjYtMi0xLTEtMjIzMTEw_639b41f4-839d-4ad8-ac1f-2d09cff86184">29,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjYtNC0xLTEtMjIzMTEw_7d7e099e-22b6-44ee-9a29-ee5fd2646f24">29,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjctMi0xLTEtMjIzMTEw_de1b0ed7-8b70-4caf-8a7f-ed540f31b861">2,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjctNC0xLTEtMjIzMTEw_13ef65ea-60d5-4baa-89a3-f4a4ab59cd33">2,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of repurchased stock</span></div><div style="padding-left:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MTJhZTg2YzJlZmYwNDgzODllYzFiZTBlYWYwYTljNGRfMzI5ODUzNDg4MzUyMQ_95b35d22-0255-490f-8da7-87245f52d3d4">1,019,815,657</ix:nonFraction> shares at March&#160;31, 2023 and </span></div><div style="padding-left:22.5pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MTJhZTg2YzJlZmYwNDgzODllYzFiZTBlYWYwYTljNGRfNjk_6eac33fe-bf2f-4512-9917-1a554f18cdaa">1,020,427,195</ix:nonFraction> shares at December&#160;31, 2022)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMi0xLTEtMjIzMTEw_e02061ba-00d6-47c1-9a1d-b984ed21c0f9">37,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtNC0xLTEtMjIzMTEw_0cc2736a-6274-4afc-9fc8-ba485b31eba6">37,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit) attributable to Altria</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjktMi0xLTEtMjIzMTEw_7ff72abb-1758-4001-a70e-9906e2935743">3,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjktNC0xLTEtMjIzMTEw_5a2a6cf0-7c94-4513-8129-e4cf45047971">3,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzEtMi0xLTEtMjI0NjM1_76f8edf3-7afd-4ba2-ba5e-f70e9737f8ae">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzEtNC0xLTEtMjI0NjA3_39b878f6-8468-4817-8b83-e98a8d894b10">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzItMi0xLTEtMjQwNzA2_d8ce0b26-ce1b-4175-8a0f-4bb91038979f">3,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzItNC0xLTEtMjQwNzAw_0d2d1e59-ee25-4f89-a685-227c82d79e4e">3,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:49.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzAtMi0xLTEtMjIzMTEw_c7b9e4b1-3a4e-48e0-af37-257d2347d356">36,826</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzAtNC0xLTEtMjIzMTEw_d760a950-b792-429e-a753-0493db00190d">36,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions of dollars, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_____________________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMi0yLTEtMS0yMjMxMTA_14281123-6680-4786-9790-1b029d64d7c7">5,719</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMi00LTEtMS0yMjMxMTA_054d6bbb-18a3-48a6-b263-835d7781b4f5">5,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMy0yLTEtMS0yMjMxMTA_d6381742-e3f7-494c-9200-5a09c12c956e">1,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMy00LTEtMS0yMjMxMTA_2409fb4f-a6ba-41bb-ad09-755254d5aefc">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise taxes on products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OtherCostOfOperatingRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNC0yLTEtMS0yMjMxMTA_63368e41-2163-4cdb-92b6-49b6474888e1">956</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OtherCostOfOperatingRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNC00LTEtMS0yMjMxMTA_bb4846b4-3d14-4805-be79-e8f04887a6be">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNS0yLTEtMS0yMjMxMTA_09cae819-30cc-4789-8a97-82584d7ca027">3,329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNS00LTEtMS0yMjMxMTA_dd8bc3ad-da2c-41de-8d63-a3d28f5e052f">3,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, administration and research costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="mo:MarketingAdministrationandResearchCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNi0yLTEtMS0yMjMxMTA_c9417e02-b72f-4323-9e6a-2580a3db86f9">572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:MarketingAdministrationandResearchCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNi00LTEtMS0yMjMxMTA_2b872e41-1404-40ff-b87a-2218384000ed">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNy0yLTEtMS0yMjMxMTA_3a68cd21-3e0e-41cf-9086-b0be4efcc920">2,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNy00LTEtMS0yMjMxMTA_c78676d8-2666-4027-bc39-f5db31662581">2,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfOC0yLTEtMS0yMjMxMTA_e7beda3a-e4f9-4c6a-8c31-675eaeb4d7f8">229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfOC00LTEtMS0yMjMxMTA_9021d319-db36-4050-9f60-546ccba6a9d6">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTAtMi0xLTEtMjIzMTEw_528542cc-7085-4bec-a234-f409b5d0768c">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTAtNC0xLTEtMjIzMTEw_485bcc40-d49e-436b-bc20-ecdaef74df96">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTEtMi0xLTEtMjIzMTEw_54e205f4-ad7e-4197-bf0f-650bc65c19be">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTEtNC0xLTEtMjIzMTEw_11035a88-c72a-4f41-9f0d-c61172369c39">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTMtMi0xLTEtMjIzMTEw_ca7ded51-bbd1-4801-b761-eb128340219c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTMtNC0xLTEtMjIzMTEw_9be264f3-a49b-44ad-a080-f5e98026c7b8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTQtMi0xLTEtMjIzMTEw_46be83c2-e0cf-418e-8582-3e62a90dbd0b">2,479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTQtNC0xLTEtMjIzMTEw_0f02ff40-1f80-4b85-a42d-0b89657ae032">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTUtMi0xLTEtMjIzMTEw_78f1b1bf-affb-4e68-96fa-e13bf01ec29c">692</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTUtNC0xLTEtMjIzMTEw_f6b53e2b-af83-4dee-a080-fdfffa9e1168">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTgtMi0xLTEtMjIzMTEw_f5f07151-35de-4977-afec-8e36861a0d5d">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTgtNC0xLTEtMjIzMTEw_46c3b641-9b88-4143-a146-3b16a385f2f5">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share data:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtMi0xLTEtMjIzMTEw_b2f5834f-24bc-4577-8a18-93142ac92603"><ix:nonFraction unitRef="usdPerShare" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtMi0xLTEtMjIzMTEw_f8563659-e0ad-40fe-9a38-3315293715ac">1.00</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtNC0xLTEtMjIzMTEw_09fe7a41-06b3-4c72-86c2-097ce40ad7a3"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtNC0xLTEtMjIzMTEw_67d37722-908c-474c-9cc6-aee83cc25368">1.08</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Earnings</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions of dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_____________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMi0yLTEtMS0yMjMxMTA_22aefacd-93ec-4509-b830-3ffd266f44f3">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMi00LTEtMS0yMjMxMTA_96654bed-2edf-40b0-a2b3-8a9366cb688f">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNC0yLTEtMS0yMjMxMTA_3e2a9748-5183-4b3c-b122-5d0c343d3571">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNC00LTEtMS0yMjMxMTA_594d1bae-386a-4c5a-b480-fbc25d2fa8f6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciEquityMethodInvestmentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNS0yLTEtMS0yMjMxMTA_863fdafd-1488-4bcd-bf3f-8b2be474e925">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OciEquityMethodInvestmentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNS00LTEtMS0yMjMxMTA_3b22d08c-4699-44d6-89c3-1010ecd347bd">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNi0yLTEtMS0yMjMxMTA_eb8cdf86-ad98-4203-8a0e-0de93ee2ecec">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNi00LTEtMS0yMjMxMTA_dfbaa222-5a42-4711-b7a8-969ea8c34369">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred </span></div><div style="padding-left:51.75pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNy0yLTEtMS0yMjMxMTA_c59d2aa5-4756-41f5-84fd-f1c4eab54c80">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNy00LTEtMS0yMjMxMTA_c478ed4b-664a-4528-94ed-db584d2cf759">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive earnings</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMTEtMi0xLTEtMjIzMTEw_f206cdc3-b482-4695-8e49-63650b4b3d4f">1,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMTEtNC0xLTEtMjIzMTEw_6fc10019-1fa7-4656-a9da-6666709bb121">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">for the Three Months Ended March 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in millions of dollars, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:28.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Attributable to Altria</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings<br/>Reinvested<br/>in the<br/>Business</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of<br/>Repurchased<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d809fc7c4b44ba92b401d313ae3b59_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0yLTEtMS0yMjMxMTA_02fdddb8-47aa-496f-8a6f-0925343ab47e">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bab0db84d941b8ba69763527b90f7f_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi00LTEtMS0yMjMxMTA_852461a5-12f8-440a-9509-3d1315ee7e7e">5,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b599b726c57473687e1536cd1d26c41_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi02LTEtMS0yMjMxMTA_eba34a96-c846-42f5-b9ff-e2fe9ed5b1fe">29,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2469a4bba094953adfa2888c0f55b57_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi04LTEtMS0yMjMxMTA_ef0b68d8-e0bf-4e74-918f-84549288d6ff">2,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee0c6e3ccab347c88032c15fcb532cd5_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xMC0xLTEtMjIzMTEw_9c8bd8d9-8194-4900-8e2b-f36efa9950b4">37,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5140f53521445993db0f74aeb56071_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xMi0xLTEtMjMwOTY3_4f4e9906-bb62-4da4-874f-c249461cd8cc">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xNC0xLTEtMjIzMTEw_6e59471c-785b-4913-bf76-d0dc444946c6">3,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMy02LTEtMS0yMjMxMTA_9ef3f04d-8b91-4864-a3aa-ade33b73fc71">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMy0xNC0xLTEtMjIzMTEw_4431e465-e644-4212-b489-bc35f621f1aa">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNC04LTEtMS0yMjMxMTA_2e556462-b873-4e72-84ff-a2d7167f83a1">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNC0xNC0xLTEtMjIzMTEw_6a9ae15e-2c59-4933-8377-804efc04035e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock award activity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7101ec192394649a415c1b63b908c30_D20230101-20230331" decimals="-6" sign="-" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS00LTEtMS0yMjMxMTA_af98bf31-759b-4e03-b3ea-2d50ef7e987b">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaf63c06a1049e695676e0481062f63_D20230101-20230331" decimals="-6" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS0xMC0xLTEtMjIzMTEw_d1f76bdb-2bd4-4008-ad84-5c04ba8d50eb">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS0xNC0xLTEtMjIzMTEw_90a6da1a-5872-4008-b0e0-7f396e573240">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi0wLTEtMS0yMjMxMTAvdGV4dHJlZ2lvbjplNjk4NWQ2YzZmZDQ0N2UxYjIzYmU2NTQxYzYwZjJhY18yMTk5MDIzMjU1NTk3_0b7af891-17d4-432f-a0a9-c8a36d720fd8">0.94</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi02LTEtMS0yMjMxMTA_65b9f929-5c2b-4a45-9537-c8dac84ce855">1,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi0xNC0xLTEtMjIzMTEw_ea2e39e9-a23a-4e4d-af84-0664814244ca">1,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66aa9b4f0ee44019b9de410d7e55ce7_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0yLTEtMS0yMjMxMTA_32fc70b8-33d2-4fe4-893b-b87d0073c977">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cccb1a7f24445ba8b43e289af3300ec_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS00LTEtMS0yMjMxMTA_e19b4f7a-d40a-4c64-bb1b-878341608e0d">5,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e819bf5bdd408a959e0b2e4e7b73d3_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS02LTEtMS0yMjMxMTA_53f0b110-ef7a-4f3d-bd2e-de64682f16a3">29,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd940594473144c68357ea9c5539af8e_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS04LTEtMS0yMjMxMTA_8fe7d3bb-a44f-4086-b9b7-142b1d2a41a2">2,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe1266b52910409c97c004b5e3046d53_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xMC0xLTEtMjIzMTEw_09934fad-deb3-42fe-a2fb-17da975086c2">37,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff121125e516451b955d8e621eab3ca2_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xMi0xLTEtMjIzMTEw_64935728-0ec5-409d-bb2f-88a05a3d26bf">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xNC0xLTEtMjIzMTEw_6d7ce28d-d156-4c3f-8224-d10ee85ddd25">3,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings<br/>Reinvested<br/>in the<br/>Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of<br/>Repurchased<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1542e02bb1e24adda3f71e99211fc9ed_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0yLTEtMS0yMjMxMTA_1dd5a406-fbf7-443b-919e-065311d2a391">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12ef6040ec2418189e3c2572fa81080_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi00LTEtMS0yMjMxMTA_cf02684d-8f45-4dd9-afee-94d22b3fc831">5,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie382e64c844d405d89091642f2a1d28c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi02LTEtMS0yMjMxMTA_eba8a23c-390d-4dcf-a6fd-e98798487f7e">30,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e09c734e014d5ea132f83014347e58_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi04LTEtMS0yMjMxMTA_01421ed8-3ff9-4273-aa48-7c555e0b4726">3,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af1b2cb80da4571ac97b869fabca161_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0xMC0xLTEtMjIzMTEw_334b48d4-78c7-4bbe-b9f1-ee8281ce07a6">36,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0xNC0xLTEtMjIzMTEw_620e337c-4e44-40f9-bce6-17d01672dcbd">1,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMy02LTEtMS0yMjMxMTA_d75cb930-70d0-4453-b774-6da54f88e1ed">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMy0xNC0xLTEtMjIzMTEw_e189c726-5b3d-4446-8da9-6fa70e6b8c7e">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNC04LTEtMS0yMjMxMTA_b6fc490b-aa3c-463b-9b4d-27b316c8e7ec">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNC0xNC0xLTEtMjIzMTEw_838288ef-150c-40df-b910-6ff3d1d50ec8">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock award activity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f5ef2d10e0747f6975b8eaabca090eb_D20220101-20220331" decimals="-6" sign="-" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS00LTEtMS0yMjMxMTA_f3468c64-7bda-4211-92a4-fd2b0116d0f4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331" decimals="-6" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS0xMC0xLTEtMjIzMTEw_59db5ec6-c8c3-409e-b127-a3cb16cb7d37">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS0xNC0xLTEtMjIzMTEw_2721b440-5485-4d20-bbba-cdbcf13d1c38">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi0wLTEtMS0yMjMxMTAvdGV4dHJlZ2lvbjo2YTQwNTdkMDM4ZTM0NDZhOTI0YWI5NTEzZWZmYmNiZl8yMTk5MDIzMjU1NTk1_3cef208b-1ac9-4817-ace6-0372e726da05">0.90</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi02LTEtMS0yMjMxMTA_a14b6be5-5d32-493f-b559-318716e99306">1,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi0xNC0xLTEtMjIzMTEw_833873d6-5824-42fc-9924-f8c11a1c88b6">1,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNy0xMC0xLTEtMjIzMTEw_6de344ed-3cef-45c9-8782-d5ac182a4d9b">576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNy0xNC0xLTEtMjIzMTEw_e40271ee-0f48-41ff-8342-1cf6e05b7cd6">576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42884e66bec24a6fbaa77ec0ef498541_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0yLTEtMS0yMjMxMTA_87eef565-d520-4eeb-a7d7-877dab6b48d9">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85e35b6659d4fc0930167fa4a8a1832_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS00LTEtMS0yMjMxMTA_b75f1d10-ed44-48e3-8770-f2823e0f420b">5,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1532672af67b495ebb54a98924a90df4_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS02LTEtMS0yMjMxMTA_6bedbaf3-c14c-4d5a-822e-144466b7e0a3">30,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS04LTEtMS0yMjMxMTA_1d94d38b-ad74-461e-9f97-87cd51f9a18c">2,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1e84fb2796b4e21bbb745b3013fe6e0_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0xMC0xLTEtMjIzMTEw_3b82b769-7033-4193-a1f6-f1caf6bffd88">36,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17705bcff8eb49498848597476b6a197_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0xNC0xLTEtMjIzMTEw_a42b7721-c5e5-4fef-9cb2-4149366c6e99">1,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions of dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_____________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Provided by (Used in) Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMi0yLTEtMS0yMjMxMTA_f8adfec4-1c70-4952-8a54-58a3cc34e075">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMi00LTEtMS0yMjMxMTA_667827e0-66c6-4853-950a-ce0ae17b9eb1">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to operating cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNC0yLTEtMS0yMjMxMTA_42008726-819b-44f1-a548-df36937d0d17">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNC00LTEtMS0yMjMxMTA_011a741c-3545-4c82-b227-33a6765f1b45">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNS0yLTEtMS0yMjMxMTA_06e11f58-2272-4d35-ad15-750c953a2e63">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNS00LTEtMS0yMjMxMTA_56f6cec3-8226-4898-a957-21e12edbd47b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNi0yLTEtMS0yMjMxMTA_a43bd5fb-efa1-4fc2-ba1a-c36fc32a35ec">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNi00LTEtMS0yMjMxMTA_0fb8c425-7dce-4252-bca1-8f0d534ff392">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfOS0yLTEtMS0yMjMxMTA_0a0b6672-ae06-4fa3-bf23-bf36eaab8f88">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfOS00LTEtMS0yMjMxMTA_bbe82649-99b0-4ebf-beda-b2226eaaa6db">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash effects of changes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTYtMi0xLTEtMjIzMTEw_b8463b52-a94c-4a9e-b502-4340a3536b9c">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTYtNC0xLTEtMjIzMTEw_ab72f0a3-20d3-45ab-8569-2b0931dd1b2d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTctMi0xLTEtMjIzMTEw_5548c6c1-7350-4bd6-843d-4cb486bbb050">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTctNC0xLTEtMjIzMTEw_948f8dae-9d58-41b6-8a42-272743f28d75">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTgtMi0xLTEtMjIzMTEw_3b5ba614-62e3-47a9-bc03-b50d66ee0470">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTgtNC0xLTEtMjIzMTEw_eaf8d40a-8dca-4ea8-a66d-72dd729ab067">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTktMi0xLTEtMjIzMTEw_f4fc071c-0346-4c95-afb6-10d4596540e0">409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTktNC0xLTEtMjIzMTEw_6f77c162-021d-4091-8dca-a5b9032eea86">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjAtMi0xLTEtMjIzMTEw_fc2c3f79-fc4d-4aa7-92ff-ab711bc15a63">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjAtNC0xLTEtMjIzMTEw_0cc7c602-064a-434f-af1f-c29b0438cb02">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued settlement charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="mo:IncreaseDecreaseInSettlementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjEtMi0xLTEtMjIzMTEw_73308449-3cdf-4fab-b2f9-6a89971cd7e7">895</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:IncreaseDecreaseInSettlementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjEtNC0xLTEtMjIzMTEw_f877b4ae-f0ee-48b7-8266-73ecd1a74fba">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjItMi0xLTEtMjIzMTEw_e1d7afdf-5696-488b-a32f-71056ae8f20a">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjItNC0xLTEtMjIzMTEw_6ed690ab-627e-48bf-898a-9adc97c5cef4">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjMtMi0xLTEtMjIzMTEw_fd972dce-801c-4577-a706-5dbd2abaecac">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjMtNC0xLTEtMjIzMTEw_71b13fe0-83b9-474d-b16c-f19f5e9befb6">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5">534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjUtMi0xLTEtMjIzMTEw_1a892d09-c9a1-4373-870b-73b58f4c24b7">2,984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjUtNC0xLTEtMjIzMTEw_e6a4fc86-1c53-4c78-8c45-63af6db23248">3,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Provided by (Used in) Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjctMi0xLTEtMjIzMTEw_a541bd4b-7722-4229-a352-55c6b44b3448">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjctNC0xLTEtMjIzMTEw_d760334b-2b5b-4bfc-93a7-deced3112cae">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzEtMi0xLTEtMjIzMTEw_89ae141f-bd34-4d66-86f3-7d8513e7f678">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzEtNC0xLTEtMjIzMTEw_838474c6-d340-47dd-87d5-05d3051b9204">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzItMi0xLTEtMjIzMTEw_ffc311d4-6f51-413a-a34a-90ddb563a68a">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzItNC0xLTEtMjIzMTEw_ae09dcc0-c9bc-4ada-84cc-5877a46b5dbd">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 includes $<ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfMTA5OTUxMTYyOTkyOQ_eb75f9e0-7dd0-4b34-aec4-3587cb82f8f5">391</ix:nonFraction> million of unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL, which is substantially offset by a corresponding change included in income taxes.  For further discussion, see Note 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions of dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_____________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Provided by (Used in) Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt repaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMy0yLTEtMS0yMjMxMTA_f1196468-e44b-455a-aabe-62675f219825">1,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMy00LTEtMS0yMjMxMTA_d3469e03-b60a-43fa-95e4-8dbb52da708d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNC0yLTEtMS0yMjMxMTA_2a229638-da3f-41aa-a25a-f46a0663f993">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNC00LTEtMS0yMjMxMTA_30081fc5-7626-40cc-ac5f-38f653b3d31b">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid on common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNS0yLTEtMS0yMjMxMTA_a217a1d9-bde3-42cb-a7d6-b2a7a872694f">1,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNS00LTEtMS0yMjMxMTA_256f4833-0bec-4f1c-a5b1-060db3952421">1,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNy0yLTEtMS0yMjMxMTA_3cc60967-79be-4dd6-8f82-9e8cc1b4780c">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNy00LTEtMS0yMjMxMTA_9ccfd230-433f-4c3e-ae11-a5cea3d47b18">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfOC0yLTEtMS0yMjMxMTA_1999abf2-15fc-438b-b322-c8f6a0290964">3,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfOC00LTEtMS0yMjMxMTA_90833483-d934-4370-bf18-b897ad693102">2,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTAtMi0xLTEtMjIzMTEw_2bd3f2db-746d-48db-b82d-088402647d59">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTAtNC0xLTEtMjIzMTEw_0a93aa8f-0742-4436-9212-f3bdd2d461a5">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTEtMi0xLTEtMjIzMTEw_fdebb6b7-8c24-4779-8deb-2c2df0fc04d1">4,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTEtNC0xLTEtMjIzMTEw_1a95a552-5c88-4b98-a4f2-1a99b4a98e79">4,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTItMi0xLTEtMjIzMTEw_0aaa21a5-20e3-40c0-a328-ff84d4ccf697">3,974</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17705bcff8eb49498848597476b6a197_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTItNC0xLTEtMjIzMTEw_60825f76-8085-4620-87e3-51a6dd581497">5,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following table provides a reconciliation of cash, cash equivalents and restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the amounts reported on our condensed consolidated balance sheets:</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTYtMi0xLTEtMjIzMTEw_12abbe29-441b-4a43-86b4-eec8d846f8b7">3,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTYtNC0xLTEtMjIzMTEw_e8462710-b8d4-4129-91ec-874c72b86c03">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1">30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMjAtMi0xLTEtMjIzMTEw_cc3117fd-19da-4e5d-8aec-a5feddc305b6">3,974</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMjAtNC0xLTEtMjIzMTEw_de307912-f87b-4a64-bf13-03461e311895">4,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals.  See Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:1pt;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span><br/></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_37"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Altria Group, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgxMA_8e58ed26-f37b-4f66-9291-b0d005e5ed49" continuedAt="i7d646ce72af741b28742ad495138a183" escape="true">Background and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i7d646ce72af741b28742ad495138a183" continuedAt="i33e6a22665774e63ba55fd2551eed480"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in these notes, the terms </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altria,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Background: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our wholly owned subsidiaries included Philip Morris USA Inc. (&#8220;PM USA&#8221;), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (&#8220;Middleton&#8221;), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (&#8220;UST&#8221;), which through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC (&#8220;USSTC&#8221;), is engaged in the manufacture and sale of moist smokeless tobacco products (&#8220;MST&#8221;) and snus products; and Helix Innovations LLC (&#8220;Helix&#8221;), which operates in the United States and Canada, and Helix Innovations GmbH and its affiliates (&#8220;Helix ROW&#8221;), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of oral nicotine pouches.  Other wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to our domestic tobacco operating companies; and Altria Client Services LLC (&#8220;ALCS&#8221;), which provides various support services to our companies in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs.  Our access to the operating cash flows of our wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by our subsidiaries.  At March&#160;31, 2023, our significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we also owned a <ix:nonFraction unitRef="number" contextRef="i87c63010612240ff9b4601af94a82301_I20230331" decimals="2" name="mo:OwnershipPercentageInConsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNzk3NA_5786ab12-6498-43a2-a97a-a4ba4ee347d6">75</ix:nonFraction>% economic interest in Horizon Innovations LLC (&#8220;Horizon&#8221;), a joint venture with Japan Tobacco, Inc., which owned the remaining <ix:nonFraction unitRef="number" contextRef="i916567e93a6f4954aee581f056c6cbac_I20230331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNzk4MA_d5c34711-ed13-4301-ab91-6b0043212bae">25</ix:nonFraction>% economic interest.  Horizon is structured to exist in perpetuity and is responsible for the U.S. marketing and commercialization of heated tobacco stick products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a stock transfer agreement with JUUL Labs, Inc. (&#8220;Stock Transfer Agreement&#8221;) pursuant to which we transferred to JUUL Labs, Inc. (&#8220;JUUL&#8221;) all of our beneficially owned JUUL equity securities.  In exchange, we received a non-exclusive, irrevocable global license to certain of JUUL&#8217;s heated tobacco intellectual property  (&#8220;JUUL Heated Tobacco IP&#8221;).  Prior to the exchange, we accounted for our investment in JUUL at fair value.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had investments in Anheuser-Busch InBev SA/NV (&#8220;ABI&#8221;) and Cronos Group Inc. (&#8220;Cronos&#8221;), which we account for <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDc5OQ_d06e60f7-809c-4d8e-9ac8-c618173ebc1e" escape="true">under the equity method of accounting using a one-quarter lag.</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of our investments in equity securities, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a definitive agreement to acquire NJOY Holdings, Inc. (&#8220;NJOY&#8221;), a U.S. based e-vapor company, for approximately $<ix:nonFraction unitRef="usd" contextRef="i5ad881c7536c4aefb9f8952e60edc5d0_D20230401-20231231" decimals="-7" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTY0NDcwOQ_b6ef7818-734c-4aa7-8a44-1c1f6cb944b4">2.75</ix:nonFraction> billion in cash payable at closing (&#8220;NJOY Transaction&#8221;) plus up to an additional $<ix:nonFraction unitRef="usd" contextRef="i3187e615f5274b95ad68a22a51aec4fb_I20231231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzI5ODUzNDkwMjA3Nw_4faeb75b-6fa8-43ce-a7fe-0c96b9b2a75d">500</ix:nonFraction> million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products.  Following completion of the NJOY Transaction, NJOY will survive as a wholly owned subsidiary of Altria.  The completion of the NJOY Transaction is subject to customary closing conditions, including clearance from the U.S. Federal Trade Commission (&#8220;FTC&#8221;), and is not subject to any financing condition.  The parties have filed for premerger clearance with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;HSR Act&#8221;), which remains under FTC review.  The current waiting period under the HSR Act expires in May 2023.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Share Repurchases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our Board of Directors (&#8220;Board of Directors&#8221; or &#8220;Board&#8221;) authorized a $<ix:nonFraction unitRef="usd" contextRef="idbf02e4d84bb4fae848037ad768f4bb2_I20210131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzA1OQ_a7569de1-a87e-4e13-a6d4-3181b3e5a168">2.0</ix:nonFraction> billion share repurchase program that it expanded to $<ix:nonFraction unitRef="usd" contextRef="i77cd95d31f3e47db905a2fce488caf88_I20211031" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzEwNw_5b0e3c52-8ce5-448a-be64-3efab44be025">3.5</ix:nonFraction> billion in October 2021 (as expanded, the &#8220;January 2021 share repurchase program&#8221;).  We completed the January 2021 share repurchase program in December 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our Board of Directors authorized a new $<ix:nonFraction unitRef="usd" contextRef="iee57b9fa9a0c4629ae346c0ca0694281_I20230131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNDAxOA_21b2fbb0-ac1f-4d62-8d8d-9ce4fa8d7a02">1.0</ix:nonFraction> billion share repurchase program (the &#8220;January 2023 share repurchase program&#8221;).  The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of our Board.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i31770ac6973b4c46a9b96965f34f8ec4_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzI5ODUzNDkwMTc5Ng_10162c87-3566-4135-bab3-525297bb0e9a">no</ix:nonFraction> share repurchases under the January 2023 share repurchase program.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i33e6a22665774e63ba55fd2551eed480"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDc5Mg_fef3f000-9fbe-4c3d-99fd-30c114de175e" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share repurchase activity was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfMi0zLTEtMS0yMjMxMTA_c921ab3d-bbc3-4c7c-9c15-61a35f1be602">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost of shares repurchased</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfMy0zLTEtMS0yMjMxMTA_b100088e-1fd5-47d6-9ba1-4d2243d14569">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share of shares repurchased</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfNC0zLTEtMS0yMjMxMTA_c3132876-3a8b-49ae-b639-9642c24bd915">50.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgwMA_585408c0-114d-43bf-b686-f35b056466a9" escape="true">Our interim condensed consolidated financial statements are unaudited.  Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements.  All such adjustments were of a normal recurring nature.  Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements should be read in conjunction with our audited consolidated financial statements and related notes, which appear in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgwOA_e2815b13-4ff4-459b-a3dc-e685fbde7970" continuedAt="i3a3fce35478e4e3c8e74b28c5592dfe5" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2023 we adopted Accounting Standards Update (&#8220;ASU&#8221;) 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2021-08&#8221;).  This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.  As of March 31, 2023, our adoption of ASU No. 2021-08 had no impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 1, 2023 we adopted ASU 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities- Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2022-04&#8221;).  This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period and potential magnitude.  As of March 31, 2023, our adoption of ASU No. 2022-04 had no material impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_40"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU1MQ_634582ba-943b-4424-bbf2-a942ae70df40" continuedAt="ie0d2a9c4d2db43c58fad0f73a42cf106" escape="true">Revenues from Contracts with Customers</ix:nonNumeric></span></div><ix:continuation id="ie0d2a9c4d2db43c58fad0f73a42cf106" continuedAt="ie0fc80e774554ccd9e7ad022be078be0"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disaggregate net revenues based on product type.  For further discussion, see Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="mo:CashDiscountsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU1Mg_f32761c1-b4ef-47c8-81fe-b2cdb896b0e9" escape="true">We calculate substantially all cash discounts, offered to customers for prompt payment, as a flat rate per unit based on agreed-upon payment terms and record receivables net of the cash discounts on our condensed consolidated balance sheets.</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="mo:RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU0Ng_ec9acbd9-5bfd-4d4a-9f6e-17bfc95f6bdd" escape="true">We record payments received by our businesses in advance of product shipment as deferred revenue.  These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer.</ix:nonNumeric>  Deferred revenue from contracts with customers was $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfODc1_59b64d09-4fc6-4837-85f8-0df4401c3dfa">268</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfODgy_db6b50ea-10dc-4d9b-8310-3476dcb3d93a">252</ix:nonFraction> million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  When cash is received in advance of product shipment, our companies satisfy their performance obligations within <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTAxNA_ae80e7ee-353d-48d9-8d1b-4f95d619155d">three days</ix:nonNumeric> of receiving payment.  At March&#160;31, 2023 and December&#160;31, 2022, there were no differences between amounts recorded as deferred revenue from contracts with customers and amounts subsequently recognized as revenue.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables (excluding receivable from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System commercialization rights) were $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTE5MA_bf20f8c5-a99c-46e0-b191-d63f5ec55808">58</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTE5Nw_f0f6de19-ea08-4b53-8484-273cf99578e2">48</ix:nonFraction> million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  At March&#160;31, 2023 and December&#160;31, 2022, there were no expected differences between amounts recorded and subsequently received, and we did <ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTM0MQ_6b70f1eb-a8c3-4558-918d-0036e6eed647"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTM0MQ_9e030e24-10e8-41b9-81b8-033e9f582e00">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses against these receivables.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU0Nw_9ee65ed5-5dcb-49a6-bd8a-eb35282be361" escape="true">We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets.  It is USSTC&#8217;s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC&#8217;s MST and snus products.  We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues.  Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions.  We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.  All returned goods are destroyed upon return and not included in inventory.  Consequently, we do not record an asset for USSTC&#8217;s right to recover goods from customers upon return.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="ie0fc80e774554ccd9e7ad022be078be0"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales incentives include variable payments related to goods sold by our businesses.  We include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers.  The sales incentives that require significant estimates and judgments are as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Price promotion payments-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We make price promotion payments, substantially all of which are made to our retail partners to incent the promotion of certain product offerings in select geographic areas.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Wholesale and retail participation payments-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We make payments to our wholesale and retail partners to incent merchandising and sharing of sales data in accordance with our trade agreements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates.  Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions.  Differences between actual and estimated payments are reflected in the period such information becomes available.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_55"></div><div><span><br/></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_58"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQyMA_f0c9821f-a631-4318-a414-4f3e34499aee" continuedAt="ia4ce5818a5ed4c33bd3c1f08408c1626" escape="true">Investments in Equity Securities</ix:nonNumeric></span></div><ix:continuation id="ia4ce5818a5ed4c33bd3c1f08408c1626" continuedAt="iaf370fc30e054d6e9dfe5e5ba458f7fe"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQxOQ_b7b62b27-029c-4250-a1f8-fc711079c442" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our investments consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMS0yLTEtMS0yMjMxMTA_9e60740a-9c12-4f1c-8a2c-948c993d0d91">9,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407056c006d54b6ab8e43c8dd4f712d7_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMS00LTEtMS0yMjMxMTA_98ee8fa4-63a9-49c1-9cd4-6fab18e8e6f0">8,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70acd0d1a18e45398127bc9cce16307f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMi0yLTEtMS0yMjMxMTA_f04a56e3-d87a-41d9-9592-01d14cca5e31">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f105c2681d04b75b6c055147bbea3bb_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMi00LTEtMS0yMjMxMTA_8eeb3907-e194-4909-8751-59fd86f939d1">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331" decimals="-6" name="mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMy0yLTEtMS0yMjMxMTA_29031785-a779-472b-b4c2-137bd234d14f">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29d9e6ebe044e90989cf465823a77f6_I20221231" decimals="-6" name="mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMy00LTEtMS0yMjMxMTA_a6b88c9c-0ef2-432a-bccb-fc203f2f6cb7">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfNC0yLTEtMS0yMjMxMTA_0f936c27-5262-4893-8874-3fa033f2e5a6">9,559</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfNC00LTEtMS0yMjMxMTA_78868c6a-b234-43b4-8439-0a5316e6bf8c">9,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) losses from investments in equity securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.290%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e30dd02c1c94a5b81ccdba16b4c25b1_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMi0xLTEtMS0yMjMxMTA_71adbe3c-f125-47a6-9a18-a954853eb4dc">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df9ced5c50845578c7a1d3348b2c11b_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMi0zLTEtMS0yMjMxMTA_f3a8630b-6612-40bd-9382-9e6e8d6729b1">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMy0xLTEtMS0yMjMxMTA_df4d1f32-7d17-46c9-b67c-dc35206a0f63">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b0728e4a964ae7a16912dba9ce4741_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMy0zLTEtMS0yMjMxMTA_b1764dbd-4eff-4b80-a4a7-d30dd03caea3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments under equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNC0xLTEtMS0yMjMxMTA_021d4c76-35e1-4b51-9437-f7379c700c0a">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNC0zLTEtMS0yMjMxMTA_c1b738bf-59e8-47b7-aacb-f410ceea3cc9">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNS0xLTEtMS0yMjMxMTA_b310b352-b5b8-499a-9cb1-d14573db3d07">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd8e983be5e4bf49bbb82139b8be78f_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNS0zLTEtMS0yMjMxMTA_e6c87a77-9c8b-4d20-864a-87025ab41c9a">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNi0xLTEtMS0yMjMxMTA_05cbd9bd-69d1-494d-91e5-2fc2904499dd">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNi0zLTEtMS0yMjMxMTA_7263ed30-9c75-4c8f-aa64-88251c580e23">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GAAP&#8221;) and (ii) adjustments to our investment required under the equity method of accounting.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents loss as a result of the disposition of our JUUL equity securities discussed below.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents the estimated change in fair value.  Prior to the disposition of our JUUL equity securities on March 3, 2023, we accounted for our investment in JUUL as an investment in an equity security measured at fair value.</span></div></ix:nonNumeric><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in ABI</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had an approximate <ix:nonFraction unitRef="number" contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTExMg_6f40a18c-1d04-45fa-85fb-2dc77825a660">10</ix:nonFraction>% ownership interest in ABI, consisting of <ix:nonFraction unitRef="shares" contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331" decimals="-6" name="mo:EquityMethodInvestmentNumberofSharesOwnedRestricted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTE1Ng_596f885e-64ba-4ca0-9d30-f8d85216fff0">185</ix:nonFraction> million restricted shares of ABI (the &#8220;Restricted Shares&#8221;) and <ix:nonFraction unitRef="shares" contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331" decimals="-6" name="mo:EquityMethodInvestmentNumberofSharesOwnedCommon" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTIxNA_8be04448-3d45-4e0c-bdf6-221f046bdb88">12</ix:nonFraction> million ordinary shares of ABI.  The Restricted Shares:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are unlisted and not admitted to trading on any stock exchange;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are convertible by us into ordinary shares of ABI on a one-for-one basis;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">rank equally with ordinary shares of ABI with regards to dividends and voting rights; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">have director nomination rights with respect to ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of this filing, we have not elected to convert our Restricted Shares into ordinary shares of ABI.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQyMg_5ed65d12-4931-47ef-a831-159a1d2812fa" continuedAt="i75a717f855c142b9948399aedcc5d063" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our investment in ABI under the equity method of accounting because we have the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI&#8217;s board of directors and certain ABI board committees.  Through this representation, we participate in ABI&#8217;s policy making processes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our share of ABI&#8217;s results using a one-quarter lag because ABI&#8217;s results are not available in time for us to record them in the concurrent period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="iaf370fc30e054d6e9dfe5e5ba458f7fe" continuedAt="i727a342509784487a8f2b6e6417b3565"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75a717f855c142b9948399aedcc5d063" continuedAt="ifcdde2f94499406497af68e2fe74b5d9">The fair value of our equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI&#8217;s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.  We can convert our Restricted Shares to ordinary shares at our discretion.  Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.</ix:continuation></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our equity investment in ABI at March&#160;31, 2023 and December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzIzNA_9b2f947f-dc6d-4d9c-8f1f-63d8e2092ff9">13.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNTE3Mw_a2ad2c96-c304-46bc-9f59-73504e0f3d8f">11.9</ix:nonFraction> billion, respectively, which exceeded its carrying value of $<ix:nonFraction unitRef="usd" contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331" decimals="-6" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzI0OA_8c212faa-89d7-44d5-a5a1-912b2a1daa61">9.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231" decimals="-6" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzE4NA_0c2c2a20-0974-4028-bcce-46edd68e9cac">9.0</ix:nonFraction> billion by approximately <ix:nonFraction unitRef="number" contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331" decimals="2" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzI1Nw_a8c0c355-8873-4ef0-b9f3-385525e5121b">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231" decimals="2" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzIxMQ_7f37b1a5-5416-498a-b4c0-281d5c2d9864">33</ix:nonFraction>%, respectively.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_61"></div><ix:continuation id="i727a342509784487a8f2b6e6417b3565" continuedAt="i4b8b922c42f04ffb8c48c37e09d6ba07"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in JUUL</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into the Stock Transfer Agreement with JUUL pursuant to which, among other things, we  transferred to JUUL all of our beneficially owned JUUL equity securities.  Concurrently with and in connection with the execution of the Stock Transfer Agreement, JUUL entered into an agreement with us that provides us with a non-exclusive, irrevocable global license to certain of the JUUL Heated Tobacco IP.  In addition, all other agreements between us, on the one hand, and JUUL, on the other hand, were terminated or we were removed as parties thereto, other than certain litigation-related agreements and a license agreement relating to our non-trademark licensable intellectual property rights in the e-vapor field, which remain in force solely with respect to our e-vapor intellectual property as of or prior to March 3, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of transferring to JUUL all of our beneficially owned JUUL equity securities pursuant to the Stock Transfer Agreement, for the three months ended March&#160;31, 2023, we recorded a non-cash, pre-tax loss on the disposition of our JUUL equity securities of $<ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RleHRyZWdpb246Yzc0OWUyMjJkZjY0NDBlZThmZGI4MTk3N2QzYzY3YTVfMTA5OTUxMTY0OTg3Ng_79cc64e9-1030-471b-b90f-d58723fcf7d7">250</ix:nonFraction> million.  Additionally, we considered specific facts and circumstances around the nature of the JUUL Heated Tobacco IP and determined that the fair value of such intellectual property was not material to our consolidated financial statements as of the date of the transaction.  As a result, we did not record an asset associated with this intellectual property on our condensed consolidated balance sheet at March 31, 2023.  The primary drivers of this conclusion were (i) our rights to the JUUL Heated Tobacco IP being non-exclusive, (ii) there being no product or technology transferred to us associated with the JUUL Heated Tobacco IP and (iii) there being no connection between the JUUL Heated Tobacco IP and our current product development plans.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In April 2020, the FTC issued an administrative complaint challenging our investment in JUUL.  In February 2022, the administrative law judge dismissed the FTC&#8217;s complaint.  FTC complaint counsel appealed that decision to the FTC, which appeal remains pending.  For further discussion, see Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Contingencies -&#160;Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RleHRyZWdpb246Yzc0OWUyMjJkZjY0NDBlZThmZGI4MTk3N2QzYzY3YTVfODIyMA_d9e13641-d69b-4238-aa64-553a2817965e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of our investment in JUUL, which was classified in Level 3 of the fair value hierarchy prior to the disposition of our JUUL equity securities discussed above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bf4062eea24ce4a949beb98cf77963_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfMi0yLTEtMS0yMjMxMTA_eefe1349-e118-4e2a-b7c9-5270f6799f37">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic849d2926e4e4725b6bfc1d0c4b15363_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfMy0yLTEtMS0yMjMxMTA_56bcf6cf-fc62-4413-9953-1ab0957d8ded">1,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18ca113bad9498b8bce774c190943af_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNC0yLTEtMS0yMjMxMTA_31345939-e6d8-40cb-ac03-4a91e90caa78">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposition of JUUL equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917aa76b7c2948a99dfaf25b1ab4249a_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNS0yLTEtMS0yMjMxMTA_979699a3-4e0e-4241-9d87-5e927038bdad">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64023a55bc9457f9694dec962ce226d_I20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNi0yLTEtMS0yMjMxMTA_db6cde09-64f9-4384-a4c8-cc5ee3abad23">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in (income) losses from investments in equity securities.</span></div></ix:nonNumeric></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_64"></div><ix:continuation id="i4b8b922c42f04ffb8c48c37e09d6ba07" continuedAt="i0937b1d4a55b415d8c340f3aa86425d4"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Cronos</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had a <ix:nonFraction unitRef="number" contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTY0OTI2NzQ0NjU4OA_726f984f-d854-44e2-856f-efa22f9099c4">41.1</ix:nonFraction>% ownership interest in Cronos, consisting of <ix:nonFraction unitRef="shares" contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331" decimals="-5" name="mo:EquityMethodInvestmentNumberofSharesOwnedCommon" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTY0OTI2NzQ0NjU4Mw_91dd9b0c-2bcc-494e-9e05-b8d14cc22c9e">156.6</ix:nonFraction> million shares, which we account for under the equity method of accounting.  We report our share of Cronos&#8217;s results using a one-quarter lag because Cronos&#8217;s results are not available in time for us to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifcdde2f94499406497af68e2fe74b5d9">The fair value of our equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos&#8217;s common shares and was classified in Level 1 of the fair value hierarchy.</ix:continuation>  At March&#160;31, 2023, the fair value of our equity method investment in Cronos was less than its carrying value by $<ix:nonFraction unitRef="usd" contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331" decimals="-6" sign="-" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NTE1OQ_1b5d6122-2669-4718-a3a5-caf7cf99f7c8">47</ix:nonFraction> million or approximately <ix:nonFraction unitRef="number" contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331" decimals="2" sign="-" name="mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NTE3NQ_bb16e2f5-b104-4eff-9dd1-36fc2715a6e7">13</ix:nonFraction>%.  Based on our evaluation of the duration and magnitude of the fair value decline, our evaluation of Cronos&#8217;s financial condition (including its strong cash position) and near-term prospects, and our intent and ability to hold our investment in Cronos until recovery, we concluded that the decline in fair value of our equity method investment in Cronos below its carrying value is temporary and, therefore, <ix:nonFraction unitRef="usd" contextRef="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331" decimals="-6" name="mo:EquityMethodInvestmentImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTA5OTUxMTY0MTg0Nw_ae14d38f-f70d-42fe-a54c-e8a6589c736e">no</ix:nonFraction> impairment was recorded.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our investment in Cronos, at March 31, 2023, we also owned anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain our ownership percentage.  Certain of the anti-dilution protections provide us the ability to purchase additional Cronos common shares at a per share exercise price of CAD $<ix:nonFraction unitRef="cadPerShare" contextRef="i22be6d10e72a4d068a5e2a59f3619789_I20230331" decimals="INF" name="mo:EquityMethodInvestmentPricePerShareIfExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzEwMQ_ad494cf5-ff3d-4e4b-becb-2f41c05123e6">16.25</ix:nonFraction> upon the occurrence of specified events (&#8220;Fixed-price Preemptive Rights&#8221;).  The Fixed-price Preemptive Rights had <ix:nonFraction unitRef="usd" contextRef="i2698ad66ea7145638fbf517179c1ee03_I20221231" decimals="INF" name="mo:EquityMethodInvestmentsFixedPreemptiveRights" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzM4OA_371bb222-9d0b-4691-8386-0fdbbffb0512"><ix:nonFraction unitRef="usd" contextRef="i22be6d10e72a4d068a5e2a59f3619789_I20230331" decimals="INF" name="mo:EquityMethodInvestmentsFixedPreemptiveRights" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzM4OA_f9c19600-5b8b-4bda-87f5-12e4fd609916">no</ix:nonFraction></ix:nonFraction> value at March 31, 2023 and December 31, 2022.  Prior to December 2022, we also owned a warrant providing us the ability to purchase an </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0937b1d4a55b415d8c340f3aa86425d4">additional approximate <ix:nonFraction unitRef="number" contextRef="ifc3ad097e6354edca8d47d2a62d0b590_D20190301-20221130" decimals="INF" name="mo:EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzE3Ng_455dacdb-e9d9-4105-a253-6527a3f76d95">10</ix:nonFraction>% of common shares of Cronos at a per share exercise price of CAD $<ix:nonFraction unitRef="cadPerShare" contextRef="i6dbdafadb4994369a437f0cb91cd5ebd_I20221130" decimals="INF" name="mo:EquityMethodInvestmentPricePerShareIfExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzE2MA_5236a3d9-5a91-429b-88cb-a6bc4b65e453">19.00</ix:nonFraction>, which would have expired on March 8, 2023.  In December 2022, we irrevocably abandoned the Cronos warrant.</ix:continuation></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_67"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzA3Mg_fc667cff-8806-451f-978c-77f43dff85f6" continuedAt="i4b93ed656bbf48c5bbc276416a48a1e4" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i4b93ed656bbf48c5bbc276416a48a1e4"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk.  We use various types of derivative financial instruments, including forward contracts, options and swaps.  We do not enter into or hold derivative financial instruments for trading or speculative purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in ABI, whose functional currency is the Euro, exposes us to foreign currency exchange risk on the carrying value of our investment.  To manage this risk, we may designate certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, &#8220;foreign currency contracts&#8221;), and Euro denominated unsecured long-term notes (&#8220;foreign currency denominated debt&#8221;) as net investment hedges of our investment in ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, we had <ix:nonFraction unitRef="contract" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:NumberOfForeignCurrencyDerivativesHeld" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzI5ODUzNDg4ODU0MA_5d059eaf-1374-42bc-a7ff-0d82110d8a62"><ix:nonFraction unitRef="contract" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:NumberOfForeignCurrencyDerivativesHeld" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzI5ODUzNDg4ODU0MA_80d97743-2ac5-44c3-b31d-316e865ff7eb">no</ix:nonFraction></ix:nonFraction> outstanding foreign currency contracts.  When we have foreign currency contracts in effect, counterparties are domestic and international financial institutions.  Under these contracts, we are exposed to potential losses in the event of non-performance by these counterparties.  We manage our credit risk by entering into transactions with counterparties that have investment grade credit ratings, limiting the amount of exposure we have with each counterparty and monitoring the financial condition of each counterparty.  The counterparty agreements contain provisions that require us to maintain an investment grade credit rating.  In the event our credit rating falls below investment grade, counterparties to our foreign currency contracts can require us to post collateral.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzA3Mw_472e0fbf-004f-4606-a8af-1df91a928c3f" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value and fair value of our total long-term debt were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMS0xLTEtMS0yMjMxMTA_9ff5c633-a2e2-47f8-b2c9-a0ab840ab9c6">25,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMS0zLTEtMS0yMjMxMTA_fb20f9db-4417-4532-8aa6-610ecb98282c">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMi0xLTEtMS0yMjMxMTA_dedab714-c140-4661-a6eb-f016aee07b42">22,565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMi0zLTEtMS0yMjMxMTA_1222d984-9070-413e-8166-9785b95966a8">22,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt included in long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e386c21ead541d7b2b8e375d8f79708_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNC0xLTEtMS0yMjMxMTA_1b3b1154-371d-47e0-bfba-53683f6b5f96">3,242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNC0zLTEtMS0yMjMxMTA_06563ec3-8db5-4b16-a3f3-d1408861a6b1">4,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e386c21ead541d7b2b8e375d8f79708_I20230331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNS0xLTEtMS0yMjMxMTA_67ba27d9-67a2-4846-8c88-c7a9df059ebf">2,940</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNS0zLTEtMS0yMjMxMTA_cf44d4ba-321f-4f35-bc0c-0b9f3b5b1e56">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the fair value of our total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedging</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized changes in the carrying value of the foreign currency denominated debt due to changes in the Euro to U.S. dollar exchange rate in accumulated other comprehensive losses related to ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized pre-tax (gains) losses of our net investment hedges of $<ix:nonFraction unitRef="usd" contextRef="i7e0ac77709a6467ea112cb5ce9968742_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMTA5OTUxMTYzMTMwNg_db857ca6-1e7e-4b89-b47e-1d7f169455ff">48</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="ie8891909d58c4512bd26716fe7321214_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMTA5OTUxMTYzMTMxOQ_a2633af1-7f07-465c-97e7-81854c992834">128</ix:nonFraction>) million for the three months ended March 31, 2023 and 2022, respectively, in accumulated other comprehensive losses.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_73"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTYwMQ_fc12ccb2-3e8e-4cb3-b4f6-c1c2f31248ef" continuedAt="i86c71205045e4a458c687e24009f7691" escape="true">Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i86c71205045e4a458c687e24009f7691" continuedAt="i5de1f763a4314a81bcfcae094663ac1e"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost (Income)</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTU4MQ_01141fe1-f152-4035-a489-ff6e53f2a806" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (income) consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy0xLTEtMS0yMjMxMTA_d0eddc83-aee6-45f9-b56b-9122a7ac4df1">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy0zLTEtMS0yMjMxMTA_db98e004-feae-46bc-8934-3bf6f635627f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy01LTEtMS0yMjMxMTA_108a5278-277c-4482-bc81-49185d8ccd97">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy03LTEtMS0yMjMxMTA_f564abbf-deb7-4d91-b2be-fd77dee69057">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC0xLTEtMS0yMjMxMTA_371131e8-2b15-4821-abfb-ff7df753450f">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC0zLTEtMS0yMjMxMTA_257f0c2e-b97d-4169-b31a-0a78c6c30aed">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC01LTEtMS0yMjMxMTA_3db90adf-52a5-47ed-ac81-bd41f2ab8035">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC03LTEtMS0yMjMxMTA_961f73df-60af-471a-bda7-7a882dcb0e11">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS0xLTEtMS0yMjMxMTA_8f430eb0-3f07-4980-9e9b-b88a6c3a377b">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS0zLTEtMS0yMjMxMTA_08c51dd6-8b97-4999-9b1d-cf08bc78c2c4">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS01LTEtMS0yMjMxMTA_ea3ce58c-2b8e-47f0-84be-514773ca8c9e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS03LTEtMS0yMjMxMTA_85c6ebab-693c-45bd-bcb9-95d7a3d9618e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy0xLTEtMS0yMjMxMTA_7fce50dd-ecbb-454a-8542-ec3ca8547202">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy0zLTEtMS0yMjMxMTA_a2cb2faf-ed19-4c3c-88c9-ff3824f2eb85">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy01LTEtMS0yMjMxMTA_18c61043-837c-4e07-bf02-233bf25ee138">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy03LTEtMS0yMjMxMTA_0213292a-1f78-4d35-b514-49dd1d5add2f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC0xLTEtMS0yMjMxMTA_1fea40af-042c-427d-963e-91f47942d6bf">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC0zLTEtMS0yMjMxMTA_fa4895b1-92b0-4f47-8f07-e0be0e952ecf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC01LTEtMS0yMjMxMTA_4f73b736-d229-4ed3-8d94-760d66fb01ea">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC03LTEtMS0yMjMxMTA_5eecce27-f5eb-4c87-a628-eb23ae2e95c1">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtMS0xLTEtMjIzMTEw_12df2fb0-5c3c-43af-a7c6-c86bf543d07f">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtMy0xLTEtMjIzMTEw_351061e7-b929-41ed-8c85-f1245419d0b7">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtNS0xLTEtMjIzMTEw_e88f952f-dc38-46ad-ad54-3201d5160eee">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtNy0xLTEtMjIzMTEw_1e1f6a92-21c8-44e0-a58e-fca2391e7c06">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employer Contributions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make contributions to our pension plans to the extent that the contributions are tax deductible and pay benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service (&#8220;IRS&#8221;) regulations.  We made employer </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5de1f763a4314a81bcfcae094663ac1e">contributions of $<ix:nonFraction unitRef="usd" contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfNDIy_805d4bb6-1d1b-431d-82b0-5907131666ed">7</ix:nonFraction> million to our pension plans and did <ix:nonFraction unitRef="usd" contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331" decimals="INF" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfNDU0_027b2d2b-e16d-4844-a1c7-aee865da1b05">no</ix:nonFraction>t make any contributions to our postretirement plans during the three months ended March 31, 2023.  Currently, we anticipate making additional employer contributions of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i69bda6f9d3044065b5cb45c86ee040ae_I20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTgxNDE5NDE4NjA4ODM_4eb18aee-2d3a-499f-9153-ac8bba1b8ec9">25</ix:nonFraction> million to our pension plans and $<ix:nonFraction unitRef="usd" contextRef="ieacd8d560cc14bb3888bf0fb293a903f_I20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTc1OTIxODYwNDcwMDU_b02a8cca-0b49-4add-a868-b8d0ba112ba6">30</ix:nonFraction> million to our postretirement plans in 2023.  However, the foregoing estimates of 2023 contributions to our pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.</ix:continuation></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_76"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RleHRyZWdpb246NDIxMzQ2ZWFlMzUyNDE0MmI5YTQ0ZDQ4MjRkOGRiNGRfMTMw_158ffba5-5977-47af-a733-1d660df9f4fa" continuedAt="ia9b45e76c4054a7f967eb3dca45f27dd" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="ia9b45e76c4054a7f967eb3dca45f27dd"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RleHRyZWdpb246NDIxMzQ2ZWFlMzUyNDE0MmI5YTQ0ZDQ4MjRkOGRiNGRfMTQ2_814ffd63-64b3-4e65-b60c-586944fb8d6b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculated basic and diluted earnings per share (&#8220;EPS&#8221;) using the following:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMi0yLTEtMS0yMjMxMTA_f7593c4c-9993-4b52-be28-81939bd3b411">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMi00LTEtMS0yMjMxMTA_7813e331-5579-47e7-9c1f-5935007540a4">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Distributed and undistributed earnings attributable to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMy0yLTEtMS0yMjMxMTA_ce09b2ab-05d5-4be7-a16e-6d9173425841">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMy00LTEtMS0yMjMxMTA_c17de535-1a3f-4420-ac92-b849f1d82423">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC0yLTEtMS0yMjMxMTA_05a033a0-e00e-4ac5-9f8f-f6df4ef5adcd"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC0yLTEtMS0yMjMxMTA_526304f7-5a8c-4cba-a646-4fc48d71dcde">1,784</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC00LTEtMS0yMjMxMTA_7c77f325-89eb-4d0c-98f6-0967a3ac4fa0"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC00LTEtMS0yMjMxMTA_d2f8a42f-73c4-47c0-a319-bc0a40386217">1,955</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC0yLTEtMS0yMjMxMTA_085072a8-6305-4355-965e-538a488bed7e"><ix:nonFraction unitRef="shares" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC0yLTEtMS0yMjMxMTA_0a745a28-2446-42ef-ac6c-cdbce0e74304">1,786</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC00LTEtMS0yMjMxMTA_70c6e756-65d6-4b2c-899a-4f2064059154"><ix:nonFraction unitRef="shares" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC00LTEtMS0yMjMxMTA_ffabd24c-c955-4096-b63e-894410ef1074">1,818</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_79"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RleHRyZWdpb246NDlkOTFlMjVhMTYwNGY1Mjg2OTk0MjdhOTgwOTZkZmRfMjA1_7cc72382-b9bf-4106-b2f9-01d83333faa5" continuedAt="if0379a965eea45f5be5bc00126f12ba9" escape="true">Other Comprehensive Earnings/Losses</ix:nonNumeric></span></div><ix:continuation id="if0379a965eea45f5be5bc00126f12ba9" continuedAt="i145e9041c0724a2a8bc7a5a20dc59bc7"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RleHRyZWdpb246NDlkOTFlMjVhMTYwNGY1Mjg2OTk0MjdhOTgwOTZkZmRfMjA2_d3d05185-f853-4705-a974-e41139e02d49" continuedAt="i6677aee598114f8ab712642a51a04c6e" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd124c60d03f419f9b32a50e8d8ad088_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi0yLTEtMS0yMjMxMTA_369a0e1d-ba84-4237-a6b5-b8e841105ba0">1,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48147e6321604e39a0674a5c9700d5cc_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi00LTEtMS0yMjMxMTA_bda3e4c9-d994-4b4c-8c9d-9083b83e19ec">1,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8248ed5a8a794be4ae798af164015026_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi02LTEtMS0yMjMxMTA_a5c18f4c-a889-4026-80ec-933ce4122861">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2469a4bba094953adfa2888c0f55b57_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi04LTEtMS0yMjMxMTA_6392b0a9-ef8b-4987-b5dd-74123366bb5a">2,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC0yLTEtMS0yMjMxMTA_6e248459-ccd5-465f-b96c-2ee16890ed04">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC00LTEtMS0yMjMxMTA_182c7974-20af-4fa3-95d1-6f696717a2dd">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC02LTEtMS0yMjMxMTA_f4f08e25-296e-4fc7-8f90-8cc9ee23baa8">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC04LTEtMS0yMjMxMTA_dd753857-3690-4e74-a36a-10eb878bc7d4">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS0yLTEtMS0yMjMxMTA_1b9c815b-5930-4e51-baf5-c15751bfbc63">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS00LTEtMS0yMjMxMTA_3e900a5e-e862-4b6f-8519-b67a9875a5be">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS02LTEtMS0yMjMxMTA_177d946b-6000-456f-98c0-da0cda7d5594">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS04LTEtMS0yMjMxMTA_3abb20b1-79d7-4cdb-8dca-f308f5e76166">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi0yLTEtMS0yMjMxMTA_cb1222ad-79ed-4d40-b723-507a8c86ef14">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi00LTEtMS0yMjMxMTA_cc9e48cc-67ed-40c5-a1f2-3e15ad81e604">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi02LTEtMS0yMjMxMTA_d5ec0cea-38f8-4ffe-a2b1-54a3581f5f13">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi04LTEtMS0yMjMxMTA_2f1633b7-177e-4189-b8a1-7ae771cd535a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC0yLTEtMS0yMjMxMTA_b82c73cf-3ce1-41bb-99e1-2e4cf045ff65">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC00LTEtMS0yMjMxMTA_c7a13494-b3f1-40c0-a475-5166bec1a6ef">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC02LTEtMS0yMjMxMTA_d9faebcb-3be5-4eb8-8a1a-c7ea51122eb7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC04LTEtMS0yMjMxMTA_3fe7b817-b798-4b56-a938-6417c5f79cf3">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS0yLTEtMS0yMjMxMTA_2d8ece35-5273-4b86-a926-cbfc8e6a6b78">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS00LTEtMS0yMjMxMTA_90da4c42-b43e-401e-aeca-668ae6bb759c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS02LTEtMS0yMjMxMTA_6002f44c-c928-406c-b889-82c1466cfcd3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS04LTEtMS0yMjMxMTA_49cd67cf-0833-4a92-b539-1744e7fae83d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtMi0xLTEtMjIzMTEw_8f038df9-11a2-424b-9979-df01a7172271">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtNC0xLTEtMjIzMTEw_aecb269a-dabb-4c54-86c8-f78da89aa338">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtNi0xLTEtMjIzMTEw_99996ed4-3d54-4f23-98a1-b7f19afd9118">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtOC0xLTEtMjIzMTEw_fc0ca9b0-b27d-4fed-a85e-3021460b0185">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItMi0xLTEtMjIzMTEw_9b3b7548-1076-4348-92ad-747e2fcf84ec">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItNC0xLTEtMjIzMTEw_7c3664a4-b40c-4190-86d2-9964cf8bb83b">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItNi0xLTEtMjIzMTEw_41065d40-367a-4cd9-86ba-d584eb995c76">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItOC0xLTEtMjIzMTEw_accb25b5-62cc-4b7e-ac72-3a27f513fa48">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae16a7ba3e464592bc4e2b2d8cc85d62_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtMi0xLTEtMjIzMTEw_cdad37fd-ec3b-4f29-9187-b404161d1221">1,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i956ac6a83c434b91ad8b518160de9170_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtNC0xLTEtMjIzMTEw_4762aecf-a3ae-4355-9010-b6d44e65ae68">1,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd1c9ebd07c34c43a75cc8eb11135003_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtNi0xLTEtMjIzMTEw_e257a60e-1b8b-49df-b697-d3bd8d7276dc">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd940594473144c68357ea9c5539af8e_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtOC0xLTEtMjIzMTEw_21e52cb2-0e4d-42ed-8d45-d9da13a85493">2,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i145e9041c0724a2a8bc7a5a20dc59bc7" continuedAt="ie5a572e79e334dec8f7839e2fe397efa"><ix:continuation id="i6677aee598114f8ab712642a51a04c6e"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53e66b45d2fd44569d4910cd6febb6c4_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi0yLTEtMS0yMjMxMTA_017e991a-9ec8-485d-8501-8af28faa29ab">1,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3671b5f23c94bf792e7730b318b4f31_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi00LTEtMS0yMjMxMTA_d6ccb8a7-35e5-4f98-8189-e8bdf4984186">1,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbd214e79b74f2da6764b8726a150ac_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi02LTEtMS0yMjMxMTA_bbc3c192-a86e-41af-8625-e01cf8ae0d21">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e09c734e014d5ea132f83014347e58_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi04LTEtMS0yMjMxMTA_79e1dace-c8fd-45b9-bf95-f78779e856aa">3,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC0yLTEtMS0yMjMxMTA_3524274c-619f-4ea5-8a22-f3d98e243ee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC00LTEtMS0yMjMxMTA_6521fa05-f69c-4b53-8fc1-394267f1a178">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC02LTEtMS0yMjMxMTA_c6c38da7-d7c1-4854-a475-dd507f49c557">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC04LTEtMS0yMjMxMTA_85b7bd85-a02d-406d-a5af-577ec56c29e0">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS0yLTEtMS0yMjMxMTA_fec886c1-8843-44a1-aa49-eec0dc19fe19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS00LTEtMS0yMjMxMTA_e8e64cca-bfb4-48df-8de6-726c6730681f">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS02LTEtMS0yMjMxMTA_b03c72c2-2a57-4fa6-aba9-0e87dfe2576b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS04LTEtMS0yMjMxMTA_d9f1872c-d3c9-4caa-a641-98e179fbc265">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi0yLTEtMS0yMjMxMTA_bfa930a9-d45b-4f37-8693-c58c24b998e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi00LTEtMS0yMjMxMTA_9e76b840-d76e-47b8-87bd-b9907d4d4972">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi02LTEtMS0yMjMxMTA_c43647d8-1baf-4ce1-a1d4-8fd12fb95ea0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi04LTEtMS0yMjMxMTA_ca2dd765-e937-4670-850f-6144d00de34e">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC0yLTEtMS0yMjMxMTA_24ae50f2-3299-40f7-8fc5-45b7e02cc185">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC00LTEtMS0yMjMxMTA_81e7087d-1505-4a45-ad0f-8263ef60bec0">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC02LTEtMS0yMjMxMTA_e065e7eb-72f1-4378-a863-6685c6a36eef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC04LTEtMS0yMjMxMTA_5f20096e-27ba-42f6-b4f4-6f6cd8a072a0">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS0yLTEtMS0yMjMxMTA_7bff852f-41c7-4d78-88bf-2f010cd2b61f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS00LTEtMS0yMjMxMTA_b6a21d68-d4fa-4a7a-911c-cd0668e05669">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS02LTEtMS0yMjMxMTA_23e921bc-ad63-4a07-bca7-5b250e9417eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS04LTEtMS0yMjMxMTA_9b04ffdf-b3c9-4104-8b26-ab186f4b5d38">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtMi0xLTEtMjIzMTEw_326beca9-748f-47eb-80cc-c471020832ef">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtNC0xLTEtMjIzMTEw_b1ab3cae-8794-44f5-839f-5525ed671a5e">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtNi0xLTEtMjIzMTEw_dcc5cb7d-1416-465d-b2b6-f27d46323e02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtOC0xLTEtMjIzMTEw_9c849461-b406-4472-95ba-6de1ca3ea401">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItMi0xLTEtMjIzMTEw_0c080c93-1461-4205-ad0b-4007d819d1e3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItNC0xLTEtMjIzMTEw_6b4b422c-a50c-4ee7-8dd8-8618f42182be">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItNi0xLTEtMjIzMTEw_52c11498-9a46-497e-a22f-fcac1c5a323d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItOC0xLTEtMjIzMTEw_0b1d0aa8-b184-4c92-80e9-f08573cc312c">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i948ca0a2116f4d7a820721a03a172caa_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtMi0xLTEtMjIzMTEw_c45d92a7-8ff7-46d3-87e9-c53fb41808dc">1,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2fc3fc500643caa6b4bcbcd6531d2a_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtNC0xLTEtMjIzMTEw_30f9ae1a-1645-44af-830a-ef7e0255a9cc">1,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15be35835b9b4c7ab7cc385c16e9f766_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtNi0xLTEtMjIzMTEw_91412a4d-c211-41cf-bc96-fa35a7e42c93">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtOC0xLTEtMjIzMTEw_4cae8683-3c6b-4707-9909-f8839c4e5dbd">2,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily reflects the impact of our designated net investment hedges related to our equity investment in ABI and our share of ABI&#8217;s currency translation adjustments.  For further discussion of designated net investment hedges, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments.</span></div></ix:continuation></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_91"></div><ix:continuation id="ie5a572e79e334dec8f7839e2fe397efa"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RleHRyZWdpb246MTljZjg0NTA4YjdjNDM2ZDlmOTJhM2IzNmJlNTYyZjlfNDE3_08e2cb08-ca38-4687-8671-73c6bb1ff74f" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.472%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a21466ce342442f9033dda351c1c76f_D20230101-20230331" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfMy0yLTEtMS0yMjMxMTA_0f2ebeb4-ccc2-48bb-b650-fe93d36b0472">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2a3ee32c4c425687e4ad4ff4d1ef09_D20220101-20220331" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfMy00LTEtMS0yMjMxMTA_f1f61c41-1f94-4683-97e7-d25ede8c1e93">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost/credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9842a26a80164a39b9d29efbd4d26e1f_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNC0yLTEtMS0yMjMxMTA_eb48e901-8735-4f7a-a65c-a8fd2d31c7de">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66ee296114304714be05372fa2564b28_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNC00LTEtMS0yMjMxMTA_d98907f2-eb96-4cbc-b568-7f7681e778dd">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i760729c61bca480fbf703974d16ebff6_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNS0yLTEtMS0yMjMxMTA_761cc41e-6d5e-41fc-85d8-f20f0e80b731">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff527c2964e844a7aaf7101d9ebd98da_D20220101-20220331" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNS00LTEtMS0yMjMxMTA_5d81db34-6d44-4361-a025-9f3de0766014">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bca93a749545458ae8cdbafd27b08d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNi0yLTEtMS0yMjMxMTA_680fef79-9e70-4624-9b69-b8a00fe75b95">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7894c01a5bf841ccac16dae6a03a17b2_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNi00LTEtMS0yMjMxMTA_f17eb1aa-acdc-4013-9a6c-7b5256a76b9f">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieae3d8b4d3ae4b3b8ab5e8ac275cd4b3_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfOC0yLTEtMS0yMjMxMTA_bdd4d80a-6bcf-4a8a-84d8-90272c9242c5">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b93671e6ac4c71b0ea9f09be8c806e_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfOC00LTEtMS0yMjMxMTA_beb1052f-6936-42f6-a36c-91e22a31d209">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in net defined benefit plan costs.  For further details, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in (income) losses from investments in equity securities.  For further information, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div></ix:nonNumeric></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_94"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0NQ_5c410682-dd1f-4c5a-b67b-9048d777d422" continuedAt="iadd19fd0b84f42a6a8c82942013a851a" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="iadd19fd0b84f42a6a8c82942013a851a" continuedAt="i12ca4888e1a14c67bb64cf55a7f7ce98"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating companies&#8217; products include (i) smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; and (ii) oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix.  These products constituted our reportable segments of smokeable products and oral tobacco products at March&#160;31, 2023.  Our former financial services business, which completed the wind-down of its portfolio of finance assets in 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System heated tobacco business and Helix ROW were included in all other.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief operating decision maker (&#8220;CODM&#8221;) reviews operating companies income (loss) (&#8220;OCI&#8221;) to evaluate the performance of, and allocate resources to, our segments.  OCI for our segments is defined as operating income before general corporate expenses and amortization of intangibles.  Interest and other debt expense, net, along with net periodic benefit income, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by our CODM.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i12ca4888e1a14c67bb64cf55a7f7ce98"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzYxOQ_974ba0d5-3897-4451-9000-0d7596eab5f7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment data were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMy0yLTEtMS0yMjMxMTA_12c7ab05-801c-4150-b4c4-831e9a274934">5,090</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMy00LTEtMS0yMjMxMTA_d782c92f-f371-4e0b-a86b-9861cd4c5a4d">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNC0yLTEtMS0yMjMxMTA_5a295223-42d5-46bc-a929-2de33bdeebb5">628</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNC00LTEtMS0yMjMxMTA_718b9411-3aaf-45eb-9032-a3d99bb03312">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNi0yLTEtMS0yMjMxMTA_4e9fd4e2-f76f-4c04-bfa2-d67323b272ba">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNi00LTEtMS0yMjMxMTA_53a14ef6-6b24-44ac-a2f2-be8dae396c37">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNy0yLTEtMS0yMjMxMTA_24e3fbf8-0e64-4a83-b8ed-416f810ae5ae">5,719</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNy00LTEtMS0yMjMxMTA_0da5a1c2-86f8-44cb-9d70-2f7efdf9b177">5,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331" decimals="-6" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTAtMi0xLTEtMjIzMTEw_e85042c1-e435-48ac-8b74-7cdfd8cfdec2">2,503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331" decimals="-6" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTAtNC0xLTEtMjIzMTEw_1001b680-dd20-4669-bb23-5e4c2be9baa5">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331" decimals="-6" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTEtMi0xLTEtMjIzMTEw_bf233e04-c5ee-4bcd-a4a3-3a6cefd89a78">416</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331" decimals="-6" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTEtNC0xLTEtMjIzMTEw_2ed1d223-eab7-4210-a3b5-1aa9f732672b">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331" decimals="-6" sign="-" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTMtMi0xLTEtMjIzMTEw_32d54983-fe41-427c-8b75-ea13ac4404c4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331" decimals="-6" sign="-" name="mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTMtNC0xLTEtMjIzMTEw_79b9934c-6bd6-4149-b85a-3cde8018eb3d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTQtMi0xLTEtMjIzMTEw_eeb46a56-4954-4735-9fe4-13aeb4b268fc">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTQtNC0xLTEtMjIzMTEw_c71160f2-5a67-45bc-8ef7-391895af39fd">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTUtMi0xLTEtMjIzMTEw_7601a227-193b-43e0-bb92-499ce5e559a8">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTUtNC0xLTEtMjIzMTEw_2cf70fec-7d76-4d23-8651-6a544bde1559">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTctMi0xLTEtMjIzMTEw_a0f9478f-a86f-45d0-9adc-e025e851e6be">2,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTctNC0xLTEtMjIzMTEw_c8141991-a8d7-4aff-ac3d-0ec420cd4561">2,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTgtMi0xLTEtMjIzMTEw_e7beda3a-e4f9-4c6a-8c31-675eaeb4d7f8">229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTgtNC0xLTEtMjIzMTEw_9021d319-db36-4050-9f60-546ccba6a9d6">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjAtMi0xLTEtMjIzMTEw_528542cc-7085-4bec-a234-f409b5d0768c">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjAtNC0xLTEtMjIzMTEw_485bcc40-d49e-436b-bc20-ecdaef74df96">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjEtMi0xLTEtMjIzMTEw_54e205f4-ad7e-4197-bf0f-650bc65c19be">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="mo:IncomeLossFromEquitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjEtNC0xLTEtMjIzMTEw_11035a88-c72a-4f41-9f0d-c61172369c39">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjMtMi0xLTEtMjIzMTEw_ca7ded51-bbd1-4801-b761-eb128340219c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjMtNC0xLTEtMjIzMTEw_9be264f3-a49b-44ad-a080-f5e98026c7b8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjQtMi0xLTEtMjIzMTEw_ccdd2a3d-6b0a-496b-8717-67c592e39b64">2,479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjQtNC0xLTEtMjIzMTEw_4edb1398-5bef-447a-8017-2eaa326bf746">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparability of OCI for our reportable segments was affected by the following:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="mo:ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0Mw_b8f02571-ecce-44b3-8707-372253f907b2" escape="true">Non-Participating Manufacturer (&#8220;NPM&#8221;) Adjustment Items:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recorded pre-tax income for NPM adjustment items of $<ix:nonFraction unitRef="usd" contextRef="i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMjE5OTAyMzI2MTg4Nw_1d14da01-661d-4b01-802f-cd6a9eb99b94">60</ix:nonFraction> million for the three months ended March&#160;31, 2022 in our smokeable products segment.  We recorded these items as reductions to cost of sales in our condensed consolidated statement of earnings, which resulted in increased OCI in our smokeable products segment.  NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the Master Settlement Agreement (such dispute resolutions are referred to as &#8220;NPM Adjustment Items&#8221; and are more fully described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Tobacco and Health and Certain Other Litigation Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="mo:ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0Nw_8de8a551-f758-42b0-a2d8-466af213f8a6" continuedAt="if343eb1acbd340dcb12ba92ebf81937f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:</span></ix:nonNumeric></div><div style="margin-bottom:5pt"><ix:continuation id="if343eb1acbd340dcb12ba92ebf81937f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4eb1d656b243898b89b6f3008cb4bf_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMi0yLTEtMS0yMjMxMTA_c275848b-ee8f-44a4-9de5-ee0ea79d31b6">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde877d815ab4397aee17c08472bdddf_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMi00LTEtMS0yMjMxMTA_689fb64c-354e-43e6-90fa-ae7636651a90">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ee8c9fc92344e99ab8d14573f9be5a_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMy0yLTEtMS0yMjMxMTA_c45fa436-efe5-4695-9930-57e54353ab7b">98</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598239b5dde34e519bcd01cb3409992e_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMy00LTEtMS0yMjMxMTA_d7080345-6a99-4936-9a78-70b7be7bcc4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1290e16c10451aa1fcb7cc789b60b2_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNC0yLTEtMS0yMjMxMTA_1919af48-5242-439c-8d60-8aaa10d176a7">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70aedc832b244d9e934f496edc7227c5_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNC00LTEtMS0yMjMxMTA_f0170ec3-d601-4412-ae49-1bc60813cbc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008bb3a34d6f4ad1a419dfbe662171e3_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNS0yLTEtMS0yMjMxMTA_420005d5-d2f0-4bec-8e3b-6f318262ab66">111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e38d13df914cd0b952143a1636ff77_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNS00LTEtMS0yMjMxMTA_436093d3-1aaf-4939-bbf2-92bc6fcdbbdf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the amounts shown in the table above for the smokeable products segment and general corporate expenses in marketing, administration and research costs in our condensed consolidated statements of earnings.  For further discussion, see Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_97"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzg3NA_6e782839-095c-4dce-92ee-b71dea2087b8" continuedAt="ibf9b45c4f7df4fd2b27db4e4583db8ba" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ibf9b45c4f7df4fd2b27db4e4583db8ba" continuedAt="i1933b3be75c74784959364c5d9379945"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Borrowings and Borrowing Arrangements</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, we had <ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODQ_26fe4c94-e9f5-4c85-82bf-02699023f907"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODQ_29f17902-49d9-4719-86a3-1891535a68ac">no</ix:nonFraction></ix:nonFraction> short-term borrowings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a $<ix:nonFraction unitRef="usd" contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzOTM5OQ_8546832a-d5f7-4f64-91c6-55fd325c2594">3.0</ix:nonFraction> billion senior unsecured <ix:nonNumeric contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331" name="us-gaap:LongTermDebtTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfNjA0NzMxMzk2NDkwOA_0bfaa999-52cd-4ad9-bbe7-1c4843639923">5-year</ix:nonNumeric> revolving credit agreement (as amended, the &#8220;Credit Agreement&#8221;), which is used for general corporate purposes and expires on August 1, 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had availability under the Credit Agreement for borrowings of up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331" decimals="-9" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODc1_1d0313c3-fd96-477b-9c00-07490809f171">3.0</ix:nonFraction> billion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i1933b3be75c74784959364c5d9379945"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of our long-term senior unsecured debt.  We expect interest rates on borrowings under the Credit Agreement to be based on the Term Secured Overnight Financing Rate plus a percentage based on the higher of the ratings of our long-term senior unsecured debt from Moody&#8217;s Investors Service, Inc. and Standard&#160;&amp; Poor&#8217;s Financial Services LLC.  The applicable percentage for borrowings under the Credit Agreement at March&#160;31, 2023 was <ix:nonFraction unitRef="number" contextRef="i16749ccbd508483a9f1550c451780fe1_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTQwMQ_fdba78f0-b77d-4b47-a832-54b6654dba86">1.0</ix:nonFraction>% based on our long-term senior unsecured debt ratings on that date.  The Credit Agreement does not include any other rating triggers or any provisions that could require the posting of collateral.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes various covenants, one of which requires us to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) to Consolidated Interest Expense of not less than <ix:nonFraction unitRef="number" contextRef="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331" decimals="INF" name="mo:DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTgzNA_707b3da5-30c8-4135-b7b7-efa78dfc837a">4.0</ix:nonFraction> to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis.  At March&#160;31, 2023, the ratio of Consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was <ix:nonFraction unitRef="number" contextRef="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331" decimals="INF" name="mo:DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjA2MQ_168e2870-fffd-4203-a398-94d02def2900">10.9</ix:nonFraction> to 1.0.  At March&#160;31, 2023, we were in compliance with our covenants in the Credit Agreement.  The terms &#8220;Consolidated EBITDA&#8221; and &#8220;Consolidated Interest Expense,&#8221; each as defined in the Credit Agreement, include certain adjustments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any commercial paper issued by us and borrowings under the Credit Agreement are guaranteed by PM&#160;USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value of our total long-term debt at March&#160;31, 2023 and December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjQ3Nw_e8a579ab-a1d2-4a5f-831d-54847b0e4c2e">25.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjQ4NA_e9ae90fd-490b-4496-8c17-ed594b040cfd">26.7</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we repaid in full our <ix:nonFraction unitRef="number" contextRef="ib1ca4b2ce75d43c8a23f0e7a04890b95_I20230228" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTY0MDc2NA_74822d82-d21d-4736-961c-36600998cf8f">1.000</ix:nonFraction>% senior unsecured Euro notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228" decimals="-8" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzMzU4MA_2faf637e-495b-4117-a1d1-3832981d9f56">1.3</ix:nonFraction> billion (&#8364;<ix:nonFraction unitRef="eur" contextRef="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228" decimals="-7" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzMzczMA_7f713499-839a-4e8d-89fa-649114bb4b2d">1.25</ix:nonFraction> billion) at maturity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, accrued interest on long-term debt of $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzU1Mw_e1b0bea7-67c6-48cf-ac5b-c7e1773f790e">233</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzU2MA_947598e4-1aef-44fc-bf81-9ce743a90dcf">411</ix:nonFraction> million, respectively, was included in other accrued liabilities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the fair value of our long-term debt and the designation of our Euro denominated senior unsecured notes as a net investment hedge of our investment in ABI, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_100"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3MzY_d6c92825-33dd-4126-aa71-3ff928c9901b" continuedAt="i7bc065d22b3a4c6a9f2d95b6de6291e9" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i7bc065d22b3a4c6a9f2d95b6de6291e9" continuedAt="i90457aaa13124590854a35db568a984d"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the U.S. Government enacted legislation commonly referred to as the Inflation Reduction Act that became effective January 1, 2023.  The main provisions of the Inflation Reduction Act that impact us are: (i) a 15% corporate alternative minimum tax (&#8220;Corporate AMT&#8221;) and (ii) a 1% excise tax on share repurchases, which we will record in equity on our consolidated statements of stockholders&#8217; equity (deficit).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are considered an &#8220;applicable corporation&#8221; for purposes of Corporate AMT.  We expect our regular federal income tax liability will generally exceed our Corporate AMT liability; however, certain unique circumstances may result in our Corporate AMT liability exceeding our regular federal income tax liability, including when tax losses are reported in a different year than book losses.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="mo:SummaryOfIncomeTaxesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3Mzg_c090cef0-37e3-4f65-a033-1932224c38ff" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzItMi0xLTEtMjIzMTEw_a85e861e-c931-4628-95af-7389705af53d">2,479</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzItNC0xLTEtMjIzMTEw_3779eee1-4e10-4685-9ee2-ebe54a69b410">2,673</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzMtMi0xLTEtMjIzMTEw_d61bdd21-06ab-450b-a79f-44866aa672e9">692</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzMtNC0xLTEtMjIzMTEw_8009c63d-6a63-421f-9ddf-585b9f6c9c9b">714</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzQtMi0xLTEtMjIzMTEw_a68fb7d0-9e37-4001-a694-ec15835313bd">27.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzQtNC0xLTEtMjIzMTEw_ae9b90f6-5f1c-489d-aaa6-b27083cd3398">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax rate for the three months ended March 31, 2023 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to the disposition of our former investment in JUUL.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax rate for the three months ended March 31, 2022 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to a decrease in the estimated fair value of our investment in JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxation in many jurisdictions.  Unrecognized tax benefits reflect the differences between tax positions we have taken or expect to take on income tax returns and the amounts recognized in the financial statements.  Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within our control.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ending December&#160;31, 2023, we expect to recognize an approximate $<ix:nonFraction unitRef="usd" contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231" decimals="-8" sign="-" name="mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDUxMDU_dd61a6cf-e74d-498d-a29b-81a8e82f5c12">6.5</ix:nonFraction> billion ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL.  For financial statement purposes, we expect to fully reserve for the tax benefit associated with this ordinary loss by recording an unrecognized tax benefit of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i90457aaa13124590854a35db568a984d"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU2MDMwMzQ_caa78592-7992-4dac-a2a4-864b8b07e6fc">1.6</ix:nonFraction> billion in 2023 on a pro-rata basis, pending the IRS&#8217;s review of our tax position.  For the three months ended March 31, 2023, we recognized a pro-rata portion of this ordinary loss, which resulted in a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU1OTk1Mzg_ef7b5090-8f10-4e62-889a-1d836de80367">380</ix:nonFraction> million and a reduction to our current income taxes payable.  We also recognized a $<ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDM2Mzg_6515e0ab-a7cc-436b-9c6f-a983f92184ca">391</ix:nonFraction> million increase in a long-term liability for unrecognized tax benefits related to this tax position, partially offset by an $<ix:nonFraction unitRef="usd" contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDUwNDM_a7c31dac-6454-4248-800e-08f5110a92ee">11</ix:nonFraction> million deferred federal benefit for state taxes.  There was no impact to our condensed consolidated statement of earnings for the three months ended March 31, 2023.  For further discussion of our former investment in JUUL, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our total unrecognized tax benefits were $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5OTM_f304ad9f-201c-4919-ae81-d563406a94cb">460</ix:nonFraction> million.  The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at March&#160;31, 2023, was $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5NjA_a19398a1-f838-4ccd-bdbc-22f2d37b719e">44</ix:nonFraction> million, along with $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5Nzg_f5bf8e64-68e3-4a55-ac23-eb7e62c3bc7b">416</ix:nonFraction> million affecting deferred taxes.  The amount of unrecognized tax benefit that, if recognized, would impact the effective tax rate at December 31, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg4OTc_e743b31e-b837-431f-b7f0-388ca2825533">44</ix:nonFraction> million, along with $<ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5MTM_8900c578-b8c9-46da-83cb-92fadc9ddb4f">25</ix:nonFraction> million affecting deferred taxes.  Unrecognized tax benefits increased by $<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2MzkwMTU_6c8a6367-843c-4f77-a819-dff954c4fa52">391</ix:nonFraction> million from December&#160;31, 2022 due to the tax position established with respect to the character of losses from our former investment in JUUL as discussed above.</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the recognition of the approximate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231" decimals="-8" sign="-" name="mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU2MDM2MzI_dd61a6cf-e74d-498d-a29b-81a8e82f5c12">6.5</ix:nonFraction> billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ordinary loss for cash tax purposes discussed above, we expect to be subject to Corporate AMT in 2023.</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3NDU_58272858-2c9c-49b6-bf1c-9164ace92821" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzEtMi0xLTEtMjIzMTEw_6d523604-790d-4503-8d85-1916ed61f9b8">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to valuation allowance charged to income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="mo:ValuationAllowanceDeferredTaxAssetIncreaseInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzItMi0xLTEtMjIzMTEw_eb20cc36-14ce-4f7b-95ce-cb32291a2ee0">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases to valuation allowance credited to income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="mo:ValuationAllowanceDeferredTaxAssetDecreaseInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzMtMi0xLTEtMjIzMTEw_984ed798-fc0c-41a4-a564-9648e1590426">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="mo:ValuationAllowanceForeignCurrencyTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzQtMi0xLTEtMjQ3MDg3_5e86fe7d-ce07-4e84-a2a2-224a06a5d923">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzQtMi0xLTEtMjIzMTEw_6a2aa057-ddb7-4a40-875b-9f4c211f22e6">663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzUtMi0xLTEtMjIzMTEw_30bd93c2-a1fd-4c78-b928-284db5d68fb2">2,204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3Mzk_cf47b357-cc0f-42ae-9646-d4ab946b7ca8" escape="true">deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.  We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized.  We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence.  In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law.</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, we reduced the deferred tax asset and corresponding valuation allowance for the portion of our JUUL capital losses that is now part of our tax basis in the shares of a foreign subsidiary.  This outside basis difference of the foreign subsidiary is not recognized as a deferred tax asset since we do not expect the temporary difference to reverse in the foreseeable future.  The cumulative valuation allowance at March&#160;31, 2023 was primarily attributable to deferred tax assets recorded in connection with the portion of our JUUL capital losses that is now included in our tax basis in the shares of a domestic subsidiary and our investment in Cronos.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_103"></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxODE0Mjc_99285583-5d60-4232-a703-9312d07442af" continuedAt="icb04fed98479403fac831aee6dff0125" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="icb04fed98479403fac831aee6dff0125" continuedAt="i018d1a253d3542e2b99bcfbe6087e201"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and certain of our subsidiaries, including PM USA and USSTC, as well as our indemnitees and investees.  Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, income tax liability, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#8221;), claims for contribution and claims of competitors, shareholders or distributors.  Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases.  An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation.  Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars.  The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome.  In certain cases, plaintiffs claim that defendants&#8217; liability is joint and several.  In such cases, we may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment.  As a result, under certain circumstances, we may </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i018d1a253d3542e2b99bcfbe6087e201" continuedAt="i30631ef285cb44b3bfad16d326ea1528"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have to pay more than our proportionate share of any bonding- or judgment-related amounts.  Furthermore, in those cases where plaintiffs are successful, we also may be required to pay interest and attorneys&#8217; fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases.  This risk has been substantially reduced given that <ix:nonFraction unitRef="state" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="INF" name="mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDAxNzc_b9191f36-82b4-4f80-b6ac-e3a413a02ac2">47</ix:nonFraction> states and Puerto Rico limit the dollar amount of bonds or require no bond at all.  As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida&#8217;s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well.  Such challenges may include the applicability of state bond caps in federal court.  States, including Florida, also may seek to repeal or alter bond cap statutes through legislation.  Although we cannot predict the outcome of such challenges, it is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record provisions in our condensed consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.  At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i)&#160;management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii)&#160;management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii)&#160;accordingly, management has not provided any amounts in our condensed consolidated financial statements for unfavorable outcomes, if any.  Litigation defense costs are expensed as incurred.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved substantial success in managing litigation.  Nevertheless, litigation is subject to uncertainty and significant challenges remain.  It is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation.  We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts.  We have defended, and will continue to defend, vigorously against litigation challenges.  However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Judgments Paid and Provisions for Tobacco and Health (Including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation) and Certain Other Litigation Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:</span></div><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzcwMDY2_72cb086e-24ae-4f28-b1ae-a991ebe35a1f" continuedAt="i239bd7d29c5d4a1d909a0b6829f55384" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:63.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzItMS0xLTEtMjIzMTEw_bf36fbdd-543f-43e9-ba48-7f862e0fd96d">71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzItMy0xLTEtMjIzMTEw_584e439d-d60b-48a9-b498-1c6cd1bbf9d3">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax charges for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc84e48cf0c42249795f0fa77b9ea65_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzQtMS0xLTEtMjIzMTEw_cd52f2b3-0d5e-4c95-ab7c-2b50a714cd97">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39fde8db86346d7af0960b18bf2989e_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzQtMy0xLTEtMjIzMTEw_88c5187e-cafb-4290-9410-d7b04d5f2863">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder derivative lawsuits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea367655f1904de580fbb5fccfbc7804_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMS0xLTEtMjQ2OTc4_188b95cc-92e2-4fcf-9980-d4e015d8b7bc">98</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaacf9fe9d5240a3bd0459f2294eff52_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMy0xLTEtMjQ3MzU3_c6ff747d-b788-4a52-9f6e-66de1ddcd4cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related interest costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fe928fcc4f4ef5ad3b60f07ca10cc7_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMS0xLTEtMjIzMTEw_a07029b4-84bd-4b72-9b87-97c2a3fcd230">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2cceb11df14f4cad29de8cb80794bd_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMy0xLTEtMjIzMTEw_eeb2f145-0369-4a6a-ac91-abcc6d131018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzktMS0xLTEtMjIzMTEw_28be64a5-dc0d-4cdd-9cf6-9a3efb3843b1">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzktMy0xLTEtMjIzMTEw_80be75d2-9f19-4b74-a67a-789e03b6ec19">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at end of period</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzEwLTEtMS0xLTIyMzExMA_d48c3ceb-4383-425e-b97e-6e3c0bbb3f6a">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17705bcff8eb49498848597476b6a197_I20220331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzEwLTMtMS0xLTIyMzExMA_6ba38170-4275-49af-a7fd-0c1d5a9774fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> below for a discussion of the pending settlement of the federal and state shareholder derivative lawsuits.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities and other liabilities on our condensed consolidated balance sheets.  Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on our condensed consolidated statements of earnings.  Pre-tax charges for related interest costs were included in interest and other debt expense, net on our condensed consolidated statements of earnings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331" decimals="-6" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk0MTg_9d27c864-8588-4ab0-876c-d9cab9053cb3">963</ix:nonFraction> million and interest totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331" decimals="-6" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk0NTg_566b882e-2a76-4973-aa60-01a344903790">231</ix:nonFraction> million as of March 31, 2023.  These amounts include payments for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny judgments (and related costs and fees) totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331" decimals="-6" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk1OTk_e46e12ef-4419-4f59-a588-c7c8b2e2b152">436</ix:nonFraction> million and related interest totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331" decimals="-6" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk2NDc_cfb787f2-6ef0-49cc-b1fa-1acc90aae1be">60</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i30631ef285cb44b3bfad16d326ea1528" continuedAt="ia7c2ff2e28ca43b1a68c0c04292313be"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security for Judgments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain stays of judgments pending appeal, PM USA has posted various forms of security.  As of March 31, 2023, PM USA has posted appeal bonds totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i66f2eaac69ca4a1e9412b845d82e98f9_I20230331" decimals="-6" name="mo:LitigationEscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk4NDY_4e71609f-66d7-4eb5-b897-7e577e612c5c">46</ix:nonFraction> million, which have been collateralized with restricted cash and are included in assets on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Types and Number of U.S. Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims related to tobacco products generally fall within the following categories: (i)&#160;smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii)&#160;health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv)&#160;other tobacco-related litigation described below.  Plaintiffs&#8217; theories of recovery and the defenses raised in tobacco-related litigation are discussed below.</span></div><ix:continuation id="i239bd7d29c5d4a1d909a0b6829f55384" continuedAt="i9323b157676743a7975427dd9e809620"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the number of certain tobacco-related cases pending in the United States against us as of:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 24, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Smoking and Health Cases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i658eb60878114979945a034aa6b1706f_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtMS0xLTEtMjIzMTEw_1ca55db2-77fd-405e-982f-27ce365a8b5b">167</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i8f59e571a0db45e8b6ec28bace62543f_I20220425" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtMy0xLTEtMjIzMTEw_3aa813ea-c0eb-410c-9d7f-85caa6548d7b">163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i2d2aadde9431454a847f57038a8a9480_I20210426" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtNS0xLTEtMjM4NDA5_ebc44f25-0cd4-4503-96a5-f31a21f665d7">162</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Care Cost Recovery Actions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i264d8c165e0f471f82f66d6e65418cff_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItMS0xLTEtMjIzMTEw_4421a393-5d62-4f70-85ed-e6edfe255357">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i22a937a6e7e14fdfacea6ad40290a42f_I20220425" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItMy0xLTEtMjIzMTEw_5d1f5fd8-8fdb-4efa-90bc-92dea05848c5">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i61f461a1aa5d4ee792394582b58b95ac_I20210426" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItNS0xLTEtMjM4NDEz_20e78235-dd19-46d7-8b61-ef741e280545">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-vapor Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtMS0xLTEtMjIzMTEw_97f22db0-491b-4ff6-9f91-d105db1ef3b0">5,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i67ca21fd598f4791b318ee5cabcbed5d_I20220425" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtMy0xLTEtMjIzMTEw_c095b8cb-9a99-47f3-9467-816fc579ddaf">3,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="iac90a0bb5f3f4b2f934b8f25141d8e55_I20210426" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtNS0xLTEtMjM4NDE3_779c2edd-ccff-4b8d-acf5-79bec1d5dd4d">2,150</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tobacco-Related Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtMS0xLTEtMjIzMTEw_f0c77a15-c583-40ad-a415-a5c95d1ad798">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="ia0a4f7f89b7241328632d436bff2aa5f_I20220425" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtMy0xLTEtMjIzMTEw_c97c3310-fd83-46af-9849-926f1c1bb0f6">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i01034fcbdec149c4be2d97e5b30b1d64_I20210426" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtNS0xLTEtMjM4NDIy_cea7806d-fe5a-4d67-87fa-8a8d63727361">3</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes as of April 24, 2023, <ix:nonFraction unitRef="claim" contextRef="i8fcf35d29f7e417fa73e1d1a62215cc3_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5MDU_1cff2ed2-bca2-43f2-9465-cb5a7f515f6a">19</ix:nonFraction> cases filed in Illinois, <ix:nonFraction unitRef="claim" contextRef="ie745a29b163b4a30b640a432516cbc0a_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5MzQ_43237601-a7fc-47fa-bcec-e1487a3f781c">22</ix:nonFraction> cases filed in New Mexico, <ix:nonFraction unitRef="claim" contextRef="i137abf0db81a4ec799690639f244c055_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5NjU_c237bbf5-8549-4826-ad95-a329421d2b30">43</ix:nonFraction> cases filed in Massachusetts and <ix:nonFraction unitRef="claim" contextRef="ib42253bd8d894b90ac70f97908963886_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTMwMDI_d170c43f-42a3-4275-bc92-53ecfe8a020d">46</ix:nonFraction> non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cases filed in Florida.  Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">case (these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> progeny cases are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  Also does not include <ix:nonFraction unitRef="case" contextRef="ib2d977c5bff94d44bd1a0a77dfc89b1c_D20230424-20230424" decimals="INF" name="mo:LossContingencyNumberOfCases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTMzNDI_4c388e58-9d48-4927-acde-582110aecf1e">1,390</ix:nonFraction> cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (&#8220;ETS&#8221;).  The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Broin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages.  Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.</span></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, <ix:nonFraction unitRef="lawsuit" contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424" decimals="INF" name="mo:LossContingencyClassActionLawsuit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQwNjE_e8632094-23ce-4e98-b90f-08e6dd5132ce">57</ix:nonFraction> class action lawsuits, <ix:nonFraction unitRef="claim" contextRef="i825d494d8ad74328a30cf05aeba68eeb_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQwODg_5084189f-9d8d-43d9-a373-6c1cd2bed9f3">3,746</ix:nonFraction> individual lawsuits and <ix:nonFraction unitRef="claim" contextRef="id749f16e66d343708ca58160babcbc3f_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQxMTY_7314b1dc-0fc8-4c19-a836-39091109c16d">1467</ix:nonFraction> &#8220;third party&#8221; lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.  The <ix:nonFraction unitRef="lawsuit" contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424" decimals="INF" name="mo:LossContingencyClassActionLawsuit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQzNTQ_e8632094-23ce-4e98-b90f-08e6dd5132ce">57</ix:nonFraction> class action lawsuits include <ix:nonFraction unitRef="claim" contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424" decimals="INF" name="mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQzODg_109baece-58b2-4c50-aada-f76c3c001309">32</ix:nonFraction> cases in the Northern District of California (&#8220;Multidistrict Litigation&#8221; or &#8220;MDL&#8221;) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, <ix:nonFraction unitRef="case" contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424" decimals="INF" name="mo:LossContingencyNumberOfInactiveCases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQ2OTQ_dc0b27b4-61ef-45ed-bc76-25701ee39aab">one</ix:nonFraction> inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and <ix:nonFraction unitRef="case" contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424" decimals="INF" name="mo:LossContingencyNumberOfInactiveClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQ4MzU_282f5f5b-241d-40de-b007-bc48210353a9">two</ix:nonFraction> inactive class action lawsuits alleging that use of the terms &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Tobacco-Related Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, (i) Altria is named as a defendant in <ix:nonFraction unitRef="claim" contextRef="i029cd62ef0e14cf7ba91174c0f57d16d_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTczNDg_0852aa5e-490f-489e-ad7a-bd357c21576a">three</ix:nonFraction> e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in <ix:nonFraction unitRef="claim" contextRef="i7c1a190fb9ad430bbd01dfd78341ef13_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc0Mjk_bceb44aa-23d0-4b22-bfa8-99ef07a07d9d">10</ix:nonFraction> health care cost recovery actions in Canada, <ix:nonFraction unitRef="claim" contextRef="ie7914aaf2c23404eaa505be9823413f4_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc0Nzg_90100d70-0b8c-4b9b-bb76-9713b27ee451">eight</ix:nonFraction> of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in <ix:nonFraction unitRef="claim" contextRef="i6905d6541f1a41eaa7e544fdf55f3804_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc1Nzk_8b7716a6-f400-47b0-af8c-b82eba88283e">seven</ix:nonFraction> smoking and health class actions filed in various Canadian provinces.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement (defined below) between Altria and Philip Morris International Inc. (&#8220;PMI&#8221;) that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tobacco-Related Cases Set for Trial: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, <ix:nonFraction unitRef="case" contextRef="i170c4207fac14878911ccdae6ebe6376_I20230424" decimals="INF" name="mo:LossContingencyNumberofCasesSetforTrial" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5MzE_47bdbc69-2189-47e4-9ad8-e2d6f06cfe14">five</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases, <ix:nonFraction unitRef="case" contextRef="ibff416dc4d4943ef96c7732293bcfb55_I20230424" decimals="INF" name="mo:LossContingencyNumberofCasesSetforTrial" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5NTY_0c1bcf4c-6570-4427-a3a5-4621ac6c48ff">four</ix:nonFraction> individual smoking and health cases and <ix:nonFraction unitRef="case" contextRef="i471e8ab3decf44de9984da88cabdc693_I20230424" decimals="INF" name="mo:LossContingencyNumberofCasesSetforTrial" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5OTk_707ec33b-5640-4bd9-9505-e073310d8baf">one</ix:nonFraction> e-vapor case are set for trial through June 30, 2023.  Trial dates are subject to change.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1999, excluding the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases (separately discussed below), verdicts have been returned in <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecided" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgyMjQ_bc7dd4d7-54ff-4f73-9240-d66530282a88">75</ix:nonFraction> tobacco-related cases in which PM USA was a defendant.  Verdicts in favor of PM USA and other defendants were returned in <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNTA_f245b205-f97e-4618-97be-73837fff6bd3">47</ix:nonFraction> of the <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecided" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNjE_bc7dd4d7-54ff-4f73-9240-d66530282a88">75</ix:nonFraction> cases.  These <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNzk_f245b205-f97e-4618-97be-73837fff6bd3">47</ix:nonFraction> cases were tried in Alaska (<ix:nonFraction unitRef="case" contextRef="ic56af47d5d86478d9aa935fb4c5fab66_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0MTE_95258588-f1f7-4aa8-b492-e1022e11c09b">1</ix:nonFraction>), California (<ix:nonFraction unitRef="case" contextRef="ic48616efb2c747e4ad07dbc20dd6318a_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0Mjk_0c7c59e4-9083-4f10-abbe-a07289f3033e">7</ix:nonFraction>), Connecticut (<ix:nonFraction unitRef="case" contextRef="i7915e288e3e547a89d5b90c15b002d85_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0NDg_a3d5a467-b3da-4451-bac0-b5c0a135b331">1</ix:nonFraction>), Florida (<ix:nonFraction unitRef="case" contextRef="iaa7d7842072042029b37c8e58321a790_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0NjM_a358b936-fccd-42d1-9de9-ae5f786945ba">10</ix:nonFraction>), Louisiana (<ix:nonFraction unitRef="case" contextRef="i9c1acd96e2d247de8e9ffbda07748403_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0ODA_24ecd4b7-9ac0-4151-a482-765d010a9411">1</ix:nonFraction>), Massachusetts (<ix:nonFraction unitRef="case" contextRef="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MDE_947c39b9-a710-463a-ada1-4a8c89d51c92">6</ix:nonFraction>), Mississippi (<ix:nonFraction unitRef="case" contextRef="i00334a51fb834684ac1bef68ec6e4629_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MjA_09a63479-8e0c-4842-b446-8d105dc8c87c">1</ix:nonFraction>), Missouri (<ix:nonFraction unitRef="case" contextRef="ie24403f03a804dd3a1742ecde12c32af_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MzY_b62b07ab-4e82-4971-bf20-b21c13a4a751">4</ix:nonFraction>), New Hampshire (<ix:nonFraction unitRef="case" contextRef="iac4943d0a50142e0a04534ccdc87f14f_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1NTc_77eda663-1c57-41d5-a26a-6f4b9575a55d">1</ix:nonFraction>), New Mexico (<ix:nonFraction unitRef="case" contextRef="ifcfafebb53104f778986825aecf004e5_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMTE5ODM_cf99878e-612e-451f-9b4e-8c2472f596bd">1</ix:nonFraction>), New Jersey (<ix:nonFraction unitRef="case" contextRef="i0a9b420fbf06470aa983786428710658_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1NzU_8171b79a-aa00-4ec0-a274-33ee79ccbed9">1</ix:nonFraction>), New York (<ix:nonFraction unitRef="case" contextRef="i6fca4395dd774138b948e3ba799dee3a_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1OTE_959f3376-0034-46ba-9234-be33a2679383">5</ix:nonFraction>), Ohio (<ix:nonFraction unitRef="case" contextRef="id8a13caf9c594420a4982e05e5743e96_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2MDM_9ec3bde5-7176-44d7-a069-dfae29ee97f5">2</ix:nonFraction>), Pennsylvania (<ix:nonFraction unitRef="case" contextRef="idf88f4821d864d0eb1215800a0c994a3_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2MjM_52a95a8a-4f23-4df4-a4b6-76e6d9cd420f">1</ix:nonFraction>), Rhode Island (<ix:nonFraction unitRef="case" contextRef="i47eb567f9bbe4ee9b586eb7e4364b47d_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2NDM_ae843161-8fad-421f-b823-0a065f9c89f5">1</ix:nonFraction>), Tennessee (<ix:nonFraction unitRef="case" contextRef="i9cd612643df6404aa5c549ad46d4bb3f_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2NjA_6ea1e41c-b7c9-41a5-9a13-780ca5a51ee5">2</ix:nonFraction>) and West Virginia (<ix:nonFraction unitRef="case" contextRef="ib83ad46dbea44d23905da42d1ade08e9_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2ODQ_d53accb1-535e-4ab2-96ad-e2966c364db9">2</ix:nonFraction>).  <ix:nonFraction unitRef="case" contextRef="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424" decimals="INF" name="mo:LossContingencyVerdictReversedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2OTE_c8a2099e-e087-4b69-a6d6-c7b2bb7ae4c6">One</ix:nonFraction> case in Massachusetts, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Main</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where the verdict was initially returned in favor of PM USA, was reversed on appeal and remanded for a new trial.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedUnfavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg4NDU_65e64d56-3f2a-471f-a830-0c7b8a656213">28</ix:nonFraction> non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs, <ix:nonFraction unitRef="case" contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424" decimals="INF" name="mo:LossContingencyClaimsResolvedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg5Mjk_3e7fc2cb-f54e-4cc1-a1a4-9a31018e80ba">24</ix:nonFraction> have reached final resolution.</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Liti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">gation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of verdicts in state and federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA as of April 24, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smoking and Health Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="ia7c2ff2e28ca43b1a68c0c04292313be" continuedAt="i4f374e51e3f040f7a411597f5d2ee28d"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes.  Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief.  Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny smoking and health cases pending during 2023 (or recently concluded) in which a verdict was returned in favor of plaintiff and against PM USA.  Charts listing certain verdicts for plaintiffs in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases can be found in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Woodley: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $<ix:nonFraction unitRef="usd" contextRef="i87ca3cff2798450a8d43bf076838e36b_I20230228" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzE2NDkyNjc2NjQzNDI_552e6f4d-c185-47c8-8c6c-cff7d64dc3ae">5</ix:nonFraction> million in compensatory damages.  There was <ix:nonFraction unitRef="usd" contextRef="i87ca3cff2798450a8d43bf076838e36b_I20230228" decimals="INF" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzE2NDkyNjc2NjQzNTc_1d349b47-884f-4fd6-833b-40ea4f1a3de6">no</ix:nonFraction> claim for punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mendez</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA and R.J. Reynolds Tobacco Company awarding approximately $<ix:nonFraction unitRef="usd" contextRef="i3d071c49dafe4c0ab73b29c76d6a6c88_I20220930" decimals="-5" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA3NDg_9e72e3e3-6e16-4179-94d9-5d953526e2e1">4.5</ix:nonFraction> million in compensatory damages and allocating <ix:nonFraction unitRef="number" contextRef="ic68023ac01c34100962358f7742dc848_I20220930" decimals="2" name="mo:LossContingencyFaultAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA3OTE_e002b700-a467-43aa-8ec9-538cf154d1f5">13</ix:nonFraction>% of the fault to PM USA.  After applying comparative fault, PM USA&#8217;s portion of the compensatory damages is less than $<ix:nonFraction unitRef="usd" contextRef="ic68023ac01c34100962358f7742dc848_I20220930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA5MTI_ff628a3c-93e6-44e6-b7cc-32f090f42948">1</ix:nonFraction> million.  There was <ix:nonFraction unitRef="usd" contextRef="ic68023ac01c34100962358f7742dc848_I20220930" decimals="INF" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA5Mjg_72b517bf-bed1-4d1b-a70a-33ecf8d16a6e">no</ix:nonFraction> claim for punitive damages.  The trial court denied PM USA&#8217;s post-trial motions, and both parties appealed.  The parties subsequently reached an agreement to resolve plaintiff&#8217;s claims.  As a result, both the appeal and cross-appeal have been dismissed and the case is concluded.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fontaine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $<ix:nonFraction unitRef="usd" contextRef="i55d5c15b72454fe3ab6a65a94179d459_I20220930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjExOTM_0d8e49a5-f0d1-494d-a7a8-ae82fa4e3ea1">8</ix:nonFraction> million in compensatory damages and $<ix:nonFraction unitRef="usd" contextRef="i55d5c15b72454fe3ab6a65a94179d459_I20220930" decimals="-9" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjEyMjU_f6a57335-75a8-476a-a9b1-508bef5bdbaa">1</ix:nonFraction> billion in punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Greene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $<ix:nonFraction unitRef="usd" contextRef="i4caa1be6dee14b7da122d03361a0b36e_I20190930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjIyMTQ_082d8152-d252-45b0-add3-170b073f754a">10</ix:nonFraction> million in compensatory damages.  In May 2020, the court ruled on plaintiffs&#8217; remaining claim and trebled the compensatory damages award to approximately $<ix:nonFraction unitRef="usd" contextRef="ibce2ab3da83c4ec2b9d87386b1b038ec_I20200531" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjIzNjQ_2c6c9374-8527-4ab7-9349-3aa1ef3d99c1">30</ix:nonFraction> million.  In February 2021, the trial court awarded plaintiffs attorneys&#8217; fees and costs in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ic4312a6e41a645e78741c53abfb9b9b7_I20210228" decimals="-5" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjI0ODA_82fb998d-96d1-46e0-bb9e-b5fa2a3904d2">2.3</ix:nonFraction> million.  In July 2021, following denial of PM USA&#8217;s post-trial motions, PM USA appealed the judgment to the Appeals Court of Massachusetts.  In September 2022, the Massachusetts Supreme Judicial Court issued an order taking jurisdiction over the appeal and heard oral arguments in January 2023.  The appeal remains pending.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Class Action: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2000, in the second phase of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $<ix:nonFraction unitRef="usd" contextRef="id14f18627ded4c498559f94480d4c268_I20000731" decimals="-9" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjMxNzM_6a92ff0e-8c28-48b8-9674-731b7a01bf71">145</ix:nonFraction> billion against various defendants, including $<ix:nonFraction unitRef="usd" contextRef="i1878a54117dd41c49cbfbb12813f60f6_I20000731" decimals="-9" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjMyMTU_59f9db7b-be2d-4a5e-b62d-f1ba6ea733d5">74</ix:nonFraction> billion against PM USA.  Following entry of judgment, PM USA appealed.  In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class.  Plaintiffs petitioned the Florida Supreme Court for further review.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within <ix:nonNumeric contextRef="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731" name="mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjM3Nzk_72c49fa6-1a79-494f-ae90-fc9c672d51df">one year</ix:nonNumeric> of issuance of the mandate.  The court further declared the following Phase I findings are entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect in such individual actions brought within <ix:nonNumeric contextRef="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731" name="mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjM5NDg_d3d99487-0898-46f0-b051-41ec40578d7b">one year</ix:nonNumeric> of the issuance of the mandate: (i)&#160;that smoking causes various diseases; (ii)&#160;that nicotine in cigarettes is addictive; (iii)&#160;that defendants&#8217; cigarettes were defective and unreasonably dangerous; (iv)&#160;that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v)&#160;that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi)&#160;that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii)&#160;that all defendants sold or supplied cigarettes that were defective; and (viii)&#160;that defendants were negligent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion.  In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect by excluding finding (v)&#160;listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants.  In February 2008, the trial court decertified the class.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e Progeny Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deadline for filing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases expired in January 2008, at which point a total of approximately <ix:nonFraction unitRef="claim" contextRef="ie99b75df4d1c4a3e929e255970a683a0_I20080131" decimals="-2" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU2Nzc_88ab743f-20d8-4f21-960d-c26c54733073">9,300</ix:nonFraction> federal and state claims were pending.  As of April 24, 2023, approximately <ix:nonFraction unitRef="claim" contextRef="ic3f5b4ed913b42fe8a04502626591600_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU3NTk_f61c6e63-a9c5-4f61-99b4-d377a4a89916">551</ix:nonFraction> state court cases were </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i4f374e51e3f040f7a411597f5d2ee28d" continuedAt="ibdd361ae691540fc99aff475c7f4cdad"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending against PM USA or Altria asserting individual claims by or on behalf of approximately <ix:nonFraction unitRef="plantiff" contextRef="ibe1d211aa1a14a2e8f642c7b33db6494_D20230424-20230424" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU4ODA_6e1753e7-626e-4ea3-adab-3d07746f5479">705</ix:nonFraction> state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates.  The 2015 federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement resolved nearly all </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases pending in federal court as of the date of the agreement, and each case excluded from that agreement subsequently has been resolved.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, <ix:nonFraction unitRef="case" contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecided" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjYzMTE_25cabd18-62fc-425d-9257-c3a675ef136a">143</ix:nonFraction> federal and state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision.  <ix:nonFraction unitRef="case" contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedUnfavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY0NDU_862d1b49-fcee-4362-aa5e-9cffe012dd11">Seventy-nine</ix:nonFraction> verdicts were returned in favor of plaintiffs, and <ix:nonFraction unitRef="case" contextRef="i170c4207fac14878911ccdae6ebe6376_I20230424" decimals="INF" name="mo:LossContingencyUnfavorableVerdictsPendingReversed" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY1MDA_5e410283-4471-4aa3-bbab-598d6c36edea">five</ix:nonFraction> verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Calloway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oshinsky-Blacker,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McCoy, Mahfuz </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Neff</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.  In  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kaplan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McLaughlin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the punitive damages award was vacated on appeal and remanded for a new trial.  In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sommers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the trial court entered final judgment dismissing the plaintiff&#8217;s punitive damages claim with prejudice, and plaintiff appealed.  The Third District Court of Appeal affirmed the award and remanded for a new trial on entitlement to punitive damages and amount.  On remand, the trial court granted PM USA&#8217;s motion for summary judgment and entered final judgment dismissing the plaintiff&#8217;s punitive damages claim with prejudice, and plaintiff has appealed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="case" contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY5Njk_be87e32f-237b-4b96-a795-3e5cf19e0d46">Fifty-seven</ix:nonFraction> verdicts were returned in favor of PM USA, of which <ix:nonFraction unitRef="case" contextRef="i296abd7b36374cefa6b045a659376f32_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjcwMjU_5a13b0b9-c6d1-4a07-af38-bd9fff19f7f2">47</ix:nonFraction> were state cases.  In addition, there have been a number of mistrials, only some of which have resulted in new trials as of April 24, 2023.  The jury in <ix:nonFraction unitRef="case" contextRef="i12c6d88f04834b87aad507967fe72e0f_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjcxODQ_887a12e9-f501-4146-ac28-6af9c5f42958">one</ix:nonFraction> case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages.  Following appeals by the plaintiff and PM USA, the appellate court in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> affirmed the compensatory damages judgment against PM USA and granted a new trial with respect to punitive damages.  The plaintiff in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsequently filed a motion to voluntarily dismiss the punitive damages claim and to enter final judgment on the compensatory damages claim, which the court granted.  <ix:nonFraction unitRef="case" contextRef="i14e9bdff03c04990be62bbba97421122_D20230424-20230424" decimals="INF" name="mo:LossContingencyVerdictReversedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjc4NTc_1d36f499-ae1d-4254-a437-780f4be04b50">Three</ix:nonFraction> verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cohen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chacon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were returned in favor of PM USA were subsequently reversed for new trials.  Juries in <ix:nonFraction unitRef="case" contextRef="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424" decimals="INF" name="mo:LossContingencyZeroDamagesVerdicts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjc5ODk_0cffb315-c019-4eab-a150-d3aa32d0afbc">two</ix:nonFraction> cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Banks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) returned <ix:nonFraction unitRef="usd" contextRef="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424" decimals="INF" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgwMjc_abb10b99-7791-45a9-b6de-6307ae3867fa">zero</ix:nonFraction> damages verdicts in favor of PM USA.  Juries in <ix:nonFraction unitRef="case" contextRef="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424" decimals="INF" name="mo:LossContingencyZeroDamagesVerdictModified" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgwNzk_1c6c0949-40af-43d9-8462-49ed7a4cdf21">two</ix:nonFraction> other cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weingart</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hancock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) returned verdicts against PM USA awarding <ix:nonFraction unitRef="usd" contextRef="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424" decimals="INF" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgxNjA_3c429746-73a0-4ecb-b6d7-f6336c011c7b">no</ix:nonFraction> damages, but the trial court in each case decided to award plaintiffs damages.  <ix:nonFraction unitRef="case" contextRef="i019cbbd7765340719c2430dc78519295_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgyNDQ_d5bb71f7-cb86-475d-b7d7-8b8e73ca72d6">One</ix:nonFraction> case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pollari</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff.  Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgment in favor of the defendants.  <ix:nonFraction unitRef="case" contextRef="ia91a4fb22e6f45518c962f7f28ad376f_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedUnfavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg1MDA_03650793-dc39-478d-ab67-7873de642220">Three</ix:nonFraction> cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gloger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rintoul </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duignan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs.  A post-trial appeal is pending in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duignan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The verdicts in the retrials in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gloger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rintoul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were reversed upon appeal and remanded for new trials.  <ix:nonFraction unitRef="case" contextRef="i300ff9979645484a96be74f4cbad94a6_D20230424-20230424" decimals="INF" name="mo:LossContingencyClaimsDecidedFavorableNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg4MjU_94b8e49e-e4e7-47cd-b7c6-3c1333407104">Two</ix:nonFraction> cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freeman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.  <ix:nonFraction unitRef="claim" contextRef="i0df68acf1505499c841787fe26736dbf_D20230424-20230424" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg5Njc_c17980d7-8587-4f5b-b3b7-d7209ae65984">One</ix:nonFraction> case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R. Douglas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was dismissed with prejudice following a verdict in favor of plaintiff.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below list the verdicts and post-trial developments in certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs.  The first chart lists cases that are pending as of April 24, 2023 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the second chart lists cases that have concluded in the past 12 months.  Unless otherwise noted for a particular case, the jury&#8217;s award for compensatory damages will not be reduced by any finding of plaintiff&#8217;s comparative fault.  Further, the damages noted reflect adjustments based on post-trial or appellate rulings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References below to &#8220;R.J. Reynolds,&#8221; &#8220;Lorillard&#8221; and &#8220;Liggett Group&#8221; are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.</span></div><ix:continuation id="i9323b157676743a7975427dd9e809620" continuedAt="i7e4a5981d2b142e5af2dd2b5880f4f08"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently Pending Engle Cases with Verdicts Against PM USA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hoffman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i94aba2dfe6f940fdaa35b3888c250151_I20230131" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZjA2ZDYxNjgxZjU0NDUzNWFjN2ZkY2ZhNzAxMDU4MjRfNA_8b8115d0-2f98-4efc-9264-be04e09567ea">5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i2dccdeba725b4dc78842d507b0a1991f_I20230131" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZjA2ZDYxNjgxZjU0NDUzNWFjN2ZkY2ZhNzAxMDU4MjRfOA_98efe92f-1383-45f3-bffb-cf2f40b38bfa">3</ix:nonFraction> million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2dccdeba725b4dc78842d507b0a1991f_I20230131" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NTVlM2VhMzY3YjdmNGZkMWE3YWVmOTc5M2U2NjJhNzNfNA_df13e3ae-f71d-45cb-9580-af086663f0ad">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendant to First District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Levine</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i033be350699e4706b3c6851d29b8b749_I20220930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzItNC0xLTEtMjIzMzkxL3RleHRyZWdpb246YTM0Nzc4Mjc5YTU0NGY5Yzk1Y2Y1NDI3M2U0NTk0OTZfNA_e105494f-e607-4bb2-a5e3-305e161199ee">1</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i17d488c73bb644d1bc0a479f11fbe8b4_I20220930" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzItNS0xLTEtMjIzMzkxL3RleHRyZWdpb246N2I4YmU5MjEzOGJjNGViMDkzMGM5NjE2ZTQwYmE1YjdfNA_0ca6b7c2-8136-4688-a497-ccba1855fac4">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeals by defendants and plaintiff to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Schertzer</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i28e721d76a5f489fbcdc920d74435591_I20220430" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzMtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246N2MyOThjODgzY2ZlNGVhNGFiYTA4ZTNjNWViMjkzMmNfNA_391a4c14-7714-43dc-b3ee-fbf5d3b19a6e">3</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ief95ac0f1b534c56a693a3370c8c913f_I20220430" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzMtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NTMyNWE4MzdkYTViNGI4NGE3MWFkOWY0MTI2YzczOTNfNA_9f606cc0-3521-4d8d-b58d-a405320e6c61">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendants to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lipp</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i017bc393a586425685f5c81ac9bbd36a_I20210930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzQtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MzllMzI1YjE5OTdjNDIyM2JmY2QwMzA1ZDliMWY0ZTRfNA_e664777a-eb3b-49cc-9044-dd9966ba2985">15</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6191346a68624c76936656e4f4e55fbe_I20210930" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzQtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MWMxNTMyYWIxZTJlNGFjM2FhNjA0NTc0ZWJhYjdjYWRfNA_562b0e2a-29d0-4a23-8e70-d64085443d68">28</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Garcia</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iadd63ebeb9da4c4e80b4d08ae9800f7b_I20210531" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Yzk5MzM5ZWE1MjkxNGM2ZTk5ZDQ3OTY3NWE1OWEyMjNfNA_8298bec9-6ce1-4809-a2a5-3b94f9c5da40">6</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i8d9ba1b77468485198eac867421125fd_I20210531" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Yzk5MzM5ZWE1MjkxNGM2ZTk5ZDQ3OTY3NWE1OWEyMjNfOA_ccf9b72f-a6f0-46ba-9f69-48a2e4dd719b">3</ix:nonFraction> million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i8d9ba1b77468485198eac867421125fd_I20210531" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246YWJjZGJiMTcxZTA3NDRmZWFlZWU4NDMwNWNiYmRhMzJfNA_f35d480b-00fc-42eb-a0f1-8a08387df056">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="ibdd361ae691540fc99aff475c7f4cdad" continuedAt="i6890056c70cf43e6936b11d1fe2bf81b"><ix:continuation id="i7e4a5981d2b142e5af2dd2b5880f4f08"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Duignan</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pinellas</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3adaf5ea11094a4cb8c711a96d4ae229_I20200229" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzYtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZmI1NjNkMGVlMjYwNDkyMDhmYTVhNWY5NDA4MmQ1OWFfNA_6e38f97a-70e4-4d02-aac7-c624ee4bb8cd">3</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib02c207b06774fd59c5484ff5302f756_I20200229" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzYtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MmVhZTIzNjgyMDNhNDg4ODk2OWYzNzliYzdiYTNhMzhfNA_b7ec91e5-d149-4981-89af-0126425878f7">12</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Supreme Court quashed the Second District Court of Appeal&#8217;s affirmation of  judgment against the defendants and remanded the case for reconsideration in light of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McCall</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$<ix:nonFraction unitRef="usd" contextRef="ia9461abd7dc04b78b0217e87d27ace97_I20190331" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MmNmOTlkYzdmZDg5NDc0M2ExMDYzZGRiMTM2YTFmZDNfNQ_d58c7b5b-c602-4728-bcf5-ea13965b1003">1</ix:nonFraction>&#160;million (&lt;$<ix:nonFraction unitRef="usd" contextRef="ia9beea181cf140f9adfcebd371d4abb8_I20190331" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MmNmOTlkYzdmZDg5NDc0M2ExMDYzZGRiMTM2YTFmZDNfMTA_93cf517f-8df4-4058-a0cf-cd389a7f4ee2">1</ix:nonFraction>&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia9beea181cf140f9adfcebd371d4abb8_I20190331" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NDc4YzQ1ODA0NzZlNGJjMjlmY2VlODZmODVhYTQ2MGRfNA_19d1ea81-ec28-4565-9237-7db468a08f63">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New trial on punitive damages is set for June 2023.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chadwell</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6d98007769944dc9b0168ff938a9dcc1_I20180930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzgtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MThiMTI5NWUzN2Q1NDdmN2IyMDlkZWUyODljNzVkZTRfNA_1c50ad53-fda6-4145-881c-69ca7d947742">2</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i11254f9a2eb24f83821b5815368b8e08_I20180930" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzgtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246YzJmMDQzOGJjOWU1NDAwOGFlNjkwMTA3OTA4YWJmNjNfNA_ee8f9d92-8c2d-46d6-94ac-ed130a72dc7b">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal has ordered supplemental briefing in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kaplan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McLaughlin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i72830ce222554341a4a9785d1ab879bd_I20180731" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzktNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Y2JlNThkYWRlYzBjNGFkM2JkYWE1ZTM4ZDQ2ODU1OTJfNA_6cafe0a5-74ac-4484-9e11-a536b89927e6">2</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i700cb3ce10984b889870b8488b2700b5_I20180731" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzktNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NWYyMGRjZWRhOGNkNDVjMDliZTM5YmE0Nzg3YmMyZWFfNA_ed60daac-b141-451f-a468-8b111c2feed4">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Florida Supreme Court vacated the punitive damages award in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sheffield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The Fourth District Court of Appeals affirmed the compensatory damages award and granted a new trial on punitive damages.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cooper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="idc078b33f7684f5296fa7045d4b552eb_I20150930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTQtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOmY2ODBjMzM2NWNiNjRlYWM4ZmFlMjEwMzg3MWVlZDRjXzQ_bb7ec701-dd4a-4993-880e-be6394483d37">5</ix:nonFraction>&#160;million </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&lt;$<ix:nonFraction unitRef="usd" contextRef="i940de6589e0b4ee69091b883a32e09d1_I20150930" decimals="-6" name="mo:LossContingencyCompensatoryDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTQtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOmY2ODBjMzM2NWNiNjRlYWM4ZmFlMjEwMzg3MWVlZDRjXzEw_843c8c94-3b91-4a89-9480-426f14d444d8">1</ix:nonFraction>&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i940de6589e0b4ee69091b883a32e09d1_I20150930" decimals="-6" name="mo:LossContingencyPunitiveDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTUtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOjI2M2IxOWZkZWRkZDQ2ZDk4ZGQzNTQ0MTYzZTBmNDk1XzQ_0af84a33-ea8f-40ba-8271-1b1889c903b4">0</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal affirmed the compensatory damages award and granted a new trial on punitive damages.</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PM USA&#8217;s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff&#8217;s verdict following a retrial of an initial verdict in favor of plaintiff.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> PM USA is not a defendant in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle Progeny Appellate Issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle Cases Concluded Within Past 12 Months </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrual Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Amount for Damages (if any)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Miller</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$<ix:nonFraction unitRef="usd" contextRef="ic81bb1c5437a44efb6f55698d59aec06_D20221201-20221231" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzEtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MGI3NTEzYjFhNjAyNGFiMmJiY2U0MzE2N2I5YjMyYWVfNQ_8d288b7c-ca9e-4861-b90a-8395845b6ff5">1</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tuttle</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$<ix:nonFraction unitRef="usd" contextRef="id2f8c13313ac4e01af20b71a719f8da6_D20221001-20221031" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzItNS0xLTEtMjIzMzkxL3RleHRyZWdpb246N2FlNzZjOThlMGIzNDVkNDkxN2VmZGQ2ZGQ2ZTRhZmFfNQ_215cbf62-631e-48e1-bf1e-3906504305d8">1</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cuddihee</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2680e01eb0d943bc86816de660361441_D20220601-20220630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzMtNS0xLTEtMjIzMzkx_566f8f3e-7dc9-4a2f-b3ed-9ae0ec10b3fa">2</ix:nonFraction> million</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Holliman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic7fbbab892b44cfeaa59dc1d86841818_D20230101-20230131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzQtNS0xLTEtMjIzMzkx_2245bd4f-6d65-49d2-a192-c4c8dd5a0a82">3</ix:nonFraction> million</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">D. Brown</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2015</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6234f79724d344e6bab36b0693d39350_D20220801-20220831" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzUtNS0xLTEtMjIzMzkx_38382131-64a0-450d-919f-cdcb9062e6ab">5</ix:nonFraction> million</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td></tr></table></div></ix:continuation><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Appellate Issues: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appellate decisions in the following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases may have wide application to other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mary Sheffield v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#8217;s District Courts of Appeal finding that the 1999 amendments to Florida&#8217;s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Linda Prentice v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#8217;s District Courts of Appeal finding that in order for an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiff to prevail on fraudulent concealment and conspiracy claims, plaintiff must prove that the smoker relied to his or her detriment on a statement that concealed or omitted material information about the health risks or addictiveness of smoking.  The Florida Supreme Court declined to revisit its prior decisions giving preclusive effect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase I findings, described above in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Florida Bond Statute: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009, Florida amended its existing bond cap statute by adding a $<ix:nonFraction unitRef="usd" contextRef="idd5c8372783a4bf6bc692e11c709e409_I20090630" decimals="INF" name="mo:MaximumBondForAllDefendants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDU3NzI_61bddecd-938f-484b-b63c-cdc9b53c018b">200</ix:nonFraction> million bond cap that applies to all state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny lawsuits in the aggregate and establishes individual bond caps for individual </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in amounts that vary depending on the number of judgments in effect at a given time.  Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i6890056c70cf43e6936b11d1fe2bf81b" continuedAt="i0a24090a1e5d4ae297d1a94afeed13b6"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases tried in federal court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Smoking and Health Class Actions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts.  In general, these cases have purported to be brought on behalf of residents of a particular state or states (although a few cases have purported to be nationwide in scope) and have raised addiction claims and, in many cases, claims of physical injury as well.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class certification has been denied or reversed by courts in <ix:nonFraction unitRef="case" contextRef="id50f063bff6144ba9d1c3bae28cb30f0_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcwNTk_e3696b5d-f351-4be6-9642-806dec166c7d">61</ix:nonFraction> smoking and health class actions involving PM USA in Arkansas (<ix:nonFraction unitRef="case" contextRef="i40081f1b6885464e9d63334981371279_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxMjY_fbbab39c-a8c6-4c77-9904-878e0c34e790">1</ix:nonFraction>), California (<ix:nonFraction unitRef="case" contextRef="i7b18f9afe75a43fca6bafec8103beadd_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxNDQ_b19f8472-fbdc-43f9-be7c-bcf6c858ab0f">1</ix:nonFraction>), Delaware (<ix:nonFraction unitRef="case" contextRef="i0dd7051cbe8249a892d2558422f99b31_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxNjA_6757f074-ae06-49ad-b220-8cb921510a9c">1</ix:nonFraction>), the District of Columbia (<ix:nonFraction unitRef="case" contextRef="i0060f473b507459fa695d7f7e862b35c_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxOTI_e9c7e324-b091-49d6-84d1-48d34f952d7b">2</ix:nonFraction>), Florida (<ix:nonFraction unitRef="case" contextRef="iff2761f6e6a84a72bf9453a2877514c2_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMDc_215ce023-1f72-441e-bf04-2375db689e21">2</ix:nonFraction>), Illinois (<ix:nonFraction unitRef="case" contextRef="iec26b5b167f64b948eb60bda8d571759_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMjM_9369c00b-09f0-4a64-ba44-9ee4b7a147d0">3</ix:nonFraction>), Iowa (<ix:nonFraction unitRef="case" contextRef="i2140db0c9f194d7598ef7666ded56ffc_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMzU_bbcf1baa-f408-4731-aee6-34ec33a21714">1</ix:nonFraction>), Kansas (<ix:nonFraction unitRef="case" contextRef="i73f23159f88b43b1ad03568c321c2d5c_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyNDk_ae1e7fb3-7d95-4df7-bb64-a24aa1c3acda">1</ix:nonFraction>), Louisiana (<ix:nonFraction unitRef="case" contextRef="i601e952e30854bf9b7959748729929fb_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyNjY_917acf08-5a54-4d41-aeda-4569a3c08630">1</ix:nonFraction>), Maryland (<ix:nonFraction unitRef="case" contextRef="ib9739c01de394810956d3ca2bb685830_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyODI_bc83bb81-4724-4fd6-b0f7-8888e0e796ad">1</ix:nonFraction>), Michigan (<ix:nonFraction unitRef="case" contextRef="ifc14a32dde064ccdae95f715a64a3ec8_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyOTg_86c3212e-77d4-401b-8640-c67881c49907">1</ix:nonFraction>), Minnesota (<ix:nonFraction unitRef="case" contextRef="icac1b63e2f934ed9a1ea24d4138a8bc9_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczMTU_bfa522f1-a2b8-4326-a1cd-3af665a616ae">1</ix:nonFraction>), Nevada (<ix:nonFraction unitRef="case" contextRef="i487924c2b1964c8e814c86ad00645620_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczMjk_f3db36b9-465b-4bf9-b350-34201d7fee15">29</ix:nonFraction>), New Jersey (<ix:nonFraction unitRef="case" contextRef="i77ddfa361b0245fc8632a21a5ab861d1_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNDc_63d5a79e-a540-4d90-909f-91aaec4a70fe">6</ix:nonFraction>), New York (<ix:nonFraction unitRef="case" contextRef="i9aeed91145b54f9e84c1ab265089eff6_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNjM_e31a6ac8-cb76-4325-b79c-19573b36d54f">2</ix:nonFraction>), Ohio (<ix:nonFraction unitRef="case" contextRef="ic41867538a1a4ecaad3784d369bba1cf_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNzU_394b77ea-9133-4152-827a-9f296622f563">1</ix:nonFraction>), Oklahoma (<ix:nonFraction unitRef="case" contextRef="ibd3dd41044494e7fb215da3b8dbf74b3_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczOTE_a5aa03b1-37ba-4009-9ac7-55a64c84250a">1</ix:nonFraction>), Oregon (<ix:nonFraction unitRef="case" contextRef="i8c235c89cfaf42189b0ee56ef85f0f77_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0MDU_df9590d7-2075-4abb-b567-c0309d337bf0">1</ix:nonFraction>), Pennsylvania (<ix:nonFraction unitRef="case" contextRef="i53df00b29f7f48839e6a9318937b699a_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0MjU_95abb048-6359-4733-a8e0-cd256ac9c2e6">1</ix:nonFraction>), Puerto Rico (<ix:nonFraction unitRef="case" contextRef="i44b75c2442dc43c0a7d18a54f55c6e42_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0NDQ_16d97437-99e8-4b04-b26d-1a98d9689217">1</ix:nonFraction>), South Carolina (<ix:nonFraction unitRef="case" contextRef="id4697be7d479446d97c049ae8736f48f_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0NjY_f471b8dc-e7c4-4245-ac9d-9aaedf0e5722">1</ix:nonFraction>), Texas (<ix:nonFraction unitRef="case" contextRef="i6bfde9de540b4ed0bb63aaf5d758c946_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0Nzk_d8e2f4a2-4c95-4d48-b97c-29b3e9938dd0">1</ix:nonFraction>)&#160;and Wisconsin (<ix:nonFraction unitRef="case" contextRef="ibf123308c49642739be1ff2dfe411383_D19960501-20230331" decimals="INF" name="mo:LossContingencyClassNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0OTk_b155a30e-c6fa-41b1-8b1c-916cbc454319">1</ix:nonFraction>).  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Tobacco-Related Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a discussion of &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; class action cases and medical monitoring class action cases pending against PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in <ix:nonFraction unitRef="claim" contextRef="i6905d6541f1a41eaa7e544fdf55f3804_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc4MDI_8b7716a6-f400-47b0-af8c-b82eba88283e">seven</ix:nonFraction> class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario.  In Saskatchewan, British Columbia (<ix:nonFraction unitRef="claim" contextRef="if79ec6e4c9a74c19997a9dca74955a22_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc5Njc_4bc62b40-d933-426c-b96c-f72c359c01cf">two</ix:nonFraction> separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants&#8217; cigarettes.  In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants&#8217; cigarettes.  In March 2019, all of these class actions were stayed as a result of <ix:nonFraction unitRef="manufacture" contextRef="i2e90104cb10647bb85cd65620e32994c_I20190331" decimals="INF" name="mo:LossContingencyNumberofManufacturers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg0NjA_2c78c5e0-1087-4536-8a3d-834e72c309d2">three</ix:nonFraction> Canadian tobacco manufacturers (<ix:nonFraction unitRef="manufacture" contextRef="ia6d6d211a38941ea89399fa49afe5f52_I20190331" decimals="INF" name="mo:LossContingencyNumberofManufacturers" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg0OTY_97d1f6d4-7998-42d5-89e9-0edd56526603">no</ix:nonFraction>ne of which is related to us) seeking protection under Canada&#8217;s Companies&#8217; Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the United States).  The companies entered into these proceedings following a Canadian appellate court upholding <ix:nonFraction unitRef="ruling" contextRef="i2e90104cb10647bb85cd65620e32994c_I20190331" decimals="INF" name="mo:LossContingencyVerdictsUpheld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg3NTk_88463d02-0635-4b70-b9ee-d2577651cad1">two</ix:nonFraction> smoking and health class action verdicts against those companies totaling approximately CAD $<ix:nonFraction unitRef="cad" contextRef="i93b593a0985a40cc8016f69134a44753_D20190301-20190331" decimals="-9" name="mo:AmountAwardedtoOtherParty" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg4NTU_f8818d1b-089e-4dd0-b864-8f7d851d324f">13</ix:nonFraction> billion.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Cost Recovery Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages.  Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there have been some decisions to the contrary, most judicial decisions in the United States have dismissed all or most health care cost recovery claims against cigarette manufacturers.  Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs&#8217; claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions.  The U.S. Supreme Court has refused to consider plaintiffs&#8217; appeals from the cases decided by five federal circuit courts of appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the cases brought in the United States, health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (<ix:nonFraction unitRef="claim" contextRef="id148113ea1ef41e0add7c35363136f03_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTA0Mjk_f1d267ef-1345-4db3-b11c-fe66428f2765">10</ix:nonFraction> cases),&#160;and other entities have stated that they are considering filing such actions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers.  PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases.  The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed.  All of these cases have been stayed pending resolution of proceedings in Canada involving <ix:nonFraction unitRef="manufacture" contextRef="i75bf439c827a43829f739f2ff5266976_I20230331" decimals="INF" name="mo:LossContingencyNumberofManufacturers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTEzMTE_45cee2cd-fb45-4589-8e70-4583fa1ae59a">three</ix:nonFraction> tobacco manufacturers (none of which are affiliated with us) under the Companies&#8217; Creditors Arrangement Act discussed above.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Other Smoking and Health Class Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for a discussion of these proceedings.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlements of Health Care Cost Recovery Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 1998, PM USA and certain other tobacco product manufacturers entered into the Master Settlement Agreement (the &#8220;MSA&#8221;) with <ix:nonFraction unitRef="state" contextRef="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130" decimals="INF" name="mo:LossContingencyNumberofStateswithSettledLitigation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTE5NTA_0ff53898-e64b-43bd-b43e-bbdf41c22cd6">46</ix:nonFraction> states, the District of Columbia and certain </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i0a24090a1e5d4ae297d1a94afeed13b6" continuedAt="i47ee794a2ff548cebe1b8b4a42e68798"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States territories to settle asserted and unasserted health care cost recovery and other claims.  PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the &#8220;State Settlement Agreements&#8221;).  The State Settlement Agreements require that the original participating manufacturers or &#8220;OPMs&#8221; (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (&#8220;ITG&#8221;)) make annual payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130" decimals="-8" name="mo:LitigationSettlementAnnualPaymentAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTI1NjA_e809f346-5c26-47fb-a69a-e975571fa23d">9.4</ix:nonFraction> billion, subject to adjustments for several factors, including inflation, market share and industry volume.  In addition, the OPMs are required to pay settling plaintiffs&#8217; attorneys&#8217; fees, subject to an annual cap of $<ix:nonFraction unitRef="usd" contextRef="i857721e1a42b4c4895342b88f12153b0_I19981130" decimals="INF" name="mo:LitigationSettlementAnnualLegalFeesPayableMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTI3NzM_13667492-ca24-45ef-a464-bc9a550a08d9">500</ix:nonFraction> million; these quarterly payments are expected to end in 2024.  For the three months ended March 31, 2023 and 2022, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $<ix:nonFraction unitRef="usd" contextRef="i0d8f32c1fb40455bb5e51678f9f29624_D20230101-20230331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzk4OTU2MDQ4NjAyNTE_03de6fd9-becf-4233-a6ba-13b1562f104a"><ix:nonFraction unitRef="usd" contextRef="i94e854b8d51348db9f3ecb6573a91237_D20220101-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzk4OTU2MDQ4NjAyNTE_6237c2f1-b00c-4b1c-9355-f68b0ad26ac5">900</ix:nonFraction></ix:nonFraction> million for each period.  These amounts include PM USA&#8217;s estimate of amounts related to NPM Adjustments discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NPM Adjustment Disputes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;NPM Adjustment&#8221; is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the &#8220;participating manufacturers&#8221; or &#8220;PMs&#8221;) that applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent auditor (&#8220;IA&#8221;) appointed under the MSA has calculated that PM USA&#8217;s share of the maximum potential NPM Adjustments for 2004-2022 is (exclusive of interest or earnings): $<ix:nonFraction unitRef="usd" contextRef="id147ed05231e49888e6eec1a1de209d8_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3MDk_a6ad4f98-1d3d-4273-80da-1e08ede15056">388</ix:nonFraction> million for 2004; $<ix:nonFraction unitRef="usd" contextRef="iaea3aff15c3244e099d22efd00005e87_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3MjM_2eea9012-d888-49fd-8506-f71339574d65">181</ix:nonFraction> million for 2005; $<ix:nonFraction unitRef="usd" contextRef="i366e41742fe34ddab3a6ac544395ef0a_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3Mzc_8921249b-66d1-48d2-b111-e6edfadc6f38">154</ix:nonFraction> million for 2006; $<ix:nonFraction unitRef="usd" contextRef="i06db80a9cb864760a78eb4b727fccc60_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3NTE_8a10700d-f2fc-49fb-a70a-564795212db9">185</ix:nonFraction> million for 2007; $<ix:nonFraction unitRef="usd" contextRef="i6a39c242a89b45ba8ba9304730ce2c3d_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3NjU_50dae0b8-d17c-40c1-af14-e61fa957988b">250</ix:nonFraction> million for 2008; $<ix:nonFraction unitRef="usd" contextRef="id52cc241f4134704b38b12055f4d1063_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3Nzk_f34499da-85fb-4027-a06c-ad800573f1a9">211</ix:nonFraction> million for 2009; $<ix:nonFraction unitRef="usd" contextRef="i98ab7c86e216435ab8c328cd46889009_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3OTM_6a328e86-43e0-436c-8436-1a298c030e7a">218</ix:nonFraction> million for 2010; $<ix:nonFraction unitRef="usd" contextRef="i88cce377b1794cafaea3109e44da8255_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MDc_3aec9cc5-e124-4381-a770-f8d979c9cb94">166</ix:nonFraction> million for 2011; $<ix:nonFraction unitRef="usd" contextRef="i717c1ffac0354612b496c8adfb4066d4_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MjE_6171f1d8-f895-4225-beb4-507d0ff47fa2">214</ix:nonFraction> million for 2012; $<ix:nonFraction unitRef="usd" contextRef="i88aa0ae8b6904cfaa051db486ab28768_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MzU_b51f5dfd-7196-447a-bd70-6bcbc4468c06">224</ix:nonFraction> million for 2013; $<ix:nonFraction unitRef="usd" contextRef="i4feaea05ac4a4fb3a34ec68b4955edbb_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4NDk_b5c7caaa-014a-40bf-b3b7-7180b9a81bd1">258</ix:nonFraction> million for 2014; $<ix:nonFraction unitRef="usd" contextRef="ia6488ac6ab1d450094cc398cf207f538_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4NjM_63bc64bf-2624-4f0e-a9a5-c3c233e1e7ac">313</ix:nonFraction> million for 2015; $<ix:nonFraction unitRef="usd" contextRef="ic812762e464a4962a618c514c4377af3_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4Nzc_d8329049-ab7f-42a1-9217-096f35a79715">292</ix:nonFraction> million for 2016; $<ix:nonFraction unitRef="usd" contextRef="i6b42de2c9385496eaa33ccd7de4d5f3a_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4OTE_4907ab63-a5c8-49a8-8729-6b80f85ff651">285</ix:nonFraction> million for 2017; $<ix:nonFraction unitRef="usd" contextRef="iafc3e2cc3c8b46a39dee066c06a6604b_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MDU_4feda39c-2965-4b0c-b975-66f0098744be">318</ix:nonFraction> million for 2018; $<ix:nonFraction unitRef="usd" contextRef="i85efb7c5447949b2a29da6afbe426465_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MTk_88f26083-a949-460a-8ae0-06a3f4effd2e">415</ix:nonFraction> million for 2019; $<ix:nonFraction unitRef="usd" contextRef="i0570863d6e264a92a3cae8a3dbab2b48_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MzM_6f6e245e-7b70-4d86-80f9-32feb0bf857e">572</ix:nonFraction> million for 2020; $<ix:nonFraction unitRef="usd" contextRef="ibc46289ddf384a55817708ab513cdea2_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5NTE_36d0c4ea-3770-42c0-9683-61e57fdeba09">675</ix:nonFraction> million for 2021; and $<ix:nonFraction unitRef="usd" contextRef="ibd2dea1c170648f5a808f3b76a33303a_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementEstimateofPossibleGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU5NTI_92359c03-924a-4635-8bc2-a7d8dc8dac93">571</ix:nonFraction> million for 2022.  These maximum amounts will be substantially reduced to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments.  PM USA&#8217;s recovery for 2004 is addressed below.  In addition, PM USA&#8217;s recovery of such reduced amounts for all subsequent years will be dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Settlements of NPM Adjustment Disputes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Multi-State Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  By the end of 2018, a total of <ix:nonFraction unitRef="state" contextRef="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231" decimals="INF" name="mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ1NzU_f3279e22-fa8b-41bf-bac5-1ba1a7c89a1b">36</ix:nonFraction> MSA states and territories had entered the multi-state settlement of NPM Adjustment disputes to which PM USA is a party.  Of these <ix:nonFraction unitRef="state" contextRef="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231" decimals="INF" name="mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU5NDc_1e7d769e-27df-461b-af8f-eb09c3c9acc7">36</ix:nonFraction> states and territories, <ix:nonFraction unitRef="state" contextRef="ib0a0d0e0236740f7be74ed7a98673a30_D19980101-20181231" decimals="INF" name="mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ2NzY_c59ad48d-e6e8-4760-9d3d-5fedcedd9c92">35</ix:nonFraction> entered settlement through 2022, and <ix:nonFraction unitRef="state" contextRef="iee8944fccf0041b29f69b6e0e45d7eab_D20180101-20181231" decimals="INF" name="mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ3MjE_30df6b9d-df59-4cfa-8b0b-795875038c98">one</ix:nonFraction> state entered settlement through 2024.  In March 2022, Illinois joined the multi-state settlement, settling the NPM Adjustment disputes through 2028 and bringing the total number of states and territories that have joined the multi-state settlement to <ix:nonFraction unitRef="state" contextRef="i0c8e8c08cbe740d4a306f6bb4a27e669_D20220301-20220331" decimals="INF" name="mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5MTA_11ae9cc3-4d03-41ef-839f-f37528b67701">37</ix:nonFraction>.  As a result, PM USA will receive approximately $<ix:nonFraction unitRef="usd" contextRef="iec5a205e894c47679bfac6bbc2c7d660_D20220301-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5NjM_dea885ec-ad86-4691-b0ed-0fcf53d2d036">80</ix:nonFraction> million for 2004-2021 ($<ix:nonFraction unitRef="usd" contextRef="i606794f712334fc29204002ba0d6ccfe_D20220301-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5ODI_c18aeb2b-a8ca-4c49-be51-91e651768b36">20</ix:nonFraction> million of which relates to the 2019-2021 &#8220;transition years&#8221;).  In connection with this development for Illinois, PM USA recorded $<ix:nonFraction unitRef="usd" contextRef="i9b807a28cc05453d86e74e69ed77073d_D20220101-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUxMDg_c599142d-0c08-4bb2-a1e9-3e0d06c12a5c">80</ix:nonFraction> million as a reduction in cost of sales in the first quarter of 2022.  Pursuant to the multi-state settlement, PM USA has received $<ix:nonFraction unitRef="usd" contextRef="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331" decimals="-7" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUyMzU_66b3c7e7-561d-485a-b068-33da8adab4f5">1.15</ix:nonFraction> billion since the first group of states entered the NPM Adjustment dispute settlement in 2014 and expects to receive approximately $<ix:nonFraction unitRef="usd" contextRef="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331" decimals="-6" name="mo:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUyNzY_0b308b21-0f10-4b17-823f-3701c95c5b24">410</ix:nonFraction> million in credits to offset PM USA&#8217;s MSA payments through 2036.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">New York Settlement.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity.  PM USA has received $<ix:nonFraction unitRef="usd" contextRef="iad95738830284f1496045d0fe44e4fb8_D20150101-20151231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTU1NDE_8080f80d-1a22-4cae-b289-10572005e20a">435</ix:nonFraction> million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Montana Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030.  This settlement resulted in a payment by PM USA of $<ix:nonFraction unitRef="usd" contextRef="ibb882978d08a4cea900603cee8983240_D20200101-20201231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTU5MTQ_761ce63b-3006-4a49-a3f4-54bc9cb2a736">4</ix:nonFraction> million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing NPM Adjustment Disputes with States That Have Not Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2004 NPM Adjustment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The PMs and the <ix:nonFraction unitRef="state" contextRef="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesWithConcludedHearings" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYwMjc_f0927ba2-a8b2-4d01-a8c7-c2121084dedf">nine</ix:nonFraction> states that have not settled the NPM Adjustment disputes participated in a multi-state arbitration of NPM Adjustment disputes for 2004.  A tenth state, Illinois, also participated in the arbitration, but joined the multi-state settlement after the arbitration panel issued its decisions described below.  Hearings for <ix:nonFraction unitRef="state" contextRef="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231" decimals="INF" name="mo:LossContingencyNumberOfStatesWithConcludedHearings" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYzNDk_3a13c5e0-8d26-445a-84f1-3464ccdb852f">nine</ix:nonFraction> of the <ix:nonFraction unitRef="state" contextRef="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231" decimals="INF" name="mo:LossContingencyNumberOfStatesNotSettled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYzNjA_1991d8ad-92c1-491a-b709-16c9f1775b98">10</ix:nonFraction> states concluded by the end of 2020.  The arbitration panels issued decisions finding that <ix:nonFraction unitRef="state" contextRef="ibcf25cd065fb4f47a44575dc187696f9_D20210901-20210930" decimals="INF" name="mo:LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTY0NTU_9fbef33c-9816-4ba4-a902-f9253014ce21">three</ix:nonFraction> states, Missouri, New Mexico and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004.  The arbitration panels further found that the remaining <ix:nonFraction unitRef="state" contextRef="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesInComplianceWithEscrowStatues" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTY2OTM_6aa58537-45ba-4ef6-a8c7-ab18bd3f1b06">seven</ix:nonFraction> states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004.  Washington and Missouri have challenged those determinations in their respective state courts and with the arbitration panels, and several issues remain to be resolved by the courts that may affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive.  PM USA recorded $<ix:nonFraction unitRef="usd" contextRef="i3a2a79113e7f4166b1ad0a873dc2709e_D20210701-20210930" decimals="-6" name="mo:LossContingencyReductionToCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTcwOTg_66eabba0-2442-48ac-8548-14a2978f8497">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ef8738bcb2b4b82b180b4ae7bcb49c2_D20221001-20221231" decimals="-6" name="mo:LossContingencyReductionToCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTcxMDY_ac1b7532-318e-47d8-a002-272523381dab">3</ix:nonFraction> million as a reduction in cost of sales in the third quarter of 2021 and fourth quarter of 2022, respectively, for its estimate of the minimum amount of the 2004 NPM adjustment it will receive.  PM USA estimates it is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i47ee794a2ff548cebe1b8b4a42e68798" continuedAt="i0f54b7d07f66467aafc639049e859da7"><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entitled to interest of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a538cd9271c481bbba5add236551969_D20210701-20210930" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTczNTg_26f68f9d-3049-4302-8fc1-b376bedbdc8e">23</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7960b6ec146940de9514bbc0a1bf4361_D20221001-20221231" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTczNjY_19dae44a-8ffb-476e-9066-f42e6832efb5">5</ix:nonFraction> million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021 and fourth quarter of 2022, respectively.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2005-2007 NPM Adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The PMs and the <ix:nonFraction unitRef="state" contextRef="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesNotSettled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc1NjY_db00c967-cebd-4a77-926a-5ed1691f2154">nine</ix:nonFraction> states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel.  The arbitration encompasses <ix:nonNumeric contextRef="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331" name="mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxODA4NzU_af53cc5b-597c-4994-a164-68c524c8b10e">three years</ix:nonNumeric>, 2005-2007, for <ix:nonFraction unitRef="state" contextRef="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesNotSettled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc3Njc_e2ad2fc1-d6cf-4642-807e-2de6f1bbfa1a">eight</ix:nonFraction> of the <ix:nonFraction unitRef="state" contextRef="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesNotSettled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc3Nzg_78b33339-8471-4d23-822a-aed05218498c">nine</ix:nonFraction> states, and <ix:nonNumeric contextRef="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331" name="mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxNzUxOTE_a269ef49-e44d-4fde-9327-ff5d7444fe23">one year</ix:nonNumeric>, 2005, for <ix:nonFraction unitRef="state" contextRef="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331" decimals="INF" name="mo:LossContingencyNumberOfStatesNotSettled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc4MTQ_c4a66f21-cc38-45b4-a8c1-8d336daddc1f">one</ix:nonFraction> state.  As of April 24, 2023, no decisions have resulted from the arbitration.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Subsequent Years.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In July 2022, the State of Iowa filed a motion in Iowa state court against the PMs, including PM USA, claiming that the PMs wrongfully disputed the applicability of NPM Adjustments to Iowa and that all adjustment amounts to date should have been paid to Iowa rather than deposited into the disputed payments account.  A similar enforcement motion was filed by the State of New Mexico against the PMs, including PM USA, in November 2022.  PM USA has placed certain disputed NPM Adjustment amounts attributed to Iowa and New Mexico in the disputed payments account established pursuant to the terms of the MSA.  Iowa and New Mexico seek a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i86a7db94469940b0bdf76635504fc1c9_D20220701-20220731" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTg3MjU_0e56234b-b9ba-4885-bc3e-5174ad80f2aa">133</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iefcfe5daa12447d29a502f1354cb8786_D20220701-20220731" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTg3MzM_6025b7c3-dda9-42c2-a284-07dda31dfe34">84</ix:nonFraction> million, respectively, in disputed payments from all defendants combined, as well as treble and punitive damages, and other relief.  The PMs filed a cross motion to compel arbitration in the Iowa matter.  In February 2023, the Iowa state court granted the PM&#8217;s motion, compelling arbitration.  In March 2023, Iowa withdrew its motion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Disputes Under the State Settlement Agreements: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds&#8217;s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the &#8220;ITG transferred brands&#8221;).  PM USA filed motions to enforce the State Settlement Agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals, although further proceedings may occur based on the resolution of certain outstanding litigation between R.J. Reynolds and ITG.  In May 2022, PM USA filed a motion to compel arbitration under the MSA regarding certain positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  In June 2022, the matter was resolved through mutual agreement of the parties.  PM USA continues to dispute how the ITG transferred brands are treated in allocating the NPM Adjustments under the MSA and related settlements and may pursue such claims.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018.  The Mississippi state court held a hearing in October 2021 and issued a decision in June 2022 granting the State&#8217;s motion.  Further proceedings remain outstanding, and a final judgment has not yet been issued.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs&#8217; claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&amp;M Brands, Inc. (&#8220;S&amp;M Brands&#8221;), under which the states released certain claims against S&amp;M Brands in exchange for receiving a portion of the funds S&amp;M Brands deposited into escrow accounts in those states pursuant to the states&#8217; escrow statutes.  In consideration for waiving its most favored nation claim, PM USA received approximately $<ix:nonFraction unitRef="usd" contextRef="ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjE1MDE_9060b02c-b922-4c9f-b05d-de187e5f5aa6">32</ix:nonFraction> million from the escrow funds paid to those MSA states under their settlement with S&amp;M Brands.  These funds were received in January 2021 and were recorded in our condensed consolidated statement of earnings (losses) for the first quarter of 2021 as a reduction in cost of sales.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal Government&#8217;s Lawsuit: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, the U.S. government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes.  The case ultimately proceeded only under the civil provisions of RICO.  In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in certain &#8220;sub-schemes&#8221; to defraud that the government had alleged.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court did not impose monetary penalties on defendants, but ordered various types of non-monetary relief, including an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including &#8220;lights,&#8221; &#8220;ultra lights&#8221; and &#8220;low tar,&#8221; which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand, and the issuance of &#8220;corrective statements&#8221; in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking &#8220;low tar&#8221; or &#8220;light&#8221; cigarettes, defendants&#8217; manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i0f54b7d07f66467aafc639049e859da7" continuedAt="i21ab8ed131dc435192ad3260af6a30b6"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corrective statements began appearing in newspapers and on television in the fourth quarter of 2017 and on websites in the second quarter of 2018, and the onserts began appearing in the fourth quarter of 2018.  In December 2022, the district court entered a consent order approving a settlement with respect to corrective statements on point-of-sale signage.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recorded provisions totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i41840f71688e4157a71edd78b25d1eb2_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjY0ODA_67f9c3a2-d475-4c95-9dd2-013ed3edef6d">28</ix:nonFraction> million for the estimated costs of implementing the corrective statements on point-of-sale signage remedy.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the U.S. government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes discussed above also applies to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a heated tobacco product used with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System.  In August 2020, we filed an opposition to the government&#8217;s motion and, in the alternative, a motion to modify the injunction to make clear it does not apply to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The district court heard arguments on the motions in July 2022 and has not yet issued any decisions.  Regardless of the district court&#8217;s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the U.S. Food and Drug Administration for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-vapor Product Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, we are defendants in <ix:nonFraction unitRef="claim" contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc0MzQ_72db9cc0-7d15-4810-be7b-f433b7ff4aba">57</ix:nonFraction> class action lawsuits relating to JUUL e-vapor products.  JUUL is an additional named defendant in each of these lawsuits.  The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices.  Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales.  The <ix:nonFraction unitRef="claim" contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc4MjE_5939f01d-2483-4a03-9d42-844f28c88fd4">57</ix:nonFraction> class action lawsuits include <ix:nonFraction unitRef="claim" contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424" decimals="INF" name="mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc4NTU_25b21ad3-ef7a-4080-8d71-f9b871d90a27">32</ix:nonFraction> cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.  <ix:nonFraction unitRef="claim" contextRef="i16021c6cb2f8452ba899a790b0995281_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgwNDc_0e36cf11-5b5a-45a7-b093-526ce539afda">Three</ix:nonFraction> of the class action lawsuits are pending in Canada.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have been named as defendants in other lawsuits involving JUUL e-vapor products, including <ix:nonFraction unitRef="claim" contextRef="i825d494d8ad74328a30cf05aeba68eeb_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgyMDI_c34366a6-8560-4f63-8acf-d746e344e54b">3,746</ix:nonFraction> individual lawsuits and <ix:nonFraction unitRef="claim" contextRef="id749f16e66d343708ca58160babcbc3f_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgyMzA_e6391883-0bc9-4d00-ac00-c6c34e73b7e2">1,467</ix:nonFraction> &#8220;third party&#8221; lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the U.S. Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of the federal individual and class action lawsuits mentioned above in the U.S. District Court for the Northern District of California for pretrial purposes.  In December 2022, JUUL reached agreements to resolve the Multidistrict Litigation through settlement.  In January 2023, the court preliminarily approved the settlement.  We are not a party to any settlements concerning the Multidistrict Litigation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court has set trial dates for <ix:nonFraction unitRef="case" contextRef="i34fa5a79a1854ef28fd89687426e80a7_I20230331" decimals="INF" name="mo:LossContingencyNumberOfCasesWithSetTrialDates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjkwMDA_e1ec6d90-0514-42ed-953f-f79655c05d96">one</ix:nonFraction> case pending in the Multidistrict Litigation.  <ix:nonFraction unitRef="case" contextRef="iad77b9a8d6704b7f94cdfd087b33ca00_I20230424" decimals="INF" name="mo:LossContingencyNumberOfTrialsOngoing" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMTA0NDA_14f70400-4bfc-4a3d-94f1-4c1a99b2531d">One</ix:nonFraction> trial in the Multidistrict Litigation is ongoing as of April 24, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim.  In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice.  Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law.  The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects.  The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020.  In January 2021, we filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021.  In June 2022, the court granted plaintiffs&#8217; motion to certify a California state class based on state law claims against JUUL and a nationwide class based on RICO claims against Altria and other defendants.  Altria and the other defendants filed petitions with the U.S. Court of Appeals for the Ninth Circuit seeking discretionary review of the class certification order, which the court granted in October 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional group of cases is pending in California state courts.  In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JUUL also is named in a significant number of additional individual and class action lawsuits to which we are not currently named.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="lawsuit" contextRef="i05d64c409aed469ba2221a94eff7af46_I20230331" decimals="INF" name="mo:NumberOfThirdPartyLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzA4NTY_d18ec8bb-5ef3-4e87-8655-a0a912b90893">Four</ix:nonFraction> of the &#8220;third party&#8221; lawsuits noted above against us and JUUL were initiated, individually, by the attorneys general of Alaska, Hawaii, Minnesota and New Mexico alleging violations of state consumer protection and other similar laws.  We filed motions to dismiss the lawsuits.  In Alaska, Hawaii and Minnesota, the motions were denied in February 2022, May 2021 and June 2021, respectively.  Our motion to dismiss remains pending in New Mexico.  In the Alaska lawsuit, although the trial court declined to dismiss most of the plaintiff&#8217;s claims, the trial court did dismiss plaintiff&#8217;s public nuisance claim.  In April 2023, we agreed to settle the Minnesota lawsuit for an immaterial amount.  The trial courts in the Alaska and Hawaii lawsuits have set the trials for April 2024 and February 2024, respectively.  As of April 24, 2023, the trial court in New Mexico has not set a trial date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i21ab8ed131dc435192ad3260af6a30b6" continuedAt="ie526298759d0451685e51422f9f231cf"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, ALCS, PMI and its affiliate, Philip Morris Products S.A., in the U.S. District Court for the Eastern District of Virginia asserting claims of patent infringement based on the sale of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System electronic device and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States.  Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys&#8217; fees.  Altria and PMI were previously dismissed from the lawsuit, and plaintiffs&#8217; claims against the other defendants have been stayed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA, ALCS and Philip Morris Products S.A. filed counterclaims against plaintiffs in the Eastern District of Virginia lawsuit alleging patent infringement by R.J. Reynolds&#8217; e-vapor products.  In June 2022, PM USA and ALCS reached an agreement with R.J. Reynolds resulting in dismissal of their counterclaims.  In addition, ALCS filed a separate lawsuit against R.J. Reynolds in the U.S. District Court for the Middle District of North Carolina also alleging patent infringement by R.J. Reynolds&#8217; e-vapor products.  In September 2022, a jury awarded ALCS $<ix:nonFraction unitRef="usd" contextRef="i014aa6b6af9b4df1a19a1a2b7dbfb8f1_D20220901-20220930" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzMwMjk_a3f95cb2-a0c6-467c-84b6-ef322d45bd21">95</ix:nonFraction> million in damages for past infringement, plus supplemental damages and interest.  In January 2023, the court ordered R.J. Reynolds to pay ALCS a <ix:nonFraction unitRef="number" contextRef="i2439b9bbedc04392b00b5bd6ac3cc370_I20230131" decimals="4" name="mo:LossContingencyRoyaltyFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzMxNzE_4d1d0f57-59bd-46f0-bc35-bf1574729c35">5.25</ix:nonFraction>% royalty on future sales of its infringing product resulting in positive net income through the expiration of the relevant patents in 2035.  R.J. Reynolds has filed a notice of appeal of the judgment.  As gains related to this lawsuit have not yet been determined to be realized or realizable in accordance with GAAP, they have not been recognized in our financial statements for the three months ended March 31, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a related patent infringement action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the U.S. International Trade Commission (&#8220;ITC&#8221;), but the remedies sought included a prohibition on the importation of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System electronic device, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and component parts into the United States and on the sale of any such products previously imported into the United States.  <ix:nonFraction unitRef="usd" contextRef="i2aaed74306e54c7498a48f427fbc3dde_D20200401-20200430" decimals="INF" name="mo:LossContingencyDamagesRecoverableValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzM5ODI_c445494d-4d81-46fd-982c-b316f7edded0">No</ix:nonFraction> damages are recoverable in the proceedings before the ITC.  In September 2021, the ITC issued a limited exclusion order barring the importation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System electronic device,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products.  The orders became effective on November 29, 2021.  Consequently, PM USA removed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System electronic device and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the marketplace.  In December 2021, defendants appealed the orders to the U.S. Court of Appeals for the Federal Circuit and, in March 2023, the U.S. Court of Appeals for the Federal Circuit issued its decision affirming the ITC exclusion order in full.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Healthier Choices Management Corp. filed an additional unrelated patent infringement case in the U.S. District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief.  In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021.  In December 2021, the U.S. District Court denied plaintiff&#8217;s motion to amend the complaint and plaintiff appealed this ruling to the U.S. Court of Appeals for the Federal Circuit, which reversed the district court&#8217;s decision and remanded for further proceedings.  The U.S. Patent Office has also issued a decision that the claims of the asserted patent are not valid, and the plaintiff has appealed that ruling.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a stock transfer agreement with JUUL pursuant to which, among other things, we transferred to JUUL all of our beneficially owned JUUL equity securities.  See Note 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our disposition of our interest in JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that our <ix:nonFraction unitRef="number" contextRef="i0661196cc9c54e3093e2f4c03321a3af_I20200430" decimals="2" name="mo:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzU0MzY_9849d911-2010-41bc-94be-f0ca291caddb">35</ix:nonFraction>% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (&#8220;Sherman Act&#8221;) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (&#8220;Clayton Act&#8221;).  If the FTC&#8217;s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party&#8217;s board of directors or attending meetings of the other party&#8217;s board of directors and notice to the FTC in advance of certain corporate actions, including acquisitions, mergers or certain corporate restructurings.  In February 2022, the administrative law judge dismissed the FTC&#8217;s complaint and, also in February 2022, FTC complaint counsel appealed the administrative law judge&#8217;s decision to the FTC.  Oral argument with respect to the appeal occurred in September 2022.  After oral argument, the FTC asked for additional briefing, which was completed in December 2022.  In March 2023, following our disposition of our interest in JUUL, we filed a motion to dismiss, or in the alternative, to stay the litigation and a motion to withdraw the matter from adjudication to discuss settlement with the FTC.  The FTC subsequently issued an order denying our request for a stay and extending to May 5, 2023 its deadline for issuance of a final decision with respect to FTC complaint counsel&#8217;s appeal of the administrative law judge&#8217;s decision and the remainder of the pending motions.  Altria can appeal any adverse ruling the FTC issues following its review to any U.S. Court of Appeals.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="ie526298759d0451685e51422f9f231cf" continuedAt="i6dd8c56d8e4846e7b747fd46815bb5e6"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as of April 24, 2023, <ix:nonFraction unitRef="lawsuit" contextRef="i41dddbdee384487d9fc710339e3a0ccc_I20230424" decimals="INF" name="mo:LossContingencyClassActionLawsuit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzY5MjY_f7c0e6e5-8d57-429c-96c9-e5faca6b3735">17</ix:nonFraction> putative class action lawsuits have been filed against Altria and JUUL in the U.S. District Court for the Northern District of California.  The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed.  In November 2020 these lawsuits were consolidated into <ix:nonFraction unitRef="complaint" contextRef="iab08827c3eeb4c2ab05097b269497f30_I20201130" decimals="INF" name="mo:LossContingencyNumberOfComplaints" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzczODk_baf21c0f-e208-4bab-987b-2f98637308c7">three</ix:nonFraction> complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers).  The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market.  Plaintiffs seek various remedies, including treble damages, attorneys&#8217; fees, a declaration that the agreements between Altria and JUUL are invalid and rescission of the transaction.  We filed a motion to dismiss these lawsuits in January 2021.  In August 2021, the U.S. District Court for the Northern District of California denied our motion to dismiss except with respect to plaintiffs&#8217; claims for injunctive and equitable relief.  However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.  In January 2022, the trial court ordered that the direct-purchaser plaintiffs&#8217; claims against JUUL be sent to arbitration pursuant to an arbitration provision in JUUL&#8217;s online purchase agreement.  The court granted plaintiffs&#8217; leave to replead the complaint with new direct-purchaser plaintiffs, which plaintiffs did in February 2022, substituting in <ix:nonFraction unitRef="claim" contextRef="i9557e21fd37641dcb6ef942359171a0b_D20220201-20220228" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzg4NzY_36cf5cdd-7132-4ae0-a89f-4a8ddf812bde">four</ix:nonFraction> new plaintiffs.  In August 2022, the court stayed all of the cases pending any appeal to the court of appeals from the FTC&#8217;s lawsuit against Altria and JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Class Action and Shareholder Derivative Lawsuits</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October and December 2019, <ix:nonFraction unitRef="shareholder" contextRef="i71b49d8d6c6d47188f21140eb5cf4f0e_D20191001-20191031" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzk5NjA_129f52a4-104b-4929-b994-75200e372ea0"><ix:nonFraction unitRef="shareholder" contextRef="idb201318b1d042eb85ed1f7dff301941_D20191201-20191231" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzk5NjA_7fce5020-cab0-4808-98d1-7fb6f3ebe3f6">two</ix:nonFraction></ix:nonFraction> purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, our former Chairman and Chief Executive Officer, and William F. Gifford, Jr., our former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the U.S. District Court for the Eastern District of New York.  In December 2019, the court consolidated the two lawsuits into a single proceeding.  The consolidated lawsuit was subsequently transferred to the U.S. District Court for the Eastern District of Virginia.  The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act.  In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit.  The claims allege false and misleading statements and omissions relating to our former investment in JUUL.  Plaintiffs seek various remedies, including damages and attorneys&#8217; fees.  In July 2020, the defendants filed motions to dismiss plaintiffs&#8217; claims, which the district court denied in March 2021.  In the fourth quarter of 2021, plaintiffs and defendants agreed upon a class action settlement under which, among other things, (i) all claims asserted against Altria and the other named defendants are resolved without any liability or wrongdoing attributed to them personally or to Altria and (ii) Altria will pay the class an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODEzNjM_ecd2a4ec-5010-464d-b552-17d74d8e14c2">90</ix:nonFraction> million, which amount includes attorneys&#8217; fees.  The class is defined to include persons and entities who purchased or otherwise acquired shares of Altria between October 25, 2018 through April 2, 2020, subject to certain exclusions.  The trial court granted final approval of the settlement in March 2022.  We recorded pre-tax provisions totaling $<ix:nonFraction unitRef="usd" contextRef="ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE3MDc_5af8c0a3-20d6-49c7-838e-fab3c2cccdd9">90</ix:nonFraction> million in 2021 and, in January 2022, paid $<ix:nonFraction unitRef="usd" contextRef="i5822c95a3a294185ab7547237ec445a4_D20220101-20220131" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE3NDY_0ef31995-62ad-40e9-901a-0b1f9477d3de">90</ix:nonFraction> million to plaintiffs&#8217; escrow account.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Shareholder Derivative Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, <ix:nonFraction unitRef="shareholder" contextRef="i9969d54475e54393ac5135266efac3d4_D20200801-20200831" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE4NDg_2dad99a5-b88c-4131-9c98-64d3508769e8">two</ix:nonFraction> purported Altria shareholders filed separate derivative lawsuits in the U.S. District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of our executives and officers.  These derivative lawsuits relate to our former investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants.  In March 2021, the U.S. District Court for the Northern District of California granted defendants&#8217; motion to transfer both lawsuits to the U.S. District Court for the Eastern District of Virginia.  <ix:nonFraction unitRef="shareholder" contextRef="iaf4d332571e345e6b507f1fb9fb044e9_D20201001-20210331" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODI1Mjg_7c23b994-2349-40c6-9104-c5c60beb7325">Three</ix:nonFraction> additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the U.S. District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws.  The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of our corporate governance and internal procedures, and attorneys&#8217; fees.  In April 2021, the court consolidated the <ix:nonFraction unitRef="claim" contextRef="i5d69782fb04745ccb891419a687d7398_D20210401-20210430" decimals="INF" name="mo:LossContingencyNumberOfPendingCasesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODMyNDQ_4621d726-c6ad-4bac-955d-cce048ae1b59">five</ix:nonFraction> cases pending in the Eastern District of Virginia into a single case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shareholder" contextRef="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODMzMTg_5ca9ff63-ab14-472c-85eb-5e15543357fc">Six</ix:nonFraction> derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (our former Chief Growth Officer and JUUL&#8217;s current Chief Executive Officer), certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively.  The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia.  In successive orders from July 2021, September 2021 and January 2022, <ix:nonFraction unitRef="contract" contextRef="ida796d6b95934fcfb7672d95fd59a0a8_D20210701-20220131" decimals="INF" name="mo:LossContingencyNumberOfPendingCasesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODQwMTQ_73320659-3983-4c31-84c2-c5395cd4b292">five</ix:nonFraction> of the <ix:nonFraction unitRef="shareholder" contextRef="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831" decimals="INF" name="mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODQwMjU_b56504c3-6a76-49fc-84f3-039075210cab">six</ix:nonFraction> state derivative cases were consolidated into a single case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, plaintiffs and defendants in all the federal and state derivative cases agreed upon a settlement of these cases.  Under the terms of the settlement, among other things, we agreed to fund underage tobacco prevention and cessation programs, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="i6dd8c56d8e4846e7b747fd46815bb5e6" continuedAt="ib4954f3fbf044d0aaa2d9801606b2d39"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may include positive youth development programs, led by independent third-party organizations.  In 2022, we recorded pre-tax provisions totaling $<ix:nonFraction unitRef="usd" contextRef="i0f4a22fdfe7e477ebc36bd80a51ce673_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE2NTAwMjc1_b768e143-d2ba-4b3d-9417-a5134512f554">27</ix:nonFraction>&#160;million for costs associated with the independent monitoring of our funding commitments and attorneys&#8217; fees.  In January 2023, the federal trial court conducted a final approval hearing, at which the court sustained an objection to a provision of the settlement, but granted the parties additional time to resolve the issue.  The parties subsequently executed an amendment to the settlement agreement, and the federal trial court granted final approval of the settlement in February 2023.  No appeal was taken.  In March 2023, pursuant to the terms of the settlement agreement, plaintiffs in the state derivative cases filed motions to dismiss their lawsuits, which the state courts granted.  The settlement will become effective upon the expiration of the deadline for any appeals of the dismissal orders, which is scheduled to occur on May 1, 2023.  In the first quarter of 2023, we recorded pre-tax provisions totaling approximately $<ix:nonFraction unitRef="usd" contextRef="icd283ff376a14d0ebdf290fc219fa37b_I20230331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU3NTQ_554a3eae-75bd-4bef-b9ef-c0b1bfa650f8">100</ix:nonFraction> million related to the settlement, and in April 2023, paid $<ix:nonFraction unitRef="usd" contextRef="i4f175730caa1454986f3279a4dbc1d37_D20230401-20230430" decimals="-6" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDUyMzc_28c8555a-d9cb-49fd-8e92-371e190c247e">15</ix:nonFraction> million to plaintiffs&#8217; escrow account for attorneys&#8217; fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Other Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Lights/Ultra Lights&#8221; Cases and Other Smoking and Health Class Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms &#8220;Lights&#8221; and/or &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages.  These class actions have been brought against PM USA and, in certain instances, Altria or our other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes.  Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment.  <ix:nonFraction unitRef="court" contextRef="ida05d85a752347c7bc48b2dd64cfe9f5_I20230424" decimals="INF" name="mo:LossContingencyStateCourtsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzM4NDgyOTA5MjQ5NDM_30231c43-3acd-490a-bf6d-a8ce4b2b2a44">Twenty-one</ix:nonFraction> state courts in <ix:nonFraction unitRef="case" contextRef="i7e11164646c440cdb43d7579fbad7dbe_I20230424" decimals="INF" name="mo:LossContingencyClaimsNotCertifiedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODU5Mzc_06db7dfd-268f-4ee1-be4b-4963db9e60b5">23</ix:nonFraction> &#8220;Lights&#8221; cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA.  As of April 24, 2023, <ix:nonFraction unitRef="claim" contextRef="i7e11164646c440cdb43d7579fbad7dbe_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODYxNDY_61fe8504-573f-47e1-99e3-d06d9b300bd3">two</ix:nonFraction> &#8220;Lights/Ultra Lights&#8221; class actions are pending in U.S. state courts.  Neither case is active.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, <ix:nonFraction unitRef="claim" contextRef="i58bffe3b3264449299e2b9f964207eda_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODYyNjk_3c248726-7c2b-4a40-bbd3-77924d32ab52">one</ix:nonFraction> smoking and health case alleging personal injury or seeking court-supervised programs or an ongoing medical monitoring program on behalf of individuals exposed to environmental tobacco smoke and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court.  The case is currently inactive.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UST Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time.  Plaintiffs&#8217; allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes.  Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement.  Defenses raised in these cases have included lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations.  As of April 24, 2023, there is <ix:nonFraction unitRef="claim" contextRef="i0b0ed1328f8e4090ade76858a871504d_I20230424" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODczOTk_b7e2846b-51be-4275-82c5-f1d2e0e1c7ea">no</ix:nonFraction> such case pending against UST and/or its tobacco subsidiaries.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and our former subsidiaries are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the United States: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as &#8220;Superfund&#8221;), which can impose joint and several liability on each responsible party.  Altria and our former subsidiaries are involved in several cost recovery/contribution cases subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations.  We expect to continue to make capital and other expenditures in connection with environmental laws and regulations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated.  Such accruals are adjusted as new information develops or circumstances change.  Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that we may undertake in the future.  In the opinion of our management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on our condensed consolidated results of operations, capital expenditures, financial position or cash flows.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Other Similar Matters</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we have agreed to indemnify a limited number of third parties in the event of future litigation.  At March&#160;31, 2023, we (i) had $<ix:nonFraction unitRef="usd" contextRef="i527b47537c2b4bf4a38a2dc591ed5842_I20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODkzMDk_8f56a5f3-776d-437a-a164-472751fd2962">46</ix:nonFraction> million of unused letters of credit obtained in the ordinary course of business and (ii) were contingently liable for guarantees related to our own performance, including $<ix:nonFraction unitRef="usd" contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODk0NzY_35cfb1eb-e76b-4d35-b3f3-17d97c076f79">19</ix:nonFraction> million for surety bonds recorded on our condensed consolidated balance sheet.  In addition, from time to time, we issue lines of credit to affiliated entities.  These items have not had, and are not expected to have, a significant impact on our liquidity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of a distribution agreement between Altria and PMI (the &#8220;Distribution Agreement&#8221;), entered into as a result of our 2008 spin-off of our former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span></div></div><ix:continuation id="ib4954f3fbf044d0aaa2d9801606b2d39"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part on the manufacturer.  PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI.  We do not have a related liability recorded on our condensed consolidated balance sheet at March&#160;31, 2023 as the fair value of this indemnification is insignificant.  PMI has agreed not to seek indemnification with respect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System patent litigation discussed above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS Litigation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excluding the patent infringement case filed with the U.S. District Court for the Northern District of Georgia.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA has issued guarantees relating to our obligations under our outstanding debt securities, borrowings under our $<ix:nonFraction unitRef="usd" contextRef="ib778b2cd5f1140bcad20a594e44c8b5c_I20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3OTA4MDk_0ceb6f04-8676-493f-bddc-959d36bd9000">3.0</ix:nonFraction> billion Credit Agreement and amounts outstanding under our commercial paper program.  For further discussion, see Note 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span></div></ix:continuation><div id="ibb819a612bfb40178ae4eeaeab3ba640_109"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDkvZnJhZzoxMzQ4MTRhNDk2OGQ0OGY2OTA0NGM4Y2RlNGE5ZDcwZi90ZXh0cmVnaW9uOjEzNDgxNGE0OTY4ZDQ4ZjY5MDQ0YzhjZGU0YTlkNzBmXzE3OA_71fd9abb-10d2-4002-b92b-842ac85e548c" continuedAt="ice53aed1d1da4bca87bc7e93e998fa4f" escape="true">New Accounting Guidance Not Yet Adopted</ix:nonNumeric></span></div><ix:continuation id="ice53aed1d1da4bca87bc7e93e998fa4f"><ix:nonNumeric contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDkvZnJhZzoxMzQ4MTRhNDk2OGQ0OGY2OTA0NGM4Y2RlNGE5ZDcwZi90ZXh0cmVnaW9uOjEzNDgxNGE0OTY4ZDQ4ZjY5MDQ0YzhjZGU0YTlkNzBmXzE4Mg_66acda69-a668-4e03-b8fe-2dd4a1045c03" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:</span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3a3fce35478e4e3c8e74b28c5592dfe5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2022-03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.</span></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt"><span><br/></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_115"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_118"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in this Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;), the terms </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altria,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) section, we refer to the following &#8220;adjusted&#8221; financial measures: adjusted operating companies income (loss) (&#8220;OCI&#8221;); adjusted OCI margins; adjusted net earnings; adjusted diluted earnings per share; and adjusted effective tax rates.  These adjusted financial measures are not required by, or calculated in accordance with, United States generally accepted accounting principles (&#8220;GAAP&#8221;) and may not be calculated the same as similarly titled measures used by other companies.  These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.  For a further description of these non-GAAP financial measures, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_121"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+.  Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future (&#8220;Vision&#8221;).  We are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moving Beyond Smoking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products.  In combustibles, we own Philip Morris USA Inc. (&#8220;PM USA&#8221;), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (&#8220;Middleton&#8221;), a leading U.S. cigar manufacturer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (&#8220;USSTC&#8221;), the leading global moist smokeless tobacco (&#8220;MST&#8221;) manufacturer, and Helix Innovations LLC (&#8220;Helix&#8221;), a leading manufacturer of oral nicotine pouches.  Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (&#8220;Horizon&#8221;), for the U.S. marketing and commercialization of heated tobacco stick products and, through a separate agreement, we have the exclusive U.S. commercialization rights to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS Tobacco Heating System </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System&#8221;) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through April 2024.  As of this filing, there are no products in the U.S. marketplace from the joint venture or exclusive rights agreement.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a stock transfer agreement with JUUL Labs, Inc. (&#8220;JUUL&#8221;) pursuant to which we transferred to JUUL all of our beneficially owned JUUL equity securities.  In exchange, we received a non-exclusive, irrevocable global license to certain of JUUL&#8217;s heated tobacco intellectual property.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities include Anheuser-Busch InBev SA/NV (&#8220;ABI&#8221;), the world&#8217;s largest brewer, and Cronos Group Inc. (&#8220;Cronos&#8221;), a leading Canadian cannabinoid company.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a definitive agreement to acquire NJOY Holdings, Inc. (&#8220;NJOY&#8221;), a U.S. based e-vapor company, for approximately $2.75 billion in cash payable at closing plus up to an additional $500 million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products (&#8220;NJOY Transaction&#8221;).  Following completion of the NJOY Transaction, NJOY will survive as a wholly owned subsidiary of Altria, and we will gain full global ownership of NJOY&#8217;s e-vapor product portfolio, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NJOY ACE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, currently the only pod-based e-vapor product with market authorizations from the U.S. Food and Drug Administration (&#8220;FDA&#8221;).  The completion of the NJOY Transaction is subject to customary closing conditions, including clearance from the U.S. Federal Trade Commission (&#8220;FTC&#8221;), and is not subject to any financing condition.  The parties have filed for premerger clearance with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;HSR Act&#8221;), which remains under FTC review.  The current waiting period under the HSR Act expires in May 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The brand portfolios of our tobacco operating companies include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Black &amp; Mild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on!</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Trademarks and service marks related to Altria referenced in this Form 10-Q are the property of Altria or our subsidiaries or are used with permission.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trends and Developments</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this MD&amp;A section, we discuss factors that have impacted our business as of the date of this Form 10-Q.  In addition, we are aware of certain trends and developments that could, individually or in the aggregate, have a material impact on our business, including the value of our investments in equity securities, in the future.  In this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trends and Developments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section, we focus on the continued elevated rate of inflation, supply chain disruptions, ongoing geopolitical events and recent regulatory actions and their potential effects on our business, including impacts on adult tobacco consumers and their purchasing behaviors.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the evolving macroeconomic and geopolitical landscapes.  While the most recent inflation report from the U.S. Bureau of Labor Statistics showed a lower rate of increase, high rates of inflation have continued in 2023, driven by increased global energy, commodity and food prices, which were further exacerbated by other factors, including supply and demand imbalances, labor shortages and the Russian invasion of Ukraine.  High inflation, high gas prices and rising interest rates could continue to impact our business by negatively impacting adult tobacco consumers&#8217; disposable income and future purchase behaviors.  During the first quarter of 2023, cigarette retail share for the industry discount segment increased.  We continue to expect potential fluctuations in discount product share for cigarettes and MST products as price sensitive adult tobacco consumers react to their economic conditions.  We will continue to monitor the effect of these dynamics on adult tobacco consumers and their purchase behaviors, including overall tobacco product expenditures, mix between premium and discount brand purchases and adoption of smoke-free products.  Increases in inflation also have a direct and adverse impact on our Master Settlement Agreement (&#8220;MSA&#8221;) expense and other direct and indirect costs.  We expect inflation to remain high in 2023, and the extent of any effects on adult tobacco consumers&#8217; purchase behaviors depends in part on the magnitude and duration of such increased inflation levels.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect volatility in domestic and global economies and disruptions in the supply and distribution chains to continue in 2023, resulting from several factors, including the on-going impacts of inflation, supply and demand imbalances across many sectors such as energy and commodities, raw materials availability and geopolitical events.  We continue to work to mitigate the potential negative impacts of these macroeconomic and geopolitical dynamics on our businesses through, among other actions, proactive engagement with current and potential suppliers and distributors, the development of alternative sourcing strategies, entry into long-term supply contracts and prudent oversight of our liquidity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tobacco companies are subject to broad and evolving regulatory and legislative frameworks that could have a material impact on our business.  For example, the FDA has issued proposed product standards regarding menthol in cigarettes and characterizing flavors in cigars, and the Biden Administration published plans for future potential regulatory actions that include the FDA&#8217;s plans to develop a proposed product standard that would establish a maximum nicotine level for cigarettes and certain other combustible tobacco products.  In California, where a ban on flavored nicotine products went into effect in late 2022, we are observing early indications of unintended consequences, such as adult tobacco consumer adoption of adulterated and unregulated products and the development of illicit markets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Results by Business Segment - Tobacco Space - Business Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the trends and developments discussed above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect adverse macroeconomic and geopolitical landscapes, which have impacted global businesses, including ABI, to continue in 2023.  ABI&#8217;s business has continued to be impacted by foreign exchange rate fluctuations, inflation and commodity cost headwinds.  Additionally, the macroeconomic and geopolitical factors have contributed to significant changes in certain foreign exchange rates, including the Euro to U.S. dollar exchange rate, and in the global equity markets.  We will continue to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitor these conditions as they could affect our equity earnings that we receive from ABI and the fair value of our equity investment in ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Part I, Item 1. Financial Statements of this Form 10-Q (&#8220;Item 1&#8221;) for additional information on our investments in equity securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating companies have not experienced any material adverse effects from the trends and developments discussed above.  Additionally, we do not believe that these trends and developments have impacted our ability to achieve our Vision.  As the trends and developments discussed above evolve and new ones emerge, we will continue to evaluate the potential impacts on our business, investments and Vision.</span></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations for the Three Months Ended March 31, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in net earnings and diluted earnings per share (&#8220;EPS&#8221;) for the three months ended March 31, 2023, from the three months ended March 31, 2022, were due primarily to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the three months ended March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 NPM Adjustment Items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Acquisition and disposition-related items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Tobacco and health and certain other litigation items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 JUUL changes in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 ABI-related special items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Cronos-related special items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Income tax items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal 2022 special items</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Acquisition and disposition-related items</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Tobacco and health and certain other litigation items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Loss on disposition of JUUL equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 ABI-related special items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Cronos-related special items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Income tax items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal 2023 special items</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fewer shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the three months ended March 31, 2023</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Reported Net Earnings</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Reported Net Earnings</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Adjusted Net Earnings and Adjusted Diluted EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Adjusted Net Earnings and Adjusted Diluted EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">For a discussion of special items and other business drivers affecting the comparability of statements of earnings amounts and reconciliations of adjusted earnings and adjusted diluted EPS, see the Consolidated Operating Results section below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Fewer Shares Outstanding:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fewer shares outstanding were due to shares we repurchased under our $3.5 billion share repurchase program, which was completed in 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Operations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $67 million in operations (which excludes the impact of special items shown in the table above) was due primarily to higher income from our equity investment in ABI and lower interest and other debt expense, net.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Forecasted Results</span></div><div style="margin-bottom:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our 2023 full-year adjusted diluted EPS to be in a range of $4.98 to $5.13, representing a growth rate of 3% to 6% over our 2022 full-year adjusted diluted EPS base of $4.84, as shown in the first table below.  While the 2023 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic.  We will continue to monitor conditions related to (i) the economy, including the impact of high inflation, rising interest rates and global supply chain disruptions, (ii) adult tobacco consumer dynamics, including disposable income, purchasing patterns and adoption of smoke-free products and (iii) regulatory and legislative developments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, such as (i) continued smoke-free product research, development and regulatory preparation expenses, (ii) enhancement of our digital consumer engagement system and (iii) marketplace activities in support of our smoke-free products.  This guidance range also includes lower expected net periodic benefit income due to market factors, including higher interest rates, and the impact of the 2022 completion of the wind-down of our former financial services business.  This guidance range does not include the potential financial impacts of the NJOY Transaction.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of 2022 Reported Diluted EPS to 2022 Adjusted Diluted EPS</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Reported diluted EPS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPM Adjustment Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL changes in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI-related special items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos-related special items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Adjusted diluted EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following (income) expense items are excluded from our 2023 forecasted adjusted diluted EPS growth rate:</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Income) Expense Excluded from 2023 Forecasted Adjusted Diluted EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation items</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposition of JUUL equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI-related special items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos-related special items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For a discussion of certain income and expense items excluded from the forecasted results above, see the Consolidated Operating Results section below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our full-year adjusted diluted EPS forecast excludes the impact of certain income and expense items, including those items noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below, that our management believes are not part of underlying operations.  Other than as set forth in the table immediately above, our management cannot estimate on a forward-looking basis the impact of these items on our reported diluted EPS because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable.  As a result, we do not provide a corresponding GAAP measure for, or reconciliation to, our adjusted diluted EPS forecast.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_124"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we report our financial results in accordance with GAAP, our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments.  Our management also reviews certain financial results, including OCI, OCI margins, net earnings and diluted EPS, on an adjusted basis, which excludes certain income and expense items that our management believes are not part of underlying operations.  These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related and disposition-related items, equity investment-related special items (including any changes in fair value of our equity investment recorded at fair value and any changes in the fair value of related warrants and preemptive rights), certain income tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (&#8220;NPM&#8221;) adjustment disputes under the MSA (such dispute resolutions are referred to as &#8220;NPM Adjustment Items&#8221;).  Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distort underlying business trends and results.  Our management also reviews income tax rates on an adjusted basis.  Our adjusted effective tax rate may exclude certain income tax items from our reported effective tax rate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results.  Our management uses adjusted financial measures and regularly provides these to our chief operating decision maker (&#8220;CODM&#8221;) for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.  These adjusted financial measures are not required by, or calculated in accordance with GAAP and may not be calculated the same as similarly titled measures used by other companies.  These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.  Except as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Forecasted Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, when we provide a non-GAAP measure in this Form 10-Q, we also provide a reconciliation of that non-GAAP financial measure to the most directly comparable GAAP financial measure.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_127"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Discussion and Analysis</span></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Operating Results</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Excise Taxes on Products:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise taxes on products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1 (&#8220;Note 8&#8221;), our CODM reviews OCI to evaluate the performance of, and allocate resources to, our segments.  Our management believes it is appropriate to disclose this measure to help investors analyze the business performance and trends of our business segments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended March 31:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions of dollars, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings before Income Taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for Income Taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted <br/>EPS</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Reported</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and disposition-related items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposition of JUUL equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI-related special items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos-related special items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Adjusted for Special Items</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,824</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Reported</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPM Adjustment Items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and disposition-related items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation items </span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL changes in fair value</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI-related special items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos-related special items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax items</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Adjusted for Special Items</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following special items affected the comparability of statements of earnings amounts for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">NPM Adjustment Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1 (&#8220;Note 11&#8221;) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NPM Adjustment Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 8, respectively.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Tobacco and Health and Certain Other Litigation Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of tobacco and health and certain other litigation items and a breakdown of these costs by segment, see Note 11 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tobacco and Health and Certain Other Litigation Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 8, respectively.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Loss on Disposition and Changes in Fair Value of JUUL Equity Securities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a non-cash, pre-tax loss of $250 million related to the disposition of our JUUL equity securities for the three months ended March 31, 2023 as (income) losses from investments in equity securities in our condensed consolidated statement of earnings.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a non-cash, pre-tax unrealized loss of $100 million for the three months ended March 31, 2022 as (income) losses from investments in equity securities in our condensed consolidated statement of earnings as a result of a decrease in the estimated fair value of our investment in JUUL.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded corresponding adjustments to the JUUL tax valuation allowance in 2023 and 2022.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1 (&#8220;Note 3&#8221;) and Note 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1 (&#8220;Note 10&#8221;).</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">ABI-Related Special Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net pre-tax income of $59 million from our equity investment in ABI for the three months ended March 31, 2022, consisting primarily of mark-to-market gains on certain ABI financial instruments associated with its share commitments.  For further discussion, see Note 3.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABI-related special items include our respective share of the amounts recorded by ABI and additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to our investment required under the equity method of accounting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Cronos-Related Special Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net pre-tax expense consisting of the following:</span></div><div style="margin-top:5pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cronos-related special items - (income) expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts include our share of special items recorded by Cronos and additional adjustments, if required under the equity method of accounting, related to our investment in Cronos.</span></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded corresponding adjustments to the Cronos tax valuation allowance in 2023 and 2022 relating to the special items.</span></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion, see Note 3 and Note 10.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2023 Compared with Three Months Ended March&#160;31, 2022</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues, which include excise taxes billed to customers, decreased $173 million (2.9%), substantially all of which was due to lower net revenues in the smokeable products segment.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was essentially unchanged, as lower shipment volume in our smokeable products segment was mostly offset by higher per unit settlement charges and NPM Adjustment Items in 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excise taxes on products decreased $117 million (10.9%), due to lower shipment volume in our smokeable products segment.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, administration and research costs increased $83 million (17.0%), due primarily to higher general corporate expenses (including an agreement to resolve shareholder derivative lawsuits in 2023 as discussed in Note 11).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income decreased $127 million (4.4%), due primarily to higher general corporate expenses and lower operating results in our smokeable products segment.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other debt expense, net decreased $52 million (18.5%), due primarily to higher interest income due to higher rates and 2023 interest income associated with the sale of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System commercialization rights.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) losses from investments in equity securities decreased $114 million (100%+), due primarily to the loss on the disposition of our JUUL equity securities, partially offset by 2022 changes in the estimated fair value of our former investment in JUUL equity securities and lower losses from our Cronos-related special items.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported net earnings of $1,787 million decreased $172 million (8.8%), due primarily to lower operating income and unfavorable results from our investments in equity securities, partially offset by lower interest and other debt expense, net.  Reported basic and diluted EPS of $1.00, each decreased by 7.4% due to lower reported net earnings, partially offset by fewer shares outstanding.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted net earnings of $2,118 million increased $71 million (3.5%) due primarily to higher income from our equity investment in ABI and lower interest and other debt expense, net.  Adjusted diluted EPS of $1.18 increased by 5.4%, due to higher adjusted net earnings and fewer shares outstanding.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_130"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Results by Business Segment</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tobacco Space</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tobacco industry faces a number of business and legal challenges that have materially adversely affected and may continue to materially adversely affect our business, results of operations, cash flows or financial position or our ability to achieve our Vision.  These challenges, some of which are discussed in more detail in Note 11 and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2022 (&#8220;2022 Form 10-K&#8221;) and in Part II, Item 1A. Risk Factors in this Form 10-Q, include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">pending and threatened litigation and bonding requirements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions and requirements imposed by the FSPTCA, and restrictions and requirements (and related enforcement actions) that have been, and in the future will be, imposed by the FDA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">actual and proposed excise tax increases, as well as changes in tax structures and tax stamping requirements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">bans and restrictions on tobacco use imposed by governmental entities and private establishments and employers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other federal, state and local government actions, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on the sale of certain tobacco products, the sale of tobacco products by certain retail establishments, the sale of tobacco products with characterizing flavors and the sale of tobacco products in certain package sizes;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">additional restrictions on the advertising and promotion of tobacco products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other actual and proposed tobacco-related legislation and regulation; and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">governmental investigations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">reductions in consumption levels of cigarettes and MST products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">increased efforts by tobacco control advocates and other private sector entities (including retail establishments) to further restrict the availability and use of tobacco products or the ability to communicate with consumers through third-party digital platforms;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">changes in adult tobacco consumer purchase behavior, which is influenced by various factors such as macroeconomic conditions (including inflation), excise taxes and price gap relationships, may result in adult tobacco consumers switching to lower-priced tobacco products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the highly competitive nature of all tobacco categories, including competitive disadvantages related to cigarette price increases attributable to the settlement of certain litigation and the proliferation of innovative tobacco products, such as e-vapor and oral nicotine pouch products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">illicit trade in tobacco products; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">potential adverse changes in prices, availability and quality of tobacco, other raw materials and component parts, including as a result of changes in macroeconomic and geopolitical conditions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to and in connection with the foregoing, evolving adult tobacco consumer preferences continue to impact the tobacco industry.  We believe that a significant number of adult tobacco consumers switch among tobacco categories, use multiple forms of tobacco products and try innovative tobacco products, such as e-vapor products and oral nicotine pouches.  Adult smokers continue to transition from cigarettes to exclusive use of smoke-free tobacco product alternatives, which aligns with our Vision.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work to meet these evolving adult tobacco consumer preferences over time by developing, manufacturing, marketing and distributing products both within and outside the United States through innovation and other growth strategies (including, where appropriate, arrangements with, or investments in, third parties).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past two years, the legislative and regulatory activities discussed below negatively impacted growth in the e-vapor category.  The total e-vapor category experienced an estimated volume decline of 11% for the three months ended March 31, 2023 compared to the same period in 2022, despite disposable e-vapor product volume growth.  In the first quarter of 2023, e-vapor industry volumes declined sequentially by 1%.  In March 2022, the U.S. Congress expanded the statutory definition of tobacco products to include products containing nicotine derived from any source, including synthetic nicotine.  The amendment became effective in April 2022.  Additionally, over the past year, the FDA has issued marketing denial orders (&#8220;MDOs&#8221;) for several vaping products.  The FDA has issued stays temporarily suspending the MDOs for further review of these products, allowing them to remain in market.  In addition, legislation recently became effective in California that bans the sale of most tobacco products with characterizing flavors.  We believe these activities, which may be subject to legal challenges, will further impact the competitive environment and e-vapor category landscape.  We are monitoring the sale and distribution of synthetic nicotine products, including in the form of e-vapor products and oral nicotine pouches.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral nicotine pouch retail share of the total oral tobacco category grew significantly from 19.1% year-to-date as of March 31, 2022 to 26.2% year-to-date as of March 31, 2023.  The oral nicotine pouch category continues to be increasingly competitive.  Oral nicotine pouch growth has sourced in significant part from smokeless tobacco and cigarette consumers.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the innovative tobacco product categories will continue to be dynamic due to competition, adult tobacco consumer exploration of a variety of tobacco product options, adult tobacco consumer perceptions of the relative risks of smoke-free products compared to cigarettes, FDA determinations on product applications, FDA enforcement activity and legislative actions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, we estimate that, when adjusted for trade inventory movements, calendar differences and other factors, domestic cigarette industry volume declined by 9%, compared to the three months ending March 31, 2022.  We expect 2023 cigarette industry volume trends to be most influenced by (i) disposable income, purchasing patterns and adoption of smoke-free products, (ii) macroeconomic conditions (including inflation, gasoline prices and unemployment levels), (iii) cross-category movement and (iv) regulatory and legislative (including excise tax) developments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic conditions (including a high inflationary environment) can impact adult tobacco consumer purchasing behavior.  For example, economic downturns have coincided with adult tobacco consumers modifying purchase behavior at retail, potentially reducing the amount of their regular brand purchases or selecting discount products and other lower priced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tobacco brands.  The Consumer Price Index (&#8220;CPI&#8221;) increased 5.0% for the 12 months ended March 2023, a decrease in the rate of CPI growth from the 8.5% increase over the 12 months ended March 2022.  Throughout the first three months ending March 31, 2023, gas prices remained fairly stable at below $3.50 per gallon.  In addition, low unemployment and stable wage inflation continued for the three months ending March 31, 2023.  Despite lower overall inflation, stable gas prices and low unemployment, elevated prices on other monthly expenses (including food, electricity and rent) continued to apply pricing pressures at retail for adult consumers.  Furthermore, the federal funds rate continued to increase, reaching 4.8% in March 2023, up 4.6% versus the prior year.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that adult tobacco consumers adapted their purchasing patterns across a variety of goods and services to compensate for the pressures on disposable income.  As price sensitive adult tobacco consumers react to their economic conditions, we expect potential fluctuations in discount product share for cigarettes and MST products.  However, if macroeconomic conditions or other factors cause greater than expected discount share growth or a reduction in purchases at retail, such factors could have a material adverse effect on our business, results of operations, cash flows or financial position, including an adverse effect on the carrying value of our assets such as our tobacco product trademarks.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FSPTCA and FDA Regulation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">The Regulatory Framework:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FSPTCA and its related regulations establish broad FDA regulatory authority over all tobacco products and, among other provisions:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impose restrictions on the advertising, promotion, sale and distribution of tobacco products (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Final Tobacco Marketing Rule</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">establish pre-market review pathways for new and modified tobacco products (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Market Review Pathways for Tobacco Products and Market Authorization Enforcement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">prohibit any express or implied claims that a tobacco product is or may be less harmful than other tobacco products without FDA authorization;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">authorize the FDA to impose tobacco product standards that are appropriate for the protection of the public health (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Product Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below); and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">equip the FDA with a variety of investigatory and enforcement tools, including the authority to inspect product manufacturing and other facilities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation and Enforcement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FSPTCA also bans descriptors such as &#8220;light,&#8221; &#8220;low&#8221; or &#8220;mild&#8221; when used as descriptors of modified risk, unless expressly authorized by the FDA.  In connection with a 2016 lawsuit initiated by Middleton, the U.S. Department of Justice, on behalf of the FDA, informed Middleton that the FDA does not intend to bring an enforcement action against Middleton for the use of the term &#8220;mild&#8221; in the trademark &#8220;Black &amp; Mild.&#8221;  Consequently, Middleton dismissed its lawsuit without prejudice.  If the FDA were to change its position at some later date, Middleton would have the opportunity to bring another lawsuit.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the U.S. Congress expanded the statutory definition of tobacco products to include products containing nicotine derived from any source, including synthetic nicotine.  The amendment became effective in April 2022.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Market Review Pathways for Tobacco Products and Market Authorization Enforcement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for additional information on the effects of the statutory change.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Final Tobacco Marketing Rule: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by the FSPTCA, in March 2010, the FDA promulgated a wide range of advertising and promotion restrictions for cigarettes and smokeless tobacco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (the &#8220;Final Tobacco Marketing Rule&#8221;).  The May 2016 deeming regulations amended the Final Tobacco Marketing Rule to expand specific provisions to all tobacco products, including cigars, pipe tobacco and e-vapor and oral nicotine products containing tobacco-derived nicotine or other tobacco derivatives.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Final Tobacco Marketing Rule, as amended, among other things:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restricts the use of non-tobacco trade and brand names on cigarettes and smokeless tobacco products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">prohibits sampling of all tobacco products except that sampling of smokeless tobacco products is permitted in qualified adult-only facilities;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">prohibits the sale or distribution of items such as hats and tee shirts with cigarette or smokeless tobacco brands or logos;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">prohibits cigarettes and smokeless tobacco brand name sponsorship of any athletic, musical, artistic or other social or cultural event, or any entry or team in any event; and</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Smokeless tobacco,&#8221; as used in this section of this Form 10-Q, refers to smokeless tobacco products first regulated by the FDA in 2009, including MST.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">It excludes oral nicotine pouches, which were first regulated by the FDA in 2016.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">requires the development by the FDA of graphic warnings for cigarettes, establishes warning requirements for other tobacco products, and gives the FDA the authority to require new warnings for any type of tobacco product (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Regulatory Actions - Graphic Warnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain limitations arising from legal challenges, the Final Tobacco Marketing Rule took effect in June 2010 for cigarettes and smokeless tobacco products, in August 2016 for all other tobacco products, including e-vapor and oral nicotine pouch products containing tobacco-derived nicotine, and in April 2022 for tobacco products, including e-vapor and oral nicotine pouch products, that contain nicotine from any source other than tobacco, such as synthetic nicotine.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Rulemaking and Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the FDA issues proposed regulations and guidance, which may be issued in draft or final form, generally involve public comment and may include scientific review.  The FDA also may request comments on broad topics through an Advanced Notice of Proposed Rulemaking (&#8220;ANPRM&#8221;).  We actively engage with the FDA to develop and implement the FSPTCA&#8217;s regulatory framework, including submission of comments to various FDA policies and proposals and participation in public hearings and engagement sessions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s implementation of the FSPTCA and related regulations and guidance also may have an impact on enforcement efforts by states, territories and localities of their laws and regulations as well as of the State Settlement Agreements (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).&#160; Such enforcement efforts may adversely affect our operating companies&#8217; ability to market and sell regulated tobacco products in those states, territories and localities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">FDA&#8217;s Comprehensive Plan for Tobacco and Nicotine Regulation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the FDA announced a &#8220;Comprehensive Plan for Tobacco and Nicotine Regulation&#8221; (&#8220;Comprehensive Plan&#8221;) designed to strike a balance between regulation and encouraging the development of innovative tobacco products that may be less risky than cigarettes.  Since then, the FDA has issued additional information about its Comprehensive Plan in response to concerns associated with the rise in the use of e-vapor products by youth and the potential youth appeal of flavored tobacco products (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Regulatory Actions - Underage Access and Use of Certain Tobacco Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).  As part of the Comprehensive Plan, the FDA:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">issued ANPRMs relating to potential product standards for nicotine in cigarettes, flavors in all tobacco products (including menthol in cigarettes and characterizing flavors in all cigars) and, for e-vapor products, to protect against known public health risks such as concerns about youth exposure to liquid nicotine;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">took actions to restrict youth access to e-vapor products; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">reconsidered the processes used by the FDA to review certain reports and new product applications.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Reagan-Udall Foundation published a report on its operational evaluation of the FDA&#8217;s Center for Tobacco Products.  Among other recommendations, the report urges the FDA to clearly define product pathways, accelerate PMTA decision-making, take enforcement actions against manufacturers and products that violate the law and address the need for risk communications to tobacco consumers.  In February 2023, the FDA responded and committed to develop a five-year strategic plan by December 2023 designed to address concerns raised by the report.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Pre-Market Review Pathways for Tobacco Products and Market Authorization Enforcement: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FSPTCA permits the sale of tobacco products on the market as of February 15, 2007 and not subsequently modified (&#8220;Pre-existing Tobacco Products&#8221;) and new or modified products authorized through the PMTA, Substantial Equivalence (&#8220;SE&#8221;) or SE Exemption pathways.  Subsequent FDA rules also provide a Supplemental PMTA pathway designed to increase the efficiency of submission and review for modified versions of previously authorized products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA pre-market authorization enforcement policy varies based on product type and date of availability in the market, specifically:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pre-existing Tobacco Products are exempt from the pre-market authorization requirement;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">cigarette and smokeless tobacco products that were modified or first introduced into the market between February 15, 2007 and March 22, 2011 are generally considered &#8220;Provisional Products&#8221; for which SE reports were required to be filed by March 22, 2011.  These reports must demonstrate that the product has the same characteristics as a product on the market as of February 15, 2007 or to a product previously determined to be substantially equivalent, or has different characteristics but does not raise different questions of public health; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">tobacco products that were first regulated by the FDA in 2016, including cigars, e-vapor products and oral nicotine pouches that are not Pre-existing Tobacco Products, are generally products for which either an SE report or PMTA needed to be filed by September 9, 2020; and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">tobacco products containing nicotine from any source other than tobacco (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, synthetic nicotine) that were on the market between March 15, 2022 and April 14, 2022 and are not Pre-existing Tobacco Products are generally products for which a manufacturer must have filed a PMTA by May 14, 2022.  A manufacturer was permitted to keep such a product on the market until July 13, 2022 provided that a PMTA was filed by May 14, 2022.  Thereafter, unless the FDA granted the product a marketing order, the product is unlawful and subject to possible FDA enforcement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Modifications to currently marketed products, including modifications that result from, for example, changes to the quantity of tobacco product(s) in a package, a manufacturer being unable to acquire ingredients or a supplier being unable to maintain the consistency required in ingredients, could trigger the FDA&#8217;s pre-market review processes.  Through these processes, a manufacturer could receive (i) a &#8220;not substantially equivalent&#8221; determination or (ii) a denial of a PMTA.  In addition, new scientific data continues to be developed relating to innovative tobacco products, which could impact the FDA&#8217;s determination as to whether a product is, or continues to be, appropriate for the protection of public health and could, therefore, result in the removal of one or more products from the market.  Any such actions affecting our operating companies&#8217; products could have a material adverse impact on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Regulated in 2009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most cigarette and smokeless tobacco products currently marketed by PM USA and USSTC are &#8220;Provisional Products.&#8221;  PM USA and USSTC timely submitted SE reports for these Provisional Products and have received SE determinations on certain Provisional Products.  Those products that were found by the FDA to be not substantially equivalent (certain smokeless tobacco products) had been discontinued for business reasons prior to the FDA&#8217;s determinations; therefore, those determinations did not impact business results.  PM USA and USSTC have other Provisional Products that continue to be subject to the FDA&#8217;s pre-market review process.  In the meantime, they can continue marketing these products unless the FDA determines that a specific Provisional Product is not substantially equivalent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA has communicated that it will not review a certain subset of Provisional Product SE reports and that the products that are the subject of those reports can continue to be legally marketed without further FDA review.  PM USA and USSTC have Provisional Products included in this subset of products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe PM USA&#8217;s and USSTC&#8217;s current Provisional Products meet the statutory requirements of the FSPTCA, we cannot predict how the FDA will ultimately apply law, regulation and guidance to their various SE reports.  Should PM USA or USSTC receive unfavorable determinations on any SE reports currently pending with the FDA, we believe PM USA and USSTC can replace the vast majority of these product volumes with other FDA authorized products or with Pre-existing Tobacco Products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cigarette and smokeless tobacco products introduced into the market or modified after March 22, 2011 are &#8220;Non-Provisional Products&#8221; and must receive a marketing order from the FDA prior to being offered for sale.  Marketing orders for Non-Provisional Products may be obtained by filing an SE report, PMTA or using another pre-market pathway established by the FDA.  PM USA and USSTC may not be able to obtain a marketing order for non-provisional products because the FDA may determine that any such product does not meet the statutory requirements for approval.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Regulated in 2016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Manufacturers of products first regulated by the FDA in 2016, including cigars, oral nicotine pouches and e-vapor products, that were on the market as of August 8, 2016 and not subsequently modified must have filed an SE report or PMTA by the filing deadline of September 9, 2020 in order for their products to remain on the market.  These products can remain on the market during FDA review through court-allowed, case-by-case discretion, so long as the report or application was timely filed with the FDA.  In September 2022, the FDA represented that it had resolved more than 99% of the timely applications it had received, with the vast majority resulting in a denial.  A number of the denials are subject to litigation challenges initiated by the affected manufacturers.  For those products still under FDA review, it is uncertain when and for how long the FDA may permit continued marketing and sale of those products pursuant to its case-by-case discretion.  For products (new or modified) not on the market as of August 8, 2016, manufacturers must file an SE report or PMTA and receive FDA authorization prior to marketing and selling the product.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helix submitted PMTAs for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;on!&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oral nicotine pouches in May 2020.  As of April 24, 2023, the FDA has not issued marketing order decisions for any </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on!</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products.  In addition, as of April 24, 2023, Middleton has received market orders or exemptions that cover over 99% of its cigar product volume.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the FDA authorized the PMTA for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in July 2020, the FDA authorized the marketing of this system as an MRTP with a reduced exposure claim.  In December 2020, the FDA authorized the PMTA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3, an updated version of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices, and in March 2022 authorized the marketing of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3 device as an MRTP with the same reduced exposure claim.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with a patent dispute, the U.S. International Trade Commission (&#8220;ITC&#8221;) issued a cease and desist order, effective as of November 29, 2021, banning (i) the importation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and infringing components into the United States and (ii) the sale, marketing and distribution of such imported products in the United States.  As a result, PM USA removed the products from the marketplace.  For a further discussion of the ITC decision, see Note 11.  We have agreed to assign the exclusive U.S. commercialization rights to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System to Philip Morris International Inc. (&#8220;PMI&#8221;) effective April 2024 in exchange for a total cash payment of approximately $2.7 billion (plus interest).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2021, the FDA authorized the marketing and sale of four of USSTC&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Verve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oral nicotine products, including Green Mint and Blue Mint varieties, representing the first flavored product authorizations issued by the FDA for newly deemed innovative products.  These products are not currently marketed or sold.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FDA authorized USSTC to communicate a modified risk claim about its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen Classic Snuff</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MST product.  This product is not currently marketed or sold.  The authorized claim for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen Classic Snuff </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is &#8220;IF YOU SMOKE, CONSIDER THIS:  Switching completely to this product from cigarettes reduces risk of lung cancer.&#8221;  USSTC&#8217;s authorization to use this claim is subject to the FDA&#8217;s post-market surveillance requirements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Market Surveillance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Manufacturers that receive product authorizations through the PMTA process must adhere to the FDA post-market record keeping and reporting requirements, as detailed in market orders and in the final PMTA rule that went into effect in November 2021.  This includes notification of all marketing activities.  The FDA may amend requirements of a market order or withdraw the market order based on this information if, among other reasons, it determines that the continued marketing of the products is no longer appropriate for the protection of the public health.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of Adverse FDA Determinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: FDA review time frames have varied.  It is therefore difficult to predict the duration of FDA reviews of SE reports or PMTAs.  An unfavorable determination on an application, the withdrawal by the FDA of a prior marketing order or other changes in FDA regulatory requirements could result in the removal of products from the market.  A &#8220;not substantially equivalent&#8221; determination, a denial of a PMTA or a marketing order withdrawal by the FDA on one or more products (which would require the removal of the product or products from the market) could have a material adverse impact on our business, results of operations, cash flows or financial position.  Also, adverse FDA determinations on innovative tobacco products could have a material adverse effect on our ability to achieve our Vision.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">FDA Regulatory Actions</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">Graphic Warnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FDA issued a final rule requiring 11 textual warnings accompanied by color graphics depicting certain negative health consequences of smoking on cigarette packaging and advertising.  The final rule was set to become effective on October 6, 2023.  However, PM USA and other cigarette manufacturers filed lawsuits challenging the final rule on substantive and procedural grounds.  In December 2022, the U.S. District Court for the Eastern District of Texas found in favor of cigarette manufacturers in one such suit and blocked the rule, finding it unconstitutional on the basis that it compelled speech in violation of the First Amendment.  The FDA has appealed the decision.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">Underage Access and Use of Certain Tobacco Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA announced regulatory actions in September 2018 to address underage access and use of e-vapor products.  We have engaged with the FDA on this topic and have reaffirmed to the FDA our ongoing and long-standing commitment to preventing underage use.  For example, we advocated raising the minimum legal age to purchase all tobacco products to 21 at the federal and state levels to further address underage use, which is now federal law.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal, State and Local Legislation to Increase the Legal Age to Purchase Tobacco Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for further discussion.  In addition, through our retailer incentive program, stores representing over 80% of PM USA&#8217;s cigarette volume have implemented point-of-sale age validation technology.</span></div><div style="margin-bottom:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA issued final guidance in April 2020, stating that it intends to prioritize enforcement action against certain product categories, including cartridge-based, flavored e-vapor products and products targeted to minors.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">Electronic Nicotine Delivery System Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: As of April 24, 2023, many manufacturers of menthol and other flavored e-vapor products have received MDOs for failure to provide sufficiently strong product-specific scientific evidence to demonstrate that the benefit of their products to adult smokers overcomes the risk that their products pose to youth.  The FDA has communicated in these MDOs that vapor products with non-tobacco flavors present unique questions relevant to the FDA&#8217;s &#8220;Appropriate for the Protection of Public Health&#8221; standard and that successful applications require strong, product-specific evidence.  A number of these manufacturers are appealing the MDOs for their products.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Potential Product Standards</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">Nicotine in Cigarettes and Other Combustible Tobacco Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the FDA issued an ANPRM seeking comments on the potential public health benefits and any possible adverse effects of lowering nicotine in combustible cigarettes to non-addictive or minimally addictive levels.  Among other issues, the FDA sought comments on (i) whether smokers would compensate by smoking more cigarettes to obtain the same level of nicotine as with their current product and (ii) whether the proposed rule would create an illicit trade of cigarettes containing nicotine at levels higher than a non-addictive threshold that may be established by the FDA.  The FDA also sought comments on whether a nicotine product standard should apply to other combustible tobacco products, including cigars.  In January 2023, the Biden Administration published its Fall 2022 Unified Regulatory Agenda, which includes the FDA&#8217;s plans to propose, by October 2023, a product standard that would establish a maximum nicotine level in cigarettes and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combustible tobacco products.  Any proposed product standard would proceed through the rulemaking process, which we believe will take multiple years to complete.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">Flavors in Tobacco Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the FDA issued two proposed product standards: (i) banning menthol in cigarettes and (ii) banning all characterizing flavors (including menthol) in cigars.  The Biden Administration&#8217;s Fall 2022 Unified Regulatory Agenda includes the FDA&#8217;s plans to complete rulemaking with respect to these proposed product standards by the end of 2023.  We submitted comments during the notice-and-comment period and plan to continue engaging with the FDA through the rulemaking process.  The FDA could propose an additional product standard for flavors in innovative tobacco products, including e-vapor products and oral nicotine products.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.46pt">N-nitrosonornicotine (&#8220;NNN&#8221;) in Smokeless Tobacco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FDA proposed a product standard for NNN levels in finished smokeless tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any one or more of the foregoing potential product standards were to become final and was appealed and upheld in the courts, it could have a material adverse effect on our business, results of operations, cash flows or financial position, including a material adverse effect on the carrying value of our assets such as our cigar trademarks.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Good Manufacturing Practices: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FDA, pursuant to the requirements of the FSPTCA, issued a proposed rule setting forth requirements for tobacco product manufacturers regarding the manufacture, design, packing and storage of their products.  This proposed rule establishes a framework of good manufacturing practices, including by:  </span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">establishing tobacco product design and development controls;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ensuring that finished and bulk tobacco products are manufactured according to established specifications;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">minimizing the manufacture and distribution of tobacco products that do not meet specifications;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">requiring manufacturers to take appropriate measures to prevent contamination of tobacco products;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">requiring investigation and identification of products that do not meet specifications and requiring manufacturers to institute appropriate corrective actions, such as a recall; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">establishing the ability to trace all components or parts, ingredients, additives and materials, as well as each batch of finished or bulk tobacco products, to aid in investigations of those that do not meet specifications.</span></div><div style="margin-bottom:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to engage with the FDA through the rulemaking process, including during the notice-and-comment period.  If the proposed rule were to take effect, compliance with these requirements could result in increased costs.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Impact on Our Business; Compliance Costs and User Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional FDA regulatory actions under the FSPTCA could have a material adverse effect on our business, results of operations, cash flows or financial position in various ways.  For example, actions by the FDA could:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impact the consumer acceptability of tobacco products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delay, discontinue or prevent the sale or distribution of existing, new or modified tobacco products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">limit adult tobacco consumer choices;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impose restrictions on communications with adult tobacco consumers;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">create a competitive advantage or disadvantage for certain tobacco companies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impose additional manufacturing, labeling or packaging requirements;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impose additional restrictions at retail;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">result in increased illicit trade in tobacco products; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">otherwise significantly increase the cost of doing business.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FSPTCA imposes user fees on cigarette, cigarette tobacco, smokeless tobacco, cigar and pipe tobacco manufacturers and importers to pay for the cost of regulation and other matters.  The FSPTCA does not impose user fees on e-vapor or oral nicotine pouch manufacturers.  The cost of the FDA user fee is allocated&#160;first among tobacco product categories subject to FDA user fees and then among manufacturers and importers within each respective category based on their relative market shares, all as prescribed by the FSPTCA and FDA regulations.  Payments for user fees are adjusted for several factors, including market share and industry volume.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources - Payments Under State Settlement Agreements and FDA Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a discussion of our FDA user fee payments.  In addition, compliance with the FSPTCA&#8217;s regulatory requirements has resulted, and will continue to result, in additional costs.  The amount of additional compliance and related costs has not been material in any given quarter or year-to-date period but could become material, either individually or in the aggregate.  The failure to comply with FDA regulatory requirements, even inadvertently, and FDA enforcement actions also could have a material adverse effect on our business, results of operations, cash flows or financial position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Investigation and Enforcement: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has a number of investigatory and enforcement tools available to it, including document requests and other required information submissions, facility inspections, facility closures, examinations and investigations, injunction proceedings, monetary penalties, product withdrawal and recall orders, and product seizures.  Investigations or enforcement actions could result in significant costs or otherwise have a material adverse effect on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excise Taxes</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tobacco products are subject to substantial excise taxes in the United States.  Significant increases in tobacco-related taxes or fees have been proposed or enacted (including with respect to e-vapor products) and are likely to continue to be proposed or enacted at the federal, state and local levels within the United States.  The frequency and magnitude of excise tax increases can be influenced by various factors, including the composition of executive and legislative bodies.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and local cigarette excise taxes have increased substantially over the past two decades, far outpacing the rate of inflation.  Between the end of 1998 and April 24, 2023, the weighted-average state cigarette excise tax increased from $0.36 to $1.89 per pack.  As of April 24, 2023, no state has enacted new legislation increasing excise taxes in 2023.  However, various increases are under consideration or have been proposed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of states currently tax MST using an ad valorem method, which is calculated as a percentage of the price of the product, typically the wholesale price.  This ad valorem method results in more tax being paid on premium products than is paid on lower-priced products of equal weight.  We support legislation to convert ad valorem taxes on MST to a weight-based methodology because, unlike the ad valorem tax, a weight-based tax subjects cans of equal weight to the same tax.  As of April 24, 2023, the federal government, 23 states, Puerto Rico, Philadelphia, Pennsylvania and Cook County, Illinois have adopted a weight-based tax methodology for MST.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increasing number of states and localities also are imposing excise taxes on e-vapor products and oral nicotine pouches.  As of April 24, 2023, 30 states, the District of Columbia, Puerto Rico and a number of cities and counties have enacted legislation to tax e-vapor products.  These taxes are calculated in varying ways and may differ based on the e-vapor product form.  Similarly, 11 states and the District of Columbia have enacted legislation to tax oral nicotine pouches.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax increases are expected to continue to have an adverse impact on sales of our operating companies&#8217; products through lower consumption levels and the potential shift in adult tobacco consumer purchases from premium to non-premium or discount cigarettes, to lower taxed tobacco products or to counterfeit and contraband products.  Lower sales volume and reported share performance of our operating companies&#8217; products could have a material adverse effect on our business, results of operations, cash flows or financial position.  In addition, substantial excise tax increases on e-vapor and oral nicotine products may negatively impact adult smokers&#8217; transition to these products, which could materially adversely affect our ability to achieve our Vision.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Treaty on Tobacco Control</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The World Health Organization&#8217;s Framework Convention on Tobacco Control (the &#8220;FCTC&#8221;) entered into force in February&#160;2005.  As of April 24, 2023, 181 countries, as well as the European Union, have become parties to the FCTC.  While the United States is a signatory of the FCTC, it is not currently a party to the agreement, as the agreement has not been submitted to, or ratified by, the U.S. Senate.  The FCTC is the first international public health treaty and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation.  The treaty recommends (and in certain instances, requires) signatory nations to enact legislation that would address various tobacco-related issues.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of proposals currently under consideration by the governing body of the FCTC, some of which call for substantial restrictions on the manufacture, marketing, distribution and sale of tobacco products.  It is not possible to predict the outcome of these proposals or the impact of any FCTC actions on legislation or regulation in the United States, either indirectly or as a result of the United States becoming a party to the FCTC, or whether or how these actions might indirectly influence FDA regulation and enforcement.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State Settlement Agreements</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11, during 1997 and 1998, PM USA and other major domestic cigarette manufacturers entered into the State Settlement Agreements.  These settlements require participating manufacturers to make substantial annual payments, which are adjusted for several factors, including inflation, operating income, market share and industry volume.  Increases in inflation can increase our financial liability under the State Settlement Agreements.  The State Settlement Agreements&#8217; inflation calculations require us to apply the higher of 3% or the U.S. Bureau of Labor Statistics&#8217; Consumer Price Index for All Urban Consumers (&#8220;CPI-U&#8221;) percentage rate as published in January of each year.  As of December 2022, the inflation calculation was approximately 6.5% based on the latest CPI-U data; however, the increase in the annual payments did not have a material impact on our financial position.  We believe that inflation will continue at increased levels in 2023, but do not expect the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corresponding increase in annual payments to result in a material financial impact.  However, we will continue to monitor the impact of increased inflation on the macroeconomic environment and our businesses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the impact of the State Settlement Agreements on us, see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Liquidity and Capital Resources - Payments Under State Settlement Agreements and FDA Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below and Note 11.  The State Settlement Agreements also place numerous requirements and restrictions on participating manufacturers&#8217; business operations, including prohibitions and restrictions on the advertising and marketing of cigarettes and smokeless tobacco products.  Among these are prohibitions of outdoor and transit brand advertising, payments for product placement and free sampling (except in adult-only facilities).  The State Settlement Agreements also place restrictions on the use of brand name sponsorships and brand name non-tobacco products and prohibitions on targeting youth and the use of cartoon characters.  In addition, the State Settlement Agreements require companies to affirm corporate principles directed at reducing underage use of cigarettes; impose requirements regarding lobbying activities; limit the industry&#8217;s ability to challenge certain tobacco control and underage use laws; and provide for the dissolution of certain tobacco-related organizations and place restrictions on the establishment of any replacement organizations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 1998, USSTC entered into the Smokeless Tobacco Master Settlement Agreement (the &#8220;STMSA&#8221;) with the attorneys general of various states and United States territories to resolve the remaining health care cost reimbursement cases initiated against USSTC.  The STMSA required USSTC to adopt various marketing and advertising restrictions.  USSTC is the only smokeless tobacco manufacturer to sign the STMSA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other International, Federal, State and Local Regulation and Governmental and Private Activity</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">International, Federal, State and Local Regulation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various states and localities have enacted or proposed legislation that imposes restrictions on tobacco products (including cigarettes, smokeless tobacco, cigars, e-vapor products and oral nicotine pouches), such as legislation that (i) prohibits the sale of all tobacco products or certain tobacco categories, such as e-vapor, (ii) prohibits the sale of tobacco products with characterizing flavors, such as menthol cigarettes and flavored e-vapor products, (iii) requires the disclosure of health information separate from or in addition to federally mandated health warnings and (iv) restricts commercial speech or imposes additional restrictions on the marketing or sale of tobacco products.  The legislation varies in terms of the type of tobacco products, the conditions under which such products are or would be restricted or prohibited, and exceptions to the restrictions or prohibitions.  For example, a number of proposals involving characterizing flavors would prohibit smokeless tobacco products with characterizing flavors without providing an exception for mint- or wintergreen-flavored products.  As of April 24, 2023, multiple states and localities are considering legislation to ban flavors in one or more tobacco products, and six states (California, Massachusetts, New Jersey, Utah, New York and Illinois) and the District of Columbia have passed such legislation.  Some of these states, such as New York, Utah and Illinois, exempt certain products that have received FDA market authorization through the PMTA pathway.  The legislation in California, which became effective in December 2022, bans the sale of most tobacco products with characterizing flavors, including menthol, mint and wintergreen.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Massachusetts passed legislation capping the amount of nicotine in e-vapor products.  Similar legislation is pending in four other states.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar restrictions to those enacted or proposed in various U.S. states and localities on e-vapor and oral nicotine pouch products have been enacted or proposed internationally.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have challenged and will continue to challenge certain federal, state and local legislation and other governmental action, including through litigation.  It is possible, however, that legislation, regulation or other governmental action could be enacted or implemented that could have a material adverse impact on our business, results of operations, cash flows or financial position.  Such action also could negatively impact adult smokers&#8217; transition to smoke-free products, which could materially adversely affect our ability to achieve our Vision.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Federal, State and Local Legislation to Increase the Legal Age to Purchase Tobacco Products: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a number of states and localities proposed and enacted legislation to increase the minimum age to purchase all tobacco products, including e-vapor products, in December 2019, the federal government passed legislation increasing the minimum age to purchase all tobacco products, including e-vapor products, to 21 nationwide.  As of April 24, 2023, 42 states, the District of Columbia and Puerto Rico have enacted laws increasing the legal age to purchase tobacco products to 21.  Although an increase in the minimum age to purchase tobacco products may have a negative impact on our operating companies&#8217; sales volumes, as discussed above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underage Access and Use of Certain Tobacco Products,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we support raising the minimum legal age to purchase all tobacco products to 21 at the federal and state levels, reflecting our longstanding commitment to combat underage tobacco use.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Health Effects of Tobacco Products, Including E-vapor Products: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reports with respect to the health effects of smoking have been publicized for many years, including various reports by the U.S. Surgeon General.  We believe that the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public should be guided by the messages of the U.S. Surgeon General and public health authorities worldwide in making decisions concerning the use of tobacco products, including e-vapor products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most jurisdictions within the United States have restricted smoking in public places and some have restricted vaping in public places.  Some public health groups have called for, and various jurisdictions have adopted or proposed, bans on smoking and vaping in outdoor places, in private apartments and in cars transporting children.  It is not possible to predict the results of ongoing scientific research or the types of future scientific research into the health risks of tobacco exposure and the impact of such research on legislation and regulation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Other Legislation or Governmental Initiatives: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions discussed above, other regulatory initiatives affecting the tobacco industry have been adopted or are being considered at the federal level and in a number of state and local jurisdictions.  For example, in recent years, legislation has been introduced or enacted at the state or local level to subject tobacco products to various reporting requirements and performance standards; establish educational campaigns relating to tobacco consumption or tobacco control programs or provide additional funding for governmental tobacco control activities; restrict the sale of tobacco products in certain retail establishments and the sale of tobacco products in certain package sizes; prohibit the sale of tobacco products based on environmental concerns; impose responsibility on manufacturers for the disposal, recycling or other treatment of post-consumer goods such as plastic packaging; require tax stamping of smokeless tobacco products; require the use of state tax stamps using data encryption technology; and further restrict the sale, marketing and advertising of cigarettes and other tobacco products.  Such legislation may be subject to constitutional or other challenges on various grounds, which may or may not be successful.  In addition, if a pandemic or similar health emergency occurs, state and local governments may reimpose additional health and safety requirements for all businesses, which could result in the potential temporary closure of certain businesses and facilities.  It is possible that tobacco manufacturing and other facilities and the facilities of our suppliers, our suppliers&#8217; suppliers and our trade partners could be subject to additional government-mandated temporary closures and restrictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not possible to predict what, if any, additional legislation, regulation or other governmental action will be enacted or implemented (and, if challenged, upheld) relating to the manufacturing, design, packaging, marketing, advertising, sale or use of tobacco products, or the tobacco industry generally.  Any such legislation, regulation or other governmental action could have a material adverse impact on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Governmental Investigations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are subject to governmental investigations on a range of matters.  For example, we are subject to a number of governmental investigations with respect to our former investment in JUUL, which we divested in March 2023, including the following: (i) the FTC issued a Civil Investigative Demand (&#8220;CID&#8221;) to us while conducting its antitrust review of our former investment in JUUL seeking information regarding, among other things, our role in the resignation of JUUL&#8217;s former chief executive officer and the hiring by JUUL of any current or former Altria director, executive or employee (see Note 11 for a description of the FTC&#8217;s administrative complaint against us and JUUL); (ii) the SEC commenced an investigation relating to our acquisition, disclosures and accounting</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controls in connection with the JUUL investment; and (iii) the New York State Office of the Attorney General and the Commonwealth of Massachusetts Office of the Attorney General, separately, issued independent subpoenas to us seeking documents relating to our former investment in and provision of services to JUUL.  For a discussion of our disposition of our interest in JUUL, see Note 3.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, JUUL is currently under investigation by various federal and state agencies, including the SEC, the FDA and the FTC, and state attorneys general.  Such investigations vary in scope but at least some include JUUL&#8217;s marketing practices, particularly as such practices relate to youth, and we may be asked in the context of those investigations to provide information concerning our former investment in JUUL or relating to our marketing of Nu Mark LLC e-vapor products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to lawsuits initiated by the attorneys general of Alaska, Hawaii and New Mexico relating to our former investment in JUUL.  In April 2023, we agreed to settle a lawsuit initiated by the attorney general of Minnesota.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Private Sector Activity on Tobacco Products</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of retailers, including national chains, have discontinued the sale of all tobacco products, and others have discontinued the sale of e-vapor products.  Reasons for the discontinuation include change in corporate policy and, with respect to e-vapor products, reported illnesses and the uncertain regulatory environment.  Furthermore, third-party digital platforms, such as app stores, have restricted, and in some cases prohibited, communications with adult tobacco consumers concerning tobacco products.  It is possible that if this private sector activity becomes more widespread it could have an adverse effect on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illicit Trade in Tobacco Products</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illicit trade in tobacco products can have an adverse impact on our business.  Illicit trade can take many forms, including the sale of counterfeit tobacco products; the sale of tobacco products in the United States that are intended for sale outside the country; the sale of untaxed tobacco products over the Internet and by other means designed to avoid the collection of applicable taxes; and diversion into one taxing jurisdiction of tobacco products intended for sale in another.  Counterfeit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tobacco products, for example, are manufactured by unknown third parties in unregulated environments.  Counterfeit versions of our products can negatively affect adult tobacco consumer experiences with and opinions of those brands.  Illicit trade in tobacco products also harms law-abiding wholesalers and retailers by depriving them of lawful sales and undermines the significant investment we have made in legitimate distribution channels.  Moreover, illicit trade in tobacco products results in federal, state and local governments losing tax revenues.  Losses in tax revenues can cause such governments to take various actions, including increasing excise taxes, imposing legislative or regulatory requirements, or asserting claims against manufacturers of tobacco products or members of the trade channels through which such tobacco products are distributed and sold, each of which may have an adverse effect on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We communicate with wholesale and retail trade members regarding illicit trade in tobacco products and how we can help prevent such activities, enforce wholesale and retail trade programs and policies that address illicit trade in tobacco products and, when necessary, litigate to protect our trademarks.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Price, Availability and Quality of Tobacco, Other Raw Materials, Ingredients and Component Parts</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shifts in crops (such as those driven by economic conditions and adverse weather patterns), government restrictions and mandated prices, production control programs, economic trade sanctions, import duties and tariffs, international trade disruptions, inflation, geopolitical instability, climate and environmental changes and disruptions due to man-made or natural disasters may increase the cost or reduce the supply or quality of tobacco, other raw materials, ingredients or component parts used to manufacture our operating companies&#8217; products.  Any significant change in such factors could negatively impact our ability to continue manufacturing and marketing existing products or impact adult consumer product acceptability and have a material adverse effect on our business and profitability.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other agricultural commodities, tobacco price, quality&#160;and availability can be influenced by variations in weather patterns, including those caused by climate change, and macroeconomic conditions and imbalances in supply and demand, among other factors.  For varieties of tobacco only available in limited geographies, government-mandated prices and production control programs, political instability or government prohibitions on the import or export of tobacco in certain countries pose additional risks to price, availability and quality.  In addition, as consumer demand increases for smoke-free products and decreases for combustible products, the volume of tobacco leaf required for production may decrease, resulting in reduced demand.  The reduced demand for tobacco leaf may result in the reduced supply and availability of domestic tobacco as growers divert resources to other crops or cease farming.  The unavailability or unacceptability of any one or more particular varieties of tobacco leaf necessary to manufacture our operating companies&#8217; products could negatively impact our ability to continue marketing existing products or impact adult tobacco consumer product acceptability, which could result in increased costs to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current macroeconomic conditions and geopolitical instability (including high inflation, high gas prices, rising interest rates, labor shortages, supply and demand imbalances and the Russian invasion of Ukraine) have caused and continue to cause worldwide disruptions and delays to supply chains and commercial markets, which limit access to, and increase the cost of, raw materials, ingredients and component parts (for example, tobacco leaf and resins and aluminum used in our packaging).  We have implemented and continue to implement various strategies to help secure sufficient supplies of raw materials, ingredients and component parts for production.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government taxes, restrictions and prohibitions on the sale and use of certain products may limit access to, and increase the costs of, raw materials and component parts and, potentially, impede our ability to sell certain of our operating companies&#8217; products.  For example, additional taxes on the use of certain single-use plastics have been proposed by the U.S. Congress, which, if passed, could increase the costs of, and impair our ability to, source certain materials used in the packaging for our operating companies&#8217; products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work to mitigate these risks by maintaining inventory levels of certain tobacco varieties that cover several years, purchasing raw materials, ingredients and component parts from disperse geographic regions throughout the world and entering into long-term contracts with some of our tobacco growers and direct material suppliers.  To date, the impact on us of changes in the price, availability and quality of tobacco, other raw materials, ingredients and component parts has not been material.  However, the effects of the current macroeconomic and geopolitical conditions on prices, availability and quality of such items may continue, which could have a material adverse effect on our business, results of operations, cash flows or financial position.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Sales</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are subject to many influences that can impact the timing of sales to customers, including the timing of holidays and other annual or special events, the timing of promotions, customer incentive programs and customer inventory programs, as well as the actual or speculated timing of pricing actions and tax-driven price increases.</span></div><div style="margin-bottom:5pt"><span><br/></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_133"></div><div style="padding-right:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smokeable Products Segment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes operating results, includes reported and adjusted OCI margins and provides a reconciliation of reported OCI to adjusted OCI for our smokeable products segment:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Results</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,090</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(928)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues net of excise taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,162</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,221</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported OCI</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPM Adjustment Items</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation items</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted OCI</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,515</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported OCI margins </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5) pp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted OCI margins </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 pp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2023 Compared with Three Months Ended March&#160;31, 2022</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues, which include excise taxes billed to customers, decreased $175 million (3.3%), due primarily to lower shipment volume ($654 million), partially offset by higher pricing ($472 million), which includes higher promotional investments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported OCI decreased $56 million (2.2%), due primarily to lower shipment volume ($404 million), higher per unit settlement charges and NPM Adjustment Items in 2022 ($60 million), partially offset by higher pricing, which includes higher promotional investments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted OCI was essentially unchanged as higher pricing, which includes higher promotional investments, was mostly offset by lower shipment volume and higher per unit settlement charges.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipment Volume and Retail Share Results</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our smokeable products segment&#8217;s shipment volume performance:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shipment Volume</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(sticks in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigarettes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Marlboro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other premium</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cigarettes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigars:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Black &amp; Mild</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cigars</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total smokeable products</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Cigarettes shipment volume includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">; Other premium brands, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Virginia Slims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Parliament </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Benson &amp; Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">; and Discount brands, which include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">L&amp;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Chesterfield.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cigarettes volume includes units sold as well as promotional units but excludes units sold for distribution to Puerto Rico, U.S. Territories to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to our smokeable products segment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cigarettes retail share performance:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retail Share</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Point Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigarettes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Marlboro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other premium</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cigarettes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Retail share results for cigarettes are based on data from Circana, Inc. and Circana Group, L.P. (&#8220;Circana&#8221;), formerly IRI, as well as, Management Science Associates, Inc. (&#8220;MSA&#8221;).  Circana is a newly formed company reflecting the recent merger of IRI and NPD Group, Inc.  Circana maintains a blended retail service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends.  Similar to prior reporting, this service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes.  For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (&#8220;STARS&#8221;), as provided by MSA.  This service is not designed to capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets.  It is retail services&#8217; standard practice to periodically refresh their retail scan services, which could restate retail share results that were previously released in this service.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of volume trends and factors that impact volume and retail share performance, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tobacco Space - Business Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2023 Compared with the Three Months Ended March&#160;31, 2022</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our smokeable products segment&#8217;s reported domestic cigarettes shipment volume decreased 11.4%, driven primarily by the industry&#8217;s decline rate, retail share losses (both of which were impacted by macroeconomic pressures on adult tobacco consumers&#8217; disposable income) and trade inventory movements, partially offset by calendar differences.  When adjusted for trade inventory movements and calendar differences, our smokeable products segment&#8217;s reported domestic cigarettes shipment volume decreased by an estimated 11%.  When adjusted for calendar differences, trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 9%.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipments of premium cigarettes accounted for 94.3% and 93.3% of our smokeable products segment&#8217;s reported domestic cigarettes shipment volume for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">retail share of the total cigarette category decreased 0.6 share points versus the prior year and 0.2 share points sequentially to 42.0%, primarily due to increased macroeconomic pressures on adult tobacco consumers&#8217; disposable income and increased competitive activity.  However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8217;s share of the premium segment grew to 58.5%, an increase of 0.7 share points versus the prior year and 0.1 share point sequentially.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cigarettes industry discount segment retail share increased 1.8 share points versus the prior year and 0.5 share points sequentially to 28.2%, primarily due to increased macroeconomic pressures on adult tobacco consumers&#8217; disposable income and increased competitive activity.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion regarding discount product dynamics in 2023 and the economic conditions, including a high inflationary environment, that impact adult tobacco consumer purchasing behavior, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Results by Business Segment - Tobacco Space - Business Environment - Summary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA and Middleton executed the following pricing and promotional allowance actions during 2023 and 2022:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective January 22, 2023, PM USA increased the list price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L&amp;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chesterfield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by $0.15 per pack.  PM USA also increased the list price of all its other cigarette brands by $0.20 per pack.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective October 16, 2022, PM USA increased the list price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L&amp;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chesterfield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by $0.15 per pack.  PM USA also increased the list price of all its other cigarette brands by $0.20 per pack.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective July 17, 2022, PM USA increased the list price on all of its cigarette brands by $0.15 per pack.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective May 22, 2022, Middleton increased various list prices across substantially all of its cigar brands resulting in a weighted-average increase of approximately $0.17 per five-pack.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective April 24, 2022, PM USA increased the list price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> L&amp;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chesterfield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $0.15 per pack.  PM USA also increased the list price of all its other cigarette brands by $0.20 per pack.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective January 9, 2022, Middleton increased various list prices across substantially all of its cigar brands resulting in a weighted-average increase of approximately $0.13 per five-pack.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective April 23, 2023, PM USA increased the list price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L&amp;M </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by $0.15 per pack.  PM USA also increased the list price of all its other cigarette brands by $0.20 per pack.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_139"></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oral Tobacco Products Segment</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Results</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes operating results, includes reported and adjusted OCI margins, and provides a reconciliation of reported OCI to adjusted OCI for our oral tobacco products segment:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Results</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues net of excise taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">600</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported and Adjusted OCI</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported and Adjusted OCI margins </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4) pp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2023 Compared with Three Months Ended March&#160;31, 2022</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues, which include excise taxes billed to customers, increased $15 million (2.4%), due primarily to higher pricing ($39 million), which includes higher promotional investments, partially offset by lower shipment volume and a higher percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on! </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shipment volume relative to MST (&#8220;volume/mix&#8221;) versus 2022 ($22 million)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported and adjusted OCI increased $9 million (2.2%), due primarily to higher pricing, which includes higher promotional investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by lower volume/mix ($25 million).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipment Volume and Retail Share Results</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our oral tobacco products segment&#8217;s shipment volume performance:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shipment Volume</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(cans and packs in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Copenhagen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Skoal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">on!</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oral tobacco products</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Other primarily includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Red Seal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  Oral tobacco products shipment volume includes cans and packs sold, as well as promotional units, but excludes international volume, which is currently not material to our oral tobacco products segment.  New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis.  To calculate volumes of cans and packs shipped, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack or can, is assumed to be equivalent to one can of MST.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our oral tobacco products segment&#8217;s retail share performance (excluding international volume):</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retail Share</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Point Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Copenhagen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Skoal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">on!</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oral tobacco products</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Our oral tobacco products segment&#8217;s retail share results exclude international volume, which is currently not material to our oral tobacco products segment.  Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends.  This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans and packs sold.  Oral tobacco products are defined by Circana as MST, snus and oral nicotine pouches.  New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis.  For example, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack or can, is assumed to be equivalent to one can of MST.  Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share.  It is retail services&#8217; standard practice to periodically refresh their retail scan services, which could restate retail share results that were previously released in this service.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of volume trends and factors that impact volume and retail share performance, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tobacco Space - Business Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2023 Compared with Three Months Ended March&#160;31, 2022</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral tobacco products segment&#8217;s reported domestic shipment volume decreased 1.8%, driven primarily by retail share losses, trade inventory movements and other factors, partially offset by calendar differences and the industry&#8217;s growth rate.  When adjusted for calendar differences and trade inventory movements, our oral tobacco products segment&#8217;s reported domestic shipment volume decreased by an estimated 3%.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total oral tobacco products category industry volume increased by an estimated 1% for the six months ended March&#160;31, 2023, primarily driven by growth in oral nicotine pouches, partially offset by declines in MST volumes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral tobacco products segment&#8217;s retail share was 45.2%, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> continued to be the leading oral tobacco brand with a retail share of 25.4%.  In the oral tobacco products segment, share declines for MST products were primarily driven by the share growth of oral nicotine pouches.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. nicotine pouch category grew to 26.2% of the U.S. oral tobacco category, an increase of 7.1 share points versus the prior year.  In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on!</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the nicotine pouch category grew to 24.6%, an increase of 3.3 share points versus the prior year.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USSTC executed the following pricing actions during 2023 and 2022:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective January 24, 2023, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal, Red Seal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.09 per can.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective July 26, 2022, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">popular price products by $0.13 per can.  USSTC also decreased the list price on select </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.11 per can.  In addition, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Red Seal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands and the balance of its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.09 per can and increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand by $0.12 per can.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective May 24, 2022, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Red Seal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.09 per can.  USSTC also increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand by $0.12 per can.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective February 22, 2022, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Red Seal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.08 per can.  USSTC also increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand by $0.12 per can.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Effective April 25, 2023, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">popular price products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Red Seal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Husky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands by $0.09 per can.  In addition, USSTC increased the list price on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skoal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands and on the balance of its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Copenhagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $0.10 per can.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company that is primarily dependent on the capital resources of our subsidiaries to satisfy our liquidity requirements.  Our access to the operating cash flows of our wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans.  At March&#160;31, 2023, our significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.  In addition, we receive cash dividends on our interest in ABI and will continue to do so as long as ABI pays dividends.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had $3.9 billion of cash and cash equivalents.  In addition to having access to the operating cash flows of our wholly owned subsidiaries, our capital resources include access to credit markets in the form of commercial paper, availability under our $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the &#8220;Credit Agreement&#8221;), which we use for general corporate purposes and access to credit markets through the issuance of long-term senior unsecured notes.  For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Markets and Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to funding current operations, we primarily use our net cash from operating activities for payment of dividends, share repurchases under our share repurchase programs, repayment of debt, acquisitions of or investments in businesses and assets, and capital expenditures.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our cash and cash equivalents balance, along with our future cash flows from operations, capacity for borrowings under the Credit Agreement and access to credit and capital markets, provide sufficient liquidity to meet the needs of our business operations and to satisfy our projected cash requirements for the next 12 months and the foreseeable future.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Markets and Other Matters</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our cost and terms of financing and our access to commercial paper markets may be impacted by applicable credit ratings.  The impact of credit ratings on the cost of borrowings under the Credit Agreement is discussed in Note 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1 (&#8220;Note 9&#8221;).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the credit ratings and outlook for our indebtedness by major credit rating agencies were:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s Investors Service, Inc. (&#8220;Moody&#8217;s&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;P-2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;A3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Stable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s Financial Services LLC (&#8220;S&amp;P&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;A-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BBB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Stable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch Ratings Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;F2</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BBB</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Stable</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Lines </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- From time to time, we have short-term borrowing needs to meet our working capital requirements arising from the timing of annual MSA payments, quarterly income tax payments and quarterly dividend payments, and generally use our commercial paper program to meet those needs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had availability under the Credit Agreement for borrowings of up to an aggregate principal amount of $3.0 billion, and we were in compliance with the covenants in the Credit Agreement.  We expect to continue to meet the covenants in the Credit Agreement.  We monitor the credit quality of our bank group and are not aware of any potential non-performing credit provider in that group.  For further discussion on short-term borrowings, see Note 9.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - At March&#160;31, 2023 and December&#160;31, 2022, our total debt was $25.4 billion and $26.7 billion, respectively.  In February 2023, we repaid in full our 1.000% senior unsecured Euro notes in the aggregate principal amount of $1.3 billion (&#8364;1.25 billion) at maturity.  As a result of the repayment and changes in the Euro exchange rate, the weighted-average coupon interest rate on our total long-term debt increased to approximately 4.2% at March 31, 2023 from approximately 4.0% at December 31, 2022.  For further details on long-term debt, see Note 9.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As discussed in Note 11, we had unused letters of credit obtained in the ordinary course of business and guarantees (including third-party guarantees) outstanding at March&#160;31, 2023.  From time to time, we also issue lines of credit to affiliated entities.  In addition, as discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Guarantor Financial Information </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in Note 9, PM USA has issued guarantees relating to our obligations under our outstanding debt securities, borrowings under the Credit Agreement and amounts outstanding under the commercial paper program.  These items have not had, and are not expected to have, a significant impact on our liquidity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments Under State Settlement Agreements and FDA Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As discussed in Note 11, PM USA has entered into State Settlement Agreements with the states, the District of Columbia and certain U.S. territories that call for certain payments.  In addition, PM USA, Middleton and USSTC are subject to quarterly user fees imposed by the FDA as a result of the FSPTCA.  For further discussion of the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the MSA, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - NPM Adjustment Disputes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 11.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current agreements, estimated market share, estimated annual industry volume decline rates and inflation rates, the estimated amounts that we may charge to cost of sales for payments related to State Settlement Agreements and FDA user fees are $4.0 billion on average for the next three years.  These amounts exclude the potential impact of any NPM Adjustment Items.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amounts due under the State Settlement Agreements charged to cost of sales in each year are generally paid in April of the following year.  The amounts charged to cost of sales for FDA user fees are generally paid in the quarter in which the fees are incurred.  We paid approximately $3.2 billion in April 2023 for amounts accrued in 2022 under the State Settlement Agreements.  We recorded $1.0 billion of charges to cost of sales for the three months ended March&#160;31, 2023 and 2022, respectively, in connection with the State Settlement Agreements and FDA user fees.  As previously stated, the payments due under the terms of the State Settlement Agreements and FDA user fees are subject to adjustment for several factors, including volume, operating income, inflation and certain contingent events and, in general, are allocated based on each manufacturer&#8217;s market share.  The future payment amounts discussed above are estimates, and actual payment amounts will differ to the extent underlying assumptions differ from actual future results.  For further discussion on the potential impact of inflation on future payments, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Results by Business Segment - Tobacco Space - State Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-Related Deposits and Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - With respect to certain adverse verdicts currently on appeal, to obtain stays of judgments pending appeals, as of March&#160;31, 2023, PM USA had posted appeal bonds totaling $46 million, which have been collateralized with restricted cash that is included in assets on our condensed consolidated balance sheet.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is subject to uncertainty, and an adverse outcome or settlement of litigation could have a material adverse effect on our results of operations, cash flows or financial position in a particular fiscal quarter or fiscal year, as more fully disclosed in Note 11.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NJOY Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In March 2023, we entered into a definitive agreement to acquire NJOY for approximately $2.75 billion in cash payable at closing plus up to an additional $500 million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products.  We have multiple sources of funding for the NJOY Transaction, including our operating cash flows, access to credit markets, committed short-term bank financing and future cash payments from PMI, as discussed below.  The completion of the NJOY Transaction is subject to customary closing conditions and is not subject to any financing condition.  For further discussion, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Summary -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altria and PMI Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2022, we entered into an agreement with PMI to, among other things, transition and ultimately conclude our relationship with respect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System in the United States.  We received a payment of $1.0 billion in 2022 and expect to receive an additional payment of $1.7 billion (plus interest) by July 2023 for a total cash payment of approximately $2.7 billion (plus interest).  We expect to use the cash proceeds for several items, which may include investments in pursuit of our Vision, repayment of debt, share repurchases and general corporate purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity and Dividends</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2023 and 2022, we paid dividends of $1,683 million and $1,645 million, respectively, an increase of 2.3%, reflecting a higher dividend rate, partially offset by fewer shares outstanding as a result of shares we repurchased under our share repurchase program.  Our current annualized dividend rate is $3.76 per share.  In March 2023, we established a new progressive dividend goal that targets mid-single digits dividend growth annually.  Future dividend payments remain subject to the discretion of our Board of Directors (&#8220;Board of Directors&#8221; or &#8220;Board&#8221;).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our share repurchase programs, see Note 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Background and Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements in Item 1  and Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds of this Form 10-Q.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Review</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided by/Used in Operating Activities</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2023, net cash provided by operating activities was $2,984 million compared with $3,075 million during the first three months of 2022.  This decrease was due primarily to lower net revenues.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a working capital deficit at March&#160;31, 2023 and December&#160;31, 2022.  Our management believes that we have the ability to fund working capital deficits with cash provided by operating activities, borrowings under the Credit Agreement and access to the credit and capital markets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided by/Used in Investing Activities</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2023, net cash used in investing activities was $56 million compared with $34 million during the first three months of 2022.  This increase was due primarily to higher capital expenditures and proceeds from finance asset sales in 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided by/Used in Financing Activities</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2023, net cash used in financing activities was $3,045 million compared with $2,232 million during the first three months of 2022.  This increase was due primarily to the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">repayment of $1.3 billion in full of our 1.000% senior unsecured Euro notes at their scheduled maturity in February 2023; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">higher dividends paid in 2023;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">repurchases of common stock in 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Guidance Not Yet Adopted</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements in Item 1 for a discussion of issued accounting guidance applicable to, but not yet adopted by, us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for a discussion of contingencies.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_148"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Guarantor Financial Information</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA (the &#8220;Guarantor&#8221;), which is a 100% owned subsidiary of Altria Group, Inc. (the &#8220;Parent&#8221;), has guaranteed the Parent&#8217;s obligations under its outstanding debt securities, borrowings under its Credit Agreement and amounts outstanding under its&#160;commercial paper program (the &#8220;Guarantees&#8221;).  Pursuant to&#160;the Guarantees, the Guarantor fully and unconditionally guarantees, as primary obligor, the payment and performance of the Parent&#8217;s obligations under the guaranteed debt instruments (the &#8220;Obligations&#8221;), subject to release under certain customary circumstances as noted below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Guarantees provide that the Guarantor guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the Obligations.  The liability of the Guarantor under the Guarantees is absolute and unconditional irrespective of: any lack of validity, enforceability or genuineness of any provision of any agreement or instrument relating thereto; any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to departure from any agreement or instrument relating thereto; any exchange, release or non-perfection of any collateral, or any release or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Obligations; or any other circumstance that might otherwise constitute a defense available to, or a discharge of, the Parent or the Guarantor.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable provisions of federal bankruptcy law or comparable provisions of state fraudulent transfer law, the Guarantees could be voided, or claims in respect of the Guarantees could be subordinated to the debts of the Guarantor, if, among other things, the Guarantor, at the time it incurred the Obligations evidenced by the Guarantees:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">received less than reasonably equivalent value or fair consideration therefor; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">either:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">was insolvent or rendered insolvent by reason of such occurrence;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">was engaged in a business or transaction for which the assets of the Guarantor constituted unreasonably small capital; or</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under such circumstances, the payment of amounts by the Guarantor pursuant to the Guarantees could be voided and required to be returned to the Guarantor, or to a fund for the benefit of the Guarantor, as the case may be.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measures of insolvency for purposes of the foregoing considerations will vary depending upon the law applied in any proceeding with respect to the foregoing.  Generally, however, the Guarantor would be considered insolvent if:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the sum of its debts, including contingent liabilities, was greater than the saleable value of its assets, all at a fair valuation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the present fair saleable value of its assets was less than the amount that would be required to pay its probable liability on its existing debts, including contingent liabilities, as they become absolute and mature; or</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">it could not pay its debts as they become due.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the Guarantees are voided as a fraudulent conveyance or held unenforceable for any other reason, the holders of the guaranteed debt obligations would not have any claim against the Guarantor and would be creditors solely of the Parent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Guarantor under the Guarantees are limited to the maximum amount as will not result in the Guarantor&#8217;s obligations under the Guarantees constituting a fraudulent transfer or conveyance, after giving effect to such maximum amount </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and all other contingent and fixed liabilities of the Guarantor that are relevant under Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to the Guarantees.  For this purpose, &#8220;Bankruptcy Law&#8221; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Guarantor will be unconditionally released and discharged from the Obligations upon the earliest to occur of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the date, if any, on which the Guarantor consolidates with or merges into the Parent or any successor;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the date, if any, on which the Parent or any successor consolidates with or merges into the Guarantor;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the payment in full of the Obligations pertaining to such Guarantees; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the rating of the Parent&#8217;s long-term senior unsecured debt by S&amp;P of A or higher.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent is a holding company; therefore, its access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries.  Neither the Guarantor nor other 100% owned subsidiaries of the Parent that are not guarantors of the debt (&#8220;Non-Guarantor Subsidiaries&#8221;) are limited by contractual obligations on their ability to pay cash dividends or make other distributions with respect to their equity interests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include summarized financial information for the Parent and the Guarantor.  Transactions between the Parent and the Guarantor (including investment and intercompany balances as well as equity earnings) have been eliminated.  The Parent&#8217;s and the Guarantor&#8217;s intercompany balances with Non-Guarantor Subsidiaries have been presented separately.  This summarized financial information is not intended to present the financial position or results of operations of the Parent or the Guarantor in accordance with GAAP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summarized Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions of dollars)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Parent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guarantor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from Non-Guarantor Subsidiaries</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from Non-Guarantor Subsidiaries</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to Non-Guarantor Subsidiaries</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summarized Statements of Earnings (Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions of dollars)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Parent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guarantor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,639</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,941)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, net earnings (losses) includes $57 million of intercompany interest income and $89 million of interest expense from non-guarantor subsidiaries.</span></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, net earnings (losses) includes $58 million of intercompany interest income from non-guarantor subsidiaries.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_151"></div><div style="margin-bottom:5pt;margin-top:10pt;padding-right:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Factors That May Affect Future Results</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking and Cautionary Statements</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains statements concerning our expectations, plans, objectives, future financial performance and other statements that are not historical facts.  You can identify these forward-looking statements by use of words such as &#8220;strategy,&#8221; &#8220;expects,&#8221; &#8220;continues,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;goals,&#8221; &#8220;objectives,&#8221; &#8220;guidance,&#8221; &#8220;targets&#8221; and other words of similar meaning.  You can also identify them by the fact that they do not relate strictly to historical or current facts.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans, estimates and assumptions.  Achievement of future results is subject to risks, uncertainties and assumptions that may prove to be inaccurate.  Should known or unknown risks or uncertainties materialize, or should underlying estimates or assumptions prove inaccurate, actual results could differ materially from those anticipated, estimated or projected.  You should bear this in mind as you consider our forward-looking statements and whether to invest in or remain invested in our securities.  In connection with the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and outcomes, including with respect to our ability to achieve our Vision, to differ materially from those contained in, or implied by, any forward-looking statements we made.  Any such statement is qualified by reference to the following cautionary statements.  We elaborate on these important factors and the risks we face throughout this Form 10-Q, particularly in the &#8220;Executive Summary&#8221; and &#8220;Business Environment&#8221; sections preceding our discussion of the operating results of our segments above, in Part II, Item 1A. Risk Factors in this Form 10-Q, and in our other publicly filed reports, including our 2022 Form 10-K.  These factors and risks include the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our inability to compete effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the growth of the e-vapor category and other innovative tobacco products, including oral nicotine pouches, contributing to reductions in cigarette and MST consumption levels and shipment volume;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our failure to commercialize innovative products, including tobacco products that may reduce health risks relative to other tobacco products and appeal to adult tobacco consumers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">changes, including in macroeconomic and geopolitical conditions (including inflation), that result in shifts in adult tobacco consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">unfavorable outcomes with respect to litigation proceedings or any governmental investigations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks associated with significant federal, state and local government actions, including FDA regulatory actions, and various private sector actions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">increases in tobacco product-related taxes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.61pt">our failure to complete or manage successfully strategic transactions, including the NJOY Transaction and other acquisitions, dispositions, joint ventures and investments in third parties or realize the anticipated benefits of such transactions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risk that we may be required to write down intangible assets, including trademarks and goodwill, due to impairment;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risk that we could decide, or be required to, recall products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the various risks related to health epidemics and pandemics, such as the COVID-19 pandemic, and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our inability to attract and retain a highly skilled and diverse workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">a downgrade or potential downgrade of our credit ratings;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our inability to attract investors due to increasing investor expectations of our performance relating to environmental, social and governance factors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the failure of our, or our key service providers&#8217; or key suppliers&#8217;, information systems to function as intended, or cyber-attacks or security breaches; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">our failure to comply with personal data protection and privacy laws;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all, including due to macroeconomic and geopolitical conditions; foreign currency exchange rates; ABI&#8217;s business results; ABI&#8217;s share price; impairment losses on the value of our investment; our incurrence of additional tax liabilities related to our investment in ABI; and potential reductions in the number of directors that we can have appointed to the ABI board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks related to the FTC&#8217;s challenge with respect to our former investment in JUUL, which, if successful, could result in a broad range of resolutions, as well as the outcome of certain other related putative class actions; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected timeframe or at all.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should understand that it is not possible to predict or identify all factors and risks.  Consequently, you should not consider the foregoing list to be complete.  We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_154"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt, all of which is fixed-rate debt, is subject to fluctuations resulting primarily from changes in market interest rates.  The following table provides the fair value of our long-term debt and the change in fair value based on a 1% increase or decrease in market interest rates at March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value from a 1% increase in market interest rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value from a 1% decrease in market interest rates</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest rates on borrowings under the Credit Agreement to be based on the Term Secured Overnight Financing Rate, plus a percentage based on the higher of the ratings of our long-term senior unsecured debt from Moody&#8217;s and S&amp;P.  The applicable percentage for borrowings under the Credit Agreement at March&#160;31, 2023 was 1.0% based on our long-term senior unsecured debt ratings on that date.  At March&#160;31, 2023 and December&#160;31, 2022, we had no borrowings under the Credit Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10"> of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carried out an evaluation, with the participation of our management, including Altria&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Form 10-Q.  Based upon that evaluation, Altria&#8217;s Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:5pt"><span><br/></span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_160"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II &#8211; OTHER INFORMATION</span></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for a discussion of legal proceedings pending against us.  See also Exhibits 99.1 and 99.2 to this Form 10-Q.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_163"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding Risk Factors appears in Part I, Item 1A. Risk Factors of our 2022 Form 10-K.  Except as set forth below, there have been no material changes to the risk factors previously disclosed in our 2022 Form 10-K.  We elaborate on these and other risks we face throughout this Form 10-Q, particularly in the &#8220;Business Environment&#8221; section preceding our discussion of our operating results above in Part 1, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our Business</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Operations Risks</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to complete or manage strategic transactions, including the NJOY Transaction and other acquisitions, dispositions, joint ventures and investments in third parties, or realize the anticipated benefits of such transactions, could have a material adverse effect on our business, financial position and our ability to achieve our Vision.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly evaluate potential strategic transactions, including acquisitions, dispositions, joint ventures and investments in third parties.  Opportunities for strategic transactions may be limited, and the success of any such transaction is dependent upon our ability to complete and realize the expected benefits of the transaction in the expected time frame or at all.  Following the completion of a transaction there may be certain financial, managerial, staffing and talent and operational risks, including diversion of management&#8217;s attention from existing core businesses, difficulties integrating other businesses into existing operations and other challenges presented by a transaction that does not achieve anticipated sales levels and profitability.  We can provide no assurance that we will be able to enter into attractive business relationships or execute and complete strategic transactions on favorable terms or at all or that any such relationships or transactions will improve our competitive position or have the intended financial outcomes.  For example, to date, our investments in JUUL and Cronos have not resulted in the economic and competitive advantages expected at the time the investments were made.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a definitive agreement to acquire NJOY.  The NJOY Transaction is subject to a number of closing conditions, including receipt of required regulatory approval, which may not occur or may take longer than expected.  We cannot provide any assurance that we will be able to complete the NJOY Transaction or that there will not be a delay in the completion of the NJOY Transaction.  In addition, there can be no assurance that, if we complete the NJOY Transaction, we will be able to realize its expected benefits in the expected manner or timeframe, if at all, including due to failure to receive regulatory authorizations, failure to comply with regulatory requirements, prevailing economic, market, regulatory or business conditions, or changes in such conditions, negatively affecting our business and our plans with respect to the e-vapor category and the outcome of any legal proceeding or investigation that may be instituted against the parties or others related to NJOY Transaction.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NJOY Transaction or any other acquisition, disposition, joint venture, investment in a third party or other strategic relationship is not successful, there could be a material negative impact on our business, financial position and our ability to achieve our Vision.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our Investments in Equity Securities</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A challenge concerning our former investment in JUUL, if successful, could result in a broad range of resolutions, including those that could limit our flexibility to pursue future corporate transactions and other investments in the e-vapor space.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that our 35% investment in JUUL and the associated agreements constituted an unreasonable restraint of trade in violation of Section 1 of the Sherman Act and Section 5 of the FTC Act, and substantially lessened competition in violation of Section 7 of the Clayton Act.  In March 2023, we entered into a stock transfer agreement with JUUL pursuant to which, among other things, we transferred to JUUL all of our beneficially owned JUUL equity securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have divested our interest in JUUL, the FTC&#8217;s administrative complaint remains pending.  The FTC seeks a broad range of remedies, including  a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products, prohibition against any officer or director of either Altria or JUUL serving on the other party&#8217;s board of directors or attending meetings of the other party&#8217;s board of directors and notice to the FTC in advance of certain corporate actions, including acquisitions, mergers or certain corporate restructurings.  The administrative trial was held before an FTC administrative law judge in June 2021.  In February 2022, the administrative law judge dismissed the FTC&#8217;s complaint.  FTC complaint counsel appealed that decision to the FTC Commissioners.  Any adverse ruling the FTC Commissioners issue following their review may be appealed to a federal appellate court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, various putative class action lawsuits have been filed against Altria (and in some cases, subsidiaries of Altria) and JUUL.  The lawsuits cite the FTC administrative complaint referenced above and allege claims similar to those made by the FTC.  Plaintiffs in these lawsuits are seeking various remedies, including treble damages and attorneys&#8217; fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A successful challenge by the FTC or the plaintiffs in the lawsuits to our former investment in JUUL could adversely affect us, including by potentially limiting our flexibility to pursue other investments in the e-vapor space.</span></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_166"></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our Board of Directors authorized a new $1.0 billion share repurchase program, which we expect to complete by December 31, 2023.  The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of our Board.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share repurchase activity for each of the three months in the period ended March 31, 2023, was as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1-31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000,000,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1-28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000,000,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1-31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000,000,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">326,455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The total number of shares purchased represents shares withheld in an amount equal to the statutory withholding taxes for vested stock-based awards previously granted to eligible employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_169"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibb819a612bfb40178ae4eeaeab3ba640_10">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 6.  Exhibits</span></div><div style="padding-left:45pt;padding-right:15.75pt;text-align:justify;text-indent:-42.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101restrictedstock2.htm">Form of Restricted Stock Unit Agreement (2023).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102performancestock.htm">Form of Performance Stock Unit Agreement (2023).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit22q12023.htm">Guarantor Subsidiary of the Registrant.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12023-quarter.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12023-quarter.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12023-quarter.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12023-quarter.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991q12023-quarter.htm">Certain Litigation Matters.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:15.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992q12023-quarter.htm">Trial Schedule for Certain Cases.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxonomy Extension Presentation Linkbase.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ibb819a612bfb40178ae4eeaeab3ba640_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Signature</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALTRIA GROUP, INC.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="padding-right:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ SALVATORE MANCUSO</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salvatore Mancuso</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 27, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101restrictedstock2.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK UNIT AGREEMENT (2023)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i007beace285148c2b75649ab9a367482_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE ALTRIA GROUP, INC.</font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 PERFORMANCE INCENTIVE PLAN </font></div><div style="padding-right:-2pt;text-align:center"><font><br></font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(________, 2023)</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;padding-right:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;ALTRIA GROUP, INC. (&#8220;Company&#8221;), a Virginia corporation, hereby grants to the employee identified in the 2023 Stock Award section of the Award Statement (&#8220;Employee&#8221;) under the Altria Group, Inc. 2020 Performance Incentive Plan (&#8220;Plan&#8221;) a restricted stock unit award (&#8220;Award&#8221;) with respect to the number of shares of Common Stock of the Company (&#8220;Common Stock&#8221;) set forth in the 2023 Stock Award section of the Award Statement (&#8220;RSUs&#8221;), all in accordance with and subject to the following terms and conditions of this Restricted Stock Unit Agreement (&#8220;Agreement&#8221;).</font></div><div style="margin-bottom:5pt;padding-right:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Whenever the following terms are used in this Agreement, they will have the meanings set forth below. Capitalized terms not otherwise defined herein will have the same meanings as in the Plan. </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Award Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means ________, 2023, the date on which the Award is granted to the Employee.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Award Statement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the written notice of a restricted stock unit award provided to the Employee by the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Compensation and Talent Development Committee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the Compensation and Talent Development Committee of the Board of Directors of Altria Group, Inc.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means a disability that entitles the Employee to benefits under the applicable long-term disability insurance program of the Company or any of its Subsidiaries. </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.02pt">&#8220;Normal Retirement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means retirement from active employment with the Company and its Subsidiaries following both attainment of age 65 and completion of five years of service with the Company and its Subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 6(a) of this Agreement.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Retirement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means retirement from active employment with the Company and its Subsidiaries following both attainment of age 50 and completion of five years of service with the Company and its Subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.63pt">&#8220;Subsidiary&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means any company in which the Company, directly or indirectly, has a beneficial ownership interest of greater than 50 percent.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.63pt">&#8220;Termination of Employment&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means a separation from service within the meaning of Code section 409A with the Company and all of its Subsidiaries, which includes circumstances in which the Employee is reasonably anticipated not to perform further services with the Company and its Subsidiaries.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Vesting Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the date set forth in the Award Statement upon which the Award is generally no longer subject to forfeiture. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:16pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Condition to Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Company or its delegate, in its sole discretion, may require the Employee to execute a Confidentiality and Non-Competition Agreement in consideration of the Award by notifying the Employee of such requirement as soon as practicable after the Award Date. In such instance, the Award is consideration for and contingent on the Employee&#8217;s execution of the Confidentiality and Non-Competition Agreement.  The Employee&#8217;s failure to execute the Confidentiality and Non-Competition Agreement within a reasonable time after receipt, as specified by the Company or its delegate, but in no event later than 90 days after the Company or its delegate provides the Employee with the Confidentiality and Non-Competition Agreement, will result in complete nullification of the Agreement, and the Employee will forfeit any and all rights to the Award.</font></div><div style="margin-bottom:16pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Normal Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The RSUs will vest on the Vesting Date, provided that the Employee remains an employee of the Company or a Subsidiary from the Award Date through the Vesting Date and otherwise satisfies the terms of this Agreement and the Plan. The Employee will have no rights to the shares of Common Stock or cash equivalent until the RSUs have vested. </font></div><div style="margin-bottom:16pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Accelerated Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In the event that the Employee experiences a Termination of Employment with the Company and all of its Subsidiaries prior to the Vesting Date due to death, Disability, or Normal Retirement, the RSUs will become fully vested on the date of such Termination of Employment. In addition, in the event of a &#8220;Change in Control&#8221; within the meaning of the Plan, the RSUs will become vested and payable in the circumstances and in the manner specified in section 6(a) of the Plan and Section 11 below.</font></div><div style="margin-bottom:16pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If the Employee experiences a Termination of Employment with the Company and all of its Subsidiaries for any reason other than death, Disability, or Normal Retirement prior to the Vesting Date, the Employee will forfeit all rights to the RSUs immediately after Termination of Employment.  For purposes of this paragraph, the sale of a Subsidiary that employs the Employee will be considered a Termination of Employment with respect to such Employee. Notwithstanding the foregoing, upon a Termination of Employment described in this paragraph, the Compensation and Talent Development Committee may, in its sole discretion, vest some or all of the RSUs.</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Payment of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The RSUs will become payable upon the normal or accelerated vesting date described in Section 3, 4, or 5 or following any later payment date described in Section 11, if applicable (&#8220;Payment Date&#8221;).  Payment, in the form of issuance of shares of Common Stock and&#47;or cash, will be made as soon as practicable following the Payment Date.  However, in all cases payment will be made by the later of (a) December 31 of the year of the Payment Date or (b) two and a half months after the Payment Date.  Upon such payment, the Company will issue and deliver to the Employee the number of shares of Common Stock equal to the number of vested RSUs or, if the Compensation and Talent Development Committee so determines in its sole discretion, the cash equivalent value of such shares of Common Stock, as determined by the Compensation and Talent Development Committee, in either case subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 9.</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Voting and Dividend Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Unless and until the RSUs vest and the underlying Common Stock has been delivered to the Employee, the Employee will not have a right to vote the RSUs or receive dividends associated with shares of Common Stock underlying the RSUs.  However, from the Award Date until the Vesting Date, the Employee will have the right to receive, free of vesting conditions (but subject to applicable withholding taxes), dividend equivalent cash payments in lieu of the dividends that the Employee would have received had the Employee held such shares of Common Stock, unless otherwise determined by the Compensation and Talent Development Committee.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Unfunded Award and Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Prior to settlement, the RSUs represent an unfunded and unsecured obligation of the Company. This Award and the RSUs are non-transferable and may not be </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sold, conveyed, assigned, transferred, pledged, or otherwise disposed of or encumbered at any time prior to vesting and settlement of the RSUs. If the Employee attempts to violate this Section 8, such action will be null and void, the Award will immediately become null and void, and the RSUs granted under the Award will be forfeited.  These restrictions will not apply, however, to any shares of Common Stock or cash payments that the Employee has received pursuant to Section 6.  If the Employee is a resident of Canada, the Employee acknowledges that the shares of Common Stock that the Employee receives pursuant to Section 6 are subject to a restriction on the first trade under Canadian securities laws.&#160; As a result, the Employee acknowledges that any first trade of such shares of Common Stock must be made (a) through an exchange, or a market, outside of Canada, (b) to a person or company outside of Canada, or (c) otherwise in compliance with applicable Canadian securities laws.</font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes and Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Company is authorized to satisfy any withholding taxes arising in connection with this Award by (a) deducting the number of RSUs having an aggregate value equal to the amount of withholding taxes due, or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in payment of vested RSUs by the Employee. The Company is authorized to satisfy any withholding taxes arising from the payment of cash in lieu of dividends pursuant to Section 7 by withholding the required amounts from such cash payment. The Company is also authorized to satisfy any withholding taxes referred to in this Section 9 by requiring a cash payment from the Employee or by withholding from other payments due to the Employee.  If the Employee is covered by a Company tax equalization policy, the Employee also agrees to pay to the Company any additional hypothetical tax obligation calculated and paid under the terms and conditions of such tax equalization policy. The Employee agrees that the Employee is responsible for, and the Company and its Subsidiaries are not responsible for, any personal tax consequences in connection with the RSUs.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Beneficiary for Payments Upon Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Upon the death of the Employee, any Common Stock or cash amounts paid in connection with the RSUs will be paid to the Employee&#8217;s estate.  Notwithstanding the foregoing, the Compensation and Talent Development Committee may elect to permit the Employee to designate a beneficiary other than the Employee&#8217;s estate, and if the Compensation and Talent Development Committee so permits, then the proceeds will be paid to such beneficiary.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Code Section 409A Special Payment Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement will be construed in a manner consistent with Code section 409A and the regulations thereunder.  Special payment provisions apply under this Section 11 in two situations&#58; (a) for RSUs with a Vesting Date between January 1 and March 15, if the Employee will become eligible for Retirement before the calendar year preceding the Vesting Date and (b) for RSUs with a Vesting Date after March 15, if the Employee will become eligible for Retirement before the calendar year in which the Vesting Date occurs.  If the special payment provisions apply, then notwithstanding anything in this Agreement to the contrary&#58;</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) If the Employee is a &#8220;specified employee&#8221; within the meaning of Code section 409A, any payment of RSUs under Section 6 that is on account of his or her Termination of Employment will be delayed until the earlier of six months following such Termination of Employment or the Employee&#8217;s death.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) In the event of a &#8220;Change in Control&#8221; under section 6(b) of the Plan that is not also a &#8220;change in control event&#8221; with the meaning of Treas. Reg. &#167;1.409A-3(i)(5)(i), any RSUs that would otherwise become vested and paid pursuant to section 6(a) of the Plan upon such Change in Control will become vested, but will not be paid upon such Change in Control, and will instead be paid at the time the RSUs would otherwise be paid pursuant to this Agreement.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii) This Section 11(iii) applies in the event of a sale of a Subsidiary that is treated as a Termination of Employment under Section 5, but that does not result in a &#8220;separation from service&#8221; within the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">meaning of Code section 409A.  In such event, any RSUs that become vested pursuant to Section 5 upon such sale will not be paid upon the accelerated vesting date, but will instead be paid upon the earlier of (A) the normal vesting date under Section 3 or (B) the Employee&#8217;s separation from service (within the meaning of Code section 409A) from the sold Subsidiary, including by reason of death or Disability.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Notwithstanding anything in this Agreement to the contrary, if the Board of Directors of the Company (&#8220;Board&#8221;) or an appropriate Committee of the Board determines that, as a result of a restatement of the Company&#8217;s financial statements, the Employee has received greater compensation in connection with the Award than would have been received absent the incorrect financial statements, the Board or Committee, in its discretion, may take such action with respect to this Award as it deems necessary or appropriate to address the events that gave rise to the restatement and to prevent its recurrence.  Such action may include, to the extent permitted by applicable law, causing the full or partial cancellation of this Award and, with respect to RSUs that have vested, requiring the Employee to repay to the Company the full or partial Fair Market Value of the Award determined at the time of vesting. This Award shall also be subject to any other policy regarding forfeiture or compensation recoupment upon a financial restatement adopted by the Board or appropriate Committee of the Board. The Employee agrees by accepting this Award that the Board or Committee may make a cancellation, impose a repayment obligation, or take other necessary or appropriate actions to enforce this paragraph.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Employment Relationship.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Nothing in this Agreement or in the Plan shall confer upon the Employee any right to continue in the employ of the Company or any Subsidiary for any period of specific duration or interfere with or restrict in any way the right of the Company or any Subsidiary, which is hereby expressly reserved, to remove, terminate or discharge the Employee at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Entire Agreement&#59; Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement and the Plan, along with the referenced information in the Award Statement, represents the entire agreement between the parties regarding the subject matter of this Agreement. The terms and provisions of the Plan are incorporated into and made a part of this Agreement.  To the extent any provision of this Agreement is inconsistent or in conflict with any term or provision of the Plan, the Plan will govern.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The provisions of this Agreement are severable, and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, this Restricted Stock Unit Agreement has been duly executed as of the date first written above.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:207pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.320%"><tr><td style="width:1.0%"></td><td style="width:2.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ALTRIA GROUP, INC.</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W. Hildebrandt Surgner, Jr. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate Secretary</font></div></td></tr></table></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102performancestock.htm
<DESCRIPTION>FORM OF PERFORMANCE STOCK UNIT AGREEMENT (2023)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iec2b5cc6e6a544f0bdc0f13d11f4f4e9_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE ALTRIA GROUP, INC.</font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 PERFORMANCE INCENTIVE PLAN </font></div><div style="padding-right:-2pt;text-align:center"><font><br></font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PERFORMANCE STOCK UNIT AGREEMENT</font></div><div style="padding-right:-2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(________, 2023)</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-right:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;ALTRIA GROUP, INC. (&#8220;Company&#8221;), a Virginia corporation, hereby grants to the employee identified in the 2023 Stock Award section of the Award Statement (&#8220;Employee&#8221;) under the Altria Group, Inc. 2020 Performance Incentive Plan (&#8220;Plan&#8221;) a performance stock unit award (&#8220;Award&#8221;) with respect to the target number of shares of Common Stock of the Company (&#8220;Common Stock&#8221;) set forth in the 2023 Stock Award section of the Award Statement (&#8220;PSUs&#8221;), all in accordance with and subject to the following terms and conditions of this Performance Stock Unit Agreement (&#8220;Agreement&#8221;).</font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Whenever the following terms are used in this Agreement, they will have the meanings set forth below. Capitalized terms not otherwise defined herein will have the same meanings as in the Plan. </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Award Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means ________, 2023, the date on which the Award is granted to the Employee.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Award Statement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the written notice of a performance stock unit award provided to the Employee by the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Compensation and Talent Development Committee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the Compensation and Talent Development Committee of the Board of Directors of Altria Group, Inc.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.8pt">&#8220;Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means a disability that entitles the Employee to benefits under the applicable long-term disability insurance program of the Company or any of its Subsidiaries.  A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;409A Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means a Disability that is also a disability within the meaning of Code section 409A.  A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Non-409A Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means a Disability that is not also a disability within the meaning of Code section 409A. </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.02pt">&#8220;Normal Retirement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means retirement from active employment with the Company and its Subsidiaries following both attainment of age 65 and completion of five years of service with the Company and its Subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.18pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 6(a) of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Performance Percentage&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means a percentage that is determined based on the Company&#8217;s performance during the applicable PSU performance period against performance goals pre-determined by the Compensation and Talent Development Committee.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.63pt">&#8220;Retirement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means retirement from active employment with the Company and its Subsidiaries following both attainment of age 50 and completion of five years of service with the Company and its Subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.63pt">&#8220;Subsidiary&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means any company in which the Company, directly or indirectly, has a beneficial ownership interest of greater than 50 percent.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.18pt">&#8220;Termination of Employment&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means a separation from service within the meaning of Code section 409A with the Company and all of its Subsidiaries, which includes circumstances in which the Employee is reasonably anticipated not to perform further services with the Company and its Subsidiaries.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:7.63pt">&#8220;Vesting Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the date set forth in the Award Statement upon which the Award is generally no longer subject to forfeiture. </font></div><div style="margin-bottom:12pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Condition to Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Company or its delegate, in its sole discretion, may require the Employee to execute a Confidentiality and Non-Competition Agreement in consideration of the Award by notifying the Employee of such requirement as soon as practicable after the Award Date. In such instance, the Award is consideration for and contingent on the Employee&#8217;s execution of the Confidentiality and Non-Competition Agreement.  The Employee&#8217;s failure to execute the Confidentiality and Non-Competition Agreement within a reasonable time after receipt, as specified by the Company or its delegate, but in no event later than 90 days after the Company or its delegate provides the Employee with the Confidentiality and Non-Competition Agreement, will result in complete nullification of the Agreement, and the Employee will forfeit any and all rights to the Award.</font></div><div style="margin-bottom:8pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Normal Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The PSUs will vest on the Vesting Date, provided that the Employee remains an employee of the Company or a Subsidiary from the Award Date through the Vesting Date and otherwise satisfies the terms of this Agreement and the Plan. The Employee will have no rights to the shares of Common Stock or cash equivalent until the PSUs have vested. </font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) The number of PSUs that become vested on the Vesting Date will be equal to the target number of PSUs multiplied by the Performance Percentage.  The Performance Percentage will be determined by the Compensation and Talent Development Committee.  Notwithstanding the foregoing, if the date on which the Compensation and Talent Development Committee makes a final determination of the Performance Percentage is after the Vesting Date, then the date of the final determination will be treated as the Vesting Date for purposes of determining the number of PSUs that become vested and for purposes of Section 6.  The Compensation and Talent Development Committee will make a final determination of the Performance Percentage no later than July 1 of the year in which the Vesting Date occurs.</font></div><div style="margin-bottom:12pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Special Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In the event of the Employee&#8217;s death or 409A Disability prior to the Vesting Date, the target number of PSUs will become vested on the date of such death or 409A Disability. In the event of the Employee&#8217;s Non-409A Disability or Termination of Employment with the Company and all of its Subsidiaries due to Normal Retirement, in either case prior to the Vesting Date, the service condition to PSU vesting set forth in Section 3(a) will be deemed satisfied, and the number of PSUs that become vested on the Vesting Date will be determined based on actual performance as set forth in Section 3(b).  In addition, in the event of a &#8220;Change in Control&#8221; within the meaning of the Plan, the PSUs will become vested and payable in the circumstances and in the manner specified in section 6(a) of the Plan and Section 11 below.</font></div><div style="margin-bottom:13pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If the Employee experiences a Termination of Employment with the Company and all of its Subsidiaries for any reason other than death, Disability, or Normal Retirement prior to the Vesting Date, the Employee will forfeit all rights to the PSUs immediately after Termination of Employment.  For purposes of this paragraph, the sale of a Subsidiary that employs the Employee will be considered a Termination of Employment with respect to such Employee. Notwithstanding the foregoing, upon a Termination of Employment described in this paragraph, the Compensation and Talent Development Committee may, in its sole discretion, determine that the service condition to PSU vesting, set forth in </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:13pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3(a), will be deemed satisfied for some or all of the PSUs.  In such event, the number of such PSUs that become vested on the Vesting Date will be determined based on actual performance as set forth in Section 3(b).</font></div><div style="margin-bottom:13pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Payment of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:13pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;PSUs will become payable upon the Vesting Date specified in Section 3, except that in the case of death or 409A Disability, the PSUs will become payable upon such event, and in the case of a &#8220;Change in Control&#8221; within the meaning of the Plan, the PSUs will become payable as provided in Section 6(a) of the Plan and Section 11 below.  The date on which the PSUs become payable is referred to herein as the Payment Date.</font></div><div style="margin-bottom:14pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Payment, in the form of issuance of shares of Common Stock and&#47;or cash, will be made as soon as practicable following the Payment Date.  However, in all cases payment will be made by the later of (i) December 31 of the year of the Payment Date or (ii) two and a half months after the Payment Date.  Upon such payment, the Company will (A) issue and deliver to the Employee the number of shares of Common Stock equal to the number of vested PSUs or, if the Compensation and Talent Development Committee so determines in its sole discretion, the cash equivalent value of such shares of Common Stock, as determined by the Compensation and Talent Development Committee, and (B) pay to the Employee in a single lump sum any cash amount accrued with respect to dividends.  Payment of such shares of Common Stock and cash amounts will be subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 9.</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Voting and Dividend Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Unless and until the PSUs vest and the underlying Common Stock has been delivered to the Employee, the Employee will not have a right to vote the PSUs or receive dividends associated with shares of Common Stock underlying the PSUs.  However, the Employee will accrue under the PSUs a cash amount in lieu of the dividends that the Employee would have received had the Employee held, from the Award Date to the date of payment, the number of shares of Common Stock that become issuable pursuant to this Agreement, unless otherwise determined by the Compensation and Talent Development Committee.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Unfunded Award and Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Prior to settlement, the PSUs represent an unfunded and unsecured obligation of the Company.  This Award and the PSUs are non-transferable and may not be sold, conveyed, assigned, transferred, pledged, or otherwise disposed of or encumbered at any time prior to vesting and settlement of the PSUs. If the Employee attempts to violate this Section 8, such action will be null and void, the Award will immediately become null and void, and the PSUs granted under the Award will be forfeited.  These restrictions will not apply, however, to any shares of Common Stock or cash payments that the Employee has received pursuant to Section 6.  If the Employee is a resident of Canada, the Employee acknowledges that the shares of Common Stock that the Employee receives pursuant to Section 6 are subject to a restriction on the first trade under Canadian securities laws.&#160; As a result, the Employee acknowledges that any first trade of such shares of Common Stock must be made (a) through an exchange, or a market, outside of Canada, (b) to a person or company outside of Canada, or (c) otherwise in compliance with applicable Canadian securities laws.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes and Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Company is authorized to satisfy any withholding taxes arising in connection with this Award by (a) deducting the number of PSUs having an aggregate value equal to the amount of withholding taxes due, or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in payment of vested PSUs by the Employee. The Company is authorized to satisfy any withholding taxes arising from the payment of cash in lieu of dividends pursuant to Section 7 by withholding the required amounts from such cash payment. The Company is also authorized to satisfy any withholding taxes referred to in this Section 9 by requiring a cash </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">payment from the Employee or by withholding from other payments due to the Employee.  If the Employee is covered by a Company tax equalization policy, the Employee also agrees to pay to the Company any additional hypothetical tax obligation calculated and paid under the terms and conditions of such tax equalization policy. The Employee agrees that the Employee is responsible for, and the Company and its Subsidiaries are not responsible for, any personal tax consequences in connection with the PSUs.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Beneficiary for Payments Upon Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Upon the death of the Employee, any Common Stock or cash amounts paid in connection with the PSUs will be paid to the Employee&#8217;s estate.  Notwithstanding the foregoing, the Compensation and Talent Development Committee may elect to permit the Employee to designate a beneficiary other than the Employee&#8217;s estate, and if the Compensation and Talent Development Committee so permits, then the proceeds will be paid to such beneficiary.</font></div><div style="margin-bottom:12pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Code Section 409A Special Payment Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement will be construed in a manner consistent with Code section 409A and the regulations thereunder.  Notwithstanding anything in this Agreement to the contrary&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the event of a &#8220;Change in Control&#8221; under section 6(b) of the Plan that is not also a &#8220;change in control event&#8221; with the meaning of Treas. Reg. &#167;1.409A-3(i)(5)(i), any PSUs that would otherwise become vested and paid pursuant to section 6(a) of the Plan upon such Change in Control will become vested as provided in the Plan, but will not be paid upon such Change in Control, and will instead be paid at the time the PSUs would otherwise be paid pursuant to this Agreement.</font></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:-4pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event of a &#8220;Change in Control&#8221; under section 6(b) of the Plan followed by a termination of employment described in section 6(a)(ii)(B) of the Plan, any PSUs that would otherwise become vested and paid pursuant to section 6(a)(ii) of the Plan upon such event will become vested as provided in the Plan, but will not be paid upon such event, and will instead be paid at the time the PSUs would otherwise be paid pursuant to this Agreement.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Notwithstanding anything in this Agreement to the contrary, if the Board of Directors of the Company (&#8220;Board&#8221;) or an appropriate Committee of the Board determines that, as a result of a restatement of the Company&#8217;s financial statements, the Employee has received greater compensation in connection with the Award than would have been received absent the incorrect financial statements, the Board or Committee, in its discretion, may take such action with respect to this Award as it deems necessary or appropriate to address the events that gave rise to the restatement and to prevent its recurrence.  Such action may include, to the extent permitted by applicable law, causing the full or partial cancellation of this Award and, with respect to PSUs that have vested, requiring the Employee to repay to the Company the full or partial Fair Market Value of the Award determined at the time of vesting.  This Award shall also be subject to any other policy regarding forfeiture or compensation recoupment upon a financial restatement adopted by the Board or appropriate Committee of the Board.  The Employee agrees by accepting this Award that the Board or Committee may make such a cancellation, impose such a repayment obligation, or take other necessary or appropriate actions to enforce this paragraph.</font></div><div style="margin-bottom:14pt;padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Employment Relationship.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Nothing in this Agreement or in the Plan shall confer upon the Employee any right to continue in the employ of the Company or any Subsidiary for any period of specific duration or interfere with or restrict in any way the right of the Company or any Subsidiary, which is hereby expressly reserved, to remove, terminate or discharge the Employee at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Entire Agreement&#59; Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the Plan, along with the referenced information in the Award Statement, represents the entire agreement between the parties regarding the subject matter of this Agreement. The terms and provisions of the Plan are incorporated into and made a part </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of this Agreement.  To the extent any provision of this Agreement is inconsistent or in conflict with any term or provision of the Plan, the Plan will govern.  The provisions of this Agreement are severable, and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-right:-4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, this Performance Stock Unit Agreement has been duly executed as of the date first written above.</font></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:207pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.402%"><tr><td style="width:1.0%"></td><td style="width:2.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ALTRIA GROUP, INC.</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W. Hildebrandt Surgner, Jr. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate Secretary</font></div></td></tr></table></div><div style="padding-right:-4pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Palatino',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>4
<FILENAME>exhibit22q12023.htm
<DESCRIPTION>ALTRIA GROUP, INC. GUARANTOR SUBSIDIARY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7510097a93234f15a9313a9ea093c989_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 22</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Altria Group, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantor Subsidiary </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philip Morris USA Inc., which is a 100% owned subsidiary of Altria Group, Inc. (the &#8220;Parent&#8221;), has fully and unconditionally guaranteed the Parent&#8217;s obligations under the following senior unsecured notes issued by the Parent&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD denominated notes</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2.950% Notes due May 2023</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.000% Notes due January 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.800% Notes due February 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2.350% Notes due May 2025</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.400% Notes due February 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2.625% Notes due September 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.800% Notes due February 2029</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.400% Notes due May 2030</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2.450% Notes due February 2032</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">9.950% Notes due November 2038</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">10.200% Notes due February 2039</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">5.800% Notes due February 2039</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.400% Notes due February 2041</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.250% Notes due August 2042</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.500% Notes due May 2043</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">5.375% Notes due January 2044</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.875% Notes due September 2046</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">5.950% Notes due February 2049</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.450% Notes due May 2050</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.700% Notes due February 2051</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">6.200% Notes due February 2059</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">4.000% Notes due February 2061</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Euro denominated notes</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">1.700% Notes due June 2025</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2.200% Notes due June 2027</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">3.125% Notes due June 2031</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit311q12023-quarter.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8f7092d6fb1148bcb5687227b2723442_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:32.62pt;padding-right:32.62pt;text-align:center;text-indent:-29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certifications</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William F. Gifford, Jr., certify that&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Altria Group, Inc.&#59;</font></div><div style="padding-left:54pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:54pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;padding-right:15.75pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;padding-right:15.75pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:40.5pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  April 27, 2023</font></div><div style="margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:64.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; WILLIAM F. GIFFORD, JR.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William F. Gifford, Jr.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div></td></tr></table></div><div style="padding-right:15.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit312q12023-quarter.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9496a5e7f0b1441a9723a28ac951a0eb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:16.87pt;padding-right:16.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certifications</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Salvatore Mancuso, certify that&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Altria Group, Inc.&#59;</font></div><div style="padding-left:15.75pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:15.75pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;padding-right:15.75pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;padding-right:15.75pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="padding-left:58.5pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:18pt;padding-right:15.75pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:40.5pt;padding-right:15.75pt"><font><br></font></div><div style="padding-left:54pt;padding-right:15.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  April 27, 2023</font></div><div style="margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:64.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:24.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; SALVATORE MANCUSO</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:24.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salvatore Mancuso</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and </font></div><div style="padding-right:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div style="padding-right:15.75pt;text-align:justify"><font><br></font></div><div style="padding-right:24.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit321q12023-quarter.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibab0d771cf8c4f5199da299c8faca98e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Altria Group, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, William F. Gifford, Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; WILLIAM F. GIFFORD, JR.</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William F. Gifford, Jr.</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">April 27, 2023</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-left:16.87pt;padding-right:16.87pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit322q12023-quarter.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc24dd1922c741bda7ffc92e0925f997_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="padding-left:7.87pt;padding-right:7.87pt;text-align:center"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Altria Group, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Salvatore Mancuso, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-right:15.75pt"><font><br></font></div><div style="padding-right:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-right:15.75pt;text-align:justify"><font><br></font></div><div style="padding-right:15.75pt;text-align:justify"><font><br></font></div><div style="padding-right:15.75pt;text-align:justify"><font><br></font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; SALVATORE MANCUSO</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salvatore Mancuso</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Vice President and</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">April 27, 2023</font></div><div style="padding-right:15.75pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>9
<FILENAME>exhibit991q12023-quarter.htm
<DESCRIPTION>CERTAIN LITIGATION MATTERS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie487624139f8497d8b0c00caf1ea0819_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN LITIGATION MATTERS</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Altria Group, Inc.&#8217;s (&#8220;Altria&#8221;) condensed consolidated financial statements in Part I, Item 1 of the Quarterly Report on Form 10-Q to which this Exhibit 99.1 is attached (&#8220;Note 11&#8221;), there are legal proceedings covering a wide range of matters pending or threatened in various United States and foreign jurisdictions against Altria, its subsidiaries, including Philip Morris USA Inc. (&#8220;PM USA&#8221;), and their respective indemnitees.  Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act, claims for contribution and claims of competitors, shareholders or distributors.  Claims related to tobacco products generally fall within the following categories&#58; (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs, (ii) smoking and health cases primarily alleging personal injury or seeking court-supervised programs for ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including cases in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, (iii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and&#47;or disgorgement of profits, (iv) class action suits alleging that the use of the terms &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law fraud or statutory fraud, unjust enrichment, breach of warranty, or violations of the Racketeer Influenced and Corrupt Organizations Act, (v) class action suits involving e-vapor products and (vi) international cases.  The following lists certain of the pending claims against Altria and PM USA included in these and other categories.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SMOKING AND HEALTH LITIGATION</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following lists the consolidated individual smoking and health cases as well as smoking and health class actions pending against PM USA and, in some cases, Altria and&#47;or its other subsidiaries and affiliates, as of April 24, 2023.  See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Cases </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a list of smoking and health class actions pending in Canada.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Flight Attendant Litigation</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement agreement entered into in 1997 in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Broin, et al. v. Philip Morris Companies Inc., et al.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was brought by flight attendants seeking damages for personal injuries allegedly caused by environmental tobacco smoke, allowed members of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Broin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages.  See Note 11 for a discussion of this litigation.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Domestic Class Actions</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle, et al. v. R.J. Reynolds Tobacco Co., et al., Circuit Court, Eleventh Judicial Circuit, Dade County, Florida, filed May 5, 1994.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 for a discussion of this case (which has concluded) and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny litigation.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Young, et al. v. The American Tobacco Company, et al., Civil District Court, Orleans Parish, Louisiana, filed November 12, 1997.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTH CARE COST RECOVERY LITIGATION</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following lists a health care cost recovery action pending against PM USA and Altria as of April 24, 2023.  See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Cases </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a list of international health care cost recovery actions.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Department of Justice Case</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The United States of America v. Philip Morris Incorporated, et al., United States District Court, District of Columbia, filed September 22, 1999</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  See Note 11 for a discussion of this case.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;LIGHTS&#47;ULTRA LIGHTS&#8221; CASES</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following lists the &#8220;Lights&#47;Ultra Lights&#8221; class actions pending against Altria and&#47;or its various subsidiaries and others as of April 24, 2023.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moore, et al. v. Philip Morris Incorporated, et al., Circuit Court, Marshall County, West Virginia, filed September 17, 2001.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virden v. Altria Group, Inc., et al., Circuit Court, Hancock County, West Virginia, filed March 28, 2003.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLASS ACTION LAWSUITS INVOLVING E-VAPOR PRODUCTS</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following lists class action lawsuits relating to e-vapor products that are pending against Altria and&#47;or its various subsidiaries and others as of April 24, 2023.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NesSmith, et al. v. JUUL Labs Inc., et al., United States District Court, Middle District of Florida, filed April 15, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Peavy (formerly Swearingen), et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Alabama, filed May 31, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R.E., et al. v. JUUL Labs, Inc., et al., United States District Court, Southern District of West Virginia, filed August 13, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M.D., et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Mississippi, filed August 15, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oberhauser, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed September 12, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hochhauser, et al. v. JUUL Labs, Inc., et al., United States District Court, Eastern District of New York, filed October 1, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emidy et al. v. JUUL Labs, Inc., et al., United States District Court, Western District of Tennessee, filed October 2, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Montgomery County, Maryland, et al. v. JUUL Labs, Inc., et al., United States District Court, District of Maryland, filed October 11, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">King County, Washington, et al. v. JUUL Labs, Inc., et al., United States District Court, Western District of Washington, filed October 16, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Rochester, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed November 6, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jefferson County School District, et al. v. JUUL Labs, Inc., et al., United States District Court, Southern District of Mississippi, filed December 5, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ledbetter, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Alabama, filed December 12, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Escambia County School District, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Florida, filed December 18, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unified School District No. 320, Pottawatomie County, KS, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed December 18, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">School Board of Miami-Dade County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The School Board of Broward County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Frederick County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imani, et al. v. JUUL Labs, Inc., et al., United States District Court, District of Oregon, filed December 20, 2019.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cooper, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Texas, filed January 9, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">O&#8217;Reilly, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed January 13, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gabbard, et al. v. JUUL Labs, Inc., et al., United States District Court, Eastern District of Kentucky, filed February 21, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Peoria Public Schools v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed May 15, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Montgomery County Public Schools, MD. v. JUUL Labs, Inc. et al., United States District Court, Northern District of California, filed December 21, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Baltimore County v. JUUL Labs, Inc., et al. United States District Court, Northern District of California, filed December 21, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ann Parker, On Behalf Of Her Daughter, S.P., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 29, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adam Jenkins, Individually And On Behalf Of Others Similarly Situated, On Behalf Of D.L.J. v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charleen Richey, On Behalf Of Her Son, T.Y., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shayla Aceti, individually and on behalf of others similarly situated v. Juul Labs Inc et al., United States District Court, Northern District of California, filed March 30, 2021. </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert Dyer, On Behalf Of His Son, B.D., individually and on behalf of others similarly situated v. Juul Labs Inc., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joan Eubanks, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bruce Gibson, on behalf of his son, K.G., individually and others similarly situated v.  Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jenika Ingram, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shirley Moses on behalf of her daughter, K.S.C., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Katherine Dentler, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vickie Perry, On Behalf Of Her Daughter LP, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jessica Pierre, individually and on behalf of others similarly situated v. Juul Labs Inc.&#59; Altria Group Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lacretia Pulce, On Behalf Of Her Daughter, K.P., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charles Tippe, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janece Wilhelm, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janece Wilhelm, on behalf of her son. D.L., individually and on behalf of others similarly situated v. Juul Labs Inc.&#59; et al., United States District Court, Northern District of California, filed April 1, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tonya Williams-Walker, On Behalf Of Her Son, M.W., and on behalf of others similarly situated v. Juul Labs Inc.et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Randi Lines, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adam Jenkins, On Behalf Of His Son, M.R.J., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ann Parker, On Behalf Of Her Daughter, S.P., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 29, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Erin Puente, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shannon Kinnard, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">John Hollis, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wolfgang and Suzanne Ziegenhagen on behalf of their son, H.Z. individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janis Kelly on behalf of her son, C.J.W., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coleman Holniker, individually and On Behalf of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Addison Altizer, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charleen Richey, On Behalf Of Her Son, T.Y., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nicholas Vogel, on behalf of his son, E.V., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed May 13, 2021.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pike County School Corp. Metropolitan School District Of Wabash County, Individually &#38; On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed April 18, 2022.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for a discussion of these cases.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IQOS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> LITIGATION</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RAI Strategic Holdings, Inc., et al. v. Altria Client Services LLC, et al., United States District Court, Eastern District of Virginia, filed April 9, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Tobacco Heating Articles and Components Thereof, United States International Trade Commission, filed April 9, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthier Choices Management Corp. v. Philip Morris USA Inc., et al., United States District Court, Northern District of Georgia, filed November 30, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for a discussion of these cases.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANTITRUST LITIGATION</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Altria Group, Inc., et al., United States of America Before the Federal Trade Commission, filed April 1, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reece, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 7, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Blomquist, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 13, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Martinez, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 14, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deadwyler, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 20, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licari, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 21, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flannery, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 27, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walsh, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 8, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redfield, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 15, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Carlson, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 21, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B&#38;C Retail, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sofijon, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noor Baig, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Somerset Party Store, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 18, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jackson, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 25, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McGhee, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed July 1, 2020.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Irwindale Fuel Station, Inc. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed July 15, 2020.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNATIONAL CASES</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following lists cases pending against Altria and&#47;or its subsidiaries in foreign jurisdictions as of April 24, 2023.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Canada</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">O&#8217;Donnell, et. al. v. JUUL Labs, Canada, Ltd., et al., Ontario, Ontario Superior Court, filed April 17, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  E-vapor class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salvatore, et al. v. JUUL Labs Canada, Ltd., et al., Quebec, District of Montreal Superior Court, filed June 12, 2019.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E-vapor class action. </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stephens, et al. v. JUUL Labs, Inc., et al., British Columbia, Canada Supreme Court, filed October 1, 2019.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E-vapor class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in Right of the Province of New Brunswick v. Rothmans, Inc., et al., Court of Queen&#8217;s Bench of New Brunswick Judicial District of Fredericton, Canada, filed March 13, 2008.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dorion v. Canadian Tobacco Manufacturers&#8217; Council, et al., Court of Queen&#8217;s Bench of Alberta, Judicial District of Calgary, Canada, filed on or about June 17, 2009</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Semple v. Canadian Tobacco Manufacturers&#8217; Council, et al., Supreme Court of Nova Scotia, Canada, filed on or about June 18, 2009.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kunka v. Canadian Tobacco Manufacturers&#8217; Council, et al., Court of Queen&#8217;s Bench of Manitoba, Winnipeg Judicial Centre, Canada, filed on an unknown date in June 2009</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adams v. Canadian Tobacco Manufacturers&#8217; Council, et al., Court of Queen&#8217;s Bench for Saskatchewan, Judicial Centre of Regina, Canada, filed on or about July 10, 2009.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Superior Court of Justice of Ontario, Canada, filed on or about September 30, 2009.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court of British Columbia, Victoria Registry, Canada, filed on or about June 25, 2010.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court of British Columbia, Victoria Registry, Canada, filed on or about June 25, 2010.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smoking and health class action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, Trial Division, Canada, filed February 8, 2011</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attorney General of Quebec v. Imperial Tobacco Canada Limited, et al., Superior Court of Quebec, Montreal District, Canada, filed June 8, 2012</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Court of Queen&#8217;s Bench of Alberta, Judicial District of Calgary, Canada, filed June 8, 2012</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in the Right of Manitoba v. Rothmans, Benson &#38; Hedges Inc., et al., Court of Queen&#8217;s Bench of Manitoba, Winnipeg Judicial Centre, Canada, filed May 31, 2012.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in Right of Saskatchewan v. Rothmans, Benson &#38; Hedges Inc., et al., Court of Queen&#8217;s Bench of Saskatchewan, Judicial Centre of Saskatoon, Canada, filed on June 8, 2012.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty in the Right of the Province of Prince Edward Island v. Rothmans, Benson &#38; Hedges, Inc., et al., Supreme Court of Prince Edward Island, filed on September 10, 2012.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Her Majesty the Queen in Right of the Province of Nova Scotia v. Benson &#38; Hedges, Inc., et al., Supreme Court of Nova Scotia, filed on January 2, 2015.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care cost recovery action.  </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jacklin v. Canadian Tobacco Manufacturers&#8217; Council et al., Ontario Superior Court of Justice, Case No. 5379412, Ontario, Canada, filed on or about June 27, 2012.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smoking and health class action.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for a discussion of these cases.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>10
<FILENAME>exhibit992q12023-quarter.htm
<DESCRIPTION>TRIAL SCHEDULE FOR CERTAIN CASES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic788f9ab032e42dba8d3598135792063_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRIAL SCHEDULE FOR CERTAIN CASES </font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a schedule, as of April 24, 2023, setting forth by month the number of individual smoking and health cases against Philip Morris USA Inc. that are scheduled for but not in trial through June 30, 2023. </font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023</font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.146%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td></tr></table></div><div style="margin-bottom:4.4pt"><font><br></font></div><div style="margin-bottom:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, there are no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in trial.</font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Individual Smoking&#160;&#38; Health </font></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.146%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, there is one non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case in trial.</font></div><div style="margin-bottom:4.4pt"><font><br></font></div><div style="margin-bottom:4.4pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:4.5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>mo-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mo="http://www.altria.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.altria.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mo-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mo-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mo-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mo-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.altria.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.altria.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveEarnings" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentation" roleURI="http://www.altria.com/role/BackgroundandBasisofPresentation">
        <link:definition>0000010 - Disclosure - Background and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomers" roleURI="http://www.altria.com/role/RevenuesfromContractswithCustomers">
        <link:definition>0000011 - Disclosure - Revenues from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecurities" roleURI="http://www.altria.com/role/InvestmentsinEquitySecurities">
        <link:definition>0000012 - Disclosure - Investments in Equity Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.altria.com/role/FinancialInstruments">
        <link:definition>0000013 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlans" roleURI="http://www.altria.com/role/BenefitPlans">
        <link:definition>0000014 - Disclosure - Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.altria.com/role/EarningsperShare">
        <link:definition>0000015 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveEarningsLosses" roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLosses">
        <link:definition>0000016 - Disclosure - Other Comprehensive Earnings/Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.altria.com/role/SegmentReporting">
        <link:definition>0000017 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.altria.com/role/Debt">
        <link:definition>0000018 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.altria.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.altria.com/role/Contingencies">
        <link:definition>0000020 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingGuidanceNotYetAdopted" roleURI="http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted">
        <link:definition>0000021 - Disclosure - New Accounting Guidance Not Yet Adopted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentationPolicies" roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationPolicies">
        <link:definition>0000022 - Disclosure - Background and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentationTables" roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationTables">
        <link:definition>0000023 - Disclosure - Background and Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesTables" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesTables">
        <link:definition>0000024 - Disclosure - Investments in Equity Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.altria.com/role/FinancialInstrumentsTables">
        <link:definition>0000025 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansTables" roleURI="http://www.altria.com/role/BenefitPlansTables">
        <link:definition>0000026 - Disclosure - Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.altria.com/role/EarningsperShareTables">
        <link:definition>0000027 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveEarningsLossesTables" roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesTables">
        <link:definition>0000028 - Disclosure - Other Comprehensive Earnings/Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.altria.com/role/SegmentReportingTables">
        <link:definition>0000029 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.altria.com/role/IncomeTaxesTables">
        <link:definition>0000030 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesTables" roleURI="http://www.altria.com/role/ContingenciesTables">
        <link:definition>0000031 - Disclosure - Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingGuidanceNotYetAdoptedTables" roleURI="http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables">
        <link:definition>0000032 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentationNarrativeDetails" roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails">
        <link:definition>0000033 - Disclosure - Background and Basis of Presentation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundandBasisofPresentationShareRepurchaseTableDetails" roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails">
        <link:definition>0000034 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersNarrativeDetails" roleURI="http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails">
        <link:definition>0000035 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails">
        <link:definition>0000036 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails">
        <link:definition>0000037 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails">
        <link:definition>0000038 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails">
        <link:definition>0000039 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details">
        <link:definition>0000040 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails">
        <link:definition>0000041 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.altria.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAggregateFairValueandCarryingValueDetails" roleURI="http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" roleURI="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails">
        <link:definition>0000044 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansNarrativeDetails" roleURI="http://www.altria.com/role/BenefitPlansNarrativeDetails">
        <link:definition>0000045 - Disclosure - Benefit Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareBasicandDilutedEarningsPerShareDetails" roleURI="http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails">
        <link:definition>0000046 - Disclosure - Earnings per Share (Basic and Diluted Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails">
        <link:definition>0000047 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveEarningsLossesReclassificationsDetails" roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails">
        <link:definition>0000048 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSegmentDataScheduleDetails" roleURI="http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails">
        <link:definition>0000049 - Disclosure - Segment Reporting (Segment Data Schedule) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.altria.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000050 - Disclosure - Segment Reporting (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" roleURI="http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails">
        <link:definition>0000051 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.altria.com/role/DebtNarrativeDetails">
        <link:definition>0000052 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofIncomeTaxesDetails" roleURI="http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails">
        <link:definition>0000053 - Disclosure - Income Taxes - Summary of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.altria.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000054 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.altria.com/role/IncomeTaxesDetails">
        <link:definition>0000055 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesGeneralInformationDetails" roleURI="http://www.altria.com/role/ContingenciesGeneralInformationDetails">
        <link:definition>0000056 - Disclosure - Contingencies (General Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" roleURI="http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails">
        <link:definition>0000057 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesScheduleofPendingCasesDetails" roleURI="http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails">
        <link:definition>0000058 - Disclosure - Contingencies (Schedule of Pending Cases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" roleURI="http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails">
        <link:definition>0000059 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesNonEngleProgenyLitigationDetails" roleURI="http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails">
        <link:definition>0000060 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" roleURI="http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails">
        <link:definition>0000061 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" roleURI="http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails">
        <link:definition>0000062 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesFloridaBondStatuteDetails" roleURI="http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails">
        <link:definition>0000063 - Disclosure - Contingencies (Florida Bond Statute) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesOtherSmokingandHealthClassActionsDetails" roleURI="http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails">
        <link:definition>0000064 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesHealthCareCostRecoveryLitigationDetails" roleURI="http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails">
        <link:definition>0000065 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesNPMAdjustmentDisputesDetails" roleURI="http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails">
        <link:definition>0000066 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" roleURI="http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails">
        <link:definition>0000067 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesFederalGovernmentsLawsuitDetails" roleURI="http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails">
        <link:definition>0000068 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesEvaporProductLitigationandIQOSLitigationDetails" roleURI="http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails">
        <link:definition>0000069 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" roleURI="http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails">
        <link:definition>0000070 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesLightsUltraLightsCasesDetails" roleURI="http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails">
        <link:definition>0000071 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesUSTLitigationsNarrativeDetails" roleURI="http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails">
        <link:definition>0000072 - Disclosure - Contingencies (UST Litigations Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" roleURI="http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails">
        <link:definition>0000073 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mo_LossContingencyRoyaltyFeePercentage" abstract="false" name="LossContingencyRoyaltyFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_LossContingencyFaultAllocationPercentage" abstract="false" name="LossContingencyFaultAllocationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_EngleProgenyCasesHollimanMember" abstract="true" name="EngleProgenyCasesHollimanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_FederalAndStateShareholderDerivativeLawsuitsMember" abstract="true" name="FederalAndStateShareholderDerivativeLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfTrialsOngoing" abstract="false" name="LossContingencyNumberOfTrialsOngoing" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" abstract="false" name="LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mo_HorizonMember" abstract="true" name="HorizonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" abstract="false" name="LossContingencyNumberOfStatesNotSettledArbitrationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mo_ImplementationofCorrectiveCommunicationsMember" abstract="true" name="ImplementationofCorrectiveCommunicationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_USTLitigationMember" abstract="true" name="USTLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2009NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_InvestmentsLineItems" abstract="true" name="InvestmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" abstract="false" name="LossContingencyNumberOfShareholdersFilingClassActionLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EngleProgenyCasesMillerMember" abstract="true" name="EngleProgenyCasesMillerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2014NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2020NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" abstract="false" name="LossContingencyNumberofStateswithSettledLitigationSettlementOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_IQOSMember" abstract="true" name="IQOSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" abstract="false" name="EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_LossContingencyReductionToCostOfSales" abstract="false" name="LossContingencyReductionToCostOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_ArbitrationPeriodDomain" abstract="true" name="ArbitrationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfComplaints" abstract="false" name="LossContingencyNumberOfComplaints" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" abstract="true" name="ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mo_LossContingencyClaimsDecided" abstract="false" name="LossContingencyClaimsDecided" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyNumberOfInactiveClassActionLawsuits" abstract="false" name="LossContingencyNumberOfInactiveClassActionLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LitigationSettlementAnnualPaymentAmount" abstract="false" name="LitigationSettlementAnnualPaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_OtherInventoryRawMaterialsNetofReserves" abstract="false" name="OtherInventoryRawMaterialsNetofReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EngleProgenyCasesStateMember" abstract="true" name="EngleProgenyCasesStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_InvestmentsTable" abstract="true" name="InvestmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mo_EquityMethodInvestmentPricePerShareIfExercised" abstract="false" name="EquityMethodInvestmentPricePerShareIfExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mo_EngleProgenyCasesR.DouglasMember" abstract="true" name="EngleProgenyCasesR.DouglasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfPendingCasesConsolidated" abstract="false" name="LossContingencyNumberOfPendingCasesConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" abstract="false" name="ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mo_NonEngleProgenyCasesMember" abstract="true" name="NonEngleProgenyCasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofStateswithSettledLitigation" abstract="false" name="LossContingencyNumberofStateswithSettledLitigation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseInAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" abstract="false" name="LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" abstract="false" name="EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_InterestExpenseRelatedToLitigationMember" abstract="true" name="InterestExpenseRelatedToLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" abstract="true" name="HealthCareCostRecoveryActionsTransitionYears20192021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfStatesWithConcludedHearings" abstract="false" name="LossContingencyNumberOfStatesWithConcludedHearings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_InterestAndOtherDebtExpenseNetMember" abstract="true" name="InterestAndOtherDebtExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyZeroDamagesVerdictModified" abstract="false" name="LossContingencyZeroDamagesVerdictModified" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ReceivableCommercializationRightsCurrent" abstract="false" name="ReceivableCommercializationRightsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_IndividualSmokingAndHealthCasesMember" abstract="true" name="IndividualSmokingAndHealthCasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_NonEngleProgenySmokingAndHealthCaseMendezMember" abstract="true" name="NonEngleProgenySmokingAndHealthCaseMendezMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2022NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EuroNotes1000MaturingFebruary2023Member" abstract="true" name="EuroNotes1000MaturingFebruary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyStateCourtsNumber" abstract="false" name="LossContingencyStateCourtsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EngleProgenyCasesD.BrownMember" abstract="true" name="EngleProgenyCasesD.BrownMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" abstract="true" name="AccumulatedEquityMethodInvestmentsAttributableToParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActionsMember" abstract="true" name="HealthCareCostRecoveryActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2005NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesCooperMember" abstract="true" name="EngleProgenyCasesCooperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyZeroDamagesVerdicts" abstract="false" name="LossContingencyZeroDamagesVerdicts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2012NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ArbitrationPeriodAxis" abstract="true" name="ArbitrationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mo_SmokingAndHealthClassActionsMember" abstract="true" name="SmokingAndHealthClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" abstract="false" name="EquityMethodInvestmentNumberofSharesOwnedRestricted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mo_AltriaGroupMember" abstract="true" name="AltriaGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ClassActionLawsuitMember" abstract="true" name="ClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesWeingartandHancockMember" abstract="true" name="EngleProgenyCasesWeingartandHancockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_BritishColumbiaSaskatchewanMember" abstract="true" name="BritishColumbiaSaskatchewanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" abstract="true" name="HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_OtherDisputesUndertheStateSettlementAgreementsMember" abstract="true" name="OtherDisputesUndertheStateSettlementAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_OralTobaccoSegmentMember" abstract="true" name="OralTobaccoSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_IncreaseDecreaseInSettlementPayable" abstract="false" name="IncreaseDecreaseInSettlementPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" abstract="false" name="ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2018NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" abstract="true" name="NonEngleProgenySmokingAndHealthCaseWoodleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_PhilipMorrisUSAandAltriaGroupMember" abstract="true" name="PhilipMorrisUSAandAltriaGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesPollariMember" abstract="true" name="EngleProgenyCasesPollariMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfCases" abstract="false" name="LossContingencyNumberOfCases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyClaimsNotCertifiedNumber" abstract="false" name="LossContingencyClaimsNotCertifiedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_PhilipMorrisUSAMember" abstract="true" name="PhilipMorrisUSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyCompensatoryDamagesAwardedValue" abstract="false" name="LossContingencyCompensatoryDamagesAwardedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_OtherTabaccoRelatedCasesMember" abstract="true" name="OtherTabaccoRelatedCasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_MaximumBondForAllDefendants" abstract="false" name="MaximumBondForAllDefendants" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EngleProgenyCasesGarciaMember" abstract="true" name="EngleProgenyCasesGarciaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ABInBevMember" abstract="true" name="ABInBevMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CommonStock3.125NotesDue2031Member" abstract="true" name="CommonStock3.125NotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_OwnershipPercentageInConsolidatedSubsidiary" abstract="false" name="OwnershipPercentageInConsolidatedSubsidiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" abstract="false" name="EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EvaporLitigationMember" abstract="true" name="EvaporLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyPunitiveDamagesAwardedValue" abstract="false" name="LossContingencyPunitiveDamagesAwardedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_IncomeLossFromEquitySecurities" abstract="false" name="IncomeLossFromEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" abstract="true" name="HealthCareCostRecoveryActionsTransitionYears20042020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_January2023ShareRepurchaseProgramMember" abstract="true" name="January2023ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LitigationEscrowDeposit" abstract="false" name="LitigationEscrowDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_NumberOfThirdPartyLawsuits" abstract="false" name="NumberOfThirdPartyLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_TermSecuredOvernightFinancingRateTermSOFRMember" abstract="true" name="TermSecuredOvernightFinancingRateTermSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_TobaccoandHealthLitigationCasesMember" abstract="true" name="TobaccoandHealthLitigationCasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_JUULMember" abstract="true" name="JUULMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_January2021ShareRepurchaseProgramMember" abstract="true" name="January2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfCasesWithSetTrialDates" abstract="false" name="LossContingencyNumberOfCasesWithSetTrialDates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyClaimsDecidedFavorableNumber" abstract="false" name="LossContingencyClaimsDecidedFavorableNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EngleProgenyCasesDuignanMember" abstract="true" name="EngleProgenyCasesDuignanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesCuddiheeMember" abstract="true" name="EngleProgenyCasesCuddiheeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyVerdictReversedNumber" abstract="false" name="LossContingencyVerdictReversedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EquityContractPreemptiveRIghtsMember" abstract="true" name="EquityContractPreemptiveRIghtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_NpmAdjustmentToCostOfSalesMember" abstract="true" name="NpmAdjustmentToCostOfSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofCasesSetforTrial" abstract="false" name="LossContingencyNumberofCasesSetforTrial" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2011NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyClaimsDecidedUnfavorableNumber" abstract="false" name="LossContingencyClaimsDecidedUnfavorableNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" abstract="false" name="ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EngleProgenyCasesLippMember" abstract="true" name="EngleProgenyCasesLippMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" abstract="false" name="AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_PeriodTwoMember" abstract="true" name="PeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CommonStock2.200NotesDue2027Member" abstract="true" name="CommonStock2.200NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_AgreementToResolveShareholderClassActionMember" abstract="true" name="AgreementToResolveShareholderClassActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2008NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EquityMethodInvestmentsFixedPreemptiveRights" abstract="false" name="EquityMethodInvestmentsFixedPreemptiveRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LossContingencyClassNotCertifiedNumber" abstract="false" name="LossContingencyClassNotCertifiedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LightsMember" abstract="true" name="LightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyDamagesRecoverableValue" abstract="false" name="LossContingencyDamagesRecoverableValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" abstract="true" name="NonEngleProgenySmokingAndHealthCaseFontaineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CommonStock1.700NotesDue2025Member" abstract="true" name="CommonStock1.700NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesHoffmanMember" abstract="true" name="EngleProgenyCasesHoffmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LitigationSettlementEstimateofPossibleGain" abstract="false" name="LitigationSettlementEstimateofPossibleGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" abstract="false" name="LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EquityContractWarrantMember" abstract="true" name="EquityContractWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2017NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_MarketingAdministrationandResearchCosts" abstract="false" name="MarketingAdministrationandResearchCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" abstract="false" name="EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2021NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions20052007NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2006NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" abstract="true" name="ScheduleofPretaxTobaccoandHealthLitigationChargesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mo_NonEngleProgenySmokingandHealthCaseGreeneMember" abstract="true" name="NonEngleProgenySmokingandHealthCaseGreeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofManufacturers" abstract="false" name="LossContingencyNumberofManufacturers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_PendingIndividualLawsuitsMember" abstract="true" name="PendingIndividualLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ForeignCurrencyDenominatedDebtAbstract" abstract="true" name="ForeignCurrencyDenominatedDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" abstract="false" name="LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" abstract="false" name="DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" abstract="true" name="PendingLawsuitsFiledByStateOrLocalGovernmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyUnfavorableVerdictsPendingReversed" abstract="false" name="LossContingencyUnfavorableVerdictsPendingReversed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" abstract="false" name="LossContingencyNumberOfStatesInComplianceWithEscrowStatues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyNumberOfInactiveCases" abstract="false" name="LossContingencyNumberOfInactiveCases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" abstract="false" name="DeferredGainOnSaleOfCommercializationRightsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EquityMethodInvestmentNumberofSharesOwnedCommon" abstract="false" name="EquityMethodInvestmentNumberofSharesOwnedCommon" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mo_EngleProgenyCasesMember" abstract="true" name="EngleProgenyCasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" abstract="true" name="PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesKaplanMcLauighlinMember" abstract="true" name="EngleProgenyCasesKaplanMcLauighlinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" abstract="false" name="LossContingencyNumberofStatesThatCapBondorRequireNoBond" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_EngleProgenyCasesGlogerRintoulandDuignamMember" abstract="true" name="EngleProgenyCasesGlogerRintoulandDuignamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_InventoryRawMaterialsPlantMaterialNetofReserves" abstract="false" name="InventoryRawMaterialsPlantMaterialNetofReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" abstract="false" name="EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_EngleProgenyCasesTuttleMember" abstract="true" name="EngleProgenyCasesTuttleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2015NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_PendingClassActionLawsuitMember" abstract="true" name="PendingClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CashDiscountsPolicyTextBlock" abstract="false" name="CashDiscountsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mo_RevolvingCreditFacilityDueAugust2025Member" abstract="true" name="RevolvingCreditFacilityDueAugust2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" abstract="true" name="HealthCareCostRecoveryActions2019NPMAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesSchertzerMember" abstract="true" name="EngleProgenyCasesSchertzerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_AccruedSettlementLiabilityCurrent" abstract="false" name="AccruedSettlementLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EquityMethodInvestmentImpairment" abstract="false" name="EquityMethodInvestmentImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" abstract="false" name="RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mo_AmountAwardedtoOtherParty" abstract="false" name="AmountAwardedtoOtherParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" abstract="false" name="LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_LossContingencyClaimsResolvedNumber" abstract="false" name="LossContingencyClaimsResolvedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2013NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesLevineMember" abstract="true" name="EngleProgenyCasesLevineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_JTIUHMember" abstract="true" name="JTIUHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CanadianTobaccoManufacturersMember" abstract="true" name="CanadianTobaccoManufacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_SmokeableProductsSegmentMember" abstract="true" name="SmokeableProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" abstract="true" name="NonParticipatingManufacturerArbitrationPanelDecisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mo_EngleProgenyCasesFreemanAndHarrisMember" abstract="true" name="EngleProgenyCasesFreemanAndHarrisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" abstract="false" name="UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_TobaccoandHealthJudgmentMember" abstract="true" name="TobaccoandHealthJudgmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesChadwellMember" abstract="true" name="EngleProgenyCasesChadwellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ValuationAllowanceRollforwardRollForward" abstract="true" name="ValuationAllowanceRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mo_LitigationCasesResultsMember" abstract="true" name="LitigationCasesResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2004NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" abstract="false" name="OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EngleProgenyCasesReiderandBanksMember" abstract="true" name="EngleProgenyCasesReiderandBanksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_CommonStock0.3313ParValueMember" abstract="true" name="CommonStock0.3313ParValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" abstract="false" name="DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" abstract="false" name="ValuationAllowanceForeignCurrencyTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LitigationSettlementAnnualLegalFeesPayableMaximum" abstract="false" name="LitigationSettlementAnnualLegalFeesPayableMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_EngleProgenyCasesMcCallMember" abstract="true" name="EngleProgenyCasesMcCallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" abstract="true" name="EngleProgenyCasesPearsonDCohenCollarChaconMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_PeriodOneMember" abstract="true" name="PeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" abstract="true" name="HealthCareCostRecoveryActionsTransitionYears20042021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetDecreaseInAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mo_LossContingencyClassActionLawsuit" abstract="false" name="LossContingencyClassActionLawsuit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_ETSSmokingandHealthCaseFlightAttendantsMember" abstract="true" name="ETSSmokingandHealthCaseFlightAttendantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_SummaryOfIncomeTaxesTableTextBlock" abstract="false" name="SummaryOfIncomeTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mo_CronosGroupInc.Member" abstract="true" name="CronosGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" abstract="false" name="LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2007NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" abstract="true" name="HealthCareCostRecoveryActions2010NPMAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyVerdictsUpheld" abstract="false" name="LossContingencyVerdictsUpheld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mo_NJOYHoldingsIncMember" abstract="true" name="NJOYHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mo_LossContingencyNumberOfStatesNotSettled" abstract="false" name="LossContingencyNumberOfStatesNotSettled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>mo-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cfff3450-f162-40ca-9ed8-3a28a0ba0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_AssetsCurrent_cfff3450-f162-40ca-9ed8-3a28a0ba0e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e4a0bfa-6b0b-496a-8467-1417d3359c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e4a0bfa-6b0b-496a-8467-1417d3359c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ffeb0874-6d12-446f-9251-d9b89fb8f795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_Goodwill_ffeb0874-6d12-446f-9251-d9b89fb8f795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1553bec-cc64-4ad2-be08-3289a2d7b644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1553bec-cc64-4ad2-be08-3289a2d7b644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_bb615b25-1280-439b-8996-ad533d76b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_Investments_bb615b25-1280-439b-8996-ad533d76b6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ec68602c-3501-4853-9690-39719da51a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf2f0623-cec8-468d-91bb-d78bf4d8f7e0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ec68602c-3501-4853-9690-39719da51a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_430d86aa-57ff-48ad-ae77-02d8c52ae8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_430d86aa-57ff-48ad-ae77-02d8c52ae8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ed11a8d4-9508-4877-bc7c-57b0caf3e1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:to="loc_us-gaap_CommonStockValue_ed11a8d4-9508-4877-bc7c-57b0caf3e1a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1fac591-234a-44b5-a1b4-d845fd0e3419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1fac591-234a-44b5-a1b4-d845fd0e3419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fd132bc8-ba30-49bb-8f1c-1f7b5fb9d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fd132bc8-ba30-49bb-8f1c-1f7b5fb9d9b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4cd1133a-d1d6-48bd-bda7-4c07e4a0b3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e5700bbb-cd0e-4112-bd87-d54c00702670" xlink:to="loc_us-gaap_TreasuryStockValue_4cd1133a-d1d6-48bd-bda7-4c07e4a0b3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51ad9acb-1834-439b-aa3f-db0f1cbdd317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_43f52857-1061-4289-bf10-1a8c73c0a6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51ad9acb-1834-439b-aa3f-db0f1cbdd317" xlink:to="loc_us-gaap_MinorityInterest_43f52857-1061-4289-bf10-1a8c73c0a6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ecf3309-f13a-4290-b7ed-b85c3da0c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51ad9acb-1834-439b-aa3f-db0f1cbdd317" xlink:to="loc_us-gaap_StockholdersEquity_6ecf3309-f13a-4290-b7ed-b85c3da0c1a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_39d28ee6-3823-4edb-8c7d-c104dd788737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_us-gaap_LongTermDebtCurrent_39d28ee6-3823-4edb-8c7d-c104dd788737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6cf9f6bc-c874-4987-a0db-d73cef5f7540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_us-gaap_AccountsPayableCurrent_6cf9f6bc-c874-4987-a0db-d73cef5f7540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_8fb4a726-f1dc-4cdf-b5fa-783a0fe20b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_8fb4a726-f1dc-4cdf-b5fa-783a0fe20b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccruedSettlementLiabilityCurrent_2a607ce0-c1bb-4bdf-b0fc-d46c6cdc8ee4" xlink:href="mo-20230331.xsd#mo_AccruedSettlementLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_mo_AccruedSettlementLiabilityCurrent_2a607ce0-c1bb-4bdf-b0fc-d46c6cdc8ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73dd3eb1-4ea1-405f-9510-d6ad53ee3767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73dd3eb1-4ea1-405f-9510-d6ad53ee3767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_3e64d392-f342-4dff-ad87-0e6ee6b476c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109c011c-3fcd-4883-a138-68f27fbd1904" xlink:to="loc_us-gaap_DividendsPayableCurrent_3e64d392-f342-4dff-ad87-0e6ee6b476c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_48915b34-b30d-4051-85df-80dc834dfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves_e521e5de-6a48-4e6e-a638-61bb4435b3c6" xlink:href="mo-20230331.xsd#mo_InventoryRawMaterialsPlantMaterialNetofReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_48915b34-b30d-4051-85df-80dc834dfba8" xlink:to="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves_e521e5de-6a48-4e6e-a638-61bb4435b3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherInventoryRawMaterialsNetofReserves_6ddadbf3-76c1-4662-a9be-41c33078290d" xlink:href="mo-20230331.xsd#mo_OtherInventoryRawMaterialsNetofReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_48915b34-b30d-4051-85df-80dc834dfba8" xlink:to="loc_mo_OtherInventoryRawMaterialsNetofReserves_6ddadbf3-76c1-4662-a9be-41c33078290d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cf46db8a-a48f-434e-9a89-6174284ce29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_48915b34-b30d-4051-85df-80dc834dfba8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cf46db8a-a48f-434e-9a89-6174284ce29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_55f21226-8101-4b69-b5c2-6cc427e21a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_48915b34-b30d-4051-85df-80dc834dfba8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_55f21226-8101-4b69-b5c2-6cc427e21a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5b7a80f6-4edf-49cc-9ed8-ec196836e4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_acbde655-d710-4dde-ad9d-8f3385f3b824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5b7a80f6-4edf-49cc-9ed8-ec196836e4bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_acbde655-d710-4dde-ad9d-8f3385f3b824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90584f3f-8954-4e23-9680-9752e2a9a310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5b7a80f6-4edf-49cc-9ed8-ec196836e4bc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90584f3f-8954-4e23-9680-9752e2a9a310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6266a01b-2ed6-4917-8573-3aebb854d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_563c1d19-bcce-4888-b1a8-b5b9b2b41215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6266a01b-2ed6-4917-8573-3aebb854d98c" xlink:to="loc_us-gaap_Liabilities_563c1d19-bcce-4888-b1a8-b5b9b2b41215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_892227a6-b6cc-48b7-bb93-d49b2619a25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6266a01b-2ed6-4917-8573-3aebb854d98c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_892227a6-b6cc-48b7-bb93-d49b2619a25f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dde86f34-29a0-4256-9c3c-e74765539fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6266a01b-2ed6-4917-8573-3aebb854d98c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dde86f34-29a0-4256-9c3c-e74765539fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ReceivableCommercializationRightsCurrent_80cd4f18-39c0-48d8-b9eb-64cdc1a33a50" xlink:href="mo-20230331.xsd#mo_ReceivableCommercializationRightsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:to="loc_mo_ReceivableCommercializationRightsCurrent_80cd4f18-39c0-48d8-b9eb-64cdc1a33a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2ccc24ed-4d05-431e-9146-ea27d0f3fc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:to="loc_us-gaap_InventoryNet_2ccc24ed-4d05-431e-9146-ea27d0f3fc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_da5d9bd3-46d4-4411-ba96-3f0ea361571a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_da5d9bd3-46d4-4411-ba96-3f0ea361571a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee5211da-bf74-4f70-93db-b571611da5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee5211da-bf74-4f70-93db-b571611da5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9ce97068-06b3-4897-af57-cca7d702e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93b9e145-6984-404c-a1e4-284e00d9925a" xlink:to="loc_us-gaap_OtherAssetsCurrent_9ce97068-06b3-4897-af57-cca7d702e5db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_79570d2c-e7a7-4fc5-9ff5-b11e1b3400e6" xlink:href="mo-20230331.xsd#mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_79570d2c-e7a7-4fc5-9ff5-b11e1b3400e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9877f9d0-2a4a-493f-a87a-26924c4066d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9877f9d0-2a4a-493f-a87a-26924c4066d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f032f6b-100b-4143-ad3d-3c7ab4bf846d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_LiabilitiesCurrent_5f032f6b-100b-4143-ad3d-3c7ab4bf846d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c8d39b77-590b-47ac-9f06-67fd3589ae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c8d39b77-590b-47ac-9f06-67fd3589ae6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_33b75282-f0e9-41ad-b837-983eb32120a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_33b75282-f0e9-41ad-b837-983eb32120a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_15e7e200-4ee0-4c87-9c4e-3dbf97d8d247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_15e7e200-4ee0-4c87-9c4e-3dbf97d8d247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_003c2873-a29e-4300-8e9d-7f677d773db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0a068b1e-1571-4f6b-a6bd-06c57bc416e9" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_003c2873-a29e-4300-8e9d-7f677d773db7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ee88a2e0-7d2d-4d59-b591-c1f43f9b7845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa287728-6bb1-4da9-8830-d9c438b128d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_ee88a2e0-7d2d-4d59-b591-c1f43f9b7845" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa287728-6bb1-4da9-8830-d9c438b128d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7ba08890-3dfa-46cb-9533-47f131ad8896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_ee88a2e0-7d2d-4d59-b591-c1f43f9b7845" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7ba08890-3dfa-46cb-9533-47f131ad8896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue_5362479e-3d90-4f44-882f-0b9ad2072856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_ee88a2e0-7d2d-4d59-b591-c1f43f9b7845" xlink:to="loc_us-gaap_OtherCostOfOperatingRevenue_5362479e-3d90-4f44-882f-0b9ad2072856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65c72637-b1f5-4f34-8922-a48157ebcd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_979ae1b8-8508-4f19-9f9d-9a14c213cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65c72637-b1f5-4f34-8922-a48157ebcd8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_979ae1b8-8508-4f19-9f9d-9a14c213cdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17df28cc-429c-4f23-9ecc-2a36981823c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65c72637-b1f5-4f34-8922-a48157ebcd8b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17df28cc-429c-4f23-9ecc-2a36981823c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af164416-4fc2-4765-8bf6-cabf87d44e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0615dc73-1929-4a2b-9c6e-430fb185f460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af164416-4fc2-4765-8bf6-cabf87d44e52" xlink:to="loc_us-gaap_GrossProfit_0615dc73-1929-4a2b-9c6e-430fb185f460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MarketingAdministrationandResearchCosts_c08f9e36-864b-4ef9-9def-cf33aa10ad17" xlink:href="mo-20230331.xsd#mo_MarketingAdministrationandResearchCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af164416-4fc2-4765-8bf6-cabf87d44e52" xlink:to="loc_mo_MarketingAdministrationandResearchCosts_c08f9e36-864b-4ef9-9def-cf33aa10ad17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2fd159b5-c058-4e40-801b-c9caa9fb8757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2fd159b5-c058-4e40-801b-c9caa9fb8757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_b48ba6b8-0d04-4cc3-953f-9a5400c0b357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_b48ba6b8-0d04-4cc3-953f-9a5400c0b357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_777f48d2-e62a-4db3-8903-d87fb36320e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:to="loc_us-gaap_OperatingIncomeLoss_777f48d2-e62a-4db3-8903-d87fb36320e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_27ae2ec5-5a3e-4536-b1c8-6cf1c486ee0b" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:to="loc_mo_IncomeLossFromEquitySecurities_27ae2ec5-5a3e-4536-b1c8-6cf1c486ee0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_62be757b-f972-4bc0-b3ff-c97c1b2726d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b483ede-485d-40a5-ae33-db23d6e96b48" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_62be757b-f972-4bc0-b3ff-c97c1b2726d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveEarnings"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3b17d68-189b-4b2d-b8a3-a9dce5ef3430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2299d95f-714b-4c9e-84e0-45e5579b8075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3b17d68-189b-4b2d-b8a3-a9dce5ef3430" xlink:to="loc_us-gaap_ProfitLoss_2299d95f-714b-4c9e-84e0-45e5579b8075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a2085108-752c-4c71-b0eb-ba382077a73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3b17d68-189b-4b2d-b8a3-a9dce5ef3430" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a2085108-752c-4c71-b0eb-ba382077a73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db80ceb0-220a-44eb-927e-afc6b1cf2f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_51b37e05-6e22-45cb-b8e9-a1d01d454f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db80ceb0-220a-44eb-927e-afc6b1cf2f67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_51b37e05-6e22-45cb-b8e9-a1d01d454f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax_978e9ceb-620e-4694-a7c3-a3532786927d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciEquityMethodInvestmentAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db80ceb0-220a-44eb-927e-afc6b1cf2f67" xlink:to="loc_us-gaap_OciEquityMethodInvestmentAfterTax_978e9ceb-620e-4694-a7c3-a3532786927d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_65b422bb-dba8-4252-9a63-c6cae081f516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db80ceb0-220a-44eb-927e-afc6b1cf2f67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_65b422bb-dba8-4252-9a63-c6cae081f516" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a185eb92-7e09-49f1-889f-eedc2dedc456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51bc759d-6442-4b71-89c5-d6e2937af4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a185eb92-7e09-49f1-889f-eedc2dedc456" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51bc759d-6442-4b71-89c5-d6e2937af4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4c9e2b3f-ab93-450f-ad34-418d4eff2434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a185eb92-7e09-49f1-889f-eedc2dedc456" xlink:to="loc_us-gaap_RestrictedCashCurrent_4c9e2b3f-ab93-450f-ad34-418d4eff2434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_cdf98576-8ec5-4c93-bdf6-61831f082096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a185eb92-7e09-49f1-889f-eedc2dedc456" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_cdf98576-8ec5-4c93-bdf6-61831f082096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae965be8-4473-4e8c-81bc-ec76ad4c088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44601996-0161-4dea-b6fd-ac2df3ada308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae965be8-4473-4e8c-81bc-ec76ad4c088f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44601996-0161-4dea-b6fd-ac2df3ada308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dbe19211-0ed7-44ab-b2c1-432a6df182c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae965be8-4473-4e8c-81bc-ec76ad4c088f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dbe19211-0ed7-44ab-b2c1-432a6df182c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21094426-8332-42d6-9591-34c2dff0f640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae965be8-4473-4e8c-81bc-ec76ad4c088f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21094426-8332-42d6-9591-34c2dff0f640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b402bf1f-4335-42b8-ad7f-1d5110ea366e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ddb9bfcc-2f0d-4d95-90e7-9306c1ea06b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b402bf1f-4335-42b8-ad7f-1d5110ea366e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ddb9bfcc-2f0d-4d95-90e7-9306c1ea06b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_929d998c-85ed-47f7-9d24-b87a9887f15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b402bf1f-4335-42b8-ad7f-1d5110ea366e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_929d998c-85ed-47f7-9d24-b87a9887f15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_518e2853-6cdd-4217-ac8f-1f6d043f0888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b9edd42e-9a42-4fbb-b52d-65a1d01e2837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_518e2853-6cdd-4217-ac8f-1f6d043f0888" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b9edd42e-9a42-4fbb-b52d-65a1d01e2837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_c69919c1-dc91-4bb2-8674-4dd3c03f408f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_518e2853-6cdd-4217-ac8f-1f6d043f0888" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_c69919c1-dc91-4bb2-8674-4dd3c03f408f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c3cf5146-0816-40db-a97b-2d71203a49e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_518e2853-6cdd-4217-ac8f-1f6d043f0888" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c3cf5146-0816-40db-a97b-2d71203a49e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8977becf-2379-47ed-87bd-7a7d3c009c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_518e2853-6cdd-4217-ac8f-1f6d043f0888" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8977becf-2379-47ed-87bd-7a7d3c009c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39032a1d-002a-481c-bf1b-b5aa3e4f807e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_ProfitLoss_39032a1d-002a-481c-bf1b-b5aa3e4f807e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_26ffff41-06c0-471b-9bf7-5e20da838d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_26ffff41-06c0-471b-9bf7-5e20da838d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_94cb1ed5-52c3-4bbe-be96-5868c24edb22" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_mo_IncomeLossFromEquitySecurities_94cb1ed5-52c3-4bbe-be96-5868c24edb22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_061d4eb9-395d-40a4-98bd-c50e3b2dc63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_061d4eb9-395d-40a4-98bd-c50e3b2dc63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c91da1f5-4523-4fd3-bcb3-98c8c25f13e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c91da1f5-4523-4fd3-bcb3-98c8c25f13e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_7b668449-cc9b-411a-a096-f5968cb10446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_7b668449-cc9b-411a-a096-f5968cb10446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncreaseDecreaseInSettlementPayable_4a2c652c-8df8-4652-bff6-a8a003b818b6" xlink:href="mo-20230331.xsd#mo_IncreaseDecreaseInSettlementPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_mo_IncreaseDecreaseInSettlementPayable_4a2c652c-8df8-4652-bff6-a8a003b818b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2d45eaff-be47-4c75-9fc5-aeda4a2a4970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2d45eaff-be47-4c75-9fc5-aeda4a2a4970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b0a254b-628b-492f-857b-14626219228c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b0a254b-628b-492f-857b-14626219228c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_6758a1c1-e673-481f-81e2-fec88be3cf90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_6758a1c1-e673-481f-81e2-fec88be3cf90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_c0654900-b100-441c-9070-331ee23f4b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_c0654900-b100-441c-9070-331ee23f4b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8599f87c-b374-4172-ae26-49c6c5b39e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8599f87c-b374-4172-ae26-49c6c5b39e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_133dd153-0f1a-4c32-8116-1077149680f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_133dd153-0f1a-4c32-8116-1077149680f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_72647054-3420-429d-944d-022aee03f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6944c6fb-deac-41d5-9c49-73737b580dfd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_72647054-3420-429d-944d-022aee03f498" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_fa0c041f-f428-4674-ab02-fcd5181f68ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_7af1b7a9-66b4-4e1a-8eac-6b97b9d4cd38" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_fa0c041f-f428-4674-ab02-fcd5181f68ed" xlink:to="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_7af1b7a9-66b4-4e1a-8eac-6b97b9d4cd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e6e73c6d-3671-4a36-ae65-8adeaa47d48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_fa0c041f-f428-4674-ab02-fcd5181f68ed" xlink:to="loc_us-gaap_EquityMethodInvestments_e6e73c6d-3671-4a36-ae65-8adeaa47d48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_20b538fe-c265-4a0e-937a-d718f3548bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_fa0c041f-f428-4674-ab02-fcd5181f68ed" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_20b538fe-c265-4a0e-937a-d718f3548bb9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_738e83cd-6ff2-401c-b04a-6c2ca7031cce" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4a42eeca-8ec6-413c-97c0-ff563ac16075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mo_IncomeLossFromEquitySecurities_738e83cd-6ff2-401c-b04a-6c2ca7031cce" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4a42eeca-8ec6-413c-97c0-ff563ac16075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b1b83c41-b334-4be7-9d27-6edd1daadaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mo_IncomeLossFromEquitySecurities_738e83cd-6ff2-401c-b04a-6c2ca7031cce" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b1b83c41-b334-4be7-9d27-6edd1daadaf7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dba15a76-d053-48e8-bd36-ba41221a73fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dba15a76-d053-48e8-bd36-ba41221a73fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1dce547e-355b-46eb-98ca-b071af7ca8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1dce547e-355b-46eb-98ca-b071af7ca8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a06a3176-633f-446f-afdb-1822bcefd1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a06a3176-633f-446f-afdb-1822bcefd1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0009db13-5bac-43c4-85f6-662dcb0d4aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0009db13-5bac-43c4-85f6-662dcb0d4aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1fa68be4-bf40-4cda-8679-d5fd7de29329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_15c92dca-7f88-43f8-9c09-25f2c1068f0c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1fa68be4-bf40-4cda-8679-d5fd7de29329" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#EarningsperShareBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_85ba7adc-ee98-465b-98a5-67ccd0fda54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_342fcb6e-c2f5-437b-9f60-3184b5efeb0d" xlink:href="mo-20230331.xsd#mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_85ba7adc-ee98-465b-98a5-67ccd0fda54e" xlink:to="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_342fcb6e-c2f5-437b-9f60-3184b5efeb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81681682-5443-4950-8521-1aedb308dfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_85ba7adc-ee98-465b-98a5-67ccd0fda54e" xlink:to="loc_us-gaap_NetIncomeLoss_81681682-5443-4950-8521-1aedb308dfae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_459447d8-e8ed-443a-bcdd-3047473063e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6eb096a-ea9b-44ea-a6d6-b9ce1633bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_459447d8-e8ed-443a-bcdd-3047473063e2" xlink:to="loc_us-gaap_NetIncomeLoss_d6eb096a-ea9b-44ea-a6d6-b9ce1633bce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_d0e50f80-3410-4765-b486-6e05d1d951f9" xlink:href="mo-20230331.xsd#mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_459447d8-e8ed-443a-bcdd-3047473063e2" xlink:to="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_d0e50f80-3410-4765-b486-6e05d1d951f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"/>
  <link:calculationLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bb0cc7e7-3e18-45c3-ba74-ef5f47761f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_a02b8eab-340b-4ace-874d-558bca2aabdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bb0cc7e7-3e18-45c3-ba74-ef5f47761f47" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_a02b8eab-340b-4ace-874d-558bca2aabdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2d74a40e-17ed-4e1d-9e0f-59690a93ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bb0cc7e7-3e18-45c3-ba74-ef5f47761f47" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2d74a40e-17ed-4e1d-9e0f-59690a93ae2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fea4f238-61de-4b26-bbd7-546b2b574401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_25402a9c-42a8-45b3-8776-9d51752f1bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fea4f238-61de-4b26-bbd7-546b2b574401" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_25402a9c-42a8-45b3-8776-9d51752f1bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4ffda88d-661b-48f9-97bd-f34fe18e2729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fea4f238-61de-4b26-bbd7-546b2b574401" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4ffda88d-661b-48f9-97bd-f34fe18e2729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_51c4d89b-78e6-467b-b087-a14d68045ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c5b6b0ee-cf4f-4df1-8572-a0b372344dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_51c4d89b-78e6-467b-b087-a14d68045ef4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c5b6b0ee-cf4f-4df1-8572-a0b372344dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f113399f-bd89-44d6-817f-11cb43e1233c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_51c4d89b-78e6-467b-b087-a14d68045ef4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f113399f-bd89-44d6-817f-11cb43e1233c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>mo-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.altria.com/role/CoverPage" xlink:type="simple" xlink:href="mo-20230331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/CoverPage" xlink:type="extended" id="i557808b8f9904b41b1ab02bdeaaf3b91_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b0223f1d-d166-4e26-a7d5-911d359b159a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentType_b0223f1d-d166-4e26-a7d5-911d359b159a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7527f901-353c-4f32-9bd8-604e451f456d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentQuarterlyReport_7527f901-353c-4f32-9bd8-604e451f456d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b52e0dee-a0aa-4f62-b8da-683d87e3da0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentPeriodEndDate_b52e0dee-a0aa-4f62-b8da-683d87e3da0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_840df29d-8652-477c-b51e-70b63dd0f99d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentTransitionReport_840df29d-8652-477c-b51e-70b63dd0f99d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac035216-f587-4f01-8274-e6d203e1e86d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityFileNumber_ac035216-f587-4f01-8274-e6d203e1e86d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc5d79c8-e7d8-4db8-89d9-c8b9bc132aee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityRegistrantName_bc5d79c8-e7d8-4db8-89d9-c8b9bc132aee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8f8101da-ce13-4162-bd24-85adbe3518ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8f8101da-ce13-4162-bd24-85adbe3518ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c171751b-163d-4620-ab63-68c8513fcf04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityTaxIdentificationNumber_c171751b-163d-4620-ab63-68c8513fcf04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7f04380b-72d0-404c-a3b2-a6115a70d0fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressAddressLine1_7f04380b-72d0-404c-a3b2-a6115a70d0fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4eb1c66f-376f-4703-81f0-fb477f6bf9b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressCityOrTown_4eb1c66f-376f-4703-81f0-fb477f6bf9b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_63ec4074-4dcb-4969-9b5d-1d0729426fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressStateOrProvince_63ec4074-4dcb-4969-9b5d-1d0729426fe4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6c068931-4168-4d97-acad-a613813e6578" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressPostalZipCode_6c068931-4168-4d97-acad-a613813e6578" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a92e4e71-22f2-49a2-9fab-a294d12e0187" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_CityAreaCode_a92e4e71-22f2-49a2-9fab-a294d12e0187" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_844ceca3-faac-47e0-b354-651c8dec751a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_LocalPhoneNumber_844ceca3-faac-47e0-b354-651c8dec751a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ab626842-9e45-4d14-ac82-a9d39ebd4d53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_Security12bTitle_ab626842-9e45-4d14-ac82-a9d39ebd4d53" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6f70ffd6-5c98-4129-9fdf-b1a7b031e47a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_TradingSymbol_6f70ffd6-5c98-4129-9fdf-b1a7b031e47a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8434e35c-7dff-484c-a104-e0b2bd913ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_SecurityExchangeName_8434e35c-7dff-484c-a104-e0b2bd913ea7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7ee59e8b-d9cb-4a50-928d-a005ea432e32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCurrentReportingStatus_7ee59e8b-d9cb-4a50-928d-a005ea432e32" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aee0a644-6173-4b90-be43-f75a56c6961c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityInteractiveDataCurrent_aee0a644-6173-4b90-be43-f75a56c6961c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c86d91b9-36a9-4014-8e2c-3fc2a606a0cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityFilerCategory_c86d91b9-36a9-4014-8e2c-3fc2a606a0cf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ebfcc4e0-3095-40a3-aa48-e1a49042e753" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntitySmallBusiness_ebfcc4e0-3095-40a3-aa48-e1a49042e753" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_04d69e7a-e1ca-424c-89ad-2ffff4e9b860" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityEmergingGrowthCompany_04d69e7a-e1ca-424c-89ad-2ffff4e9b860" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_772e3389-8151-4d0e-bc2a-d54f268a2a21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityShellCompany_772e3389-8151-4d0e-bc2a-d54f268a2a21" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_59da3c57-e247-4297-834b-b08b1f091a6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_59da3c57-e247-4297-834b-b08b1f091a6b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_21e4bb3e-bbd4-4d4a-8ba5-d8399e7f239d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_AmendmentFlag_21e4bb3e-bbd4-4d4a-8ba5-d8399e7f239d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0435fb45-39f0-4a78-9298-97c060686ed0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentFiscalYearFocus_0435fb45-39f0-4a78-9298-97c060686ed0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57af6a42-3877-4a46-bdb4-08bd5c811d36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57af6a42-3877-4a46-bdb4-08bd5c811d36" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_276c5464-422e-45da-8490-2fb2c8e9f0b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCentralIndexKey_276c5464-422e-45da-8490-2fb2c8e9f0b2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_59aa7244-dfea-40f2-a60f-bc988e02f4aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_CurrentFiscalYearEndDate_59aa7244-dfea-40f2-a60f-bc988e02f4aa" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62d02704-cb15-4102-b7ce-990fbb929e63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:to="loc_us-gaap_ClassOfStockDomain_62d02704-cb15-4102-b7ce-990fbb929e63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:to="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock0.3313ParValueMember_efb05856-9f11-4d50-baed-86bd4413d3c0" xlink:href="mo-20230331.xsd#mo_CommonStock0.3313ParValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock0.3313ParValueMember_efb05856-9f11-4d50-baed-86bd4413d3c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock1.700NotesDue2025Member_03b11a99-d246-445c-86bd-64341c730598" xlink:href="mo-20230331.xsd#mo_CommonStock1.700NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock1.700NotesDue2025Member_03b11a99-d246-445c-86bd-64341c730598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock2.200NotesDue2027Member_dd159b59-cd8d-4deb-8137-9654d97a3c9f" xlink:href="mo-20230331.xsd#mo_CommonStock2.200NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock2.200NotesDue2027Member_dd159b59-cd8d-4deb-8137-9654d97a3c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock3.125NotesDue2031Member_a608f79d-e619-4c43-b233-862e80bb5329" xlink:href="mo-20230331.xsd#mo_CommonStock3.125NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock3.125NotesDue2031Member_a608f79d-e619-4c43-b233-862e80bb5329" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended" id="i3ed2db79d64d44d1b78d93692efd399d_CondensedConsolidatedStatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4765f827-4eca-4d08-b71f-963ab6b4897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4765f827-4eca-4d08-b71f-963ab6b4897e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_bda5cab9-eb6f-45dd-8ee3-76aa9b8d54e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_bda5cab9-eb6f-45dd-8ee3-76aa9b8d54e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5c0c157e-7fe3-42a3-8e1a-5beb167f4c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5c0c157e-7fe3-42a3-8e1a-5beb167f4c7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_e847ae31-0eee-46d4-bacd-47955d79b4ca" xlink:href="mo-20230331.xsd#mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_e847ae31-0eee-46d4-bacd-47955d79b4ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_17fc2c0c-aaab-418c-99a6-0d702b2037eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_DividendsCommonStockCash_17fc2c0c-aaab-418c-99a6-0d702b2037eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e24519a4-8c9d-4b36-8d07-7a091f4c3ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e24519a4-8c9d-4b36-8d07-7a091f4c3ee9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14e1cb33-f8a7-47ea-abaa-7791d10fc1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:to="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2235768f-46a0-4a04-ba2d-fac5395b8539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:to="loc_us-gaap_EquityComponentDomain_2235768f-46a0-4a04-ba2d-fac5395b8539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:to="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f72d66a1-fbe5-44c4-a190-fe76144cd651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_CommonStockMember_f72d66a1-fbe5-44c4-a190-fe76144cd651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_283fbd9e-4ae9-49eb-8923-d1410721ffa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_283fbd9e-4ae9-49eb-8923-d1410721ffa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7532ecf2-cef9-4000-89cc-929529511a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_RetainedEarningsMember_7532ecf2-cef9-4000-89cc-929529511a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_275cbd7f-1918-4a00-b249-da9aa5cf56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_275cbd7f-1918-4a00-b249-da9aa5cf56a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_208e7b17-75e7-4bcd-87e2-46ddd25ddb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_TreasuryStockMember_208e7b17-75e7-4bcd-87e2-46ddd25ddb55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fc90bdf8-102c-4d7a-acf3-34bbc5360881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fc90bdf8-102c-4d7a-acf3-34bbc5360881" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i2fc49935696b4c1ca2b8b5e26adfab21_CondensedConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_04eea800-8ae5-4d4d-9456-de43dc2b2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_04eea800-8ae5-4d4d-9456-de43dc2b2c0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:to="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8b6fe707-14f4-434a-a054-7775d3992596_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8b6fe707-14f4-434a-a054-7775d3992596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_f55dcc8b-c581-43d9-9cdf-cc1018006603" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:to="loc_mo_JUULMember_f55dcc8b-c581-43d9-9cdf-cc1018006603" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" xlink:type="extended" id="i83fc39553e5141c89bf40c5cd371384e_BackgroundandBasisofPresentationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OwnershipPercentageInConsolidatedSubsidiary_f199e7db-1e09-4247-a521-06ddd95a8aed" xlink:href="mo-20230331.xsd#mo_OwnershipPercentageInConsolidatedSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_mo_OwnershipPercentageInConsolidatedSubsidiary_f199e7db-1e09-4247-a521-06ddd95a8aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_696ccf01-3557-41d8-b7c0-9f5c40cc6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_696ccf01-3557-41d8-b7c0-9f5c40cc6cd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a15acdc4-2c3a-406f-ac71-9abc995ded91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a15acdc4-2c3a-406f-ac71-9abc995ded91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f694e8a-68c2-4fbc-8383-0cadf8a854e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f694e8a-68c2-4fbc-8383-0cadf8a854e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_187e94b0-99f7-4510-8b3f-b64a59faca22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_187e94b0-99f7-4510-8b3f-b64a59faca22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d052a390-ea8c-48fd-97e4-e105b7225102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d052a390-ea8c-48fd-97e4-e105b7225102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2021ShareRepurchaseProgramMember_7eff3596-21f2-47ec-9d4d-d04a5ccf273a" xlink:href="mo-20230331.xsd#mo_January2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:to="loc_mo_January2021ShareRepurchaseProgramMember_7eff3596-21f2-47ec-9d4d-d04a5ccf273a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2023ShareRepurchaseProgramMember_6b61467d-c11b-42c8-b4a6-c40cfe25cc6f" xlink:href="mo-20230331.xsd#mo_January2023ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:to="loc_mo_January2023ShareRepurchaseProgramMember_6b61467d-c11b-42c8-b4a6-c40cfe25cc6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f8023-03dc-4f60-af53-847ff1f466ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f8023-03dc-4f60-af53-847ff1f466ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NJOYHoldingsIncMember_09709ce7-882c-42be-86f4-e760e0413b09" xlink:href="mo-20230331.xsd#mo_NJOYHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:to="loc_mo_NJOYHoldingsIncMember_09709ce7-882c-42be-86f4-e760e0413b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b9b2e75b-0380-418e-a487-27900efb30e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:to="loc_srt_OwnershipDomain_b9b2e75b-0380-418e-a487-27900efb30e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:to="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HorizonMember_6920f521-b2b7-48e2-abeb-6624898d3464" xlink:href="mo-20230331.xsd#mo_HorizonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:to="loc_mo_HorizonMember_6920f521-b2b7-48e2-abeb-6624898d3464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_38c6b853-eb4f-4aad-85a0-7fd4317cca69_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:to="loc_dei_EntityDomain_38c6b853-eb4f-4aad-85a0-7fd4317cca69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:to="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_ef1ad0d5-153d-447d-b00e-fca521d84fa0" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:to="loc_mo_PhilipMorrisUSAMember_ef1ad0d5-153d-447d-b00e-fca521d84fa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JTIUHMember_4804dad7-91b9-4951-a341-ce95c3edec5a" xlink:href="mo-20230331.xsd#mo_JTIUHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:to="loc_mo_JTIUHMember_4804dad7-91b9-4951-a341-ce95c3edec5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_db5ca9fe-f609-4ab0-80d3-2b73d744e642_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:to="loc_srt_ScenarioUnspecifiedDomain_db5ca9fe-f609-4ab0-80d3-2b73d744e642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f834c927-371e-4c4e-b935-7f3e0c55f9a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:to="loc_srt_ScenarioForecastMember_f834c927-371e-4c4e-b935-7f3e0c55f9a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationShareRepurchaseTableDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" xlink:type="extended" id="i0a3e6db3fce04457a7cc6c1b5e645a69_BackgroundandBasisofPresentationShareRepurchaseTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_22e031df-a48c-4efd-97fe-7971ed7c48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_22e031df-a48c-4efd-97fe-7971ed7c48a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_296ce585-54a2-42d9-8cce-7f37b50c0e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_296ce585-54a2-42d9-8cce-7f37b50c0e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2c367848-f75b-478c-a0a6-e3b95c0bc226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2c367848-f75b-478c-a0a6-e3b95c0bc226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_92c67c32-8542-437a-840c-37f5aa78ae53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_92c67c32-8542-437a-840c-37f5aa78ae53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2021ShareRepurchaseProgramMember_c0f82467-61b4-4ca5-bfee-7f0a2c1a3502" xlink:href="mo-20230331.xsd#mo_January2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:to="loc_mo_January2021ShareRepurchaseProgramMember_c0f82467-61b4-4ca5-bfee-7f0a2c1a3502" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="extended" id="i9a51da7e62ac4738a66040a62fe2ba73_InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4aab6d2c-f45a-4d2c-bc78-5c05195a4e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_EquityMethodInvestments_4aab6d2c-f45a-4d2c-bc78-5c05195a4e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b827bb6f-5a5d-4430-8a1c-2a2542f5adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b827bb6f-5a5d-4430-8a1c-2a2542f5adb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_a56cb62c-c979-4f76-835b-4d6f8432b5e1" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_a56cb62c-c979-4f76-835b-4d6f8432b5e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_b8d2e556-6523-46bd-98e8-44f333b5d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_Investments_b8d2e556-6523-46bd-98e8-44f333b5d709" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b1826316-0f56-48be-9f44-e0504477f7bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b1826316-0f56-48be-9f44-e0504477f7bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_23012fa7-1fcc-459c-881f-166215edaa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:to="loc_us-gaap_CommonStockMember_23012fa7-1fcc-459c-881f-166215edaa8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c215bb81-8133-4ea7-93c1-e7eaaba838b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c215bb81-8133-4ea7-93c1-e7eaaba838b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_fa1ae3e1-6488-4e40-abbd-5754a51116fa" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_ABInBevMember_fa1ae3e1-6488-4e40-abbd-5754a51116fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_eb03b451-424b-4c2b-bd8e-dcd720bf84c2" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_JUULMember_eb03b451-424b-4c2b-bd8e-dcd720bf84c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_ef2f00f3-3502-4e8e-bb48-e10a1567430b" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_CronosGroupInc.Member_ef2f00f3-3502-4e8e-bb48-e10a1567430b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="extended" id="ib8ab071870c8487c8290e16a95b8e83a_InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa11bbb6-35d9-4d28-9dcb-1866450a0ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa11bbb6-35d9-4d28-9dcb-1866450a0ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3c70b060-fbf9-49c6-841e-e790c7829766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3c70b060-fbf9-49c6-841e-e790c7829766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_f0757f90-11db-4baa-9a07-b8d90a57268b" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_mo_IncomeLossFromEquitySecurities_f0757f90-11db-4baa-9a07-b8d90a57268b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_35e9e082-d687-4642-bedd-a1ff13aa9c4a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_35e9e082-d687-4642-bedd-a1ff13aa9c4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_39d6770d-fe16-499a-b5ed-308f602fa8ee" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_ABInBevMember_39d6770d-fe16-499a-b5ed-308f602fa8ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_e0261fdf-0414-4b05-aa53-a64ce7fdbf4a" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_CronosGroupInc.Member_e0261fdf-0414-4b05-aa53-a64ce7fdbf4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_ca2360f2-51c1-4da2-9bb2-7b260b1f7c35" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_JUULMember_ca2360f2-51c1-4da2-9bb2-7b260b1f7c35" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" xlink:type="extended" id="i9f1bb42bf4d84c1ab28c530a54617b95_InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b806c0bc-1c56-45a3-9a65-d8b8fdb0a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b806c0bc-1c56-45a3-9a65-d8b8fdb0a537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_e1f36a33-974c-495f-b255-6d61d9442001" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_e1f36a33-974c-495f-b255-6d61d9442001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_3bbd9236-3752-433d-b919-b44edc9e095d" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedCommon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_3bbd9236-3752-433d-b919-b44edc9e095d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_04d5fe2a-edf8-4179-aa69-7f3fc314b881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_04d5fe2a-edf8-4179-aa69-7f3fc314b881" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_8f182daf-f4af-4175-9bd3-52ba320ed1f3" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_8f182daf-f4af-4175-9bd3-52ba320ed1f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_0403fa75-7cac-4ac9-9b84-10ce2ee4d6b1" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_0403fa75-7cac-4ac9-9b84-10ce2ee4d6b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87dcebf2-b798-4696-b457-a0535e36e294_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87dcebf2-b798-4696-b457-a0535e36e294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8af429b-27bc-4738-b20b-2172d351b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8af429b-27bc-4738-b20b-2172d351b9e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_64c61319-7ada-4c45-bda2-5aa12481db16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_64c61319-7ada-4c45-bda2-5aa12481db16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_46757f57-314d-4ae8-a5bf-30d5f91a865a" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:to="loc_mo_ABInBevMember_46757f57-314d-4ae8-a5bf-30d5f91a865a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" xlink:type="extended" id="id50570e2c92a4c6099b2933ba66e983e_InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_82578a85-33cb-4baa-a59e-48f2f8c158fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_82578a85-33cb-4baa-a59e-48f2f8c158fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a89c4a4d-2919-4068-8bfa-a2185615b652_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a89c4a4d-2919-4068-8bfa-a2185615b652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_c6f4ae59-ddd0-4dea-90b5-e3c930659e6a" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:to="loc_mo_JUULMember_c6f4ae59-ddd0-4dea-90b5-e3c930659e6a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" xlink:type="extended" id="i139efe4ef15546d1a46fe8ba94e376d8_InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_36ae9934-e814-4da2-acbc-e28c060bfc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_36ae9934-e814-4da2-acbc-e28c060bfc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d0005ae9-23d4-45de-9738-0f18c0713722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d0005ae9-23d4-45de-9738-0f18c0713722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2c47d240-b159-404c-94a8-f905bee51c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:to="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f8dfe000-37b5-4574-b9fe-c957f106b5ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f8dfe000-37b5-4574-b9fe-c957f106b5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cf8d4cf5-b537-4c98-a7f4-64d40fb0ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:to="loc_us-gaap_EquitySecuritiesMember_cf8d4cf5-b537-4c98-a7f4-64d40fb0ba46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_15f4f474-53d9-4a27-9a50-b394d245b4c6" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:to="loc_mo_JUULMember_15f4f474-53d9-4a27-9a50-b394d245b4c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" xlink:type="extended" id="i11781c2ec38f43f9833ae73302700ddb_InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5946e207-456b-41e1-bc57-d1686fc2a754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5946e207-456b-41e1-bc57-d1686fc2a754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_b32d82ed-83d4-4209-a219-5378a006bd63" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedCommon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_b32d82ed-83d4-4209-a219-5378a006bd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_6ad92b13-dd70-490e-bf13-15e766769ea6" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_6ad92b13-dd70-490e-bf13-15e766769ea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_23417d5f-dbcf-4ba1-b608-70c890006fa8" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_23417d5f-dbcf-4ba1-b608-70c890006fa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPricePerShareIfExercised_44219838-f5e2-4be2-b2d7-fd4d61865511" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPricePerShareIfExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentPricePerShareIfExercised_44219838-f5e2-4be2-b2d7-fd4d61865511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights_11bad089-11c4-44c7-a226-d34e4b52b43d" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsFixedPreemptiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights_11bad089-11c4-44c7-a226-d34e4b52b43d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_7dac6989-1b1c-41cc-b3a7-ca00f22875ba" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_7dac6989-1b1c-41cc-b3a7-ca00f22875ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentImpairment_48cd6981-d368-4bf4-930a-49052c55d2bc" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentImpairment_48cd6981-d368-4bf4-930a-49052c55d2bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cb870d48-00b4-4a0f-9596-4a68fd55aa5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cb870d48-00b4-4a0f-9596-4a68fd55aa5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractPreemptiveRIghtsMember_4866dd1c-2a53-45ff-99e1-2a8982c269f3" xlink:href="mo-20230331.xsd#mo_EquityContractPreemptiveRIghtsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:to="loc_mo_EquityContractPreemptiveRIghtsMember_4866dd1c-2a53-45ff-99e1-2a8982c269f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractWarrantMember_6b300870-67b0-4186-a398-1a0298204b5a" xlink:href="mo-20230331.xsd#mo_EquityContractWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:to="loc_mo_EquityContractWarrantMember_6b300870-67b0-4186-a398-1a0298204b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d81fe604-6c80-4446-acd5-97839b1d61dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d81fe604-6c80-4446-acd5-97839b1d61dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_8952cd7a-fefa-43ff-a634-dfb327191453" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:to="loc_mo_CronosGroupInc.Member_8952cd7a-fefa-43ff-a634-dfb327191453" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ibb409073cb3c4feabadf6b0ab7a546be_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld_d437eb1c-3e95-4f1a-8ee4-99a1059f74f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfForeignCurrencyDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:to="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld_d437eb1c-3e95-4f1a-8ee4-99a1059f74f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b7460ad6-54ee-4513-891e-18e88c79a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b7460ad6-54ee-4513-891e-18e88c79a3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_785f49c6-4726-41c2-a93d-d7521aae8daa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_785f49c6-4726-41c2-a93d-d7521aae8daa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtMember_d5d4e685-bbf7-46d4-a246-ad49064e3a17" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtMember_d5d4e685-bbf7-46d4-a246-ad49064e3a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_89622619-9622-41e4-95bf-94b44edb9072_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:to="loc_us-gaap_HedgingRelationshipDomain_89622619-9622-41e4-95bf-94b44edb9072_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_947f5619-48f3-4682-8dee-26f81123beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_947f5619-48f3-4682-8dee-26f81123beea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstrumentsAggregateFairValueandCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails" xlink:type="extended" id="i2558cfb80eaa4bf3834adac3da1806e8_FinancialInstrumentsAggregateFairValueandCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_78a52b37-a322-4fc9-a6e6-d93a4799a976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_us-gaap_LongTermDebt_78a52b37-a322-4fc9-a6e6-d93a4799a976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5e4cc9df-8515-4abf-9da4-6aa98cc320fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_us-gaap_LongTermDebtFairValue_5e4cc9df-8515-4abf-9da4-6aa98cc320fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b62b24c-62a1-4e0a-950e-5a99d177e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3f001646-c7b1-4c22-b7c9-a13705c548a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3f001646-c7b1-4c22-b7c9-a13705c548a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea35c3d6-fbba-4e5e-9307-7a879e936383_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea35c3d6-fbba-4e5e-9307-7a879e936383_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtMember_2be692ef-0fff-45ba-bf71-72606ed60809" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtMember_2be692ef-0fff-45ba-bf71-72606ed60809" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="extended" id="i5001feadcfa54105805134f4aadbda5a_BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_37cc8933-c664-4e21-a46c-437227839ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_37cc8933-c664-4e21-a46c-437227839ca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_7f0583c6-cae9-4766-bd17-cff2b976444b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_7f0583c6-cae9-4766-bd17-cff2b976444b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ddf6e51c-6bc5-428c-a94b-a12897184634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ddf6e51c-6bc5-428c-a94b-a12897184634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7d650664-d15d-481f-98fc-4e07f0b7ea3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7d650664-d15d-481f-98fc-4e07f0b7ea3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1c5e1567-36ee-4df6-b0f7-cd445c167039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1c5e1567-36ee-4df6-b0f7-cd445c167039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5f56a778-f4a6-4876-ab22-506e2688c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5f56a778-f4a6-4876-ab22-506e2688c2c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c12ce5e9-4098-408d-afda-df0adabb857b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c12ce5e9-4098-408d-afda-df0adabb857b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4ce983b7-1100-4154-8f2b-72b0ee95dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4ce983b7-1100-4154-8f2b-72b0ee95dbc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_782306b7-7b39-4d88-8d99-008ee93dd581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_782306b7-7b39-4d88-8d99-008ee93dd581" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/BenefitPlansNarrativeDetails" xlink:type="extended" id="if715a1f9aa5f4f63a26dc93175363304_BenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_facf35dd-d97f-4799-9c31-766b4319041d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_facf35dd-d97f-4799-9c31-766b4319041d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_1aff6d32-839d-400f-ae00-ff090f5eaeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_1aff6d32-839d-400f-ae00-ff090f5eaeea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_da768f4f-4be7-4dc4-8047-1c15a566e4d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_da768f4f-4be7-4dc4-8047-1c15a566e4d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2a8ae8d0-5e9f-4c7a-9d67-844628352730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2a8ae8d0-5e9f-4c7a-9d67-844628352730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c4a6c3e5-8471-4535-ae55-2dacc6b88d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c4a6c3e5-8471-4535-ae55-2dacc6b88d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:to="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1afe3418-2866-41e0-b2f4-a8c3c6549890_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:to="loc_srt_RangeMember_1afe3418-2866-41e0-b2f4-a8c3c6549890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:to="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e74a2290-7a63-4d84-b417-c2c326ce6467" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:to="loc_srt_MaximumMember_e74a2290-7a63-4d84-b417-c2c326ce6467" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="extended" id="i3ed0e7f1ae3c4ff781216c19fb99b3be_OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7a3e906-a681-410f-ae6d-97395a7438c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7a3e906-a681-410f-ae6d-97395a7438c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_d5444e9c-53ee-4f69-8c5b-f86fdd6ee611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_d5444e9c-53ee-4f69-8c5b-f86fdd6ee611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_324a86c8-bf39-410d-87a1-d64904bb84f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_324a86c8-bf39-410d-87a1-d64904bb84f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a9fc106b-9b0e-4352-923d-e99aef9b42d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a9fc106b-9b0e-4352-923d-e99aef9b42d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_06c02252-f2b3-4d31-872d-a87bb70e77eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_06c02252-f2b3-4d31-872d-a87bb70e77eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_6253fda4-2fb0-4341-af14-a726a3a7466a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_6253fda4-2fb0-4341-af14-a726a3a7466a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3ee101e0-239a-4df8-993b-262b19842b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3ee101e0-239a-4df8-993b-262b19842b89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_136375ff-0bbb-40b1-9369-5cc22884aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_136375ff-0bbb-40b1-9369-5cc22884aba8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5fa52b5-9e9c-46cc-95ce-9d505313d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:to="loc_us-gaap_EquityComponentDomain_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:to="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2aa6fd61-a9c7-430f-bc87-f3523f46e8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2aa6fd61-a9c7-430f-bc87-f3523f46e8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_b62e2b0b-4d22-43cb-813a-54319865ac1f" xlink:href="mo-20230331.xsd#mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_b62e2b0b-4d22-43cb-813a-54319865ac1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_85414a60-c02a-4686-9599-85999a457819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_85414a60-c02a-4686-9599-85999a457819" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesReclassificationsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" xlink:type="extended" id="if297e1559c104e619b2dd3bb70086ad8_OtherComprehensiveEarningsLossesReclassificationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_13da21eb-5587-46a9-9b91-7c904ff3be5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_13da21eb-5587-46a9-9b91-7c904ff3be5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e43172cb-52b2-46ab-aedb-a944b70e6785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e43172cb-52b2-46ab-aedb-a944b70e6785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4858a5ad-8efb-436b-b3a3-73ee0652e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_ProfitLoss_4858a5ad-8efb-436b-b3a3-73ee0652e89d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6082329-23a4-4602-ad75-ded6e03275e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:to="loc_us-gaap_EquityComponentDomain_f6082329-23a4-4602-ad75-ded6e03275e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:to="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_d7a4b4bc-8b6f-48f5-a25a-f4e61ff2b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_d7a4b4bc-8b6f-48f5-a25a-f4e61ff2b7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_fc4d954d-f163-45bb-a43f-838ead499d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_fc4d954d-f163-45bb-a43f-838ead499d8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_3de5f6be-6ecb-45b4-a097-7098ae560cdf" xlink:href="mo-20230331.xsd#mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_3de5f6be-6ecb-45b4-a097-7098ae560cdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eca63e25-b137-4e56-9cba-1001ca6113b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eca63e25-b137-4e56-9cba-1001ca6113b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d2ab9bcb-bd84-418e-9715-07186c33b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d2ab9bcb-bd84-418e-9715-07186c33b022" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingSegmentDataScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" xlink:type="extended" id="ia053b8f0eadd4d2bad5a4232f8ecc82f_SegmentReportingSegmentDataScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d4233d7-0493-468b-90a1-0195e0c72589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d4233d7-0493-468b-90a1-0195e0c72589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_5c16182c-4e0e-4ca8-a14f-2dad7df9b5f0" xlink:href="mo-20230331.xsd#mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_5c16182c-4e0e-4ca8-a14f-2dad7df9b5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3d217389-52ff-460b-b558-f20aab671fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3d217389-52ff-460b-b558-f20aab671fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ec98672c-495c-46ba-813b-810b17b1a657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ec98672c-495c-46ba-813b-810b17b1a657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eaf5e05c-f98b-428e-bf4e-f5948720bc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_OperatingIncomeLoss_eaf5e05c-f98b-428e-bf4e-f5948720bc8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_b120b599-4e64-4bb2-87e6-49fa7a53ba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_b120b599-4e64-4bb2-87e6-49fa7a53ba4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b09b201a-bf28-43c1-9d96-bc56a35f4ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b09b201a-bf28-43c1-9d96-bc56a35f4ef1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_3b5abd59-1460-4acc-bf0d-a526b1a76897" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_mo_IncomeLossFromEquitySecurities_3b5abd59-1460-4acc-bf0d-a526b1a76897" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e3eb9507-f43f-4853-8a8a-f112adefd23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e3eb9507-f43f-4853-8a8a-f112adefd23f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d69ee194-27f5-4162-8aa7-58e2b43aebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d69ee194-27f5-4162-8aa7-58e2b43aebb1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:to="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d151d62a-1c8d-457a-9e02-ecbbf8622923_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:to="loc_srt_ConsolidationItemsDomain_d151d62a-1c8d-457a-9e02-ecbbf8622923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:to="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_b5d970e6-d110-4f05-af61-033da519b662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_b5d970e6-d110-4f05-af61-033da519b662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_38c22aa1-41c5-455b-83ea-2387133582e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_38c22aa1-41c5-455b-83ea-2387133582e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d16efb4-7bcf-43a4-9742-a12858eeb490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:to="loc_us-gaap_SegmentDomain_7d16efb4-7bcf-43a4-9742-a12858eeb490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:to="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_285c8de5-5d13-4d69-845e-5d92d9a8417d" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_mo_SmokeableProductsSegmentMember_285c8de5-5d13-4d69-845e-5d92d9a8417d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OralTobaccoSegmentMember_b31edff2-bb4e-4e4c-99e6-4083fc96ffd1" xlink:href="mo-20230331.xsd#mo_OralTobaccoSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_mo_OralTobaccoSegmentMember_b31edff2-bb4e-4e4c-99e6-4083fc96ffd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_af243729-a6c4-4f5c-be6e-9a859f46d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_af243729-a6c4-4f5c-be6e-9a859f46d7a1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/SegmentReportingNarrativeDetails" xlink:type="extended" id="icb6edb45fdb94005bd2f1337520083da_SegmentReportingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_094667bd-9aba-4977-9a14-a8a214399cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_094667bd-9aba-4977-9a14-a8a214399cfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c249264-ddb8-4393-86f7-306c779b71a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:to="loc_us-gaap_SegmentDomain_4c249264-ddb8-4393-86f7-306c779b71a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:to="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_ce630f4d-c7c4-4e51-9b44-f457b219b376" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:to="loc_mo_SmokeableProductsSegmentMember_ce630f4d-c7c4-4e51-9b44-f457b219b376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a653a1d5-f7af-4d24-8f1a-475c78b82340_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:to="loc_srt_ConsolidationItemsDomain_a653a1d5-f7af-4d24-8f1a-475c78b82340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:to="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4b75b75b-28e4-4f57-bde5-ace4b33b01b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:to="loc_us-gaap_OperatingSegmentsMember_4b75b75b-28e4-4f57-bde5-ace4b33b01b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d13f10e-2e87-4e82-b36a-9374dfb1f352_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:to="loc_srt_LitigationCaseTypeDomain_2d13f10e-2e87-4e82-b36a-9374dfb1f352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:to="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_eb202426-ba3a-4ffd-8a85-0524d73cbbf1" xlink:href="mo-20230331.xsd#mo_NonParticipatingManufacturerArbitrationPanelDecisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:to="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_eb202426-ba3a-4ffd-8a85-0524d73cbbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ad37d32-5370-4923-b444-38ca3ff82a1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ad37d32-5370-4923-b444-38ca3ff82a1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossMember_e1fdda88-d0b1-4965-8f96-bc881097cade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:to="loc_us-gaap_OperatingIncomeLossMember_e1fdda88-d0b1-4965-8f96-bc881097cade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8c0f7515-50f5-4814-9ac2-e29627ea8548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8c0f7515-50f5-4814-9ac2-e29627ea8548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NpmAdjustmentToCostOfSalesMember_7c9c170b-7636-4283-982e-40fba3cd1fb5" xlink:href="mo-20230331.xsd#mo_NpmAdjustmentToCostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:to="loc_mo_NpmAdjustmentToCostOfSalesMember_7c9c170b-7636-4283-982e-40fba3cd1fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5dd78b92-058c-4dbc-a1b0-108e0610b5c0_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:to="loc_dei_EntityDomain_5dd78b92-058c-4dbc-a1b0-108e0610b5c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:to="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c6701d05-f8bc-4a58-bfa6-935cf8d094b0" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:to="loc_mo_PhilipMorrisUSAMember_c6701d05-f8bc-4a58-bfa6-935cf8d094b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" xlink:type="extended" id="i9fa439f2dcb0439c840bbeef0d168dea_SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_f25fec10-995d-4aca-8250-eb605890ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_f25fec10-995d-4aca-8250-eb605890ed86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:to="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7968aa99-98ba-448d-a05a-1af03b943674_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:to="loc_dei_EntityDomain_7968aa99-98ba-448d-a05a-1af03b943674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:to="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c042ea7d-0f48-41b2-85c9-3854094831f5" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:to="loc_mo_PhilipMorrisUSAMember_c042ea7d-0f48-41b2-85c9-3854094831f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:to="loc_srt_LitigationCaseTypeDomain_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:to="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthLitigationCasesMember_3ac5c890-c34b-4e94-b133-28c1635edeb0" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthLitigationCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:to="loc_mo_TobaccoandHealthLitigationCasesMember_3ac5c890-c34b-4e94-b133-28c1635edeb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c91121ed-0655-4c7e-976c-1835f0ea625e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:to="loc_srt_ConsolidationItemsDomain_c91121ed-0655-4c7e-976c-1835f0ea625e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:to="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_be39db21-0df4-4ad5-bd5a-4f4f5c9a8b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_OperatingSegmentsMember_be39db21-0df4-4ad5-bd5a-4f4f5c9a8b54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_636c5c48-19fd-4437-a4a8-36d5b6e8c472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_636c5c48-19fd-4437-a4a8-36d5b6e8c472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5adb72aa-2437-4428-86d1-685e425e6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5adb72aa-2437-4428-86d1-685e425e6ae9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:to="loc_us-gaap_SegmentDomain_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:to="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_b5df34dc-7cf4-4b18-81ee-f6f41605ea59" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:to="loc_mo_SmokeableProductsSegmentMember_b5df34dc-7cf4-4b18-81ee-f6f41605ea59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aab19ea0-7dfb-4076-924c-d514c32b2b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aab19ea0-7dfb-4076-924c-d514c32b2b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossMember_588fde62-4cc2-4b8e-b11e-36f5ce97feaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:to="loc_us-gaap_OperatingIncomeLossMember_588fde62-4cc2-4b8e-b11e-36f5ce97feaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestAndOtherDebtExpenseNetMember_f25ca041-d4ab-4e55-8a00-9927c0bd29a2" xlink:href="mo-20230331.xsd#mo_InterestAndOtherDebtExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:to="loc_mo_InterestAndOtherDebtExpenseNetMember_f25ca041-d4ab-4e55-8a00-9927c0bd29a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/DebtNarrativeDetails" xlink:type="extended" id="iee831e96f96d414aabe4602c9ee2d95b_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4ee848a4-e218-47b3-baf2-c46b19176c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_ShortTermBorrowings_4ee848a4-e218-47b3-baf2-c46b19176c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7da9085d-5a7a-42dc-bce6-001aa0780f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7da9085d-5a7a-42dc-bce6-001aa0780f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_0a1100f3-82b3-47f2-b5a4-b841c60d58ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_LongTermDebtTerm_0a1100f3-82b3-47f2-b5a4-b841c60d58ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_d1941aa6-c0da-42bb-ae5c-fb8a1e791d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_d1941aa6-c0da-42bb-ae5c-fb8a1e791d96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_672dceba-ef4f-4b41-b537-a9e82bce7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_672dceba-ef4f-4b41-b537-a9e82bce7a3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_23bb5c7e-b6d2-401f-b658-7454e63a4593" xlink:href="mo-20230331.xsd#mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_23bb5c7e-b6d2-401f-b658-7454e63a4593" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_ec54bae3-477b-447b-be97-056d07955538" xlink:href="mo-20230331.xsd#mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_ec54bae3-477b-447b-be97-056d07955538" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_54482cb1-15f1-4ff6-961a-15fc20971b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_LongTermDebt_54482cb1-15f1-4ff6-961a-15fc20971b5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1d222508-bb0d-4d40-8329-46bcb1166e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1d222508-bb0d-4d40-8329-46bcb1166e47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_53364e30-7f1f-43bb-b92e-fddf401ebfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_53364e30-7f1f-43bb-b92e-fddf401ebfa2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b5f532a6-3699-4b40-8b37-c334b95c94d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b5f532a6-3699-4b40-8b37-c334b95c94d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_de261313-f0e1-40fc-99b2-9a16df388b99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:to="loc_us-gaap_VariableRateDomain_de261313-f0e1-40fc-99b2-9a16df388b99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:to="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember_c3c8bd37-1cee-4cdd-8523-d8daed46ac42" xlink:href="mo-20230331.xsd#mo_TermSecuredOvernightFinancingRateTermSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:to="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember_c3c8bd37-1cee-4cdd-8523-d8daed46ac42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c23a1d42-7c71-45a4-8588-d14649a7058f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:to="loc_us-gaap_CreditFacilityDomain_c23a1d42-7c71-45a4-8588-d14649a7058f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:to="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f3cf371-4991-4f1e-af6b-d6cbc0ca686b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f3cf371-4991-4f1e-af6b-d6cbc0ca686b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96282bb1-e133-4c09-9637-43f2eb2f4bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96282bb1-e133-4c09-9637-43f2eb2f4bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1580d4d1-0bfc-4143-aca4-32784e276e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:to="loc_us-gaap_LineOfCreditMember_1580d4d1-0bfc-4143-aca4-32784e276e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_dc61f04a-7860-4e59-97ed-5ef737514a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_dc61f04a-7860-4e59-97ed-5ef737514a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_RevolvingCreditFacilityDueAugust2025Member_a2964d47-befc-4788-8fdc-bcad0deab145" xlink:href="mo-20230331.xsd#mo_RevolvingCreditFacilityDueAugust2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:to="loc_mo_RevolvingCreditFacilityDueAugust2025Member_a2964d47-befc-4788-8fdc-bcad0deab145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EuroNotes1000MaturingFebruary2023Member_d4b331df-2c9c-43c3-9a20-4258d18d9677" xlink:href="mo-20230331.xsd#mo_EuroNotes1000MaturingFebruary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:to="loc_mo_EuroNotes1000MaturingFebruary2023Member_d4b331df-2c9c-43c3-9a20-4258d18d9677" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i475cfb5b79af410ebc5a445a9b89bb98_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_fe4a2029-4b52-4569-893b-4eed4a3326c2" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_fe4a2029-4b52-4569-893b-4eed4a3326c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c853667a-5614-4c2d-b2c3-b155ae2f286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c853667a-5614-4c2d-b2c3-b155ae2f286b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_251d2e42-544e-4e1b-bd4b-132e4b47907c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_251d2e42-544e-4e1b-bd4b-132e4b47907c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_0450f3df-cbff-48db-8feb-6c0c42005379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_0450f3df-cbff-48db-8feb-6c0c42005379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d1dfeb37-7236-4c36-a085-0c865f1c22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d1dfeb37-7236-4c36-a085-0c865f1c22c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83d8f3f0-1d68-47ab-a2b6-7a83a51868f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83d8f3f0-1d68-47ab-a2b6-7a83a51868f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_4aee6e59-963c-4558-baed-9f7fde9ab66e" xlink:href="mo-20230331.xsd#mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_4aee6e59-963c-4558-baed-9f7fde9ab66e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:to="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b2bde9c6-0a57-4fce-b608-ae92f4ac225b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b2bde9c6-0a57-4fce-b608-ae92f4ac225b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6c921c1d-90c0-438e-ab6b-79daaeef6fbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:to="loc_srt_ScenarioForecastMember_6c921c1d-90c0-438e-ab6b-79daaeef6fbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_611b71ca-3bff-4a75-938a-547b20f030ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_611b71ca-3bff-4a75-938a-547b20f030ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_03022fb5-37c2-48a2-89a1-7031c065f9e6" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:to="loc_mo_JUULMember_03022fb5-37c2-48a2-89a1-7031c065f9e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" xlink:type="extended" id="ief27e15bd6c74510ac8e181dbea2cce7_ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_7ac6319d-349e-4d9e-bf91-bf00a7233a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_7ac6319d-349e-4d9e-bf91-bf00a7233a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_8b00ee36-510d-4179-8fbd-a1fd53d0d423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LitigationSettlementInterest_8b00ee36-510d-4179-8fbd-a1fd53d0d423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationEscrowDeposit_162d8856-730f-4c6d-ba04-db384c29e1e0" xlink:href="mo-20230331.xsd#mo_LitigationEscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_mo_LitigationEscrowDeposit_162d8856-730f-4c6d-ba04-db384c29e1e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_48879585-9ae8-4854-b703-cf918ff63366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_48879585-9ae8-4854-b703-cf918ff63366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_5d3d26b2-9686-46cf-a5f2-7fe4b2277971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_5d3d26b2-9686-46cf-a5f2-7fe4b2277971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_9bb9d4e0-cf10-4a13-9202-ff8127d93090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_9bb9d4e0-cf10-4a13-9202-ff8127d93090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_9e907722-29a1-4f55-ac8f-fb0c1a0c3698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:to="loc_srt_LitigationCaseTypeDomain_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:to="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthJudgmentMember_8de25d43-9944-4ac3-8274-9d29966036b4" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthJudgmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_TobaccoandHealthJudgmentMember_8de25d43-9944-4ac3-8274-9d29966036b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_dc2b907b-6ee4-4034-9cc9-19d666d835fa" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_EngleProgenyCasesMember_dc2b907b-6ee4-4034-9cc9-19d666d835fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AgreementToResolveShareholderClassActionMember_0ce4194b-7c99-47f8-9ff2-a69234463a32" xlink:href="mo-20230331.xsd#mo_AgreementToResolveShareholderClassActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_AgreementToResolveShareholderClassActionMember_0ce4194b-7c99-47f8-9ff2-a69234463a32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_60159922-4c0f-4eab-84fe-abcb3b70a09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_60159922-4c0f-4eab-84fe-abcb3b70a09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_bfc3efc2-6c89-40af-bdc8-6613f89f2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:to="loc_us-gaap_AssetsMember_bfc3efc2-6c89-40af-bdc8-6613f89f2e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9c549982-1eb9-4247-b5f8-948a5d4ce892_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:to="loc_us-gaap_LitigationStatusDomain_9c549982-1eb9-4247-b5f8-948a5d4ce892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:to="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4beea546-3dbd-43c9-b675-e9794f249588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:to="loc_us-gaap_PendingLitigationMember_4beea546-3dbd-43c9-b675-e9794f249588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0f87669b-1860-4490-9be8-68d20c73a448_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:to="loc_dei_EntityDomain_0f87669b-1860-4490-9be8-68d20c73a448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:to="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_8e278cdf-33f5-4080-a0d9-84c19359f3b4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:to="loc_mo_PhilipMorrisUSAMember_8e278cdf-33f5-4080-a0d9-84c19359f3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d4ca5898-2fb6-4afc-a197-54e75105072f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d4ca5898-2fb6-4afc-a197-54e75105072f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationCasesResultsMember_734c859a-6ef4-49ec-b252-cb7796c68ecd" xlink:href="mo-20230331.xsd#mo_LitigationCasesResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:to="loc_mo_LitigationCasesResultsMember_734c859a-6ef4-49ec-b252-cb7796c68ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestExpenseRelatedToLitigationMember_12787805-bea3-4b8f-a99a-1108a31a081d" xlink:href="mo-20230331.xsd#mo_InterestExpenseRelatedToLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:to="loc_mo_InterestExpenseRelatedToLitigationMember_12787805-bea3-4b8f-a99a-1108a31a081d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00e9a778-6422-4569-bbbd-403022b8b043_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00e9a778-6422-4569-bbbd-403022b8b043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_abc2db2d-525e-4083-aca3-4bdd92064e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:to="loc_us-gaap_SubsequentEventMember_abc2db2d-525e-4083-aca3-4bdd92064e46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesScheduleofPendingCasesDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" xlink:type="extended" id="i738e73a88741401e98549ad19ddafd25_ContingenciesScheduleofPendingCasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_74d42136-5858-404f-848e-59d6265f86d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_74d42136-5858-404f-848e-59d6265f86d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCases_d1a4521a-895b-4195-829c-ebff2aae091c" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfCases_d1a4521a-895b-4195-829c-ebff2aae091c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassActionLawsuit_54e8a076-a881-4f61-9ae6-bd306e764da5" xlink:href="mo-20230331.xsd#mo_LossContingencyClassActionLawsuit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyClassActionLawsuit_54e8a076-a881-4f61-9ae6-bd306e764da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveCases_075dc84b-5d03-4d28-8c33-e33eee563dce" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfInactiveCases_075dc84b-5d03-4d28-8c33-e33eee563dce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits_96baf5c4-842a-4cfe-873a-f1368d20ab80" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits_96baf5c4-842a-4cfe-873a-f1368d20ab80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_73240a3d-bf7c-45fe-b0f7-cee51671cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_73240a3d-bf7c-45fe-b0f7-cee51671cdcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_de58ea44-8ec9-417f-bd38-474a6f1560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_de58ea44-8ec9-417f-bd38-474a6f1560e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_2056cb68-30ca-41b3-ab6b-f0c8529da7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_2056cb68-30ca-41b3-ab6b-f0c8529da7fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_b391f128-23c7-4cce-9c7a-9d7c2c3a5e96" xlink:href="mo-20230331.xsd#mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_b391f128-23c7-4cce-9c7a-9d7c2c3a5e96" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_84f6dd1c-8180-44a4-82ad-720a7ca705d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_84f6dd1c-8180-44a4-82ad-720a7ca705d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ec402fcc-88e0-4a10-8213-43ed780a5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:to="loc_us-gaap_SubsequentEventMember_ec402fcc-88e0-4a10-8213-43ed780a5549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:to="loc_srt_LitigationCaseTypeDomain_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:to="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:href="mo-20230331.xsd#mo_IndividualSmokingAndHealthCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember_9b02733b-447a-4d14-9ec6-fb8c26e87b7a" xlink:href="mo-20230331.xsd#mo_ETSSmokingandHealthCaseFlightAttendantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:to="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember_9b02733b-447a-4d14-9ec6-fb8c26e87b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_7bf32d0a-724e-44d7-bdda-55845037c461" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_7bf32d0a-724e-44d7-bdda-55845037c461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_e60b82b5-a185-47bf-bbe8-bc9a4eb22efd" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_EvaporLitigationMember_e60b82b5-a185-47bf-bbe8-bc9a4eb22efd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherTabaccoRelatedCasesMember_9197fc5e-8239-4329-89ca-ab8283316f1d" xlink:href="mo-20230331.xsd#mo_OtherTabaccoRelatedCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_OtherTabaccoRelatedCasesMember_9197fc5e-8239-4329-89ca-ab8283316f1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthJudgmentMember_55775b66-c318-4e55-b8e1-62b47f78f662" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthJudgmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_TobaccoandHealthJudgmentMember_55775b66-c318-4e55-b8e1-62b47f78f662" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AgreementToResolveShareholderClassActionMember_a229b7ab-0dbb-4732-b608-e8f452150750" xlink:href="mo-20230331.xsd#mo_AgreementToResolveShareholderClassActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_AgreementToResolveShareholderClassActionMember_a229b7ab-0dbb-4732-b608-e8f452150750" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:to="loc_us-gaap_LitigationStatusDomain_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:to="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1b2c922b-2f27-421b-bec4-9b604ec2bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_us-gaap_PendingLitigationMember_1b2c922b-2f27-421b-bec4-9b604ec2bbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_5e4c15b2-0dac-48c8-8457-c8e4d85999b9" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_PendingIndividualLawsuitsMember_5e4c15b2-0dac-48c8-8457-c8e4d85999b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_78ba41f1-06e4-4b7d-98e2-b6af041069b2" xlink:href="mo-20230331.xsd#mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_78ba41f1-06e4-4b7d-98e2-b6af041069b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ClassActionLawsuitMember_faadcac2-5d67-445e-a333-787226a2fc09" xlink:href="mo-20230331.xsd#mo_ClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_ClassActionLawsuitMember_faadcac2-5d67-445e-a333-787226a2fc09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d7f985d-d69c-49df-bb6b-0f21f6f18bec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:to="loc_srt_SegmentGeographicalDomain_4d7f985d-d69c-49df-bb6b-0f21f6f18bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:to="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_75b4d831-1ca0-4fd4-971d-3644f88dcbed" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_IL_75b4d831-1ca0-4fd4-971d-3644f88dcbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_352257ad-180e-4081-ac46-9a9c2a5ecd50" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_NM_352257ad-180e-4081-ac46-9a9c2a5ecd50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4de8cf18-658f-405d-bbaa-6868bbb8dc49" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_MA_4de8cf18-658f-405d-bbaa-6868bbb8dc49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_084d06d7-6c50-4fc4-955e-87ec9c1d18a6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_FL_084d06d7-6c50-4fc4-955e-87ec9c1d18a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_56323e2b-5588-47fc-b666-6e23e696c8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_56323e2b-5588-47fc-b666-6e23e696c8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationCasesResultsMember_eb974a6b-f830-4ae2-bb88-23ae2299412c" xlink:href="mo-20230331.xsd#mo_LitigationCasesResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:to="loc_mo_LitigationCasesResultsMember_eb974a6b-f830-4ae2-bb88-23ae2299412c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" xlink:type="extended" id="i3187d8f99bb04134bccf0d6a17649b9b_ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_f3e7e2db-6545-452f-9b3b-eb22d9b61f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_f3e7e2db-6545-452f-9b3b-eb22d9b61f3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofCasesSetforTrial_9dbb7e8f-009c-44fe-b644-b8ba0477b460" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofCasesSetforTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyNumberofCasesSetforTrial_9dbb7e8f-009c-44fe-b644-b8ba0477b460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecided_72720d04-7f6d-4b8d-adee-f1abdbae2ba4" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecided"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecided_72720d04-7f6d-4b8d-adee-f1abdbae2ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedFavorableNumber_f3fe339e-daf3-44d5-baff-1e84c767cccc" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedFavorableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecidedFavorableNumber_f3fe339e-daf3-44d5-baff-1e84c767cccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_da173e8d-34ad-4dcc-b0dd-6a2ea6c6ec6b" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedUnfavorableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_da173e8d-34ad-4dcc-b0dd-6a2ea6c6ec6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsResolvedNumber_14bace35-673a-4a90-8cc1-a0961085d95a" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsResolvedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsResolvedNumber_14bace35-673a-4a90-8cc1-a0961085d95a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictReversedNumber_bf954072-cd7f-414d-88a9-2f0afbf3594e" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictReversedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyVerdictReversedNumber_bf954072-cd7f-414d-88a9-2f0afbf3594e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f0ef807c-30da-4276-9fd8-5c877fa189b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f0ef807c-30da-4276-9fd8-5c877fa189b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e4b3b8a1-2295-4a9c-9afa-96e3673a0c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:to="loc_us-gaap_SubsequentEventMember_e4b3b8a1-2295-4a9c-9afa-96e3673a0c21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cef04b88-c87e-4ed8-8b84-8efd263de8d4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:to="loc_dei_EntityDomain_cef04b88-c87e-4ed8-8b84-8efd263de8d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:to="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_501fc530-d1ac-4f00-b155-46a85ecd71e4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:to="loc_mo_PhilipMorrisUSAMember_501fc530-d1ac-4f00-b155-46a85ecd71e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAandAltriaGroupMember_8c58782e-1a85-41ee-b275-211182a57730" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAandAltriaGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:to="loc_mo_PhilipMorrisUSAandAltriaGroupMember_8c58782e-1a85-41ee-b275-211182a57730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1bd8ec86-f8dd-44ab-a306-61b9854a002a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:to="loc_srt_LitigationCaseTypeDomain_1bd8ec86-f8dd-44ab-a306-61b9854a002a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:to="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_7d447f4b-e274-4b94-bc92-1917688176fc" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_7d447f4b-e274-4b94-bc92-1917688176fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_6d6c0858-2b3b-4c9c-bd2c-0b3a14442bae" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_6d6c0858-2b3b-4c9c-bd2c-0b3a14442bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_1412e18d-3376-4d21-bd93-8ff61223dd3d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_EngleProgenyCasesMember_1412e18d-3376-4d21-bd93-8ff61223dd3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenyCasesMember_a3d35b55-23a6-4dfe-aca3-4585a41d812a" xlink:href="mo-20230331.xsd#mo_NonEngleProgenyCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_NonEngleProgenyCasesMember_a3d35b55-23a6-4dfe-aca3-4585a41d812a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IndividualSmokingAndHealthCasesMember_d133544a-1107-4bdd-ac28-813943c24d08" xlink:href="mo-20230331.xsd#mo_IndividualSmokingAndHealthCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_IndividualSmokingAndHealthCasesMember_d133544a-1107-4bdd-ac28-813943c24d08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_fa52e772-6fab-4df8-b433-6ff1981f3ea0" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_EvaporLitigationMember_fa52e772-6fab-4df8-b433-6ff1981f3ea0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:to="loc_srt_SegmentGeographicalDomain_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:to="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6f3972bd-c1e8-4b93-afd3-dc9d0ed19aa4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_country_CA_6f3972bd-c1e8-4b93-afd3-dc9d0ed19aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AK_237ddcb5-906d-44ce-9a50-5af7ea2487c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_AK_237ddcb5-906d-44ce-9a50-5af7ea2487c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_37d7b7c4-849e-455c-9171-3e7cdf5b206b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_CA_37d7b7c4-849e-455c-9171-3e7cdf5b206b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_52c94b06-17f9-4fb8-9024-314dd17031bb" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_CT_52c94b06-17f9-4fb8-9024-314dd17031bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_bfbac1d7-0aa2-47ef-8a11-5636bb124fae" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_FL_bfbac1d7-0aa2-47ef-8a11-5636bb124fae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_LA_6d095b8e-c499-47f4-ac4d-2fec439efff7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_LA_6d095b8e-c499-47f4-ac4d-2fec439efff7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_ab33de05-04ed-41c8-a5be-3148dd9d53c0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MA_ab33de05-04ed-41c8-a5be-3148dd9d53c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_5991e928-172d-476f-883e-5b6c713de860" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MS_5991e928-172d-476f-883e-5b6c713de860" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MO_8771697d-efb9-4ce9-af25-9d574c5b3caf" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MO_8771697d-efb9-4ce9-af25-9d574c5b3caf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NH_3b1ea1bc-e84f-420b-977d-a1c77cf31b62" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NH_3b1ea1bc-e84f-420b-977d-a1c77cf31b62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_777fd8b7-9a90-45b1-9453-bf1a84bcf8be" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NM_777fd8b7-9a90-45b1-9453-bf1a84bcf8be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_70e34274-ba92-42c7-ab29-70fa5e10b26e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NJ_70e34274-ba92-42c7-ab29-70fa5e10b26e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_8bb1e094-120e-414b-9c74-66d94af7d42f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NY_8bb1e094-120e-414b-9c74-66d94af7d42f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OH_8da5532c-5e95-4af6-a4a1-c861306b97a7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_OH_8da5532c-5e95-4af6-a4a1-c861306b97a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_da006613-bb0d-4d0a-bca9-67d5ae3b223d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_PA_da006613-bb0d-4d0a-bca9-67d5ae3b223d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_RI_f5039a2e-34e6-4771-b1cf-e2ba23905d7f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_RI_f5039a2e-34e6-4771-b1cf-e2ba23905d7f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_20d12045-2d91-4f7c-ae96-ffd26602f8c8" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_TN_20d12045-2d91-4f7c-ae96-ffd26602f8c8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_772d0dda-5398-4c34-9067-fe564db2073a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_WV_772d0dda-5398-4c34-9067-fe564db2073a" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesNonEngleProgenyLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" xlink:type="extended" id="i5f9cd93dccc24049a7f89abb5438f2f7_ContingenciesNonEngleProgenyLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_b47ce26e-12f9-40b6-83f0-6e7e4ffb5cd6" xlink:href="mo-20230331.xsd#mo_LossContingencyCompensatoryDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_b47ce26e-12f9-40b6-83f0-6e7e4ffb5cd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyFaultAllocationPercentage_70536ba7-9666-424c-b9e7-0f78a92e2bad" xlink:href="mo-20230331.xsd#mo_LossContingencyFaultAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyFaultAllocationPercentage_70536ba7-9666-424c-b9e7-0f78a92e2bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_5ad14fc9-e04e-4c22-8f45-ab2f2981a02c" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_5ad14fc9-e04e-4c22-8f45-ab2f2981a02c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_01095110-3910-4478-8d0a-0e23bdedf78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_01095110-3910-4478-8d0a-0e23bdedf78d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_aebf0e9c-3332-41d5-af3c-678eb6d7c1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_aebf0e9c-3332-41d5-af3c-678eb6d7c1ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:to="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ddd7f0b9-9368-424e-b6f8-21e381e137e4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:to="loc_srt_LitigationCaseTypeDomain_ddd7f0b9-9368-424e-b6f8-21e381e137e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:to="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_a84e8f60-886b-4c32-9ff7-4a431c2a5b44" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_a84e8f60-886b-4c32-9ff7-4a431c2a5b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_4f4caa60-0794-4cc9-908d-f23ba88ce049" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseMendezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_4f4caa60-0794-4cc9-908d-f23ba88ce049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_5277e686-b16c-4efe-a626-de0a6e41b79c" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseFontaineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_5277e686-b16c-4efe-a626-de0a6e41b79c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_01e645d2-3048-410e-b4b9-f41a55439694" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingandHealthCaseGreeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_01e645d2-3048-410e-b4b9-f41a55439694" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:to="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6825ae53-91cf-4e06-9b94-4eea1ec3ab06_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:to="loc_dei_EntityDomain_6825ae53-91cf-4e06-9b94-4eea1ec3ab06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:to="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_3eb49cbd-03e2-4166-bfb7-07483936fbb4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:to="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_3eb49cbd-03e2-4166-bfb7-07483936fbb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_7df7fc90-70f5-45d1-98db-1448b975d840" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:to="loc_mo_PhilipMorrisUSAMember_7df7fc90-70f5-45d1-98db-1448b975d840" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" xlink:type="extended" id="i21002ae3062c4e6698a6a31bf0508962_ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_7235fb10-38a6-44b5-8f4c-1f88173fd355" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_7235fb10-38a6-44b5-8f4c-1f88173fd355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_262cd2f7-0fbc-4a33-8e9c-16493d76517c" xlink:href="mo-20230331.xsd#mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_262cd2f7-0fbc-4a33-8e9c-16493d76517c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ad093b66-5e5f-4ada-99a7-fde1b2685571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ad093b66-5e5f-4ada-99a7-fde1b2685571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_98a1844d-a09a-4dc1-94ae-09389d5e60ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_98a1844d-a09a-4dc1-94ae-09389d5e60ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecided_58723a67-3fc0-41c5-81a0-5e5aee096125" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecided"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecided_58723a67-3fc0-41c5-81a0-5e5aee096125" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_51ff83fb-7f99-4d41-9375-031695ac64f5" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedUnfavorableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_51ff83fb-7f99-4d41-9375-031695ac64f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed_6ce18462-accf-42f6-90ef-eb70af94218b" xlink:href="mo-20230331.xsd#mo_LossContingencyUnfavorableVerdictsPendingReversed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed_6ce18462-accf-42f6-90ef-eb70af94218b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedFavorableNumber_3b6b267d-1083-4ea3-9098-c956288005e8" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedFavorableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecidedFavorableNumber_3b6b267d-1083-4ea3-9098-c956288005e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictReversedNumber_cf94453f-966b-49c2-836b-64e70b90c654" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictReversedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyVerdictReversedNumber_cf94453f-966b-49c2-836b-64e70b90c654" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdicts_1693b9d3-3aa2-402e-b241-fa7a95835401" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdicts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyZeroDamagesVerdicts_1693b9d3-3aa2-402e-b241-fa7a95835401" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1eabe809-0c66-4554-ad44-e0748286dea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1eabe809-0c66-4554-ad44-e0748286dea3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdictModified_0eee826e-fc18-4348-842a-b8a1e1e6065c" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdictModified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyZeroDamagesVerdictModified_0eee826e-fc18-4348-842a-b8a1e1e6065c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_3003bd37-73a5-412e-a511-cde8c765b41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_3003bd37-73a5-412e-a511-cde8c765b41c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e017837e-35d1-4cbc-9c22-e3776d72fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:to="loc_us-gaap_SubsequentEventMember_e017837e-35d1-4cbc-9c22-e3776d72fd83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_935529d2-a25c-406b-af0a-909dd91eaf2b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:to="loc_srt_LitigationCaseTypeDomain_935529d2-a25c-406b-af0a-909dd91eaf2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:to="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:to="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesStateMember_2ddd5494-4c03-4a91-84ab-9a41e0a578b1" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesStateMember_2ddd5494-4c03-4a91-84ab-9a41e0a578b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGarciaMember_18bd68e9-cd84-4f62-811f-8e0e4d8e3a50" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGarciaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesGarciaMember_18bd68e9-cd84-4f62-811f-8e0e4d8e3a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_5247d64a-589e-4132-8d4b-83c60080f179" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPearsonDCohenCollarChaconMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_5247d64a-589e-4132-8d4b-83c60080f179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesReiderandBanksMember_53a512ad-6d2e-4562-bd6f-c3f74525e8d2" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesReiderandBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesReiderandBanksMember_53a512ad-6d2e-4562-bd6f-c3f74525e8d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesWeingartandHancockMember_71bdc033-7f62-4cf1-8f7c-0d8dda5210c9" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesWeingartandHancockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesWeingartandHancockMember_71bdc033-7f62-4cf1-8f7c-0d8dda5210c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPollariMember_004e5836-761c-4bc2-a89f-fc528bccf84d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPollariMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesPollariMember_004e5836-761c-4bc2-a89f-fc528bccf84d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_f1dce8d3-0b61-4ced-86bb-2c382de7b2f5" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGlogerRintoulandDuignamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_f1dce8d3-0b61-4ced-86bb-2c382de7b2f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesFreemanAndHarrisMember_bbd09a71-c853-426d-9783-9d70b3cc3f11" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesFreemanAndHarrisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesFreemanAndHarrisMember_bbd09a71-c853-426d-9783-9d70b3cc3f11" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesR.DouglasMember_7e999aff-a948-403f-b7ed-a5577f70bf2d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesR.DouglasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesR.DouglasMember_7e999aff-a948-403f-b7ed-a5577f70bf2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_84cba66c-1c11-47e1-9453-6efde2f98d97_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:to="loc_dei_EntityDomain_84cba66c-1c11-47e1-9453-6efde2f98d97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:to="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_f6339c12-1e0a-47bd-bc4e-d59b5cb5ceb8" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:to="loc_mo_PhilipMorrisUSAMember_f6339c12-1e0a-47bd-bc4e-d59b5cb5ceb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" xlink:type="extended" id="ibd51935298e24096adf55cd0e9d67f6b_ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_238e3d1f-5949-449e-a13c-995fb4117aac" xlink:href="mo-20230331.xsd#mo_LossContingencyCompensatoryDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_238e3d1f-5949-449e-a13c-995fb4117aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_afd27a1d-90a6-4ac5-b9bb-b627aab57b20" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_afd27a1d-90a6-4ac5-b9bb-b627aab57b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a48d806c-36b3-489a-8369-cfa7ccb4de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a48d806c-36b3-489a-8369-cfa7ccb4de13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f8b45af6-c36c-4d54-9bb1-ae27407d0153_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:to="loc_srt_LitigationCaseTypeDomain_f8b45af6-c36c-4d54-9bb1-ae27407d0153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:to="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHoffmanMember_8ef59445-c91d-4e5a-ba13-4695a7de9b6a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHoffmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesHoffmanMember_8ef59445-c91d-4e5a-ba13-4695a7de9b6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLevineMember_4053dd79-4cad-4c53-b966-72be684cef8a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLevineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesLevineMember_4053dd79-4cad-4c53-b966-72be684cef8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesSchertzerMember_6456803c-99e2-4501-8c7a-4d27a445a1d3" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesSchertzerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesSchertzerMember_6456803c-99e2-4501-8c7a-4d27a445a1d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLippMember_ec88fcd0-7325-4a3a-bc00-902667c9831a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLippMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesLippMember_ec88fcd0-7325-4a3a-bc00-902667c9831a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGarciaMember_d7665fce-bbb7-4f82-9c31-1a8d19655d5f" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGarciaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesGarciaMember_d7665fce-bbb7-4f82-9c31-1a8d19655d5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesDuignanMember_0c0f9ba8-60a4-420b-8079-0a2afff3bc4b" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesDuignanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesDuignanMember_0c0f9ba8-60a4-420b-8079-0a2afff3bc4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMcCallMember_d730f981-ba8a-4d3a-a32b-7e897d12d426" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMcCallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesMcCallMember_d730f981-ba8a-4d3a-a32b-7e897d12d426" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesChadwellMember_4a0f8ab7-f227-473c-8f91-7fdd1d8a7a72" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesChadwellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesChadwellMember_4a0f8ab7-f227-473c-8f91-7fdd1d8a7a72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember_9a36940f-320d-46e7-89a4-e88c5b5e300a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesKaplanMcLauighlinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember_9a36940f-320d-46e7-89a4-e88c5b5e300a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCooperMember_3659d34a-a5df-42f5-bd63-38458078918d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCooperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesCooperMember_3659d34a-a5df-42f5-bd63-38458078918d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMillerMember_18193dc1-3106-48d5-8bf2-7becd70280b1" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMillerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesMillerMember_18193dc1-3106-48d5-8bf2-7becd70280b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesTuttleMember_05724458-8bf9-4c11-8543-37c5c64b032d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesTuttleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesTuttleMember_05724458-8bf9-4c11-8543-37c5c64b032d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCuddiheeMember_78665a43-7344-49ab-8d63-fda4e9842999" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCuddiheeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesCuddiheeMember_78665a43-7344-49ab-8d63-fda4e9842999" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHollimanMember_85261c1c-61f7-4218-aaa7-4ce0264718b6" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHollimanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesHollimanMember_85261c1c-61f7-4218-aaa7-4ce0264718b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesD.BrownMember_874974d9-d2fe-4813-bff7-015865779280" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesD.BrownMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesD.BrownMember_874974d9-d2fe-4813-bff7-015865779280" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4896209d-e995-4f82-af9e-cc46640c9c62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:to="loc_us-gaap_LitigationStatusDomain_4896209d-e995-4f82-af9e-cc46640c9c62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:to="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_0ccdaf92-c6c9-40c3-8631-b641a581b986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:to="loc_us-gaap_PendingLitigationMember_0ccdaf92-c6c9-40c3-8631-b641a581b986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ffb37494-7f21-45b5-b94a-ffdfd6ee052b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:to="loc_us-gaap_SettledLitigationMember_ffb37494-7f21-45b5-b94a-ffdfd6ee052b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_425d967a-5501-40a1-9c71-0c78e5ca235c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:to="loc_dei_EntityDomain_425d967a-5501-40a1-9c71-0c78e5ca235c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:to="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_3f581ee7-4f08-48d2-9d0d-20f3f237fb4f" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:to="loc_mo_PhilipMorrisUSAMember_3f581ee7-4f08-48d2-9d0d-20f3f237fb4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesFloridaBondStatuteDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" xlink:type="extended" id="i28674b005e144a789ca02beebc3e5080_ContingenciesFloridaBondStatuteDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MaximumBondForAllDefendants_cb5eb67d-815a-4f1e-9229-b7761fdc7e5f" xlink:href="mo-20230331.xsd#mo_MaximumBondForAllDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:to="loc_mo_MaximumBondForAllDefendants_cb5eb67d-815a-4f1e-9229-b7761fdc7e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:to="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:to="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c4b7e369-fd88-4988-a029-89454d211577_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:to="loc_srt_SegmentGeographicalDomain_c4b7e369-fd88-4988-a029-89454d211577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:to="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_07904241-1d31-40a0-8aca-15b5eebe3ac6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:to="loc_stpr_FL_07904241-1d31-40a0-8aca-15b5eebe3ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:to="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f96743a3-d967-4bfa-8e21-c1e38507f94d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:to="loc_srt_LitigationCaseTypeDomain_f96743a3-d967-4bfa-8e21-c1e38507f94d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:to="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesStateMember_f2fa9eb9-94f6-40a8-b72e-dc23496716ae" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:to="loc_mo_EngleProgenyCasesStateMember_f2fa9eb9-94f6-40a8-b72e-dc23496716ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOtherSmokingandHealthClassActionsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" xlink:type="extended" id="i33f9fe0672d4412e907cb808cabfa90d_ContingenciesOtherSmokingandHealthClassActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassNotCertifiedNumber_cbb13b99-3109-4bf0-a17c-fba7e05e8162" xlink:href="mo-20230331.xsd#mo_LossContingencyClassNotCertifiedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyClassNotCertifiedNumber_cbb13b99-3109-4bf0-a17c-fba7e05e8162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_75ea5e77-2277-469a-812a-d5607a508083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_75ea5e77-2277-469a-812a-d5607a508083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofManufacturers_1db1059f-77f8-4b92-a5e3-4dd48e0f8828" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyNumberofManufacturers_1db1059f-77f8-4b92-a5e3-4dd48e0f8828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictsUpheld_e7f695d1-aca2-41d9-9380-1e5ade835a03" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictsUpheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyVerdictsUpheld_e7f695d1-aca2-41d9-9380-1e5ade835a03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AmountAwardedtoOtherParty_4490642b-9d71-46b2-8b4e-893d87a8b83f" xlink:href="mo-20230331.xsd#mo_AmountAwardedtoOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_AmountAwardedtoOtherParty_4490642b-9d71-46b2-8b4e-893d87a8b83f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_158d6d55-c71a-4f09-99d9-5c34293167fa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:to="loc_srt_SegmentGeographicalDomain_158d6d55-c71a-4f09-99d9-5c34293167fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:to="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AR_8e74a063-8ecd-4831-8589-77f96261a71f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_AR_8e74a063-8ecd-4831-8589-77f96261a71f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_54e7da8f-33d9-48b6-9c83-1b3d494f6ab3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_CA_54e7da8f-33d9-48b6-9c83-1b3d494f6ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DE_f377c3bd-078e-4e39-b063-6e9483eeea28" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_DE_f377c3bd-078e-4e39-b063-6e9483eeea28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_1e46ba66-cfd6-4ad7-a50a-1e3c860cce34" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_DC_1e46ba66-cfd6-4ad7-a50a-1e3c860cce34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_1ea79afb-7578-495d-9d9d-fd306b6c7b46" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_FL_1ea79afb-7578-495d-9d9d-fd306b6c7b46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_dc5ea74c-81b3-4bef-8f2c-9aa243c54eb4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_IL_dc5ea74c-81b3-4bef-8f2c-9aa243c54eb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_8e0a8d47-f9eb-46ec-ad00-52bff158f4c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_IA_8e0a8d47-f9eb-46ec-ad00-52bff158f4c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KS_f722c785-cdc6-48ba-864f-de240e43f46d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_KS_f722c785-cdc6-48ba-864f-de240e43f46d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_LA_32716fd5-3a05-49c5-9212-a0798e57cc10" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_LA_32716fd5-3a05-49c5-9212-a0798e57cc10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_6c69dceb-c7ba-447e-aa60-5233493b3774" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MD_6c69dceb-c7ba-447e-aa60-5233493b3774" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_ec116dd4-fbf0-4060-9452-a8f9479378da" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MI_ec116dd4-fbf0-4060-9452-a8f9479378da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_a56643ad-9124-4e03-9a8a-e691c5000730" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MN_a56643ad-9124-4e03-9a8a-e691c5000730" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NV_1a2c8738-3a4c-4fc0-9073-41256c958eb2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NV_1a2c8738-3a4c-4fc0-9073-41256c958eb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_ef51280f-11de-4770-9f91-58eb009a2c15" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NJ_ef51280f-11de-4770-9f91-58eb009a2c15" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_66378662-1708-4aa0-b952-f03dd4567484" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NY_66378662-1708-4aa0-b952-f03dd4567484" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OH_ea39bb2e-3e36-4acc-8b13-34f44d81cc01" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OH_ea39bb2e-3e36-4acc-8b13-34f44d81cc01" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_22e1457c-ca29-413c-99cf-efddd4b86cc5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OK_22e1457c-ca29-413c-99cf-efddd4b86cc5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OR_39bdbc38-ab9f-4328-9a86-9fa5b517aeda" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OR_39bdbc38-ab9f-4328-9a86-9fa5b517aeda" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_7284c1a6-8b74-4f9f-b2c0-17f06d95e83a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_PA_7284c1a6-8b74-4f9f-b2c0-17f06d95e83a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_88d44b7e-fe35-4831-a617-bc569479a1bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_country_PR_88d44b7e-fe35-4831-a617-bc569479a1bf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_499d4156-7f53-46b2-a707-6db48c53072a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_SC_499d4156-7f53-46b2-a707-6db48c53072a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_2ad77416-672f-4c74-b91e-bf46b04aaf98" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_TX_2ad77416-672f-4c74-b91e-bf46b04aaf98" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_59b11d24-7691-435f-bd39-397d6c1b7d58" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_WI_59b11d24-7691-435f-bd39-397d6c1b7d58" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5044a9d1-2dd4-4b60-ae56-2be9b8c34337" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_country_CA_5044a9d1-2dd4-4b60-ae56-2be9b8c34337" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_BritishColumbiaSaskatchewanMember_3b713b79-865b-4f6f-bf08-02f9343597c9" xlink:href="mo-20230331.xsd#mo_BritishColumbiaSaskatchewanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_mo_BritishColumbiaSaskatchewanMember_3b713b79-865b-4f6f-bf08-02f9343597c9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:to="loc_dei_EntityDomain_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:to="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_6f090bdf-8254-4228-963c-b3df6ca5ed52" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_PhilipMorrisUSAMember_6f090bdf-8254-4228-963c-b3df6ca5ed52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAandAltriaGroupMember_bde35d7f-43a2-4374-8748-597a3eb13866" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAandAltriaGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_PhilipMorrisUSAandAltriaGroupMember_bde35d7f-43a2-4374-8748-597a3eb13866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CanadianTobaccoManufacturersMember_be2a35e3-3e4d-4a78-b568-8fecf0346710" xlink:href="mo-20230331.xsd#mo_CanadianTobaccoManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_CanadianTobaccoManufacturersMember_be2a35e3-3e4d-4a78-b568-8fecf0346710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AltriaGroupMember_a6946689-8168-486f-a523-a530e4389010" xlink:href="mo-20230331.xsd#mo_AltriaGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_AltriaGroupMember_a6946689-8168-486f-a523-a530e4389010" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c18697c2-4753-4c56-8c2d-9061fa7fab6d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:to="loc_srt_LitigationCaseTypeDomain_c18697c2-4753-4c56-8c2d-9061fa7fab6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:to="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_435c59c8-79b6-43e4-b27a-ed8c2c97df5f" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_435c59c8-79b6-43e4-b27a-ed8c2c97df5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b7055556-3343-40ce-8982-5c36cbe618e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b7055556-3343-40ce-8982-5c36cbe618e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9fd2f91c-9978-4445-83a1-cda9c160446a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:to="loc_us-gaap_SubsequentEventMember_9fd2f91c-9978-4445-83a1-cda9c160446a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesHealthCareCostRecoveryLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" xlink:type="extended" id="icb8d9979b293462989285a9b059f520b_ContingenciesHealthCareCostRecoveryLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_45eaaf26-17e4-4dd6-be2e-3a2b5a3bd5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_45eaaf26-17e4-4dd6-be2e-3a2b5a3bd5a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofManufacturers_3bf4e8fb-d1c1-497d-86ba-ff89953e4813" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LossContingencyNumberofManufacturers_3bf4e8fb-d1c1-497d-86ba-ff89953e4813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigation_4cc6f493-805d-4189-bfad-c20f2281b8d0" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LossContingencyNumberofStateswithSettledLitigation_4cc6f493-805d-4189-bfad-c20f2281b8d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualPaymentAmount_7a232d51-37c1-42b0-8843-3ebcb2983daa" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LitigationSettlementAnnualPaymentAmount_7a232d51-37c1-42b0-8843-3ebcb2983daa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_a79ecaaa-cc8c-4ddc-a53f-f619c138fcc3" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualLegalFeesPayableMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_a79ecaaa-cc8c-4ddc-a53f-f619c138fcc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_291e4abe-d1e8-4e66-b582-3c2b2a15af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_291e4abe-d1e8-4e66-b582-3c2b2a15af60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_022df789-1ce5-42fa-9278-79dde240ae88_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:to="loc_dei_EntityDomain_022df789-1ce5-42fa-9278-79dde240ae88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:to="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CanadianTobaccoManufacturersMember_b3926653-85e3-483b-81e6-dd134772c353" xlink:href="mo-20230331.xsd#mo_CanadianTobaccoManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:to="loc_mo_CanadianTobaccoManufacturersMember_b3926653-85e3-483b-81e6-dd134772c353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b50c682b-b73f-457e-9baa-54079171fb8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:to="loc_us-gaap_LitigationStatusDomain_b50c682b-b73f-457e-9baa-54079171fb8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:to="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThreatenedLitigationMember_8e7d8550-dd68-405d-96d6-91a64de89f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThreatenedLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:to="loc_us-gaap_ThreatenedLitigationMember_8e7d8550-dd68-405d-96d6-91a64de89f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_af70b790-7938-4943-905f-6004b6da170a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:to="loc_srt_SegmentGeographicalDomain_af70b790-7938-4943-905f-6004b6da170a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:to="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fb1dde98-a576-427b-a4eb-3303eddac2a9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:to="loc_country_CA_fb1dde98-a576-427b-a4eb-3303eddac2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_16cfcc9d-140d-4721-81a9-956686bace33_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:to="loc_srt_LitigationCaseTypeDomain_16cfcc9d-140d-4721-81a9-956686bace33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:to="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_c6ef3ba9-7710-4ba5-853b-37ec8f4fb6f2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_c6ef3ba9-7710-4ba5-853b-37ec8f4fb6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_a55ffa54-f428-47ee-9985-ddd5588919e6" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_a55ffa54-f428-47ee-9985-ddd5588919e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesNPMAdjustmentDisputesDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" xlink:type="extended" id="i8c955c0f118643a798dc751dafbacaec_ContingenciesNPMAdjustmentDisputesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementEstimateofPossibleGain_ea7d9272-4a28-4851-9750-86b6710898b8" xlink:href="mo-20230331.xsd#mo_LitigationSettlementEstimateofPossibleGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LitigationSettlementEstimateofPossibleGain_ea7d9272-4a28-4851-9750-86b6710898b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_ea8d1c2d-8100-4fad-8e37-b2f70a314ea1" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_ea8d1c2d-8100-4fad-8e37-b2f70a314ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_37f22b23-75c2-45a5-8d42-9544a07ca696" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_37f22b23-75c2-45a5-8d42-9544a07ca696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fbe6fccc-f108-46a1-af52-6adeb004fe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fbe6fccc-f108-46a1-af52-6adeb004fe0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2f79695d-672b-4c99-ba58-b2d65742f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2f79695d-672b-4c99-ba58-b2d65742f3a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_21e4d44c-7b02-4176-983d-168ea7c4cc93" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_21e4d44c-7b02-4176-983d-168ea7c4cc93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings_74604afa-e928-47a3-8824-68df2ab36556" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesWithConcludedHearings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings_74604afa-e928-47a3-8824-68df2ab36556" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettled_e1a26934-46ec-4119-acb6-9941076af678" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotSettled_e1a26934-46ec-4119-acb6-9941076af678" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_c5eddd00-67c9-4a13-84cf-7e8d69533bcf" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_c5eddd00-67c9-4a13-84cf-7e8d69533bcf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_9553374d-b260-47a0-b3c7-a1c3f0bffcb7" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_9553374d-b260-47a0-b3c7-a1c3f0bffcb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyReductionToCostOfSales_2e64fc38-c2e4-4500-9218-15a4c9dd1aea" xlink:href="mo-20230331.xsd#mo_LossContingencyReductionToCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyReductionToCostOfSales_2e64fc38-c2e4-4500-9218-15a4c9dd1aea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cfff6b70-9bd8-4a4b-8aac-19eec4d0abb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cfff6b70-9bd8-4a4b-8aac-19eec4d0abb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_740106db-9c71-4c2e-ad4c-76a5060d2f15" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_740106db-9c71-4c2e-ad4c-76a5060d2f15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:to="loc_srt_SegmentGeographicalDomain_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:to="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_96adeaae-8b1e-4bd9-8f97-0901e2d1937c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_NY_96adeaae-8b1e-4bd9-8f97-0901e2d1937c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MT_fbd86e19-92a1-4cf4-b3f5-4555b900078e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_MT_fbd86e19-92a1-4cf4-b3f5-4555b900078e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_4241f36e-52e9-4954-9541-9e43b7f5a132" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_IL_4241f36e-52e9-4954-9541-9e43b7f5a132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_0c340f84-d109-4084-b6c3-2bce26be6e5e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_IA_0c340f84-d109-4084-b6c3-2bce26be6e5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_8adfddac-dc0f-4458-8282-e3e79826d8ba" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_NM_8adfddac-dc0f-4458-8282-e3e79826d8ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:to="loc_dei_EntityDomain_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:to="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c407aa64-ec6b-454a-a0f1-cf95ace54769" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:to="loc_mo_PhilipMorrisUSAMember_c407aa64-ec6b-454a-a0f1-cf95ace54769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6ec18e44-ed0d-47b7-b199-6668c2f37c8e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:to="loc_srt_LitigationCaseTypeDomain_6ec18e44-ed0d-47b7-b199-6668c2f37c8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:to="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_c8a06797-f799-493e-b1d5-7dbdd85fe4f5" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_c8a06797-f799-493e-b1d5-7dbdd85fe4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_cffcbabd-0fb8-427d-acad-6ac283e21d63" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_cffcbabd-0fb8-427d-acad-6ac283e21d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_665139ee-dbab-43a3-baaa-99b89bc13b35" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_665139ee-dbab-43a3-baaa-99b89bc13b35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_5a5fd3c1-0438-4e3f-b4d1-a85931ba4f9f" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_5a5fd3c1-0438-4e3f-b4d1-a85931ba4f9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_959efa7d-0202-47f2-83ac-f1875f8fa70b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_959efa7d-0202-47f2-83ac-f1875f8fa70b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_74dd8adf-7c5f-4939-bcda-4867a228ad93" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_74dd8adf-7c5f-4939-bcda-4867a228ad93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_723d758c-2f1b-4d4a-8a7f-102115711e83" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_723d758c-2f1b-4d4a-8a7f-102115711e83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_aa3ca7c6-0d7e-4ee8-afff-92bdacf507c9" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_aa3ca7c6-0d7e-4ee8-afff-92bdacf507c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_507d92a0-eb72-4420-ac21-16512af6d08f" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_507d92a0-eb72-4420-ac21-16512af6d08f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_e35c63c2-de67-4e87-ba84-f36f11400c81" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_e35c63c2-de67-4e87-ba84-f36f11400c81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_93c346f4-fc56-449c-9a9e-fa84d5bcc884" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_93c346f4-fc56-449c-9a9e-fa84d5bcc884" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_6d569b0b-a890-4dc8-885b-5c57610c92db" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_6d569b0b-a890-4dc8-885b-5c57610c92db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_e929ddf9-043a-4473-a5f9-6e128fc98d3b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_e929ddf9-043a-4473-a5f9-6e128fc98d3b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_4bcd5563-da6e-4c9b-beac-1c7760c2cf31" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_4bcd5563-da6e-4c9b-beac-1c7760c2cf31" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_73e07f65-e6df-4cd9-976c-3ed98297ae7d" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_73e07f65-e6df-4cd9-976c-3ed98297ae7d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_d5e9c9ee-e82d-4b76-9e55-9ff7e2e8492e" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_d5e9c9ee-e82d-4b76-9e55-9ff7e2e8492e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_97099213-43e3-44f8-99b2-85450a1b6b00" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_97099213-43e3-44f8-99b2-85450a1b6b00" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_b71ee33d-8bb4-4196-90ed-fb5ba03682f4" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_b71ee33d-8bb4-4196-90ed-fb5ba03682f4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_e611fc64-80f2-4f05-9b70-56fefa9554b2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_e611fc64-80f2-4f05-9b70-56fefa9554b2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_2b99731e-f059-48a2-a452-709a0719400b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_2b99731e-f059-48a2-a452-709a0719400b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_c1509a52-ad1a-4cc2-b7ef-74c7bf45375b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_c1509a52-ad1a-4cc2-b7ef-74c7bf45375b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_4e51b88f-a887-48a1-b1f5-82b07e6b46d7" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20192021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_4e51b88f-a887-48a1-b1f5-82b07e6b46d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_6d2ce112-6861-4995-94cb-2a6e263c7f8a" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_6d2ce112-6861-4995-94cb-2a6e263c7f8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_909646f7-afe5-4359-8473-c3ae2ea378c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:to="loc_us-gaap_LitigationStatusDomain_909646f7-afe5-4359-8473-c3ae2ea378c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:to="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5d5e3da6-491e-49e5-bcf4-ec8aca9a2ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:to="loc_us-gaap_SettledLitigationMember_5d5e3da6-491e-49e5-bcf4-ec8aca9a2ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_722b651c-811c-4404-a538-20ee40c97c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:to="loc_us-gaap_PendingLitigationMember_722b651c-811c-4404-a538-20ee40c97c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodDomain_b5c0580b-ab32-47d9-9c55-942b4aab89dd_default" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:to="loc_mo_ArbitrationPeriodDomain_b5c0580b-ab32-47d9-9c55-942b4aab89dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:to="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodOneMember_3cedd869-3e93-4f33-b2fe-bb570691417b" xlink:href="mo-20230331.xsd#mo_PeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:to="loc_mo_PeriodOneMember_3cedd869-3e93-4f33-b2fe-bb570691417b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodTwoMember_1709d971-52a6-4f1d-a852-99ef27f56eba" xlink:href="mo-20230331.xsd#mo_PeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:to="loc_mo_PeriodTwoMember_1709d971-52a6-4f1d-a852-99ef27f56eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0893ddd5-3fc2-4a6e-bcce-14829da076a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0893ddd5-3fc2-4a6e-bcce-14829da076a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d679c7d1-25a1-43ee-a4ed-494b30de5e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:to="loc_us-gaap_CostOfSalesMember_d679c7d1-25a1-43ee-a4ed-494b30de5e57" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" xlink:type="extended" id="ie06974f6deff44158a9d2f172943f79f_ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_371c7c49-a8a3-4306-9c62-a266bb57479c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_371c7c49-a8a3-4306-9c62-a266bb57479c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:to="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:to="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:to="loc_dei_EntityDomain_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:to="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_800996f2-700e-4d0d-a014-7fd513aa7589" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:to="loc_mo_PhilipMorrisUSAMember_800996f2-700e-4d0d-a014-7fd513aa7589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:to="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5fdfbd65-186f-4e22-9438-63557e976abd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:to="loc_srt_LitigationCaseTypeDomain_5fdfbd65-186f-4e22-9438-63557e976abd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:to="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember_1dd31f61-32f7-49d0-9cc6-33e53a6a311c" xlink:href="mo-20230331.xsd#mo_OtherDisputesUndertheStateSettlementAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:to="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember_1dd31f61-32f7-49d0-9cc6-33e53a6a311c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesFederalGovernmentsLawsuitDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" xlink:type="extended" id="i4585723157d448f1bbe9e6c261134d2f_ContingenciesFederalGovernmentsLawsuitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_b1d83cc0-f670-4bd8-8d00-7d0e60f3b053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_b1d83cc0-f670-4bd8-8d00-7d0e60f3b053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:to="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_236f3530-b8c8-4030-9693-5c1687c04122_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:to="loc_us-gaap_LossContingencyNatureDomain_236f3530-b8c8-4030-9693-5c1687c04122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:to="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ImplementationofCorrectiveCommunicationsMember_b08e5db8-7a18-4a7c-8878-2538c87b274f" xlink:href="mo-20230331.xsd#mo_ImplementationofCorrectiveCommunicationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:to="loc_mo_ImplementationofCorrectiveCommunicationsMember_b08e5db8-7a18-4a7c-8878-2538c87b274f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:to="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6d01f1ef-af5f-4c63-9e4d-175e5db9804d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:to="loc_dei_EntityDomain_6d01f1ef-af5f-4c63-9e4d-175e5db9804d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:to="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_0a5ffce7-baa8-4d93-9c70-5cd03d83d1fe" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:to="loc_mo_PhilipMorrisUSAMember_0a5ffce7-baa8-4d93-9c70-5cd03d83d1fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AltriaGroupMember_398553a2-3690-4987-8337-7b071d688e80" xlink:href="mo-20230331.xsd#mo_AltriaGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:to="loc_mo_AltriaGroupMember_398553a2-3690-4987-8337-7b071d688e80" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEvaporProductLitigationandIQOSLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" xlink:type="extended" id="if39fccf288594f02a138d55bd636ff1d_ContingenciesEvaporProductLitigationandIQOSLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_999bf713-afe9-4d79-9fb7-a46e9b2224c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_999bf713-afe9-4d79-9fb7-a46e9b2224c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_3971b62a-377e-406c-bbc7-85e0ce7669ee" xlink:href="mo-20230331.xsd#mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_3971b62a-377e-406c-bbc7-85e0ce7669ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates_05894cb8-96f3-455e-b74c-753e642e6748" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCasesWithSetTrialDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates_05894cb8-96f3-455e-b74c-753e642e6748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfTrialsOngoing_6c61bbfd-a88b-41a9-89a4-9fb70c6a8fe0" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfTrialsOngoing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyNumberOfTrialsOngoing_6c61bbfd-a88b-41a9-89a4-9fb70c6a8fe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NumberOfThirdPartyLawsuits_17fd6ac8-26e0-4b36-958d-3cea15d563ae" xlink:href="mo-20230331.xsd#mo_NumberOfThirdPartyLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_NumberOfThirdPartyLawsuits_17fd6ac8-26e0-4b36-958d-3cea15d563ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9be259a9-562f-45e5-9689-98cc4f86592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9be259a9-562f-45e5-9689-98cc4f86592f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyRoyaltyFeePercentage_82f3abf3-597a-4752-9ac3-164abfbb8ff3" xlink:href="mo-20230331.xsd#mo_LossContingencyRoyaltyFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyRoyaltyFeePercentage_82f3abf3-597a-4752-9ac3-164abfbb8ff3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyDamagesRecoverableValue_351cce0c-2514-4386-8c12-8b1cf28dd323" xlink:href="mo-20230331.xsd#mo_LossContingencyDamagesRecoverableValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyDamagesRecoverableValue_351cce0c-2514-4386-8c12-8b1cf28dd323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_99ff9f0c-492a-4cf6-87ca-aa01791db0d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:to="loc_us-gaap_LitigationStatusDomain_99ff9f0c-492a-4cf6-87ca-aa01791db0d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:to="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ClassActionLawsuitMember_bf829d12-57bb-4c19-905f-9bfbe8dd6e6d" xlink:href="mo-20230331.xsd#mo_ClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_ClassActionLawsuitMember_bf829d12-57bb-4c19-905f-9bfbe8dd6e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_0e3fdb3f-d5fe-4f4e-9d05-3b8b0e063a95" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_PendingIndividualLawsuitsMember_0e3fdb3f-d5fe-4f4e-9d05-3b8b0e063a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_2dacfc77-6164-4d24-b64b-1ba5292df9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_us-gaap_SettledLitigationMember_2dacfc77-6164-4d24-b64b-1ba5292df9ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingClassActionLawsuitMember_ddfa59bf-d78e-424a-9b4c-b84c282501cf" xlink:href="mo-20230331.xsd#mo_PendingClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_PendingClassActionLawsuitMember_ddfa59bf-d78e-424a-9b4c-b84c282501cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_40f89817-8204-48da-8393-c09b838d392f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_us-gaap_PendingLitigationMember_40f89817-8204-48da-8393-c09b838d392f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5f3280cb-9926-4909-a8ee-f85913f1fde8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5f3280cb-9926-4909-a8ee-f85913f1fde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_04b84c53-99d6-4939-9930-2b1a3fb7d41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:to="loc_us-gaap_SubsequentEventMember_04b84c53-99d6-4939-9930-2b1a3fb7d41e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d5a1540a-5429-4b94-8839-205e75dfa75a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:to="loc_srt_LitigationCaseTypeDomain_d5a1540a-5429-4b94-8839-205e75dfa75a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:to="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_c83cd17b-3625-41e2-85b9-845c4beaa102" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:to="loc_mo_EvaporLitigationMember_c83cd17b-3625-41e2-85b9-845c4beaa102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IQOSMember_9fb6092b-fa29-4355-8870-514dd038497a" xlink:href="mo-20230331.xsd#mo_IQOSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:to="loc_mo_IQOSMember_9fb6092b-fa29-4355-8870-514dd038497a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_49f146ef-ff05-40f5-a34d-93131f17bfea_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:to="loc_srt_SegmentGeographicalDomain_49f146ef-ff05-40f5-a34d-93131f17bfea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:to="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_27acb30a-145d-41b5-942a-fdf986ae4424" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:to="loc_country_CA_27acb30a-145d-41b5-942a-fdf986ae4424" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" xlink:type="extended" id="i6aba732668374cc5ad828036b9e9e5ee_ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_2b143b28-3a1d-4868-ad7f-5dd1d924105f" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_2b143b28-3a1d-4868-ad7f-5dd1d924105f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassActionLawsuit_96dc28c4-ecd9-44e1-b486-b9978a838e2f" xlink:href="mo-20230331.xsd#mo_LossContingencyClassActionLawsuit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyClassActionLawsuit_96dc28c4-ecd9-44e1-b486-b9978a838e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfComplaints_033629e6-f9ee-4ffa-b4f7-b0ca788ddb8d" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfComplaints"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfComplaints_033629e6-f9ee-4ffa-b4f7-b0ca788ddb8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_419f35dd-221b-4013-9ba4-8962dbc7eb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_419f35dd-221b-4013-9ba4-8962dbc7eb47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_2bf56fd2-9f5f-4851-a86f-16f0a1cd5a0d" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_2bf56fd2-9f5f-4851-a86f-16f0a1cd5a0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58d5a15f-dd10-44bb-93f2-7f5593b7e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58d5a15f-dd10-44bb-93f2-7f5593b7e63f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_4d4c3345-2e5b-48c6-bfed-ed52cc8bffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_4d4c3345-2e5b-48c6-bfed-ed52cc8bffc2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_60209c21-29f2-4d64-bdb6-c36f0ffcd7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_60209c21-29f2-4d64-bdb6-c36f0ffcd7fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfPendingCasesConsolidated_460e6dfb-b496-49c2-b6ca-c5430581d472" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfPendingCasesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfPendingCasesConsolidated_460e6dfb-b496-49c2-b6ca-c5430581d472" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_91fb5367-7fdd-4a60-9dfc-e1c6a09f2264" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_91fb5367-7fdd-4a60-9dfc-e1c6a09f2264" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_b23e6cbc-6787-431a-965a-d14eff8785c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_b23e6cbc-6787-431a-965a-d14eff8785c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a366bc1-0de0-4c8c-9588-81feb91f078f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a366bc1-0de0-4c8c-9588-81feb91f078f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb106092-09dd-4388-8091-b40243eec75a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb106092-09dd-4388-8091-b40243eec75a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2c519ab-7ac0-4f8e-8d88-e904d8d64d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:to="loc_us-gaap_SubsequentEventMember_c2c519ab-7ac0-4f8e-8d88-e904d8d64d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_8336795f-d53f-4499-9a1b-4a65bbbebce8" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:to="loc_mo_JUULMember_8336795f-d53f-4499-9a1b-4a65bbbebce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f914817c-a51e-4e02-be22-933399050f43_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:to="loc_srt_LitigationCaseTypeDomain_f914817c-a51e-4e02-be22-933399050f43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:to="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember_f217a1dc-16f2-4fe9-b51a-d2bdd2f55e62" xlink:href="mo-20230331.xsd#mo_FederalAndStateShareholderDerivativeLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:to="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember_f217a1dc-16f2-4fe9-b51a-d2bdd2f55e62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesLightsUltraLightsCasesDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" xlink:type="extended" id="i61faa54de47444279bf702809d6acb7f_ContingenciesLightsUltraLightsCasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsNotCertifiedNumber_32e21a8c-16c4-44de-9989-2ddd5ac881ce" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsNotCertifiedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_mo_LossContingencyClaimsNotCertifiedNumber_32e21a8c-16c4-44de-9989-2ddd5ac881ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_fd6ee5cb-d19d-4dca-90ff-d12d955046dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_fd6ee5cb-d19d-4dca-90ff-d12d955046dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyStateCourtsNumber_90d8cd3f-c03f-4bd4-9b6f-ff41d5c2357a" xlink:href="mo-20230331.xsd#mo_LossContingencyStateCourtsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_mo_LossContingencyStateCourtsNumber_90d8cd3f-c03f-4bd4-9b6f-ff41d5c2357a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9a449f62-078c-4e25-91b8-a0f1dc07c423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9a449f62-078c-4e25-91b8-a0f1dc07c423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38d57bda-a898-4818-80a2-193533aa9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:to="loc_us-gaap_SubsequentEventMember_38d57bda-a898-4818-80a2-193533aa9ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9e244c47-e337-4c5f-b257-27809549cf6a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:to="loc_srt_LitigationCaseTypeDomain_9e244c47-e337-4c5f-b257-27809549cf6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:to="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LightsMember_b30ab3a2-a5c4-4509-a890-2b4581f5258c" xlink:href="mo-20230331.xsd#mo_LightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_LightsMember_b30ab3a2-a5c4-4509-a890-2b4581f5258c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_6ceecab0-497d-427d-b98c-8faf1fe03348" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_6ceecab0-497d-427d-b98c-8faf1fe03348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_USTLitigationMember_24f4cb21-f0e9-41a7-a9ff-3764b98da53c" xlink:href="mo-20230331.xsd#mo_USTLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_USTLitigationMember_24f4cb21-f0e9-41a7-a9ff-3764b98da53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9d2395af-bf5f-4f0b-993a-46b841e724a8_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:to="loc_dei_EntityDomain_9d2395af-bf5f-4f0b-993a-46b841e724a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:to="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_e82cf025-754b-47eb-8aaf-9318970bda85" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:to="loc_mo_PhilipMorrisUSAMember_e82cf025-754b-47eb-8aaf-9318970bda85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesUSTLitigationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" xlink:type="extended" id="i429b1b42a82e4eb3ae46d0d9c66e4717_ContingenciesUSTLitigationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4f49ca1b-5d42-4925-9a16-e50240fa7979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4f49ca1b-5d42-4925-9a16-e50240fa7979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:to="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:to="loc_us-gaap_LitigationStatusDomain_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:to="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_a103517f-701d-41b8-93ca-c5d9fe6d69dc" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:to="loc_mo_PendingIndividualLawsuitsMember_a103517f-701d-41b8-93ca-c5d9fe6d69dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5b9ed672-c3e6-42d6-ae63-fa060920283b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5b9ed672-c3e6-42d6-ae63-fa060920283b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bd5428ea-d5ba-45c4-b854-43be00fe972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:to="loc_us-gaap_SubsequentEventMember_bd5428ea-d5ba-45c4-b854-43be00fe972d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_981e8b19-7b74-43be-aefe-351934ca6447_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:to="loc_srt_LitigationCaseTypeDomain_981e8b19-7b74-43be-aefe-351934ca6447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:to="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_USTLitigationMember_d37ceede-ef2c-4523-9f64-b7af8892a190" xlink:href="mo-20230331.xsd#mo_USTLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:to="loc_mo_USTLitigationMember_d37ceede-ef2c-4523-9f64-b7af8892a190" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" xlink:type="extended" id="ie9750bba16544a03a4602b5ad4d6fd1e_ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fdc5f860-cc26-46c9-98a8-ccd05069d0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fdc5f860-cc26-46c9-98a8-ccd05069d0db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_2309f85d-97f3-4a75-9e06-45f847f2a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_2309f85d-97f3-4a75-9e06-45f847f2a65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:to="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9283dc00-9d1b-40f4-bfcb-14ba678e0faa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9283dc00-9d1b-40f4-bfcb-14ba678e0faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_191349db-7897-4806-8735-da573374645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_191349db-7897-4806-8735-da573374645e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5fb1e63-9109-4a40-b614-0c8e7a31edca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5fb1e63-9109-4a40-b614-0c8e7a31edca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CreditAgreementMember_878cd7d5-bd40-4f7c-be97-208cf4aa363d" xlink:href="mo-20230331.xsd#mo_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:to="loc_mo_CreditAgreementMember_878cd7d5-bd40-4f7c-be97-208cf4aa363d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5a713e59-746e-4b9e-95b7-3a0b364c37a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:to="loc_us-gaap_CreditFacilityDomain_5a713e59-746e-4b9e-95b7-3a0b364c37a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:to="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_ba10e28f-cc4b-49f2-a6ac-eed46344f282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:to="loc_us-gaap_LetterOfCreditMember_ba10e28f-cc4b-49f2-a6ac-eed46344f282" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>mo-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mo_InvestmentsLineItems_b47e7d46-ae83-47b9-b2ba-eda31413c70e_terseLabel_en-US" xlink:label="lab_mo_InvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Line Items]</link:label>
    <link:label id="lab_mo_InvestmentsLineItems_label_en-US" xlink:label="lab_mo_InvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Line Items]</link:label>
    <link:label id="lab_mo_InvestmentsLineItems_documentation_en-US" xlink:label="lab_mo_InvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_InvestmentsLineItems" xlink:to="lab_mo_InvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_09de9352-4d56-4b50-8d36-da60ddb2ad40_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_482d3c5d-3f0c-4920-acd6-2e1900cb54a8_terseLabel_en-US" xlink:label="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, consolidated EBITDA to interest expense ratio</link:label>
    <link:label id="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_label_en-US" xlink:label="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated EBITDA to Interest Expense Ratio</link:label>
    <link:label id="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_documentation_en-US" xlink:label="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated EBITDA to Interest Expense Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:href="mo-20230331.xsd#mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:to="lab_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_805f49e1-8ac2-46fe-900b-b14f6c8fa1d0_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_956d4476-776e-4fac-81e5-188b1c055b79_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to net earnings, net of deferred income taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CashDiscountsPolicyTextBlock_dfcde824-b11d-4253-8cbf-f8890bc6df67_terseLabel_en-US" xlink:label="lab_mo_CashDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts</link:label>
    <link:label id="lab_mo_CashDiscountsPolicyTextBlock_label_en-US" xlink:label="lab_mo_CashDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts [Policy Text Block]</link:label>
    <link:label id="lab_mo_CashDiscountsPolicyTextBlock_documentation_en-US" xlink:label="lab_mo_CashDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CashDiscountsPolicyTextBlock" xlink:href="mo-20230331.xsd#mo_CashDiscountsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CashDiscountsPolicyTextBlock" xlink:to="lab_mo_CashDiscountsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_11107515-1d76-46b9-96f1-7085a25fc4b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_27564245-4046-48c6-a648-6933a56fbe51_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7f3a31b8-e107-45db-83fa-7cc32f5e1cd1_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_e4bb4900-a23a-461c-b324-94880dfe6a33_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock_da9d8639-a53e-4a53-9373-a0105259049f_terseLabel_en-US" xlink:label="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Participating Manufacturer Adjustment Items</link:label>
    <link:label id="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock_label_en-US" xlink:label="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Participating Manufacturer Adjustment Items [Table Text Block]</link:label>
    <link:label id="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock_documentation_en-US" xlink:label="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Participating Manufacturer Adjustment Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:href="mo-20230331.xsd#mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:to="lab_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_dde075f1-6c29-4394-ba3b-e8037e855443_terseLabel_en-US" xlink:label="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Participating Manufacturer Arbitration Panel Decision [Member]</link:label>
    <link:label id="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_label_en-US" xlink:label="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Participating Manufacturer Arbitration Panel Decision [Member]</link:label>
    <link:label id="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_documentation_en-US" xlink:label="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Participating Manufacturer Arbitration Panel Decision [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:href="mo-20230331.xsd#mo_NonParticipatingManufacturerArbitrationPanelDecisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:to="lab_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a2a3c1cb-81ea-4518-bef7-8877630f7329_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_0aace4e9-9c7d-49e5-ad55-ba55db18ad0d_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, difference between carrying amount and fair value, percentage (approximately)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_46ee5a61-89cc-4fa2-8c18-30948047c356_negatedLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, difference between carrying amount and fair value, percentage (approximately)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:to="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_2751c36b-da65-4283-b29e-b906ce084f48_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares owned (in shares)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_303bdd05-cb29-488b-975a-76e5a684f6ab_verboseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares owned (approximately) (in shares)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number of Shares Owned, Common</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number of Shares Owned, Common</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedCommon"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:to="lab_mo_EquityMethodInvestmentNumberofSharesOwnedCommon" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HorizonMember_81776712-5cee-4320-9d0a-be186f1cbc29_terseLabel_en-US" xlink:label="lab_mo_HorizonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon [Member]</link:label>
    <link:label id="lab_mo_HorizonMember_label_en-US" xlink:label="lab_mo_HorizonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon [Member]</link:label>
    <link:label id="lab_mo_HorizonMember_documentation_en-US" xlink:label="lab_mo_HorizonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HorizonMember" xlink:href="mo-20230331.xsd#mo_HorizonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HorizonMember" xlink:to="lab_mo_HorizonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_840f3915-89b5-4d67-8234-157b3e8c5fbd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesTuttleMember_a07d4ef4-70d8-4f65-89f5-a756d728276e_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesTuttleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Tuttle [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesTuttleMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesTuttleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Tuttle [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesTuttleMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesTuttleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Tuttle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesTuttleMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesTuttleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesTuttleMember" xlink:to="lab_mo_EngleProgenyCasesTuttleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_e78c3b6d-6252-4008-bfac-42ce85ad1c8d_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other [Member]</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_942c3b00-9ee3-4f26-bc6d-a651998e159e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesSchertzerMember_0135f52a-4e7b-4217-85a5-b7fab71616e9_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesSchertzerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Schertzer [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesSchertzerMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesSchertzerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Schertzer [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesSchertzerMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesSchertzerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Schertzer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesSchertzerMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesSchertzerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesSchertzerMember" xlink:to="lab_mo_EngleProgenyCasesSchertzerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_09ac5069-e413-4021-8581-719067cb73d6_terseLabel_en-US" xlink:label="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum</link:label>
    <link:label id="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_label_en-US" xlink:label="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum</link:label>
    <link:label id="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_documentation_en-US" xlink:label="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:href="mo-20230331.xsd#mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:to="lab_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates_6bc4168f-8ecd-4ee8-8bc8-695f78288b08_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of cases with set trial dates</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Cases With Set Trial Dates</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Cases With Set Trial Dates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCasesWithSetTrialDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:to="lab_mo_LossContingencyNumberOfCasesWithSetTrialDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_e530fb40-47e8-4c88-b6d8-f16763f7bcf5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid on common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5ff44689-9e52-4609-af5c-6f3aa3d6637c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_177f6532-0dea-4325-942e-cf96772c68f4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit line available under the agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsMember_75316f94-bd27-4715-ab00-65c51499b0db_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember" xlink:to="lab_mo_HealthCareCostRecoveryActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ac6443a8-0fb7-4db5-b7a5-d9eb4fd26841_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_5ed0ceb2-9c63-4622-83fc-41180d3c58e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_fc5e8d27-8895-4644-b527-31f351c86ba3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_20f0f10f-e124-4934-9efd-21ed9fe8b271_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories:</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_3bdb7b6d-3cec-4924-9005-c3ed15cad65b_terseLabel_en-US" xlink:label="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABI [Member]</link:label>
    <link:label id="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_label_en-US" xlink:label="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Equity Method Investments Attributable To Parent [Member]</link:label>
    <link:label id="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_documentation_en-US" xlink:label="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Equity Method Investments Attributable To Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:href="mo-20230331.xsd#mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:to="lab_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClaimsDecidedFavorableNumber_373b7b49-c2e0-4290-a74c-d3cab0e8abe4_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of favorable verdicts</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecidedFavorableNumber_label_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided Favorable, Number</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecidedFavorableNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided Favorable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedFavorableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:to="lab_mo_LossContingencyClaimsDecidedFavorableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_825f4aa9-ec3b-46bb-adc0-69cea460cea3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount_e24102fe-7dd6-41b3-a8d4-4fcd671b988a_terseLabel_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to valuation allowance charged to income tax expense</link:label>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount_label_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase In Amount</link:label>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount_documentation_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase In Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:to="lab_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c512799-d399-43a7-b3ab-97914667f55b_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_8e7f8546-2499-4647-bf0a-03a263e7120c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1d8289bb-b9d1-40d2-b193-805c8f412f60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits_837bc18d-788c-497d-9201-aee3d211671c_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of inactive class action lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Inactive Class Action Lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Inactive Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:to="lab_mo_LossContingencyNumberOfInactiveClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_abd0d768-8d17-4f76-b5a3-0647aaa70396_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_74d2bd50-6bc7-4bc7-94c6-a611d1ca748a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_d8a51dec-43d2-464d-811c-a26f17d5fad7_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2021 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2021 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2021 NPM Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_cdcc615a-2406-4d7d-abd1-d1e2dc081c22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4d329ee0-da40-4f8d-9724-d773013f1041_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationSettlementEstimateofPossibleGain_f2c8281b-2d9f-47ad-904d-13f151a5411b_terseLabel_en-US" xlink:label="lab_mo_LitigationSettlementEstimateofPossibleGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible gain</link:label>
    <link:label id="lab_mo_LitigationSettlementEstimateofPossibleGain_label_en-US" xlink:label="lab_mo_LitigationSettlementEstimateofPossibleGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Estimate of Possible Gain</link:label>
    <link:label id="lab_mo_LitigationSettlementEstimateofPossibleGain_documentation_en-US" xlink:label="lab_mo_LitigationSettlementEstimateofPossibleGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Estimate of Possible Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementEstimateofPossibleGain" xlink:href="mo-20230331.xsd#mo_LitigationSettlementEstimateofPossibleGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationSettlementEstimateofPossibleGain" xlink:to="lab_mo_LitigationSettlementEstimateofPossibleGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a5d15a18-3d13-42e7-a277-412bf2ede762_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d1cd0595-12ff-40cf-ac9e-e403f09460ca_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_77e13e45-9678-4609-83d6-3703e535d353_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (income)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_1ac34b5b-d8f4-481c-9c05-7de8d4435d87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ce7fcb38-67cf-46c9-9fc9-6ca53bbd985d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost of shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a409dbd7-03df-4782-ba6f-dc4cdbfc32c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ebc58844-deb8-4a1b-a3d4-911a3f60e0e4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AltriaGroupMember_394937e1-3238-4b5c-a25d-b1a28f16e48b_terseLabel_en-US" xlink:label="lab_mo_AltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altria Group [Member]</link:label>
    <link:label id="lab_mo_AltriaGroupMember_label_en-US" xlink:label="lab_mo_AltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altria Group [Member]</link:label>
    <link:label id="lab_mo_AltriaGroupMember_documentation_en-US" xlink:label="lab_mo_AltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altria Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AltriaGroupMember" xlink:href="mo-20230331.xsd#mo_AltriaGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AltriaGroupMember" xlink:to="lab_mo_AltriaGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c656a9c5-ed27-4293-84ac-ae3230c4d29c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_375a6cd0-2f5e-4c39-b2c1-a3a6d801dae7_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfComplaints_a002bc50-e39b-460d-93f4-43794ebc90f8_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfComplaints" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of complaints</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfComplaints_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfComplaints" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfComplaints_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfComplaints" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfComplaints" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfComplaints"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfComplaints" xlink:to="lab_mo_LossContingencyNumberOfComplaints" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_c4354a24-c3b1-489b-a361-4b89aea85a24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_36e18a46-924c-460f-b97c-5f258ad1c957_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:to="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8f05dd15-1a63-4380-a575-8ac2bddfda8e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesChadwellMember_88ce92cb-46de-4af0-ad8f-8ba0865f393a_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesChadwellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Chadwell [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesChadwellMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesChadwellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Chadwell [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesChadwellMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesChadwellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Chadwell [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesChadwellMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesChadwellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesChadwellMember" xlink:to="lab_mo_EngleProgenyCasesChadwellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_db211e57-3616-4e7e-a68b-01935a1e5fd7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_13b9267d-1c95-4c7e-8ba4-d3fa872dc303_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_2543d919-db07-48cd-bfa7-78b965ed4b46_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Virginia [Member]</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_617ed645-0f21-4281-83f0-c935439b2a3f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_09b4e52c-f865-4e44-884b-7050ec344122_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_067d03bf-a7f6-4e63-91ca-ba589983b936_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states in compliance with escrow statues</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Compliance With Escrow Statues</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Compliance With Escrow Statues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:to="lab_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesHollimanMember_d47c43c3-9beb-4130-8a0e-724473a18441_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesHollimanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Holliman [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesHollimanMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesHollimanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Holliman [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesHollimanMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesHollimanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Holliman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHollimanMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHollimanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesHollimanMember" xlink:to="lab_mo_EngleProgenyCasesHollimanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_95c0637b-4c89-448e-b72e-09f4729c3630_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, difference between carrying amount and fair value</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_13b81713-7478-406c-84fb-03e184392b36_negatedLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, difference between carrying amount and fair value</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Fair Value</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:to="lab_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofCasesSetforTrial_7b8bd9a7-5e6d-44af-bd78-395f60753eb7_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofCasesSetforTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases set for trial</link:label>
    <link:label id="lab_mo_LossContingencyNumberofCasesSetforTrial_label_en-US" xlink:label="lab_mo_LossContingencyNumberofCasesSetforTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Cases Set for Trial</link:label>
    <link:label id="lab_mo_LossContingencyNumberofCasesSetforTrial_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofCasesSetforTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Cases Set for Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofCasesSetforTrial" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofCasesSetforTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofCasesSetforTrial" xlink:to="lab_mo_LossContingencyNumberofCasesSetforTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_81a9be2b-723f-49bd-97e9-180b741be382_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyStateCourtsNumber_d5298b34-d579-4d0a-b4aa-7806151b5344_terseLabel_en-US" xlink:label="lab_mo_LossContingencyStateCourtsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of state courts</link:label>
    <link:label id="lab_mo_LossContingencyStateCourtsNumber_label_en-US" xlink:label="lab_mo_LossContingencyStateCourtsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, State Courts, Number</link:label>
    <link:label id="lab_mo_LossContingencyStateCourtsNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyStateCourtsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, State Courts, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyStateCourtsNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyStateCourtsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyStateCourtsNumber" xlink:to="lab_mo_LossContingencyStateCourtsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationCasesResultsMember_d5d27151-26f1-464a-b9f0-2c30a0c21e64_terseLabel_en-US" xlink:label="lab_mo_LitigationCasesResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health and Certain Other Litigation [Member]</link:label>
    <link:label id="lab_mo_LitigationCasesResultsMember_label_en-US" xlink:label="lab_mo_LitigationCasesResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Cases Results [Member]</link:label>
    <link:label id="lab_mo_LitigationCasesResultsMember_documentation_en-US" xlink:label="lab_mo_LitigationCasesResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Cases Results [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationCasesResultsMember" xlink:href="mo-20230331.xsd#mo_LitigationCasesResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationCasesResultsMember" xlink:to="lab_mo_LitigationCasesResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PeriodOneMember_d2cd7717-b88a-4899-99d2-4f16eb83ebfc_terseLabel_en-US" xlink:label="lab_mo_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_mo_PeriodOneMember_label_en-US" xlink:label="lab_mo_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One [Member]</link:label>
    <link:label id="lab_mo_PeriodOneMember_documentation_en-US" xlink:label="lab_mo_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodOneMember" xlink:href="mo-20230331.xsd#mo_PeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PeriodOneMember" xlink:to="lab_mo_PeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_38aefcc7-5106-4899-89ad-b95dfe5d77f5_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a8bed08b-2d0c-4764-bbd4-59debdf47c34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_01c3d553-7165-41ce-98a9-9f7651bdb2d9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_82148e17-bd80-4163-9ee1-5cd561c3f0f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtMember_bb0da2ff-b8f0-4dd2-975b-ee1e6f96ad4e_verboseLabel_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency denominated debt [Member]</link:label>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtMember_c5140d5e-90fb-427e-9a30-045669365938_terseLabel_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtMember" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_mo_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AmountAwardedtoOtherParty_c0eb8ea0-68c9-4521-a3b1-31654267d904_terseLabel_en-US" xlink:label="lab_mo_AmountAwardedtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded to other party</link:label>
    <link:label id="lab_mo_AmountAwardedtoOtherParty_label_en-US" xlink:label="lab_mo_AmountAwardedtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Awarded to Other Party</link:label>
    <link:label id="lab_mo_AmountAwardedtoOtherParty_documentation_en-US" xlink:label="lab_mo_AmountAwardedtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AmountAwardedtoOtherParty" xlink:href="mo-20230331.xsd#mo_AmountAwardedtoOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AmountAwardedtoOtherParty" xlink:to="lab_mo_AmountAwardedtoOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66334463-2d94-4d3c-9870-046327576a50_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive earnings (losses), net of deferred income taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_a38f5450-1626-463c-b2f5-c3905d918c8a_terseLabel_en-US" xlink:label="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims, consolidated for pre-trial purposes</link:label>
    <link:label id="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_label_en-US" xlink:label="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number</link:label>
    <link:label id="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:to="lab_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c4cf9d4-997a-4bb9-9320-21e0012875d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettled_1fc88db2-cb10-436d-9abe-6268bbb9319b_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states not settled</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettled_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not Settled</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettled_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettled" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfStatesNotSettled" xlink:to="lab_mo_LossContingencyNumberOfStatesNotSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfPendingCasesConsolidated_74677823-239d-46d9-96b4-5778dca47cd0_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of pending cases consolidated</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfPendingCasesConsolidated_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Pending Cases Consolidated</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfPendingCasesConsolidated_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Pending Cases Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfPendingCasesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:to="lab_mo_LossContingencyNumberOfPendingCasesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ValuationAllowanceRollforwardRollForward_4587aebd-56d7-4b3b-8a6f-d6b78d2385f3_terseLabel_en-US" xlink:label="lab_mo_ValuationAllowanceRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Rollforward [Roll Forward]</link:label>
    <link:label id="lab_mo_ValuationAllowanceRollforwardRollForward_label_en-US" xlink:label="lab_mo_ValuationAllowanceRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Rollforward [Roll Forward]</link:label>
    <link:label id="lab_mo_ValuationAllowanceRollforwardRollForward_documentation_en-US" xlink:label="lab_mo_ValuationAllowanceRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Rollforward [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceRollforwardRollForward" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward" xlink:to="lab_mo_ValuationAllowanceRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_15c31d29-64ca-4427-8f12-f9145ad5b110_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit income, excluding service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_80199c28-48bb-4c9b-882f-33bfd47986ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_5d4001b5-a583-449d-bfed-90dd79de3c27_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables:</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_f0907195-612c-4597-b955-2b119e8888b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated additional employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesD.BrownMember_2266d3f6-0419-4ee1-9464-845fd85fab28_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesD.BrownMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, D. Brown [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesD.BrownMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesD.BrownMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, D. Brown [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesD.BrownMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesD.BrownMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, D. Brown [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesD.BrownMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesD.BrownMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesD.BrownMember" xlink:to="lab_mo_EngleProgenyCasesD.BrownMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond_f4381518-3861-46ca-946c-97d4b50d4902_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states that cap bond or require no bond</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond_label_en-US" xlink:label="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States That Cap Bond or Require No Bond</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States That Cap Bond or Require No Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:to="lab_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_IQOSMember_e6ee6e8d-a05a-43ee-b0fd-4bc37ac8157f_terseLabel_en-US" xlink:label="lab_mo_IQOSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IQOS [Member]</link:label>
    <link:label id="lab_mo_IQOSMember_label_en-US" xlink:label="lab_mo_IQOSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IQOS [Member]</link:label>
    <link:label id="lab_mo_IQOSMember_documentation_en-US" xlink:label="lab_mo_IQOSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IQOS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IQOSMember" xlink:href="mo-20230331.xsd#mo_IQOSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_IQOSMember" xlink:to="lab_mo_IQOSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_817ddc7a-1334-45b7-9176-96e78ef958e5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_cbafcf27-5b5c-4929-94ea-08cc79f5776f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_010c55a1-87e4-4b2e-ae72-de21ded530ad_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of additional states extended with settled litigation</link:label>
    <link:label id="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_label_en-US" xlink:label="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Additional States Extended with Settled Litigation</link:label>
    <link:label id="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Additional States Extended with Settled Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:to="lab_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_22737a39-1b2d-43f3-a2bf-4934a4f13d7d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_19828909-836c-4c3d-b6c0-402e346df40a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ea0abcf3-3d3f-42c1-a246-201f35914349_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember_bb6eaeb7-c10f-4023-b4e4-068a2c9f7543_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Kaplan [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Kaplan (McLauighlin) [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Kaplan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesKaplanMcLauighlinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:to="lab_mo_EngleProgenyCasesKaplanMcLauighlinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_95f85ce5-f75d-49d3-89c4-e3d4c75d80b4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_28fdf82a-6f8e-49fa-92ef-d2d94e8f0dcb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f98dddf3-5da8-4965-9cd3-c33f83695892_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_b675a43d-68ab-42cd-bb71-f784addff54b_terseLabel_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Woodley [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_label_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Woodley [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_documentation_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Woodley</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:to="lab_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_95bc27e8-ee8a-4a20-8753-b9182faf4457_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_60a39b2f-bc52-4c28-ac87-021a26b2bcae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_725a762c-512a-41bc-af62-fb94dc9106a5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_58a16e06-1812-45d6-ba39-f49de0c7ffbd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3343d59e-c509-4d02-95f4-aaac04f416ce_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesStateMember_b62c8674-2892-401a-b244-84c1d7a0a282_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, State [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesStateMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, State [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesStateMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, State [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesStateMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesStateMember" xlink:to="lab_mo_EngleProgenyCasesStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofManufacturers_e5cd448e-93d8-4cd7-8689-6d7559d0af83_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of manufacturers</link:label>
    <link:label id="lab_mo_LossContingencyNumberofManufacturers_label_en-US" xlink:label="lab_mo_LossContingencyNumberofManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Manufacturers</link:label>
    <link:label id="lab_mo_LossContingencyNumberofManufacturers_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofManufacturers" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofManufacturers" xlink:to="lab_mo_LossContingencyNumberofManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3df9faf5-ea12-4f94-af29-1d034441b8be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_97ee9678-623e-48b7-92ee-8ce32024cfad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostOfOperatingRevenue_d1c35a05-4af1-4c19-891c-ccb5a6386642_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excise taxes on products</link:label>
    <link:label id="lab_us-gaap_OtherCostOfOperatingRevenue_label_en-US" xlink:label="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost of Operating Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostOfOperatingRevenue" xlink:to="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_3dd8df4e-cfb6-4420-9e64-ce8ca4c47a67_terseLabel_en-US" xlink:label="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred gain from the sale of IQOS System commercialization rights</link:label>
    <link:label id="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_label_en-US" xlink:label="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain On Sale Of Commercialization Rights, Noncurrent</link:label>
    <link:label id="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_documentation_en-US" xlink:label="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain On Sale Of Commercialization Rights, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:href="mo-20230331.xsd#mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:to="lab_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CreditAgreementMember_13f87611-7dac-40be-82b4-6f9ce2a18d58_terseLabel_en-US" xlink:label="lab_mo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_mo_CreditAgreementMember_label_en-US" xlink:label="lab_mo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_mo_CreditAgreementMember_documentation_en-US" xlink:label="lab_mo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CreditAgreementMember" xlink:href="mo-20230331.xsd#mo_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CreditAgreementMember" xlink:to="lab_mo_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e01daeee-6442-4ee6-b115-58c27fd754a9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_6bf91f8f-b602-461e-b207-db948f27a35a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_35ab1a64-cc44-419e-8ea9-106d41588a54_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CommonStock3.125NotesDue2031Member_22324ba0-5e16-4fb8-9061-f839a26a9d5e_terseLabel_en-US" xlink:label="lab_mo_CommonStock3.125NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% Notes due 2031 [Member]</link:label>
    <link:label id="lab_mo_CommonStock3.125NotesDue2031Member_label_en-US" xlink:label="lab_mo_CommonStock3.125NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 3.125% Notes Due 2031 [Member]</link:label>
    <link:label id="lab_mo_CommonStock3.125NotesDue2031Member_documentation_en-US" xlink:label="lab_mo_CommonStock3.125NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 3.125% Notes Due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock3.125NotesDue2031Member" xlink:href="mo-20230331.xsd#mo_CommonStock3.125NotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CommonStock3.125NotesDue2031Member" xlink:to="lab_mo_CommonStock3.125NotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_07d2c21f-ba9a-43f0-a0d7-eb5a2b7c9136_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f60bcb2b-22d5-40b5-a618-051c35e0f986_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_2e005d46-1df9-4f9b-8521-ee3e4235cd57_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_af2bbc59-0a08-4f12-a776-60dfdc3c516f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_a6893909-0f3f-4a5f-b259-4330b14f388c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_1ff5a84f-2b1f-4313-bfb2-429818ce27fe_terseLabel_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Fontaine [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_label_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Fontaine [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_documentation_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Fontaine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseFontaineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:to="lab_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_48a12ace-8ac9-4bbb-9328-bbc5ce849b5d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_36df1f67-9e97-454a-b8b0-df84a3466cc9_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2020 NPM Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_ffbc6d21-0f97-4413-9cc9-c3b91de00974_terseLabel_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Mendez [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_label_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Mendez [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_documentation_en-US" xlink:label="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking And Health Case, Mendez</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseMendezMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:to="lab_mo_NonEngleProgenySmokingAndHealthCaseMendezMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_JUULMember_f7b552af-65b5-40a5-8bea-9740a5440a39_terseLabel_en-US" xlink:label="lab_mo_JUULMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JUUL [Member]</link:label>
    <link:label id="lab_mo_JUULMember_label_en-US" xlink:label="lab_mo_JUULMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JUUL [Member]</link:label>
    <link:label id="lab_mo_JUULMember_documentation_en-US" xlink:label="lab_mo_JUULMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JUUL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_JUULMember" xlink:to="lab_mo_JUULMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember_24353543-b414-47e2-91d9-372dfd2a5c56_terseLabel_en-US" xlink:label="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State Shareholder Derivative Lawsuits [Member]</link:label>
    <link:label id="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember_label_en-US" xlink:label="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State Shareholder Derivative Lawsuits [Member]</link:label>
    <link:label id="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember_documentation_en-US" xlink:label="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State Shareholder Derivative Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:href="mo-20230331.xsd#mo_FederalAndStateShareholderDerivativeLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:to="lab_mo_FederalAndStateShareholderDerivativeLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClassNotCertifiedNumber_a22f603c-5bdf-4b6f-bac7-cf81b6f31fb4_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClassNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class not certified</link:label>
    <link:label id="lab_mo_LossContingencyClassNotCertifiedNumber_label_en-US" xlink:label="lab_mo_LossContingencyClassNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Not Certified, Number</link:label>
    <link:label id="lab_mo_LossContingencyClassNotCertifiedNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyClassNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Not Certified, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassNotCertifiedNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyClassNotCertifiedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClassNotCertifiedNumber" xlink:to="lab_mo_LossContingencyClassNotCertifiedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b0332d08-2de8-440a-ad47-1cc045c82448_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e119dad9-7006-42b3-8f06-a6128d790771_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a1b99fdf-3401-4328-8a03-24b7184d0091_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6f7a6450-f66c-43ea-a62d-239101bcc243_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_db6c62a0-ff48-454f-ae54-3cc03a1e146a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share data:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_754b6c22-0324-4acc-bf51-7e8985e8962a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, credits to offset payments</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_be882e6f-4f7a-4160-90b4-6f12bfcb66d8_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount ordered to be paid from other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7550f947-da9d-4f0f-b1b3-0ee014d8f776_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CanadianTobaccoManufacturersMember_81e1474c-4c53-44ab-b465-a4d0b7dd64b8_terseLabel_en-US" xlink:label="lab_mo_CanadianTobaccoManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Tobacco Manufacturers [Member]</link:label>
    <link:label id="lab_mo_CanadianTobaccoManufacturersMember_label_en-US" xlink:label="lab_mo_CanadianTobaccoManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Tobacco Manufacturers [Member]</link:label>
    <link:label id="lab_mo_CanadianTobaccoManufacturersMember_documentation_en-US" xlink:label="lab_mo_CanadianTobaccoManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Tobacco Manufacturers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CanadianTobaccoManufacturersMember" xlink:href="mo-20230331.xsd#mo_CanadianTobaccoManufacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CanadianTobaccoManufacturersMember" xlink:to="lab_mo_CanadianTobaccoManufacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5540681d-9747-4b52-ac85-6c314a745a34_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, plan assets, contributions by employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ArbitrationPeriodDomain_f7b6bf5f-e48f-4d95-b389-acfedec1437f_terseLabel_en-US" xlink:label="lab_mo_ArbitrationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period [Domain]</link:label>
    <link:label id="lab_mo_ArbitrationPeriodDomain_label_en-US" xlink:label="lab_mo_ArbitrationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period [Domain]</link:label>
    <link:label id="lab_mo_ArbitrationPeriodDomain_documentation_en-US" xlink:label="lab_mo_ArbitrationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodDomain" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ArbitrationPeriodDomain" xlink:to="lab_mo_ArbitrationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_InvestmentsTable_91f647d1-24cd-4bbb-94a3-a4b11cdd5d8e_terseLabel_en-US" xlink:label="lab_mo_InvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Table]</link:label>
    <link:label id="lab_mo_InvestmentsTable_label_en-US" xlink:label="lab_mo_InvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Table]</link:label>
    <link:label id="lab_mo_InvestmentsTable_documentation_en-US" xlink:label="lab_mo_InvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_InvestmentsTable" xlink:to="lab_mo_InvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_25842c05-5849-412b-a735-d8d18a83bf38_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7530877b-f070-43e6-9a99-012ccd0fb1bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_dd8f55ba-8025-4852-8ae4-61a711cbee1f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember_bff1a650-a69a-40a5-a109-d779d587f1bd_terseLabel_en-US" xlink:label="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disputes Under the State Settlement Agreements [Member]</link:label>
    <link:label id="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember_label_en-US" xlink:label="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disputes Under the State Settlement Agreements [Member]</link:label>
    <link:label id="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember_documentation_en-US" xlink:label="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disputes Under the State Settlement Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:href="mo-20230331.xsd#mo_OtherDisputesUndertheStateSettlementAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:to="lab_mo_OtherDisputesUndertheStateSettlementAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0b7c8bdb-e8fb-473a-b58f-97228768f492_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned share repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentImpairment_474d64e3-6a6e-4d2c-8110-6fe496c70b6e_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, impairment</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentImpairment_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Impairment</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentImpairment_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentImpairment" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentImpairment" xlink:to="lab_mo_EquityMethodInvestmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_cb63bbac-ca7b-406d-9789-5e5471b40910_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unused borrowing capacity, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_2c23e799-7603-45b4-a5bb-c8ca9cb000c4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember_52164414-c8e2-48e1-b4e1-76613f0cc70a_terseLabel_en-US" xlink:label="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Secured Overnight Financing Rate ("Term SOFR") [Member]</link:label>
    <link:label id="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember_label_en-US" xlink:label="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Secured Overnight Financing Rate ("Term SOFR") [Member]</link:label>
    <link:label id="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember_documentation_en-US" xlink:label="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Secured Overnight Financing Rate ("Term SOFR")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:href="mo-20230331.xsd#mo_TermSecuredOvernightFinancingRateTermSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:to="lab_mo_TermSecuredOvernightFinancingRateTermSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d126468-ca4d-47ba-9f11-f332eeabac8a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14306336-a012-4c03-99ba-16f5ab9333c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4e63f235-a121-4012-bcfc-5af596cf737f_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_d3373a25-fdca-4405-9e97-3c37a3199a78_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_b09bf22f-64df-44f0-8b03-eade2af60a5b_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2019-2021 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2019-2021 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2019-2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20192021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:to="lab_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_39afa748-ee02-4302-86be-0b0418da23ca_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_15eb7d01-dc6d-4f8a-a202-1eacd317995a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Losses) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_42ee61d6-cebd-4e2e-ab53-dfea61ff3d4d_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fe8036e7-dca5-4504-9adb-8dfd4adfe853_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_0403f2ff-be82-44ce-9b0a-906c26b14520_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2022 NPM Adjustments</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2022 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2022 NPM Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AR_df58b516-da25-4eac-94ab-c52dd955856f_terseLabel_en-US" xlink:label="lab_stpr_AR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arkansas [Member]</link:label>
    <link:label id="lab_stpr_AR_label_en-US" xlink:label="lab_stpr_AR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARKANSAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AR" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AR" xlink:to="lab_stpr_AR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_41481129-0f82-4f48-9bcb-fe3e14d8a6a5_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (income) loss, net investment hedge, (gain) loss, before reclassification and tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AK_b5928bb0-a470-4134-9263-95072c621c48_terseLabel_en-US" xlink:label="lab_stpr_AK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alaska [Member]</link:label>
    <link:label id="lab_stpr_AK_label_en-US" xlink:label="lab_stpr_AK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALASKA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AK" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AK" xlink:to="lab_stpr_AK" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_58f29890-00f5-495f-b6e8-f5fb2dbcd944_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8fe4a01b-cd29-425e-acc9-72ae6e7a3fe7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e409ddc0-1688-4ea3-aa2a-9e75cd2ad806_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_7a2364b6-de31-47ad-8db9-c1c713618a73_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_402533c1-db6b-4d2b-93a6-f93983552be8_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6151a8ac-a9db-4fde-8fad-325a75457b31_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock_75a88d2a-e292-4d1a-b526-5fd821f09025_terseLabel_en-US" xlink:label="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Deferred Revenue</link:label>
    <link:label id="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock_label_en-US" xlink:label="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Deferred Revenue [Policy Text Block]</link:label>
    <link:label id="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:href="mo-20230331.xsd#mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:to="lab_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyVerdictsUpheld_4a1df6bb-da8c-43e4-8f0f-94c96c784bdc_terseLabel_en-US" xlink:label="lab_mo_LossContingencyVerdictsUpheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of verdicts upheld</link:label>
    <link:label id="lab_mo_LossContingencyVerdictsUpheld_label_en-US" xlink:label="lab_mo_LossContingencyVerdictsUpheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Verdicts Upheld</link:label>
    <link:label id="lab_mo_LossContingencyVerdictsUpheld_documentation_en-US" xlink:label="lab_mo_LossContingencyVerdictsUpheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Verdicts Upheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictsUpheld" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictsUpheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyVerdictsUpheld" xlink:to="lab_mo_LossContingencyVerdictsUpheld" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LightsMember_4dade1bc-1ecc-4c1c-a506-bb9376508ce3_terseLabel_en-US" xlink:label="lab_mo_LightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lights [Member]</link:label>
    <link:label id="lab_mo_LightsMember_label_en-US" xlink:label="lab_mo_LightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lights [Member]</link:label>
    <link:label id="lab_mo_LightsMember_documentation_en-US" xlink:label="lab_mo_LightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LightsMember" xlink:href="mo-20230331.xsd#mo_LightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LightsMember" xlink:to="lab_mo_LightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8d2e3098-284d-4f16-84b8-0f3004d0189a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Translation Adjustments and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d2981315-20ce-4b2a-8533-eee9cbf31bf8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesMillerMember_28116c6d-f5b6-4ec9-9324-488d3cff73f7_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesMillerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Miller [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMillerMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesMillerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Miller [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMillerMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesMillerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Miller</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMillerMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMillerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesMillerMember" xlink:to="lab_mo_EngleProgenyCasesMillerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c0967ce9-2674-481c-9422-8c5b9ef6aa2d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_3d92289b-74cc-4e80-b2be-84744f34cbcc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTerm_d37a66c2-a5c4-46b9-807d-09dbcaa5afcc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTerm_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67e660be-fcd2-4cf1-9c09-788b2bd137e2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba1e5afc-3340-4f9f-a4cf-581d4ce0c777_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_316c5864-c343-41b8-a132-0b97217f8336_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_b115ce58-979e-40a5-a71f-0230baf6f51a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_JTIUHMember_5b3153e8-58ec-4270-8e3d-63885fc1d0c8_terseLabel_en-US" xlink:label="lab_mo_JTIUHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JTIUH [Member]</link:label>
    <link:label id="lab_mo_JTIUHMember_label_en-US" xlink:label="lab_mo_JTIUHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JTIUH [Member]</link:label>
    <link:label id="lab_mo_JTIUHMember_documentation_en-US" xlink:label="lab_mo_JTIUHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JTIUH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JTIUHMember" xlink:href="mo-20230331.xsd#mo_JTIUHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_JTIUHMember" xlink:to="lab_mo_JTIUHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bed273ad-1bad-44c6-8178-0e428f0ffdf0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_IncreaseDecreaseInSettlementPayable_4adf1d2b-67fd-44f1-b95b-cf7ffda1276f_terseLabel_en-US" xlink:label="lab_mo_IncreaseDecreaseInSettlementPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued settlement charges</link:label>
    <link:label id="lab_mo_IncreaseDecreaseInSettlementPayable_label_en-US" xlink:label="lab_mo_IncreaseDecreaseInSettlementPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Settlement Payable</link:label>
    <link:label id="lab_mo_IncreaseDecreaseInSettlementPayable_documentation_en-US" xlink:label="lab_mo_IncreaseDecreaseInSettlementPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the period in Settlement payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncreaseDecreaseInSettlementPayable" xlink:href="mo-20230331.xsd#mo_IncreaseDecreaseInSettlementPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_IncreaseDecreaseInSettlementPayable" xlink:to="lab_mo_IncreaseDecreaseInSettlementPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_33bdf3d5-b7e5-4204-af78-1026d60ee2c3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyRoyaltyFeePercentage_c6742dcf-e784-4424-ab75-aa2cce612282_terseLabel_en-US" xlink:label="lab_mo_LossContingencyRoyaltyFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Fee Percentage</link:label>
    <link:label id="lab_mo_LossContingencyRoyaltyFeePercentage_label_en-US" xlink:label="lab_mo_LossContingencyRoyaltyFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Fee Percentage</link:label>
    <link:label id="lab_mo_LossContingencyRoyaltyFeePercentage_documentation_en-US" xlink:label="lab_mo_LossContingencyRoyaltyFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyRoyaltyFeePercentage" xlink:href="mo-20230331.xsd#mo_LossContingencyRoyaltyFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyRoyaltyFeePercentage" xlink:to="lab_mo_LossContingencyRoyaltyFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c009f25f-d41e-494e-b70c-fcc8011d0413_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bfb1794f-b3c5-4c86-9a0b-2dab42b1f859_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesCooperMember_f966e934-b7eb-4f7e-b7cc-9865fd625088_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesCooperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cooper [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesCooperMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesCooperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cooper [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesCooperMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesCooperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cooper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCooperMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCooperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesCooperMember" xlink:to="lab_mo_EngleProgenyCasesCooperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_InterestAndOtherDebtExpenseNetMember_8fd995b0-7272-4987-9213-33203e5bf58a_terseLabel_en-US" xlink:label="lab_mo_InterestAndOtherDebtExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other debt expense, net [Member]</link:label>
    <link:label id="lab_mo_InterestAndOtherDebtExpenseNetMember_label_en-US" xlink:label="lab_mo_InterestAndOtherDebtExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Debt Expense, Net [Member]</link:label>
    <link:label id="lab_mo_InterestAndOtherDebtExpenseNetMember_documentation_en-US" xlink:label="lab_mo_InterestAndOtherDebtExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Debt Expense, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestAndOtherDebtExpenseNetMember" xlink:href="mo-20230331.xsd#mo_InterestAndOtherDebtExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_InterestAndOtherDebtExpenseNetMember" xlink:to="lab_mo_InterestAndOtherDebtExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a0e75702-251a-4281-8b77-c16716be95bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_29ede340-f6ad-4895-b2f3-635fa96c9109_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cronos</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Including Fixed-Price Preemptive Rights</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Including Fixed-Price Preemptive Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:to="lab_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b76d39f0-4ffc-4008-8d18-1ae71b4987ec_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a0e4471e-03e9-4355-8285-a65083d45e97_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ImplementationofCorrectiveCommunicationsMember_09441103-9e13-4fdc-b872-593b6e709667_terseLabel_en-US" xlink:label="lab_mo_ImplementationofCorrectiveCommunicationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of Corrective Communications [Member]</link:label>
    <link:label id="lab_mo_ImplementationofCorrectiveCommunicationsMember_label_en-US" xlink:label="lab_mo_ImplementationofCorrectiveCommunicationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of Corrective Communications [Member]</link:label>
    <link:label id="lab_mo_ImplementationofCorrectiveCommunicationsMember_documentation_en-US" xlink:label="lab_mo_ImplementationofCorrectiveCommunicationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of Corrective Communications [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ImplementationofCorrectiveCommunicationsMember" xlink:href="mo-20230331.xsd#mo_ImplementationofCorrectiveCommunicationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ImplementationofCorrectiveCommunicationsMember" xlink:to="lab_mo_ImplementationofCorrectiveCommunicationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_09b03b50-e283-486c-99be-2cf4f81398f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_fe582842-acc1-4e4e-8c9d-c8eadd17d0b1_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_2e116f27-13f2-4965-895a-1255c69bced3_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fc0e7d6-152f-42e3-8eeb-568198c2c313_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6ab4d35a-d6cb-4286-87c0-633d98c36efd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bea3d082-90fb-4374-a3a1-2366df4d305e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AgreementToResolveShareholderClassActionMember_14d630a1-874b-444b-a07e-795326c53c0d_terseLabel_en-US" xlink:label="lab_mo_AgreementToResolveShareholderClassActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement To Resolve Shareholder Class Action</link:label>
    <link:label id="lab_mo_AgreementToResolveShareholderClassActionMember_label_en-US" xlink:label="lab_mo_AgreementToResolveShareholderClassActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement To Resolve Shareholder Class Action [Member]</link:label>
    <link:label id="lab_mo_AgreementToResolveShareholderClassActionMember_documentation_en-US" xlink:label="lab_mo_AgreementToResolveShareholderClassActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement To Resolve Shareholder Class Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AgreementToResolveShareholderClassActionMember" xlink:href="mo-20230331.xsd#mo_AgreementToResolveShareholderClassActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AgreementToResolveShareholderClassActionMember" xlink:to="lab_mo_AgreementToResolveShareholderClassActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3a0d2ba1-dc19-4830-a177-c9a19a4e9a0e_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share of shares repurchased (usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyPunitiveDamagesAwardedValue_1c72667d-805b-4ef5-b73f-e79703ba1b30_terseLabel_en-US" xlink:label="lab_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Punitive damages awarded</link:label>
    <link:label id="lab_mo_LossContingencyPunitiveDamagesAwardedValue_label_en-US" xlink:label="lab_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Punitive Damages Awarded, Value</link:label>
    <link:label id="lab_mo_LossContingencyPunitiveDamagesAwardedValue_documentation_en-US" xlink:label="lab_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Punitive Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:to="lab_mo_LossContingencyPunitiveDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_c9038ed2-7998-43fb-aae8-f65b578e1b4c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_afae60bf-1242-4284-bed3-c76885c9c33c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6c66290b-7279-4705-a84c-7d7138361f0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NumberOfThirdPartyLawsuits_cc5901eb-2964-40d4-b77c-5218f169b8da_terseLabel_en-US" xlink:label="lab_mo_NumberOfThirdPartyLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of third party lawsuits</link:label>
    <link:label id="lab_mo_NumberOfThirdPartyLawsuits_label_en-US" xlink:label="lab_mo_NumberOfThirdPartyLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Third Party Lawsuits</link:label>
    <link:label id="lab_mo_NumberOfThirdPartyLawsuits_documentation_en-US" xlink:label="lab_mo_NumberOfThirdPartyLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Third Party Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NumberOfThirdPartyLawsuits" xlink:href="mo-20230331.xsd#mo_NumberOfThirdPartyLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NumberOfThirdPartyLawsuits" xlink:to="lab_mo_NumberOfThirdPartyLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_ec8655c2-c514-41e6-bd62-84deebd964fc_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada [Member]</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityContractPreemptiveRIghtsMember_09a2f897-93d7-41ca-9afa-8df71ddb4eec_verboseLabel_en-US" xlink:label="lab_mo_EquityContractPreemptiveRIghtsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Preemptive Rights [Member]</link:label>
    <link:label id="lab_mo_EquityContractPreemptiveRIghtsMember_label_en-US" xlink:label="lab_mo_EquityContractPreemptiveRIghtsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Preemptive RIghts [Member]</link:label>
    <link:label id="lab_mo_EquityContractPreemptiveRIghtsMember_documentation_en-US" xlink:label="lab_mo_EquityContractPreemptiveRIghtsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Preemptive RIghts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractPreemptiveRIghtsMember" xlink:href="mo-20230331.xsd#mo_EquityContractPreemptiveRIghtsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityContractPreemptiveRIghtsMember" xlink:to="lab_mo_EquityContractPreemptiveRIghtsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_1d2ba7d6-d407-4378-9480-5da692f72e04_terseLabel_en-US" xlink:label="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount expected to be awarded from other party</link:label>
    <link:label id="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_label_en-US" xlink:label="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Expected To Be Awarded from Other Party</link:label>
    <link:label id="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_documentation_en-US" xlink:label="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Expected To Be Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:to="lab_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_IndividualSmokingAndHealthCasesMember_966f3d96-c214-4f85-8b2e-83636cd44a2d_terseLabel_en-US" xlink:label="lab_mo_IndividualSmokingAndHealthCasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Smoking and Health Cases [Member]</link:label>
    <link:label id="lab_mo_IndividualSmokingAndHealthCasesMember_label_en-US" xlink:label="lab_mo_IndividualSmokingAndHealthCasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Smoking And Health Cases [Member]</link:label>
    <link:label id="lab_mo_IndividualSmokingAndHealthCasesMember_documentation_en-US" xlink:label="lab_mo_IndividualSmokingAndHealthCasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Smoking and Health Cases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IndividualSmokingAndHealthCasesMember" xlink:href="mo-20230331.xsd#mo_IndividualSmokingAndHealthCasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_IndividualSmokingAndHealthCasesMember" xlink:to="lab_mo_IndividualSmokingAndHealthCasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_9d29de1b-9957-4cda-9f3f-de240705b3b2_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGlogerRintoulandDuignamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:to="lab_mo_EngleProgenyCasesGlogerRintoulandDuignamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_c64a6bfe-49b8-4daa-a147-ca61a500dccd_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior unsecured debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_44e231c6-03d7-4de3-a79a-c221fc401ee3_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_959ec7ee-a640-4e86-8446-a258fcaa8120_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_c1b455eb-a1ba-4bb6-bd59-d0e5a6486c76_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted shares owned (in shares)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number of Shares Owned, Restricted</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number of Shares Owned, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:to="lab_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9f807b10-b270-425f-ae4e-a762d9af3802_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_a93f354e-0c84-433c-9be2-0c97a12db622_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued postretirement health care costs</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f4247829-1818-4fdf-8c9e-a5904662d13e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClaimsNotCertifiedNumber_65f88f4c-7886-4247-9216-bb4b3b02d027_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClaimsNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims not certified, number</link:label>
    <link:label id="lab_mo_LossContingencyClaimsNotCertifiedNumber_label_en-US" xlink:label="lab_mo_LossContingencyClaimsNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Not Certified, Number</link:label>
    <link:label id="lab_mo_LossContingencyClaimsNotCertifiedNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyClaimsNotCertifiedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Not Certified, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsNotCertifiedNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsNotCertifiedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClaimsNotCertifiedNumber" xlink:to="lab_mo_LossContingencyClaimsNotCertifiedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ea184e4f-0af3-439c-920b-3ae80a6d6b80_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished product</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesFreemanAndHarrisMember_51051631-fb48-46b9-9adf-847fbbe2d508_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Freeman [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesFreemanAndHarrisMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Freeman And Harris [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesFreemanAndHarrisMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Freeman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesFreemanAndHarrisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:to="lab_mo_EngleProgenyCasesFreemanAndHarrisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2badac52-9975-4c9c-bc62-b17688e88d58_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ReceivableCommercializationRightsCurrent_4469b7bf-9e6d-454c-be46-6803622dbe93_terseLabel_en-US" xlink:label="lab_mo_ReceivableCommercializationRightsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from the sale of IQOS System commercialization rights</link:label>
    <link:label id="lab_mo_ReceivableCommercializationRightsCurrent_label_en-US" xlink:label="lab_mo_ReceivableCommercializationRightsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable, Commercialization Rights, Current</link:label>
    <link:label id="lab_mo_ReceivableCommercializationRightsCurrent_documentation_en-US" xlink:label="lab_mo_ReceivableCommercializationRightsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable, Commercialization Rights, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ReceivableCommercializationRightsCurrent" xlink:href="mo-20230331.xsd#mo_ReceivableCommercializationRightsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ReceivableCommercializationRightsCurrent" xlink:to="lab_mo_ReceivableCommercializationRightsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2f168db2-b5d8-4be8-88af-05816d8a0bce_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_efa17b6a-892d-4306-98d0-a0da0a13debe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5914c809-6b39-4d54-91d6-a8c3bb2657fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0ef4570-29e7-4efd-a421-ff3d30f4ffe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d4e4f005-c376-433b-bb31-545dbf8f614a_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to net earnings</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_aa1849c1-e59e-4f55-a97f-f698e1e3216e_negatedLabel_en-US" xlink:label="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Distributed and undistributed earnings attributable to share-based awards</link:label>
    <link:label id="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_label_en-US" xlink:label="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted</link:label>
    <link:label id="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_documentation_en-US" xlink:label="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:href="mo-20230331.xsd#mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:to="lab_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_863de816-ded1-441f-9e98-b156472c5482_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_e04dbc2d-08ab-49eb-bf12-0193e8f41953_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_0ad8fd2c-2746-456e-ab70-3777158044f7_netLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate expenses [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_7305d829-4611-43a2-bfc2-d9c8ec26238d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plans [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_January2021ShareRepurchaseProgramMember_e902b3ef-7ddc-43d2-bcb9-b2407d275f99_terseLabel_en-US" xlink:label="lab_mo_January2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_mo_January2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_mo_January2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_mo_January2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_mo_January2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2021ShareRepurchaseProgramMember" xlink:href="mo-20230331.xsd#mo_January2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_January2021ShareRepurchaseProgramMember" xlink:to="lab_mo_January2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesGarciaMember_38c9a3ef-81d0-4001-b9ee-45ff0a733654_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesGarciaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Garcia [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesGarciaMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesGarciaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Garcia [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesGarciaMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesGarciaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Garcia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGarciaMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGarciaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesGarciaMember" xlink:to="lab_mo_EngleProgenyCasesGarciaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyFaultAllocationPercentage_c179b5ee-7ba1-4000-9b97-0f5b3b6e199b_terseLabel_en-US" xlink:label="lab_mo_LossContingencyFaultAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, fault allocation percentage</link:label>
    <link:label id="lab_mo_LossContingencyFaultAllocationPercentage_label_en-US" xlink:label="lab_mo_LossContingencyFaultAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Fault Allocation Percentage</link:label>
    <link:label id="lab_mo_LossContingencyFaultAllocationPercentage_documentation_en-US" xlink:label="lab_mo_LossContingencyFaultAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Fault Allocation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyFaultAllocationPercentage" xlink:href="mo-20230331.xsd#mo_LossContingencyFaultAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyFaultAllocationPercentage" xlink:to="lab_mo_LossContingencyFaultAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_8aeb430b-1bf7-45a4-8ec7-750d337d76ef_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Repurchased Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_566425cb-a2ff-4cc8-9e6e-044422e2116c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b5b0dca5-7f25-490d-81f0-08025b1264c5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit) attributable to Altria</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ccab879e-6f52-47c7-81e5-87e7204d21ff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesMcCallMember_d77ab84c-7078-41ba-bd4a-5573dec0ab2e_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesMcCallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, McCall [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMcCallMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesMcCallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, McCall [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMcCallMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesMcCallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, McCall [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMcCallMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMcCallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesMcCallMember" xlink:to="lab_mo_EngleProgenyCasesMcCallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OtherInventoryRawMaterialsNetofReserves_aaf6c411-a8a3-4b15-905f-0678b3e3415e_terseLabel_en-US" xlink:label="lab_mo_OtherInventoryRawMaterialsNetofReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other raw materials</link:label>
    <link:label id="lab_mo_OtherInventoryRawMaterialsNetofReserves_label_en-US" xlink:label="lab_mo_OtherInventoryRawMaterialsNetofReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label id="lab_mo_OtherInventoryRawMaterialsNetofReserves_documentation_en-US" xlink:label="lab_mo_OtherInventoryRawMaterialsNetofReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherInventoryRawMaterialsNetofReserves" xlink:href="mo-20230331.xsd#mo_OtherInventoryRawMaterialsNetofReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OtherInventoryRawMaterialsNetofReserves" xlink:to="lab_mo_OtherInventoryRawMaterialsNetofReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ArbitrationPeriodAxis_ca0c85e6-77f3-4493-ad3b-cad3c0908d35_terseLabel_en-US" xlink:label="lab_mo_ArbitrationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period [Axis]</link:label>
    <link:label id="lab_mo_ArbitrationPeriodAxis_label_en-US" xlink:label="lab_mo_ArbitrationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period [Axis]</link:label>
    <link:label id="lab_mo_ArbitrationPeriodAxis_documentation_en-US" xlink:label="lab_mo_ArbitrationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodAxis" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ArbitrationPeriodAxis" xlink:to="lab_mo_ArbitrationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed_07210c15-8133-4caf-9165-7edf78c64615_terseLabel_en-US" xlink:label="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims with unfavorable verdicts pending/reversed</link:label>
    <link:label id="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed_label_en-US" xlink:label="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Unfavorable Verdicts Pending/Reversed</link:label>
    <link:label id="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed_documentation_en-US" xlink:label="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Unfavorable Verdicts Pending/Reversed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:href="mo-20230331.xsd#mo_LossContingencyUnfavorableVerdictsPendingReversed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:to="lab_mo_LossContingencyUnfavorableVerdictsPendingReversed" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_79313106-b413-45d3-b18e-c523b05bb24f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfCases_35e70db0-c41e-43df-b18a-fb388766e57d_verboseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfCases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfCases_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Cases</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfCases_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCases" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfCases" xlink:to="lab_mo_LossContingencyNumberOfCases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_04be9715-fb6f-4ddc-90d0-8939a8200543_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_147fa339-6d11-4e76-9c4e-2b8e9a6e0c5a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6aa1c18d-ef6f-4c74-b100-9a1f110bff39_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash effects of changes:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_19dcabc1-e63b-4dc5-8a2b-e0a4a99dda19_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Reinvested in the Business [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_72069f63-622b-4f80-b864-f180275825a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_668a1e60-9613-4d62-b514-be651ce0b5b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_a457e42b-861e-4f88-a1d0-c2aa42ad2814_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_f804f34a-cfce-4c59-9aec-59822b06c5e6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7a4580c3-e6fd-4f9e-a481-f33705157a29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5b806846-54ff-441d-a9c3-bd2dec7e98a1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_a2475db1-ff50-4b5d-9aa5-e80905faaa0b_terseLabel_en-US" xlink:label="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking and Health Case, Greene [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_label_en-US" xlink:label="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking and Health Case, Greene [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_documentation_en-US" xlink:label="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Engle Progeny Smoking and Health Case, Greene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingandHealthCaseGreeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:to="lab_mo_NonEngleProgenySmokingandHealthCaseGreeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9ba5b20c-69cc-45d2-b10e-10a3a93ba57b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ca5c7c91-308d-48c8-b1af-c4b9da8499a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_302d114c-9125-49ec-9ea9-5b4495542e19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves_75f1b73e-3f16-4cab-8589-e6307bee97c9_terseLabel_en-US" xlink:label="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaf tobacco</link:label>
    <link:label id="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves_label_en-US" xlink:label="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Plant Material, Net of Reserves</link:label>
    <link:label id="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves_documentation_en-US" xlink:label="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of products consisting of plant matter that is not used in the growth of plant goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:href="mo-20230331.xsd#mo_InventoryRawMaterialsPlantMaterialNetofReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:to="lab_mo_InventoryRawMaterialsPlantMaterialNetofReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b0e8ae9d-43d8-4bd6-8332-cf08137ecb05_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_3c7989dc-60ca-4687-a045-e41772e2eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_da0d1f5a-e2ca-4203-899d-8917faf67538_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_2c20cb38-50eb-4967-9f04-c65a508f2b06_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_a416bcf1-dd4a-48e7-b9ca-6c6d2fbb5781_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida [Member]</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_ba8fa307-5971-43ab-82c0-28d77d94b9a2_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states with settled litigation including New York, subsequent expansion</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_label_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States with Settled Litigation, Settlement One</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States with Settled Litigation, Settlement One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:to="lab_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyVerdictReversedNumber_f9aa76fd-61fb-4942-97f7-7ac371fbfec6_terseLabel_en-US" xlink:label="lab_mo_LossContingencyVerdictReversedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of verdicts reversed</link:label>
    <link:label id="lab_mo_LossContingencyVerdictReversedNumber_label_en-US" xlink:label="lab_mo_LossContingencyVerdictReversedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Verdict Reversed, Number</link:label>
    <link:label id="lab_mo_LossContingencyVerdictReversedNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyVerdictReversedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Verdict Reversed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictReversedNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictReversedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyVerdictReversedNumber" xlink:to="lab_mo_LossContingencyVerdictReversedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_1b2bb13a-7a4c-4597-9b46-35cf7b199357_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Repurchase Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_11c97ade-64b6-4ad3-8e45-e9461217ff99_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bc153da7-3ae4-460b-aa47-403d17fd46c8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2542493f-f800-410b-a2de-e4c6d4870408_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_a11f1eb3-122d-4c49-a4c9-45241eea54d2_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of shareholders filing class action lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:to="lab_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7db9d7a0-5f12-4628-b383-e44fc7d17e96_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8631a6bd-6740-4d7c-be15-b51c089f44c7_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings reinvested in the business</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_c3607568-411d-4470-be91-565773b52a9b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (1)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_616ab048-6ebb-43a4-999a-cee2517ca6a3_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f52ea139-5fa6-4345-96dc-bb82bf485a23_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_828e48de-5947-4ffb-aedd-a6660d749ba5_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_d86b7b62-c0c6-40ec-83d7-c27e10bcf08f_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_f18cfcf4-9ca7-4115-a694-5c71c92d4527_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_4017a888-542f-4d78-88d7-35b9646a99e5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ee8a209f-27b4-4225-bd00-45b574e4dc72_verboseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_30a1ca50-dbdc-4da5-983b-1b14cf37b412_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Connecticut [Member]</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_IncomeLossFromEquitySecurities_026fbb9e-e14b-4609-8ad1-662b4101774b_negatedTerseLabel_en-US" xlink:label="lab_mo_IncomeLossFromEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) losses from investments in equity securities</link:label>
    <link:label id="lab_mo_IncomeLossFromEquitySecurities_23d4d3ef-35a0-4b50-9cad-630a9add364f_negatedTotalLabel_en-US" xlink:label="lab_mo_IncomeLossFromEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) losses from investments in equity securities</link:label>
    <link:label id="lab_mo_IncomeLossFromEquitySecurities_label_en-US" xlink:label="lab_mo_IncomeLossFromEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Securities</link:label>
    <link:label id="lab_mo_IncomeLossFromEquitySecurities_documentation_en-US" xlink:label="lab_mo_IncomeLossFromEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_IncomeLossFromEquitySecurities" xlink:to="lab_mo_IncomeLossFromEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8f94321f-64af-4059-8d5d-bd03b2e8281f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4830446-2fc7-4aee-b2bd-96f45f595d03_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9d822673-1c48-4ec0-92ca-95dd84dee248_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OtherTabaccoRelatedCasesMember_6c35ad14-b32b-4e2d-af65-9aca7a8cbf58_terseLabel_en-US" xlink:label="lab_mo_OtherTabaccoRelatedCasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tabacco-Related Cases [Member]</link:label>
    <link:label id="lab_mo_OtherTabaccoRelatedCasesMember_label_en-US" xlink:label="lab_mo_OtherTabaccoRelatedCasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tabacco-Related Cases [Member]</link:label>
    <link:label id="lab_mo_OtherTabaccoRelatedCasesMember_documentation_en-US" xlink:label="lab_mo_OtherTabaccoRelatedCasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tabacco-Related Cases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherTabaccoRelatedCasesMember" xlink:href="mo-20230331.xsd#mo_OtherTabaccoRelatedCasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OtherTabaccoRelatedCasesMember" xlink:to="lab_mo_OtherTabaccoRelatedCasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9da2bec9-68ce-4717-8f08-f216bab484d2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e88fe63-2847-4a31-a4e3-70f2e0ab556d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_e8b467f0-046d-4247-a2c2-9e0e797c6eb3_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California [Member]</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_21d451f3-9a9c-4cd5-954a-85453850c8ed_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Guidance Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_dc6c9613-6d65-4369-b525-d9ac662f6464_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2effa6a9-c666-4903-9eb0-7778ce7c0c2f_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement, net</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9135f627-cceb-4752-841c-7bf4887f6bf6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Losses [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_f8c04966-9741-40bc-930a-9a019a3a07ae_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Earnings/Losses</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount_39f1691d-f7d4-4236-8a07-59eb8a97cb5c_negatedTerseLabel_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Releases to valuation allowance credited to income tax benefit</link:label>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount_label_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease In Amount</link:label>
    <link:label id="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount_documentation_en-US" xlink:label="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease In Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:to="lab_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3c953cee-75d5-4ed0-98ba-0fd2dfab8d05_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bf77bc71-e355-40b3-9ae9-87d08a98c8b4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsMember_374adae1-f434-4a14-aa2e-b5592c5eb703_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Member]</link:label>
    <link:label id="lab_us-gaap_AssetsMember_label_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsMember" xlink:to="lab_us-gaap_AssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_283e80bd-7cd2-4f42-90dd-869990535c20_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fecce51f-60b7-457e-af8a-4b1f2b5727e5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fb0bd0fa-6c83-42bb-8f34-7ac41a83b2e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_53d32719-4860-4e2d-9381-3788087bdea4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_ba94848a-edc9-4ed8-b6c7-09d684fc86d2_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPearsonDCohenCollarChaconMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:to="lab_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_773f50c4-86a4-4a1c-a312-6d12a93cb7a0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_51f28502-9284-402c-9aa5-ab5039457e28_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AccruedSettlementLiabilityCurrent_55df52eb-ff7f-4e4f-8d2b-828059cdd212_terseLabel_en-US" xlink:label="lab_mo_AccruedSettlementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement charges</link:label>
    <link:label id="lab_mo_AccruedSettlementLiabilityCurrent_label_en-US" xlink:label="lab_mo_AccruedSettlementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Settlement Liability, Current</link:label>
    <link:label id="lab_mo_AccruedSettlementLiabilityCurrent_documentation_en-US" xlink:label="lab_mo_AccruedSettlementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Settlement Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccruedSettlementLiabilityCurrent" xlink:href="mo-20230331.xsd#mo_AccruedSettlementLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AccruedSettlementLiabilityCurrent" xlink:to="lab_mo_AccruedSettlementLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_e78b299b-f73c-4206-ad34-54fbac0b419a_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_DE_351862a3-5e84-42fd-be68-6b3eca622a5d_terseLabel_en-US" xlink:label="lab_stpr_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delaware [Member]</link:label>
    <link:label id="lab_stpr_DE_label_en-US" xlink:label="lab_stpr_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DELAWARE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DE" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_DE" xlink:to="lab_stpr_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0c8a542f-c70e-427d-b3bc-22a5eb8ba4eb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_554f900c-5781-4bae-99da-f0d914452dac_terseLabel_en-US" xlink:label="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, ownership percentage</link:label>
    <link:label id="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_DC_864a54e0-8645-4718-b62f-8d21e170df85_terseLabel_en-US" xlink:label="lab_stpr_DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">District of Columbia [Member]</link:label>
    <link:label id="lab_stpr_DC_label_en-US" xlink:label="lab_stpr_DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISTRICT OF COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_DC" xlink:to="lab_stpr_DC" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesR.DouglasMember_ffd5a7a1-e98d-4800-a79d-eca5687b9e20_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesR.DouglasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, R. Douglas [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesR.DouglasMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesR.DouglasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, R. Douglas [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesR.DouglasMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesR.DouglasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, R. Douglas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesR.DouglasMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesR.DouglasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesR.DouglasMember" xlink:to="lab_mo_EngleProgenyCasesR.DouglasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_dce58b77-f7b7-4e7f-82d6-7bfddc8c41c0_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2021 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2021 [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, Transition Years 2004-2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:to="lab_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock_1e09f726-866d-4ecd-b376-f50af035a4c3_terseLabel_en-US" xlink:label="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tobacco and Health and Certain Other Litigation Items</link:label>
    <link:label id="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock_label_en-US" xlink:label="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tobacco and Health and Certain Other Litigation Items [Table Text Block]</link:label>
    <link:label id="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock_documentation_en-US" xlink:label="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tobacco and Health and Certain Other Litigation Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:href="mo-20230331.xsd#mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:to="lab_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ab033f6-aac9-4322-a1cf-bd3e5868c327_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to operating cash flows:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ae2bb402-a3b9-4a68-a37f-57512ea45d3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_673d3175-a45a-45f4-94db-09461c088fe2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CommonStock1.700NotesDue2025Member_c0742256-f96a-4a10-87cb-6f7de24fc01f_terseLabel_en-US" xlink:label="lab_mo_CommonStock1.700NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2025 [Member]</link:label>
    <link:label id="lab_mo_CommonStock1.700NotesDue2025Member_label_en-US" xlink:label="lab_mo_CommonStock1.700NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 1.700% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_mo_CommonStock1.700NotesDue2025Member_documentation_en-US" xlink:label="lab_mo_CommonStock1.700NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 1.700% Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock1.700NotesDue2025Member" xlink:href="mo-20230331.xsd#mo_CommonStock1.700NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CommonStock1.700NotesDue2025Member" xlink:to="lab_mo_CommonStock1.700NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_386ecc3e-3b97-43af-9c28-862e651caf7b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_95815378-940a-475f-b7a0-4e58999f15f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0c2607a6-1fff-4209-affc-4a50e451e97d_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_e53db5ab-0aa1-447c-871e-3afa82538587_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost/credit [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8f4794a4-a090-4e8d-8572-5c1b32ee65b8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_63a8ce59-348f-4ad9-a1cd-3cf6e2e13237_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a0df2708-784c-4edc-9212-9723f4c9418b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15889be1-9f1e-4df8-82a2-c2a6f5dab96a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_bf5e5d71-c22f-43cc-a562-9fde6b01db19_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for satisfaction of performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b7c2d6fe-a81b-47ee-aa74-40fb29c5bd01_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2b2c2ffc-e195-4e61-bc93-acf196e27742_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9fad5cc8-748a-47ed-8678-3bc7b3cf381a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClaimsResolvedNumber_24e9a3c9-6d15-44c8-8db0-7af3decffcc5_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClaimsResolvedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims resolved</link:label>
    <link:label id="lab_mo_LossContingencyClaimsResolvedNumber_label_en-US" xlink:label="lab_mo_LossContingencyClaimsResolvedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Resolved, Number</link:label>
    <link:label id="lab_mo_LossContingencyClaimsResolvedNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyClaimsResolvedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Resolved, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsResolvedNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsResolvedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClaimsResolvedNumber" xlink:to="lab_mo_LossContingencyClaimsResolvedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_fdb79f87-7e01-4379-86bd-2dfb0b3aecb7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_86bd1481-33b4-40ce-9a0c-afcab6ba489e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3697b4b8-01e9-40c5-93ca-aeefbf769d81_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for diluted EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_4bc4b815-80d2-4033-8a00-20002686f172_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PeriodTwoMember_6d4958b4-0725-4799-8643-c1ac2e0db851_terseLabel_en-US" xlink:label="lab_mo_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_mo_PeriodTwoMember_label_en-US" xlink:label="lab_mo_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two [Member]</link:label>
    <link:label id="lab_mo_PeriodTwoMember_documentation_en-US" xlink:label="lab_mo_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodTwoMember" xlink:href="mo-20230331.xsd#mo_PeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PeriodTwoMember" xlink:to="lab_mo_PeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df1a6793-87e5-4920-a378-18bd8e303c28_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_72c55b28-0b80-4e51-aa80-b4aa93e1a8cb_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illinois [Member]</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_71009299-3420-440c-8080-4d4f65441311_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_SmokeableProductsSegmentMember_79476e56-35e6-46e7-9131-0c29f10a36ea_terseLabel_en-US" xlink:label="lab_mo_SmokeableProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smokeable Products Segment [Member]</link:label>
    <link:label id="lab_mo_SmokeableProductsSegmentMember_label_en-US" xlink:label="lab_mo_SmokeableProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smokeable Products Segment [Member]</link:label>
    <link:label id="lab_mo_SmokeableProductsSegmentMember_documentation_en-US" xlink:label="lab_mo_SmokeableProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smokeable Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_SmokeableProductsSegmentMember" xlink:to="lab_mo_SmokeableProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NpmAdjustmentToCostOfSalesMember_d741e5ae-3af2-4eb1-9f67-194d7e7ad2f1_terseLabel_en-US" xlink:label="lab_mo_NpmAdjustmentToCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NPM Adjustment to Cost Of Sales [Member]</link:label>
    <link:label id="lab_mo_NpmAdjustmentToCostOfSalesMember_label_en-US" xlink:label="lab_mo_NpmAdjustmentToCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NPM Adjustment to Cost Of Sales [Member]</link:label>
    <link:label id="lab_mo_NpmAdjustmentToCostOfSalesMember_documentation_en-US" xlink:label="lab_mo_NpmAdjustmentToCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NPM Adjustment to Cost Of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NpmAdjustmentToCostOfSalesMember" xlink:href="mo-20230331.xsd#mo_NpmAdjustmentToCostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NpmAdjustmentToCostOfSalesMember" xlink:to="lab_mo_NpmAdjustmentToCostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_223b3628-3177-42b1-b402-cb9a0ee0dd23_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesCuddiheeMember_a0487a03-a8c5-4977-8468-634b64a52364_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesCuddiheeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cuddihee [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesCuddiheeMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesCuddiheeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cuddihee [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesCuddiheeMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesCuddiheeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Cuddihee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCuddiheeMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCuddiheeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesCuddiheeMember" xlink:to="lab_mo_EngleProgenyCasesCuddiheeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_05c7d0f4-06b7-43d3-b411-db51572e898a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_4c329a56-5f38-4695-b38d-1f09631d415c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JUUL</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OralTobaccoSegmentMember_22614887-7097-47e0-a11a-88ceee9926d3_verboseLabel_en-US" xlink:label="lab_mo_OralTobaccoSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Tobacco Segment [Member]</link:label>
    <link:label id="lab_mo_OralTobaccoSegmentMember_label_en-US" xlink:label="lab_mo_OralTobaccoSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Tobacco Segment [Member]</link:label>
    <link:label id="lab_mo_OralTobaccoSegmentMember_documentation_en-US" xlink:label="lab_mo_OralTobaccoSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Tobacco Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OralTobaccoSegmentMember" xlink:href="mo-20230331.xsd#mo_OralTobaccoSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OralTobaccoSegmentMember" xlink:to="lab_mo_OralTobaccoSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_8ad382ba-3b8d-421a-8ba5-30ec26e9aa5e_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states not settled, arbitration period</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not Settled, Arbitration Period</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not Settled, Arbitration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:to="lab_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_49b7846d-13d9-4983-aff5-78fd4ba517d3_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities ($0 million and $250 million at March 31, 2023 and December&#160;31, 2022, respectively, measured at fair value)</link:label>
    <link:label id="lab_us-gaap_Investments_a5383db5-079d-4c2f-8b90-dec85a53770a_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_c96c83cb-3587-4ca2-97d7-daf8c0edbc16_netLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement interest expense (income)</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_January2023ShareRepurchaseProgramMember_4bbc714b-dcda-43fa-9c48-7718fe69b887_terseLabel_en-US" xlink:label="lab_mo_January2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2023 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_mo_January2023ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_mo_January2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2023 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_mo_January2023ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_mo_January2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2023 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2023ShareRepurchaseProgramMember" xlink:href="mo-20230331.xsd#mo_January2023ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_January2023ShareRepurchaseProgramMember" xlink:to="lab_mo_January2023ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c97b3529-d41b-472c-a632-99201178e5cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.33 1/3&#160;per share (2,805,961,317 shares issued)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5872d35d-98bf-4370-b4b4-30cebaa8b671_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_bf2c9351-26b4-4fea-a3b6-ad0bbac4e3ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_07a3373c-f8c6-4b31-9f4d-17e623a5fc96_terseLabel_en-US" xlink:label="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, period for decertified class members to file individual actions against defendants</link:label>
    <link:label id="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_label_en-US" xlink:label="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants</link:label>
    <link:label id="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_documentation_en-US" xlink:label="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:href="mo-20230331.xsd#mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:to="lab_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_MarketingAdministrationandResearchCosts_6c70a64a-7d89-4210-ba10-1ce700b302ba_terseLabel_en-US" xlink:label="lab_mo_MarketingAdministrationandResearchCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, administration and research costs</link:label>
    <link:label id="lab_mo_MarketingAdministrationandResearchCosts_label_en-US" xlink:label="lab_mo_MarketingAdministrationandResearchCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, Administration and Research Costs</link:label>
    <link:label id="lab_mo_MarketingAdministrationandResearchCosts_documentation_en-US" xlink:label="lab_mo_MarketingAdministrationandResearchCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate total costs related to selling a firm's product and services, as well as research and development costs and all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. Research and development costs represent the aggregate costs incurred during an accounting period to research and develop new products/technologies when the technological feasibility has not been reached. General and administrative expenses include salaries of nonsales personnel, rent, utilities, communication, etc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MarketingAdministrationandResearchCosts" xlink:href="mo-20230331.xsd#mo_MarketingAdministrationandResearchCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_MarketingAdministrationandResearchCosts" xlink:to="lab_mo_MarketingAdministrationandResearchCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfForeignCurrencyDerivativesHeld_8957d994-2d7d-4500-b600-11741f6cdcce_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfForeignCurrencyDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of foreign currency derivatives held</link:label>
    <link:label id="lab_us-gaap_NumberOfForeignCurrencyDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfForeignCurrencyDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Foreign Currency Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfForeignCurrencyDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld" xlink:to="lab_us-gaap_NumberOfForeignCurrencyDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_ac126a06-0854-4377-a0cb-e90fb7ab03a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_11d8d654-f2be-4f35-9b2c-ed2f60bd24a7_terseLabel_en-US" xlink:label="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI</link:label>
    <link:label id="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_label_en-US" xlink:label="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles</link:label>
    <link:label id="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_documentation_en-US" xlink:label="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:href="mo-20230331.xsd#mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:to="lab_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CronosGroupInc.Member_993dc68e-d92d-4055-a44e-46496117326d_verboseLabel_en-US" xlink:label="lab_mo_CronosGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cronos [Member]</link:label>
    <link:label id="lab_mo_CronosGroupInc.Member_label_en-US" xlink:label="lab_mo_CronosGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cronos Group Inc. [Member]</link:label>
    <link:label id="lab_mo_CronosGroupInc.Member_documentation_en-US" xlink:label="lab_mo_CronosGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cronos Group Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CronosGroupInc.Member" xlink:to="lab_mo_CronosGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_caaf3b8a-b937-4056-a3a9-07601bf28405_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46abb61e-11c1-4701-aea9-20dd36016e02_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1ddb33d-d21a-4fc8-adbd-2b493329b848_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_89428f50-444f-461c-9544-2590c8a692e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_TobaccoandHealthLitigationCasesMember_224a03e0-d783-4d97-a683-6ea0301c8be4_terseLabel_en-US" xlink:label="lab_mo_TobaccoandHealthLitigationCasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Litigation Cases [Member]</link:label>
    <link:label id="lab_mo_TobaccoandHealthLitigationCasesMember_label_en-US" xlink:label="lab_mo_TobaccoandHealthLitigationCasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Litigation Cases [Member]</link:label>
    <link:label id="lab_mo_TobaccoandHealthLitigationCasesMember_documentation_en-US" xlink:label="lab_mo_TobaccoandHealthLitigationCasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Litigation Cases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthLitigationCasesMember" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthLitigationCasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_TobaccoandHealthLitigationCasesMember" xlink:to="lab_mo_TobaccoandHealthLitigationCasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1e72803d-8c0b-449b-9861-8e48efb5611f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings for basic EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesLippMember_0ae47a96-a32f-4899-9d4f-3a82d0a4ac2a_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesLippMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Lipp [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesLippMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesLippMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Lipp [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesLippMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesLippMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Lipp</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLippMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLippMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesLippMember" xlink:to="lab_mo_EngleProgenyCasesLippMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_657f38c1-b80b-4718-800b-23f4bbbc4847_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_14414c21-162f-4b42-a5c3-8b8aa2b07186_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABI</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_a58fc793-7b7d-4042-9042-5f68ec7391c7_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_8d74294c-c3a9-4d6a-8553-b4037b68d5ea_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5d5d3fbc-e1c7-4162-9eef-0cabb4c1d52e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_020dc4ca-b649-473a-821e-f258717e495c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigation_7fa90e6f-b257-42fa-ad3b-30c9912445c8_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with settled litigation</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigation_label_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States with Settled Litigation</link:label>
    <link:label id="lab_mo_LossContingencyNumberofStateswithSettledLitigation_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States with Settled Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:to="lab_mo_LossContingencyNumberofStateswithSettledLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dd1ef050-8c73-4952-9b72-d13e14fff4a0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_dae22c5c-6590-4bcd-9ea7-7a6dc6633b92_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fafff3ed-e5c0-4720-891b-444e679f0bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EvaporLitigationMember_bad56f89-a9e0-4f1e-9658-7e347519213c_terseLabel_en-US" xlink:label="lab_mo_EvaporLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E-vapor Litigation [Member]</link:label>
    <link:label id="lab_mo_EvaporLitigationMember_label_en-US" xlink:label="lab_mo_EvaporLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E-vapor Litigation [Member]</link:label>
    <link:label id="lab_mo_EvaporLitigationMember_documentation_en-US" xlink:label="lab_mo_EvaporLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E-vapor Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EvaporLitigationMember" xlink:to="lab_mo_EvaporLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_fdc2019b-cad9-4dee-9cd1-ee10007c75b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_0b8762fb-1b61-4e1a-834e-04cd1586ef7b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1b227f4e-e787-4db0-a7ed-acd0627d9edf_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive earnings (losses), net of deferred income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_305c2b33-25cf-4382-9efa-e20cafc6294c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive earnings (losses), net of deferred income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9ad49749-18a3-41ba-8675-976cb91f0808_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive earnings</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment_1067fafb-1097-45a4-b18b-28c4bc686cc8_terseLabel_en-US" xlink:label="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment_label_en-US" xlink:label="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment_documentation_en-US" xlink:label="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Foreign Currency Translation Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceForeignCurrencyTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:to="lab_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IA_9b2d41d8-a333-4e72-a9e9-e535edaff627_terseLabel_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Iowa [Member]</link:label>
    <link:label id="lab_stpr_IA_label_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOWA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IA" xlink:to="lab_stpr_IA" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f96125cb-bc52-4fd9-b14a-ad8a3a7da3a5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_RevolvingCreditFacilityDueAugust2025Member_710b9265-e64e-4de2-971f-36f8d1a14725_terseLabel_en-US" xlink:label="lab_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due August 2024 [Member]</link:label>
    <link:label id="lab_mo_RevolvingCreditFacilityDueAugust2025Member_label_en-US" xlink:label="lab_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due August 2025 [Member]</link:label>
    <link:label id="lab_mo_RevolvingCreditFacilityDueAugust2025Member_documentation_en-US" xlink:label="lab_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due August 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:href="mo-20230331.xsd#mo_RevolvingCreditFacilityDueAugust2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:to="lab_mo_RevolvingCreditFacilityDueAugust2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_346c264c-f0a4-4069-a765-4c47bf505da6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClaimsDecided_94f66814-d0e5-4cef-b687-4dc384a167e4_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClaimsDecided" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of verdicts returned</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecided_label_en-US" xlink:label="lab_mo_LossContingencyClaimsDecided" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecided_documentation_en-US" xlink:label="lab_mo_LossContingencyClaimsDecided" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecided" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecided"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClaimsDecided" xlink:to="lab_mo_LossContingencyClaimsDecided" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_68d1854d-a25d-4f7d-8e10-93635e81acb7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c22f8655-3966-4765-bc85-66b35b729d4e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtAbstract_ec010873-101b-4115-87be-6ce2b214f5f5_terseLabel_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency denominated debt included in long-term debt:</link:label>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtAbstract_label_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Abstract]</link:label>
    <link:label id="lab_mo_ForeignCurrencyDenominatedDebtAbstract_documentation_en-US" xlink:label="lab_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:to="lab_mo_ForeignCurrencyDenominatedDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9e8209ff-4a3e-41a9-bf25-b3b5194b780b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings_42df8500-bafa-4fda-ada1-8873d4eadad9_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states with concluded hearings</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States With Concluded Hearings</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States With Concluded Hearings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesWithConcludedHearings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:to="lab_mo_LossContingencyNumberOfStatesWithConcludedHearings" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesHoffmanMember_79dea46e-a298-4ad2-a8d5-ab470aa6f76a_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesHoffmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Hoffman [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesHoffmanMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesHoffmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Hoffman [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesHoffmanMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesHoffmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Hoffman</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHoffmanMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHoffmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesHoffmanMember" xlink:to="lab_mo_EngleProgenyCasesHoffmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NH_04c5b351-5931-4648-8ad2-ac844fe7e078_terseLabel_en-US" xlink:label="lab_stpr_NH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Hampshire [Member]</link:label>
    <link:label id="lab_stpr_NH_label_en-US" xlink:label="lab_stpr_NH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW HAMPSHIRE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NH" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NH" xlink:to="lab_stpr_NH" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyReductionToCostOfSales_48a3b4b9-7d72-46c0-b70e-1a55fe122610_terseLabel_en-US" xlink:label="lab_mo_LossContingencyReductionToCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, reduction to cost of sales</link:label>
    <link:label id="lab_mo_LossContingencyReductionToCostOfSales_label_en-US" xlink:label="lab_mo_LossContingencyReductionToCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reduction To Cost Of Sales</link:label>
    <link:label id="lab_mo_LossContingencyReductionToCostOfSales_documentation_en-US" xlink:label="lab_mo_LossContingencyReductionToCostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reduction To Cost Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyReductionToCostOfSales" xlink:href="mo-20230331.xsd#mo_LossContingencyReductionToCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyReductionToCostOfSales" xlink:to="lab_mo_LossContingencyReductionToCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_3edeaf60-42e2-45db-93e2-de80b6ea4572_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d494152-0c15-4765-b121-1eeafef93411_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesDuignanMember_cf16707b-5981-4f77-af37-15b25705a4e3_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesDuignanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Duignan [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesDuignanMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesDuignanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Duignan [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesDuignanMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesDuignanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Duignan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesDuignanMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesDuignanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesDuignanMember" xlink:to="lab_mo_EngleProgenyCasesDuignanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_8cd9e012-c3fc-4abe-aab9-e642f1905d37_terseLabel_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]</link:label>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_label_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]</link:label>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_documentation_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:to="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_99116fd7-8907-468f-a63d-b77a0e5ed428_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingencies</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b234f843-b88c-45bf-a8cd-83ae2617e368_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CommonStock0.3313ParValueMember_3356c2d1-5984-4716-8f23-102746411b52_terseLabel_en-US" xlink:label="lab_mo_CommonStock0.3313ParValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.33 1/3 par value [Member]</link:label>
    <link:label id="lab_mo_CommonStock0.3313ParValueMember_label_en-US" xlink:label="lab_mo_CommonStock0.3313ParValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 0.33 1/3 Par Value [Member]</link:label>
    <link:label id="lab_mo_CommonStock0.3313ParValueMember_documentation_en-US" xlink:label="lab_mo_CommonStock0.3313ParValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 0.33 1/3 Par Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock0.3313ParValueMember" xlink:href="mo-20230331.xsd#mo_CommonStock0.3313ParValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CommonStock0.3313ParValueMember" xlink:to="lab_mo_CommonStock0.3313ParValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_33839fac-558a-498a-94d9-d3fa47d32b0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesLevineMember_bb173fe0-c588-4076-9ab9-84bae7d4b263_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesLevineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Levine [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesLevineMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesLevineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Levine [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesLevineMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesLevineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Levine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLevineMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLevineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesLevineMember" xlink:to="lab_mo_EngleProgenyCasesLevineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_41a81194-4234-4596-9a1c-24ee69036c6f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cd9b30b0-400c-44a0-8100-9da6756b2b2d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_936be0b5-de10-428c-981a-bc47b3431209_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6c0fdb81-9ca5-4359-9364-3e6dd87356ef_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_ac6705ab-0ada-48fd-9140-1f29fbcb672d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, receivables</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_86c7eee2-19ad-410e-bab9-5ce925653385_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MS_ed16503a-ede2-4b15-9c72-646e1c1ace0c_terseLabel_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mississippi [Member]</link:label>
    <link:label id="lab_stpr_MS_label_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MISSISSIPPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MS" xlink:to="lab_stpr_MS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ab51758a-5b7a-4ba0-9485-9c022bd36def_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt repaid</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MT_2bc0b5a3-6860-4755-9eb3-4199e262e5f9_terseLabel_en-US" xlink:label="lab_stpr_MT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MONTANA [Member]</link:label>
    <link:label id="lab_stpr_MT_label_en-US" xlink:label="lab_stpr_MT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MONTANA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MT" xlink:to="lab_stpr_MT" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MO_cdc2f690-7b08-45a9-b006-67b82f26e102_terseLabel_en-US" xlink:label="lab_stpr_MO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Missouri [Member]</link:label>
    <link:label id="lab_stpr_MO_label_en-US" xlink:label="lab_stpr_MO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MISSOURI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MO" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MO" xlink:to="lab_stpr_MO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_0841c01a-2005-46f8-9074-7302d65e513f_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of repurchased stock (1,019,815,657 shares at March&#160;31, 2023 and 1,020,427,195 shares at December&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_dd14724d-5ada-4020-b4ca-842d54437471_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_ae377ca7-c29e-4da8-ae26-f5172b57e2d3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MN_e5958d2e-6616-4892-b7dc-65a312128779_terseLabel_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minnesota [Member]</link:label>
    <link:label id="lab_stpr_MN_label_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNESOTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MN" xlink:to="lab_stpr_MN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_10e2ca89-59e5-467b-a2ad-0a33540e9436_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plan contributions</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MI_0845b807-becb-4801-b418-32d2f4e589c0_terseLabel_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Michigan [Member]</link:label>
    <link:label id="lab_stpr_MI_label_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MICHIGAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MI" xlink:to="lab_stpr_MI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_395ed89d-7149-4cf0-8b9b-b5adea5cb78e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_342a77d9-8767-4b1d-9b1a-fd273d35828c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d14d3c25-9a6c-4178-a37c-07cca8f1768b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OH_48585008-f3ea-4bb6-829a-102dcf23ee3e_terseLabel_en-US" xlink:label="lab_stpr_OH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohio [Member]</link:label>
    <link:label id="lab_stpr_OH_label_en-US" xlink:label="lab_stpr_OH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OHIO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OH" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OH" xlink:to="lab_stpr_OH" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesPollariMember_ea7676af-e327-482d-ad58-8103115fe580_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesPollariMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pollari [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesPollariMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesPollariMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pollari [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesPollariMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesPollariMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Pollari [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPollariMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPollariMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesPollariMember" xlink:to="lab_mo_EngleProgenyCasesPollariMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_54f1f008-3d50-49ec-ac79-856f2f6f79f8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b5972bc0-4e52-47ff-a883-74fd497eb447_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PhilipMorrisUSAMember_2627442a-b5d6-4b73-b846-4f11f15aa873_terseLabel_en-US" xlink:label="lab_mo_PhilipMorrisUSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PM USA [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAMember_label_en-US" xlink:label="lab_mo_PhilipMorrisUSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAMember_documentation_en-US" xlink:label="lab_mo_PhilipMorrisUSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PhilipMorrisUSAMember" xlink:to="lab_mo_PhilipMorrisUSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ClassActionLawsuitMember_09f739cf-dece-428a-9783-36edc48bd275_terseLabel_en-US" xlink:label="lab_mo_ClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_mo_ClassActionLawsuitMember_label_en-US" xlink:label="lab_mo_ClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_mo_ClassActionLawsuitMember_documentation_en-US" xlink:label="lab_mo_ClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ClassActionLawsuitMember" xlink:href="mo-20230331.xsd#mo_ClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ClassActionLawsuitMember" xlink:to="lab_mo_ClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5106a693-e2ec-446f-8c9a-74c444ab3bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive losses</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_8516b1ea-f3f5-4020-9b84-645054afebb4_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NonEngleProgenyCasesMember_261ec756-330c-4491-a4d4-af3e7a109050_terseLabel_en-US" xlink:label="lab_mo_NonEngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Engle Progeny Cases [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenyCasesMember_label_en-US" xlink:label="lab_mo_NonEngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Engle Progeny Cases [Member]</link:label>
    <link:label id="lab_mo_NonEngleProgenyCasesMember_documentation_en-US" xlink:label="lab_mo_NonEngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Engle Progeny Cases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenyCasesMember" xlink:href="mo-20230331.xsd#mo_NonEngleProgenyCasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NonEngleProgenyCasesMember" xlink:to="lab_mo_NonEngleProgenyCasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_9ba233be-8263-4f11-a147-7a5452b5ae81_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_0f6924e1-a73c-4816-9d56-81ecc319bd0a_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York [Member]</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NV_89782672-6fd4-4bda-8652-8573a1d0dcfa_terseLabel_en-US" xlink:label="lab_stpr_NV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nevada [Member]</link:label>
    <link:label id="lab_stpr_NV_label_en-US" xlink:label="lab_stpr_NV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEVADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NV" xlink:to="lab_stpr_NV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_86861f8b-4fcb-48b1-8e50-5759979a0196_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_35fa12d7-213c-4f96-ba63-6e5fe5e9a069_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_02acf73b-aa78-4f6a-be37-e11cf2eea477_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposition of JUUL equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3fcc0a30-359a-440f-bd32-87bcabfdc998_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_USTLitigationMember_78b2a6d5-4b89-4239-803d-2ff66f43bce6_terseLabel_en-US" xlink:label="lab_mo_USTLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UST Litigation [Member]</link:label>
    <link:label id="lab_mo_USTLitigationMember_label_en-US" xlink:label="lab_mo_USTLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UST Litigation [Member]</link:label>
    <link:label id="lab_mo_USTLitigationMember_documentation_en-US" xlink:label="lab_mo_USTLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UST Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_USTLitigationMember" xlink:href="mo-20230331.xsd#mo_USTLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_USTLitigationMember" xlink:to="lab_mo_USTLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PR_555118f9-34a1-4cc2-ab3d-3f9d4f1fee99_terseLabel_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puerto Rico [Member]</link:label>
    <link:label id="lab_country_PR_label_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PR" xlink:to="lab_country_PR" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentPricePerShareIfExercised_bfb13215-16ac-4d14-be7a-eb02f332149a_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, shares purchased, (CAD per share)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentPricePerShareIfExercised_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Price Per Share If Exercised</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentPricePerShareIfExercised_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Price Per Share If Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPricePerShareIfExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:to="lab_mo_EquityMethodInvestmentPricePerShareIfExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_fb0c9d42-12d6-40c1-8bfd-b8cff104549d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_b5e5a7b4-27ec-407e-b897-c507c83958b1_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c48d419b-b96e-4bd6-811d-51659b783099_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NM_f7cc7182-88ec-4d58-baf0-cbab653f1dc1_terseLabel_en-US" xlink:label="lab_stpr_NM" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Mexico [Member]</link:label>
    <link:label id="lab_stpr_NM_label_en-US" xlink:label="lab_stpr_NM" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NM" xlink:to="lab_stpr_NM" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_d7dd91ce-19c7-45b4-ac32-3d4ee2571105_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey [Member]</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_73d5aefe-6708-4067-98da-62cce80840aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit (Income) Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_97e729d8-67a7-4992-bef9-f80fd66ff2eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_CommonStock2.200NotesDue2027Member_6bf1102e-7076-4464-ab59-c0440e422136_terseLabel_en-US" xlink:label="lab_mo_CommonStock2.200NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.200% Notes due 2027 [Member]</link:label>
    <link:label id="lab_mo_CommonStock2.200NotesDue2027Member_label_en-US" xlink:label="lab_mo_CommonStock2.200NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 2.200% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_mo_CommonStock2.200NotesDue2027Member_documentation_en-US" xlink:label="lab_mo_CommonStock2.200NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, 2.200% Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock2.200NotesDue2027Member" xlink:href="mo-20230331.xsd#mo_CommonStock2.200NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_CommonStock2.200NotesDue2027Member" xlink:to="lab_mo_CommonStock2.200NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_LA_2a12070b-856a-4109-b278-6c651e6d149e_terseLabel_en-US" xlink:label="lab_stpr_LA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Louisiana [Member]</link:label>
    <link:label id="lab_stpr_LA_label_en-US" xlink:label="lab_stpr_LA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOUISIANA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_LA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_LA" xlink:to="lab_stpr_LA" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PendingIndividualLawsuitsMember_1d70450b-99e3-40a7-ba21-46479bbdf79f_terseLabel_en-US" xlink:label="lab_mo_PendingIndividualLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Individual Lawsuits [Member]</link:label>
    <link:label id="lab_mo_PendingIndividualLawsuitsMember_label_en-US" xlink:label="lab_mo_PendingIndividualLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Individual Lawsuits [Member]</link:label>
    <link:label id="lab_mo_PendingIndividualLawsuitsMember_documentation_en-US" xlink:label="lab_mo_PendingIndividualLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Individual Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PendingIndividualLawsuitsMember" xlink:to="lab_mo_PendingIndividualLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_f0c67959-33fe-47a3-9d60-d7f00087487a_terseLabel_en-US" xlink:label="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Lawsuits Filed By State Or Local Governments [Member]</link:label>
    <link:label id="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_label_en-US" xlink:label="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Lawsuits Filed By State Or Local Governments [Member]</link:label>
    <link:label id="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_documentation_en-US" xlink:label="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Lawsuits Filed By State Or Local Governments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:href="mo-20230331.xsd#mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:to="lab_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KS_c730e827-ec5f-45bb-a40e-bdf9821fc607_terseLabel_en-US" xlink:label="lab_stpr_KS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kansas [Member]</link:label>
    <link:label id="lab_stpr_KS_label_en-US" xlink:label="lab_stpr_KS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KANSAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KS" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KS" xlink:to="lab_stpr_KS" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveCases_dc6c4915-3f0a-4683-a6d9-dfabc630a170_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of inactive cases</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveCases_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Inactive Cases</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfInactiveCases_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfInactiveCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Inactive Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveCases" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfInactiveCases" xlink:to="lab_mo_LossContingencyNumberOfInactiveCases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_00e16754-8028-4df5-a2d5-a8d035445f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7877a15e-b5b8-48a7-a62f-24b2f95dbce5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6865d61-1a94-43b8-b19a-ee869373fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b1b1a338-74cc-4236-b3bb-bfa9eb66d2a2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Background and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciEquityMethodInvestmentAfterTax_fe0fde6b-44b7-43ee-98e4-102c033fd9be_terseLabel_en-US" xlink:label="lab_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABI</link:label>
    <link:label id="lab_us-gaap_OciEquityMethodInvestmentAfterTax_label_en-US" xlink:label="lab_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Equity Method Investment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciEquityMethodInvestmentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:to="lab_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8cf8a5aa-980e-4ab8-8a6f-feb40c51a7cc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_SummaryOfIncomeTaxesTableTextBlock_8c0c522b-23eb-47dc-8ee6-d0fabad8fea1_terseLabel_en-US" xlink:label="lab_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Taxes</link:label>
    <link:label id="lab_mo_SummaryOfIncomeTaxesTableTextBlock_label_en-US" xlink:label="lab_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Taxes [Table Text Block]</link:label>
    <link:label id="lab_mo_SummaryOfIncomeTaxesTableTextBlock_documentation_en-US" xlink:label="lab_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:href="mo-20230331.xsd#mo_SummaryOfIncomeTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:to="lab_mo_SummaryOfIncomeTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_e5aa288e-25e5-451e-bc7c-840b7800937e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesMember_bc34947a-6778-4a9a-a7af-361d96692b05_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesMember" xlink:to="lab_mo_EngleProgenyCasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_07b7749c-8cbb-4d70-bf37-f3867ed10f39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_70fc9423-7fdb-4cff-9333-4eeac5ed0f48_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland [Member]</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_b19ce438-8f1a-480b-9582-efa4d74f3a54_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on long-term debt</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_e7561c41-c94f-42b5-aa0f-f0821ccc4cb4_verboseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts [Member]</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_197eedeb-67bd-4808-a482-d71291fe10f4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_345476ca-a592-4ca0-895f-d4cd36cd2eae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Cronos-related financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7b5776fa-1db4-4097-b6d8-a1de51a4f816_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesWeingartandHancockMember_a26b0b92-4969-47f1-92c6-d47778cb4fbf_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesWeingartandHancockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Weingart and Hancock [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesWeingartandHancockMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesWeingartandHancockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Weingart and Hancock [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesWeingartandHancockMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesWeingartandHancockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Weingart and Hancock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesWeingartandHancockMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesWeingartandHancockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesWeingartandHancockMember" xlink:to="lab_mo_EngleProgenyCasesWeingartandHancockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_BritishColumbiaSaskatchewanMember_e6313cfe-108b-4ffd-aa65-225bbdd618d2_terseLabel_en-US" xlink:label="lab_mo_BritishColumbiaSaskatchewanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia and Saskatchewan [Member]</link:label>
    <link:label id="lab_mo_BritishColumbiaSaskatchewanMember_label_en-US" xlink:label="lab_mo_BritishColumbiaSaskatchewanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia, Saskatchewan [Member]</link:label>
    <link:label id="lab_mo_BritishColumbiaSaskatchewanMember_documentation_en-US" xlink:label="lab_mo_BritishColumbiaSaskatchewanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia, Saskatchewan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_BritishColumbiaSaskatchewanMember" xlink:href="mo-20230331.xsd#mo_BritishColumbiaSaskatchewanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_BritishColumbiaSaskatchewanMember" xlink:to="lab_mo_BritishColumbiaSaskatchewanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_cecece1e-0183-4ee6-be81-9841870917f6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdicts_68e7bbd2-905b-4d76-89ec-f16f366224bd_terseLabel_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdicts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero damages verdicts</link:label>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdicts_label_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdicts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Zero Damages Verdicts</link:label>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdicts_documentation_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdicts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Zero Damages Verdicts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdicts" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdicts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyZeroDamagesVerdicts" xlink:to="lab_mo_LossContingencyZeroDamagesVerdicts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f03344f4-245c-4a59-8c00-094d5f888233_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_RI_849131d3-ade8-4ef8-9961-bfd4989ae981_terseLabel_en-US" xlink:label="lab_stpr_RI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rhode Island [Member]</link:label>
    <link:label id="lab_stpr_RI_label_en-US" xlink:label="lab_stpr_RI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RHODE ISLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_RI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_RI" xlink:to="lab_stpr_RI" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_e9dd1242-6aca-4144-9ad6-c3fcbd843a72_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7e48cd0c-5bf6-4a66-9686-6b327e749f3a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_694f8f1b-2a2d-4851-b809-9dacf8db9418_terseLabel_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</link:label>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_label_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</link:label>
    <link:label id="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_documentation_en-US" xlink:label="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:to="lab_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_e58184f1-5560-4f37-b260-57397dbb7e87_terseLabel_en-US" xlink:label="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State settlement agreements attorney fees annual cap</link:label>
    <link:label id="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_label_en-US" xlink:label="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Annual Legal Fees Payable, Maximum</link:label>
    <link:label id="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_documentation_en-US" xlink:label="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Annual Legal Fees Payable, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualLegalFeesPayableMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:to="lab_mo_LitigationSettlementAnnualLegalFeesPayableMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_5ccff1dc-78ad-467b-8a45-e91dceca0330_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued pension costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7ee06970-750e-4fa3-91ba-203b6075001f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca923f2f-bbba-4112-8027-7f4276b96244_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for basic EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1b110745-83e0-4a87-9b5c-fee42d82296a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_24cb2c17-ff32-491a-b7ae-112cc5dd71b6_terseLabel_en-US" xlink:label="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact deferred tax rate</link:label>
    <link:label id="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_label_en-US" xlink:label="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Deferred Tax Rate</link:label>
    <link:label id="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_documentation_en-US" xlink:label="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Deferred Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:href="mo-20230331.xsd#mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:to="lab_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_23c77c9b-5998-41b0-b6d0-85dec0be67ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liability for tobacco and health litigation items at beginning of period</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_3f65ea36-3828-4883-97f2-9aa2089eceb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liability for tobacco and health litigation items at end of period</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_9ddc8d65-389f-4088-b9b3-0c95e41781ad_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_fb7d5667-6b1a-4919-981a-098b18702f09_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_8f2a0626-0365-4620-9000-0fd6e3978e62_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_dc9585e5-ca59-4dd3-8744-8e86ab736d98_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_212ef640-a8fd-4af0-bcb6-22f9b03edbaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b18e847d-d667-43ea-ba48-7d2bd294d586_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6d47c622-8dd4-449b-9490-35b1af310d5d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_1f970f0d-d9e4-4204-88fd-9fb7be149af8_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of states not in compliance with escrow statues</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not In Compliance With Escrow Statues</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States Not In Compliance With Escrow Statues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:to="lab_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_88b04b5b-6e43-44dc-a413-72998fdf65da_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_NJOYHoldingsIncMember_0b68fe9b-0065-438d-a92c-15f7763921c4_terseLabel_en-US" xlink:label="lab_mo_NJOYHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NJOY Holdings, Inc. [Member]</link:label>
    <link:label id="lab_mo_NJOYHoldingsIncMember_label_en-US" xlink:label="lab_mo_NJOYHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NJOY Holdings, Inc. [Member]</link:label>
    <link:label id="lab_mo_NJOYHoldingsIncMember_documentation_en-US" xlink:label="lab_mo_NJOYHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NJOY Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NJOYHoldingsIncMember" xlink:href="mo-20230331.xsd#mo_NJOYHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_NJOYHoldingsIncMember" xlink:to="lab_mo_NJOYHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PendingClassActionLawsuitMember_653153fe-1c92-4e03-8b5e-7f086164ab79_terseLabel_en-US" xlink:label="lab_mo_PendingClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_mo_PendingClassActionLawsuitMember_label_en-US" xlink:label="lab_mo_PendingClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_mo_PendingClassActionLawsuitMember_documentation_en-US" xlink:label="lab_mo_PendingClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Class Action Lawsuit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingClassActionLawsuitMember" xlink:href="mo-20230331.xsd#mo_PendingClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PendingClassActionLawsuitMember" xlink:to="lab_mo_PendingClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLossMember_822a3302-5893-4863-8e0c-fb34d5aef077_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLossMember_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLossMember" xlink:to="lab_us-gaap_OperatingIncomeLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_665a42fe-03eb-4cbb-bd0d-15e462ebadc3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_ed89b1a3-771c-414c-a0df-11b41cce461b_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PhilipMorrisUSAandAltriaGroupMember_233b5f2d-08e4-49fc-b6a2-98e9ea7ae099_terseLabel_en-US" xlink:label="lab_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA and Altria Group [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAandAltriaGroupMember_label_en-US" xlink:label="lab_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA and Altria Group [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAandAltriaGroupMember_documentation_en-US" xlink:label="lab_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA and Altria Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAandAltriaGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:to="lab_mo_PhilipMorrisUSAandAltriaGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_7844918c-e30a-4899-a380-ef774413647e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f7e3259-d64b-48c4-ba4e-8843bd9739ed_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_6e240b8e-b119-4824-b574-3dd974900b8f_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina [Member]</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_501b2ff1-13cd-4033-9bac-401e9c01eaa5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_0b3e8410-ef09-4602-be48-0f2296bf94ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_88f4ac9d-d33d-445d-850a-2c2d1ae71419_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgments paid (approximately)</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ec0d53ff-ca0c-4512-8d0f-97ef202daba6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c1b8ecd0-5c14-402c-9e75-89e049281cea_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_1efbfe26-c72e-400e-a313-4ba8c207f9a6_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7aa98334-6294-48d1-be58-aee2bc8e19e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_455e830f-4aa8-4ac6-a4e5-929d905249c9_negatedTerseLabel_en-US" xlink:label="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI, ordinary gain (loss), tax basis of investments</link:label>
    <link:label id="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_label_en-US" xlink:label="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Ordinary Gain (Loss), Tax Basis Of Investments</link:label>
    <link:label id="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_documentation_en-US" xlink:label="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Ordinary Gain (Loss), Tax Basis Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:to="lab_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_22d34718-4f73-4324-a699-e89a6dd162f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_20467dbb-c25b-4810-834c-d225033be51d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_71529d37-6d6f-4863-b854-9ff247574157_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from Contracts with Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_729596dd-8653-49d8-bd45-bd332c9078a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_45ff8720-6d01-49cd-a448-b0d324c726a7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_5dcfcba9-8b6f-4043-829b-f4c7bab5b413_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EuroNotes1000MaturingFebruary2023Member_201dc502-0c65-450e-bb7c-de4714fdaf8e_terseLabel_en-US" xlink:label="lab_mo_EuroNotes1000MaturingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Notes, 1.000%, Maturing February 2023 [Member]</link:label>
    <link:label id="lab_mo_EuroNotes1000MaturingFebruary2023Member_label_en-US" xlink:label="lab_mo_EuroNotes1000MaturingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Notes, 1.000%, Maturing February 2023 [Member]</link:label>
    <link:label id="lab_mo_EuroNotes1000MaturingFebruary2023Member_documentation_en-US" xlink:label="lab_mo_EuroNotes1000MaturingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Notes, 1.000%, Maturing February 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EuroNotes1000MaturingFebruary2023Member" xlink:href="mo-20230331.xsd#mo_EuroNotes1000MaturingFebruary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EuroNotes1000MaturingFebruary2023Member" xlink:to="lab_mo_EuroNotes1000MaturingFebruary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_d54fb9c0-59c6-4e7f-87fd-fece82d877d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other debt expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_919ac970-0e93-419c-8de5-efa7592517b1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, provision</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_27312947-1a1e-4b89-a566-d030ec5cf94e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_73d2156f-064f-4f95-a6d0-9103107caab4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_bcbfc641-6249-478f-b289-8dfcd607d3a1_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania [Member]</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_45317131-3bb9-4f29-8f3d-74d41e18921a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1217bf8a-a9d2-4db3-b7ad-f75044a2210e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_1c14b68e-6f3c-4af0-9379-8f5820e6e938_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyDamagesRecoverableValue_3dd76a4b-dd76-4c66-8e5b-b8d9e6b083f1_terseLabel_en-US" xlink:label="lab_mo_LossContingencyDamagesRecoverableValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages recoverable, value</link:label>
    <link:label id="lab_mo_LossContingencyDamagesRecoverableValue_label_en-US" xlink:label="lab_mo_LossContingencyDamagesRecoverableValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Recoverable, Value</link:label>
    <link:label id="lab_mo_LossContingencyDamagesRecoverableValue_documentation_en-US" xlink:label="lab_mo_LossContingencyDamagesRecoverableValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Recoverable, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyDamagesRecoverableValue" xlink:href="mo-20230331.xsd#mo_LossContingencyDamagesRecoverableValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyDamagesRecoverableValue" xlink:to="lab_mo_LossContingencyDamagesRecoverableValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fefdbba3-0fec-4a7b-9de8-ff82a6736f0d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_1283e479-f780-4041-8008-8bf8a23a110f_terseLabel_en-US" xlink:label="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award activity</link:label>
    <link:label id="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_label_en-US" xlink:label="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition and Income Tax Effect, Net</link:label>
    <link:label id="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_documentation_en-US" xlink:label="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Additional Paid In Capital, Share Based Compensation, Restricted And Deferred Stock Awards and the tax benefits associated with vestings of prior period restricted and deferred stock awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:href="mo-20230331.xsd#mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:to="lab_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_79ff292c-e473-40c1-b08e-3ac68c7f77ee_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OR_9832fced-9b5b-482d-af49-6e4940c09541_terseLabel_en-US" xlink:label="lab_stpr_OR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oregon [Member]</link:label>
    <link:label id="lab_stpr_OR_label_en-US" xlink:label="lab_stpr_OR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OREGON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OR" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OR" xlink:to="lab_stpr_OR" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a7726cc8-b743-4f89-82fc-a828030d04df_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OK_28d549e5-ab22-45c4-9ffe-634b4160f748_terseLabel_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma [Member]</link:label>
    <link:label id="lab_stpr_OK_label_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OK" xlink:to="lab_stpr_OK" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dd9eaf88-efe9-426e-8600-f58dce560133_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings for diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_886a8681-2ac9-46ad-947f-6341243c79bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d38f3a1-17ce-4900-b401-7c782d4f70f7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_SmokingAndHealthClassActionsMember_6110b67d-463c-462f-b23b-17ea227179fd_terseLabel_en-US" xlink:label="lab_mo_SmokingAndHealthClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smoking and Health Class Actions and Aggregated Claims Litigation [Member]</link:label>
    <link:label id="lab_mo_SmokingAndHealthClassActionsMember_label_en-US" xlink:label="lab_mo_SmokingAndHealthClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smoking And Health Class Actions [Member]</link:label>
    <link:label id="lab_mo_SmokingAndHealthClassActionsMember_documentation_en-US" xlink:label="lab_mo_SmokingAndHealthClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smoking and Health Class Actions and Aggregated Claims Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_SmokingAndHealthClassActionsMember" xlink:to="lab_mo_SmokingAndHealthClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_35e948fa-c075-4d31-b3d0-67a96fb17bae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4fa57667-3767-4769-984f-ce036dcfb675_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_InterestExpenseRelatedToLitigationMember_47405207-6ef5-4f20-a885-2fc37b298c2f_terseLabel_en-US" xlink:label="lab_mo_InterestExpenseRelatedToLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Interest Costs [Member]</link:label>
    <link:label id="lab_mo_InterestExpenseRelatedToLitigationMember_label_en-US" xlink:label="lab_mo_InterestExpenseRelatedToLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Related To Litigation [Member]</link:label>
    <link:label id="lab_mo_InterestExpenseRelatedToLitigationMember_documentation_en-US" xlink:label="lab_mo_InterestExpenseRelatedToLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Related To Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestExpenseRelatedToLitigationMember" xlink:href="mo-20230331.xsd#mo_InterestExpenseRelatedToLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_InterestExpenseRelatedToLitigationMember" xlink:to="lab_mo_InterestExpenseRelatedToLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6aad194d-614e-45b1-ac45-c97e804871e0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_c95c9d5e-f50b-4f1e-99c9-a43b9e3230aa_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of shareholders filing derivative lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:to="lab_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_c6d77499-cc7b-47fe-9a0b-ec6894d618d4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_383ac358-8034-44c5-b256-93a1f7dab224_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7d5005a6-6d06-4b76-ba60-ba924cc0ad0f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_0c1f680c-fc90-4450-b1e3-de2c5172e486_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdictModified_0b523de5-8562-4ed2-985f-08328a406592_terseLabel_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdictModified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero damages verdict modified</link:label>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdictModified_label_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdictModified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Zero Damages Verdict Modified</link:label>
    <link:label id="lab_mo_LossContingencyZeroDamagesVerdictModified_documentation_en-US" xlink:label="lab_mo_LossContingencyZeroDamagesVerdictModified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Zero Damages Verdict Modified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdictModified" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdictModified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyZeroDamagesVerdictModified" xlink:to="lab_mo_LossContingencyZeroDamagesVerdictModified" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EngleProgenyCasesReiderandBanksMember_5ec44354-40fd-44d5-a326-5de8d7a9e037_terseLabel_en-US" xlink:label="lab_mo_EngleProgenyCasesReiderandBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Reider and Banks [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesReiderandBanksMember_label_en-US" xlink:label="lab_mo_EngleProgenyCasesReiderandBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Reider and Banks [Member]</link:label>
    <link:label id="lab_mo_EngleProgenyCasesReiderandBanksMember_documentation_en-US" xlink:label="lab_mo_EngleProgenyCasesReiderandBanksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engle Progeny Cases, Reider and Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesReiderandBanksMember" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesReiderandBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EngleProgenyCasesReiderandBanksMember" xlink:to="lab_mo_EngleProgenyCasesReiderandBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e952339d-0bc6-4a29-83ea-8b29f75986d6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact the effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_880022a7-2760-4f37-b2b4-99041ce760be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationSettlementAnnualPaymentAmount_e7f5b701-0b93-4025-a66f-199c2e3bb188_terseLabel_en-US" xlink:label="lab_mo_LitigationSettlementAnnualPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State settlement agreements annual payments</link:label>
    <link:label id="lab_mo_LitigationSettlementAnnualPaymentAmount_label_en-US" xlink:label="lab_mo_LitigationSettlementAnnualPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Annual Payment Amount</link:label>
    <link:label id="lab_mo_LitigationSettlementAnnualPaymentAmount_documentation_en-US" xlink:label="lab_mo_LitigationSettlementAnnualPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Annual Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualPaymentAmount" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationSettlementAnnualPaymentAmount" xlink:to="lab_mo_LitigationSettlementAnnualPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_d586bcc1-70e9-4847-b05a-cc70fefe505f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive earnings (losses) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_48c6ca90-4c0b-4d82-be02-f422bcc5d1eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_79d90947-3c24-43d8-90e8-90c74fe5c195_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ef082f97-2b51-46a9-bfd1-1d16b2d3a02d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cbe168e8-40d5-4258-9f11-d212dcb106a4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_e3a50c60-3af9-4eb5-9c4a-82414bd94594_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3a62888d-ba5d-4d48-be8d-189b2484f46b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_761ceb28-5f48-4751-b4ef-17a111a1cbd6_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4f58b539-cfbd-45a6-97f7-f53345bc4c04_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_957f161a-dae2-4512-9bf7-2d6c1778d086_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_df8f2504-6250-45c6-bf97-5e0af580006e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_04f665a5-63f3-4d0b-95b0-85f2933ec7c5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_c9053282-cb73-400d-89a3-45ce934fbbf0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_78cd3553-4fb0-4fbe-95fd-7c8e4eaf93f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_64282809-1558-4afe-b0a4-e05eccfd1444_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f8e3ab01-9fd6-4d5c-af89-aa7a4030624d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityContractWarrantMember_7dfbf597-33ea-4dca-94f2-bbb53acec63b_terseLabel_en-US" xlink:label="lab_mo_EquityContractWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Warrant [Member]</link:label>
    <link:label id="lab_mo_EquityContractWarrantMember_label_en-US" xlink:label="lab_mo_EquityContractWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Warrant [Member]</link:label>
    <link:label id="lab_mo_EquityContractWarrantMember_documentation_en-US" xlink:label="lab_mo_EquityContractWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Contract, Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractWarrantMember" xlink:href="mo-20230331.xsd#mo_EquityContractWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityContractWarrantMember" xlink:to="lab_mo_EquityContractWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_3289cf7d-3114-489a-bc31-4a258d9ff188_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin [Member]</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyCompensatoryDamagesAwardedValue_3d16c254-a784-4767-8ea6-0a63f102f0be_terseLabel_en-US" xlink:label="lab_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensatory damages awarded</link:label>
    <link:label id="lab_mo_LossContingencyCompensatoryDamagesAwardedValue_label_en-US" xlink:label="lab_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Compensatory Damages Awarded, Value</link:label>
    <link:label id="lab_mo_LossContingencyCompensatoryDamagesAwardedValue_documentation_en-US" xlink:label="lab_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Compensatory Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:href="mo-20230331.xsd#mo_LossContingencyCompensatoryDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:to="lab_mo_LossContingencyCompensatoryDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber_73abeff5-98c3-4da6-8728-dcd7632bf432_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of unfavorable verdicts</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber_label_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided Unfavorable, Number</link:label>
    <link:label id="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber_documentation_en-US" xlink:label="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Decided Unfavorable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedUnfavorableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:to="lab_mo_LossContingencyClaimsDecidedUnfavorableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e016fa96-9dd9-4d21-a192-690d073e0ef6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_MaximumBondForAllDefendants_8b70e962-a41a-40c5-9524-66b3b1070ac3_terseLabel_en-US" xlink:label="lab_mo_MaximumBondForAllDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum bond for all defendants</link:label>
    <link:label id="lab_mo_MaximumBondForAllDefendants_label_en-US" xlink:label="lab_mo_MaximumBondForAllDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Bond For All Defendants</link:label>
    <link:label id="lab_mo_MaximumBondForAllDefendants_documentation_en-US" xlink:label="lab_mo_MaximumBondForAllDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Bond For All Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MaximumBondForAllDefendants" xlink:href="mo-20230331.xsd#mo_MaximumBondForAllDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_MaximumBondForAllDefendants" xlink:to="lab_mo_MaximumBondForAllDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThreatenedLitigationMember_4c68e44d-d227-40ce-ab5b-157c86f3b059_terseLabel_en-US" xlink:label="lab_us-gaap_ThreatenedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threatened Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_ThreatenedLitigationMember_label_en-US" xlink:label="lab_us-gaap_ThreatenedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threatened Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThreatenedLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThreatenedLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThreatenedLitigationMember" xlink:to="lab_us-gaap_ThreatenedLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_5dc55fab-d9ef-4d37-aedc-a2704c1f08ec_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability related to performance surety bonds</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_26064339-debe-4fe0-9003-6436f3adf4ec_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_b9372971-58db-4ccc-afc8-a37647ab3118_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62064d01-9111-4c42-83be-7b3a7b6f7cfe_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_4ae63916-1459-4bc7-8730-addedf7dbc1b_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_45700ff0-af7e-4822-8d0c-0e4f03b1638d_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7bfedb6d-61a6-40b3-8044-3b192777cf49_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyClassActionLawsuit_60fbc881-a5df-4417-857d-8c57c8e224bd_terseLabel_en-US" xlink:label="lab_mo_LossContingencyClassActionLawsuit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, class action lawsuit</link:label>
    <link:label id="lab_mo_LossContingencyClassActionLawsuit_label_en-US" xlink:label="lab_mo_LossContingencyClassActionLawsuit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Action Lawsuit</link:label>
    <link:label id="lab_mo_LossContingencyClassActionLawsuit_documentation_en-US" xlink:label="lab_mo_LossContingencyClassActionLawsuit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Action Lawsuit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassActionLawsuit" xlink:href="mo-20230331.xsd#mo_LossContingencyClassActionLawsuit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyClassActionLawsuit" xlink:to="lab_mo_LossContingencyClassActionLawsuit" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_07e99a1f-3d5e-4ef0-a06d-4be0a3eb1ebc_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_080b2d32-e3e8-443c-b072-0506297dbb7a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LossContingencyNumberOfTrialsOngoing_71f6bde6-bb4b-4ec7-bbf3-a6e0e9092e31_terseLabel_en-US" xlink:label="lab_mo_LossContingencyNumberOfTrialsOngoing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of trials ongoing</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfTrialsOngoing_label_en-US" xlink:label="lab_mo_LossContingencyNumberOfTrialsOngoing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Trials Ongoing</link:label>
    <link:label id="lab_mo_LossContingencyNumberOfTrialsOngoing_documentation_en-US" xlink:label="lab_mo_LossContingencyNumberOfTrialsOngoing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Trials Ongoing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfTrialsOngoing" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfTrialsOngoing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LossContingencyNumberOfTrialsOngoing" xlink:to="lab_mo_LossContingencyNumberOfTrialsOngoing" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_ed3712d7-7e7d-4e52-b136-0f1459fa1fb4_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a03669a8-7d89-44c0-8da3-53a99045bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_49692f7b-c316-4cc6-be0b-c73c228dbf44_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bdf25e34-1e14-4f86-a2f9-87edcba717b6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e9738837-6f62-4a16-a613-a714bc326293_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1fe127eb-38b3-4df0-b56a-5d2d5666d75f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e3794bec-492f-4e3a-8833-e7571ba5d48f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ABInBevMember_15fbce77-ae7f-43ac-971d-1918e758f752_terseLabel_en-US" xlink:label="lab_mo_ABInBevMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABI [Member]</link:label>
    <link:label id="lab_mo_ABInBevMember_label_en-US" xlink:label="lab_mo_ABInBevMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AB InBev [Member]</link:label>
    <link:label id="lab_mo_ABInBevMember_documentation_en-US" xlink:label="lab_mo_ABInBevMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AB InBev [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ABInBevMember" xlink:to="lab_mo_ABInBevMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_413e14ac-4507-4a55-b6c1-f9504f5d2660_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember_ee008d91-3182-4c4a-8afd-e78f0e7b8c9a_terseLabel_en-US" xlink:label="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ETS Smoking and Health Case, Flight Attendants [Member]</link:label>
    <link:label id="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember_label_en-US" xlink:label="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ETS Smoking and Health Case, Flight Attendants [Member]</link:label>
    <link:label id="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember_documentation_en-US" xlink:label="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ETS Smoking and Health Case, Flight Attendants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:href="mo-20230331.xsd#mo_ETSSmokingandHealthCaseFlightAttendantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:to="lab_mo_ETSSmokingandHealthCaseFlightAttendantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_523e5bdc-bb68-4239-bc50-0406dfa279de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_285864d1-57ec-4a26-92f6-1440a622141d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e58ea6f4-ace6-4535-8ee6-ec87fbe052f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_OwnershipPercentageInConsolidatedSubsidiary_e85d019a-2569-44a2-ac54-f1de27b02f18_terseLabel_en-US" xlink:label="lab_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage in consolidated subsidiary</link:label>
    <link:label id="lab_mo_OwnershipPercentageInConsolidatedSubsidiary_label_en-US" xlink:label="lab_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage In Consolidated Subsidiary</link:label>
    <link:label id="lab_mo_OwnershipPercentageInConsolidatedSubsidiary_documentation_en-US" xlink:label="lab_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage In Consolidated Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:href="mo-20230331.xsd#mo_OwnershipPercentageInConsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:to="lab_mo_OwnershipPercentageInConsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_b90ab5e8-5a70-48c8-b786-f64ca96694f4_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, percentage of shares eligible for purchase (approximately)</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Percentage of Shares Eligible For Purchase</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Percentage of Shares Eligible For Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:to="lab_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_TobaccoandHealthJudgmentMember_2fbf0813-652f-4ef9-b511-2312c93c8065_terseLabel_en-US" xlink:label="lab_mo_TobaccoandHealthJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Judgment [Member]</link:label>
    <link:label id="lab_mo_TobaccoandHealthJudgmentMember_label_en-US" xlink:label="lab_mo_TobaccoandHealthJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Judgment [Member]</link:label>
    <link:label id="lab_mo_TobaccoandHealthJudgmentMember_documentation_en-US" xlink:label="lab_mo_TobaccoandHealthJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tobacco and Health Judgment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthJudgmentMember" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthJudgmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_TobaccoandHealthJudgmentMember" xlink:to="lab_mo_TobaccoandHealthJudgmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b6a4725-60dd-40c9-a4c9-86c542cd8439_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1843ca98-3143-4d82-b802-f610e225de9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5ced60db-405f-4fa8-9984-c6a7fa95abed_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_82b8d3de-7486-42ba-ac3a-59dfdf94f74a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_LitigationEscrowDeposit_98dd589f-157e-4c9f-a836-f0498827d01e_terseLabel_en-US" xlink:label="lab_mo_LitigationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security posted for appeal of judgments</link:label>
    <link:label id="lab_mo_LitigationEscrowDeposit_label_en-US" xlink:label="lab_mo_LitigationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Escrow Deposit</link:label>
    <link:label id="lab_mo_LitigationEscrowDeposit_documentation_en-US" xlink:label="lab_mo_LitigationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationEscrowDeposit" xlink:href="mo-20230331.xsd#mo_LitigationEscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_LitigationEscrowDeposit" xlink:to="lab_mo_LitigationEscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_af6c06bf-698e-4962-8f93-1792d6a1d4da_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) losses from investments under equity method of accounting</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_0cab25f4-30bc-4a94-9930-a8ca4271fd40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) losses from investments in equity securities</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_e83e9972-2a43-4c04-a04e-d2a4893be55f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a44980ec-7a39-40ad-84a7-cacdfad6252e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights_3c5da833-c2d7-403a-84bd-30de0adedcc5_terseLabel_en-US" xlink:label="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, fixed preemptive rights</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights_label_en-US" xlink:label="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fixed Preemptive Rights</link:label>
    <link:label id="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights_documentation_en-US" xlink:label="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fixed Preemptive Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsFixedPreemptiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:to="lab_mo_EquityMethodInvestmentsFixedPreemptiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bc299a3d-c034-4077-a452-42fa9c1298d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_1968f6e6-ea22-4c9e-b6ab-7f37c1b2f1a3_terseLabel_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_label_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]</link:label>
    <link:label id="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_documentation_en-US" xlink:label="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:to="lab_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_c6633c9a-a039-4b23-b2cc-90dbf6d00e2c_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas [Member]</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_2c4af708-79e5-44e5-b5ab-6f8703b475a3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_3e3db5d9-515c-464b-8dd6-7d822da468ce_terseLabel_en-US" xlink:label="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PM USA And R.J. Reynolds Tobacco Company [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_label_en-US" xlink:label="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA And R.J. Reynolds Tobacco Company [Member]</link:label>
    <link:label id="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_documentation_en-US" xlink:label="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philip Morris USA And R.J. Reynolds Tobacco Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:to="lab_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e0cb7fb5-1dd0-4190-a6bf-75f812d8e045_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>mo-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5a260f78-ef17-4e48-807d-8a35d0aaba50,g:03db3f23-a13f-4954-b4e2-dbb157db74a9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.altria.com/role/CoverPage" xlink:type="simple" xlink:href="mo-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e1ecdabb-c090-464d-b28b-3c8febba2b0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1ecdabb-c090-464d-b28b-3c8febba2b0d" xlink:to="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62d02704-cb15-4102-b7ce-990fbb929e63" xlink:to="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock0.3313ParValueMember_efb05856-9f11-4d50-baed-86bd4413d3c0" xlink:href="mo-20230331.xsd#mo_CommonStock0.3313ParValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock0.3313ParValueMember_efb05856-9f11-4d50-baed-86bd4413d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock1.700NotesDue2025Member_03b11a99-d246-445c-86bd-64341c730598" xlink:href="mo-20230331.xsd#mo_CommonStock1.700NotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock1.700NotesDue2025Member_03b11a99-d246-445c-86bd-64341c730598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock2.200NotesDue2027Member_dd159b59-cd8d-4deb-8137-9654d97a3c9f" xlink:href="mo-20230331.xsd#mo_CommonStock2.200NotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock2.200NotesDue2027Member_dd159b59-cd8d-4deb-8137-9654d97a3c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CommonStock3.125NotesDue2031Member_a608f79d-e619-4c43-b233-862e80bb5329" xlink:href="mo-20230331.xsd#mo_CommonStock3.125NotesDue2031Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a355e31e-2d98-4ae7-9cd8-a41ebfa613f7" xlink:to="loc_mo_CommonStock3.125NotesDue2031Member_a608f79d-e619-4c43-b233-862e80bb5329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_f0c94bea-18df-4d78-a680-e2b6c059af34" xlink:to="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b0223f1d-d166-4e26-a7d5-911d359b159a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentType_b0223f1d-d166-4e26-a7d5-911d359b159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7527f901-353c-4f32-9bd8-604e451f456d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentQuarterlyReport_7527f901-353c-4f32-9bd8-604e451f456d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b52e0dee-a0aa-4f62-b8da-683d87e3da0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentPeriodEndDate_b52e0dee-a0aa-4f62-b8da-683d87e3da0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_840df29d-8652-477c-b51e-70b63dd0f99d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentTransitionReport_840df29d-8652-477c-b51e-70b63dd0f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac035216-f587-4f01-8274-e6d203e1e86d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityFileNumber_ac035216-f587-4f01-8274-e6d203e1e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc5d79c8-e7d8-4db8-89d9-c8b9bc132aee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityRegistrantName_bc5d79c8-e7d8-4db8-89d9-c8b9bc132aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8f8101da-ce13-4162-bd24-85adbe3518ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8f8101da-ce13-4162-bd24-85adbe3518ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c171751b-163d-4620-ab63-68c8513fcf04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityTaxIdentificationNumber_c171751b-163d-4620-ab63-68c8513fcf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7f04380b-72d0-404c-a3b2-a6115a70d0fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressAddressLine1_7f04380b-72d0-404c-a3b2-a6115a70d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4eb1c66f-376f-4703-81f0-fb477f6bf9b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressCityOrTown_4eb1c66f-376f-4703-81f0-fb477f6bf9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_63ec4074-4dcb-4969-9b5d-1d0729426fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressStateOrProvince_63ec4074-4dcb-4969-9b5d-1d0729426fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6c068931-4168-4d97-acad-a613813e6578" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityAddressPostalZipCode_6c068931-4168-4d97-acad-a613813e6578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a92e4e71-22f2-49a2-9fab-a294d12e0187" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_CityAreaCode_a92e4e71-22f2-49a2-9fab-a294d12e0187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_844ceca3-faac-47e0-b354-651c8dec751a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_LocalPhoneNumber_844ceca3-faac-47e0-b354-651c8dec751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ab626842-9e45-4d14-ac82-a9d39ebd4d53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_Security12bTitle_ab626842-9e45-4d14-ac82-a9d39ebd4d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6f70ffd6-5c98-4129-9fdf-b1a7b031e47a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_TradingSymbol_6f70ffd6-5c98-4129-9fdf-b1a7b031e47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8434e35c-7dff-484c-a104-e0b2bd913ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_SecurityExchangeName_8434e35c-7dff-484c-a104-e0b2bd913ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7ee59e8b-d9cb-4a50-928d-a005ea432e32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCurrentReportingStatus_7ee59e8b-d9cb-4a50-928d-a005ea432e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aee0a644-6173-4b90-be43-f75a56c6961c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityInteractiveDataCurrent_aee0a644-6173-4b90-be43-f75a56c6961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c86d91b9-36a9-4014-8e2c-3fc2a606a0cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityFilerCategory_c86d91b9-36a9-4014-8e2c-3fc2a606a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ebfcc4e0-3095-40a3-aa48-e1a49042e753" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntitySmallBusiness_ebfcc4e0-3095-40a3-aa48-e1a49042e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_04d69e7a-e1ca-424c-89ad-2ffff4e9b860" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityEmergingGrowthCompany_04d69e7a-e1ca-424c-89ad-2ffff4e9b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_772e3389-8151-4d0e-bc2a-d54f268a2a21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityShellCompany_772e3389-8151-4d0e-bc2a-d54f268a2a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_59da3c57-e247-4297-834b-b08b1f091a6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_59da3c57-e247-4297-834b-b08b1f091a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_21e4bb3e-bbd4-4d4a-8ba5-d8399e7f239d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_AmendmentFlag_21e4bb3e-bbd4-4d4a-8ba5-d8399e7f239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0435fb45-39f0-4a78-9298-97c060686ed0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentFiscalYearFocus_0435fb45-39f0-4a78-9298-97c060686ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57af6a42-3877-4a46-bdb4-08bd5c811d36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57af6a42-3877-4a46-bdb4-08bd5c811d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_276c5464-422e-45da-8490-2fb2c8e9f0b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_EntityCentralIndexKey_276c5464-422e-45da-8490-2fb2c8e9f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_59aa7244-dfea-40f2-a60f-bc988e02f4aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2caa71d-1c9b-465a-9621-ce01012d50fc" xlink:to="loc_dei_CurrentFiscalYearEndDate_59aa7244-dfea-40f2-a60f-bc988e02f4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:to="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37f9ca17-62a6-47d9-a322-b29bd3ee5a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37f9ca17-62a6-47d9-a322-b29bd3ee5a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_b7d33c90-168e-4218-b043-3be4db730b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_ReceivablesAbstract_b7d33c90-168e-4218-b043-3be4db730b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ReceivableCommercializationRightsCurrent_f2101d3a-c201-46bf-8167-7771400ace3a" xlink:href="mo-20230331.xsd#mo_ReceivableCommercializationRightsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_b7d33c90-168e-4218-b043-3be4db730b98" xlink:to="loc_mo_ReceivableCommercializationRightsCurrent_f2101d3a-c201-46bf-8167-7771400ace3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d2d5a340-a81a-4ac8-9155-bf179a336540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_b7d33c90-168e-4218-b043-3be4db730b98" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d2d5a340-a81a-4ac8-9155-bf179a336540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves_050764e8-9319-466a-a896-3e53c28f835a" xlink:href="mo-20230331.xsd#mo_InventoryRawMaterialsPlantMaterialNetofReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:to="loc_mo_InventoryRawMaterialsPlantMaterialNetofReserves_050764e8-9319-466a-a896-3e53c28f835a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherInventoryRawMaterialsNetofReserves_977a8b58-2e24-42f6-939a-0e1284506a46" xlink:href="mo-20230331.xsd#mo_OtherInventoryRawMaterialsNetofReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:to="loc_mo_OtherInventoryRawMaterialsNetofReserves_977a8b58-2e24-42f6-939a-0e1284506a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_28003532-1a1c-4eeb-961b-c19070e21301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_28003532-1a1c-4eeb-961b-c19070e21301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d10bbb0f-0a1c-4e0f-ab8e-eedf7260556b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d10bbb0f-0a1c-4e0f-ab8e-eedf7260556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0fba472f-9f3b-415b-97ce-2d3329a93450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_403e90f8-3bf9-4a96-adfa-6b914cd1a078" xlink:to="loc_us-gaap_InventoryNet_0fba472f-9f3b-415b-97ce-2d3329a93450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cca2633a-60a7-4e40-9b25-09dda7eeb7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_OtherAssetsCurrent_cca2633a-60a7-4e40-9b25-09dda7eeb7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e5962f7-16db-41e3-a9d9-eff17a8c4a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_AssetsCurrent_7e5962f7-16db-41e3-a9d9-eff17a8c4a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0578f6bd-8376-41ae-811f-90f88640766b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0578f6bd-8376-41ae-811f-90f88640766b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_34522857-716e-4596-a8d4-98e04b329d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_34522857-716e-4596-a8d4-98e04b329d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6619ffd8-3569-4e10-af25-714e6c1079b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6619ffd8-3569-4e10-af25-714e6c1079b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be734c8a-8b8d-4cb9-9f0d-8054c95d6326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_Goodwill_be734c8a-8b8d-4cb9-9f0d-8054c95d6326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_da44575c-bd27-4f17-b482-33aac83e516f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_da44575c-bd27-4f17-b482-33aac83e516f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_aac5a407-3002-4580-8eb8-dfd4487fbbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_Investments_aac5a407-3002-4580-8eb8-dfd4487fbbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_573ac270-26b1-4816-bfc3-7b2ab86db749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_573ac270-26b1-4816-bfc3-7b2ab86db749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_12736248-0ada-48b8-83be-2f017564cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18f15dcc-0d8b-4944-aad8-34ac45b63bac" xlink:to="loc_us-gaap_Assets_12736248-0ada-48b8-83be-2f017564cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:to="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2f57d8bb-c8fb-456b-9eca-326f7f9a35ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_LongTermDebtCurrent_2f57d8bb-c8fb-456b-9eca-326f7f9a35ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c438874-e5b6-4002-a79a-8638ad05a137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c438874-e5b6-4002-a79a-8638ad05a137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2fed6860-ccde-49b4-9136-f07440e2b474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2fed6860-ccde-49b4-9136-f07440e2b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_b32f33e0-839e-4509-bf70-2d7a1d1ef75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2fed6860-ccde-49b4-9136-f07440e2b474" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_b32f33e0-839e-4509-bf70-2d7a1d1ef75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccruedSettlementLiabilityCurrent_7f960449-485f-408a-ba0f-8848aa14892c" xlink:href="mo-20230331.xsd#mo_AccruedSettlementLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2fed6860-ccde-49b4-9136-f07440e2b474" xlink:to="loc_mo_AccruedSettlementLiabilityCurrent_7f960449-485f-408a-ba0f-8848aa14892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4ce03a3e-2c5a-4e47-9298-ea914672b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_2fed6860-ccde-49b4-9136-f07440e2b474" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4ce03a3e-2c5a-4e47-9298-ea914672b51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_2febb45c-ccfe-4530-8cb3-79a0b74c7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_DividendsPayableCurrent_2febb45c-ccfe-4530-8cb3-79a0b74c7b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7a25144b-cab1-45ce-9a28-261039b06bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_LiabilitiesCurrent_7a25144b-cab1-45ce-9a28-261039b06bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eb961e1a-5b10-4616-bd8a-1c95cc12fb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eb961e1a-5b10-4616-bd8a-1c95cc12fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10e9df3d-9fed-4b2e-888a-3cfbb12881d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10e9df3d-9fed-4b2e-888a-3cfbb12881d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_54aca10e-d44e-4a0a-88fd-492311e23feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_54aca10e-d44e-4a0a-88fd-492311e23feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_c82641f1-aa4d-4a25-9296-4993e9acab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_c82641f1-aa4d-4a25-9296-4993e9acab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_31f4297f-55cb-4aad-8903-155ef0ee1cb4" xlink:href="mo-20230331.xsd#mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent_31f4297f-55cb-4aad-8903-155ef0ee1cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_741580c6-19f9-4696-81d7-c3fab31ef188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_741580c6-19f9-4696-81d7-c3fab31ef188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2b022caf-1c04-44d7-a278-4210e79090ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c9adf0f6-f9fc-44ce-ab91-8bd00bccb7d2" xlink:to="loc_us-gaap_Liabilities_2b022caf-1c04-44d7-a278-4210e79090ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_591da5cc-1a9f-47b7-88bc-1cdb6eb5d9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:to="loc_us-gaap_CommitmentsAndContingencies_591da5cc-1a9f-47b7-88bc-1cdb6eb5d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4a99facb-c295-4a9b-81fe-723dccf9154a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_CommonStockValue_4a99facb-c295-4a9b-81fe-723dccf9154a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f9e3ab09-bcae-44ac-8922-c9b44acb1b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f9e3ab09-bcae-44ac-8922-c9b44acb1b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5cae9b00-ca5b-49b5-bdb0-8a9642ea4201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5cae9b00-ca5b-49b5-bdb0-8a9642ea4201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ad10d40-f12c-4536-8737-6785d43ab5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ad10d40-f12c-4536-8737-6785d43ab5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6de8b93a-750e-49c7-b214-c3e5f2093aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_TreasuryStockValue_6de8b93a-750e-49c7-b214-c3e5f2093aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_246c883a-fa08-42da-a8d3-55548e563082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_StockholdersEquity_246c883a-fa08-42da-a8d3-55548e563082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6d1bb68c-8843-464f-902c-5aa98acd6379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_MinorityInterest_6d1bb68c-8843-464f-902c-5aa98acd6379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7582f7aa-5544-42bb-90ef-9436e4d36b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d37251f1-76fa-4a71-9ff8-b667a4c8a9e6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7582f7aa-5544-42bb-90ef-9436e4d36b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_646beb42-1763-42b8-b2fc-d3303bd170ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7179e21-0d37-4312-bc2e-b4a7a0541f53" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_646beb42-1763-42b8-b2fc-d3303bd170ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3e4f699c-be60-41b1-9c4a-909af586443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3e4f699c-be60-41b1-9c4a-909af586443a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_62cce571-7621-4298-8f08-62bb43b93485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_62cce571-7621-4298-8f08-62bb43b93485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fef345b2-8b7e-49db-a52e-f5e61e4e60ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fef345b2-8b7e-49db-a52e-f5e61e4e60ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e37ce618-e703-4581-a950-87a68767f952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:to="loc_us-gaap_CommonStockSharesIssued_e37ce618-e703-4581-a950-87a68767f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9f04648c-c2eb-4631-b4db-f62d3d3f5b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b55868b7-32fc-43d9-bec9-14818f3bb7b0" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9f04648c-c2eb-4631-b4db-f62d3d3f5b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2e97cd-035b-403a-8441-ea91ac170505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2e97cd-035b-403a-8441-ea91ac170505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98f589b7-9939-490a-9d02-0e3d311580d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98f589b7-9939-490a-9d02-0e3d311580d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue_44981461-9213-4703-bcc9-b3c050c3822b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_OtherCostOfOperatingRevenue_44981461-9213-4703-bcc9-b3c050c3822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e75527bb-fda2-4c63-9471-35b651ce2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_GrossProfit_e75527bb-fda2-4c63-9471-35b651ce2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MarketingAdministrationandResearchCosts_1a7441d6-89e9-47ce-ae5e-750a5560e7da" xlink:href="mo-20230331.xsd#mo_MarketingAdministrationandResearchCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_mo_MarketingAdministrationandResearchCosts_1a7441d6-89e9-47ce-ae5e-750a5560e7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c42a832-2168-4dc1-9fc8-366a45608e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_OperatingIncomeLoss_7c42a832-2168-4dc1-9fc8-366a45608e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_d805e2d3-516e-4663-84e9-ec289a5b231e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_d805e2d3-516e-4663-84e9-ec289a5b231e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_69ad55c4-a237-4ee7-a55a-10c57a69fa66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_69ad55c4-a237-4ee7-a55a-10c57a69fa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_46eb0ba9-6de9-44c0-9cec-28557bfac62e" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_mo_IncomeLossFromEquitySecurities_46eb0ba9-6de9-44c0-9cec-28557bfac62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3c51c107-d420-4eb3-807d-ae0785fde11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3c51c107-d420-4eb3-807d-ae0785fde11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bf81a37-7153-4ed2-a81b-eec560dc5292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bf81a37-7153-4ed2-a81b-eec560dc5292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_348aee46-d7e5-4b50-9829-cd12d7eac391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_348aee46-d7e5-4b50-9829-cd12d7eac391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb7eb1de-170b-4d62-8ebc-c1a20b1e66bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_NetIncomeLoss_eb7eb1de-170b-4d62-8ebc-c1a20b1e66bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_68ddad88-62ad-4198-996d-e99150597b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_16f27a76-39f1-45be-9c40-d6554803dc28" xlink:to="loc_us-gaap_EarningsPerShareAbstract_68ddad88-62ad-4198-996d-e99150597b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0989d22a-38ef-4fda-8f60-2761d49abb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_68ddad88-62ad-4198-996d-e99150597b65" xlink:to="loc_us-gaap_EarningsPerShareBasic_0989d22a-38ef-4fda-8f60-2761d49abb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5151551f-5a7a-4afc-b4e5-28f089c9035a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_68ddad88-62ad-4198-996d-e99150597b65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5151551f-5a7a-4afc-b4e5-28f089c9035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveEarnings"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8cd7d401-941b-4389-be2e-05488b3e9851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_573f4263-09cb-40f2-92e7-c589c9642f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8cd7d401-941b-4389-be2e-05488b3e9851" xlink:to="loc_us-gaap_ProfitLoss_573f4263-09cb-40f2-92e7-c589c9642f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8cd7d401-941b-4389-be2e-05488b3e9851" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6a2ee548-19a8-46c0-b8a1-6f24045b1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6a2ee548-19a8-46c0-b8a1-6f24045b1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax_75b36eb8-1b86-4b06-a8bc-1a9bca5a93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciEquityMethodInvestmentAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:to="loc_us-gaap_OciEquityMethodInvestmentAfterTax_75b36eb8-1b86-4b06-a8bc-1a9bca5a93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60a1565e-40bf-486b-a9d6-9722761441cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60a1565e-40bf-486b-a9d6-9722761441cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f815badc-a46f-40c1-95b6-dcae3a2ca134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f103d7e5-a0d2-4bea-9b0c-940a8679e071" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f815badc-a46f-40c1-95b6-dcae3a2ca134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_573438fb-0a09-4767-98bf-283465dc7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8cd7d401-941b-4389-be2e-05488b3e9851" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_573438fb-0a09-4767-98bf-283465dc7f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4596779e-f93e-436c-ac7a-f2987cd4aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4596779e-f93e-436c-ac7a-f2987cd4aae5" xlink:to="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2235768f-46a0-4a04-ba2d-fac5395b8539" xlink:to="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f72d66a1-fbe5-44c4-a190-fe76144cd651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_CommonStockMember_f72d66a1-fbe5-44c4-a190-fe76144cd651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_283fbd9e-4ae9-49eb-8923-d1410721ffa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_283fbd9e-4ae9-49eb-8923-d1410721ffa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7532ecf2-cef9-4000-89cc-929529511a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_RetainedEarningsMember_7532ecf2-cef9-4000-89cc-929529511a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_275cbd7f-1918-4a00-b249-da9aa5cf56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_275cbd7f-1918-4a00-b249-da9aa5cf56a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_208e7b17-75e7-4bcd-87e2-46ddd25ddb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_TreasuryStockMember_208e7b17-75e7-4bcd-87e2-46ddd25ddb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fc90bdf8-102c-4d7a-acf3-34bbc5360881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3b6d6c9-b6c8-4ff7-a91a-e2b473c650a1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fc90bdf8-102c-4d7a-acf3-34bbc5360881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29f52b6f-0d61-4cae-8cba-c6ddaafc6506" xlink:to="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09311130-14f9-42be-8907-5cd588ece6d7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4765f827-4eca-4d08-b71f-963ab6b4897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4765f827-4eca-4d08-b71f-963ab6b4897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_bda5cab9-eb6f-45dd-8ee3-76aa9b8d54e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_bda5cab9-eb6f-45dd-8ee3-76aa9b8d54e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5c0c157e-7fe3-42a3-8e1a-5beb167f4c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5c0c157e-7fe3-42a3-8e1a-5beb167f4c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_e847ae31-0eee-46d4-bacd-47955d79b4ca" xlink:href="mo-20230331.xsd#mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet_e847ae31-0eee-46d4-bacd-47955d79b4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_17fc2c0c-aaab-418c-99a6-0d702b2037eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_DividendsCommonStockCash_17fc2c0c-aaab-418c-99a6-0d702b2037eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e24519a4-8c9d-4b36-8d07-7a091f4c3ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e24519a4-8c9d-4b36-8d07-7a091f4c3ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14e1cb33-f8a7-47ea-abaa-7791d10fc1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7fd31746-13c7-44ad-b410-f1261400517b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14e1cb33-f8a7-47ea-abaa-7791d10fc1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_95ad45c4-b860-43c4-b820-d795712f58f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_eebf6319-ac0f-4b52-8a62-27defa9aeb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_95ad45c4-b860-43c4-b820-d795712f58f5" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_eebf6319-ac0f-4b52-8a62-27defa9aeb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_53bdfadf-8281-4528-824c-2bae64871e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_53bdfadf-8281-4528-824c-2bae64871e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_00bb098f-6684-43e2-86f1-e98d58b41989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_53bdfadf-8281-4528-824c-2bae64871e63" xlink:to="loc_us-gaap_ProfitLoss_00bb098f-6684-43e2-86f1-e98d58b41989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_53bdfadf-8281-4528-824c-2bae64871e63" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b7aa436-e691-476b-9b81-e9f35a5abe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b7aa436-e691-476b-9b81-e9f35a5abe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3277915-db9d-4912-a7da-88bb011865d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3277915-db9d-4912-a7da-88bb011865d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_8cf1d17e-d5db-4b8a-a180-1e5bc8f5da10" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_mo_IncomeLossFromEquitySecurities_8cf1d17e-d5db-4b8a-a180-1e5bc8f5da10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_37dc2071-8f65-4b33-8d87-60628f566e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_37dc2071-8f65-4b33-8d87-60628f566e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_63094664-9b5e-4086-baac-a209403485ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_63094664-9b5e-4086-baac-a209403485ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5881d48f-7069-4e47-ae79-1518a4f3b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5881d48f-7069-4e47-ae79-1518a4f3b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f050e24f-ebb2-4aa3-9b67-781276f7d9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f050e24f-ebb2-4aa3-9b67-781276f7d9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7d3aac79-1158-48ad-b7a3-e431fdd987b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7d3aac79-1158-48ad-b7a3-e431fdd987b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_ede3a07d-dbac-44c0-8c58-55aa553611a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_ede3a07d-dbac-44c0-8c58-55aa553611a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncreaseDecreaseInSettlementPayable_c326ad8e-8381-455a-aeda-bc609769154b" xlink:href="mo-20230331.xsd#mo_IncreaseDecreaseInSettlementPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08fde4ce-d619-4f28-9c1a-ea0ba08d638d" xlink:to="loc_mo_IncreaseDecreaseInSettlementPayable_c326ad8e-8381-455a-aeda-bc609769154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_1bc71ef7-09e4-4972-8fef-b88b249b2547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_1bc71ef7-09e4-4972-8fef-b88b249b2547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_a7f661cd-b2f7-4e02-a70b-e836a17be7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_a7f661cd-b2f7-4e02-a70b-e836a17be7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_93b4061c-dba9-4241-85db-9fe9464d1f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef0c0a49-0771-496e-b415-5ad7268a1ef0" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_93b4061c-dba9-4241-85db-9fe9464d1f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e100623c-273d-49cf-bbe8-b282c4e4d069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_53bdfadf-8281-4528-824c-2bae64871e63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e100623c-273d-49cf-bbe8-b282c4e4d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18f11e1a-8269-4ee8-b9b3-e267dc0f446e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18f11e1a-8269-4ee8-b9b3-e267dc0f446e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47155c9f-8ad2-449f-87f8-10dfa09a08d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18f11e1a-8269-4ee8-b9b3-e267dc0f446e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47155c9f-8ad2-449f-87f8-10dfa09a08d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5cdbc778-78a9-474f-972a-b54edb92eaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18f11e1a-8269-4ee8-b9b3-e267dc0f446e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5cdbc778-78a9-474f-972a-b54edb92eaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6547db86-875f-41dc-a202-1786575dbc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18f11e1a-8269-4ee8-b9b3-e267dc0f446e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6547db86-875f-41dc-a202-1786575dbc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_94b5339a-9bb2-4925-86ce-c740030b2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_94b5339a-9bb2-4925-86ce-c740030b2a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b5d127a-0182-413d-a8da-abd7b7de46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b5d127a-0182-413d-a8da-abd7b7de46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_48833dc1-523c-4351-823f-9869a4d64e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_48833dc1-523c-4351-823f-9869a4d64e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0c50c38e-8eb8-45b0-ad68-f95d5aad8c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0c50c38e-8eb8-45b0-ad68-f95d5aad8c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_806c1a71-cb44-4d6c-8ac3-140d3704eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d4e5af9-5351-4d34-b496-89edc0d2fc10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_806c1a71-cb44-4d6c-8ac3-140d3704eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ad02d3ac-c6e2-48ec-be6b-dd259f8604c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ad02d3ac-c6e2-48ec-be6b-dd259f8604c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3b293de-8e68-4743-9854-e92b49817b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ad02d3ac-c6e2-48ec-be6b-dd259f8604c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3b293de-8e68-4743-9854-e92b49817b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f04fc720-f265-4a65-a769-fc06ce38cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ad02d3ac-c6e2-48ec-be6b-dd259f8604c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f04fc720-f265-4a65-a769-fc06ce38cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_932a61a5-f5ad-4589-80ce-d2c6766848c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ad02d3ac-c6e2-48ec-be6b-dd259f8604c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_932a61a5-f5ad-4589-80ce-d2c6766848c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdcc151f-9f38-4551-a6ee-6ebf56dd9e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdcc151f-9f38-4551-a6ee-6ebf56dd9e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a8607c3e-c1ce-4e42-8110-f9eb1f8b6dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_RestrictedCashCurrent_a8607c3e-c1ce-4e42-8110-f9eb1f8b6dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_61978903-89cb-4c16-9676-d5127c69af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_61978903-89cb-4c16-9676-d5127c69af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1a76f80-a588-43ae-8884-1a84bc0144cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f410adbd-3464-460d-ad73-ac0a74e6985e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1a76f80-a588-43ae-8884-1a84bc0144cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="mo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_62df0508-b5b8-4b68-b92d-b0acc5b4c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_62df0508-b5b8-4b68-b92d-b0acc5b4c64b" xlink:to="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b6fe707-14f4-434a-a054-7775d3992596" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_f55dcc8b-c581-43d9-9cdf-cc1018006603" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_010b88b5-9830-4e2c-bb28-a9c3908200c0" xlink:to="loc_mo_JUULMember_f55dcc8b-c581-43d9-9cdf-cc1018006603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_738a035b-6c4a-4ef6-a129-d6940c6788c5" xlink:to="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_04eea800-8ae5-4d4d-9456-de43dc2b2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_beab87a9-17a0-4825-8003-f84060b10975" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_04eea800-8ae5-4d4d-9456-de43dc2b2c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentation" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d871af99-5663-4be0-b267-7921e50ddbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_da9bf792-085c-4233-ad56-2ba9afbddc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d871af99-5663-4be0-b267-7921e50ddbb1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_da9bf792-085c-4233-ad56-2ba9afbddc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/RevenuesfromContractswithCustomers" xlink:type="simple" xlink:href="mo-20230331.xsd#RevenuesfromContractswithCustomers"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/RevenuesfromContractswithCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ea75061-f904-40fa-808e-4f63917729df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d579f938-5cd9-4f6c-91d4-78508600db55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ea75061-f904-40fa-808e-4f63917729df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d579f938-5cd9-4f6c-91d4-78508600db55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecurities" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecurities"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_be7c27a2-d142-45f7-87eb-1feb05156c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_e0e1db21-f393-42eb-b221-29f75eae0d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_be7c27a2-d142-45f7-87eb-1feb05156c30" xlink:to="loc_us-gaap_InvestmentTextBlock_e0e1db21-f393-42eb-b221-29f75eae0d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da2987ae-9f34-4891-b29e-c32d68779c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_afb6d2ad-f6c5-4e1c-b9bf-f2bcec72bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da2987ae-9f34-4891-b29e-c32d68779c59" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_afb6d2ad-f6c5-4e1c-b9bf-f2bcec72bc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlans" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlans"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6a305974-1944-4188-93a0-c07c7889fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_93a1d64f-6653-432a-9789-ca6bcde42eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6a305974-1944-4188-93a0-c07c7889fcdc" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_93a1d64f-6653-432a-9789-ca6bcde42eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/EarningsperShare" xlink:type="simple" xlink:href="mo-20230331.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e6bf3964-ee6e-4da3-87a8-48896f417b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8eadd985-f904-49a6-b3e6-92c4a4960556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e6bf3964-ee6e-4da3-87a8-48896f417b3d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8eadd985-f904-49a6-b3e6-92c4a4960556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLosses" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLosses"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1342c19c-265e-4f99-b3fa-35cd64d9624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_56cd2a66-cc22-46ce-99fd-58b4c71af62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1342c19c-265e-4f99-b3fa-35cd64d9624b" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_56cd2a66-cc22-46ce-99fd-58b4c71af62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReporting" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_55879ab2-1b02-480c-bfc6-07b6e7e81da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_54df4198-c7e0-43cd-8a4a-27e7abc8b8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_55879ab2-1b02-480c-bfc6-07b6e7e81da0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_54df4198-c7e0-43cd-8a4a-27e7abc8b8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/Debt" xlink:type="simple" xlink:href="mo-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fdb55347-d973-4975-b07f-7ad4076d6025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_83eb03e8-400b-4611-8591-e4d885b92afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fdb55347-d973-4975-b07f-7ad4076d6025" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_83eb03e8-400b-4611-8591-e4d885b92afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6211c0f6-0784-49d8-8fab-a49758f6385c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_aa174313-a684-4f52-b2e0-933154e435fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6211c0f6-0784-49d8-8fab-a49758f6385c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_aa174313-a684-4f52-b2e0-933154e435fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/Contingencies" xlink:type="simple" xlink:href="mo-20230331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c2c7bf5-f8fa-4060-bee1-1ee426274884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_06a025b7-9f0a-4e2f-a62f-03aa5f986d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c2c7bf5-f8fa-4060-bee1-1ee426274884" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_06a025b7-9f0a-4e2f-a62f-03aa5f986d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted" xlink:type="simple" xlink:href="mo-20230331.xsd#NewAccountingGuidanceNotYetAdopted"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_fac504c1-25e7-47d8-8ca9-80dc596b638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d512e6e0-c6a3-4700-af91-f72d7eeb7982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_fac504c1-25e7-47d8-8ca9-80dc596b638d" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d512e6e0-c6a3-4700-af91-f72d7eeb7982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_85f0e526-110e-410d-8596-7e6629862f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_85f0e526-110e-410d-8596-7e6629862f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3500eb35-cec4-40f3-8644-9e48c1f2e024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3500eb35-cec4-40f3-8644-9e48c1f2e024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1f15b80b-56cb-4bae-a134-7777aa4470e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1f15b80b-56cb-4bae-a134-7777aa4470e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CashDiscountsPolicyTextBlock_3a436461-fb8a-4fc7-892b-686a97299f02" xlink:href="mo-20230331.xsd#mo_CashDiscountsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_mo_CashDiscountsPolicyTextBlock_3a436461-fb8a-4fc7-892b-686a97299f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e35ba773-1a0d-4b6d-ba01-32cb4cafa6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e35ba773-1a0d-4b6d-ba01-32cb4cafa6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_7cf08f21-a60c-4c96-a7be-43ad12abfb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_7cf08f21-a60c-4c96-a7be-43ad12abfb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a7508b0f-1a0a-4cc8-bbfc-bb3b7aed7215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a7508b0f-1a0a-4cc8-bbfc-bb3b7aed7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock_ba075f8b-8276-40dd-b824-864f2efb8b7c" xlink:href="mo-20230331.xsd#mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477d5868-0d8e-4d74-ba1d-00daececc0ca" xlink:to="loc_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock_ba075f8b-8276-40dd-b824-864f2efb8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationTables" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e068046e-ae76-4e80-bc68-3928b4caaef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_f8daad04-5b11-4cc0-9f12-426e468766dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e068046e-ae76-4e80-bc68-3928b4caaef0" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_f8daad04-5b11-4cc0-9f12-426e468766dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesTables" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_e70599ab-fa9b-4ef2-8fe7-88b59a4c73ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_2a39f153-e498-4b8a-8fe3-226b2996cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e70599ab-fa9b-4ef2-8fe7-88b59a4c73ff" xlink:to="loc_us-gaap_InvestmentTableTextBlock_2a39f153-e498-4b8a-8fe3-226b2996cb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_bb4bbce5-608b-4daa-bd94-19b5c37085b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e70599ab-fa9b-4ef2-8fe7-88b59a4c73ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_bb4bbce5-608b-4daa-bd94-19b5c37085b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e94d97c-e527-4a8b-a2c0-89e34a1bf262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_08207550-b834-4918-b346-19907c0493da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e94d97c-e527-4a8b-a2c0-89e34a1bf262" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_08207550-b834-4918-b346-19907c0493da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansTables" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eefa69b2-979a-4de2-b39b-62780cc38a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8c5c81a9-b1bb-4d98-975d-2efe2b0c0ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eefa69b2-979a-4de2-b39b-62780cc38a85" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8c5c81a9-b1bb-4d98-975d-2efe2b0c0ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mo-20230331.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b23a10f7-ece3-4013-b040-55f1d22671bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_391a831a-f9f2-413d-a62a-2b349ff95244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b23a10f7-ece3-4013-b040-55f1d22671bb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_391a831a-f9f2-413d-a62a-2b349ff95244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesTables" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0f1ce552-bcf4-47da-b7f4-994d86e975f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bc9618b7-a511-4798-aa26-bcc28b7a7757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0f1ce552-bcf4-47da-b7f4-994d86e975f7" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bc9618b7-a511-4798-aa26-bcc28b7a7757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_6ce8cad9-5811-4a77-85ad-b672e7227351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0f1ce552-bcf4-47da-b7f4-994d86e975f7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_6ce8cad9-5811-4a77-85ad-b672e7227351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3a42f8cd-1414-4eb2-acf8-aee5313f5061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5b65d861-1e2c-4f54-88f6-89dd2bb19263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a42f8cd-1414-4eb2-acf8-aee5313f5061" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5b65d861-1e2c-4f54-88f6-89dd2bb19263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock_274938e2-edbc-4581-a3d5-4b0e102b3dbd" xlink:href="mo-20230331.xsd#mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a42f8cd-1414-4eb2-acf8-aee5313f5061" xlink:to="loc_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock_274938e2-edbc-4581-a3d5-4b0e102b3dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock_5abf933d-c3b8-48f9-bb42-b4435c9b903e" xlink:href="mo-20230331.xsd#mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a42f8cd-1414-4eb2-acf8-aee5313f5061" xlink:to="loc_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock_5abf933d-c3b8-48f9-bb42-b4435c9b903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d7c2146e-3ef4-4e19-aec9-b8b0665313b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SummaryOfIncomeTaxesTableTextBlock_18552900-c245-4abf-af13-2dddf14979a4" xlink:href="mo-20230331.xsd#mo_SummaryOfIncomeTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7c2146e-3ef4-4e19-aec9-b8b0665313b8" xlink:to="loc_mo_SummaryOfIncomeTaxesTableTextBlock_18552900-c245-4abf-af13-2dddf14979a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_10686db6-8606-4a12-85a1-1a5fe71c200d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7c2146e-3ef4-4e19-aec9-b8b0665313b8" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_10686db6-8606-4a12-85a1-1a5fe71c200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesTables" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5c660f8-943b-4ab3-9fbb-c0cd1ae8c49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_923e1b25-e75c-43aa-8b0d-0bb92c14b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5c660f8-943b-4ab3-9fbb-c0cd1ae8c49e" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_923e1b25-e75c-43aa-8b0d-0bb92c14b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables" xlink:type="simple" xlink:href="mo-20230331.xsd#NewAccountingGuidanceNotYetAdoptedTables"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_881b0e9c-3e52-400a-8fe4-8f17f3e4d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d14561cd-a609-43f6-8e48-6eaa1f5d15d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_881b0e9c-3e52-400a-8fe4-8f17f3e4d0e4" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d14561cd-a609-43f6-8e48-6eaa1f5d15d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4dbb24ea-470a-4595-af7c-5d38ec4a9893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4dbb24ea-470a-4595-af7c-5d38ec4a9893" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d052a390-ea8c-48fd-97e4-e105b7225102" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2021ShareRepurchaseProgramMember_7eff3596-21f2-47ec-9d4d-d04a5ccf273a" xlink:href="mo-20230331.xsd#mo_January2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:to="loc_mo_January2021ShareRepurchaseProgramMember_7eff3596-21f2-47ec-9d4d-d04a5ccf273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2023ShareRepurchaseProgramMember_6b61467d-c11b-42c8-b4a6-c40cfe25cc6f" xlink:href="mo-20230331.xsd#mo_January2023ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ad1e7bbd-6ea8-4c79-9a99-40b71a2a2363" xlink:to="loc_mo_January2023ShareRepurchaseProgramMember_6b61467d-c11b-42c8-b4a6-c40cfe25cc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2d8f8023-03dc-4f60-af53-847ff1f466ef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NJOYHoldingsIncMember_09709ce7-882c-42be-86f4-e760e0413b09" xlink:href="mo-20230331.xsd#mo_NJOYHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db89c5b5-1d7d-463d-b39c-c8bf9d1fab1b" xlink:to="loc_mo_NJOYHoldingsIncMember_09709ce7-882c-42be-86f4-e760e0413b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b9b2e75b-0380-418e-a487-27900efb30e5" xlink:to="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HorizonMember_6920f521-b2b7-48e2-abeb-6624898d3464" xlink:href="mo-20230331.xsd#mo_HorizonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_04fc500c-20c5-48f0-a112-6266624d9cf3" xlink:to="loc_mo_HorizonMember_6920f521-b2b7-48e2-abeb-6624898d3464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_38c6b853-eb4f-4aad-85a0-7fd4317cca69" xlink:to="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_ef1ad0d5-153d-447d-b00e-fca521d84fa0" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:to="loc_mo_PhilipMorrisUSAMember_ef1ad0d5-153d-447d-b00e-fca521d84fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JTIUHMember_4804dad7-91b9-4951-a341-ce95c3edec5a" xlink:href="mo-20230331.xsd#mo_JTIUHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4c932711-3c77-4e2f-ab1a-48f060fc9d7b" xlink:to="loc_mo_JTIUHMember_4804dad7-91b9-4951-a341-ce95c3edec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_db5ca9fe-f609-4ab0-80d3-2b73d744e642" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f834c927-371e-4c4e-b935-7f3e0c55f9a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2477ff0a-8596-4e29-a9f5-0a575f17f625" xlink:to="loc_srt_ScenarioForecastMember_f834c927-371e-4c4e-b935-7f3e0c55f9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c8b634ce-df1b-446b-8d4d-68397e1812bc" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OwnershipPercentageInConsolidatedSubsidiary_f199e7db-1e09-4247-a521-06ddd95a8aed" xlink:href="mo-20230331.xsd#mo_OwnershipPercentageInConsolidatedSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_mo_OwnershipPercentageInConsolidatedSubsidiary_f199e7db-1e09-4247-a521-06ddd95a8aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_696ccf01-3557-41d8-b7c0-9f5c40cc6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_696ccf01-3557-41d8-b7c0-9f5c40cc6cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a15acdc4-2c3a-406f-ac71-9abc995ded91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a15acdc4-2c3a-406f-ac71-9abc995ded91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f694e8a-68c2-4fbc-8383-0cadf8a854e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f694e8a-68c2-4fbc-8383-0cadf8a854e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_187e94b0-99f7-4510-8b3f-b64a59faca22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0ccff3d8-603d-42fb-98da-a098d87e48ff" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_187e94b0-99f7-4510-8b3f-b64a59faca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BackgroundandBasisofPresentationShareRepurchaseTableDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b3a50a8-21e5-40af-83fd-389cc652f9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b3a50a8-21e5-40af-83fd-389cc652f9dc" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_92c67c32-8542-437a-840c-37f5aa78ae53" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_January2021ShareRepurchaseProgramMember_c0f82467-61b4-4ca5-bfee-7f0a2c1a3502" xlink:href="mo-20230331.xsd#mo_January2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5b6089ad-8cfc-4984-b9e3-db65cbfc5b31" xlink:to="loc_mo_January2021ShareRepurchaseProgramMember_c0f82467-61b4-4ca5-bfee-7f0a2c1a3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b1b6a12f-836d-4a1f-9592-94b4873e817e" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_22e031df-a48c-4efd-97fe-7971ed7c48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_22e031df-a48c-4efd-97fe-7971ed7c48a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_296ce585-54a2-42d9-8cce-7f37b50c0e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_296ce585-54a2-42d9-8cce-7f37b50c0e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2c367848-f75b-478c-a0a6-e3b95c0bc226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_0a175045-11b9-4a3d-b1c6-de0d8ad5cf30" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2c367848-f75b-478c-a0a6-e3b95c0bc226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#RevenuesfromContractswithCustomersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa665105-1aeb-43cf-ab02-5144d708c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_416c34e9-af4d-45ec-92b3-6ad4c7bda8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa665105-1aeb-43cf-ab02-5144d708c0ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_416c34e9-af4d-45ec-92b3-6ad4c7bda8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6587edb0-aba7-4ba8-9ac8-772a7a26714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa665105-1aeb-43cf-ab02-5144d708c0ba" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6587edb0-aba7-4ba8-9ac8-772a7a26714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_733c127e-3fc7-4315-8adb-721f8aea815b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa665105-1aeb-43cf-ab02-5144d708c0ba" xlink:to="loc_us-gaap_ReceivablesNetCurrent_733c127e-3fc7-4315-8adb-721f8aea815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_f522550a-a801-4978-b11a-73bb7bea1f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa665105-1aeb-43cf-ab02-5144d708c0ba" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_f522550a-a801-4978-b11a-73bb7bea1f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_c0b6710f-038d-48ce-802d-718790ce6013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_c0b6710f-038d-48ce-802d-718790ce6013" xlink:to="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1826316-0f56-48be-9f44-e0504477f7bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_23012fa7-1fcc-459c-881f-166215edaa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4c99dad-12fd-4873-9075-5c9833c755ca" xlink:to="loc_us-gaap_CommonStockMember_23012fa7-1fcc-459c-881f-166215edaa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c215bb81-8133-4ea7-93c1-e7eaaba838b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_fa1ae3e1-6488-4e40-abbd-5754a51116fa" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_ABInBevMember_fa1ae3e1-6488-4e40-abbd-5754a51116fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_eb03b451-424b-4c2b-bd8e-dcd720bf84c2" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_JUULMember_eb03b451-424b-4c2b-bd8e-dcd720bf84c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_ef2f00f3-3502-4e8e-bb48-e10a1567430b" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_431dfe07-7673-4561-ae66-1b723da74aca" xlink:to="loc_mo_CronosGroupInc.Member_ef2f00f3-3502-4e8e-bb48-e10a1567430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_53555c73-b587-4d56-9c68-30f5626cec17" xlink:to="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4aab6d2c-f45a-4d2c-bc78-5c05195a4e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_EquityMethodInvestments_4aab6d2c-f45a-4d2c-bc78-5c05195a4e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b827bb6f-5a5d-4430-8a1c-2a2542f5adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b827bb6f-5a5d-4430-8a1c-2a2542f5adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_a56cb62c-c979-4f76-835b-4d6f8432b5e1" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights_a56cb62c-c979-4f76-835b-4d6f8432b5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_b8d2e556-6523-46bd-98e8-44f333b5d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_0866cd36-f2c2-4878-8e83-b325702d1e4b" xlink:to="loc_us-gaap_Investments_b8d2e556-6523-46bd-98e8-44f333b5d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_ea947188-cb5f-4f49-bd6b-99ed7a433dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ea947188-cb5f-4f49-bd6b-99ed7a433dfd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_35e9e082-d687-4642-bedd-a1ff13aa9c4a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_39d6770d-fe16-499a-b5ed-308f602fa8ee" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_ABInBevMember_39d6770d-fe16-499a-b5ed-308f602fa8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_e0261fdf-0414-4b05-aa53-a64ce7fdbf4a" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_CronosGroupInc.Member_e0261fdf-0414-4b05-aa53-a64ce7fdbf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_ca2360f2-51c1-4da2-9bb2-7b260b1f7c35" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_74b07d22-c671-4c95-a349-0f24a417ea77" xlink:to="loc_mo_JUULMember_ca2360f2-51c1-4da2-9bb2-7b260b1f7c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_761544fb-52b1-45f8-884f-e516a31bf2ba" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa11bbb6-35d9-4d28-9dcb-1866450a0ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa11bbb6-35d9-4d28-9dcb-1866450a0ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3c70b060-fbf9-49c6-841e-e790c7829766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3c70b060-fbf9-49c6-841e-e790c7829766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_f0757f90-11db-4baa-9a07-b8d90a57268b" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6c97ef2c-beaf-4087-93cd-8d38d9a6e334" xlink:to="loc_mo_IncomeLossFromEquitySecurities_f0757f90-11db-4baa-9a07-b8d90a57268b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_2a69266c-0b0e-4bd3-bad1-e04c8a490072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_2a69266c-0b0e-4bd3-bad1-e04c8a490072" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87dcebf2-b798-4696-b457-a0535e36e294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8af429b-27bc-4738-b20b-2172d351b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0645efe4-365e-4fec-bf7e-cd950606cde2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8af429b-27bc-4738-b20b-2172d351b9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64c61319-7ada-4c45-bda2-5aa12481db16" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ABInBevMember_46757f57-314d-4ae8-a5bf-30d5f91a865a" xlink:href="mo-20230331.xsd#mo_ABInBevMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c19cbe03-57cc-4139-93e1-17e2aedf0247" xlink:to="loc_mo_ABInBevMember_46757f57-314d-4ae8-a5bf-30d5f91a865a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_496b37bb-1e5e-4aa0-b34c-8caa87271655" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b806c0bc-1c56-45a3-9a65-d8b8fdb0a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b806c0bc-1c56-45a3-9a65-d8b8fdb0a537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_e1f36a33-974c-495f-b255-6d61d9442001" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedRestricted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted_e1f36a33-974c-495f-b255-6d61d9442001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_3bbd9236-3752-433d-b919-b44edc9e095d" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedCommon"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_3bbd9236-3752-433d-b919-b44edc9e095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_04d5fe2a-edf8-4179-aa69-7f3fc314b881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_04d5fe2a-edf8-4179-aa69-7f3fc314b881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_8f182daf-f4af-4175-9bd3-52ba320ed1f3" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_8f182daf-f4af-4175-9bd3-52ba320ed1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_0403fa75-7cac-4ac9-9b84-10ce2ee4d6b1" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d697f28c-1990-47bd-9b03-4f6652dabf47" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_0403fa75-7cac-4ac9-9b84-10ce2ee4d6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_e16c1c1e-dce5-463e-8f01-69a55957b259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e16c1c1e-dce5-463e-8f01-69a55957b259" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a89c4a4d-2919-4068-8bfa-a2185615b652" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_c6f4ae59-ddd0-4dea-90b5-e3c930659e6a" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32f15155-9a3a-45d1-a759-cde6bee3ac94" xlink:to="loc_mo_JUULMember_c6f4ae59-ddd0-4dea-90b5-e3c930659e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bba8db5e-fbae-4b8a-bf34-a53ef2e038a7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_82578a85-33cb-4baa-a59e-48f2f8c158fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31a68997-dfe2-45c3-b5d4-73834b7a68f2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_82578a85-33cb-4baa-a59e-48f2f8c158fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6679398c-db98-4d82-82eb-1b87122526ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6679398c-db98-4d82-82eb-1b87122526ad" xlink:to="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f8dfe000-37b5-4574-b9fe-c957f106b5ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cf8d4cf5-b537-4c98-a7f4-64d40fb0ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7dfe1e3c-d5a8-42dd-957c-1e0d2929c8c4" xlink:to="loc_us-gaap_EquitySecuritiesMember_cf8d4cf5-b537-4c98-a7f4-64d40fb0ba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c9e6d625-eae6-4c49-bae8-1c8d8e4a7403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_15f4f474-53d9-4a27-9a50-b394d245b4c6" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cb8956c4-1b61-44b8-b355-2fb3a7bf7465" xlink:to="loc_mo_JUULMember_15f4f474-53d9-4a27-9a50-b394d245b4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_eaaae465-b4b2-4393-8c86-faea4a156a54" xlink:to="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_00669d47-0f2c-4bc7-9bc3-e49316197740" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_36ae9934-e814-4da2-acbc-e28c060bfc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_36ae9934-e814-4da2-acbc-e28c060bfc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d0005ae9-23d4-45de-9738-0f18c0713722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d0005ae9-23d4-45de-9738-0f18c0713722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2c47d240-b159-404c-94a8-f905bee51c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be491d7a-20a1-492e-8b44-a5afea849a21" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2c47d240-b159-404c-94a8-f905bee51c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_acf572e6-bb06-4839-b244-cd7e3261fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_acf572e6-bb06-4839-b244-cd7e3261fda3" xlink:to="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb870d48-00b4-4a0f-9596-4a68fd55aa5b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractPreemptiveRIghtsMember_4866dd1c-2a53-45ff-99e1-2a8982c269f3" xlink:href="mo-20230331.xsd#mo_EquityContractPreemptiveRIghtsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:to="loc_mo_EquityContractPreemptiveRIghtsMember_4866dd1c-2a53-45ff-99e1-2a8982c269f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityContractWarrantMember_6b300870-67b0-4186-a398-1a0298204b5a" xlink:href="mo-20230331.xsd#mo_EquityContractWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0a56dc5-fdf3-49af-951d-c37b221d4f34" xlink:to="loc_mo_EquityContractWarrantMember_6b300870-67b0-4186-a398-1a0298204b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d81fe604-6c80-4446-acd5-97839b1d61dd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CronosGroupInc.Member_8952cd7a-fefa-43ff-a634-dfb327191453" xlink:href="mo-20230331.xsd#mo_CronosGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7d39fa05-93b1-4179-8311-4778b55a2c8b" xlink:to="loc_mo_CronosGroupInc.Member_8952cd7a-fefa-43ff-a634-dfb327191453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_1a74ba97-2bcb-4d3d-8e68-9b0ccb03cc53" xlink:to="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5946e207-456b-41e1-bc57-d1686fc2a754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5946e207-456b-41e1-bc57-d1686fc2a754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_b32d82ed-83d4-4209-a219-5378a006bd63" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentNumberofSharesOwnedCommon"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentNumberofSharesOwnedCommon_b32d82ed-83d4-4209-a219-5378a006bd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_6ad92b13-dd70-490e-bf13-15e766769ea6" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue_6ad92b13-dd70-490e-bf13-15e766769ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_23417d5f-dbcf-4ba1-b608-70c890006fa8" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage_23417d5f-dbcf-4ba1-b608-70c890006fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPricePerShareIfExercised_44219838-f5e2-4be2-b2d7-fd4d61865511" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPricePerShareIfExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentPricePerShareIfExercised_44219838-f5e2-4be2-b2d7-fd4d61865511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights_11bad089-11c4-44c7-a226-d34e4b52b43d" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentsFixedPreemptiveRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentsFixedPreemptiveRights_11bad089-11c4-44c7-a226-d34e4b52b43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_7dac6989-1b1c-41cc-b3a7-ca00f22875ba" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase_7dac6989-1b1c-41cc-b3a7-ca00f22875ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquityMethodInvestmentImpairment_48cd6981-d368-4bf4-930a-49052c55d2bc" xlink:href="mo-20230331.xsd#mo_EquityMethodInvestmentImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_520e91f7-eb5c-4897-b092-b65271a11e5f" xlink:to="loc_mo_EquityMethodInvestmentImpairment_48cd6981-d368-4bf4-930a-49052c55d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_412547b3-b7b1-43f8-a789-0681f9746b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_412547b3-b7b1-43f8-a789-0681f9746b8c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_785f49c6-4726-41c2-a93d-d7521aae8daa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtMember_d5d4e685-bbf7-46d4-a246-ad49064e3a17" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_90dc6b0c-dfe7-426f-9976-654f9247838f" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtMember_d5d4e685-bbf7-46d4-a246-ad49064e3a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89622619-9622-41e4-95bf-94b44edb9072" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_947f5619-48f3-4682-8dee-26f81123beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2caf7d6e-1870-40fa-8c14-937196c7a685" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_947f5619-48f3-4682-8dee-26f81123beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e03d3683-1a59-4de3-b3fb-428daa7795b3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld_d437eb1c-3e95-4f1a-8ee4-99a1059f74f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfForeignCurrencyDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:to="loc_us-gaap_NumberOfForeignCurrencyDerivativesHeld_d437eb1c-3e95-4f1a-8ee4-99a1059f74f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b7460ad6-54ee-4513-891e-18e88c79a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e77d59af-3c0e-435d-98ca-feea034e504b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b7460ad6-54ee-4513-891e-18e88c79a3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#FinancialInstrumentsAggregateFairValueandCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3d2d69e9-7b6b-41a4-bb02-9550ccb100e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3d2d69e9-7b6b-41a4-bb02-9550ccb100e3" xlink:to="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea35c3d6-fbba-4e5e-9307-7a879e936383" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtMember_2be692ef-0fff-45ba-bf71-72606ed60809" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c00e0615-87b8-41b7-bfff-303bad94e533" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtMember_2be692ef-0fff-45ba-bf71-72606ed60809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1726c6be-170a-4cd5-b09b-79ea7f7539f4" xlink:to="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_78a52b37-a322-4fc9-a6e6-d93a4799a976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_us-gaap_LongTermDebt_78a52b37-a322-4fc9-a6e6-d93a4799a976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5e4cc9df-8515-4abf-9da4-6aa98cc320fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_us-gaap_LongTermDebtFairValue_5e4cc9df-8515-4abf-9da4-6aa98cc320fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:href="mo-20230331.xsd#mo_ForeignCurrencyDenominatedDebtAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e7ef2668-d9f2-4c2e-97a8-187d26bddfc5" xlink:to="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b62b24c-62a1-4e0a-950e-5a99d177e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:to="loc_us-gaap_LongTermDebt_0b62b24c-62a1-4e0a-950e-5a99d177e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3f001646-c7b1-4c22-b7c9-a13705c548a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ForeignCurrencyDenominatedDebtAbstract_50236f6e-9658-4639-a2a4-e927aef3fc11" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3f001646-c7b1-4c22-b7c9-a13705c548a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_710db5e8-d8b1-458f-ac72-adb4a1881ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_710db5e8-d8b1-458f-ac72-adb4a1881ca8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c12ce5e9-4098-408d-afda-df0adabb857b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4ce983b7-1100-4154-8f2b-72b0ee95dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4ce983b7-1100-4154-8f2b-72b0ee95dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_782306b7-7b39-4d88-8d99-008ee93dd581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b275edc-1289-4c27-8af8-2697ada233e8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_782306b7-7b39-4d88-8d99-008ee93dd581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3cf20bfd-c650-4728-80c0-4dd61d83975c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_37cc8933-c664-4e21-a46c-437227839ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_37cc8933-c664-4e21-a46c-437227839ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_7f0583c6-cae9-4766-bd17-cff2b976444b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_7f0583c6-cae9-4766-bd17-cff2b976444b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ddf6e51c-6bc5-428c-a94b-a12897184634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ddf6e51c-6bc5-428c-a94b-a12897184634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7d650664-d15d-481f-98fc-4e07f0b7ea3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7d650664-d15d-481f-98fc-4e07f0b7ea3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1c5e1567-36ee-4df6-b0f7-cd445c167039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_a99bc078-5067-4dee-b97b-3d6a49ecace0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1c5e1567-36ee-4df6-b0f7-cd445c167039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5f56a778-f4a6-4876-ab22-506e2688c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1cf10d04-bef5-44fd-8097-adf6193f4848" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5f56a778-f4a6-4876-ab22-506e2688c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/BenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#BenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/BenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_032f7fdf-02c8-4560-ba8f-67beef43e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_032f7fdf-02c8-4560-ba8f-67beef43e63f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_da768f4f-4be7-4dc4-8047-1c15a566e4d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2a8ae8d0-5e9f-4c7a-9d67-844628352730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2a8ae8d0-5e9f-4c7a-9d67-844628352730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c4a6c3e5-8471-4535-ae55-2dacc6b88d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_83ced478-0760-4009-9c87-eb26ee4e32fb" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c4a6c3e5-8471-4535-ae55-2dacc6b88d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:to="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1afe3418-2866-41e0-b2f4-a8c3c6549890" xlink:to="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e74a2290-7a63-4d84-b417-c2c326ce6467" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f3a94ec-4587-4aa4-8608-7da6267ca396" xlink:to="loc_srt_MaximumMember_e74a2290-7a63-4d84-b417-c2c326ce6467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f740799-10a9-49c2-8326-83e608a40211" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_facf35dd-d97f-4799-9c31-766b4319041d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_facf35dd-d97f-4799-9c31-766b4319041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_1aff6d32-839d-400f-ae00-ff090f5eaeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a2e27d13-b1ed-4513-adf9-4f2238d72a56" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_1aff6d32-839d-400f-ae00-ff090f5eaeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#EarningsperShareBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_992c292a-2db2-46fe-b82b-3debc581b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_us-gaap_NetIncomeLoss_992c292a-2db2-46fe-b82b-3debc581b3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_2e055de3-5695-45ce-a9db-52fa3e369681" xlink:href="mo-20230331.xsd#mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted_2e055de3-5695-45ce-a9db-52fa3e369681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e56c9d5e-f56f-4670-aa28-8d17f9612bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e56c9d5e-f56f-4670-aa28-8d17f9612bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_adae4011-de27-43f0-861a-5e60e9ae194d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_adae4011-de27-43f0-861a-5e60e9ae194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6bd245d1-b98a-49eb-b928-23e66f034d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6bd245d1-b98a-49eb-b928-23e66f034d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea862587-1885-48f7-9178-d26327d7fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cf607e-0e17-4088-a124-83ca651b5c64" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea862587-1885-48f7-9178-d26327d7fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_979599cf-822b-470d-ade7-ff1492af5145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_979599cf-822b-470d-ade7-ff1492af5145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e93ee70f-50fe-4a4b-b45c-6d3ea414a5bb" xlink:to="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d68e477-33cb-4122-8d27-40df13ff77e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2aa6fd61-a9c7-430f-bc87-f3523f46e8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2aa6fd61-a9c7-430f-bc87-f3523f46e8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_b62e2b0b-4d22-43cb-813a-54319865ac1f" xlink:href="mo-20230331.xsd#mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_b62e2b0b-4d22-43cb-813a-54319865ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_85414a60-c02a-4686-9599-85999a457819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f945909e-d614-4a67-813d-faf7d295f5d9" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_85414a60-c02a-4686-9599-85999a457819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_24dba9d5-214d-4d16-9abd-5ca77c0e6713" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_78ac35f8-38e1-493c-9389-b98900e16371" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7a3e906-a681-410f-ae6d-97395a7438c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7a3e906-a681-410f-ae6d-97395a7438c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_d5444e9c-53ee-4f69-8c5b-f86fdd6ee611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_d5444e9c-53ee-4f69-8c5b-f86fdd6ee611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_324a86c8-bf39-410d-87a1-d64904bb84f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_324a86c8-bf39-410d-87a1-d64904bb84f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a9fc106b-9b0e-4352-923d-e99aef9b42d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a9fc106b-9b0e-4352-923d-e99aef9b42d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_06c02252-f2b3-4d31-872d-a87bb70e77eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_06c02252-f2b3-4d31-872d-a87bb70e77eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_6253fda4-2fb0-4341-af14-a726a3a7466a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_6253fda4-2fb0-4341-af14-a726a3a7466a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3ee101e0-239a-4df8-993b-262b19842b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3ee101e0-239a-4df8-993b-262b19842b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_136375ff-0bbb-40b1-9369-5cc22884aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_136375ff-0bbb-40b1-9369-5cc22884aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5fa52b5-9e9c-46cc-95ce-9d505313d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_65e1cff8-5d06-4504-8153-a43c7f9ebbc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5fa52b5-9e9c-46cc-95ce-9d505313d43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#OtherComprehensiveEarningsLossesReclassificationsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_596132cb-2e28-4f4f-9bb2-069f9f7ffce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_596132cb-2e28-4f4f-9bb2-069f9f7ffce8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6082329-23a4-4602-ad75-ded6e03275e3" xlink:to="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30432af7-beb1-4061-ac84-dced9c029658" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_d7a4b4bc-8b6f-48f5-a25a-f4e61ff2b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_d7a4b4bc-8b6f-48f5-a25a-f4e61ff2b7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_fc4d954d-f163-45bb-a43f-838ead499d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_fc4d954d-f163-45bb-a43f-838ead499d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_3de5f6be-6ecb-45b4-a097-7098ae560cdf" xlink:href="mo-20230331.xsd#mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_965e31c1-4dde-441d-a471-21e1ea3a9023" xlink:to="loc_mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember_3de5f6be-6ecb-45b4-a097-7098ae560cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eca63e25-b137-4e56-9cba-1001ca6113b8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d2ab9bcb-bd84-418e-9715-07186c33b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3e78370-2816-45d6-9e43-0d2f45aa0ce1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d2ab9bcb-bd84-418e-9715-07186c33b022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_740ec9ef-f42a-46e0-8d84-7fd43e51b36f" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_13da21eb-5587-46a9-9b91-7c904ff3be5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_13da21eb-5587-46a9-9b91-7c904ff3be5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e43172cb-52b2-46ab-aedb-a944b70e6785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e43172cb-52b2-46ab-aedb-a944b70e6785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4858a5ad-8efb-436b-b3a3-73ee0652e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8512d06d-95eb-474b-aeed-3b02035a6975" xlink:to="loc_us-gaap_ProfitLoss_4858a5ad-8efb-436b-b3a3-73ee0652e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingSegmentDataScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f4d31d83-e3e7-4278-ac9c-40f7c627a190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f4d31d83-e3e7-4278-ac9c-40f7c627a190" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:to="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d151d62a-1c8d-457a-9e02-ecbbf8622923" xlink:to="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_b5d970e6-d110-4f05-af61-033da519b662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_b5d970e6-d110-4f05-af61-033da519b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_38c22aa1-41c5-455b-83ea-2387133582e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_24cd0b6f-ff97-44fd-ad3a-62da2d4541e0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_38c22aa1-41c5-455b-83ea-2387133582e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d16efb4-7bcf-43a4-9742-a12858eeb490" xlink:to="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_285c8de5-5d13-4d69-845e-5d92d9a8417d" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_mo_SmokeableProductsSegmentMember_285c8de5-5d13-4d69-845e-5d92d9a8417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OralTobaccoSegmentMember_b31edff2-bb4e-4e4c-99e6-4083fc96ffd1" xlink:href="mo-20230331.xsd#mo_OralTobaccoSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_mo_OralTobaccoSegmentMember_b31edff2-bb4e-4e4c-99e6-4083fc96ffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_af243729-a6c4-4f5c-be6e-9a859f46d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2edae58d-a563-4f2c-9559-6dbff2bca15a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_af243729-a6c4-4f5c-be6e-9a859f46d7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e901bc65-c288-45de-a725-a438117659c7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d4233d7-0493-468b-90a1-0195e0c72589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d4233d7-0493-468b-90a1-0195e0c72589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_5c16182c-4e0e-4ca8-a14f-2dad7df9b5f0" xlink:href="mo-20230331.xsd#mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles_5c16182c-4e0e-4ca8-a14f-2dad7df9b5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3d217389-52ff-460b-b558-f20aab671fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3d217389-52ff-460b-b558-f20aab671fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ec98672c-495c-46ba-813b-810b17b1a657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ec98672c-495c-46ba-813b-810b17b1a657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eaf5e05c-f98b-428e-bf4e-f5948720bc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_OperatingIncomeLoss_eaf5e05c-f98b-428e-bf4e-f5948720bc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_b120b599-4e64-4bb2-87e6-49fa7a53ba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_b120b599-4e64-4bb2-87e6-49fa7a53ba4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b09b201a-bf28-43c1-9d96-bc56a35f4ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b09b201a-bf28-43c1-9d96-bc56a35f4ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IncomeLossFromEquitySecurities_3b5abd59-1460-4acc-bf0d-a526b1a76897" xlink:href="mo-20230331.xsd#mo_IncomeLossFromEquitySecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_mo_IncomeLossFromEquitySecurities_3b5abd59-1460-4acc-bf0d-a526b1a76897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e3eb9507-f43f-4853-8a8a-f112adefd23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e3eb9507-f43f-4853-8a8a-f112adefd23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d69ee194-27f5-4162-8aa7-58e2b43aebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9da28bd4-093e-429d-a9c2-45b6d689a69b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d69ee194-27f5-4162-8aa7-58e2b43aebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e59dc2e1-20d0-4bdb-8071-8e37e7fcee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e59dc2e1-20d0-4bdb-8071-8e37e7fcee4e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c249264-ddb8-4393-86f7-306c779b71a6" xlink:to="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_ce630f4d-c7c4-4e51-9b44-f457b219b376" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bea6bf70-229b-48ca-9edc-35f8373babeb" xlink:to="loc_mo_SmokeableProductsSegmentMember_ce630f4d-c7c4-4e51-9b44-f457b219b376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a653a1d5-f7af-4d24-8f1a-475c78b82340" xlink:to="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4b75b75b-28e4-4f57-bde5-ace4b33b01b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d90e846c-39d3-4c2a-995f-a9ee5df01376" xlink:to="loc_us-gaap_OperatingSegmentsMember_4b75b75b-28e4-4f57-bde5-ace4b33b01b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2d13f10e-2e87-4e82-b36a-9374dfb1f352" xlink:to="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_eb202426-ba3a-4ffd-8a85-0524d73cbbf1" xlink:href="mo-20230331.xsd#mo_NonParticipatingManufacturerArbitrationPanelDecisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b4e52327-eea1-482b-859a-5744b5d97468" xlink:to="loc_mo_NonParticipatingManufacturerArbitrationPanelDecisionMember_eb202426-ba3a-4ffd-8a85-0524d73cbbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ad37d32-5370-4923-b444-38ca3ff82a1d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossMember_e1fdda88-d0b1-4965-8f96-bc881097cade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2addf4fd-079b-416d-b943-761830a97be1" xlink:to="loc_us-gaap_OperatingIncomeLossMember_e1fdda88-d0b1-4965-8f96-bc881097cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8c0f7515-50f5-4814-9ac2-e29627ea8548" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NpmAdjustmentToCostOfSalesMember_7c9c170b-7636-4283-982e-40fba3cd1fb5" xlink:href="mo-20230331.xsd#mo_NpmAdjustmentToCostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_2b7bfd16-a0ee-453d-942e-53b965e6d6e0" xlink:to="loc_mo_NpmAdjustmentToCostOfSalesMember_7c9c170b-7636-4283-982e-40fba3cd1fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5dd78b92-058c-4dbc-a1b0-108e0610b5c0" xlink:to="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c6701d05-f8bc-4a58-bfa6-935cf8d094b0" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_25f095a6-9d6b-4e7d-8a34-d35ab8f16960" xlink:to="loc_mo_PhilipMorrisUSAMember_c6701d05-f8bc-4a58-bfa6-935cf8d094b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706b2c4-3b41-4652-aba8-9c5a2742ad35" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_094667bd-9aba-4977-9a14-a8a214399cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_807fa854-7d90-4af3-ba46-837eb5b03235" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_094667bd-9aba-4977-9a14-a8a214399cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a907506-59fa-43f8-8af9-2409fd4607d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a907506-59fa-43f8-8af9-2409fd4607d7" xlink:to="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7968aa99-98ba-448d-a05a-1af03b943674" xlink:to="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c042ea7d-0f48-41b2-85c9-3854094831f5" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e2d3b0b6-3a01-419c-9a12-6d8574b661bf" xlink:to="loc_mo_PhilipMorrisUSAMember_c042ea7d-0f48-41b2-85c9-3854094831f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b72fbd36-144f-4b2c-83b0-ad391eb2cdf0" xlink:to="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthLitigationCasesMember_3ac5c890-c34b-4e94-b133-28c1635edeb0" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthLitigationCasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_692740e6-72a3-4656-94da-f8e5ed79b3b2" xlink:to="loc_mo_TobaccoandHealthLitigationCasesMember_3ac5c890-c34b-4e94-b133-28c1635edeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c91121ed-0655-4c7e-976c-1835f0ea625e" xlink:to="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_be39db21-0df4-4ad5-bd5a-4f4f5c9a8b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_OperatingSegmentsMember_be39db21-0df4-4ad5-bd5a-4f4f5c9a8b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_636c5c48-19fd-4437-a4a8-36d5b6e8c472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_636c5c48-19fd-4437-a4a8-36d5b6e8c472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5adb72aa-2437-4428-86d1-685e425e6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a1293d9b-613b-4952-860f-9f19abfedc9b" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5adb72aa-2437-4428-86d1-685e425e6ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5b750de3-cbb9-4687-9d5a-6efdc7eeda9d" xlink:to="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokeableProductsSegmentMember_b5df34dc-7cf4-4b18-81ee-f6f41605ea59" xlink:href="mo-20230331.xsd#mo_SmokeableProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_403c32e4-6a94-4c4d-9b9c-f1f33df93511" xlink:to="loc_mo_SmokeableProductsSegmentMember_b5df34dc-7cf4-4b18-81ee-f6f41605ea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aab19ea0-7dfb-4076-924c-d514c32b2b28" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossMember_588fde62-4cc2-4b8e-b11e-36f5ce97feaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:to="loc_us-gaap_OperatingIncomeLossMember_588fde62-4cc2-4b8e-b11e-36f5ce97feaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestAndOtherDebtExpenseNetMember_f25ca041-d4ab-4e55-8a00-9927c0bd29a2" xlink:href="mo-20230331.xsd#mo_InterestAndOtherDebtExpenseNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63806b7d-905e-49ba-ae60-162c9daabbf8" xlink:to="loc_mo_InterestAndOtherDebtExpenseNetMember_f25ca041-d4ab-4e55-8a00-9927c0bd29a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:href="mo-20230331.xsd#mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable_51d4faae-125b-46b0-9b9b-1f16aedc330e" xlink:to="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_f25fec10-995d-4aca-8250-eb605890ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems_8efd9567-5e4d-497c-a773-6ddebf0c02ae" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_f25fec10-995d-4aca-8250-eb605890ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_957e3e87-d9b1-41cb-a857-ca6c6a59ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_957e3e87-d9b1-41cb-a857-ca6c6a59ba90" xlink:to="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_de261313-f0e1-40fc-99b2-9a16df388b99" xlink:to="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember_c3c8bd37-1cee-4cdd-8523-d8daed46ac42" xlink:href="mo-20230331.xsd#mo_TermSecuredOvernightFinancingRateTermSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0d4d4634-90ed-4fdb-b73b-0a66d7b4ce1c" xlink:to="loc_mo_TermSecuredOvernightFinancingRateTermSOFRMember_c3c8bd37-1cee-4cdd-8523-d8daed46ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c23a1d42-7c71-45a4-8588-d14649a7058f" xlink:to="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f3cf371-4991-4f1e-af6b-d6cbc0ca686b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80d570c0-ed56-4743-89be-6f8410dba610" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f3cf371-4991-4f1e-af6b-d6cbc0ca686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96282bb1-e133-4c09-9637-43f2eb2f4bef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1580d4d1-0bfc-4143-aca4-32784e276e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:to="loc_us-gaap_LineOfCreditMember_1580d4d1-0bfc-4143-aca4-32784e276e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_dc61f04a-7860-4e59-97ed-5ef737514a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5588e87a-eb00-4c80-96af-1ef664334dc4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_dc61f04a-7860-4e59-97ed-5ef737514a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8a9b716-f9cd-435c-9d3c-d0328dabf6e1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_RevolvingCreditFacilityDueAugust2025Member_a2964d47-befc-4788-8fdc-bcad0deab145" xlink:href="mo-20230331.xsd#mo_RevolvingCreditFacilityDueAugust2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:to="loc_mo_RevolvingCreditFacilityDueAugust2025Member_a2964d47-befc-4788-8fdc-bcad0deab145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EuroNotes1000MaturingFebruary2023Member_d4b331df-2c9c-43c3-9a20-4258d18d9677" xlink:href="mo-20230331.xsd#mo_EuroNotes1000MaturingFebruary2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf3ab40d-0d21-45da-acdd-306f143c3bb8" xlink:to="loc_mo_EuroNotes1000MaturingFebruary2023Member_d4b331df-2c9c-43c3-9a20-4258d18d9677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_135c1193-99d1-4ab3-b443-fd88f88b0b63" xlink:to="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4ee848a4-e218-47b3-baf2-c46b19176c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_ShortTermBorrowings_4ee848a4-e218-47b3-baf2-c46b19176c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7da9085d-5a7a-42dc-bce6-001aa0780f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7da9085d-5a7a-42dc-bce6-001aa0780f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_0a1100f3-82b3-47f2-b5a4-b841c60d58ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_LongTermDebtTerm_0a1100f3-82b3-47f2-b5a4-b841c60d58ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_d1941aa6-c0da-42bb-ae5c-fb8a1e791d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_d1941aa6-c0da-42bb-ae5c-fb8a1e791d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_672dceba-ef4f-4b41-b537-a9e82bce7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_672dceba-ef4f-4b41-b537-a9e82bce7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_23bb5c7e-b6d2-401f-b658-7454e63a4593" xlink:href="mo-20230331.xsd#mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum_23bb5c7e-b6d2-401f-b658-7454e63a4593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_ec54bae3-477b-447b-be97-056d07955538" xlink:href="mo-20230331.xsd#mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio_ec54bae3-477b-447b-be97-056d07955538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_54482cb1-15f1-4ff6-961a-15fc20971b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_LongTermDebt_54482cb1-15f1-4ff6-961a-15fc20971b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1d222508-bb0d-4d40-8329-46bcb1166e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1d222508-bb0d-4d40-8329-46bcb1166e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_53364e30-7f1f-43bb-b92e-fddf401ebfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_53364e30-7f1f-43bb-b92e-fddf401ebfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b5f532a6-3699-4b40-8b37-c334b95c94d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18f8b796-c546-4fc5-9cbb-355048508299" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b5f532a6-3699-4b40-8b37-c334b95c94d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxesSummaryofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6ade45f-020d-441c-90b5-30be6679ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b0a5df0b-561e-4098-870e-02a5d44ab2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6ade45f-020d-441c-90b5-30be6679ec0f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b0a5df0b-561e-4098-870e-02a5d44ab2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a2c35257-0a5f-4a00-b85c-999f2c97dcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6ade45f-020d-441c-90b5-30be6679ec0f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a2c35257-0a5f-4a00-b85c-999f2c97dcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3c9dff85-dcac-43b1-b753-7de41b7c4315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6ade45f-020d-441c-90b5-30be6679ec0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3c9dff85-dcac-43b1-b753-7de41b7c4315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d83b1d02-8964-443e-b72f-4a6ad74411c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:href="mo-20230331.xsd#mo_InvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d83b1d02-8964-443e-b72f-4a6ad74411c2" xlink:to="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:to="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b2bde9c6-0a57-4fce-b608-ae92f4ac225b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6c921c1d-90c0-438e-ab6b-79daaeef6fbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_53c0d07d-6f97-4ae2-899b-dfed7fe63b25" xlink:to="loc_srt_ScenarioForecastMember_6c921c1d-90c0-438e-ab6b-79daaeef6fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_611b71ca-3bff-4a75-938a-547b20f030ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_03022fb5-37c2-48a2-89a1-7031c065f9e6" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f5126ebd-9d12-4b8e-afc3-cd6b080edf29" xlink:to="loc_mo_JUULMember_03022fb5-37c2-48a2-89a1-7031c065f9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:href="mo-20230331.xsd#mo_InvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsTable_681c146c-ac51-4188-987f-54373d77a5e8" xlink:to="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_fe4a2029-4b52-4569-893b-4eed4a3326c2" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments_fe4a2029-4b52-4569-893b-4eed4a3326c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c853667a-5614-4c2d-b2c3-b155ae2f286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c853667a-5614-4c2d-b2c3-b155ae2f286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_251d2e42-544e-4e1b-bd4b-132e4b47907c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_251d2e42-544e-4e1b-bd4b-132e4b47907c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_0450f3df-cbff-48db-8feb-6c0c42005379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_0450f3df-cbff-48db-8feb-6c0c42005379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d1dfeb37-7236-4c36-a085-0c865f1c22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d1dfeb37-7236-4c36-a085-0c865f1c22c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83d8f3f0-1d68-47ab-a2b6-7a83a51868f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83d8f3f0-1d68-47ab-a2b6-7a83a51868f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_4aee6e59-963c-4558-baed-9f7fde9ab66e" xlink:href="mo-20230331.xsd#mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_InvestmentsLineItems_9d93209a-8d36-4c0b-8c95-960135612dff" xlink:to="loc_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate_4aee6e59-963c-4558-baed-9f7fde9ab66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9d3d99a1-3d57-4a4e-ab5e-ebf9403840d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9d3d99a1-3d57-4a4e-ab5e-ebf9403840d5" xlink:to="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e16903e7-e7b5-44e5-8010-e9cb8a31a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e16903e7-e7b5-44e5-8010-e9cb8a31a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount_3a729abd-9c5d-4873-9b84-fb6f5f1bceb8" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount_3a729abd-9c5d-4873-9b84-fb6f5f1bceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount_faa14a38-7e20-446a-b139-202890e7d47b" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount_faa14a38-7e20-446a-b139-202890e7d47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment_f72e5c30-07cb-42e7-8060-a5c98595323a" xlink:href="mo-20230331.xsd#mo_ValuationAllowanceForeignCurrencyTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment_f72e5c30-07cb-42e7-8060-a5c98595323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7b29f714-4fa3-4e00-b766-f4d5b63e055b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7b29f714-4fa3-4e00-b766-f4d5b63e055b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3cea31d9-8f1e-494a-b2ea-a38de2a601bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ValuationAllowanceRollforwardRollForward_bb0d5815-6f48-4fb6-ad33-4e378f34613d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3cea31d9-8f1e-494a-b2ea-a38de2a601bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesGeneralInformationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesGeneralInformationDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesGeneralInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71f3b7e1-339b-4d13-b520-457fc8dc1224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond_4a112a7f-02fd-467e-8c23-99e48c79ca11" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71f3b7e1-339b-4d13-b520-457fc8dc1224" xlink:to="loc_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond_4a112a7f-02fd-467e-8c23-99e48c79ca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02cab620-eaa7-481e-8223-2d4bd918ffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02cab620-eaa7-481e-8223-2d4bd918ffb7" xlink:to="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4b2777e5-30ec-4b8f-a921-58f7c6cfe3f2" xlink:to="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthJudgmentMember_8de25d43-9944-4ac3-8274-9d29966036b4" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthJudgmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_TobaccoandHealthJudgmentMember_8de25d43-9944-4ac3-8274-9d29966036b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_dc2b907b-6ee4-4034-9cc9-19d666d835fa" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_EngleProgenyCasesMember_dc2b907b-6ee4-4034-9cc9-19d666d835fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AgreementToResolveShareholderClassActionMember_0ce4194b-7c99-47f8-9ff2-a69234463a32" xlink:href="mo-20230331.xsd#mo_AgreementToResolveShareholderClassActionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4a016e2a-4739-4d5a-8b06-67dffb7aa094" xlink:to="loc_mo_AgreementToResolveShareholderClassActionMember_0ce4194b-7c99-47f8-9ff2-a69234463a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60159922-4c0f-4eab-84fe-abcb3b70a09b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_bfc3efc2-6c89-40af-bdc8-6613f89f2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_dd52e7e2-80f0-4d92-bfb1-110bab21f5e0" xlink:to="loc_us-gaap_AssetsMember_bfc3efc2-6c89-40af-bdc8-6613f89f2e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_9c549982-1eb9-4247-b5f8-948a5d4ce892" xlink:to="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4beea546-3dbd-43c9-b675-e9794f249588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_b5628669-4a83-403b-a3ab-2e8bcfb406ce" xlink:to="loc_us-gaap_PendingLitigationMember_4beea546-3dbd-43c9-b675-e9794f249588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0f87669b-1860-4490-9be8-68d20c73a448" xlink:to="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_8e278cdf-33f5-4080-a0d9-84c19359f3b4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_219c7df4-61ce-4600-87be-d435a92d2198" xlink:to="loc_mo_PhilipMorrisUSAMember_8e278cdf-33f5-4080-a0d9-84c19359f3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d4ca5898-2fb6-4afc-a197-54e75105072f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationCasesResultsMember_734c859a-6ef4-49ec-b252-cb7796c68ecd" xlink:href="mo-20230331.xsd#mo_LitigationCasesResultsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:to="loc_mo_LitigationCasesResultsMember_734c859a-6ef4-49ec-b252-cb7796c68ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_InterestExpenseRelatedToLitigationMember_12787805-bea3-4b8f-a99a-1108a31a081d" xlink:href="mo-20230331.xsd#mo_InterestExpenseRelatedToLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f092630f-afaf-4d19-9c69-163e1d796f90" xlink:to="loc_mo_InterestExpenseRelatedToLitigationMember_12787805-bea3-4b8f-a99a-1108a31a081d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00e9a778-6422-4569-bbbd-403022b8b043" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_abc2db2d-525e-4083-aca3-4bdd92064e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bc714673-f07e-4c1d-90dc-fbcaec304132" xlink:to="loc_us-gaap_SubsequentEventMember_abc2db2d-525e-4083-aca3-4bdd92064e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d3ca5c5b-c6f3-4c0d-a220-a54493a2805a" xlink:to="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_7ac6319d-349e-4d9e-bf91-bf00a7233a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_7ac6319d-349e-4d9e-bf91-bf00a7233a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_8b00ee36-510d-4179-8fbd-a1fd53d0d423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LitigationSettlementInterest_8b00ee36-510d-4179-8fbd-a1fd53d0d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationEscrowDeposit_162d8856-730f-4c6d-ba04-db384c29e1e0" xlink:href="mo-20230331.xsd#mo_LitigationEscrowDeposit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_mo_LitigationEscrowDeposit_162d8856-730f-4c6d-ba04-db384c29e1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1be6e666-b69f-4bde-b35a-741b5a46cc72" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_48879585-9ae8-4854-b703-cf918ff63366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_48879585-9ae8-4854-b703-cf918ff63366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_5d3d26b2-9686-46cf-a5f2-7fe4b2277971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_5d3d26b2-9686-46cf-a5f2-7fe4b2277971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_9bb9d4e0-cf10-4a13-9202-ff8127d93090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_9bb9d4e0-cf10-4a13-9202-ff8127d93090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_9e907722-29a1-4f55-ac8f-fb0c1a0c3698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_8373ce71-77b1-4fb3-b202-3035b1ae9d76" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_9e907722-29a1-4f55-ac8f-fb0c1a0c3698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesScheduleofPendingCasesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d44a3dee-eb29-461e-933a-5946bf27af2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d44a3dee-eb29-461e-933a-5946bf27af2b" xlink:to="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84f6dd1c-8180-44a4-82ad-720a7ca705d0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ec402fcc-88e0-4a10-8213-43ed780a5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b78d04a4-ba75-4142-9f72-0071fc254088" xlink:to="loc_us-gaap_SubsequentEventMember_ec402fcc-88e0-4a10-8213-43ed780a5549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c1302cc4-bed5-4d7f-9a3e-0e0e54093fb2" xlink:to="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:href="mo-20230331.xsd#mo_IndividualSmokingAndHealthCasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember_9b02733b-447a-4d14-9ec6-fb8c26e87b7a" xlink:href="mo-20230331.xsd#mo_ETSSmokingandHealthCaseFlightAttendantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_IndividualSmokingAndHealthCasesMember_342c243c-b404-4d25-a25d-b7c315f93934" xlink:to="loc_mo_ETSSmokingandHealthCaseFlightAttendantsMember_9b02733b-447a-4d14-9ec6-fb8c26e87b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_7bf32d0a-724e-44d7-bdda-55845037c461" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_7bf32d0a-724e-44d7-bdda-55845037c461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_e60b82b5-a185-47bf-bbe8-bc9a4eb22efd" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_EvaporLitigationMember_e60b82b5-a185-47bf-bbe8-bc9a4eb22efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherTabaccoRelatedCasesMember_9197fc5e-8239-4329-89ca-ab8283316f1d" xlink:href="mo-20230331.xsd#mo_OtherTabaccoRelatedCasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_OtherTabaccoRelatedCasesMember_9197fc5e-8239-4329-89ca-ab8283316f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_TobaccoandHealthJudgmentMember_55775b66-c318-4e55-b8e1-62b47f78f662" xlink:href="mo-20230331.xsd#mo_TobaccoandHealthJudgmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_TobaccoandHealthJudgmentMember_55775b66-c318-4e55-b8e1-62b47f78f662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AgreementToResolveShareholderClassActionMember_a229b7ab-0dbb-4732-b608-e8f452150750" xlink:href="mo-20230331.xsd#mo_AgreementToResolveShareholderClassActionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_126e3704-dad6-47dc-b670-3c91a12732ef" xlink:to="loc_mo_AgreementToResolveShareholderClassActionMember_a229b7ab-0dbb-4732-b608-e8f452150750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4fb2f7db-3c44-44b5-bd0f-32e2cf6f29c5" xlink:to="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1b2c922b-2f27-421b-bec4-9b604ec2bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_us-gaap_PendingLitigationMember_1b2c922b-2f27-421b-bec4-9b604ec2bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_5e4c15b2-0dac-48c8-8457-c8e4d85999b9" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_PendingIndividualLawsuitsMember_5e4c15b2-0dac-48c8-8457-c8e4d85999b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_78ba41f1-06e4-4b7d-98e2-b6af041069b2" xlink:href="mo-20230331.xsd#mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember_78ba41f1-06e4-4b7d-98e2-b6af041069b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ClassActionLawsuitMember_faadcac2-5d67-445e-a333-787226a2fc09" xlink:href="mo-20230331.xsd#mo_ClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a3bd5c7b-468a-4f3e-ada8-3ef53b536f50" xlink:to="loc_mo_ClassActionLawsuitMember_faadcac2-5d67-445e-a333-787226a2fc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4d7f985d-d69c-49df-bb6b-0f21f6f18bec" xlink:to="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_75b4d831-1ca0-4fd4-971d-3644f88dcbed" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_IL_75b4d831-1ca0-4fd4-971d-3644f88dcbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_352257ad-180e-4081-ac46-9a9c2a5ecd50" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_NM_352257ad-180e-4081-ac46-9a9c2a5ecd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4de8cf18-658f-405d-bbaa-6868bbb8dc49" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_MA_4de8cf18-658f-405d-bbaa-6868bbb8dc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_084d06d7-6c50-4fc4-955e-87ec9c1d18a6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd31c3e7-7a71-430c-9eb4-eccb2d1036cd" xlink:to="loc_stpr_FL_084d06d7-6c50-4fc4-955e-87ec9c1d18a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_56323e2b-5588-47fc-b666-6e23e696c8c2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationCasesResultsMember_eb974a6b-f830-4ae2-bb88-23ae2299412c" xlink:href="mo-20230331.xsd#mo_LitigationCasesResultsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_3ae9a73e-edca-4cb7-addd-0d32579d9809" xlink:to="loc_mo_LitigationCasesResultsMember_eb974a6b-f830-4ae2-bb88-23ae2299412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4c420fd-63f4-470e-ae55-fd13055cf774" xlink:to="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_74d42136-5858-404f-848e-59d6265f86d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_74d42136-5858-404f-848e-59d6265f86d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCases_d1a4521a-895b-4195-829c-ebff2aae091c" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfCases_d1a4521a-895b-4195-829c-ebff2aae091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassActionLawsuit_54e8a076-a881-4f61-9ae6-bd306e764da5" xlink:href="mo-20230331.xsd#mo_LossContingencyClassActionLawsuit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyClassActionLawsuit_54e8a076-a881-4f61-9ae6-bd306e764da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveCases_075dc84b-5d03-4d28-8c33-e33eee563dce" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveCases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfInactiveCases_075dc84b-5d03-4d28-8c33-e33eee563dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits_96baf5c4-842a-4cfe-873a-f1368d20ab80" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfInactiveClassActionLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyNumberOfInactiveClassActionLawsuits_96baf5c4-842a-4cfe-873a-f1368d20ab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_73240a3d-bf7c-45fe-b0f7-cee51671cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_73240a3d-bf7c-45fe-b0f7-cee51671cdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_de58ea44-8ec9-417f-bd38-474a6f1560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_de58ea44-8ec9-417f-bd38-474a6f1560e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_2056cb68-30ca-41b3-ab6b-f0c8529da7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_2056cb68-30ca-41b3-ab6b-f0c8529da7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_b391f128-23c7-4cce-9c7a-9d7c2c3a5e96" xlink:href="mo-20230331.xsd#mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a1dbda-c243-4c14-9887-5425af639fd4" xlink:to="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_b391f128-23c7-4cce-9c7a-9d7c2c3a5e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e451181c-2081-4d31-b50c-3382606795a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e451181c-2081-4d31-b50c-3382606795a5" xlink:to="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ef807c-30da-4276-9fd8-5c877fa189b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e4b3b8a1-2295-4a9c-9afa-96e3673a0c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f4a9690e-65e8-410a-bc7b-99a3a7f93d87" xlink:to="loc_us-gaap_SubsequentEventMember_e4b3b8a1-2295-4a9c-9afa-96e3673a0c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cef04b88-c87e-4ed8-8b84-8efd263de8d4" xlink:to="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_501fc530-d1ac-4f00-b155-46a85ecd71e4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:to="loc_mo_PhilipMorrisUSAMember_501fc530-d1ac-4f00-b155-46a85ecd71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAandAltriaGroupMember_8c58782e-1a85-41ee-b275-211182a57730" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAandAltriaGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4420c990-8f85-48f9-b1dc-26b0658e5150" xlink:to="loc_mo_PhilipMorrisUSAandAltriaGroupMember_8c58782e-1a85-41ee-b275-211182a57730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_1bd8ec86-f8dd-44ab-a306-61b9854a002a" xlink:to="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_7d447f4b-e274-4b94-bc92-1917688176fc" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_7d447f4b-e274-4b94-bc92-1917688176fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_6d6c0858-2b3b-4c9c-bd2c-0b3a14442bae" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_6d6c0858-2b3b-4c9c-bd2c-0b3a14442bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_1412e18d-3376-4d21-bd93-8ff61223dd3d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_EngleProgenyCasesMember_1412e18d-3376-4d21-bd93-8ff61223dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenyCasesMember_a3d35b55-23a6-4dfe-aca3-4585a41d812a" xlink:href="mo-20230331.xsd#mo_NonEngleProgenyCasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_NonEngleProgenyCasesMember_a3d35b55-23a6-4dfe-aca3-4585a41d812a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IndividualSmokingAndHealthCasesMember_d133544a-1107-4bdd-ac28-813943c24d08" xlink:href="mo-20230331.xsd#mo_IndividualSmokingAndHealthCasesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_IndividualSmokingAndHealthCasesMember_d133544a-1107-4bdd-ac28-813943c24d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_fa52e772-6fab-4df8-b433-6ff1981f3ea0" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dfc23ccf-15bf-4912-9a87-aa05d26f6f35" xlink:to="loc_mo_EvaporLitigationMember_fa52e772-6fab-4df8-b433-6ff1981f3ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f5e95d72-e1e1-4de0-a2d2-887ddbac8c14" xlink:to="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6f3972bd-c1e8-4b93-afd3-dc9d0ed19aa4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_country_CA_6f3972bd-c1e8-4b93-afd3-dc9d0ed19aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AK_237ddcb5-906d-44ce-9a50-5af7ea2487c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AK"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_AK_237ddcb5-906d-44ce-9a50-5af7ea2487c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_37d7b7c4-849e-455c-9171-3e7cdf5b206b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_CA_37d7b7c4-849e-455c-9171-3e7cdf5b206b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_52c94b06-17f9-4fb8-9024-314dd17031bb" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_CT_52c94b06-17f9-4fb8-9024-314dd17031bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_bfbac1d7-0aa2-47ef-8a11-5636bb124fae" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_FL_bfbac1d7-0aa2-47ef-8a11-5636bb124fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_LA_6d095b8e-c499-47f4-ac4d-2fec439efff7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_LA_6d095b8e-c499-47f4-ac4d-2fec439efff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_ab33de05-04ed-41c8-a5be-3148dd9d53c0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MA_ab33de05-04ed-41c8-a5be-3148dd9d53c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_5991e928-172d-476f-883e-5b6c713de860" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MS_5991e928-172d-476f-883e-5b6c713de860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MO_8771697d-efb9-4ce9-af25-9d574c5b3caf" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MO"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_MO_8771697d-efb9-4ce9-af25-9d574c5b3caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NH_3b1ea1bc-e84f-420b-977d-a1c77cf31b62" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NH"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NH_3b1ea1bc-e84f-420b-977d-a1c77cf31b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_777fd8b7-9a90-45b1-9453-bf1a84bcf8be" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NM_777fd8b7-9a90-45b1-9453-bf1a84bcf8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_70e34274-ba92-42c7-ab29-70fa5e10b26e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NJ_70e34274-ba92-42c7-ab29-70fa5e10b26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_8bb1e094-120e-414b-9c74-66d94af7d42f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_NY_8bb1e094-120e-414b-9c74-66d94af7d42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OH_8da5532c-5e95-4af6-a4a1-c861306b97a7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OH"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_OH_8da5532c-5e95-4af6-a4a1-c861306b97a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_da006613-bb0d-4d0a-bca9-67d5ae3b223d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_PA_da006613-bb0d-4d0a-bca9-67d5ae3b223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_RI_f5039a2e-34e6-4771-b1cf-e2ba23905d7f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_RI_f5039a2e-34e6-4771-b1cf-e2ba23905d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_20d12045-2d91-4f7c-ae96-ffd26602f8c8" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_TN_20d12045-2d91-4f7c-ae96-ffd26602f8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_772d0dda-5398-4c34-9067-fe564db2073a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78fa210d-bcb0-47a6-9f9c-69831233cbf9" xlink:to="loc_stpr_WV_772d0dda-5398-4c34-9067-fe564db2073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5df21f6e-b53e-4109-aaae-763c7795673a" xlink:to="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_f3e7e2db-6545-452f-9b3b-eb22d9b61f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_f3e7e2db-6545-452f-9b3b-eb22d9b61f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofCasesSetforTrial_9dbb7e8f-009c-44fe-b644-b8ba0477b460" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofCasesSetforTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyNumberofCasesSetforTrial_9dbb7e8f-009c-44fe-b644-b8ba0477b460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecided_72720d04-7f6d-4b8d-adee-f1abdbae2ba4" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecided"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecided_72720d04-7f6d-4b8d-adee-f1abdbae2ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedFavorableNumber_f3fe339e-daf3-44d5-baff-1e84c767cccc" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedFavorableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecidedFavorableNumber_f3fe339e-daf3-44d5-baff-1e84c767cccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_da173e8d-34ad-4dcc-b0dd-6a2ea6c6ec6b" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedUnfavorableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_da173e8d-34ad-4dcc-b0dd-6a2ea6c6ec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsResolvedNumber_14bace35-673a-4a90-8cc1-a0961085d95a" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsResolvedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyClaimsResolvedNumber_14bace35-673a-4a90-8cc1-a0961085d95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictReversedNumber_bf954072-cd7f-414d-88a9-2f0afbf3594e" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictReversedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4046e654-6ff1-42a2-b850-ad94a5663d75" xlink:to="loc_mo_LossContingencyVerdictReversedNumber_bf954072-cd7f-414d-88a9-2f0afbf3594e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesNonEngleProgenyLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7df0ec6f-0dca-4baf-8a98-eb542ad35dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7df0ec6f-0dca-4baf-8a98-eb542ad35dac" xlink:to="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:to="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ddd7f0b9-9368-424e-b6f8-21e381e137e4" xlink:to="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_a84e8f60-886b-4c32-9ff7-4a431c2a5b44" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember_a84e8f60-886b-4c32-9ff7-4a431c2a5b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_4f4caa60-0794-4cc9-908d-f23ba88ce049" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseMendezMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseMendezMember_4f4caa60-0794-4cc9-908d-f23ba88ce049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_5277e686-b16c-4efe-a626-de0a6e41b79c" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingAndHealthCaseFontaineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingAndHealthCaseFontaineMember_5277e686-b16c-4efe-a626-de0a6e41b79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_01e645d2-3048-410e-b4b9-f41a55439694" xlink:href="mo-20230331.xsd#mo_NonEngleProgenySmokingandHealthCaseGreeneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_062a0a14-f2fe-47d1-a3dc-e00dd54ec73b" xlink:to="loc_mo_NonEngleProgenySmokingandHealthCaseGreeneMember_01e645d2-3048-410e-b4b9-f41a55439694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:to="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6825ae53-91cf-4e06-9b94-4eea1ec3ab06" xlink:to="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_3eb49cbd-03e2-4166-bfb7-07483936fbb4" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:to="loc_mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember_3eb49cbd-03e2-4166-bfb7-07483936fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_7df7fc90-70f5-45d1-98db-1448b975d840" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8b01f22f-cd49-4079-83df-060646c9d593" xlink:to="loc_mo_PhilipMorrisUSAMember_7df7fc90-70f5-45d1-98db-1448b975d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_35a07561-12f0-4b48-ad86-901e2654156f" xlink:to="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_b47ce26e-12f9-40b6-83f0-6e7e4ffb5cd6" xlink:href="mo-20230331.xsd#mo_LossContingencyCompensatoryDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_b47ce26e-12f9-40b6-83f0-6e7e4ffb5cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyFaultAllocationPercentage_70536ba7-9666-424c-b9e7-0f78a92e2bad" xlink:href="mo-20230331.xsd#mo_LossContingencyFaultAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyFaultAllocationPercentage_70536ba7-9666-424c-b9e7-0f78a92e2bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_5ad14fc9-e04e-4c22-8f45-ab2f2981a02c" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_5ad14fc9-e04e-4c22-8f45-ab2f2981a02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_01095110-3910-4478-8d0a-0e23bdedf78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_01095110-3910-4478-8d0a-0e23bdedf78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_aebf0e9c-3332-41d5-af3c-678eb6d7c1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1c5f0f0-3675-477f-afbf-7220c161faa0" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_aebf0e9c-3332-41d5-af3c-678eb6d7c1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ffd6f27e-e37d-4376-a2f9-76c2fd30c897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ffd6f27e-e37d-4376-a2f9-76c2fd30c897" xlink:to="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d14f14b-4cc8-418d-8d5f-1d1ac0aa032e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e017837e-35d1-4cbc-9c22-e3776d72fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f01ddb0a-a1cc-49ce-80a4-4f464dc22316" xlink:to="loc_us-gaap_SubsequentEventMember_e017837e-35d1-4cbc-9c22-e3776d72fd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_935529d2-a25c-406b-af0a-909dd91eaf2b" xlink:to="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2bd13905-1afc-4de7-a30e-7a769fa8c087" xlink:to="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesStateMember_2ddd5494-4c03-4a91-84ab-9a41e0a578b1" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesStateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesStateMember_2ddd5494-4c03-4a91-84ab-9a41e0a578b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGarciaMember_18bd68e9-cd84-4f62-811f-8e0e4d8e3a50" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGarciaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesGarciaMember_18bd68e9-cd84-4f62-811f-8e0e4d8e3a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_5247d64a-589e-4132-8d4b-83c60080f179" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPearsonDCohenCollarChaconMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesPearsonDCohenCollarChaconMember_5247d64a-589e-4132-8d4b-83c60080f179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesReiderandBanksMember_53a512ad-6d2e-4562-bd6f-c3f74525e8d2" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesReiderandBanksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesReiderandBanksMember_53a512ad-6d2e-4562-bd6f-c3f74525e8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesWeingartandHancockMember_71bdc033-7f62-4cf1-8f7c-0d8dda5210c9" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesWeingartandHancockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesWeingartandHancockMember_71bdc033-7f62-4cf1-8f7c-0d8dda5210c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesPollariMember_004e5836-761c-4bc2-a89f-fc528bccf84d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesPollariMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesPollariMember_004e5836-761c-4bc2-a89f-fc528bccf84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_f1dce8d3-0b61-4ced-86bb-2c382de7b2f5" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGlogerRintoulandDuignamMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesGlogerRintoulandDuignamMember_f1dce8d3-0b61-4ced-86bb-2c382de7b2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesFreemanAndHarrisMember_bbd09a71-c853-426d-9783-9d70b3cc3f11" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesFreemanAndHarrisMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesFreemanAndHarrisMember_bbd09a71-c853-426d-9783-9d70b3cc3f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesR.DouglasMember_7e999aff-a948-403f-b7ed-a5577f70bf2d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesR.DouglasMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_EngleProgenyCasesMember_c618d20b-cba3-41e6-8c25-aa5e78daf0dc" xlink:to="loc_mo_EngleProgenyCasesR.DouglasMember_7e999aff-a948-403f-b7ed-a5577f70bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_84cba66c-1c11-47e1-9453-6efde2f98d97" xlink:to="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_f6339c12-1e0a-47bd-bc4e-d59b5cb5ceb8" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_01178620-12a8-4f78-b2e8-dee1988a1819" xlink:to="loc_mo_PhilipMorrisUSAMember_f6339c12-1e0a-47bd-bc4e-d59b5cb5ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c3e16d0c-11fb-40c7-a1a8-00da3bb004d0" xlink:to="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_7235fb10-38a6-44b5-8f4c-1f88173fd355" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_7235fb10-38a6-44b5-8f4c-1f88173fd355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_262cd2f7-0fbc-4a33-8e9c-16493d76517c" xlink:href="mo-20230331.xsd#mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants_262cd2f7-0fbc-4a33-8e9c-16493d76517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ad093b66-5e5f-4ada-99a7-fde1b2685571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ad093b66-5e5f-4ada-99a7-fde1b2685571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_98a1844d-a09a-4dc1-94ae-09389d5e60ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_98a1844d-a09a-4dc1-94ae-09389d5e60ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecided_58723a67-3fc0-41c5-81a0-5e5aee096125" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecided"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecided_58723a67-3fc0-41c5-81a0-5e5aee096125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_51ff83fb-7f99-4d41-9375-031695ac64f5" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedUnfavorableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecidedUnfavorableNumber_51ff83fb-7f99-4d41-9375-031695ac64f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed_6ce18462-accf-42f6-90ef-eb70af94218b" xlink:href="mo-20230331.xsd#mo_LossContingencyUnfavorableVerdictsPendingReversed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyUnfavorableVerdictsPendingReversed_6ce18462-accf-42f6-90ef-eb70af94218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsDecidedFavorableNumber_3b6b267d-1083-4ea3-9098-c956288005e8" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsDecidedFavorableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyClaimsDecidedFavorableNumber_3b6b267d-1083-4ea3-9098-c956288005e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictReversedNumber_cf94453f-966b-49c2-836b-64e70b90c654" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictReversedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyVerdictReversedNumber_cf94453f-966b-49c2-836b-64e70b90c654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdicts_1693b9d3-3aa2-402e-b241-fa7a95835401" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdicts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyZeroDamagesVerdicts_1693b9d3-3aa2-402e-b241-fa7a95835401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1eabe809-0c66-4554-ad44-e0748286dea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1eabe809-0c66-4554-ad44-e0748286dea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyZeroDamagesVerdictModified_0eee826e-fc18-4348-842a-b8a1e1e6065c" xlink:href="mo-20230331.xsd#mo_LossContingencyZeroDamagesVerdictModified"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_mo_LossContingencyZeroDamagesVerdictModified_0eee826e-fc18-4348-842a-b8a1e1e6065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_3003bd37-73a5-412e-a511-cde8c765b41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6082d325-df4f-450e-bca3-edbfec7427b9" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_3003bd37-73a5-412e-a511-cde8c765b41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e47eb595-8e17-41d6-bd4b-449e65080dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e47eb595-8e17-41d6-bd4b-449e65080dc0" xlink:to="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f8b45af6-c36c-4d54-9bb1-ae27407d0153" xlink:to="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHoffmanMember_8ef59445-c91d-4e5a-ba13-4695a7de9b6a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHoffmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesHoffmanMember_8ef59445-c91d-4e5a-ba13-4695a7de9b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLevineMember_4053dd79-4cad-4c53-b966-72be684cef8a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLevineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesLevineMember_4053dd79-4cad-4c53-b966-72be684cef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesSchertzerMember_6456803c-99e2-4501-8c7a-4d27a445a1d3" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesSchertzerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesSchertzerMember_6456803c-99e2-4501-8c7a-4d27a445a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesLippMember_ec88fcd0-7325-4a3a-bc00-902667c9831a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesLippMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesLippMember_ec88fcd0-7325-4a3a-bc00-902667c9831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesGarciaMember_d7665fce-bbb7-4f82-9c31-1a8d19655d5f" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesGarciaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesGarciaMember_d7665fce-bbb7-4f82-9c31-1a8d19655d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesDuignanMember_0c0f9ba8-60a4-420b-8079-0a2afff3bc4b" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesDuignanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesDuignanMember_0c0f9ba8-60a4-420b-8079-0a2afff3bc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMcCallMember_d730f981-ba8a-4d3a-a32b-7e897d12d426" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMcCallMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesMcCallMember_d730f981-ba8a-4d3a-a32b-7e897d12d426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesChadwellMember_4a0f8ab7-f227-473c-8f91-7fdd1d8a7a72" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesChadwellMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesChadwellMember_4a0f8ab7-f227-473c-8f91-7fdd1d8a7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember_9a36940f-320d-46e7-89a4-e88c5b5e300a" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesKaplanMcLauighlinMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesKaplanMcLauighlinMember_9a36940f-320d-46e7-89a4-e88c5b5e300a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCooperMember_3659d34a-a5df-42f5-bd63-38458078918d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCooperMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesCooperMember_3659d34a-a5df-42f5-bd63-38458078918d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesMillerMember_18193dc1-3106-48d5-8bf2-7becd70280b1" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesMillerMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesMillerMember_18193dc1-3106-48d5-8bf2-7becd70280b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesTuttleMember_05724458-8bf9-4c11-8543-37c5c64b032d" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesTuttleMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesTuttleMember_05724458-8bf9-4c11-8543-37c5c64b032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesCuddiheeMember_78665a43-7344-49ab-8d63-fda4e9842999" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesCuddiheeMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesCuddiheeMember_78665a43-7344-49ab-8d63-fda4e9842999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesHollimanMember_85261c1c-61f7-4218-aaa7-4ce0264718b6" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesHollimanMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesHollimanMember_85261c1c-61f7-4218-aaa7-4ce0264718b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesD.BrownMember_874974d9-d2fe-4813-bff7-015865779280" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesD.BrownMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d95eaa71-ec86-4081-8056-a2b7e2906a86" xlink:to="loc_mo_EngleProgenyCasesD.BrownMember_874974d9-d2fe-4813-bff7-015865779280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4896209d-e995-4f82-af9e-cc46640c9c62" xlink:to="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_0ccdaf92-c6c9-40c3-8631-b641a581b986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:to="loc_us-gaap_PendingLitigationMember_0ccdaf92-c6c9-40c3-8631-b641a581b986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ffb37494-7f21-45b5-b94a-ffdfd6ee052b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ea4e032d-7613-463f-bda9-ba2913cbb356" xlink:to="loc_us-gaap_SettledLitigationMember_ffb37494-7f21-45b5-b94a-ffdfd6ee052b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_425d967a-5501-40a1-9c71-0c78e5ca235c" xlink:to="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_3f581ee7-4f08-48d2-9d0d-20f3f237fb4f" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a6748714-887b-477b-bc72-e112d49f8455" xlink:to="loc_mo_PhilipMorrisUSAMember_3f581ee7-4f08-48d2-9d0d-20f3f237fb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_792d8197-933c-4917-b357-697c7a13b218" xlink:to="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_238e3d1f-5949-449e-a13c-995fb4117aac" xlink:href="mo-20230331.xsd#mo_LossContingencyCompensatoryDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_mo_LossContingencyCompensatoryDamagesAwardedValue_238e3d1f-5949-449e-a13c-995fb4117aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPunitiveDamagesAwardedValue_afd27a1d-90a6-4ac5-b9bb-b627aab57b20" xlink:href="mo-20230331.xsd#mo_LossContingencyPunitiveDamagesAwardedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_mo_LossContingencyPunitiveDamagesAwardedValue_afd27a1d-90a6-4ac5-b9bb-b627aab57b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a48d806c-36b3-489a-8369-cfa7ccb4de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca1cf8-fb81-43c8-a9f3-c495ee018c8b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a48d806c-36b3-489a-8369-cfa7ccb4de13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesFloridaBondStatuteDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7493cbf-2996-43a2-8f9e-8ea372eb0018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7493cbf-2996-43a2-8f9e-8ea372eb0018" xlink:to="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:to="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c4b7e369-fd88-4988-a029-89454d211577" xlink:to="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_07904241-1d31-40a0-8aca-15b5eebe3ac6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_11cfea34-295b-4be4-ac74-035faf3ffeb4" xlink:to="loc_stpr_FL_07904241-1d31-40a0-8aca-15b5eebe3ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:to="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f96743a3-d967-4bfa-8e21-c1e38507f94d" xlink:to="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EngleProgenyCasesStateMember_f2fa9eb9-94f6-40a8-b72e-dc23496716ae" xlink:href="mo-20230331.xsd#mo_EngleProgenyCasesStateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_33b0d74a-2add-403a-a561-5176119f1854" xlink:to="loc_mo_EngleProgenyCasesStateMember_f2fa9eb9-94f6-40a8-b72e-dc23496716ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c43a8a8-3f5f-439b-b2d6-b6625f788796" xlink:to="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_MaximumBondForAllDefendants_cb5eb67d-815a-4f1e-9229-b7761fdc7e5f" xlink:href="mo-20230331.xsd#mo_MaximumBondForAllDefendants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_daff49cf-042e-4cd4-9eab-bd612cf0e5de" xlink:to="loc_mo_MaximumBondForAllDefendants_cb5eb67d-815a-4f1e-9229-b7761fdc7e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOtherSmokingandHealthClassActionsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbea1e23-da4e-42da-8321-6c5b71002f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbea1e23-da4e-42da-8321-6c5b71002f95" xlink:to="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_158d6d55-c71a-4f09-99d9-5c34293167fa" xlink:to="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AR_8e74a063-8ecd-4831-8589-77f96261a71f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_AR_8e74a063-8ecd-4831-8589-77f96261a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_54e7da8f-33d9-48b6-9c83-1b3d494f6ab3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_CA_54e7da8f-33d9-48b6-9c83-1b3d494f6ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DE_f377c3bd-078e-4e39-b063-6e9483eeea28" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_DE_f377c3bd-078e-4e39-b063-6e9483eeea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_1e46ba66-cfd6-4ad7-a50a-1e3c860cce34" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_DC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_DC_1e46ba66-cfd6-4ad7-a50a-1e3c860cce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_1ea79afb-7578-495d-9d9d-fd306b6c7b46" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_FL_1ea79afb-7578-495d-9d9d-fd306b6c7b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_dc5ea74c-81b3-4bef-8f2c-9aa243c54eb4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_IL_dc5ea74c-81b3-4bef-8f2c-9aa243c54eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_8e0a8d47-f9eb-46ec-ad00-52bff158f4c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_IA_8e0a8d47-f9eb-46ec-ad00-52bff158f4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KS_f722c785-cdc6-48ba-864f-de240e43f46d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_KS_f722c785-cdc6-48ba-864f-de240e43f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_LA_32716fd5-3a05-49c5-9212-a0798e57cc10" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_LA_32716fd5-3a05-49c5-9212-a0798e57cc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_6c69dceb-c7ba-447e-aa60-5233493b3774" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MD_6c69dceb-c7ba-447e-aa60-5233493b3774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_ec116dd4-fbf0-4060-9452-a8f9479378da" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MI"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MI_ec116dd4-fbf0-4060-9452-a8f9479378da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_a56643ad-9124-4e03-9a8a-e691c5000730" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MN"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_MN_a56643ad-9124-4e03-9a8a-e691c5000730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NV_1a2c8738-3a4c-4fc0-9073-41256c958eb2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NV"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NV_1a2c8738-3a4c-4fc0-9073-41256c958eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_ef51280f-11de-4770-9f91-58eb009a2c15" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NJ_ef51280f-11de-4770-9f91-58eb009a2c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_66378662-1708-4aa0-b952-f03dd4567484" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_NY_66378662-1708-4aa0-b952-f03dd4567484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OH_ea39bb2e-3e36-4acc-8b13-34f44d81cc01" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OH"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OH_ea39bb2e-3e36-4acc-8b13-34f44d81cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_22e1457c-ca29-413c-99cf-efddd4b86cc5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OK_22e1457c-ca29-413c-99cf-efddd4b86cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OR_39bdbc38-ab9f-4328-9a86-9fa5b517aeda" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_OR_39bdbc38-ab9f-4328-9a86-9fa5b517aeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_7284c1a6-8b74-4f9f-b2c0-17f06d95e83a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_PA_7284c1a6-8b74-4f9f-b2c0-17f06d95e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_88d44b7e-fe35-4831-a617-bc569479a1bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_country_PR_88d44b7e-fe35-4831-a617-bc569479a1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_499d4156-7f53-46b2-a707-6db48c53072a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_SC_499d4156-7f53-46b2-a707-6db48c53072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_2ad77416-672f-4c74-b91e-bf46b04aaf98" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_TX_2ad77416-672f-4c74-b91e-bf46b04aaf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_59b11d24-7691-435f-bd39-397d6c1b7d58" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_stpr_WI_59b11d24-7691-435f-bd39-397d6c1b7d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5044a9d1-2dd4-4b60-ae56-2be9b8c34337" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_country_CA_5044a9d1-2dd4-4b60-ae56-2be9b8c34337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_BritishColumbiaSaskatchewanMember_3b713b79-865b-4f6f-bf08-02f9343597c9" xlink:href="mo-20230331.xsd#mo_BritishColumbiaSaskatchewanMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c90fe5b-3966-461e-a4c3-e531a1a3edf3" xlink:to="loc_mo_BritishColumbiaSaskatchewanMember_3b713b79-865b-4f6f-bf08-02f9343597c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cfa8e9d7-5048-4d0c-a119-62abc11c1ba3" xlink:to="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_6f090bdf-8254-4228-963c-b3df6ca5ed52" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_PhilipMorrisUSAMember_6f090bdf-8254-4228-963c-b3df6ca5ed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAandAltriaGroupMember_bde35d7f-43a2-4374-8748-597a3eb13866" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAandAltriaGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_PhilipMorrisUSAandAltriaGroupMember_bde35d7f-43a2-4374-8748-597a3eb13866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CanadianTobaccoManufacturersMember_be2a35e3-3e4d-4a78-b568-8fecf0346710" xlink:href="mo-20230331.xsd#mo_CanadianTobaccoManufacturersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_CanadianTobaccoManufacturersMember_be2a35e3-3e4d-4a78-b568-8fecf0346710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AltriaGroupMember_a6946689-8168-486f-a523-a530e4389010" xlink:href="mo-20230331.xsd#mo_AltriaGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42481d68-2d32-4527-8401-2d4342956edf" xlink:to="loc_mo_AltriaGroupMember_a6946689-8168-486f-a523-a530e4389010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c18697c2-4753-4c56-8c2d-9061fa7fab6d" xlink:to="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_435c59c8-79b6-43e4-b27a-ed8c2c97df5f" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e41ad2e-81e6-4335-a764-e6b091f344ca" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_435c59c8-79b6-43e4-b27a-ed8c2c97df5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7055556-3343-40ce-8982-5c36cbe618e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9fd2f91c-9978-4445-83a1-cda9c160446a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_608e471a-9e9f-4c2c-838f-1d1989466671" xlink:to="loc_us-gaap_SubsequentEventMember_9fd2f91c-9978-4445-83a1-cda9c160446a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_498d240c-3216-4785-b595-0d63905bc70e" xlink:to="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassNotCertifiedNumber_cbb13b99-3109-4bf0-a17c-fba7e05e8162" xlink:href="mo-20230331.xsd#mo_LossContingencyClassNotCertifiedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyClassNotCertifiedNumber_cbb13b99-3109-4bf0-a17c-fba7e05e8162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_75ea5e77-2277-469a-812a-d5607a508083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_75ea5e77-2277-469a-812a-d5607a508083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofManufacturers_1db1059f-77f8-4b92-a5e3-4dd48e0f8828" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofManufacturers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyNumberofManufacturers_1db1059f-77f8-4b92-a5e3-4dd48e0f8828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyVerdictsUpheld_e7f695d1-aca2-41d9-9380-1e5ade835a03" xlink:href="mo-20230331.xsd#mo_LossContingencyVerdictsUpheld"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_LossContingencyVerdictsUpheld_e7f695d1-aca2-41d9-9380-1e5ade835a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AmountAwardedtoOtherParty_4490642b-9d71-46b2-8b4e-893d87a8b83f" xlink:href="mo-20230331.xsd#mo_AmountAwardedtoOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f3d9a0e3-77a6-4f81-90ec-a3c53c5f0980" xlink:to="loc_mo_AmountAwardedtoOtherParty_4490642b-9d71-46b2-8b4e-893d87a8b83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesHealthCareCostRecoveryLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b517b5b-90da-40d5-849a-fb056a385cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b517b5b-90da-40d5-849a-fb056a385cc7" xlink:to="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_022df789-1ce5-42fa-9278-79dde240ae88" xlink:to="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CanadianTobaccoManufacturersMember_b3926653-85e3-483b-81e6-dd134772c353" xlink:href="mo-20230331.xsd#mo_CanadianTobaccoManufacturersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_67f7ea25-d4c6-45d3-9bef-dc382cc47a99" xlink:to="loc_mo_CanadianTobaccoManufacturersMember_b3926653-85e3-483b-81e6-dd134772c353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_b50c682b-b73f-457e-9baa-54079171fb8b" xlink:to="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThreatenedLitigationMember_8e7d8550-dd68-405d-96d6-91a64de89f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThreatenedLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_988e89ef-d497-4064-af5d-66072ba0299a" xlink:to="loc_us-gaap_ThreatenedLitigationMember_8e7d8550-dd68-405d-96d6-91a64de89f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_af70b790-7938-4943-905f-6004b6da170a" xlink:to="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fb1dde98-a576-427b-a4eb-3303eddac2a9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dac855f4-7395-4921-8722-46670587a79f" xlink:to="loc_country_CA_fb1dde98-a576-427b-a4eb-3303eddac2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_16cfcc9d-140d-4721-81a9-956686bace33" xlink:to="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_c6ef3ba9-7710-4ba5-853b-37ec8f4fb6f2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_c6ef3ba9-7710-4ba5-853b-37ec8f4fb6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_a55ffa54-f428-47ee-9985-ddd5588919e6" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9e8303b4-e677-4aba-8a73-24c5f3310df0" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_a55ffa54-f428-47ee-9985-ddd5588919e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5099fdac-e967-4a29-93ae-4a6577ca6a99" xlink:to="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_45eaaf26-17e4-4dd6-be2e-3a2b5a3bd5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_45eaaf26-17e4-4dd6-be2e-3a2b5a3bd5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofManufacturers_3bf4e8fb-d1c1-497d-86ba-ff89953e4813" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofManufacturers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LossContingencyNumberofManufacturers_3bf4e8fb-d1c1-497d-86ba-ff89953e4813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigation_4cc6f493-805d-4189-bfad-c20f2281b8d0" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LossContingencyNumberofStateswithSettledLitigation_4cc6f493-805d-4189-bfad-c20f2281b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualPaymentAmount_7a232d51-37c1-42b0-8843-3ebcb2983daa" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualPaymentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LitigationSettlementAnnualPaymentAmount_7a232d51-37c1-42b0-8843-3ebcb2983daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_a79ecaaa-cc8c-4ddc-a53f-f619c138fcc3" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAnnualLegalFeesPayableMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_mo_LitigationSettlementAnnualLegalFeesPayableMaximum_a79ecaaa-cc8c-4ddc-a53f-f619c138fcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_291e4abe-d1e8-4e66-b582-3c2b2a15af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7c0b333-86cf-4804-81b9-ae29e962b126" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_291e4abe-d1e8-4e66-b582-3c2b2a15af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesNPMAdjustmentDisputesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0476a765-3adb-4c3a-ab79-ed2f5f6e1b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0476a765-3adb-4c3a-ab79-ed2f5f6e1b00" xlink:to="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0be8bdce-4556-488c-a9c2-7c52a9ad1f4f" xlink:to="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_96adeaae-8b1e-4bd9-8f97-0901e2d1937c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_NY_96adeaae-8b1e-4bd9-8f97-0901e2d1937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MT_fbd86e19-92a1-4cf4-b3f5-4555b900078e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_MT_fbd86e19-92a1-4cf4-b3f5-4555b900078e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_4241f36e-52e9-4954-9541-9e43b7f5a132" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_IL_4241f36e-52e9-4954-9541-9e43b7f5a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_0c340f84-d109-4084-b6c3-2bce26be6e5e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_IA_0c340f84-d109-4084-b6c3-2bce26be6e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NM_8adfddac-dc0f-4458-8282-e3e79826d8ba" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NM"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_694140e8-1bad-417d-89fa-9b8bc8125f92" xlink:to="loc_stpr_NM_8adfddac-dc0f-4458-8282-e3e79826d8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e1b4f6d0-cb6c-48d3-a09a-1aae43ec2a56" xlink:to="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_c407aa64-ec6b-454a-a0f1-cf95ace54769" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1c9b0bf2-4ea2-453c-9e99-d297dbbf7aa8" xlink:to="loc_mo_PhilipMorrisUSAMember_c407aa64-ec6b-454a-a0f1-cf95ace54769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6ec18e44-ed0d-47b7-b199-6668c2f37c8e" xlink:to="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_c8a06797-f799-493e-b1d5-7dbdd85fe4f5" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember_c8a06797-f799-493e-b1d5-7dbdd85fe4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_cffcbabd-0fb8-427d-acad-6ac283e21d63" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember_cffcbabd-0fb8-427d-acad-6ac283e21d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_665139ee-dbab-43a3-baaa-99b89bc13b35" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember_665139ee-dbab-43a3-baaa-99b89bc13b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_5a5fd3c1-0438-4e3f-b4d1-a85931ba4f9f" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember_5a5fd3c1-0438-4e3f-b4d1-a85931ba4f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_959efa7d-0202-47f2-83ac-f1875f8fa70b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember_959efa7d-0202-47f2-83ac-f1875f8fa70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_74dd8adf-7c5f-4939-bcda-4867a228ad93" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember_74dd8adf-7c5f-4939-bcda-4867a228ad93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_723d758c-2f1b-4d4a-8a7f-102115711e83" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember_723d758c-2f1b-4d4a-8a7f-102115711e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_aa3ca7c6-0d7e-4ee8-afff-92bdacf507c9" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember_aa3ca7c6-0d7e-4ee8-afff-92bdacf507c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_507d92a0-eb72-4420-ac21-16512af6d08f" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember_507d92a0-eb72-4420-ac21-16512af6d08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_e35c63c2-de67-4e87-ba84-f36f11400c81" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember_e35c63c2-de67-4e87-ba84-f36f11400c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_93c346f4-fc56-449c-9a9e-fa84d5bcc884" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember_93c346f4-fc56-449c-9a9e-fa84d5bcc884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_6d569b0b-a890-4dc8-885b-5c57610c92db" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember_6d569b0b-a890-4dc8-885b-5c57610c92db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_e929ddf9-043a-4473-a5f9-6e128fc98d3b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember_e929ddf9-043a-4473-a5f9-6e128fc98d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_4bcd5563-da6e-4c9b-beac-1c7760c2cf31" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember_4bcd5563-da6e-4c9b-beac-1c7760c2cf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_73e07f65-e6df-4cd9-976c-3ed98297ae7d" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember_73e07f65-e6df-4cd9-976c-3ed98297ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_d5e9c9ee-e82d-4b76-9e55-9ff7e2e8492e" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember_d5e9c9ee-e82d-4b76-9e55-9ff7e2e8492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_97099213-43e3-44f8-99b2-85450a1b6b00" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember_97099213-43e3-44f8-99b2-85450a1b6b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_b71ee33d-8bb4-4196-90ed-fb5ba03682f4" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember_b71ee33d-8bb4-4196-90ed-fb5ba03682f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_e611fc64-80f2-4f05-9b70-56fefa9554b2" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042020Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042020Member_e611fc64-80f2-4f05-9b70-56fefa9554b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_2b99731e-f059-48a2-a452-709a0719400b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_HealthCareCostRecoveryActionsMember_b854603f-ea19-4d1c-b8c8-f3d22981ddb2" xlink:to="loc_mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember_2b99731e-f059-48a2-a452-709a0719400b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_c1509a52-ad1a-4cc2-b7ef-74c7bf45375b" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20042021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20042021Member_c1509a52-ad1a-4cc2-b7ef-74c7bf45375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_4e51b88f-a887-48a1-b1f5-82b07e6b46d7" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActionsTransitionYears20192021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActionsTransitionYears20192021Member_4e51b88f-a887-48a1-b1f5-82b07e6b46d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_6d2ce112-6861-4995-94cb-2a6e263c7f8a" xlink:href="mo-20230331.xsd#mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_27b7946f-8a16-4200-a53c-00c56fbc59b6" xlink:to="loc_mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember_6d2ce112-6861-4995-94cb-2a6e263c7f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_909646f7-afe5-4359-8473-c3ae2ea378c6" xlink:to="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5d5e3da6-491e-49e5-bcf4-ec8aca9a2ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:to="loc_us-gaap_SettledLitigationMember_5d5e3da6-491e-49e5-bcf4-ec8aca9a2ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_722b651c-811c-4404-a538-20ee40c97c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1c0946ad-3b87-4907-8bc0-6bed38eb0ccb" xlink:to="loc_us-gaap_PendingLitigationMember_722b651c-811c-4404-a538-20ee40c97c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:href="mo-20230331.xsd#mo_ArbitrationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ArbitrationPeriodAxis_b5c0580b-ab32-47d9-9c55-942b4aab89dd" xlink:to="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodOneMember_3cedd869-3e93-4f33-b2fe-bb570691417b" xlink:href="mo-20230331.xsd#mo_PeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:to="loc_mo_PeriodOneMember_3cedd869-3e93-4f33-b2fe-bb570691417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PeriodTwoMember_1709d971-52a6-4f1d-a852-99ef27f56eba" xlink:href="mo-20230331.xsd#mo_PeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mo_ArbitrationPeriodDomain_367c2118-8dbd-4b29-a8a8-e7141a1ada2d" xlink:to="loc_mo_PeriodTwoMember_1709d971-52a6-4f1d-a852-99ef27f56eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0893ddd5-3fc2-4a6e-bcce-14829da076a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d679c7d1-25a1-43ee-a4ed-494b30de5e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f863e98f-1e5f-419e-b6a8-211a214b0f78" xlink:to="loc_us-gaap_CostOfSalesMember_d679c7d1-25a1-43ee-a4ed-494b30de5e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7b16ed7f-3429-4d01-93d8-7bf5dde10bac" xlink:to="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementEstimateofPossibleGain_ea7d9272-4a28-4851-9750-86b6710898b8" xlink:href="mo-20230331.xsd#mo_LitigationSettlementEstimateofPossibleGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LitigationSettlementEstimateofPossibleGain_ea7d9272-4a28-4851-9750-86b6710898b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_ea8d1c2d-8100-4fad-8e37-b2f70a314ea1" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne_ea8d1c2d-8100-4fad-8e37-b2f70a314ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_37f22b23-75c2-45a5-8d42-9544a07ca696" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation_37f22b23-75c2-45a5-8d42-9544a07ca696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fbe6fccc-f108-46a1-af52-6adeb004fe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fbe6fccc-f108-46a1-af52-6adeb004fe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2f79695d-672b-4c99-ba58-b2d65742f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2f79695d-672b-4c99-ba58-b2d65742f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_21e4d44c-7b02-4176-983d-168ea7c4cc93" xlink:href="mo-20230331.xsd#mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_21e4d44c-7b02-4176-983d-168ea7c4cc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings_74604afa-e928-47a3-8824-68df2ab36556" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesWithConcludedHearings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesWithConcludedHearings_74604afa-e928-47a3-8824-68df2ab36556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettled_e1a26934-46ec-4119-acb6-9941076af678" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettled"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotSettled_e1a26934-46ec-4119-acb6-9941076af678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_c5eddd00-67c9-4a13-84cf-7e8d69533bcf" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues_c5eddd00-67c9-4a13-84cf-7e8d69533bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_9553374d-b260-47a0-b3c7-a1c3f0bffcb7" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues_9553374d-b260-47a0-b3c7-a1c3f0bffcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyReductionToCostOfSales_2e64fc38-c2e4-4500-9218-15a4c9dd1aea" xlink:href="mo-20230331.xsd#mo_LossContingencyReductionToCostOfSales"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyReductionToCostOfSales_2e64fc38-c2e4-4500-9218-15a4c9dd1aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cfff6b70-9bd8-4a4b-8aac-19eec4d0abb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cfff6b70-9bd8-4a4b-8aac-19eec4d0abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_740106db-9c71-4c2e-ad4c-76a5060d2f15" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2cb9e5ed-01bb-40a2-a462-c1ad0a2e1418" xlink:to="loc_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod_740106db-9c71-4c2e-ad4c-76a5060d2f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_311aea27-8cea-47ba-a931-16bf1ca7e228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_311aea27-8cea-47ba-a931-16bf1ca7e228" xlink:to="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:to="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fcf7c7b3-592b-435e-9ccc-c03c1f3958e5" xlink:to="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_800996f2-700e-4d0d-a014-7fd513aa7589" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_04f5c256-49da-4123-8ecb-b51dc968b776" xlink:to="loc_mo_PhilipMorrisUSAMember_800996f2-700e-4d0d-a014-7fd513aa7589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:to="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5fdfbd65-186f-4e22-9438-63557e976abd" xlink:to="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember_1dd31f61-32f7-49d0-9cc6-33e53a6a311c" xlink:href="mo-20230331.xsd#mo_OtherDisputesUndertheStateSettlementAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f8f01419-146e-43df-8e39-9847e0331787" xlink:to="loc_mo_OtherDisputesUndertheStateSettlementAgreementsMember_1dd31f61-32f7-49d0-9cc6-33e53a6a311c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8c4de632-2e2b-4715-96fa-27c82a640f6b" xlink:to="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_371c7c49-a8a3-4306-9c62-a266bb57479c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_781ed878-6579-4501-a73b-062e326106b6" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_371c7c49-a8a3-4306-9c62-a266bb57479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesFederalGovernmentsLawsuitDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a21df6a2-36bb-494c-8146-ca91f9187970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a21df6a2-36bb-494c-8146-ca91f9187970" xlink:to="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_236f3530-b8c8-4030-9693-5c1687c04122" xlink:to="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ImplementationofCorrectiveCommunicationsMember_b08e5db8-7a18-4a7c-8878-2538c87b274f" xlink:href="mo-20230331.xsd#mo_ImplementationofCorrectiveCommunicationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_33783abf-68f9-45ab-8e1e-c93d5062a51a" xlink:to="loc_mo_ImplementationofCorrectiveCommunicationsMember_b08e5db8-7a18-4a7c-8878-2538c87b274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:to="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6d01f1ef-af5f-4c63-9e4d-175e5db9804d" xlink:to="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_0a5ffce7-baa8-4d93-9c70-5cd03d83d1fe" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:to="loc_mo_PhilipMorrisUSAMember_0a5ffce7-baa8-4d93-9c70-5cd03d83d1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_AltriaGroupMember_398553a2-3690-4987-8337-7b071d688e80" xlink:href="mo-20230331.xsd#mo_AltriaGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c9b583b3-30f4-4549-8618-2cec79a53393" xlink:to="loc_mo_AltriaGroupMember_398553a2-3690-4987-8337-7b071d688e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_de3c18cc-564a-4e26-a375-93b4f723269c" xlink:to="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_b1d83cc0-f670-4bd8-8d00-7d0e60f3b053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b220d1c5-9ab1-494e-9d72-e78f68581efa" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_b1d83cc0-f670-4bd8-8d00-7d0e60f3b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesEvaporProductLitigationandIQOSLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9d3c73c-0b9d-4804-a0b7-a3e39c5372b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9d3c73c-0b9d-4804-a0b7-a3e39c5372b2" xlink:to="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_99ff9f0c-492a-4cf6-87ca-aa01791db0d1" xlink:to="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_ClassActionLawsuitMember_bf829d12-57bb-4c19-905f-9bfbe8dd6e6d" xlink:href="mo-20230331.xsd#mo_ClassActionLawsuitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_ClassActionLawsuitMember_bf829d12-57bb-4c19-905f-9bfbe8dd6e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_0e3fdb3f-d5fe-4f4e-9d05-3b8b0e063a95" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_PendingIndividualLawsuitsMember_0e3fdb3f-d5fe-4f4e-9d05-3b8b0e063a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_2dacfc77-6164-4d24-b64b-1ba5292df9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_us-gaap_SettledLitigationMember_2dacfc77-6164-4d24-b64b-1ba5292df9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingClassActionLawsuitMember_ddfa59bf-d78e-424a-9b4c-b84c282501cf" xlink:href="mo-20230331.xsd#mo_PendingClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_mo_PendingClassActionLawsuitMember_ddfa59bf-d78e-424a-9b4c-b84c282501cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_40f89817-8204-48da-8393-c09b838d392f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_faebfa6b-1d1b-4137-a072-6caf0dfc062a" xlink:to="loc_us-gaap_PendingLitigationMember_40f89817-8204-48da-8393-c09b838d392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3280cb-9926-4909-a8ee-f85913f1fde8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_04b84c53-99d6-4939-9930-2b1a3fb7d41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2641f98c-77d3-4a69-b301-b141de8673bc" xlink:to="loc_us-gaap_SubsequentEventMember_04b84c53-99d6-4939-9930-2b1a3fb7d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d5a1540a-5429-4b94-8839-205e75dfa75a" xlink:to="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EvaporLitigationMember_c83cd17b-3625-41e2-85b9-845c4beaa102" xlink:href="mo-20230331.xsd#mo_EvaporLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:to="loc_mo_EvaporLitigationMember_c83cd17b-3625-41e2-85b9-845c4beaa102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_IQOSMember_9fb6092b-fa29-4355-8870-514dd038497a" xlink:href="mo-20230331.xsd#mo_IQOSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1f14d13e-6aa8-4234-9ccf-4ff1ecd552f7" xlink:to="loc_mo_IQOSMember_9fb6092b-fa29-4355-8870-514dd038497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_49f146ef-ff05-40f5-a34d-93131f17bfea" xlink:to="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_27acb30a-145d-41b5-942a-fdf986ae4424" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fe34a13c-5666-4629-9e45-02295497f7e1" xlink:to="loc_country_CA_27acb30a-145d-41b5-942a-fdf986ae4424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0ad67c-64fa-414a-89c7-12c820fb4ce5" xlink:to="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_999bf713-afe9-4d79-9fb7-a46e9b2224c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_999bf713-afe9-4d79-9fb7-a46e9b2224c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_3971b62a-377e-406c-bbc7-85e0ce7669ee" xlink:href="mo-20230331.xsd#mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber_3971b62a-377e-406c-bbc7-85e0ce7669ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates_05894cb8-96f3-455e-b74c-753e642e6748" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfCasesWithSetTrialDates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyNumberOfCasesWithSetTrialDates_05894cb8-96f3-455e-b74c-753e642e6748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfTrialsOngoing_6c61bbfd-a88b-41a9-89a4-9fb70c6a8fe0" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfTrialsOngoing"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyNumberOfTrialsOngoing_6c61bbfd-a88b-41a9-89a4-9fb70c6a8fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_NumberOfThirdPartyLawsuits_17fd6ac8-26e0-4b36-958d-3cea15d563ae" xlink:href="mo-20230331.xsd#mo_NumberOfThirdPartyLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_NumberOfThirdPartyLawsuits_17fd6ac8-26e0-4b36-958d-3cea15d563ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9be259a9-562f-45e5-9689-98cc4f86592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9be259a9-562f-45e5-9689-98cc4f86592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyRoyaltyFeePercentage_82f3abf3-597a-4752-9ac3-164abfbb8ff3" xlink:href="mo-20230331.xsd#mo_LossContingencyRoyaltyFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyRoyaltyFeePercentage_82f3abf3-597a-4752-9ac3-164abfbb8ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyDamagesRecoverableValue_351cce0c-2514-4386-8c12-8b1cf28dd323" xlink:href="mo-20230331.xsd#mo_LossContingencyDamagesRecoverableValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6f616364-e98a-4be9-bcc9-5997d85e81bb" xlink:to="loc_mo_LossContingencyDamagesRecoverableValue_351cce0c-2514-4386-8c12-8b1cf28dd323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f92b1ce2-f8c9-41e0-b5be-753cc485f9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f92b1ce2-f8c9-41e0-b5be-753cc485f9c5" xlink:to="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb106092-09dd-4388-8091-b40243eec75a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2c519ab-7ac0-4f8e-8d88-e904d8d64d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_db22684b-d0ee-46af-b11a-e3ff7006d999" xlink:to="loc_us-gaap_SubsequentEventMember_c2c519ab-7ac0-4f8e-8d88-e904d8d64d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_929ae2c3-1599-4fe8-bbbe-7a4c74ef215d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_JUULMember_8336795f-d53f-4499-9a1b-4a65bbbebce8" xlink:href="mo-20230331.xsd#mo_JUULMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_93381e5b-1a69-46a1-9c4e-caef32dc47de" xlink:to="loc_mo_JUULMember_8336795f-d53f-4499-9a1b-4a65bbbebce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f914817c-a51e-4e02-be22-933399050f43" xlink:to="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember_f217a1dc-16f2-4fe9-b51a-d2bdd2f55e62" xlink:href="mo-20230331.xsd#mo_FederalAndStateShareholderDerivativeLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_44fbe82c-d004-411d-8343-6ef02a3f0dc6" xlink:to="loc_mo_FederalAndStateShareholderDerivativeLawsuitsMember_f217a1dc-16f2-4fe9-b51a-d2bdd2f55e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8bbf0e3a-f9d7-4ef4-9038-ee5a6040258b" xlink:to="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_2b143b28-3a1d-4868-ad7f-5dd1d924105f" xlink:href="mo-20230331.xsd#mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_2b143b28-3a1d-4868-ad7f-5dd1d924105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClassActionLawsuit_96dc28c4-ecd9-44e1-b486-b9978a838e2f" xlink:href="mo-20230331.xsd#mo_LossContingencyClassActionLawsuit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyClassActionLawsuit_96dc28c4-ecd9-44e1-b486-b9978a838e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfComplaints_033629e6-f9ee-4ffa-b4f7-b0ca788ddb8d" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfComplaints"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfComplaints_033629e6-f9ee-4ffa-b4f7-b0ca788ddb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_419f35dd-221b-4013-9ba4-8962dbc7eb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_419f35dd-221b-4013-9ba4-8962dbc7eb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_2bf56fd2-9f5f-4851-a86f-16f0a1cd5a0d" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits_2bf56fd2-9f5f-4851-a86f-16f0a1cd5a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58d5a15f-dd10-44bb-93f2-7f5593b7e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58d5a15f-dd10-44bb-93f2-7f5593b7e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_4d4c3345-2e5b-48c6-bfed-ed52cc8bffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_4d4c3345-2e5b-48c6-bfed-ed52cc8bffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_60209c21-29f2-4d64-bdb6-c36f0ffcd7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_60209c21-29f2-4d64-bdb6-c36f0ffcd7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfPendingCasesConsolidated_460e6dfb-b496-49c2-b6ca-c5430581d472" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfPendingCasesConsolidated"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfPendingCasesConsolidated_460e6dfb-b496-49c2-b6ca-c5430581d472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_91fb5367-7fdd-4a60-9dfc-e1c6a09f2264" xlink:href="mo-20230331.xsd#mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits_91fb5367-7fdd-4a60-9dfc-e1c6a09f2264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_b23e6cbc-6787-431a-965a-d14eff8785c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_b23e6cbc-6787-431a-965a-d14eff8785c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a366bc1-0de0-4c8c-9588-81feb91f078f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c476670d-00ab-44f7-84de-394c4c707093" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a366bc1-0de0-4c8c-9588-81feb91f078f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesLightsUltraLightsCasesDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61a08026-7458-48f2-9aca-f94f806bd731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61a08026-7458-48f2-9aca-f94f806bd731" xlink:to="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9a449f62-078c-4e25-91b8-a0f1dc07c423" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38d57bda-a898-4818-80a2-193533aa9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a8a736e8-f41e-4d04-a192-43dbe5e49928" xlink:to="loc_us-gaap_SubsequentEventMember_38d57bda-a898-4818-80a2-193533aa9ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9e244c47-e337-4c5f-b257-27809549cf6a" xlink:to="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LightsMember_b30ab3a2-a5c4-4509-a890-2b4581f5258c" xlink:href="mo-20230331.xsd#mo_LightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_LightsMember_b30ab3a2-a5c4-4509-a890-2b4581f5258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_SmokingAndHealthClassActionsMember_6ceecab0-497d-427d-b98c-8faf1fe03348" xlink:href="mo-20230331.xsd#mo_SmokingAndHealthClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_SmokingAndHealthClassActionsMember_6ceecab0-497d-427d-b98c-8faf1fe03348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_USTLitigationMember_24f4cb21-f0e9-41a7-a9ff-3764b98da53c" xlink:href="mo-20230331.xsd#mo_USTLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e3c63c85-3cc6-403f-b885-e5a10bccb371" xlink:to="loc_mo_USTLitigationMember_24f4cb21-f0e9-41a7-a9ff-3764b98da53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9d2395af-bf5f-4f0b-993a-46b841e724a8" xlink:to="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PhilipMorrisUSAMember_e82cf025-754b-47eb-8aaf-9318970bda85" xlink:href="mo-20230331.xsd#mo_PhilipMorrisUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_05416690-0a8b-4db6-b8fb-34aad44cee26" xlink:to="loc_mo_PhilipMorrisUSAMember_e82cf025-754b-47eb-8aaf-9318970bda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_675f49cd-c7b9-4c25-88a0-bb903e460818" xlink:to="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyClaimsNotCertifiedNumber_32e21a8c-16c4-44de-9989-2ddd5ac881ce" xlink:href="mo-20230331.xsd#mo_LossContingencyClaimsNotCertifiedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_mo_LossContingencyClaimsNotCertifiedNumber_32e21a8c-16c4-44de-9989-2ddd5ac881ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_fd6ee5cb-d19d-4dca-90ff-d12d955046dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_fd6ee5cb-d19d-4dca-90ff-d12d955046dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_LossContingencyStateCourtsNumber_90d8cd3f-c03f-4bd4-9b6f-ff41d5c2357a" xlink:href="mo-20230331.xsd#mo_LossContingencyStateCourtsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_684865da-8cea-4fc9-9232-86e6b73555ef" xlink:to="loc_mo_LossContingencyStateCourtsNumber_90d8cd3f-c03f-4bd4-9b6f-ff41d5c2357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesUSTLitigationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86968fe8-20fa-439e-a3ec-f726dc26c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86968fe8-20fa-439e-a3ec-f726dc26c4d9" xlink:to="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_9c7611e8-0ab4-4ca8-adc7-aa11b1a9e45c" xlink:to="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_PendingIndividualLawsuitsMember_a103517f-701d-41b8-93ca-c5d9fe6d69dc" xlink:href="mo-20230331.xsd#mo_PendingIndividualLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1cc4bb01-0e5d-4cf4-bf84-5376f5e982ec" xlink:to="loc_mo_PendingIndividualLawsuitsMember_a103517f-701d-41b8-93ca-c5d9fe6d69dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5b9ed672-c3e6-42d6-ae63-fa060920283b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bd5428ea-d5ba-45c4-b854-43be00fe972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_90824657-fd54-47a1-b263-f2ba7d3cfa9f" xlink:to="loc_us-gaap_SubsequentEventMember_bd5428ea-d5ba-45c4-b854-43be00fe972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_981e8b19-7b74-43be-aefe-351934ca6447" xlink:to="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_USTLitigationMember_d37ceede-ef2c-4523-9f64-b7af8892a190" xlink:href="mo-20230331.xsd#mo_USTLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0cf0f2be-dae2-4c25-87e5-82471de12a4d" xlink:to="loc_mo_USTLitigationMember_d37ceede-ef2c-4523-9f64-b7af8892a190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fe1dfc18-427e-4d21-a27e-2e41ec023372" xlink:to="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4f49ca1b-5d42-4925-9a16-e50240fa7979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c9360c6-7e11-4aef-b325-6efc5744eb96" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4f49ca1b-5d42-4925-9a16-e50240fa7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" xlink:type="simple" xlink:href="mo-20230331.xsd#ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b73a3433-84ff-4d09-9f98-3bf0b543edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b73a3433-84ff-4d09-9f98-3bf0b543edc8" xlink:to="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9283dc00-9d1b-40f4-bfcb-14ba678e0faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_191349db-7897-4806-8735-da573374645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_31f4c172-bb1e-4767-beaf-c39a1c309d10" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_191349db-7897-4806-8735-da573374645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5fb1e63-9109-4a40-b614-0c8e7a31edca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mo_CreditAgreementMember_878cd7d5-bd40-4f7c-be97-208cf4aa363d" xlink:href="mo-20230331.xsd#mo_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b2e80fa-42b0-43a1-866a-d944ae5cb942" xlink:to="loc_mo_CreditAgreementMember_878cd7d5-bd40-4f7c-be97-208cf4aa363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5a713e59-746e-4b9e-95b7-3a0b364c37a7" xlink:to="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_ba10e28f-cc4b-49f2-a6ac-eed46344f282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_90354037-d444-4a0f-9b70-813512a6a55d" xlink:to="loc_us-gaap_LetterOfCreditMember_ba10e28f-cc4b-49f2-a6ac-eed46344f282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cc4da9cc-2c64-4af9-9c75-8242ba939a9b" xlink:to="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fdc5f860-cc26-46c9-98a8-ccd05069d0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fdc5f860-cc26-46c9-98a8-ccd05069d0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_2309f85d-97f3-4a75-9e06-45f847f2a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e66f18a3-f309-4e8e-9a43-ef078d097754" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_2309f85d-97f3-4a75-9e06-45f847f2a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057431024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-08940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Altria Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3260245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6601 West Broad Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">23230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785,039,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000764180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock0.3313ParValueMember', window );">Common Stock, $0.33 1/3 par value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.33 1/3 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock1.700NotesDue2025Member', window );">1.700% Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MO25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock2.200NotesDue2027Member', window );">2.200% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.200% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MO27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock3.125NotesDue2031Member', window );">3.125% Notes due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.125% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MO31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock0.3313ParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mo_CommonStock0.3313ParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock1.700NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mo_CommonStock1.700NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock2.200NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mo_CommonStock2.200NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mo_CommonStock3.125NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mo_CommonStock3.125NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052928224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,913<span></span>
</td>
<td class="nump">$ 4,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ReceivableCommercializationRightsCurrent', window );">Receivable from the sale of IQOS System commercialization rights</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Other</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InventoryRawMaterialsPlantMaterialNetofReserves', window );">Leaf tobacco</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_OtherInventoryRawMaterialsNetofReserves', window );">Other raw materials</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished product</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,152<span></span>
</td>
<td class="nump">7,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">4,413<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">2,820<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">12,366<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments in equity securities ($0 million and $250 million at March 31, 2023 and December&#160;31, 2022, respectively, measured at fair value)</a></td>
<td class="nump">9,559<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">36,826<span></span>
</td>
<td class="nump">36,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Marketing</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_AccruedSettlementLiabilityCurrent', window );">Settlement charges</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">2,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,146<span></span>
</td>
<td class="nump">8,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">24,048<span></span>
</td>
<td class="nump">25,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">2,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Accrued pension costs</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Accrued postretirement health care costs</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent', window );">Deferred gain from the sale of IQOS System commercialization rights</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,652<span></span>
</td>
<td class="nump">40,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.33 1/3&#160;per share (2,805,961,317 shares issued)</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">5,866<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Earnings reinvested in the business</a></td>
<td class="nump">29,898<span></span>
</td>
<td class="nump">29,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive losses</a></td>
<td class="num">(2,779)<span></span>
</td>
<td class="num">(2,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Cost of repurchased stock (1,019,815,657 shares at March&#160;31, 2023 and 1,020,427,195 shares at December&#160;31, 2022)</a></td>
<td class="num">(37,796)<span></span>
</td>
<td class="num">(37,816)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) attributable to Altria</a></td>
<td class="num">(3,876)<span></span>
</td>
<td class="num">(3,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="num">(3,826)<span></span>
</td>
<td class="num">(3,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">$ 36,826<span></span>
</td>
<td class="nump">$ 36,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_AccruedSettlementLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Settlement Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_AccruedSettlementLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Gain On Sale Of Commercialization Rights, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_InventoryRawMaterialsPlantMaterialNetofReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of products consisting of plant matter that is not used in the growth of plant goods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_InventoryRawMaterialsPlantMaterialNetofReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_OtherInventoryRawMaterialsNetofReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Inventory, Raw Materials, Net of Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_OtherInventoryRawMaterialsNetofReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ReceivableCommercializationRightsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable, Commercialization Rights, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ReceivableCommercializationRightsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057308672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.3333<span></span>
</td>
<td class="nump">$ 0.3333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,805,961,317<span></span>
</td>
<td class="nump">2,805,961,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">1,019,815,657<span></span>
</td>
<td class="nump">1,020,427,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052901200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 5,719<span></span>
</td>
<td class="nump">$ 5,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostOfOperatingRevenue', window );">Excise taxes on products</a></td>
<td class="nump">956<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,329<span></span>
</td>
<td class="nump">3,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_MarketingAdministrationandResearchCosts', window );">Marketing, administration and research costs</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest and other debt expense, net</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_IncomeLossFromEquitySecurities', window );">(Income) losses from investments in equity securities</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on Cronos-related financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income taxes</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 1,787<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in usd per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in usd per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_IncomeLossFromEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_IncomeLossFromEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_MarketingAdministrationandResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as research and development costs and all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. Research and development costs represent the aggregate costs incurred during an accounting period to research and develop new products/technologies when the technological feasibility has not been reached. General and administrative expenses include salaries of nonsales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_MarketingAdministrationandResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostOfOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other costs incurred during the reporting period related to other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostOfOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612049883824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Earnings - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">$ 1,787<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive earnings (losses), net of deferred income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Benefit plans</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciEquityMethodInvestmentAfterTax', window );">ABI</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustments and other</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive earnings</a></td>
<td class="nump">$ 1,779<span></span>
</td>
<td class="nump">$ 2,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciEquityMethodInvestmentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32472-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciEquityMethodInvestmentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612053215408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Earnings Reinvested in the Business [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Losses [Member]</div></th>
<th class="th"><div>Cost of Repurchased Stock [Member]</div></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (1,606)<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 5,857<span></span>
</td>
<td class="nump">$ 30,664<span></span>
</td>
<td class="num">$ (3,056)<span></span>
</td>
<td class="num">$ (36,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net earnings</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet', window );">Stock award activity</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared</a></td>
<td class="num">(1,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock</a></td>
<td class="num">(576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">(1,760)<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">30,988<span></span>
</td>
<td class="num">(2,962)<span></span>
</td>
<td class="num">(36,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(3,923)<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
<td class="nump">29,792<span></span>
</td>
<td class="num">(2,771)<span></span>
</td>
<td class="num">(37,816)<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net earnings</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet', window );">Stock award activity</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared</a></td>
<td class="num">(1,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (3,826)<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 5,866<span></span>
</td>
<td class="nump">$ 29,898<span></span>
</td>
<td class="num">$ (2,779)<span></span>
</td>
<td class="num">$ (37,796)<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital, Share Based Compensation, Restricted And Deferred Stock Awards and the tax benefits associated with vestings of prior period restricted and deferred stock awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057309712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (usd per share)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612147880064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Provided by (Used in) Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,787<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to operating cash flows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_IncomeLossFromEquitySecurities', window );">(Income) losses from investments in equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on Cronos-related financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Cash effects of changes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">409<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Accrued liabilities and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_IncreaseDecreaseInSettlementPayable', window );">Accrued settlement charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">895<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Pension plan contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash', window );">Pension and postretirement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">534<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Provided by (Used in) Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Provided by (Used in) Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Long-term debt repaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,348)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid on common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,683)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,045)<span></span>
</td>
<td class="num">(2,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,091<span></span>
</td>
<td class="nump">4,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,974<span></span>
</td>
<td class="nump">$ 5,403<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 includes $391 million of unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL, which is substantially offset by a corresponding change included in income taxes.  For further discussion, see Note 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals.  See Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_IncomeLossFromEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_IncomeLossFromEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_IncreaseDecreaseInSettlementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the period in Settlement payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_IncreaseDecreaseInSettlementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052864256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase (decrease)</a></td>
<td class="nump">$ 391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase (decrease)</a></td>
<td class="nump">$ 391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054593424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background and Basis of Presentation</a></td>
<td class="text">Background and Basis of Presentation<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in these notes, the terms </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altria,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Background: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our wholly owned subsidiaries included Philip Morris USA Inc. (&#8220;PM USA&#8221;), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (&#8220;Middleton&#8221;), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (&#8220;UST&#8221;), which through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC (&#8220;USSTC&#8221;), is engaged in the manufacture and sale of moist smokeless tobacco products (&#8220;MST&#8221;) and snus products; and Helix Innovations LLC (&#8220;Helix&#8221;), which operates in the United States and Canada, and Helix Innovations GmbH and its affiliates (&#8220;Helix ROW&#8221;), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of oral nicotine pouches.  Other wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to our domestic tobacco operating companies; and Altria Client Services LLC (&#8220;ALCS&#8221;), which provides various support services to our companies in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs.  Our access to the operating cash flows of our wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by our subsidiaries.  At March&#160;31, 2023, our significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we also owned a 75% economic interest in Horizon Innovations LLC (&#8220;Horizon&#8221;), a joint venture with Japan Tobacco, Inc., which owned the remaining 25% economic interest.  Horizon is structured to exist in perpetuity and is responsible for the U.S. marketing and commercialization of heated tobacco stick products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a stock transfer agreement with JUUL Labs, Inc. (&#8220;Stock Transfer Agreement&#8221;) pursuant to which we transferred to JUUL Labs, Inc. (&#8220;JUUL&#8221;) all of our beneficially owned JUUL equity securities.  In exchange, we received a non-exclusive, irrevocable global license to certain of JUUL&#8217;s heated tobacco intellectual property  (&#8220;JUUL Heated Tobacco IP&#8221;).  Prior to the exchange, we accounted for our investment in JUUL at fair value.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had investments in Anheuser-Busch InBev SA/NV (&#8220;ABI&#8221;) and Cronos Group Inc. (&#8220;Cronos&#8221;), which we account for under the equity method of accounting using a one-quarter lag.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of our investments in equity securities, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into a definitive agreement to acquire NJOY Holdings, Inc. (&#8220;NJOY&#8221;), a U.S. based e-vapor company, for approximately $2.75 billion in cash payable at closing (&#8220;NJOY Transaction&#8221;) plus up to an additional $500 million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products.  Following completion of the NJOY Transaction, NJOY will survive as a wholly owned subsidiary of Altria.  The completion of the NJOY Transaction is subject to customary closing conditions, including clearance from the U.S. Federal Trade Commission (&#8220;FTC&#8221;), and is not subject to any financing condition.  The parties have filed for premerger clearance with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;HSR Act&#8221;), which remains under FTC review.  The current waiting period under the HSR Act expires in May 2023.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Share Repurchases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our Board of Directors (&#8220;Board of Directors&#8221; or &#8220;Board&#8221;) authorized a $2.0 billion share repurchase program that it expanded to $3.5 billion in October 2021 (as expanded, the &#8220;January 2021 share repurchase program&#8221;).  We completed the January 2021 share repurchase program in December 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our Board of Directors authorized a new $1.0 billion share repurchase program (the &#8220;January 2023 share repurchase program&#8221;).  The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of our Board.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no share repurchases under the January 2023 share repurchase program.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share repurchase activity was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interim condensed consolidated financial statements are unaudited.  Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements.  All such adjustments were of a normal recurring nature.  Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements should be read in conjunction with our audited consolidated financial statements and related notes, which appear in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2023 we adopted Accounting Standards Update (&#8220;ASU&#8221;) 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2021-08&#8221;).  This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.  As of March 31, 2023, our adoption of ASU No. 2021-08 had no impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 1, 2023 we adopted ASU 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities- Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2022-04&#8221;).  This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period and potential magnitude.  As of March 31, 2023, our adoption of ASU No. 2022-04 had no material impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055357376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues from Contracts with Customers</a></td>
<td class="text">Revenues from Contracts with Customers<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disaggregate net revenues based on product type.  For further discussion, see Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate substantially all cash discounts, offered to customers for prompt payment, as a flat rate per unit based on agreed-upon payment terms and record receivables net of the cash discounts on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record payments received by our businesses in advance of product shipment as deferred revenue.  These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer.  Deferred revenue from contracts with customers was $268 million and $252 million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  When cash is received in advance of product shipment, our companies satisfy their performance obligations within three days of receiving payment.  At March&#160;31, 2023 and December&#160;31, 2022, there were no differences between amounts recorded as deferred revenue from contracts with customers and amounts subsequently recognized as revenue.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables (excluding receivable from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System commercialization rights) were $58 million and $48 million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  At March&#160;31, 2023 and December&#160;31, 2022, there were no expected differences between amounts recorded and subsequently received, and we did not record an allowance for credit losses against these receivables.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets.  It is USSTC&#8217;s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC&#8217;s MST and snus products.  We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues.  Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions.  We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.  All returned goods are destroyed upon return and not included in inventory.  Consequently, we do not record an asset for USSTC&#8217;s right to recover goods from customers upon return.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales incentives include variable payments related to goods sold by our businesses.  We include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers.  The sales incentives that require significant estimates and judgments are as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Price promotion payments-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We make price promotion payments, substantially all of which are made to our retail partners to incent the promotion of certain product offerings in select geographic areas.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Wholesale and retail participation payments-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We make payments to our wholesale and retail partners to incent merchandising and sharing of sales data in accordance with our trade agreements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates.  Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions.  Differences between actual and estimated payments are reflected in the period such information becomes available.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054509280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text">Investments in Equity Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our investments consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) losses from investments in equity securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.290%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments under equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GAAP&#8221;) and (ii) adjustments to our investment required under the equity method of accounting.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents loss as a result of the disposition of our JUUL equity securities discussed below.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents the estimated change in fair value.  Prior to the disposition of our JUUL equity securities on March 3, 2023, we accounted for our investment in JUUL as an investment in an equity security measured at fair value.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in ABI</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had an approximate 10% ownership interest in ABI, consisting of 185 million restricted shares of ABI (the &#8220;Restricted Shares&#8221;) and 12 million ordinary shares of ABI.  The Restricted Shares:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are unlisted and not admitted to trading on any stock exchange;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are convertible by us into ordinary shares of ABI on a one-for-one basis;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">rank equally with ordinary shares of ABI with regards to dividends and voting rights; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">have director nomination rights with respect to ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of this filing, we have not elected to convert our Restricted Shares into ordinary shares of ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our investment in ABI under the equity method of accounting because we have the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI&#8217;s board of directors and certain ABI board committees.  Through this representation, we participate in ABI&#8217;s policy making processes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our share of ABI&#8217;s results using a one-quarter lag because ABI&#8217;s results are not available in time for us to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI&#8217;s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.  We can convert our Restricted Shares to ordinary shares at our discretion.  Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our equity investment in ABI at March&#160;31, 2023 and December&#160;31, 2022 was $13.1 billion and $11.9 billion, respectively, which exceeded its carrying value of $9.2 billion and $9.0 billion by approximately 42% and 33%, respectively.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in JUUL</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2023, we entered into the Stock Transfer Agreement with JUUL pursuant to which, among other things, we  transferred to JUUL all of our beneficially owned JUUL equity securities.  Concurrently with and in connection with the execution of the Stock Transfer Agreement, JUUL entered into an agreement with us that provides us with a non-exclusive, irrevocable global license to certain of the JUUL Heated Tobacco IP.  In addition, all other agreements between us, on the one hand, and JUUL, on the other hand, were terminated or we were removed as parties thereto, other than certain litigation-related agreements and a license agreement relating to our non-trademark licensable intellectual property rights in the e-vapor field, which remain in force solely with respect to our e-vapor intellectual property as of or prior to March 3, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of transferring to JUUL all of our beneficially owned JUUL equity securities pursuant to the Stock Transfer Agreement, for the three months ended March&#160;31, 2023, we recorded a non-cash, pre-tax loss on the disposition of our JUUL equity securities of $250 million.  Additionally, we considered specific facts and circumstances around the nature of the JUUL Heated Tobacco IP and determined that the fair value of such intellectual property was not material to our consolidated financial statements as of the date of the transaction.  As a result, we did not record an asset associated with this intellectual property on our condensed consolidated balance sheet at March 31, 2023.  The primary drivers of this conclusion were (i) our rights to the JUUL Heated Tobacco IP being non-exclusive, (ii) there being no product or technology transferred to us associated with the JUUL Heated Tobacco IP and (iii) there being no connection between the JUUL Heated Tobacco IP and our current product development plans.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In April 2020, the FTC issued an administrative complaint challenging our investment in JUUL.  In February 2022, the administrative law judge dismissed the FTC&#8217;s complaint.  FTC complaint counsel appealed that decision to the FTC, which appeal remains pending.  For further discussion, see Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Contingencies -&#160;Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of our investment in JUUL, which was classified in Level 3 of the fair value hierarchy prior to the disposition of our JUUL equity securities discussed above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposition of JUUL equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in (income) losses from investments in equity securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Cronos</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had a 41.1% ownership interest in Cronos, consisting of 156.6 million shares, which we account for under the equity method of accounting.  We report our share of Cronos&#8217;s results using a one-quarter lag because Cronos&#8217;s results are not available in time for us to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos&#8217;s common shares and was classified in Level 1 of the fair value hierarchy.  At March&#160;31, 2023, the fair value of our equity method investment in Cronos was less than its carrying value by $47 million or approximately 13%.  Based on our evaluation of the duration and magnitude of the fair value decline, our evaluation of Cronos&#8217;s financial condition (including its strong cash position) and near-term prospects, and our intent and ability to hold our investment in Cronos until recovery, we concluded that the decline in fair value of our equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our investment in Cronos, at March 31, 2023, we also owned anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain our ownership percentage.  Certain of the anti-dilution protections provide us the ability to purchase additional Cronos common shares at a per share exercise price of CAD $16.25 upon the occurrence of specified events (&#8220;Fixed-price Preemptive Rights&#8221;).  The Fixed-price Preemptive Rights had no value at March 31, 2023 and December 31, 2022.  Prior to December 2022, we also owned a warrant providing us the ability to purchase an </span></div>additional approximate 10% of common shares of Cronos at a per share exercise price of CAD $19.00, which would have expired on March 8, 2023.  In December 2022, we irrevocably abandoned the Cronos warrant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054594000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk.  We use various types of derivative financial instruments, including forward contracts, options and swaps.  We do not enter into or hold derivative financial instruments for trading or speculative purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in ABI, whose functional currency is the Euro, exposes us to foreign currency exchange risk on the carrying value of our investment.  To manage this risk, we may designate certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, &#8220;foreign currency contracts&#8221;), and Euro denominated unsecured long-term notes (&#8220;foreign currency denominated debt&#8221;) as net investment hedges of our investment in ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, we had no outstanding foreign currency contracts.  When we have foreign currency contracts in effect, counterparties are domestic and international financial institutions.  Under these contracts, we are exposed to potential losses in the event of non-performance by these counterparties.  We manage our credit risk by entering into transactions with counterparties that have investment grade credit ratings, limiting the amount of exposure we have with each counterparty and monitoring the financial condition of each counterparty.  The counterparty agreements contain provisions that require us to maintain an investment grade credit rating.  In the event our credit rating falls below investment grade, counterparties to our foreign currency contracts can require us to post collateral.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value and fair value of our total long-term debt were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt included in long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the fair value of our total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedging</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized changes in the carrying value of the foreign currency denominated debt due to changes in the Euro to U.S. dollar exchange rate in accumulated other comprehensive losses related to ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized pre-tax (gains) losses of our net investment hedges of $48 million and $(128) million for the three months ended March 31, 2023 and 2022, respectively, in accumulated other comprehensive losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054353888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plans</a></td>
<td class="text">Benefit Plans<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost (Income)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (income) consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employer Contributions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make contributions to our pension plans to the extent that the contributions are tax deductible and pay benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service (&#8220;IRS&#8221;) regulations.  We made employer </span></div>contributions of $7 million to our pension plans and did not make any contributions to our postretirement plans during the three months ended March 31, 2023.  Currently, we anticipate making additional employer contributions of up to approximately $25 million to our pension plans and $30 million to our postretirement plans in 2023.  However, the foregoing estimates of 2023 contributions to our pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054486192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Losses) per Share</a></td>
<td class="text">Earnings per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculated basic and diluted earnings per share (&#8220;EPS&#8221;) using the following:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Distributed and undistributed earnings attributable to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054486192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Earnings/Losses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Earnings/Losses</a></td>
<td class="text">Other Comprehensive Earnings/Losses<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,771)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,442)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,779)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,597)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,962)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily reflects the impact of our designated net investment hedges related to our equity investment in ABI and our share of ABI&#8217;s currency translation adjustments.  For further discussion of designated net investment hedges, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.472%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost/credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in net defined benefit plan costs.  For further details, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in (income) losses from investments in equity securities.  For further information, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054464496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating companies&#8217; products include (i) smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; and (ii) oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix.  These products constituted our reportable segments of smokeable products and oral tobacco products at March&#160;31, 2023.  Our former financial services business, which completed the wind-down of its portfolio of finance assets in 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System heated tobacco business and Helix ROW were included in all other.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief operating decision maker (&#8220;CODM&#8221;) reviews operating companies income (loss) (&#8220;OCI&#8221;) to evaluate the performance of, and allocate resources to, our segments.  OCI for our segments is defined as operating income before general corporate expenses and amortization of intangibles.  Interest and other debt expense, net, along with net periodic benefit income, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by our CODM.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment data were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparability of OCI for our reportable segments was affected by the following:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Non-Participating Manufacturer (&#8220;NPM&#8221;) Adjustment Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recorded pre-tax income for NPM adjustment items of $60 million for the three months ended March&#160;31, 2022 in our smokeable products segment.  We recorded these items as reductions to cost of sales in our condensed consolidated statement of earnings, which resulted in increased OCI in our smokeable products segment.  NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the Master Settlement Agreement (such dispute resolutions are referred to as &#8220;NPM Adjustment Items&#8221; and are more fully described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Tobacco and Health and Certain Other Litigation Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the amounts shown in the table above for the smokeable products segment and general corporate expenses in marketing, administration and research costs in our condensed consolidated statements of earnings.  For further discussion, see Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054558752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Borrowings and Borrowing Arrangements</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, we had no short-term borrowings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the &#8220;Credit Agreement&#8221;), which is used for general corporate purposes and expires on August 1, 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had availability under the Credit Agreement for borrowings of up to an aggregate principal amount of $3.0 billion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of our long-term senior unsecured debt.  We expect interest rates on borrowings under the Credit Agreement to be based on the Term Secured Overnight Financing Rate plus a percentage based on the higher of the ratings of our long-term senior unsecured debt from Moody&#8217;s Investors Service, Inc. and Standard&#160;&amp; Poor&#8217;s Financial Services LLC.  The applicable percentage for borrowings under the Credit Agreement at March&#160;31, 2023 was 1.0% based on our long-term senior unsecured debt ratings on that date.  The Credit Agreement does not include any other rating triggers or any provisions that could require the posting of collateral.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes various covenants, one of which requires us to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis.  At March&#160;31, 2023, the ratio of Consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 10.9 to 1.0.  At March&#160;31, 2023, we were in compliance with our covenants in the Credit Agreement.  The terms &#8220;Consolidated EBITDA&#8221; and &#8220;Consolidated Interest Expense,&#8221; each as defined in the Credit Agreement, include certain adjustments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any commercial paper issued by us and borrowings under the Credit Agreement are guaranteed by PM&#160;USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value of our total long-term debt at March&#160;31, 2023 and December&#160;31, 2022 was $25.4 billion and $26.7 billion, respectively.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we repaid in full our 1.000% senior unsecured Euro notes in the aggregate principal amount of $1.3 billion (&#8364;1.25 billion) at maturity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and December&#160;31, 2022, accrued interest on long-term debt of $233 million and $411 million, respectively, was included in other accrued liabilities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the fair value of our long-term debt and the designation of our Euro denominated senior unsecured notes as a net investment hedge of our investment in ABI, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054617968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the U.S. Government enacted legislation commonly referred to as the Inflation Reduction Act that became effective January 1, 2023.  The main provisions of the Inflation Reduction Act that impact us are: (i) a 15% corporate alternative minimum tax (&#8220;Corporate AMT&#8221;) and (ii) a 1% excise tax on share repurchases, which we will record in equity on our consolidated statements of stockholders&#8217; equity (deficit).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are considered an &#8220;applicable corporation&#8221; for purposes of Corporate AMT.  We expect our regular federal income tax liability will generally exceed our Corporate AMT liability; however, certain unique circumstances may result in our Corporate AMT liability exceeding our regular federal income tax liability, including when tax losses are reported in a different year than book losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,479</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">692</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax rate for the three months ended March 31, 2023 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to the disposition of our former investment in JUUL.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax rate for the three months ended March 31, 2022 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to a decrease in the estimated fair value of our investment in JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxation in many jurisdictions.  Unrecognized tax benefits reflect the differences between tax positions we have taken or expect to take on income tax returns and the amounts recognized in the financial statements.  Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within our control.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ending December&#160;31, 2023, we expect to recognize an approximate $6.5 billion ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL.  For financial statement purposes, we expect to fully reserve for the tax benefit associated with this ordinary loss by recording an unrecognized tax benefit of </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.6 billion in 2023 on a pro-rata basis, pending the IRS&#8217;s review of our tax position.  For the three months ended March 31, 2023, we recognized a pro-rata portion of this ordinary loss, which resulted in a tax benefit of $380 million and a reduction to our current income taxes payable.  We also recognized a $391 million increase in a long-term liability for unrecognized tax benefits related to this tax position, partially offset by an $11 million deferred federal benefit for state taxes.  There was no impact to our condensed consolidated statement of earnings for the three months ended March 31, 2023.  For further discussion of our former investment in JUUL, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our total unrecognized tax benefits were $460 million.  The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at March&#160;31, 2023, was $44 million, along with $416 million affecting deferred taxes.  The amount of unrecognized tax benefit that, if recognized, would impact the effective tax rate at December 31, 2022, was $44 million, along with $25 million affecting deferred taxes.  Unrecognized tax benefits increased by $391 million from December&#160;31, 2022 due to the tax position established with respect to the character of losses from our former investment in JUUL as discussed above.</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the recognition of the approximate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.5 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ordinary loss for cash tax purposes discussed above, we expect to be subject to Corporate AMT in 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to valuation allowance charged to income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases to valuation allowance credited to income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.  We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized.  We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence.  In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, we reduced the deferred tax asset and corresponding valuation allowance for the portion of our JUUL capital losses that is now part of our tax basis in the shares of a foreign subsidiary.  This outside basis difference of the foreign subsidiary is not recognized as a deferred tax asset since we do not expect the temporary difference to reverse in the foreseeable future.  The cumulative valuation allowance at March&#160;31, 2023 was primarily attributable to deferred tax assets recorded in connection with the portion of our JUUL capital losses that is now included in our tax basis in the shares of a domestic subsidiary and our investment in Cronos.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055345680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and certain of our subsidiaries, including PM USA and USSTC, as well as our indemnitees and investees.  Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, income tax liability, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#8221;), claims for contribution and claims of competitors, shareholders or distributors.  Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases.  An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation.  Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars.  The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome.  In certain cases, plaintiffs claim that defendants&#8217; liability is joint and several.  In such cases, we may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment.  As a result, under certain circumstances, we may </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have to pay more than our proportionate share of any bonding- or judgment-related amounts.  Furthermore, in those cases where plaintiffs are successful, we also may be required to pay interest and attorneys&#8217; fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases.  This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all.  As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida&#8217;s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well.  Such challenges may include the applicability of state bond caps in federal court.  States, including Florida, also may seek to repeal or alter bond cap statutes through legislation.  Although we cannot predict the outcome of such challenges, it is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record provisions in our condensed consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.  At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i)&#160;management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii)&#160;management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii)&#160;accordingly, management has not provided any amounts in our condensed consolidated financial statements for unfavorable outcomes, if any.  Litigation defense costs are expensed as incurred.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved substantial success in managing litigation.  Nevertheless, litigation is subject to uncertainty and significant challenges remain.  It is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation.  We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts.  We have defended, and will continue to defend, vigorously against litigation challenges.  However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Judgments Paid and Provisions for Tobacco and Health (Including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation) and Certain Other Litigation Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax charges for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder derivative lawsuits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related interest costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at end of period</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> below for a discussion of the pending settlement of the federal and state shareholder derivative lawsuits.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities and other liabilities on our condensed consolidated balance sheets.  Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on our condensed consolidated statements of earnings.  Pre-tax charges for related interest costs were included in interest and other debt expense, net on our condensed consolidated statements of earnings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $963 million and interest totaling approximately $231 million as of March 31, 2023.  These amounts include payments for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny judgments (and related costs and fees) totaling approximately $436 million and related interest totaling approximately $60 million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security for Judgments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain stays of judgments pending appeal, PM USA has posted various forms of security.  As of March 31, 2023, PM USA has posted appeal bonds totaling approximately $46 million, which have been collateralized with restricted cash and are included in assets on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Types and Number of U.S. Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims related to tobacco products generally fall within the following categories: (i)&#160;smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii)&#160;health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv)&#160;other tobacco-related litigation described below.  Plaintiffs&#8217; theories of recovery and the defenses raised in tobacco-related litigation are discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the number of certain tobacco-related cases pending in the United States against us as of:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 24, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Smoking and Health Cases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Care Cost Recovery Actions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-vapor Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,744</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tobacco-Related Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes as of April 24, 2023, 19 cases filed in Illinois, 22 cases filed in New Mexico, 43 cases filed in Massachusetts and 46 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cases filed in Florida.  Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">case (these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> progeny cases are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  Also does not include 1,390 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (&#8220;ETS&#8221;).  The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Broin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages.  Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.</span></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, 57 class action lawsuits, 3,746 individual lawsuits and 1467 &#8220;third party&#8221; lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.  The 57 class action lawsuits include 32 cases in the Northern District of California (&#8220;Multidistrict Litigation&#8221; or &#8220;MDL&#8221;) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.</span></div><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Tobacco-Related Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement (defined below) between Altria and Philip Morris International Inc. (&#8220;PMI&#8221;) that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tobacco-Related Cases Set for Trial: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, five </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases, four individual smoking and health cases and one e-vapor case are set for trial through June 30, 2023.  Trial dates are subject to change.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1999, excluding the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases (separately discussed below), verdicts have been returned in 75 tobacco-related cases in which PM USA was a defendant.  Verdicts in favor of PM USA and other defendants were returned in 47 of the 75 cases.  These 47 cases were tried in Alaska (1), California (7), Connecticut (1), Florida (10), Louisiana (1), Massachusetts (6), Mississippi (1), Missouri (4), New Hampshire (1), New Mexico (1), New Jersey (1), New York (5), Ohio (2), Pennsylvania (1), Rhode Island (1), Tennessee (2) and West Virginia (2).  One case in Massachusetts, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Main</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where the verdict was initially returned in favor of PM USA, was reversed on appeal and remanded for a new trial.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 28 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs, 24 have reached final resolution.</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Liti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">gation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of verdicts in state and federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA as of April 24, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smoking and Health Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes.  Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief.  Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny smoking and health cases pending during 2023 (or recently concluded) in which a verdict was returned in favor of plaintiff and against PM USA.  Charts listing certain verdicts for plaintiffs in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases can be found in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Woodley: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $5 million in compensatory damages.  There was no claim for punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mendez</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA and R.J. Reynolds Tobacco Company awarding approximately $4.5 million in compensatory damages and allocating 13% of the fault to PM USA.  After applying comparative fault, PM USA&#8217;s portion of the compensatory damages is less than $1 million.  There was no claim for punitive damages.  The trial court denied PM USA&#8217;s post-trial motions, and both parties appealed.  The parties subsequently reached an agreement to resolve plaintiff&#8217;s claims.  As a result, both the appeal and cross-appeal have been dismissed and the case is concluded.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fontaine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $8 million in compensatory damages and $1 billion in punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Greene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages.  In May 2020, the court ruled on plaintiffs&#8217; remaining claim and trebled the compensatory damages award to approximately $30 million.  In February 2021, the trial court awarded plaintiffs attorneys&#8217; fees and costs in the amount of approximately $2.3 million.  In July 2021, following denial of PM USA&#8217;s post-trial motions, PM USA appealed the judgment to the Appeals Court of Massachusetts.  In September 2022, the Massachusetts Supreme Judicial Court issued an order taking jurisdiction over the appeal and heard oral arguments in January 2023.  The appeal remains pending.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Class Action: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2000, in the second phase of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA.  Following entry of judgment, PM USA appealed.  In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class.  Plaintiffs petitioned the Florida Supreme Court for further review.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate.  The court further declared the following Phase I findings are entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect in such individual actions brought within one year of the issuance of the mandate: (i)&#160;that smoking causes various diseases; (ii)&#160;that nicotine in cigarettes is addictive; (iii)&#160;that defendants&#8217; cigarettes were defective and unreasonably dangerous; (iv)&#160;that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v)&#160;that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi)&#160;that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii)&#160;that all defendants sold or supplied cigarettes that were defective; and (viii)&#160;that defendants were negligent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion.  In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect by excluding finding (v)&#160;listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants.  In February 2008, the trial court decertified the class.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e Progeny Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deadline for filing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending.  As of April 24, 2023, approximately 551 state court cases were </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending against PM USA or Altria asserting individual claims by or on behalf of approximately 705 state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates.  The 2015 federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement resolved nearly all </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases pending in federal court as of the date of the agreement, and each case excluded from that agreement subsequently has been resolved.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, 143 federal and state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision.  Seventy-nine verdicts were returned in favor of plaintiffs, and five verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Calloway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oshinsky-Blacker,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McCoy, Mahfuz </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Neff</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.  In  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kaplan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McLaughlin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the punitive damages award was vacated on appeal and remanded for a new trial.  In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sommers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the trial court entered final judgment dismissing the plaintiff&#8217;s punitive damages claim with prejudice, and plaintiff appealed.  The Third District Court of Appeal affirmed the award and remanded for a new trial on entitlement to punitive damages and amount.  On remand, the trial court granted PM USA&#8217;s motion for summary judgment and entered final judgment dismissing the plaintiff&#8217;s punitive damages claim with prejudice, and plaintiff has appealed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifty-seven verdicts were returned in favor of PM USA, of which 47 were state cases.  In addition, there have been a number of mistrials, only some of which have resulted in new trials as of April 24, 2023.  The jury in one case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages.  Following appeals by the plaintiff and PM USA, the appellate court in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> affirmed the compensatory damages judgment against PM USA and granted a new trial with respect to punitive damages.  The plaintiff in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsequently filed a motion to voluntarily dismiss the punitive damages claim and to enter final judgment on the compensatory damages claim, which the court granted.  Three verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cohen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chacon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were returned in favor of PM USA were subsequently reversed for new trials.  Juries in two cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Banks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) returned zero damages verdicts in favor of PM USA.  Juries in two other cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weingart</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hancock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages.  One case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pollari</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff.  Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgment in favor of the defendants.  Three cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gloger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rintoul </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duignan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs.  A post-trial appeal is pending in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duignan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The verdicts in the retrials in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gloger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rintoul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were reversed upon appeal and remanded for new trials.  Two cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freeman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.  One case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R. Douglas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was dismissed with prejudice following a verdict in favor of plaintiff.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below list the verdicts and post-trial developments in certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs.  The first chart lists cases that are pending as of April 24, 2023 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the second chart lists cases that have concluded in the past 12 months.  Unless otherwise noted for a particular case, the jury&#8217;s award for compensatory damages will not be reduced by any finding of plaintiff&#8217;s comparative fault.  Further, the damages noted reflect adjustments based on post-trial or appellate rulings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References below to &#8220;R.J. Reynolds,&#8221; &#8220;Lorillard&#8221; and &#8220;Liggett Group&#8221; are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently Pending Engle Cases with Verdicts Against PM USA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hoffman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million ($3 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendant to First District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Levine</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeals by defendants and plaintiff to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Schertzer</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendants to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lipp</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Garcia</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6 million ($3 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Duignan</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pinellas</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Supreme Court quashed the Second District Court of Appeal&#8217;s affirmation of  judgment against the defendants and remanded the case for reconsideration in light of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McCall</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1&#160;million (&lt;$1&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New trial on punitive damages is set for June 2023.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chadwell</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal has ordered supplemental briefing in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kaplan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McLaughlin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2&#160;million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Florida Supreme Court vacated the punitive damages award in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sheffield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The Fourth District Court of Appeals affirmed the compensatory damages award and granted a new trial on punitive damages.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cooper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5&#160;million </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&lt;$1&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal affirmed the compensatory damages award and granted a new trial on punitive damages.</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PM USA&#8217;s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff&#8217;s verdict following a retrial of an initial verdict in favor of plaintiff.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> PM USA is not a defendant in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle Progeny Appellate Issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle Cases Concluded Within Past 12 Months </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrual Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Amount for Damages (if any)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Miller</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tuttle</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cuddihee</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Holliman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">D. Brown</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2015</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Appellate Issues: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appellate decisions in the following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases may have wide application to other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mary Sheffield v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#8217;s District Courts of Appeal finding that the 1999 amendments to Florida&#8217;s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Linda Prentice v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#8217;s District Courts of Appeal finding that in order for an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiff to prevail on fraudulent concealment and conspiracy claims, plaintiff must prove that the smoker relied to his or her detriment on a statement that concealed or omitted material information about the health risks or addictiveness of smoking.  The Florida Supreme Court declined to revisit its prior decisions giving preclusive effect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase I findings, described above in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Florida Bond Statute: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny lawsuits in the aggregate and establishes individual bond caps for individual </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in amounts that vary depending on the number of judgments in effect at a given time.  Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases tried in federal court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Smoking and Health Class Actions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts.  In general, these cases have purported to be brought on behalf of residents of a particular state or states (although a few cases have purported to be nationwide in scope) and have raised addiction claims and, in many cases, claims of physical injury as well.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1)&#160;and Wisconsin (1).  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Tobacco-Related Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a discussion of &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; class action cases and medical monitoring class action cases pending against PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario.  In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants&#8217; cigarettes.  In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants&#8217; cigarettes.  In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to us) seeking protection under Canada&#8217;s Companies&#8217; Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the United States).  The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Cost Recovery Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages.  Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there have been some decisions to the contrary, most judicial decisions in the United States have dismissed all or most health care cost recovery claims against cigarette manufacturers.  Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs&#8217; claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions.  The U.S. Supreme Court has refused to consider plaintiffs&#8217; appeals from the cases decided by five federal circuit courts of appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the cases brought in the United States, health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases),&#160;and other entities have stated that they are considering filing such actions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers.  PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases.  The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed.  All of these cases have been stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with us) under the Companies&#8217; Creditors Arrangement Act discussed above.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Other Smoking and Health Class Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for a discussion of these proceedings.  See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlements of Health Care Cost Recovery Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 1998, PM USA and certain other tobacco product manufacturers entered into the Master Settlement Agreement (the &#8220;MSA&#8221;) with 46 states, the District of Columbia and certain </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States territories to settle asserted and unasserted health care cost recovery and other claims.  PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the &#8220;State Settlement Agreements&#8221;).  The State Settlement Agreements require that the original participating manufacturers or &#8220;OPMs&#8221; (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (&#8220;ITG&#8221;)) make annual payments of approximately $9.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume.  In addition, the OPMs are required to pay settling plaintiffs&#8217; attorneys&#8217; fees, subject to an annual cap of $500 million; these quarterly payments are expected to end in 2024.  For the three months ended March 31, 2023 and 2022, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $900 million for each period.  These amounts include PM USA&#8217;s estimate of amounts related to NPM Adjustments discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NPM Adjustment Disputes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;NPM Adjustment&#8221; is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the &#8220;participating manufacturers&#8221; or &#8220;PMs&#8221;) that applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent auditor (&#8220;IA&#8221;) appointed under the MSA has calculated that PM USA&#8217;s share of the maximum potential NPM Adjustments for 2004-2022 is (exclusive of interest or earnings): $388 million for 2004; $181 million for 2005; $154 million for 2006; $185 million for 2007; $250 million for 2008; $211 million for 2009; $218 million for 2010; $166 million for 2011; $214 million for 2012; $224 million for 2013; $258 million for 2014; $313 million for 2015; $292 million for 2016; $285 million for 2017; $318 million for 2018; $415 million for 2019; $572 million for 2020; $675 million for 2021; and $571 million for 2022.  These maximum amounts will be substantially reduced to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments.  PM USA&#8217;s recovery for 2004 is addressed below.  In addition, PM USA&#8217;s recovery of such reduced amounts for all subsequent years will be dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Settlements of NPM Adjustment Disputes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Multi-State Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  By the end of 2018, a total of 36 MSA states and territories had entered the multi-state settlement of NPM Adjustment disputes to which PM USA is a party.  Of these 36 states and territories, 35 entered settlement through 2022, and one state entered settlement through 2024.  In March 2022, Illinois joined the multi-state settlement, settling the NPM Adjustment disputes through 2028 and bringing the total number of states and territories that have joined the multi-state settlement to 37.  As a result, PM USA will receive approximately $80 million for 2004-2021 ($20 million of which relates to the 2019-2021 &#8220;transition years&#8221;).  In connection with this development for Illinois, PM USA recorded $80 million as a reduction in cost of sales in the first quarter of 2022.  Pursuant to the multi-state settlement, PM USA has received $1.15 billion since the first group of states entered the NPM Adjustment dispute settlement in 2014 and expects to receive approximately $410 million in credits to offset PM USA&#8217;s MSA payments through 2036.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">New York Settlement.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity.  PM USA has received $435 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Montana Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030.  This settlement resulted in a payment by PM USA of $4 million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing NPM Adjustment Disputes with States That Have Not Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2004 NPM Adjustment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The PMs and the nine states that have not settled the NPM Adjustment disputes participated in a multi-state arbitration of NPM Adjustment disputes for 2004.  A tenth state, Illinois, also participated in the arbitration, but joined the multi-state settlement after the arbitration panel issued its decisions described below.  Hearings for nine of the 10 states concluded by the end of 2020.  The arbitration panels issued decisions finding that three states, Missouri, New Mexico and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004.  The arbitration panels further found that the remaining seven states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004.  Washington and Missouri have challenged those determinations in their respective state courts and with the arbitration panels, and several issues remain to be resolved by the courts that may affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive.  PM USA recorded $21 million and $3 million as a reduction in cost of sales in the third quarter of 2021 and fourth quarter of 2022, respectively, for its estimate of the minimum amount of the 2004 NPM adjustment it will receive.  PM USA estimates it is </span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entitled to interest of approximately $23 million and $5 million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021 and fourth quarter of 2022, respectively.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2005-2007 NPM Adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The PMs and the nine states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel.  The arbitration encompasses three years, 2005-2007, for eight of the nine states, and one year, 2005, for one state.  As of April 24, 2023, no decisions have resulted from the arbitration.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Subsequent Years.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In July 2022, the State of Iowa filed a motion in Iowa state court against the PMs, including PM USA, claiming that the PMs wrongfully disputed the applicability of NPM Adjustments to Iowa and that all adjustment amounts to date should have been paid to Iowa rather than deposited into the disputed payments account.  A similar enforcement motion was filed by the State of New Mexico against the PMs, including PM USA, in November 2022.  PM USA has placed certain disputed NPM Adjustment amounts attributed to Iowa and New Mexico in the disputed payments account established pursuant to the terms of the MSA.  Iowa and New Mexico seek a total of approximately $133 million and $84 million, respectively, in disputed payments from all defendants combined, as well as treble and punitive damages, and other relief.  The PMs filed a cross motion to compel arbitration in the Iowa matter.  In February 2023, the Iowa state court granted the PM&#8217;s motion, compelling arbitration.  In March 2023, Iowa withdrew its motion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Disputes Under the State Settlement Agreements: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds&#8217;s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the &#8220;ITG transferred brands&#8221;).  PM USA filed motions to enforce the State Settlement Agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals, although further proceedings may occur based on the resolution of certain outstanding litigation between R.J. Reynolds and ITG.  In May 2022, PM USA filed a motion to compel arbitration under the MSA regarding certain positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  In June 2022, the matter was resolved through mutual agreement of the parties.  PM USA continues to dispute how the ITG transferred brands are treated in allocating the NPM Adjustments under the MSA and related settlements and may pursue such claims.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018.  The Mississippi state court held a hearing in October 2021 and issued a decision in June 2022 granting the State&#8217;s motion.  Further proceedings remain outstanding, and a final judgment has not yet been issued.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs&#8217; claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&amp;M Brands, Inc. (&#8220;S&amp;M Brands&#8221;), under which the states released certain claims against S&amp;M Brands in exchange for receiving a portion of the funds S&amp;M Brands deposited into escrow accounts in those states pursuant to the states&#8217; escrow statutes.  In consideration for waiving its most favored nation claim, PM USA received approximately $32 million from the escrow funds paid to those MSA states under their settlement with S&amp;M Brands.  These funds were received in January 2021 and were recorded in our condensed consolidated statement of earnings (losses) for the first quarter of 2021 as a reduction in cost of sales.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal Government&#8217;s Lawsuit: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, the U.S. government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes.  The case ultimately proceeded only under the civil provisions of RICO.  In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in certain &#8220;sub-schemes&#8221; to defraud that the government had alleged.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court did not impose monetary penalties on defendants, but ordered various types of non-monetary relief, including an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including &#8220;lights,&#8221; &#8220;ultra lights&#8221; and &#8220;low tar,&#8221; which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand, and the issuance of &#8220;corrective statements&#8221; in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking &#8220;low tar&#8221; or &#8220;light&#8221; cigarettes, defendants&#8217; manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corrective statements began appearing in newspapers and on television in the fourth quarter of 2017 and on websites in the second quarter of 2018, and the onserts began appearing in the fourth quarter of 2018.  In December 2022, the district court entered a consent order approving a settlement with respect to corrective statements on point-of-sale signage.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recorded provisions totaling approximately $28 million for the estimated costs of implementing the corrective statements on point-of-sale signage remedy.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the U.S. government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes discussed above also applies to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a heated tobacco product used with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System.  In August 2020, we filed an opposition to the government&#8217;s motion and, in the alternative, a motion to modify the injunction to make clear it does not apply to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The district court heard arguments on the motions in July 2022 and has not yet issued any decisions.  Regardless of the district court&#8217;s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the U.S. Food and Drug Administration for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-vapor Product Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, we are defendants in 57 class action lawsuits relating to JUUL e-vapor products.  JUUL is an additional named defendant in each of these lawsuits.  The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices.  Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales.  The 57 class action lawsuits include 32 cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.  Three of the class action lawsuits are pending in Canada.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have been named as defendants in other lawsuits involving JUUL e-vapor products, including 3,746 individual lawsuits and 1,467 &#8220;third party&#8221; lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the U.S. Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of the federal individual and class action lawsuits mentioned above in the U.S. District Court for the Northern District of California for pretrial purposes.  In December 2022, JUUL reached agreements to resolve the Multidistrict Litigation through settlement.  In January 2023, the court preliminarily approved the settlement.  We are not a party to any settlements concerning the Multidistrict Litigation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court has set trial dates for one case pending in the Multidistrict Litigation.  One trial in the Multidistrict Litigation is ongoing as of April 24, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim.  In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice.  Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law.  The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects.  The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020.  In January 2021, we filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021.  In June 2022, the court granted plaintiffs&#8217; motion to certify a California state class based on state law claims against JUUL and a nationwide class based on RICO claims against Altria and other defendants.  Altria and the other defendants filed petitions with the U.S. Court of Appeals for the Ninth Circuit seeking discretionary review of the class certification order, which the court granted in October 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional group of cases is pending in California state courts.  In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JUUL also is named in a significant number of additional individual and class action lawsuits to which we are not currently named.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four of the &#8220;third party&#8221; lawsuits noted above against us and JUUL were initiated, individually, by the attorneys general of Alaska, Hawaii, Minnesota and New Mexico alleging violations of state consumer protection and other similar laws.  We filed motions to dismiss the lawsuits.  In Alaska, Hawaii and Minnesota, the motions were denied in February 2022, May 2021 and June 2021, respectively.  Our motion to dismiss remains pending in New Mexico.  In the Alaska lawsuit, although the trial court declined to dismiss most of the plaintiff&#8217;s claims, the trial court did dismiss plaintiff&#8217;s public nuisance claim.  In April 2023, we agreed to settle the Minnesota lawsuit for an immaterial amount.  The trial courts in the Alaska and Hawaii lawsuits have set the trials for April 2024 and February 2024, respectively.  As of April 24, 2023, the trial court in New Mexico has not set a trial date.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, ALCS, PMI and its affiliate, Philip Morris Products S.A., in the U.S. District Court for the Eastern District of Virginia asserting claims of patent infringement based on the sale of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System electronic device and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States.  Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys&#8217; fees.  Altria and PMI were previously dismissed from the lawsuit, and plaintiffs&#8217; claims against the other defendants have been stayed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA, ALCS and Philip Morris Products S.A. filed counterclaims against plaintiffs in the Eastern District of Virginia lawsuit alleging patent infringement by R.J. Reynolds&#8217; e-vapor products.  In June 2022, PM USA and ALCS reached an agreement with R.J. Reynolds resulting in dismissal of their counterclaims.  In addition, ALCS filed a separate lawsuit against R.J. Reynolds in the U.S. District Court for the Middle District of North Carolina also alleging patent infringement by R.J. Reynolds&#8217; e-vapor products.  In September 2022, a jury awarded ALCS $95 million in damages for past infringement, plus supplemental damages and interest.  In January 2023, the court ordered R.J. Reynolds to pay ALCS a 5.25% royalty on future sales of its infringing product resulting in positive net income through the expiration of the relevant patents in 2035.  R.J. Reynolds has filed a notice of appeal of the judgment.  As gains related to this lawsuit have not yet been determined to be realized or realizable in accordance with GAAP, they have not been recognized in our financial statements for the three months ended March 31, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a related patent infringement action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the U.S. International Trade Commission (&#8220;ITC&#8221;), but the remedies sought included a prohibition on the importation of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System electronic device, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and component parts into the United States and on the sale of any such products previously imported into the United States.  No damages are recoverable in the proceedings before the ITC.  In September 2021, the ITC issued a limited exclusion order barring the importation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System electronic device,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products.  The orders became effective on November 29, 2021.  Consequently, PM USA removed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System electronic device and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Marlboro HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the marketplace.  In December 2021, defendants appealed the orders to the U.S. Court of Appeals for the Federal Circuit and, in March 2023, the U.S. Court of Appeals for the Federal Circuit issued its decision affirming the ITC exclusion order in full.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Healthier Choices Management Corp. filed an additional unrelated patent infringement case in the U.S. District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief.  In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021.  In December 2021, the U.S. District Court denied plaintiff&#8217;s motion to amend the complaint and plaintiff appealed this ruling to the U.S. Court of Appeals for the Federal Circuit, which reversed the district court&#8217;s decision and remanded for further proceedings.  The U.S. Patent Office has also issued a decision that the claims of the asserted patent are not valid, and the plaintiff has appealed that ruling.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a stock transfer agreement with JUUL pursuant to which, among other things, we transferred to JUUL all of our beneficially owned JUUL equity securities.  See Note 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our disposition of our interest in JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that our 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (&#8220;Sherman Act&#8221;) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (&#8220;Clayton Act&#8221;).  If the FTC&#8217;s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party&#8217;s board of directors or attending meetings of the other party&#8217;s board of directors and notice to the FTC in advance of certain corporate actions, including acquisitions, mergers or certain corporate restructurings.  In February 2022, the administrative law judge dismissed the FTC&#8217;s complaint and, also in February 2022, FTC complaint counsel appealed the administrative law judge&#8217;s decision to the FTC.  Oral argument with respect to the appeal occurred in September 2022.  After oral argument, the FTC asked for additional briefing, which was completed in December 2022.  In March 2023, following our disposition of our interest in JUUL, we filed a motion to dismiss, or in the alternative, to stay the litigation and a motion to withdraw the matter from adjudication to discuss settlement with the FTC.  The FTC subsequently issued an order denying our request for a stay and extending to May 5, 2023 its deadline for issuance of a final decision with respect to FTC complaint counsel&#8217;s appeal of the administrative law judge&#8217;s decision and the remainder of the pending motions.  Altria can appeal any adverse ruling the FTC issues following its review to any U.S. Court of Appeals.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as of April 24, 2023, 17 putative class action lawsuits have been filed against Altria and JUUL in the U.S. District Court for the Northern District of California.  The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed.  In November 2020 these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers).  The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market.  Plaintiffs seek various remedies, including treble damages, attorneys&#8217; fees, a declaration that the agreements between Altria and JUUL are invalid and rescission of the transaction.  We filed a motion to dismiss these lawsuits in January 2021.  In August 2021, the U.S. District Court for the Northern District of California denied our motion to dismiss except with respect to plaintiffs&#8217; claims for injunctive and equitable relief.  However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.  In January 2022, the trial court ordered that the direct-purchaser plaintiffs&#8217; claims against JUUL be sent to arbitration pursuant to an arbitration provision in JUUL&#8217;s online purchase agreement.  The court granted plaintiffs&#8217; leave to replead the complaint with new direct-purchaser plaintiffs, which plaintiffs did in February 2022, substituting in four new plaintiffs.  In August 2022, the court stayed all of the cases pending any appeal to the court of appeals from the FTC&#8217;s lawsuit against Altria and JUUL.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Class Action and Shareholder Derivative Lawsuits</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October and December 2019, two purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, our former Chairman and Chief Executive Officer, and William F. Gifford, Jr., our former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the U.S. District Court for the Eastern District of New York.  In December 2019, the court consolidated the two lawsuits into a single proceeding.  The consolidated lawsuit was subsequently transferred to the U.S. District Court for the Eastern District of Virginia.  The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act.  In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit.  The claims allege false and misleading statements and omissions relating to our former investment in JUUL.  Plaintiffs seek various remedies, including damages and attorneys&#8217; fees.  In July 2020, the defendants filed motions to dismiss plaintiffs&#8217; claims, which the district court denied in March 2021.  In the fourth quarter of 2021, plaintiffs and defendants agreed upon a class action settlement under which, among other things, (i) all claims asserted against Altria and the other named defendants are resolved without any liability or wrongdoing attributed to them personally or to Altria and (ii) Altria will pay the class an aggregate amount of $90 million, which amount includes attorneys&#8217; fees.  The class is defined to include persons and entities who purchased or otherwise acquired shares of Altria between October 25, 2018 through April 2, 2020, subject to certain exclusions.  The trial court granted final approval of the settlement in March 2022.  We recorded pre-tax provisions totaling $90 million in 2021 and, in January 2022, paid $90 million to plaintiffs&#8217; escrow account.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Shareholder Derivative Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, two purported Altria shareholders filed separate derivative lawsuits in the U.S. District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of our executives and officers.  These derivative lawsuits relate to our former investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants.  In March 2021, the U.S. District Court for the Northern District of California granted defendants&#8217; motion to transfer both lawsuits to the U.S. District Court for the Eastern District of Virginia.  Three additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the U.S. District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws.  The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of our corporate governance and internal procedures, and attorneys&#8217; fees.  In April 2021, the court consolidated the five cases pending in the Eastern District of Virginia into a single case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (our former Chief Growth Officer and JUUL&#8217;s current Chief Executive Officer), certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively.  The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia.  In successive orders from July 2021, September 2021 and January 2022, five of the six state derivative cases were consolidated into a single case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, plaintiffs and defendants in all the federal and state derivative cases agreed upon a settlement of these cases.  Under the terms of the settlement, among other things, we agreed to fund underage tobacco prevention and cessation programs, </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may include positive youth development programs, led by independent third-party organizations.  In 2022, we recorded pre-tax provisions totaling $27&#160;million for costs associated with the independent monitoring of our funding commitments and attorneys&#8217; fees.  In January 2023, the federal trial court conducted a final approval hearing, at which the court sustained an objection to a provision of the settlement, but granted the parties additional time to resolve the issue.  The parties subsequently executed an amendment to the settlement agreement, and the federal trial court granted final approval of the settlement in February 2023.  No appeal was taken.  In March 2023, pursuant to the terms of the settlement agreement, plaintiffs in the state derivative cases filed motions to dismiss their lawsuits, which the state courts granted.  The settlement will become effective upon the expiration of the deadline for any appeals of the dismissal orders, which is scheduled to occur on May 1, 2023.  In the first quarter of 2023, we recorded pre-tax provisions totaling approximately $100 million related to the settlement, and in April 2023, paid $15 million to plaintiffs&#8217; escrow account for attorneys&#8217; fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Other Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Lights/Ultra Lights&#8221; Cases and Other Smoking and Health Class Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms &#8220;Lights&#8221; and/or &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages.  These class actions have been brought against PM USA and, in certain instances, Altria or our other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes.  Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment.  Twenty-one state courts in 23 &#8220;Lights&#8221; cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA.  As of April 24, 2023, two &#8220;Lights/Ultra Lights&#8221; class actions are pending in U.S. state courts.  Neither case is active.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 24, 2023, one smoking and health case alleging personal injury or seeking court-supervised programs or an ongoing medical monitoring program on behalf of individuals exposed to environmental tobacco smoke and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court.  The case is currently inactive.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UST Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time.  Plaintiffs&#8217; allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes.  Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement.  Defenses raised in these cases have included lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations.  As of April 24, 2023, there is no such case pending against UST and/or its tobacco subsidiaries.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and our former subsidiaries are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the United States: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as &#8220;Superfund&#8221;), which can impose joint and several liability on each responsible party.  Altria and our former subsidiaries are involved in several cost recovery/contribution cases subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations.  We expect to continue to make capital and other expenditures in connection with environmental laws and regulations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated.  Such accruals are adjusted as new information develops or circumstances change.  Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that we may undertake in the future.  In the opinion of our management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on our condensed consolidated results of operations, capital expenditures, financial position or cash flows.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Other Similar Matters</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we have agreed to indemnify a limited number of third parties in the event of future litigation.  At March&#160;31, 2023, we (i) had $46 million of unused letters of credit obtained in the ordinary course of business and (ii) were contingently liable for guarantees related to our own performance, including $19 million for surety bonds recorded on our condensed consolidated balance sheet.  In addition, from time to time, we issue lines of credit to affiliated entities.  These items have not had, and are not expected to have, a significant impact on our liquidity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of a distribution agreement between Altria and PMI (the &#8220;Distribution Agreement&#8221;), entered into as a result of our 2008 spin-off of our former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part on the manufacturer.  PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI.  We do not have a related liability recorded on our condensed consolidated balance sheet at March&#160;31, 2023 as the fair value of this indemnification is insignificant.  PMI has agreed not to seek indemnification with respect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> System patent litigation discussed above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS Litigation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excluding the patent infringement case filed with the U.S. District Court for the Northern District of Georgia.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA has issued guarantees relating to our obligations under our outstanding debt securities, borrowings under our $3.0 billion Credit Agreement and amounts outstanding under our commercial paper program.  For further discussion, see Note 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055463536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Guidance Not Yet Adopted<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Guidance Not Yet Adopted</a></td>
<td class="text">New Accounting Guidance Not Yet Adopted<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2022-03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612056397584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text">under the equity method of accounting using a one-quarter lag.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Our interim condensed consolidated financial statements are unaudited.  Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements.  All such adjustments were of a normal recurring nature.  Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2023 we adopted Accounting Standards Update (&#8220;ASU&#8221;) 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2021-08&#8221;).  This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.  As of March 31, 2023, our adoption of ASU No. 2021-08 had no impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 1, 2023 we adopted ASU 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities- Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU No. 2022-04&#8221;).  This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period and potential magnitude.  As of March 31, 2023, our adoption of ASU No. 2022-04 had no material impact on our condensed consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2022-03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_CashDiscountsPolicyTextBlock', window );">Cash Discounts</a></td>
<td class="text">We calculate substantially all cash discounts, offered to customers for prompt payment, as a flat rate per unit based on agreed-upon payment terms and record receivables net of the cash discounts on our condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer</a></td>
<td class="text">We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets.  It is USSTC&#8217;s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC&#8217;s MST and snus products.  We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues.  Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions.  We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.  All returned goods are destroyed upon return and not included in inventory.  Consequently, we do not record an asset for USSTC&#8217;s right to recover goods from customers upon return.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our investment in ABI under the equity method of accounting because we have the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI&#8217;s board of directors and certain ABI board committees.  Through this representation, we participate in ABI&#8217;s policy making processes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our share of ABI&#8217;s results using a one-quarter lag because ABI&#8217;s results are not available in time for us to record them in the concurrent period.</span></div>The fair value of our equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI&#8217;s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.  We can convert our Restricted Shares to ordinary shares at our discretion.  Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.The fair value of our equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos&#8217;s common shares and was classified in Level 1 of the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.  We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized.  We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence.  In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock', window );">Revenue From Contract With Customer, Deferred Revenue</a></td>
<td class="text">We record payments received by our businesses in advance of product shipment as deferred revenue.  These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_CashDiscountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_CashDiscountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Share Repurchase Activity</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share repurchase activity was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share of shares repurchased</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054567664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Investment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our investments consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) losses from investments in equity securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.290%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments under equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GAAP&#8221;) and (ii) adjustments to our investment required under the equity method of accounting.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents loss as a result of the disposition of our JUUL equity securities discussed below.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents the estimated change in fair value.  Prior to the disposition of our JUUL equity securities on March 3, 2023, we accounted for our investment in JUUL as an investment in an equity security measured at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of our investment in JUUL, which was classified in Level 3 of the fair value hierarchy prior to the disposition of our JUUL equity securities discussed above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposition of JUUL equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in (income) losses from investments in equity securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value and fair value of our total long-term debt were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt included in long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612141970848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit (Income) Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (income) consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612141824736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculated basic and diluted earnings per share (&#8220;EPS&#8221;) using the following:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Distributed and undistributed earnings attributable to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054404704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Earnings/Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,771)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,442)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,779)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings, net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,597)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,962)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily reflects the impact of our designated net investment hedges related to our equity investment in ABI and our share of ABI&#8217;s currency translation adjustments.  For further discussion of designated net investment hedges, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.472%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost/credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in net defined benefit plan costs.  For further details, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in (income) losses from investments in equity securities.  For further information, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054271856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment data were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) losses from investments in equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock', window );">Schedule of Non-Participating Manufacturer Adjustment Items</a></td>
<td class="text">Non-Participating Manufacturer (&#8220;NPM&#8221;) Adjustment Items:<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock', window );">Schedule of Tobacco and Health and Certain Other Litigation Items</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Non-Participating Manufacturer Adjustment Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Tobacco and Health and Certain Other Litigation Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054382288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_SummaryOfIncomeTaxesTableTextBlock', window );">Summary of Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,479</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">692</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to valuation allowance charged to income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Releases to valuation allowance credited to income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_SummaryOfIncomeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_SummaryOfIncomeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054571792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Contingencies</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax charges for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder derivative lawsuits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related interest costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at end of period</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> below for a discussion of the pending settlement of the federal and state shareholder derivative lawsuits.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the number of certain tobacco-related cases pending in the United States against us as of:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 24, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Smoking and Health Cases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Care Cost Recovery Actions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-vapor Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,744</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tobacco-Related Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes as of April 24, 2023, 19 cases filed in Illinois, 22 cases filed in New Mexico, 43 cases filed in Massachusetts and 46 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cases filed in Florida.  Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">case (these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> progeny cases are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  Also does not include 1,390 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (&#8220;ETS&#8221;).  The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Broin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).  The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages.  Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.</span></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government&#8217;s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, 57 class action lawsuits, 3,746 individual lawsuits and 1467 &#8220;third party&#8221; lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.  The 57 class action lawsuits include 32 cases in the Northern District of California (&#8220;Multidistrict Litigation&#8221; or &#8220;MDL&#8221;) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes as of April 24, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms &#8220;Lights&#8221; and &#8220;Ultra Lights&#8221; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently Pending Engle Cases with Verdicts Against PM USA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hoffman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million ($3 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendant to First District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Levine</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeals by defendants and plaintiff to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Schertzer</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Appeal by defendants to the Third District Court of Appeal pending.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lipp</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Garcia</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6 million ($3 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to the Third District Court of Appeal pending.</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Post-Trial Status</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Duignan</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pinellas</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Supreme Court quashed the Second District Court of Appeal&#8217;s affirmation of  judgment against the defendants and remanded the case for reconsideration in light of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McCall</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1&#160;million (&lt;$1&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New trial on punitive damages is set for June 2023.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chadwell</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal has ordered supplemental briefing in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kaplan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McLaughlin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2&#160;million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Florida Supreme Court vacated the punitive damages award in accordance with the decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sheffield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The Fourth District Court of Appeals affirmed the compensatory damages award and granted a new trial on punitive damages.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cooper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5&#160;million </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&lt;$1&#160;million PM USA)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal affirmed the compensatory damages award and granted a new trial on punitive damages.</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PM USA&#8217;s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff&#8217;s verdict following a retrial of an initial verdict in favor of plaintiff.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> PM USA is not a defendant in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle Progeny Appellate Issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle Cases Concluded Within Past 12 Months </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrual Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Amount for Damages (if any)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Miller</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tuttle</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cuddihee</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Holliman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">D. Brown</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2015</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054401984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Guidance Not Yet Adopted (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Guidance Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2022-03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048994128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mo_HorizonMember', window );">Horizon [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_OwnershipPercentageInConsolidatedSubsidiary', window );">Ownership percentage in consolidated subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mo_HorizonMember', window );">Horizon [Member] | JTIUH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mo_NJOYHoldingsIncMember', window );">NJOY Holdings, Inc. [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, gross</a></td>
<td class="nump">$ 2,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember', window );">January 2021 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Planned share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2023ShareRepurchaseProgramMember', window );">January 2023 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Planned share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_OwnershipPercentageInConsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage In Consolidated Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_OwnershipPercentageInConsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mo_HorizonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mo_HorizonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_JTIUHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_JTIUHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mo_NJOYHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mo_NJOYHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2023ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mo_January2023ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055363936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Basis of Presentation (Share Repurchase Table) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Aggregate cost of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember', window );">January 2021 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Total number of shares repurchased (shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Aggregate cost of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share of shares repurchased (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mo_January2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057226080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 268,000,000<span></span>
</td>
<td class="nump">$ 252,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Expected period for satisfaction of performance obligation</a></td>
<td class="text">three days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Other</a></td>
<td class="nump">$ 58,000,000<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for doubtful accounts, receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052016480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Equity Securities (Summary of Investments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">$ 9,559<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">ABI</a></td>
<td class="nump">9,211<span></span>
</td>
<td class="nump">8,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">JUUL</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member', window );">Cronos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights', window );">Cronos</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Including Fixed-Price Preemptive Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_InvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Investments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_InvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057296880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities (Earnings in Equity Securities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) losses from investments under equity method of accounting</a></td>
<td class="num">$ (170)<span></span>
</td>
<td class="num">$ (134)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_IncomeLossFromEquitySecurities', window );">(Income) losses from investments in equity securities</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) losses from investments under equity method of accounting</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member', window );">Cronos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) losses from investments under equity method of accounting</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss on disposition of JUUL equity securities</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_IncomeLossFromEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_IncomeLossFromEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612053141968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Equity Securities (Investment in ABI Narrative) (Details) - ABI [Member] - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted', window );">Number of restricted shares owned (in shares)</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentNumberofSharesOwnedCommon', window );">Number of ordinary shares owned (in shares)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of equity investment</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue', window );">Equity method investment, difference between carrying amount and fair value</a></td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage', window );">Equity method investment, difference between carrying amount and fair value, percentage (approximately)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Difference Between Carrying Amount and Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentNumberofSharesOwnedCommon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Number of Shares Owned, Common</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentNumberofSharesOwnedCommon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentNumberofSharesOwnedRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Number of Shares Owned, Restricted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentNumberofSharesOwnedRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126960272&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_ABInBevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612056428672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities (Investment in JUUL Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss on disposition of JUUL equity securities</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612046985168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details) - Equity Securities [Member] - JUUL [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at beginning of period</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized losses</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048198080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Securities (Investment in Cronos Narrative) (Details) - Cronos [Member]<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentNumberofSharesOwnedCommon', window );">Number of ordinary shares owned (approximately) (in shares) | shares</a></td>
<td class="nump">156.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue', window );">Equity method investment, difference between carrying amount and fair value</a></td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage', window );">Equity method investment, difference between carrying amount and fair value, percentage (approximately)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentImpairment', window );">Equity method investment, impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractPreemptiveRIghtsMember', window );">Equity Contract, Preemptive Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentPricePerShareIfExercised', window );">Equity method investment, shares purchased, (CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentsFixedPreemptiveRights', window );">Equity method investments, fixed preemptive rights</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractWarrantMember', window );">Equity Contract, Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentPricePerShareIfExercised', window );">Equity method investment, shares purchased, (CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase', window );">Equity method investment, percentage of shares eligible for purchase (approximately)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Difference Between Carrying Amount and Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentNumberofSharesOwnedCommon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Number of Shares Owned, Common</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentNumberofSharesOwnedCommon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Percentage of Shares Eligible For Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentPricePerShareIfExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Price Per Share If Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentPricePerShareIfExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquityMethodInvestmentsFixedPreemptiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Fixed Preemptive Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquityMethodInvestmentsFixedPreemptiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_InvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Investments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_InvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_CronosGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractPreemptiveRIghtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractPreemptiveRIghtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mo_EquityContractWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612056583136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfForeignCurrencyDerivativesHeld', window );">Number of foreign currency derivatives held | contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mo_ForeignCurrencyDenominatedDebtMember', window );">Foreign currency denominated debt [Member] | Net Investment Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other comprehensive (income) loss, net investment hedge, (gain) loss, before reclassification and tax | $</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfForeignCurrencyDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of foreign currency exchange rate derivatives held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfForeignCurrencyDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mo_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mo_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048381952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Aggregate Fair Value and Carrying Value) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 25,387<span></span>
</td>
<td class="nump">$ 26,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">22,565<span></span>
</td>
<td class="nump">22,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ForeignCurrencyDenominatedDebtAbstract', window );"><strong>Foreign currency denominated debt included in long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">25,387<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mo_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">4,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ForeignCurrencyDenominatedDebtAbstract', window );"><strong>Foreign currency denominated debt included in long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">4,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value</a></td>
<td class="nump">$ 2,940<span></span>
</td>
<td class="nump">$ 4,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ForeignCurrencyDenominatedDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Denominated Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ForeignCurrencyDenominatedDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mo_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mo_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048090608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service cost (credit)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (income)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service cost (credit)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (income)</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052932624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan, plan assets, contributions by employer</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Anticipated additional employer contributions</a></td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan, plan assets, contributions by employer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Anticipated additional employer contributions</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048636496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Basic and Diluted Earnings Per Share) (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 1,787<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted', window );">Less: Distributed and undistributed earnings attributable to share-based awards</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Earnings for basic EPS</a></td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Earnings for diluted EPS</a></td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">$ 1,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS (in shares)</a></td>
<td class="nump">1,786,000<span></span>
</td>
<td class="nump">1,818,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS (in shares)</a></td>
<td class="nump">1,786,000<span></span>
</td>
<td class="nump">1,818,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612049246736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">$ (3,923)<span></span>
</td>
<td class="num">$ (1,606)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3,826)<span></span>
</td>
<td class="num">(1,760)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,771)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive earnings (losses) before reclassifications</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Deferred income taxes</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified to net earnings</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Deferred income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to net earnings, net of deferred income taxes</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,779)<span></span>
</td>
<td class="num">(2,962)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Benefit Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,436)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive earnings (losses) before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified to net earnings</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Deferred income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to net earnings, net of deferred income taxes</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,442)<span></span>
</td>
<td class="num">(1,597)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(1,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive earnings (losses) before reclassifications</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Deferred income taxes</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified to net earnings</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to net earnings, net of deferred income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,381)<span></span>
</td>
<td class="num">(1,434)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency Translation Adjustments and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive earnings (losses) before reclassifications</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified to net earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to net earnings, net of deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive earnings (losses), net of deferred income taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612058455408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Earnings/Losses (Reclassifications) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) losses from investments in equity securities</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</a></td>
<td class="num">(1,787)<span></span>
</td>
<td class="num">(1,959)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Benefit Plans [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Net loss [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior service cost/credit [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember', window );">ABI [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) losses from investments in equity securities</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612058454896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Segment Data Schedule) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 5,719<span></span>
</td>
<td class="nump">$ 5,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General corporate expenses</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest and other debt expense, net</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit income, excluding service cost</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_IncomeLossFromEquitySecurities', window );">(Income) losses from investments in equity securities</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on Cronos-related financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income taxes</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember', window );">Smokeable Products Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">5,090<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles', window );">OCI</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mo_OralTobaccoSegmentMember', window );">Oral Tobacco Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles', window );">OCI</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles', window );">OCI</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_IncomeLossFromEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_IncomeLossFromEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mo_OralTobaccoSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mo_OralTobaccoSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612054304336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember', window );">Smokeable Products Segment [Member] | Operating Segments [Member] | Non-Participating Manufacturer Arbitration Panel Decision [Member] | Operating Income (Loss) [Member] | NPM Adjustment to Cost Of Sales [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (loss) related to litigation settlement</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonParticipatingManufacturerArbitrationPanelDecisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonParticipatingManufacturerArbitrationPanelDecisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=mo_NpmAdjustmentToCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=mo_NpmAdjustmentToCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612053053632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems', window );"><strong>Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthLitigationCasesMember', window );">Tobacco and Health Litigation Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems', window );"><strong>Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthLitigationCasesMember', window );">Tobacco and Health Litigation Cases [Member] | General corporate expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems', window );"><strong>Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthLitigationCasesMember', window );">Tobacco and Health Litigation Cases [Member] | Segment Reconciling Items [Member] | Interest and other debt expense, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems', window );"><strong>Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Tobacco and Health Litigation Cases [Member] | Operating Segments [Member] | Smokeable Products Segment [Member] | Operating Income (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems', window );"><strong>Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_TobaccoandHealthLitigationCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_TobaccoandHealthLitigationCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mo_InterestAndOtherDebtExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mo_InterestAndOtherDebtExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mo_SmokeableProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612052857824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,387,000,000<span></span>
</td>
<td class="nump">26,680,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="nump">$ 411,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables [Member] | Euro Notes, 1.000%, Maturing February 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured debt</a></td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum', window );">Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio', window );">Debt instrument, consolidated EBITDA to interest expense ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Long-term debt, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt instrument, unused borrowing capacity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=mo_TermSecuredOvernightFinancingRateTermSOFRMember', window );">Term Secured Overnight Financing Rate ("Term SOFR") [Member] | Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Consolidated EBITDA to Interest Expense Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mo_EuroNotes1000MaturingFebruary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mo_EuroNotes1000MaturingFebruary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mo_RevolvingCreditFacilityDueAugust2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mo_RevolvingCreditFacilityDueAugust2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=mo_TermSecuredOvernightFinancingRateTermSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=mo_TermSecuredOvernightFinancingRateTermSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612053209824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income taxes</a></td>
<td class="nump">$ 2,479<span></span>
</td>
<td class="nump">$ 2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax rate</a></td>
<td class="nump">27.90%<span></span>
</td>
<td class="nump">26.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057250272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">$ (714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase (decrease)</a></td>
<td class="nump">391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact the effective tax rate</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate', window );">Unrecognized tax benefits that would impact deferred tax rate</a></td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase (decrease)</a></td>
<td class="nump">391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred federal income tax benefit</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments', window );">Equity securities, FV-NI, ordinary gain (loss), tax basis of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Ordinary Gain (Loss), Tax Basis Of Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_InvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Investments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_InvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits that Would Impact Deferred Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612147863312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ValuationAllowanceRollforwardRollForward', window );"><strong>Valuation Allowance Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at beginning of year</a></td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount', window );">Additions to valuation allowance charged to income tax expense</a></td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount', window );">Releases to valuation allowance credited to income tax benefit</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment', window );">Foreign currency translation</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)</a></td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at end of period</a></td>
<td class="nump">$ 2,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Decrease In Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase In Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ValuationAllowanceForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Foreign Currency Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ValuationAllowanceForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ValuationAllowanceRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance Rollforward [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ValuationAllowanceRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612056583376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (General Information) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond', window );">Number of states that cap bond or require no bond</a></td>
<td class="nump">47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of States That Cap Bond or Require No Bond</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612056346048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">222 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued liability for tobacco and health litigation items at beginning of period</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued liability for tobacco and health litigation items at end of period</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_InterestExpenseRelatedToLitigationMember', window );">Related Interest Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationEscrowDeposit', window );">Security posted for appeal of judgments</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember', window );">Tobacco and Health Judgment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Judgments paid (approximately)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember', window );">Tobacco and Health Judgment [Member] | Tobacco and Health and Certain Other Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember', window );">Engle Progeny Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Judgments paid (approximately)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember', window );">Agreement To Resolve Shareholder Class Action | Tobacco and Health and Certain Other Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LitigationEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Escrow Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LitigationEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_InterestExpenseRelatedToLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_InterestExpenseRelatedToLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_LitigationCasesResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_LitigationCasesResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055901136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Schedule of Pending Cases) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>case </div>
<div>claim </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 26, 2021 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Pre-tax charge | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember', window );">Individual Smoking and Health Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember', window );">Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember', window );">E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,744<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_OtherTabaccoRelatedCasesMember', window );">Other Tabacco-Related Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember', window );">Tobacco and Health Judgment [Member] | Tobacco and Health and Certain Other Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember', window );">Agreement To Resolve Shareholder Class Action | Tobacco and Health and Certain Other Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassActionLawsuit', window );">Loss contingency, class action lawsuit | lawsuit</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Illinois [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | New Mexico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfCases', window );">Number of cases | case</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">5,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassActionLawsuit', window );">Loss contingency, class action lawsuit | lawsuit</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Individual Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Lawsuits Filed By State Or Local Governments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member] | Class Action Lawsuit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber', window );">Number of pending claims, consolidated for pre-trial purposes</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Other Tabacco-Related Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfInactiveCases', window );">Loss contingency, number of inactive cases | case</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfInactiveClassActionLawsuits', window );">Loss contingency, number of inactive class action lawsuits | case</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClassActionLawsuit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Action Lawsuit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClassActionLawsuit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfInactiveCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Inactive Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfInactiveCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfInactiveClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Inactive Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfInactiveClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EvaporLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_OtherTabaccoRelatedCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_OtherTabaccoRelatedCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_TobaccoandHealthJudgmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_LitigationCasesResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_LitigationCasesResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_AgreementToResolveShareholderClassActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_ETSSmokingandHealthCaseFlightAttendantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_ETSSmokingandHealthCaseFlightAttendantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_ClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_ClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612046581152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">292 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>claim </div>
<div>case</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>case </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 26, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jan. 31, 2008 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember', window );">Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember', window );">Engle Progeny Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember', window );">Individual Smoking and Health Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember', window );">E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,744<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Individual Smoking and Health Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">5,270<span></span>
</td>
<td class="nump">5,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Engle Progeny Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofCasesSetforTrial', window );">Number of cases set for trial</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecided', window );">Number of verdicts returned</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedUnfavorableNumber', window );">Number of unfavorable verdicts</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecided', window );">Number of verdicts returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedUnfavorableNumber', window );">Number of unfavorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsResolvedNumber', window );">Number of claims resolved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Alaska [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Connecticut [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Louisiana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyVerdictReversedNumber', window );">Number of verdicts reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Mississippi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Missouri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Hampshire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Mexico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Jersey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New York [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Pennsylvania [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Rhode Island [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Tennessee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | Individual Smoking and Health Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofCasesSetforTrial', window );">Number of cases set for trial</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PM USA [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofCasesSetforTrial', window );">Number of cases set for trial</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecidedFavorableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided Favorable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecidedFavorableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecidedUnfavorableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided Unfavorable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecidedUnfavorableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsResolvedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Resolved, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsResolvedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofCasesSetforTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Cases Set for Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofCasesSetforTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyVerdictReversedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Verdict Reversed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyVerdictReversedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_IndividualSmokingAndHealthCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EvaporLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonEngleProgenyCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonEngleProgenyCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_LA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_LA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_RI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_RI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAandAltriaGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAandAltriaGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612046524672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Non-Engle Progeny Litigation) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember', window );">Non-Engle Progeny Smoking And Health Case, Woodley [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseMendezMember', window );">Non-Engle Progeny Smoking And Health Case, Mendez [Member] | PM USA And R.J. Reynolds Tobacco Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseMendezMember', window );">Non-Engle Progeny Smoking And Health Case, Mendez [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyFaultAllocationPercentage', window );">Loss contingency, fault allocation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseFontaineMember', window );">Non-Engle Progeny Smoking And Health Case, Fontaine [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingandHealthCaseGreeneMember', window );">Non-Engle Progeny Smoking and Health Case, Greene [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyCompensatoryDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Compensatory Damages Awarded, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyCompensatoryDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyFaultAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Fault Allocation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyFaultAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPunitiveDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Punitive Damages Awarded, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPunitiveDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseMendezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseMendezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseFontaineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonEngleProgenySmokingAndHealthCaseFontaineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_NonEngleProgenySmokingandHealthCaseGreeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_NonEngleProgenySmokingandHealthCaseGreeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612049459008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>USD ($) </div>
<div>case </div>
<div>plantiff </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>claim</div>
</th>
<th class="th"><div>Jul. 31, 2006</div></th>
<th class="th">
<div>Jan. 31, 2008 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 31, 2000 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember', window );">Engle Progeny Cases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember', window );">Engle Progeny Cases [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants', window );">Loss contingency, period for decertified class members to file individual actions against defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecided', window );">Number of verdicts returned</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedUnfavorableNumber', window );">Number of unfavorable verdicts</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyUnfavorableVerdictsPendingReversed', window );">Number of claims with unfavorable verdicts pending/reversed</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plantiff</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, State [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Garcia [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyVerdictReversedNumber', window );">Number of verdicts reversed</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Reider and Banks [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyZeroDamagesVerdicts', window );">Zero damages verdicts</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Weingart and Hancock [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyZeroDamagesVerdictModified', window );">Zero damages verdict modified</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Pollari [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedUnfavorableNumber', window );">Number of unfavorable verdicts</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, Freeman [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsDecidedFavorableNumber', window );">Number of favorable verdicts</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engle Progeny Cases, R. Douglas [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | claim</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecidedFavorableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided Favorable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecidedFavorableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsDecidedUnfavorableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Decided Unfavorable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsDecidedUnfavorableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPunitiveDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Punitive Damages Awarded, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPunitiveDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyUnfavorableVerdictsPendingReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Unfavorable Verdicts Pending/Reversed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyUnfavorableVerdictsPendingReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyVerdictReversedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Verdict Reversed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyVerdictReversedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyZeroDamagesVerdictModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Zero Damages Verdict Modified</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyZeroDamagesVerdictModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyZeroDamagesVerdicts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Zero Damages Verdicts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyZeroDamagesVerdicts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesPearsonDCohenCollarChaconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesPearsonDCohenCollarChaconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesReiderandBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesReiderandBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesWeingartandHancockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesWeingartandHancockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesPollariMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesPollariMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesGlogerRintoulandDuignamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesGlogerRintoulandDuignamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesFreemanAndHarrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesFreemanAndHarrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesR.DouglasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesR.DouglasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612045709264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesHoffmanMember', window );">Engle Progeny Cases, Hoffman [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesHoffmanMember', window );">Engle Progeny Cases, Hoffman [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLevineMember', window );">Engle Progeny Cases, Levine [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLevineMember', window );">Engle Progeny Cases, Levine [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesSchertzerMember', window );">Engle Progeny Cases, Schertzer [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesSchertzerMember', window );">Engle Progeny Cases, Schertzer [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLippMember', window );">Engle Progeny Cases, Lipp [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLippMember', window );">Engle Progeny Cases, Lipp [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember', window );">Engle Progeny Cases, Garcia [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember', window );">Engle Progeny Cases, Garcia [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesDuignanMember', window );">Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesDuignanMember', window );">Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMcCallMember', window );">Engle Progeny Cases, McCall [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMcCallMember', window );">Engle Progeny Cases, McCall [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesChadwellMember', window );">Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesChadwellMember', window );">Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesKaplanMcLauighlinMember', window );">Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesKaplanMcLauighlinMember', window );">Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesCooperMember', window );">Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesCooperMember', window );">Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyCompensatoryDamagesAwardedValue', window );">Compensatory damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPunitiveDamagesAwardedValue', window );">Punitive damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMillerMember', window );">Engle Progeny Cases, Miller [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesTuttleMember', window );">Engle Progeny Cases, Tuttle [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesCuddiheeMember', window );">Engle Progeny Cases, Cuddihee [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesHollimanMember', window );">Engle Progeny Cases, Holliman [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesD.BrownMember', window );">Engle Progeny Cases, D. Brown [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyCompensatoryDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Compensatory Damages Awarded, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyCompensatoryDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPunitiveDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Punitive Damages Awarded, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPunitiveDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesHoffmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesHoffmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLevineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesLevineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesSchertzerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesSchertzerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesLippMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesLippMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesGarciaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesDuignanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesDuignanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMcCallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesMcCallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesChadwellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesChadwellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesKaplanMcLauighlinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesKaplanMcLauighlinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesCooperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesCooperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesMillerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesMillerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesTuttleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesTuttleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesCuddiheeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesCuddiheeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesHollimanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesHollimanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesD.BrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesD.BrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612141648832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Florida Bond Statute) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2009 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">Florida [Member] | Engle Progeny Cases, State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_MaximumBondForAllDefendants', window );">Maximum bond for all defendants</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_MaximumBondForAllDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Bond For All Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_MaximumBondForAllDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EngleProgenyCasesStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EngleProgenyCasesStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048293264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Other Smoking and Health Class Actions) (Details) - Smoking and Health Class Actions and Aggregated Claims Litigation [Member]<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">323 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($) </div>
<div>manufacture </div>
<div>ruling</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>case </div>
<div>manufacture</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_AR', window );">Arkansas [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_DE', window );">Delaware [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_DC', window );">District of Columbia [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">Florida [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Illinois [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IA', window );">Iowa [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_KS', window );">Kansas [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_LA', window );">Louisiana [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Maryland [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MI', window );">Michigan [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MN', window );">Minnesota [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NV', window );">Nevada [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">New Jersey [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OH', window );">Ohio [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OK', window );">Oklahoma [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OR', window );">Oregon [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PR', window );">Puerto Rico [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">Texas [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassNotCertifiedNumber', window );">Class not certified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member] | Philip Morris USA and Altria Group [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member] | Canadian Tobacco Manufacturers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofManufacturers', window );">Number of manufacturers | manufacture</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyVerdictsUpheld', window );">Number of verdicts upheld | ruling</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_AmountAwardedtoOtherParty', window );">Amount awarded to other party | $</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member] | Altria Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofManufacturers', window );">Number of manufacturers | manufacture</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mo_BritishColumbiaSaskatchewanMember', window );">British Columbia and Saskatchewan [Member] | Philip Morris USA and Altria Group [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_AmountAwardedtoOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Awarded to Other Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_AmountAwardedtoOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClassNotCertifiedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Not Certified, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClassNotCertifiedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Manufacturers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyVerdictsUpheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Verdicts Upheld</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyVerdictsUpheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_DC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_DC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_KS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_KS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_LA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_LA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAandAltriaGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAandAltriaGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_CanadianTobaccoManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_CanadianTobaccoManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_AltriaGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_AltriaGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mo_BritishColumbiaSaskatchewanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mo_BritishColumbiaSaskatchewanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612049167632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Health Care Cost Recovery Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 1998 </div>
<div>USD ($) </div>
<div>state</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>claim </div>
<div>manufacture</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 26, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>manufacture</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember', window );">Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofStateswithSettledLitigation', window );">Number of states with settled litigation | state</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementAnnualPaymentAmount', window );">State settlement agreements annual payments</a></td>
<td class="nump">$ 9,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementAnnualLegalFeesPayableMaximum', window );">State settlement agreements attorney fees annual cap</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_ThreatenedLitigationMember', window );">Threatened Litigation [Member] | Canada [Member] | Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_CanadianTobaccoManufacturersMember', window );">Canadian Tobacco Manufacturers [Member] | Canada [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofManufacturers', window );">Number of manufacturers | manufacture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LitigationSettlementAnnualLegalFeesPayableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Annual Legal Fees Payable, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LitigationSettlementAnnualLegalFeesPayableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LitigationSettlementAnnualPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Annual Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LitigationSettlementAnnualPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Manufacturers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofStateswithSettledLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of States with Settled Litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofStateswithSettledLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_ThreatenedLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_ThreatenedLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_CanadianTobaccoManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_CanadianTobaccoManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612043803712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (NPM Adjustment Disputes) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">252 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>state</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>state</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember', window );">Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne', window );">Loss contingency, number of states with settled litigation including New York, subsequent expansion | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Loss contingency, credits to offset payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty', window );">Litigation settlement, amount expected to be awarded from other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation', window );">Loss contingency, number of additional states extended with settled litigation | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation', window );">Loss contingency, number of additional states extended with settled litigation | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesWithConcludedHearings', window );">Loss contingency, number of states with concluded hearings | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettled', window );">Loss contingency, number of states not settled | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues', window );">Loss contingency, number of states not in compliance with escrow statues | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues', window );">Loss contingency, number of states in compliance with escrow statues | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] | Pending Litigation [Member] | Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyReductionToCostOfSales', window );">Loss contingency, reduction to cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2021 NPM Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettled', window );">Loss contingency, number of states not settled | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member] | Pending Litigation [Member] | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettled', window );">Loss contingency, number of states not settled | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod', window );">Loss contingency, number of states not settled, arbitration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member] | Pending Litigation [Member] | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettled', window );">Loss contingency, number of states not settled | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod', window );">Loss contingency, number of states not settled, arbitration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Health Care Cost Recovery Actions, 2022 NPM Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LitigationSettlementEstimateofPossibleGain', window );">Estimate of possible gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MT', window );">MONTANA [Member] | PM USA [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Illinois [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Illinois [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2021 [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Illinois [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2019-2021 [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IA', window );">Iowa [Member] | PM USA [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NM', window );">New Mexico [Member] | PM USA [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Expected To Be Awarded from Other Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LitigationSettlementEstimateofPossibleGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Estimate of Possible Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LitigationSettlementEstimateofPossibleGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States In Compliance With Escrow Statues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States Not In Compliance With Escrow Statues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfStatesNotSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States Not Settled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfStatesNotSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States Not Settled, Arbitration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfStatesWithConcludedHearings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States With Concluded Hearings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfStatesWithConcludedHearings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Additional States Extended with Settled Litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of States with Settled Litigation, Settlement One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyReductionToCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reduction To Cost Of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyReductionToCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ArbitrationPeriodAxis=mo_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ArbitrationPeriodAxis=mo_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_ArbitrationPeriodAxis=mo_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_ArbitrationPeriodAxis=mo_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20042020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20042020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20042021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20042021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20192021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_HealthCareCostRecoveryActionsTransitionYears20192021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612144768560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Other Disputes Under the State Settlement Agreements) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember', window );">PM USA [Member] | Other Disputes Under the State Settlement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount ordered to be paid from other party</a></td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_OtherDisputesUndertheStateSettlementAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_OtherDisputesUndertheStateSettlementAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612057432976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Federal Government's Lawsuit) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_ImplementationofCorrectiveCommunicationsMember', window );">Implementation of Corrective Communications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_ImplementationofCorrectiveCommunicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mo_ImplementationofCorrectiveCommunicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612048247456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>claim </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>lawsuit </div>
<div>case</div>
</th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 26, 2021 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember', window );">E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,744<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_NumberOfThirdPartyLawsuits', window );">Number of third party lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_IQOSMember', window );">IQOS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value | $</a></td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyRoyaltyFeePercentage', window );">Loss Contingency, Royalty Fee Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyDamagesRecoverableValue', window );">Loss contingency, damages recoverable, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=mo_ClassActionLawsuitMember', window );">Class Action Lawsuit [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber', window );">Number of pending claims, consolidated for pre-trial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember', window );">Pending Individual Lawsuits [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=mo_PendingClassActionLawsuitMember', window );">Pending Class Action Lawsuit [Member] | Subsequent Event [Member] | E-vapor Litigation [Member] | Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfCasesWithSetTrialDates', window );">Loss contingency, number of cases with set trial dates | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfTrialsOngoing', window );">Loss contingency, number of trials ongoing | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyDamagesRecoverableValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Recoverable, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyDamagesRecoverableValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfCasesWithSetTrialDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Cases With Set Trial Dates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfCasesWithSetTrialDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfTrialsOngoing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Trials Ongoing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfTrialsOngoing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyRoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Royalty Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyRoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_NumberOfThirdPartyLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Third Party Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_NumberOfThirdPartyLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_EvaporLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_EvaporLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_IQOSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_IQOSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_ClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_ClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_PendingClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_PendingClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612043769856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>complaint</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfComplaints', window );">Loss contingency, number of complaints | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits', window );">Loss contingency, number of shareholders filing class action lawsuits | shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfPendingCasesConsolidated', window );">Loss contingency, number of pending cases consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits', window );">Loss contingency, number of shareholders filing derivative lawsuits | shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Pre-tax charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mo_FederalAndStateShareholderDerivativeLawsuitsMember', window );">Federal And State Shareholder Derivative Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Pre-tax charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember', window );">JUUL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Equity securities, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClassActionLawsuit', window );">Loss contingency, class action lawsuit | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Federal And State Shareholder Derivative Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Judgments paid (approximately)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClassActionLawsuit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Action Lawsuit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClassActionLawsuit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfComplaints">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Complaints</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfComplaints</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfPendingCasesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Pending Cases Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfPendingCasesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_FederalAndStateShareholderDerivativeLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_FederalAndStateShareholderDerivativeLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mo_JUULMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612049002608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Lights/Ultra Lights Cases) (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>claim </div>
<div>court </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Lights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyClaimsNotCertifiedNumber', window );">Claims not certified, number | case</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Lights [Member] | PM USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mo_LossContingencyStateCourtsNumber', window );">Number of state courts | court</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Smoking and Health Class Actions and Aggregated Claims Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyClaimsNotCertifiedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Not Certified, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyClaimsNotCertifiedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mo_LossContingencyStateCourtsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, State Courts, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mo_LossContingencyStateCourtsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_LightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_LightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mo_PhilipMorrisUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mo_PhilipMorrisUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_SmokingAndHealthClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612055355424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (UST Litigations Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember', window );">Pending Individual Lawsuits [Member] | Subsequent Event [Member] | UST Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=mo_PendingIndividualLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mo_USTLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mo_USTLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612053065408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Guarantees and Other Similar Matters Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Contingent liability related to performance surety bonds</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit line available under the agreement</a></td>
<td class="nump">46,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit line available under the agreement</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mo_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mo_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140612141826112">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="2">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted Cash, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashNoncurrent</td>
<td colspan="2" class="nump">$ 46,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td colspan="2" class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals.  See Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>mo-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mo="http://www.altria.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mo-20230331.xsd" xlink:type="simple"/>
    <context id="i000128edea2348af9dda2888d5316af0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock0.3313ParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock1.700NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7dfa2174fce6411089552f283d69732e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock2.200NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mo:CommonStock3.125NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c6b503caf294c76a5e851c01965e8e5_I20230418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2023-04-18</instant>
        </period>
    </context>
    <context id="i66477b67e5d24411a9b94a8ac9d67205_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i90474c1a016f4bcab8003b2f31a36b35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2d809fc7c4b44ba92b401d313ae3b59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57bab0db84d941b8ba69763527b90f7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b599b726c57473687e1536cd1d26c41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2469a4bba094953adfa2888c0f55b57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee0c6e3ccab347c88032c15fcb532cd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f5140f53521445993db0f74aeb56071_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic7101ec192394649a415c1b63b908c30_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idaaf63c06a1049e695676e0481062f63_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie66aa9b4f0ee44019b9de410d7e55ce7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6cccb1a7f24445ba8b43e289af3300ec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i90e819bf5bdd408a959e0b2e4e7b73d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idd940594473144c68357ea9c5539af8e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe1266b52910409c97c004b5e3046d53_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iff121125e516451b955d8e621eab3ca2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1542e02bb1e24adda3f71e99211fc9ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if12ef6040ec2418189e3c2572fa81080_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie382e64c844d405d89091642f2a1d28c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3e09c734e014d5ea132f83014347e58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2af1b2cb80da4571ac97b869fabca161_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0217eb87e2e241b8ad4da3c44ced3300_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iede722b699a244e0918c6683fa366e9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f5ef2d10e0747f6975b8eaabca090eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i42884e66bec24a6fbaa77ec0ef498541_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic85e35b6659d4fc0930167fa4a8a1832_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1532672af67b495ebb54a98924a90df4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1e84fb2796b4e21bbb745b3013fe6e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17705bcff8eb49498848597476b6a197_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i87c63010612240ff9b4601af94a82301_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mo:HorizonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i916567e93a6f4954aee581f056c6cbac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mo:HorizonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:JTIUHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ad881c7536c4aefb9f8952e60edc5d0_D20230401-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mo:NJOYHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i3187e615f5274b95ad68a22a51aec4fb_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mo:NJOYHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="idbf02e4d84bb4fae848037ad768f4bb2_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i77cd95d31f3e47db905a2fce488caf88_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="iee57b9fa9a0c4629ae346c0ca0694281_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i31770ac6973b4c46a9b96965f34f8ec4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mo:January2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i407056c006d54b6ab8e43c8dd4f712d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70acd0d1a18e45398127bc9cce16307f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f105c2681d04b75b6c055147bbea3bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c2317db73d949bf97a1f0ae5666c118_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic29d9e6ebe044e90989cf465823a77f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e30dd02c1c94a5b81ccdba16b4c25b1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2df9ced5c50845578c7a1d3348b2c11b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i37b0728e4a964ae7a16912dba9ce4741_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cd8e983be5e4bf49bbb82139b8be78f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i038f67664cef4a289bd2e7482068a8df_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:ABInBevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7bf4062eea24ce4a949beb98cf77963_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic849d2926e4e4725b6bfc1d0c4b15363_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic18ca113bad9498b8bce774c190943af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i917aa76b7c2948a99dfaf25b1ab4249a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic64023a55bc9457f9694dec962ce226d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22be6d10e72a4d068a5e2a59f3619789_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractPreemptiveRIghtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2698ad66ea7145638fbf517179c1ee03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractPreemptiveRIghtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc3ad097e6354edca8d47d2a62d0b590_D20190301-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i6dbdafadb4994369a437f0cb91cd5ebd_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:CronosGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:EquityContractWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i1e386c21ead541d7b2b8e375d8f79708_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e0ac77709a6467ea112cb5ce9968742_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8891909d58c4512bd26716fe7321214_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mo:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69bda6f9d3044065b5cb45c86ee040ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieacd8d560cc14bb3888bf0fb293a903f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd124c60d03f419f9b32a50e8d8ad088_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48147e6321604e39a0674a5c9700d5cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8248ed5a8a794be4ae798af164015026_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae16a7ba3e464592bc4e2b2d8cc85d62_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i956ac6a83c434b91ad8b518160de9170_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd1c9ebd07c34c43a75cc8eb11135003_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i53e66b45d2fd44569d4910cd6febb6c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3671b5f23c94bf792e7730b318b4f31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bbd214e79b74f2da6764b8726a150ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i948ca0a2116f4d7a820721a03a172caa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf2fc3fc500643caa6b4bcbcd6531d2a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15be35835b9b4c7ab7cc385c16e9f766_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a21466ce342442f9033dda351c1c76f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd2a3ee32c4c425687e4ad4ff4d1ef09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9842a26a80164a39b9d29efbd4d26e1f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66ee296114304714be05372fa2564b28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i760729c61bca480fbf703974d16ebff6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff527c2964e844a7aaf7101d9ebd98da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31bca93a749545458ae8cdbafd27b08d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7894c01a5bf841ccac16dae6a03a17b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieae3d8b4d3ae4b3b8ab5e8ac275cd4b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06b93671e6ac4c71b0ea9f09be8c806e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:OralTobaccoSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:OralTobaccoSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonParticipatingManufacturerArbitrationPanelDecisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">mo:NpmAdjustmentToCostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc4eb1d656b243898b89b6f3008cb4bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idde877d815ab4397aee17c08472bdddf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mo:SmokeableProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84ee8c9fc92344e99ab8d14573f9be5a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i598239b5dde34e519bcd01cb3409992e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e1290e16c10451aa1fcb7cc789b60b2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mo:InterestAndOtherDebtExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70aedc832b244d9e934f496edc7227c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mo:InterestAndOtherDebtExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i008bb3a34d6f4ad1a419dfbe662171e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if3e38d13df914cd0b952143a1636ff77_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthLitigationCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia15af32ff38f4d6d8a39d7de79017b26_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:RevolvingCreditFacilityDueAugust2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16749ccbd508483a9f1550c451780fe1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:RevolvingCreditFacilityDueAugust2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mo:TermSecuredOvernightFinancingRateTermSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib1ca4b2ce75d43c8a23f0e7a04890b95_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:EuroNotes1000MaturingFebruary2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:EuroNotes1000MaturingFebruary2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="ie2f1978595a44dcbb3a13c8eaf072373_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="iefc84e48cf0c42249795f0fa77b9ea65_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id39fde8db86346d7af0960b18bf2989e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea367655f1904de580fbb5fccfbc7804_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:AgreementToResolveShareholderClassActionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieaacf9fe9d5240a3bd0459f2294eff52_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:AgreementToResolveShareholderClassActionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:LitigationCasesResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3fe928fcc4f4ef5ad3b60f07ca10cc7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:InterestExpenseRelatedToLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b2cceb11df14f4cad29de8cb80794bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:InterestExpenseRelatedToLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:TobaccoandHealthJudgmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66f2eaac69ca4a1e9412b845d82e98f9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i658eb60878114979945a034aa6b1706f_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i8f59e571a0db45e8b6ec28bace62543f_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i2d2aadde9431454a847f57038a8a9480_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i264d8c165e0f471f82f66d6e65418cff_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i22a937a6e7e14fdfacea6ad40290a42f_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i61f461a1aa5d4ee792394582b58b95ac_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i67ca21fd598f4791b318ee5cabcbed5d_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="iac90a0bb5f3f4b2f934b8f25141d8e55_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i8e19c07da3604784b1f61734070f38d0_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ia0a4f7f89b7241328632d436bff2aa5f_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i01034fcbdec149c4be2d97e5b30b1d64_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherTabaccoRelatedCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i8fcf35d29f7e417fa73e1d1a62215cc3_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ie745a29b163b4a30b640a432516cbc0a_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i137abf0db81a4ec799690639f244c055_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ib42253bd8d894b90ac70f97908963886_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ib2d977c5bff94d44bd1a0a77dfc89b1c_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:ETSSmokingandHealthCaseFlightAttendantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i825d494d8ad74328a30cf05aeba68eeb_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingIndividualLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="id749f16e66d343708ca58160babcbc3f_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i4f7b74edbd44460c84d012b02edc884a_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:ClassActionLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i029cd62ef0e14cf7ba91174c0f57d16d_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i7c1a190fb9ad430bbd01dfd78341ef13_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ie7914aaf2c23404eaa505be9823413f4_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i6905d6541f1a41eaa7e544fdf55f3804_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i170c4207fac14878911ccdae6ebe6376_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ibff416dc4d4943ef96c7732293bcfb55_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IndividualSmokingAndHealthCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i471e8ab3decf44de9984da88cabdc693_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ic56af47d5d86478d9aa935fb4c5fab66_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ic48616efb2c747e4ad07dbc20dd6318a_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i7915e288e3e547a89d5b90c15b002d85_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="iaa7d7842072042029b37c8e58321a790_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i9c1acd96e2d247de8e9ffbda07748403_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i00334a51fb834684ac1bef68ec6e4629_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ie24403f03a804dd3a1742ecde12c32af_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MO</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="iac4943d0a50142e0a04534ccdc87f14f_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ifcfafebb53104f778986825aecf004e5_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i0a9b420fbf06470aa983786428710658_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i6fca4395dd774138b948e3ba799dee3a_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="id8a13caf9c594420a4982e05e5743e96_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="idf88f4821d864d0eb1215800a0c994a3_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i47eb567f9bbe4ee9b586eb7e4364b47d_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:RI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i9cd612643df6404aa5c549ad46d4bb3f_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ib83ad46dbea44d23905da42d1ade08e9_D19990101-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-01-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i87ca3cff2798450a8d43bf076838e36b_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseWoodleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i3d071c49dafe4c0ab73b29c76d6a6c88_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseMendezMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic68023ac01c34100962358f7742dc848_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseMendezMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i55d5c15b72454fe3ab6a65a94179d459_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingAndHealthCaseFontaineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4caa1be6dee14b7da122d03361a0b36e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibce2ab3da83c4ec2b9d87386b1b038ec_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ic4312a6e41a645e78741c53abfb9b9b7_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:NonEngleProgenySmokingandHealthCaseGreeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="id14f18627ded4c498559f94480d4c268_I20000731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-07-31</instant>
        </period>
    </context>
    <context id="i1878a54117dd41c49cbfbb12813f60f6_I20000731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-07-31</instant>
        </period>
    </context>
    <context id="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-07-01</startDate>
            <endDate>2006-07-31</endDate>
        </period>
    </context>
    <context id="ie99b75df4d1c4a3e929e255970a683a0_I20080131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-01-31</instant>
        </period>
    </context>
    <context id="ic3f5b4ed913b42fe8a04502626591600_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="ibe1d211aa1a14a2e8f642c7b33db6494_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i296abd7b36374cefa6b045a659376f32_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i12c6d88f04834b87aad507967fe72e0f_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i14e9bdff03c04990be62bbba97421122_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesPearsonDCohenCollarChaconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesReiderandBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesWeingartandHancockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i019cbbd7765340719c2430dc78519295_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesPollariMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="ia91a4fb22e6f45518c962f7f28ad376f_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGlogerRintoulandDuignamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i300ff9979645484a96be74f4cbad94a6_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesFreemanAndHarrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i0df68acf1505499c841787fe26736dbf_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesR.DouglasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i94aba2dfe6f940fdaa35b3888c250151_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHoffmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i2dccdeba725b4dc78842d507b0a1991f_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHoffmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i033be350699e4706b3c6851d29b8b749_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLevineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17d488c73bb644d1bc0a479f11fbe8b4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLevineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i28e721d76a5f489fbcdc920d74435591_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesSchertzerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ief95ac0f1b534c56a693a3370c8c913f_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesSchertzerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i017bc393a586425685f5c81ac9bbd36a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLippMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6191346a68624c76936656e4f4e55fbe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesLippMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iadd63ebeb9da4c4e80b4d08ae9800f7b_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i8d9ba1b77468485198eac867421125fd_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesGarciaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i3adaf5ea11094a4cb8c711a96d4ae229_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesDuignanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ib02c207b06774fd59c5484ff5302f756_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesDuignanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia9461abd7dc04b78b0217e87d27ace97_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMcCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia9beea181cf140f9adfcebd371d4abb8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMcCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6d98007769944dc9b0168ff938a9dcc1_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesChadwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i11254f9a2eb24f83821b5815368b8e08_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesChadwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i72830ce222554341a4a9785d1ab879bd_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesKaplanMcLauighlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i700cb3ce10984b889870b8488b2700b5_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesKaplanMcLauighlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="idc078b33f7684f5296fa7045d4b552eb_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCooperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="i940de6589e0b4ee69091b883a32e09d1_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCooperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="ic81bb1c5437a44efb6f55698d59aec06_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesMillerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id2f8c13313ac4e01af20b71a719f8da6_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesTuttleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i2680e01eb0d943bc86816de660361441_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesCuddiheeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7fbbab892b44cfeaa59dc1d86841818_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesHollimanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i6234f79724d344e6bab36b0693d39350_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesD.BrownMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="idd5c8372783a4bf6bc692e11c709e409_I20090630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EngleProgenyCasesStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-06-30</instant>
        </period>
    </context>
    <context id="id50f063bff6144ba9d1c3bae28cb30f0_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40081f1b6885464e9d63334981371279_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7b18f9afe75a43fca6bafec8103beadd_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0dd7051cbe8249a892d2558422f99b31_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0060f473b507459fa695d7f7e862b35c_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff2761f6e6a84a72bf9453a2877514c2_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iec26b5b167f64b948eb60bda8d571759_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2140db0c9f194d7598ef7666ded56ffc_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i73f23159f88b43b1ad03568c321c2d5c_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i601e952e30854bf9b7959748729929fb_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib9739c01de394810956d3ca2bb685830_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc14a32dde064ccdae95f715a64a3ec8_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icac1b63e2f934ed9a1ea24d4138a8bc9_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i487924c2b1964c8e814c86ad00645620_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i77ddfa361b0245fc8632a21a5ab861d1_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9aeed91145b54f9e84c1ab265089eff6_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic41867538a1a4ecaad3784d369bba1cf_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd3dd41044494e7fb215da3b8dbf74b3_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8c235c89cfaf42189b0ee56ef85f0f77_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i53df00b29f7f48839e6a9318937b699a_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44b75c2442dc43c0a7d18a54f55c6e42_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4697be7d479446d97c049ae8736f48f_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6bfde9de540b4ed0bb63aaf5d758c946_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibf123308c49642739be1ff2dfe411383_D19960501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1996-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if79ec6e4c9a74c19997a9dca74955a22_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mo:BritishColumbiaSaskatchewanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAandAltriaGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i2e90104cb10647bb85cd65620e32994c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia6d6d211a38941ea89399fa49afe5f52_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:AltriaGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i93b593a0985a40cc8016f69134a44753_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id148113ea1ef41e0add7c35363136f03_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:ThreatenedLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75bf439c827a43829f739f2ff5266976_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:CanadianTobaccoManufacturersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1998-11-01</startDate>
            <endDate>1998-11-30</endDate>
        </period>
    </context>
    <context id="i857721e1a42b4c4895342b88f12153b0_I19981130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>1998-11-30</instant>
        </period>
    </context>
    <context id="i0d8f32c1fb40455bb5e51678f9f29624_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i94e854b8d51348db9f3ecb6573a91237_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id147ed05231e49888e6eec1a1de209d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaea3aff15c3244e099d22efd00005e87_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2005NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i366e41742fe34ddab3a6ac544395ef0a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2006NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06db80a9cb864760a78eb4b727fccc60_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2007NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a39c242a89b45ba8ba9304730ce2c3d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2008NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id52cc241f4134704b38b12055f4d1063_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2009NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98ab7c86e216435ab8c328cd46889009_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2010NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88cce377b1794cafaea3109e44da8255_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2011NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i717c1ffac0354612b496c8adfb4066d4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2012NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88aa0ae8b6904cfaa051db486ab28768_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2013NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4feaea05ac4a4fb3a34ec68b4955edbb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2014NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6488ac6ab1d450094cc398cf207f538_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2015NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic812762e464a4962a618c514c4377af3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b42de2c9385496eaa33ccd7de4d5f3a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iafc3e2cc3c8b46a39dee066c06a6604b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2018NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i85efb7c5447949b2a29da6afbe426465_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2019NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0570863d6e264a92a3cae8a3dbab2b48_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2020NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibc46289ddf384a55817708ab513cdea2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2021NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd2dea1c170648f5a808f3b76a33303a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2022NPMAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1998-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib0a0d0e0236740f7be74ed7a98673a30_D19980101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1998-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iee8944fccf0041b29f69b6e0e45d7eab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0c8e8c08cbe740d4a306f6bb4a27e669_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec5a205e894c47679bfac6bbc2c7d660_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20042021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i606794f712334fc29204002ba0d6ccfe_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20192021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b807a28cc05453d86e74e69ed77073d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad95738830284f1496045d0fe44e4fb8_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActionsTransitionYears20042020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="ibb882978d08a4cea900603cee8983240_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcf25cd065fb4f47a44575dc187696f9_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a2a79113e7f4166b1ad0a873dc2709e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ef8738bcb2b4b82b180b4ae7bcb49c2_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a538cd9271c481bbba5add236551969_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7960b6ec146940de9514bbc0a1bf4361_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mo:ArbitrationPeriodAxis">mo:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mo:ArbitrationPeriodAxis">mo:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i86a7db94469940b0bdf76635504fc1c9_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="iefcfe5daa12447d29a502f1354cb8786_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NM</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:OtherDisputesUndertheStateSettlementAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i41840f71688e4157a71edd78b25d1eb2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mo:ImplementationofCorrectiveCommunicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16021c6cb2f8452ba899a790b0995281_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingClassActionLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i34fa5a79a1854ef28fd89687426e80a7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad77b9a8d6704b7f94cdfd087b33ca00_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i05d64c409aed469ba2221a94eff7af46_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:EvaporLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i014aa6b6af9b4df1a19a1a2b7dbfb8f1_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2439b9bbedc04392b00b5bd6ac3cc370_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i2aaed74306e54c7498a48f427fbc3dde_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:IQOSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i0661196cc9c54e3093e2f4c03321a3af_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mo:JUULMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i41dddbdee384487d9fc710339e3a0ccc_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="iab08827c3eeb4c2ab05097b269497f30_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i9557e21fd37641dcb6ef942359171a0b_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i71b49d8d6c6d47188f21140eb5cf4f0e_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="idb201318b1d042eb85ed1f7dff301941_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5822c95a3a294185ab7547237ec445a4_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i9969d54475e54393ac5135266efac3d4_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iaf4d332571e345e6b507f1fb9fb044e9_D20201001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d69782fb04745ccb891419a687d7398_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="ida796d6b95934fcfb7672d95fd59a0a8_D20210701-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i0f4a22fdfe7e477ebc36bd80a51ce673_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd283ff376a14d0ebdf290fc219fa37b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f175730caa1454986f3279a4dbc1d37_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:FederalAndStateShareholderDerivativeLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="ida05d85a752347c7bc48b2dd64cfe9f5_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:LightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mo:PhilipMorrisUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i7e11164646c440cdb43d7579fbad7dbe_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:LightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i58bffe3b3264449299e2b9f964207eda_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:SmokingAndHealthClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i0b0ed1328f8e4090ade76858a871504d_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mo:USTLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">mo:PendingIndividualLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i527b47537c2b4bf4a38a2dc591ed5842_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib778b2cd5f1140bcad20a594e44c8b5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000764180</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="contract">
        <measure>mo:contract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="state">
        <measure>mo:state</measure>
    </unit>
    <unit id="claim">
        <measure>mo:claim</measure>
    </unit>
    <unit id="case">
        <measure>mo:case</measure>
    </unit>
    <unit id="lawsuit">
        <measure>mo:lawsuit</measure>
    </unit>
    <unit id="plantiff">
        <measure>mo:plantiff</measure>
    </unit>
    <unit id="manufacture">
        <measure>mo:manufacture</measure>
    </unit>
    <unit id="ruling">
        <measure>mo:ruling</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="complaint">
        <measure>mo:complaint</measure>
    </unit>
    <unit id="shareholder">
        <measure>mo:shareholder</measure>
    </unit>
    <unit id="court">
        <measure>mo:court</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8xLTEtMS0xLTIyMzExMA_e79d68b3-6b7d-46d0-96a0-7e4fa0969c9e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8yLTEtMS0xLTIyMzExMA_f7aa699a-7007-4e6c-a0ef-53f6c6898c36">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF8zLTEtMS0xLTIyMzExMA_d19ef989-194b-4c3b-87b3-5f3c5e2957f2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF80LTEtMS0xLTIyMzExMA_b8cbb5dd-df12-4b5b-bcb3-0aed19cfd9cf">0000764180</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80L2ZyYWc6NjdhYzc0ZWI0NTAxNDI5OWI3ZWM4ZWRhZjBlYTNkNmYvdGFibGU6NDBkNjUxZmNhZjRiNGJmNjlkODdlYTcyZTkzYmU4MTQvdGFibGVyYW5nZTo0MGQ2NTFmY2FmNGI0YmY2OWQ4N2VhNzJlOTNiZTgxNF81LTEtMS0xLTIyMzExMA_18b5100c-7022-4223-aba4-9a075db3da19">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xNi9mcmFnOjhkZWU2YzBiMGZhMTRhMDliNTk5MmI1MmQ4N2U4YTc2L3RhYmxlOjAyMzU4NGM5MzBmYzQ0ZjFhNDgxODU1ZTgxODMzMTliL3RhYmxlcmFuZ2U6MDIzNTg0YzkzMGZjNDRmMWE0ODE4NTVlODE4MzMxOWJfMi0xLTEtMS0yMjMxMTA_25fcd563-7e7d-425e-9501-9aa6ed895dd2"
      unitRef="usdPerShare">0.3333</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xNi9mcmFnOjhkZWU2YzBiMGZhMTRhMDliNTk5MmI1MmQ4N2U4YTc2L3RhYmxlOjAyMzU4NGM5MzBmYzQ0ZjFhNDgxODU1ZTgxODMzMTliL3RhYmxlcmFuZ2U6MDIzNTg0YzkzMGZjNDRmMWE0ODE4NTVlODE4MzMxOWJfMi0yLTEtMS0yMjMxMTA_0cc07ac3-bd3d-429b-9eb6-b3875392e13a"
      unitRef="usdPerShare">0.3333</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMDk5_0d963085-be3b-4ea0-90c4-fb8e81c66363">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OTk2ZGEwNjYyODk2NDg3MDk4MWE4OThkYjRmYjA3MTkvdGFibGVyYW5nZTo5OTZkYTA2NjI4OTY0ODcwOTgxYTg5OGRiNGZiMDcxOV8wLTAtMS0xLTIyMzExMA_3ba91723-f18e-4070-9712-3bc3efca9ae9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAw_c70984c7-9967-46fa-8a7d-b1ab4c782dc2">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6YTQxNTJiMWQ5NTFhNGIxMDkxOTRmYTY3NGNiM2ExMDMvdGFibGVyYW5nZTphNDE1MmIxZDk1MWE0YjEwOTE5NGZhNjc0Y2IzYTEwM18wLTAtMS0xLTIyMzExMA_f7725f35-99c9-439b-8009-3ede83cd4e74">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAx_5618bb90-989b-486f-8cf4-bba6f224de46">1-08940</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAy_c346ff27-cfdd-4286-8bbd-327443a6e39d">Altria Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl8xLTAtMS0xLTIyMzExMA_03028537-6f85-469d-aced-dd7d56c4d64f">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl8xLTMtMS0xLTIyMzExMA_bdd82ee2-981c-4567-97ec-f40f50843f24">13-3260245</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTAtMS0xLTIyMzExMA_88d3808a-0a44-4c1f-b407-ea1e5ec97ccc">6601 West Broad Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTEtMS0xLTIyMzExMA_e21652b2-9b9c-428d-b231-9b6d0e7ef440">Richmond,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTItMS0xLTIyMzExMA_bb8c9d34-554e-4fbe-9892-656231633585">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6NTM1MTYyOTZhYTNiNGU4ZWEyMzg2MjJjMjZmMThjNDYvdGFibGVyYW5nZTo1MzUxNjI5NmFhM2I0ZThlYTIzODYyMmMyNmYxOGM0Nl80LTMtMS0xLTIyMzExMA_58296682-d315-466b-bb9f-d72694ebd7d3">23230</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA1_cd7407ad-74f2-4ed8-8acd-8634cd83c329">804</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA2_de6660ca-c18e-4ad9-8c55-68cf064c9f2d">274-2200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTAtMS0xLTIyMzExMA_a3578dd1-3e04-4689-a865-afff29fbc23c">Common Stock, $0.33 1/3 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTEtMS0xLTIyMzExMA_703c259f-ea0c-49dc-8b19-197dd95c7da8">MO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0e5405a3195248ba8ca8732ee80ddd91_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8xLTItMS0xLTIyMzExMA_e3a98f9c-44b3-49fe-9788-1dbf345a9379">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTAtMS0xLTIyMzExMA_7a78d0c5-2a5b-466b-9422-1b1faa119d61">1.700% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTEtMS0xLTIyMzExMA_76d18f00-107a-4765-9de6-470efa89d8dd">MO25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibcf440af44f1428a8b472e6254451d12_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV8zLTItMS0xLTIyMzExMA_9242a73d-04b1-4292-9c68-3d22a7b8a39a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTAtMS0xLTIyMzExMA_aea3e2a3-c6aa-4cf6-9760-bb61e25cde6a">2.200% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTEtMS0xLTIyMzExMA_f7264951-c2e6-4666-b868-e0609908b242">MO27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7dfa2174fce6411089552f283d69732e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV80LTItMS0xLTIyMzExMA_01d8bb6d-5c2a-40bf-b0a4-35185ba8a495">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTAtMS0xLTIyMzExMA_e47f6afb-5e89-4818-997d-4af47d09342e">3.125% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTEtMS0xLTIyMzExMA_2cd3935a-45c3-4ee4-b1ad-08f4ff3713d2">MO31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id09b03dd89b847f9946d4aef197aed66_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6OWQ0MDg1YWQ1Y2JmNDFhZDgyMmMwZmMxNmFhNzE2ZDkvdGFibGVyYW5nZTo5ZDQwODVhZDVjYmY0MWFkODIyYzBmYzE2YWE3MTZkOV81LTItMS0xLTIyMzExMA_a86ec828-2998-4490-accc-6a093361ddb6">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA3_84e890f1-9703-44b8-be04-45a750e084e0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTAz_e3ef0694-6388-4acc-bcd6-875da926c017">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18wLTAtMS0xLTIyMzExMA_4c1035be-0a76-4b01-9967-458817c43719">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18yLTYtMS0xLTIyMzExMA_e1c39d2b-bcaf-4c09-b5dc-c4701e0386a4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGFibGU6Y2ZlZWNkNzkwNzMyNGNiN2I0NDM3OTdlNGVjMjE3ZDMvdGFibGVyYW5nZTpjZmVlY2Q3OTA3MzI0Y2I3YjQ0Mzc5N2U0ZWMyMTdkM18zLTYtMS0xLTIyMzExMA_781cead4-2c98-4c40-b1e0-887e7b0f492a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMTA4_d86078b4-eb9a-4125-9c84-8ccd3fc29760">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9c6b503caf294c76a5e851c01965e8e5_I20230418"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xL2ZyYWc6MjI0NDhmZjQzMTI0NDk1YWJjZmU1OTFiYWYyNDU4MDkvdGV4dHJlZ2lvbjoyMjQ0OGZmNDMxMjQ0OTVhYmNmZTU5MWJhZjI0NTgwOV8yMDE0_ad88e48b-cc16-48d3-9d9f-be1c492ad6ae"
      unitRef="shares">1785039536</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMi0yLTEtMS0yMjMxMTA_3cf04aca-c950-404c-8c18-6da06a74ae55"
      unitRef="usd">3913000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMi00LTEtMS0yMjMxMTA_5c5cb04e-3d70-4705-9c0e-d41ea87b5577"
      unitRef="usd">4030000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <mo:ReceivableCommercializationRightsCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNC0yLTEtMS0yMjM3OTI_ec530d24-0824-45df-b2dc-f1c7b0d91c67"
      unitRef="usd">1746000000</mo:ReceivableCommercializationRightsCurrent>
    <mo:ReceivableCommercializationRightsCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNC00LTEtMS0yMjM3ODM_82f3135c-56df-4225-aa13-af675781d1db"
      unitRef="usd">1721000000</mo:ReceivableCommercializationRightsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMy0yLTEtMS0yMjMxMTA_5ce21df0-9371-47d5-b094-4266de3e2663"
      unitRef="usd">58000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMy00LTEtMS0yMjMxMTA_d320fab4-4a60-4aec-982c-41e4d9e90ec7"
      unitRef="usd">48000000</us-gaap:ReceivablesNetCurrent>
    <mo:InventoryRawMaterialsPlantMaterialNetofReserves
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNS0yLTEtMS0yMjMxMTA_3376ec31-b94a-4148-ad5c-3930723c5e4b"
      unitRef="usd">664000000</mo:InventoryRawMaterialsPlantMaterialNetofReserves>
    <mo:InventoryRawMaterialsPlantMaterialNetofReserves
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNS00LTEtMS0yMjMxMTA_9469ef07-f8d2-47d3-8415-b3b3a7fb0d28"
      unitRef="usd">704000000</mo:InventoryRawMaterialsPlantMaterialNetofReserves>
    <mo:OtherInventoryRawMaterialsNetofReserves
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNi0yLTEtMS0yMjMxMTA_847436ad-181a-48a3-85c4-c190588952c6"
      unitRef="usd">202000000</mo:OtherInventoryRawMaterialsNetofReserves>
    <mo:OtherInventoryRawMaterialsNetofReserves
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNi00LTEtMS0yMjMxMTA_eab6a51b-cbe8-40eb-8647-766c269f51bf"
      unitRef="usd">186000000</mo:OtherInventoryRawMaterialsNetofReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNy0yLTEtMS0yMjMxMTA_a2265bce-2dad-4966-8bf4-e4b71cd434fa"
      unitRef="usd">30000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfNy00LTEtMS0yMjMxMTA_90235714-763d-4812-bbf3-62935814d49b"
      unitRef="usd">24000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOC0yLTEtMS0yMjMxMTA_6579a1f6-dbd6-4a11-baa7-f7afc182a574"
      unitRef="usd">356000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOC00LTEtMS0yMjMxMTA_e57084e4-1b50-4dfe-8e42-4d8286bcc005"
      unitRef="usd">266000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOS0yLTEtMS0yMjMxMTA_6fa8aaa9-137d-4e90-9868-1d98d227716a"
      unitRef="usd">1252000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfOS00LTEtMS0yMjMxMTA_8b315544-4ee7-4641-9301-2740cf47d46e"
      unitRef="usd">1180000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTMtMi0xLTEtMjIzMTEw_95fb2eb5-b7c6-42ca-b47f-2785dd509495"
      unitRef="usd">183000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTMtNC0xLTEtMjIzMTEw_d244edda-1d47-45b0-ba44-7bd40543b694"
      unitRef="usd">241000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTQtMi0xLTEtMjIzMTEw_d888cf65-fcd7-43ff-bae8-8ecf84d1da19"
      unitRef="usd">7152000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTQtNC0xLTEtMjIzMTEw_e6bad8a3-9cfc-44e8-95cb-e2ca0c886a7b"
      unitRef="usd">7220000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTUtMi0xLTEtMjIzMTEw_b8ef197a-2f05-4c02-9d8d-705323da2b1f"
      unitRef="usd">4413000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTUtNC0xLTEtMjIzMTEw_e8c639fc-cc13-4558-a330-47b52c359c5e"
      unitRef="usd">4427000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTYtMi0xLTEtMjIzMTEw_0aaaeb4b-b0c7-4b41-a84c-9b1298246246"
      unitRef="usd">2820000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTYtNC0xLTEtMjIzMTEw_aee80cb4-9ad0-4e43-a670-2300190797b4"
      unitRef="usd">2819000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTctMi0xLTEtMjIzMTEw_3b9d929f-9463-4c6e-857c-0231255a2f1c"
      unitRef="usd">1593000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTctNC0xLTEtMjIzMTEw_5f4516fe-ff57-4107-b6a7-5cceb6ec3769"
      unitRef="usd">1608000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTgtMi0xLTEtMjIzMTEw_d391f314-22b6-4177-a8fa-7f106a76d5f3"
      unitRef="usd">5177000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTgtNC0xLTEtMjIzMTEw_98a221ac-02e4-475b-9476-dcf664751252"
      unitRef="usd">5177000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTktMi0xLTEtMjIzMTEw_e000d7e0-53a1-47a3-b332-5481686145c3"
      unitRef="usd">12366000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMTktNC0xLTEtMjIzMTEw_5a773f6c-74d2-430e-83ee-b18fc476ea5b"
      unitRef="usd">12384000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MjI4ZTUwNDlmMDA4NGU5MDhkNjlmZmUyNzk4ODdhNDJfMzI5ODUzNDg4MzY0Nw_2611aa4b-e8e7-4069-8f61-7a85fc9d244b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MjI4ZTUwNDlmMDA4NGU5MDhkNjlmZmUyNzk4ODdhNDJfNDU_e37f8354-edc6-4ed4-b8fe-43285dc3cf68"
      unitRef="usd">250000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtMi0xLTEtMjIzMTEw_122d07f3-836c-481a-bd03-9b4dd18ad4bf"
      unitRef="usd">9559000000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjAtNC0xLTEtMjIzMTEw_f8429373-eb21-44dc-b68e-ebb26941d1f8"
      unitRef="usd">9600000000</us-gaap:Investments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjItMi0xLTEtMjIzMTEw_5f69022b-830f-45ed-a8f2-fb23ea427b06"
      unitRef="usd">979000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjItNC0xLTEtMjIzMTEw_fd97436a-80c3-4895-b307-bba0ddcf3cce"
      unitRef="usd">965000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjMtMi0xLTEtMjIzMTEw_a6b335ab-43ce-4b09-9a3a-4c87ff339cd2"
      unitRef="usd">36826000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjlkZjhkNDE2NjQ3MDRmODE4YzMzYzQzMjUwNTY1Mjc1L3RhYmxlcmFuZ2U6OWRmOGQ0MTY2NDcwNGY4MThjMzNjNDMyNTA1NjUyNzVfMjMtNC0xLTEtMjIzMTEw_3d2836c0-14cc-4806-8836-4cd6d234f807"
      unitRef="usd">36954000000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMy0yLTEtMS0yMjMxMTA_0d67b0ab-d4c2-47fd-9f94-db8c8675b11f"
      unitRef="usd">1339000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMy00LTEtMS0yMjMxMTA_234384d7-1a3e-475d-a73f-1f855a04e65e"
      unitRef="usd">1556000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNC0yLTEtMS0yMjMxMTA_090b94c0-bc44-4d4b-a696-7fa47bc5d188"
      unitRef="usd">412000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNC00LTEtMS0yMjMxMTA_1e6b7e0a-e526-4719-8c6a-c999e70a2603"
      unitRef="usd">552000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNi0yLTEtMS0yMjMxMTA_9f59c499-f8df-4fcd-ae59-d3b0b48b311e"
      unitRef="usd">587000000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfNi00LTEtMS0yMjMxMTA_f8f19388-67e6-41b2-861e-ba2790ccaaff"
      unitRef="usd">599000000</us-gaap:AccruedMarketingCostsCurrent>
    <mo:AccruedSettlementLiabilityCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfOS0yLTEtMS0yMjMxMTA_11eee933-4a7c-4c94-a881-2afa6e413dda"
      unitRef="usd">3820000000</mo:AccruedSettlementLiabilityCurrent>
    <mo:AccruedSettlementLiabilityCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfOS00LTEtMS0yMjMxMTA_75740422-ccf7-4cec-a1cc-36c4dc76403a"
      unitRef="usd">2925000000</mo:AccruedSettlementLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTAtMi0xLTEtMjIzMTEw_e0c2135d-d2c2-401c-a729-dab0ced51776"
      unitRef="usd">1303000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTAtNC0xLTEtMjIzMTEw_ea27fcb0-257c-4755-b63a-13e905123f88"
      unitRef="usd">1299000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTItMi0xLTEtMjIzMTEw_57d57016-b0d0-4c96-ac56-33b5a2446b12"
      unitRef="usd">1685000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTItNC0xLTEtMjIzMTEw_1b818f2a-3fcc-45ce-80de-2d64c286e347"
      unitRef="usd">1685000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTQtMi0xLTEtMjIzMTEw_cec50704-7021-49ff-bb5f-f58d8da45574"
      unitRef="usd">9146000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTQtNC0xLTEtMjIzMTEw_d2896faa-7b7a-4477-9aba-8774b41ffea0"
      unitRef="usd">8616000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTUtMi0xLTEtMjIzMTEw_5c6d8c0b-f3a9-4164-82f1-5d81417c63df"
      unitRef="usd">24048000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTUtNC0xLTEtMjIzMTEw_0cf8ae40-dc07-46c1-b789-73f81fca86cf"
      unitRef="usd">25124000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTYtMi0xLTEtMjIzMTEw_a942de44-8843-4122-b299-2564cd75a431"
      unitRef="usd">2735000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTYtNC0xLTEtMjIzMTEw_abff64de-49d2-4407-8855-e704b39a502f"
      unitRef="usd">2897000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTctMi0xLTEtMjIzMTEw_b4b71a99-b1ca-4348-bdf2-2fba502f642f"
      unitRef="usd">128000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTctNC0xLTEtMjIzMTEw_0c3370cb-d42d-4b2c-abea-362c2d7c0964"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTgtMi0xLTEtMjIzMTEw_33e462ff-b227-4852-87db-e691cac486ab"
      unitRef="usd">1086000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTgtNC0xLTEtMjIzMTEw_5804e906-2e37-4712-b073-e52e40ac1cb0"
      unitRef="usd">1083000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktMi0xLTEtMjIzODM1_45b904fa-0d00-412b-8f94-9583c1438d2f"
      unitRef="usd">2700000000</mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent>
    <mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktNC0xLTEtMjIzODI5_83a531a4-9278-4be4-b362-43e8e1b2f715"
      unitRef="usd">2700000000</mo:DeferredGainOnSaleOfCommercializationRightsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktMi0xLTEtMjIzMTEw_35393c7c-a1ea-4359-a095-0800e3ad3b9e"
      unitRef="usd">809000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMTktNC0xLTEtMjIzMTEw_1d9341e8-612b-45e1-9d89-686d279854c1"
      unitRef="usd">324000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjAtMi0xLTEtMjIzMTEw_60307d70-aee3-425d-9f92-7b28081e1429"
      unitRef="usd">40652000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjAtNC0xLTEtMjIzMTEw_c9e3e0f8-7a44-4c86-a13c-5fc4cc03ed8c"
      unitRef="usd">40877000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjEtMi0xLTEtMjIzMTEw_c1e108de-bebc-4858-b3bb-9f491d0b3063"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjEtNC0xLTEtMjIzMTEw_4ef5120b-77d8-4c01-8214-c5c1be762676"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246YjhiODdhNzkxMzc1NGFjNzk0MzJiMTk1ZTRkYTIxZGFfNTA_00b1a730-fc25-49d3-ba1e-1b7e89408533"
      unitRef="shares">2805961317</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246YjhiODdhNzkxMzc1NGFjNzk0MzJiMTk1ZTRkYTIxZGFfNTA_fdb45978-348f-437d-9cc5-261797dd1b26"
      unitRef="shares">2805961317</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtMi0xLTEtMjIzMTEw_f371abda-8318-4b4c-b4cd-26fe0bc2d519"
      unitRef="usd">935000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjQtNC0xLTEtMjIzMTEw_11f19c07-6cf3-4d3f-a40c-cdf0734aa72d"
      unitRef="usd">935000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjUtMi0xLTEtMjIzMTEw_76714759-a8fb-4c65-a536-385f13e269e6"
      unitRef="usd">5866000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjUtNC0xLTEtMjIzMTEw_de34a1de-afa9-4ef8-b50f-c6ea3d4d06c3"
      unitRef="usd">5887000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjYtMi0xLTEtMjIzMTEw_639b41f4-839d-4ad8-ac1f-2d09cff86184"
      unitRef="usd">29898000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjYtNC0xLTEtMjIzMTEw_7d7e099e-22b6-44ee-9a29-ee5fd2646f24"
      unitRef="usd">29792000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjctMi0xLTEtMjIzMTEw_de1b0ed7-8b70-4caf-8a7f-ed540f31b861"
      unitRef="usd">-2779000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjctNC0xLTEtMjIzMTEw_13ef65ea-60d5-4baa-89a3-f4a4ab59cd33"
      unitRef="usd">-2771000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MTJhZTg2YzJlZmYwNDgzODllYzFiZTBlYWYwYTljNGRfMzI5ODUzNDg4MzUyMQ_95b35d22-0255-490f-8da7-87245f52d3d4"
      unitRef="shares">1019815657</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMC0xLTEtMjIzMTEwL3RleHRyZWdpb246MTJhZTg2YzJlZmYwNDgzODllYzFiZTBlYWYwYTljNGRfNjk_6eac33fe-bf2f-4512-9917-1a554f18cdaa"
      unitRef="shares">1020427195</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtMi0xLTEtMjIzMTEw_e02061ba-00d6-47c1-9a1d-b984ed21c0f9"
      unitRef="usd">37796000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjgtNC0xLTEtMjIzMTEw_0cc2736a-6274-4afc-9fc8-ba485b31eba6"
      unitRef="usd">37816000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjktMi0xLTEtMjIzMTEw_7ff72abb-1758-4001-a70e-9906e2935743"
      unitRef="usd">-3876000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMjktNC0xLTEtMjIzMTEw_5a2a6cf0-7c94-4513-8129-e4cf45047971"
      unitRef="usd">-3973000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzEtMi0xLTEtMjI0NjM1_76f8edf3-7afd-4ba2-ba5e-f70e9737f8ae"
      unitRef="usd">50000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzEtNC0xLTEtMjI0NjA3_39b878f6-8468-4817-8b83-e98a8d894b10"
      unitRef="usd">50000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzItMi0xLTEtMjQwNzA2_d8ce0b26-ce1b-4175-8a0f-4bb91038979f"
      unitRef="usd">-3826000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzItNC0xLTEtMjQwNzAw_0d2d1e59-ee25-4f89-a685-227c82d79e4e"
      unitRef="usd">-3923000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzAtMi0xLTEtMjIzMTEw_c7b9e4b1-3a4e-48e0-af37-257d2347d356"
      unitRef="usd">36826000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMy9mcmFnOjViY2Y4OTdiZjk5ODQxZTVhYmY0MWMyZWIwZGUwOWY2L3RhYmxlOjExYmExYzE5ODJiMDRlZjg5YTVlZDVkYTgwOWMyMjg2L3RhYmxlcmFuZ2U6MTFiYTFjMTk4MmIwNGVmODlhNWVkNWRhODA5YzIyODZfMzAtNC0xLTEtMjIzMTEw_d760a950-b792-429e-a753-0493db00190d"
      unitRef="usd">36954000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMi0yLTEtMS0yMjMxMTA_14281123-6680-4786-9790-1b029d64d7c7"
      unitRef="usd">5719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMi00LTEtMS0yMjMxMTA_054d6bbb-18a3-48a6-b263-835d7781b4f5"
      unitRef="usd">5892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMy0yLTEtMS0yMjMxMTA_d6381742-e3f7-494c-9200-5a09c12c956e"
      unitRef="usd">1434000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMy00LTEtMS0yMjMxMTA_2409fb4f-a6ba-41bb-ad09-755254d5aefc"
      unitRef="usd">1446000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNC0yLTEtMS0yMjMxMTA_63368e41-2163-4cdb-92b6-49b6474888e1"
      unitRef="usd">956000000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNC00LTEtMS0yMjMxMTA_bb4846b4-3d14-4805-be79-e8f04887a6be"
      unitRef="usd">1073000000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:GrossProfit
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNS0yLTEtMS0yMjMxMTA_09cae819-30cc-4789-8a97-82584d7ca027"
      unitRef="usd">3329000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNS00LTEtMS0yMjMxMTA_dd8bc3ad-da2c-41de-8d63-a3d28f5e052f"
      unitRef="usd">3373000000</us-gaap:GrossProfit>
    <mo:MarketingAdministrationandResearchCosts
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNi0yLTEtMS0yMjMxMTA_c9417e02-b72f-4323-9e6a-2580a3db86f9"
      unitRef="usd">572000000</mo:MarketingAdministrationandResearchCosts>
    <mo:MarketingAdministrationandResearchCosts
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNi00LTEtMS0yMjMxMTA_2b872e41-1404-40ff-b87a-2218384000ed"
      unitRef="usd">489000000</mo:MarketingAdministrationandResearchCosts>
    <us-gaap:OperatingIncomeLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNy0yLTEtMS0yMjMxMTA_3a68cd21-3e0e-41cf-9086-b0be4efcc920"
      unitRef="usd">2757000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfNy00LTEtMS0yMjMxMTA_c78676d8-2666-4027-bc39-f5db31662581"
      unitRef="usd">2884000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfOC0yLTEtMS0yMjMxMTA_e7beda3a-e4f9-4c6a-8c31-675eaeb4d7f8"
      unitRef="usd">-229000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfOC00LTEtMS0yMjMxMTA_9021d319-db36-4050-9f60-546ccba6a9d6"
      unitRef="usd">-281000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTAtMi0xLTEtMjIzMTEw_528542cc-7085-4bec-a234-f409b5d0768c"
      unitRef="usd">-31000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTAtNC0xLTEtMjIzMTEw_485bcc40-d49e-436b-bc20-ecdaef74df96"
      unitRef="usd">-46000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTEtMi0xLTEtMjIzMTEw_54e205f4-ad7e-4197-bf0f-650bc65c19be"
      unitRef="usd">-80000000</mo:IncomeLossFromEquitySecurities>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTEtNC0xLTEtMjIzMTEw_11035a88-c72a-4f41-9f0d-c61172369c39"
      unitRef="usd">34000000</mo:IncomeLossFromEquitySecurities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTMtMi0xLTEtMjIzMTEw_ca7ded51-bbd1-4801-b761-eb128340219c"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTMtNC0xLTEtMjIzMTEw_9be264f3-a49b-44ad-a080-f5e98026c7b8"
      unitRef="usd">-10000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTQtMi0xLTEtMjIzMTEw_46be83c2-e0cf-418e-8582-3e62a90dbd0b"
      unitRef="usd">2479000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTQtNC0xLTEtMjIzMTEw_0f02ff40-1f80-4b85-a42d-0b89657ae032"
      unitRef="usd">2673000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTUtMi0xLTEtMjIzMTEw_78f1b1bf-affb-4e68-96fa-e13bf01ec29c"
      unitRef="usd">692000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTUtNC0xLTEtMjIzMTEw_f6b53e2b-af83-4dee-a080-fdfffa9e1168"
      unitRef="usd">714000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTgtMi0xLTEtMjIzMTEw_f5f07151-35de-4977-afec-8e36861a0d5d"
      unitRef="usd">1787000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMTgtNC0xLTEtMjIzMTEw_46c3b641-9b88-4143-a146-3b16a385f2f5"
      unitRef="usd">1959000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtMi0xLTEtMjIzMTEw_b2f5834f-24bc-4577-8a18-93142ac92603"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtMi0xLTEtMjIzMTEw_f8563659-e0ad-40fe-9a38-3315293715ac"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtNC0xLTEtMjIzMTEw_09fe7a41-06b3-4c72-86c2-097ce40ad7a3"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xOS9mcmFnOjgyYmZkMTNhYmY5YzRhZWNiODRiOGEwY2Y3ZGQ5NDBjL3RhYmxlOmNjODg3MDhkOWJmNDRiN2M5MzJhMWJjOWVkMDg3OWJhL3RhYmxlcmFuZ2U6Y2M4ODcwOGQ5YmY0NGI3YzkzMmExYmM5ZWQwODc5YmFfMjAtNC0xLTEtMjIzMTEw_67d37722-908c-474c-9cc6-aee83cc25368"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMi0yLTEtMS0yMjMxMTA_22aefacd-93ec-4509-b830-3ffd266f44f3"
      unitRef="usd">1787000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMi00LTEtMS0yMjMxMTA_96654bed-2edf-40b0-a2b3-8a9366cb688f"
      unitRef="usd">1959000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNC0yLTEtMS0yMjMxMTA_3e2a9748-5183-4b3c-b122-5d0c343d3571"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNC00LTEtMS0yMjMxMTA_594d1bae-386a-4c5a-b480-fbc25d2fa8f6"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OciEquityMethodInvestmentAfterTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNS0yLTEtMS0yMjMxMTA_863fdafd-1488-4bcd-bf3f-8b2be474e925"
      unitRef="usd">-12000000</us-gaap:OciEquityMethodInvestmentAfterTax>
    <us-gaap:OciEquityMethodInvestmentAfterTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNS00LTEtMS0yMjMxMTA_3b22d08c-4699-44d6-89c3-1010ecd347bd"
      unitRef="usd">78000000</us-gaap:OciEquityMethodInvestmentAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNi0yLTEtMS0yMjMxMTA_eb8cdf86-ad98-4203-8a0e-0de93ee2ecec"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNi00LTEtMS0yMjMxMTA_dfbaa222-5a42-4711-b7a8-969ea8c34369"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNy0yLTEtMS0yMjMxMTA_c59d2aa5-4756-41f5-84fd-f1c4eab54c80"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfNy00LTEtMS0yMjMxMTA_c478ed4b-664a-4528-94ed-db584d2cf759"
      unitRef="usd">94000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMTEtMi0xLTEtMjIzMTEw_f206cdc3-b482-4695-8e49-63650b4b3d4f"
      unitRef="usd">1779000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yMi9mcmFnOmYyYWE1ZDg2M2VjYjRhMGRhM2Y0MzUzZjAwZDVmZGE0L3RhYmxlOjY3YzIzYzUyMThmMTRiMjY4MmNmZWRmODE2NWI5NTEyL3RhYmxlcmFuZ2U6NjdjMjNjNTIxOGYxNGIyNjgyY2ZlZGY4MTY1Yjk1MTJfMTEtNC0xLTEtMjIzMTEw_6fc10019-1fa7-4656-a9da-6666709bb121"
      unitRef="usd">2053000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2d809fc7c4b44ba92b401d313ae3b59_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0yLTEtMS0yMjMxMTA_02fdddb8-47aa-496f-8a6f-0925343ab47e"
      unitRef="usd">935000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57bab0db84d941b8ba69763527b90f7f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi00LTEtMS0yMjMxMTA_852461a5-12f8-440a-9509-3d1315ee7e7e"
      unitRef="usd">5887000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b599b726c57473687e1536cd1d26c41_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi02LTEtMS0yMjMxMTA_eba34a96-c846-42f5-b9ff-e2fe9ed5b1fe"
      unitRef="usd">29792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2469a4bba094953adfa2888c0f55b57_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi04LTEtMS0yMjMxMTA_ef0b68d8-e0bf-4e74-918f-84549288d6ff"
      unitRef="usd">-2771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee0c6e3ccab347c88032c15fcb532cd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xMC0xLTEtMjIzMTEw_9c8bd8d9-8194-4900-8e2b-f36efa9950b4"
      unitRef="usd">-37816000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f5140f53521445993db0f74aeb56071_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xMi0xLTEtMjMwOTY3_4f4e9906-bb62-4da4-874f-c249461cd8cc"
      unitRef="usd">50000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMi0xNC0xLTEtMjIzMTEw_6e59471c-785b-4913-bf76-d0dc444946c6"
      unitRef="usd">-3923000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMy02LTEtMS0yMjMxMTA_9ef3f04d-8b91-4864-a3aa-ade33b73fc71"
      unitRef="usd">1787000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfMy0xNC0xLTEtMjIzMTEw_4431e465-e644-4212-b489-bc35f621f1aa"
      unitRef="usd">1787000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNC04LTEtMS0yMjMxMTA_2e556462-b873-4e72-84ff-a2d7167f83a1"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNC0xNC0xLTEtMjIzMTEw_6a9ae15e-2c59-4933-8377-804efc04035e"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="ic7101ec192394649a415c1b63b908c30_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS00LTEtMS0yMjMxMTA_af98bf31-759b-4e03-b3ea-2d50ef7e987b"
      unitRef="usd">-21000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="idaaf63c06a1049e695676e0481062f63_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS0xMC0xLTEtMjIzMTEw_d1f76bdb-2bd4-4008-ad84-5c04ba8d50eb"
      unitRef="usd">20000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNS0xNC0xLTEtMjIzMTEw_90a6da1a-5872-4008-b0e0-7f396e573240"
      unitRef="usd">-1000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi0wLTEtMS0yMjMxMTAvdGV4dHJlZ2lvbjplNjk4NWQ2YzZmZDQ0N2UxYjIzYmU2NTQxYzYwZjJhY18yMTk5MDIzMjU1NTk3_0b7af891-17d4-432f-a0a9-c8a36d720fd8"
      unitRef="usdPerShare">0.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8c17f7ca3fb049e0af92c53fc1165ae1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi02LTEtMS0yMjMxMTA_65b9f929-5c2b-4a45-9537-c8dac84ce855"
      unitRef="usd">1681000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfNi0xNC0xLTEtMjIzMTEw_ea2e39e9-a23a-4e4d-af84-0664814244ca"
      unitRef="usd">1681000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie66aa9b4f0ee44019b9de410d7e55ce7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0yLTEtMS0yMjMxMTA_32fc70b8-33d2-4fe4-893b-b87d0073c977"
      unitRef="usd">935000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cccb1a7f24445ba8b43e289af3300ec_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS00LTEtMS0yMjMxMTA_e19b4f7a-d40a-4c64-bb1b-878341608e0d"
      unitRef="usd">5866000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90e819bf5bdd408a959e0b2e4e7b73d3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS02LTEtMS0yMjMxMTA_53f0b110-ef7a-4f3d-bd2e-de64682f16a3"
      unitRef="usd">29898000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd940594473144c68357ea9c5539af8e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS04LTEtMS0yMjMxMTA_8fe7d3bb-a44f-4086-b9b7-142b1d2a41a2"
      unitRef="usd">-2779000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe1266b52910409c97c004b5e3046d53_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xMC0xLTEtMjIzMTEw_09934fad-deb3-42fe-a2fb-17da975086c2"
      unitRef="usd">-37796000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff121125e516451b955d8e621eab3ca2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xMi0xLTEtMjIzMTEw_64935728-0ec5-409d-bb2f-88a05a3d26bf"
      unitRef="usd">50000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOmUzNTQ1MDkxMWNjNDQzMzc5OTA1MTAyMmUwZTEyMDYyL3RhYmxlcmFuZ2U6ZTM1NDUwOTExY2M0NDMzNzk5MDUxMDIyZTBlMTIwNjJfOS0xNC0xLTEtMjIzMTEw_6d7ce28d-d156-4c3f-8224-d10ee85ddd25"
      unitRef="usd">-3826000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1542e02bb1e24adda3f71e99211fc9ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0yLTEtMS0yMjMxMTA_1dd5a406-fbf7-443b-919e-065311d2a391"
      unitRef="usd">935000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if12ef6040ec2418189e3c2572fa81080_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi00LTEtMS0yMjMxMTA_cf02684d-8f45-4dd9-afee-94d22b3fc831"
      unitRef="usd">5857000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie382e64c844d405d89091642f2a1d28c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi02LTEtMS0yMjMxMTA_eba8a23c-390d-4dcf-a6fd-e98798487f7e"
      unitRef="usd">30664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3e09c734e014d5ea132f83014347e58_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi04LTEtMS0yMjMxMTA_01421ed8-3ff9-4273-aa48-7c555e0b4726"
      unitRef="usd">-3056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2af1b2cb80da4571ac97b869fabca161_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0xMC0xLTEtMjIzMTEw_334b48d4-78c7-4bbe-b9f1-ee8281ce07a6"
      unitRef="usd">-36006000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMi0xNC0xLTEtMjIzMTEw_620e337c-4e44-40f9-bce6-17d01672dcbd"
      unitRef="usd">-1606000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMy02LTEtMS0yMjMxMTA_d75cb930-70d0-4453-b774-6da54f88e1ed"
      unitRef="usd">1959000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfMy0xNC0xLTEtMjIzMTEw_e189c726-5b3d-4446-8da9-6fa70e6b8c7e"
      unitRef="usd">1959000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNC04LTEtMS0yMjMxMTA_b6fc490b-aa3c-463b-9b4d-27b316c8e7ec"
      unitRef="usd">94000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNC0xNC0xLTEtMjIzMTEw_838288ef-150c-40df-b910-6ff3d1d50ec8"
      unitRef="usd">94000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="i0f5ef2d10e0747f6975b8eaabca090eb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS00LTEtMS0yMjMxMTA_f3468c64-7bda-4211-92a4-fd2b0116d0f4"
      unitRef="usd">-9000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS0xMC0xLTEtMjIzMTEw_59db5ec6-c8c3-409e-b127-a3cb16cb7d37"
      unitRef="usd">13000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNS0xNC0xLTEtMjIzMTEw_2721b440-5485-4d20-bbba-cdbcf13d1c38"
      unitRef="usd">4000000</mo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi0wLTEtMS0yMjMxMTAvdGV4dHJlZ2lvbjo2YTQwNTdkMDM4ZTM0NDZhOTI0YWI5NTEzZWZmYmNiZl8yMTk5MDIzMjU1NTk1_3cef208b-1ac9-4817-ace6-0372e726da05"
      unitRef="usdPerShare">0.90</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iba5bc0339ee94d61b770618ca40331f4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi02LTEtMS0yMjMxMTA_a14b6be5-5d32-493f-b559-318716e99306"
      unitRef="usd">1635000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNi0xNC0xLTEtMjIzMTEw_833873d6-5824-42fc-9924-f8c11a1c88b6"
      unitRef="usd">1635000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i99992380382e4fbbabd0e976bab92f31_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNy0xMC0xLTEtMjIzMTEw_6de344ed-3cef-45c9-8782-d5ac182a4d9b"
      unitRef="usd">576000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfNy0xNC0xLTEtMjIzMTEw_e40271ee-0f48-41ff-8342-1cf6e05b7cd6"
      unitRef="usd">576000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42884e66bec24a6fbaa77ec0ef498541_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0yLTEtMS0yMjMxMTA_87eef565-d520-4eeb-a7d7-877dab6b48d9"
      unitRef="usd">935000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic85e35b6659d4fc0930167fa4a8a1832_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS00LTEtMS0yMjMxMTA_b75f1d10-ed44-48e3-8770-f2823e0f420b"
      unitRef="usd">5848000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1532672af67b495ebb54a98924a90df4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS02LTEtMS0yMjMxMTA_6bedbaf3-c14c-4d5a-822e-144466b7e0a3"
      unitRef="usd">30988000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS04LTEtMS0yMjMxMTA_1d94d38b-ad74-461e-9f97-87cd51f9a18c"
      unitRef="usd">-2962000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1e84fb2796b4e21bbb745b3013fe6e0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0xMC0xLTEtMjIzMTEw_3b82b769-7033-4193-a1f6-f1caf6bffd88"
      unitRef="usd">-36569000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17705bcff8eb49498848597476b6a197_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8yOC9mcmFnOmY4MjJiMzk1YWY1NjQ1YzA5NmNiYWY3NTIyOTRhNDJmL3RhYmxlOjUzNzFkNzdiYWMyMjQ0MTJiMDljZTA4YmUzNTExZDhkL3RhYmxlcmFuZ2U6NTM3MWQ3N2JhYzIyNDQxMmIwOWNlMDhiZTM1MTFkOGRfOS0xNC0xLTEtMjIzMTEw_a42b7721-c5e5-4fef-9cb2-4149366c6e99"
      unitRef="usd">-1760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMi0yLTEtMS0yMjMxMTA_f8adfec4-1c70-4952-8a54-58a3cc34e075"
      unitRef="usd">1787000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMi00LTEtMS0yMjMxMTA_667827e0-66c6-4853-950a-ce0ae17b9eb1"
      unitRef="usd">1959000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNC0yLTEtMS0yMjMxMTA_42008726-819b-44f1-a548-df36937d0d17"
      unitRef="usd">52000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNC00LTEtMS0yMjMxMTA_011a741c-3545-4c82-b227-33a6765f1b45"
      unitRef="usd">52000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNS0yLTEtMS0yMjMxMTA_06e11f58-2272-4d35-ad15-750c953a2e63"
      unitRef="usd">-142000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNS00LTEtMS0yMjMxMTA_56f6cec3-8226-4898-a957-21e12edbd47b"
      unitRef="usd">43000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNi0yLTEtMS0yMjMxMTA_a43bd5fb-efa1-4fc2-ba1a-c36fc32a35ec"
      unitRef="usd">-80000000</mo:IncomeLossFromEquitySecurities>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfNi00LTEtMS0yMjMxMTA_0fb8c425-7dce-4252-bca1-8f0d534ff392"
      unitRef="usd">34000000</mo:IncomeLossFromEquitySecurities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfOS0yLTEtMS0yMjMxMTA_0a0b6672-ae06-4fa3-bf23-bf36eaab8f88"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfOS00LTEtMS0yMjMxMTA_bbe82649-99b0-4ebf-beda-b2226eaaa6db"
      unitRef="usd">-10000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTYtMi0xLTEtMjIzMTEw_b8463b52-a94c-4a9e-b502-4340a3536b9c"
      unitRef="usd">34000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTYtNC0xLTEtMjIzMTEw_ab72f0a3-20d3-45ab-8569-2b0931dd1b2d"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTctMi0xLTEtMjIzMTEw_5548c6c1-7350-4bd6-843d-4cb486bbb050"
      unitRef="usd">72000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTctNC0xLTEtMjIzMTEw_948f8dae-9d58-41b6-8a42-272743f28d75"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTgtMi0xLTEtMjIzMTEw_3b5ba614-62e3-47a9-bc03-b50d66ee0470"
      unitRef="usd">-115000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTgtNC0xLTEtMjIzMTEw_eaf8d40a-8dca-4ea8-a66d-72dd729ab067"
      unitRef="usd">-59000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTktMi0xLTEtMjIzMTEw_f4fc071c-0346-4c95-afb6-10d4596540e0"
      unitRef="usd">409000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMTktNC0xLTEtMjIzMTEw_6f77c162-021d-4091-8dca-a5b9032eea86"
      unitRef="usd">637000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjAtMi0xLTEtMjIzMTEw_fc2c3f79-fc4d-4aa7-92ff-ab711bc15a63"
      unitRef="usd">369000000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjAtNC0xLTEtMjIzMTEw_0cc7c602-064a-434f-af1f-c29b0438cb02"
      unitRef="usd">372000000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <mo:IncreaseDecreaseInSettlementPayable
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjEtMi0xLTEtMjIzMTEw_73308449-3cdf-4fab-b2f9-6a89971cd7e7"
      unitRef="usd">895000000</mo:IncreaseDecreaseInSettlementPayable>
    <mo:IncreaseDecreaseInSettlementPayable
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjEtNC0xLTEtMjIzMTEw_f877b4ae-f0ee-48b7-8266-73ecd1a74fba"
      unitRef="usd">880000000</mo:IncreaseDecreaseInSettlementPayable>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjItMi0xLTEtMjIzMTEw_e1d7afdf-5696-488b-a32f-71056ae8f20a"
      unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjItNC0xLTEtMjIzMTEw_6ed690ab-627e-48bf-898a-9adc97c5cef4"
      unitRef="usd">3000000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjMtMi0xLTEtMjIzMTEw_fd972dce-801c-4577-a706-5dbd2abaecac"
      unitRef="usd">-34000000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjMtNC0xLTEtMjIzMTEw_71b13fe0-83b9-474d-b16c-f19f5e9befb6"
      unitRef="usd">-35000000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5"
      unitRef="usd">534000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c"
      unitRef="usd">16000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjUtMi0xLTEtMjIzMTEw_1a892d09-c9a1-4373-870b-73b58f4c24b7"
      unitRef="usd">2984000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjUtNC0xLTEtMjIzMTEw_e6a4fc86-1c53-4c78-8c45-63af6db23248"
      unitRef="usd">3075000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjctMi0xLTEtMjIzMTEw_a541bd4b-7722-4229-a352-55c6b44b3448"
      unitRef="usd">55000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjctNC0xLTEtMjIzMTEw_d760334b-2b5b-4bfc-93a7-deced3112cae"
      unitRef="usd">45000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzEtMi0xLTEtMjIzMTEw_89ae141f-bd34-4d66-86f3-7d8513e7f678"
      unitRef="usd">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzEtNC0xLTEtMjIzMTEw_838474c6-d340-47dd-87d5-05d3051b9204"
      unitRef="usd">-11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzItMi0xLTEtMjIzMTEw_ffc311d4-6f51-413a-a34a-90ddb563a68a"
      unitRef="usd">-56000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMzItNC0xLTEtMjIzMTEw_ae09dcc0-c9bc-4ada-84cc-5877a46b5dbd"
      unitRef="usd">-34000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfMTA5OTUxMTYyOTkyOQ_eb75f9e0-7dd0-4b34-aec4-3587cb82f8f5"
      unitRef="usd">391000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMy0yLTEtMS0yMjMxMTA_f1196468-e44b-455a-aabe-62675f219825"
      unitRef="usd">1348000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMy00LTEtMS0yMjMxMTA_d3469e03-b60a-43fa-95e4-8dbb52da708d"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNC0yLTEtMS0yMjMxMTA_2a229638-da3f-41aa-a25a-f46a0663f993"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNC00LTEtMS0yMjMxMTA_30081fc5-7626-40cc-ac5f-38f653b3d31b"
      unitRef="usd">576000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNS0yLTEtMS0yMjMxMTA_a217a1d9-bde3-42cb-a7d6-b2a7a872694f"
      unitRef="usd">1683000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNS00LTEtMS0yMjMxMTA_256f4833-0bec-4f1c-a5b1-060db3952421"
      unitRef="usd">1645000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNy0yLTEtMS0yMjMxMTA_3cc60967-79be-4dd6-8f82-9e8cc1b4780c"
      unitRef="usd">-14000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfNy00LTEtMS0yMjMxMTA_9ccfd230-433f-4c3e-ae11-a5cea3d47b18"
      unitRef="usd">-11000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfOC0yLTEtMS0yMjMxMTA_1999abf2-15fc-438b-b322-c8f6a0290964"
      unitRef="usd">-3045000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfOC00LTEtMS0yMjMxMTA_90833483-d934-4370-bf18-b897ad693102"
      unitRef="usd">-2232000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTAtMi0xLTEtMjIzMTEw_2bd3f2db-746d-48db-b82d-088402647d59"
      unitRef="usd">-117000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTAtNC0xLTEtMjIzMTEw_0a93aa8f-0742-4436-9212-f3bdd2d461a5"
      unitRef="usd">809000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTEtMi0xLTEtMjIzMTEw_fdebb6b7-8c24-4779-8deb-2c2df0fc04d1"
      unitRef="usd">4091000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTEtNC0xLTEtMjIzMTEw_1a95a552-5c88-4b98-a4f2-1a99b4a98e79"
      unitRef="usd">4594000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTItMi0xLTEtMjIzMTEw_0aaa21a5-20e3-40c0-a328-ff84d4ccf697"
      unitRef="usd">3974000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17705bcff8eb49498848597476b6a197_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTItNC0xLTEtMjIzMTEw_60825f76-8085-4620-87e3-51a6dd581497"
      unitRef="usd">5403000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTYtMi0xLTEtMjIzMTEw_12abbe29-441b-4a43-86b4-eec8d846f8b7"
      unitRef="usd">3913000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTYtNC0xLTEtMjIzMTEw_e8462710-b8d4-4129-91ec-874c72b86c03"
      unitRef="usd">4030000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1"
      unitRef="usd">30000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd"
      unitRef="usd">15000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4"
      unitRef="usd">31000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3"
      unitRef="usd">46000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMjAtMi0xLTEtMjIzMTEw_cc3117fd-19da-4e5d-8aec-a5feddc305b6"
      unitRef="usd">3974000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMjAtNC0xLTEtMjIzMTEw_de307912-f87b-4a64-bf13-03461e311895"
      unitRef="usd">4091000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgxMA_8e58ed26-f37b-4f66-9291-b0d005e5ed49">Background and Basis of Presentation&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;When used in these notes, the terms &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altria,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"&gt;Background: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, our wholly owned subsidiaries included Philip Morris USA Inc. (&#x201c;PM USA&#x201d;), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (&#x201c;Middleton&#x201d;), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (&#x201c;UST&#x201d;), which through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC (&#x201c;USSTC&#x201d;), is engaged in the manufacture and sale of moist smokeless tobacco products (&#x201c;MST&#x201d;) and snus products; and Helix Innovations LLC (&#x201c;Helix&#x201d;), which operates in the United States and Canada, and Helix Innovations GmbH and its affiliates (&#x201c;Helix ROW&#x201d;), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of oral nicotine pouches.  Other wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to our domestic tobacco operating companies; and Altria Client Services LLC (&#x201c;ALCS&#x201d;), which provides various support services to our companies in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs.  Our access to the operating cash flows of our wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by our subsidiaries.  At March&#160;31, 2023, our significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we also owned a 75% economic interest in Horizon Innovations LLC (&#x201c;Horizon&#x201d;), a joint venture with Japan Tobacco, Inc., which owned the remaining 25% economic interest.  Horizon is structured to exist in perpetuity and is responsible for the U.S. marketing and commercialization of heated tobacco stick products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2023, we entered into a stock transfer agreement with JUUL Labs, Inc. (&#x201c;Stock Transfer Agreement&#x201d;) pursuant to which we transferred to JUUL Labs, Inc. (&#x201c;JUUL&#x201d;) all of our beneficially owned JUUL equity securities.  In exchange, we received a non-exclusive, irrevocable global license to certain of JUUL&#x2019;s heated tobacco intellectual property  (&#x201c;JUUL Heated Tobacco IP&#x201d;).  Prior to the exchange, we accounted for our investment in JUUL at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we had investments in Anheuser-Busch InBev SA/NV (&#x201c;ABI&#x201d;) and Cronos Group Inc. (&#x201c;Cronos&#x201d;), which we account for under the equity method of accounting using a one-quarter lag.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further discussion of our investments in equity securities, see Note 3. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2023, we entered into a definitive agreement to acquire NJOY Holdings, Inc. (&#x201c;NJOY&#x201d;), a U.S. based e-vapor company, for approximately $2.75 billion in cash payable at closing (&#x201c;NJOY Transaction&#x201d;) plus up to an additional $500 million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products.  Following completion of the NJOY Transaction, NJOY will survive as a wholly owned subsidiary of Altria.  The completion of the NJOY Transaction is subject to customary closing conditions, including clearance from the U.S. Federal Trade Commission (&#x201c;FTC&#x201d;), and is not subject to any financing condition.  The parties have filed for premerger clearance with&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#x201c;HSR Act&#x201d;), which remains under FTC review.  The current waiting period under the HSR Act expires in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"&gt;Share Repurchases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, our Board of Directors (&#x201c;Board of Directors&#x201d; or &#x201c;Board&#x201d;) authorized a $2.0 billion share repurchase program that it expanded to $3.5 billion in October 2021 (as expanded, the &#x201c;January 2021 share repurchase program&#x201d;).  We completed the January 2021 share repurchase program in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, our Board of Directors authorized a new $1.0 billion share repurchase program (the &#x201c;January 2023 share repurchase program&#x201d;).  The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of our Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, there were no share repurchases under the January 2023 share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share repurchase activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate cost of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"&gt;Basis of Presentation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interim condensed consolidated financial statements are unaudited.  Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements.  All such adjustments were of a normal recurring nature.  Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These statements should be read in conjunction with our audited consolidated financial statements and related notes, which appear in our Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2023 we adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU No. 2021-08&#x201d;).  This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.  As of March 31, 2023, our adoption of ASU No. 2021-08 had no impact on our condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on January 1, 2023 we adopted ASU 2022-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liabilities- Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU No. 2022-04&#x201d;).  This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period and potential magnitude.  As of March 31, 2023, our adoption of ASU No. 2022-04 had no material impact on our condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mo:OwnershipPercentageInConsolidatedSubsidiary
      contextRef="i87c63010612240ff9b4601af94a82301_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNzk3NA_5786ab12-6498-43a2-a97a-a4ba4ee347d6"
      unitRef="number">0.75</mo:OwnershipPercentageInConsolidatedSubsidiary>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i916567e93a6f4954aee581f056c6cbac_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNzk4MA_d5c34711-ed13-4301-ab91-6b0043212bae"
      unitRef="number">0.25</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDc5OQ_d06e60f7-809c-4d8e-9ac8-c618173ebc1e">under the equity method of accounting using a one-quarter lag.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5ad881c7536c4aefb9f8952e60edc5d0_D20230401-20231231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTY0NDcwOQ_b6ef7818-734c-4aa7-8a44-1c1f6cb944b4"
      unitRef="usd">2750000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3187e615f5274b95ad68a22a51aec4fb_I20231231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzI5ODUzNDkwMjA3Nw_4faeb75b-6fa8-43ce-a7fe-0c96b9b2a75d"
      unitRef="usd">500000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="idbf02e4d84bb4fae848037ad768f4bb2_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzA1OQ_a7569de1-a87e-4e13-a6d4-3181b3e5a168"
      unitRef="usd">2000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i77cd95d31f3e47db905a2fce488caf88_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzEwNw_5b0e3c52-8ce5-448a-be64-3efab44be025"
      unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iee57b9fa9a0c4629ae346c0ca0694281_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMTA5OTUxMTYzNDAxOA_21b2fbb0-ac1f-4d62-8d8d-9ce4fa8d7a02"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i31770ac6973b4c46a9b96965f34f8ec4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfMzI5ODUzNDkwMTc5Ng_10162c87-3566-4135-bab3-525297bb0e9a"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDc5Mg_fef3f000-9fbe-4c3d-99fd-30c114de175e">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share repurchase activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate cost of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share of shares repurchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfMi0zLTEtMS0yMjMxMTA_c921ab3d-bbc3-4c7c-9c15-61a35f1be602"
      unitRef="shares">11300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfMy0zLTEtMS0yMjMxMTA_b100088e-1fd5-47d6-9ba1-4d2243d14569"
      unitRef="usd">576000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if5b471262ecb43fbac9c1d2d69921fd8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RhYmxlOjMwNDY1NTkyMGIzNzQ2MDRhZDc5OWUzN2ZmNmI5ODc3L3RhYmxlcmFuZ2U6MzA0NjU1OTIwYjM3NDYwNGFkNzk5ZTM3ZmY2Yjk4NzdfNC0zLTEtMS0yMjMxMTA_c3132876-3a8b-49ae-b639-9642c24bd915"
      unitRef="usdPerShare">50.69</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgwMA_585408c0-114d-43bf-b686-f35b056466a9">Our interim condensed consolidated financial statements are unaudited.  Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements.  All such adjustments were of a normal recurring nature.  Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zNy9mcmFnOmMyMTU4NTQxYmIyMTRiZGY5YzZjZmY3ZDU1ZDk2NTIzL3RleHRyZWdpb246YzIxNTg1NDFiYjIxNGJkZjljNmNmZjdkNTVkOTY1MjNfNDgwOA_e2815b13-4ff4-459b-a3dc-e685fbde7970">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2023 we adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU No. 2021-08&#x201d;).  This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.  As of March 31, 2023, our adoption of ASU No. 2021-08 had no impact on our condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on January 1, 2023 we adopted ASU 2022-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liabilities- Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU No. 2022-04&#x201d;).  This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period and potential magnitude.  As of March 31, 2023, our adoption of ASU No. 2022-04 had no material impact on our condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Standards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective Date for Public Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect on Financial Statements &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASU 2022-03&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU1MQ_634582ba-943b-4424-bbf2-a942ae70df40">Revenues from Contracts with Customers&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We disaggregate net revenues based on product type.  For further discussion, see Note 8. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate substantially all cash discounts, offered to customers for prompt payment, as a flat rate per unit based on agreed-upon payment terms and record receivables net of the cash discounts on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record payments received by our businesses in advance of product shipment as deferred revenue.  These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer.  Deferred revenue from contracts with customers was $268 million and $252 million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  When cash is received in advance of product shipment, our companies satisfy their performance obligations within three days of receiving payment.  At March&#160;31, 2023 and December&#160;31, 2022, there were no differences between amounts recorded as deferred revenue from contracts with customers and amounts subsequently recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables (excluding receivable from the sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;System commercialization rights) were $58 million and $48 million at March&#160;31, 2023 and December&#160;31, 2022, respectively.  At March&#160;31, 2023 and December&#160;31, 2022, there were no expected differences between amounts recorded and subsequently received, and we did not record an allowance for credit losses against these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets.  It is USSTC&#x2019;s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC&#x2019;s MST and snus products.  We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues.  Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions.  We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.  All returned goods are destroyed upon return and not included in inventory.  Consequently, we do not record an asset for USSTC&#x2019;s right to recover goods from customers upon return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales incentives include variable payments related to goods sold by our businesses.  We include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers.  The sales incentives that require significant estimates and judgments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Price promotion payments-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We make price promotion payments, substantially all of which are made to our retail partners to incent the promotion of certain product offerings in select geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Wholesale and retail participation payments-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We make payments to our wholesale and retail partners to incent merchandising and sharing of sales data in accordance with our trade agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates.  Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions.  Differences between actual and estimated payments are reflected in the period such information becomes available.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <mo:CashDiscountsPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU1Mg_f32761c1-b4ef-47c8-81fe-b2cdb896b0e9">We calculate substantially all cash discounts, offered to customers for prompt payment, as a flat rate per unit based on agreed-upon payment terms and record receivables net of the cash discounts on our condensed consolidated balance sheets.</mo:CashDiscountsPolicyTextBlock>
    <mo:RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU0Ng_ec9acbd9-5bfd-4d4a-9f6e-17bfc95f6bdd">We record payments received by our businesses in advance of product shipment as deferred revenue.  These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer.</mo:RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfODc1_59b64d09-4fc6-4837-85f8-0df4401c3dfa"
      unitRef="usd">268000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfODgy_db6b50ea-10dc-4d9b-8310-3476dcb3d93a"
      unitRef="usd">252000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTAxNA_ae80e7ee-353d-48d9-8d1b-4f95d619155d">three days</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTE5MA_bf20f8c5-a99c-46e0-b191-d63f5ec55808"
      unitRef="usd">58000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTE5Nw_f0f6de19-ea08-4b53-8484-273cf99578e2"
      unitRef="usd">48000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTM0MQ_6b70f1eb-a8c3-4558-918d-0036e6eed647"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMTM0MQ_9e030e24-10e8-41b9-81b8-033e9f582e00"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF80MC9mcmFnOmI5OGQ1YzA0ZTVkYzQ5ZTliODQ3NDg3YmU5YjM2ZWUyL3RleHRyZWdpb246Yjk4ZDVjMDRlNWRjNDllOWI4NDc0ODdiZTliMzZlZTJfMzU0Nw_9ee65ed5-5dcb-49a6-bd8a-eb35282be361">We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets.  It is USSTC&#x2019;s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC&#x2019;s MST and snus products.  We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues.  Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions.  We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known.  These differences, if any, have not had a material impact on our condensed consolidated financial statements.  All returned goods are destroyed upon return and not included in inventory.  Consequently, we do not record an asset for USSTC&#x2019;s right to recover goods from customers upon return.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:InvestmentTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQyMA_f0c9821f-a631-4318-a414-4f3e34499aee">Investments in Equity Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JUUL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cronos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Income) losses from investments in equity securities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cronos &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments under equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JUUL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GAAP&#x201d;) and (ii) adjustments to our investment required under the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents loss as a result of the disposition of our JUUL equity securities discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents the estimated change in fair value.  Prior to the disposition of our JUUL equity securities on March 3, 2023, we accounted for our investment in JUUL as an investment in an equity security measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in ABI&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we had an approximate 10% ownership interest in ABI, consisting of 185 million restricted shares of ABI (the &#x201c;Restricted Shares&#x201d;) and 12 million ordinary shares of ABI.  The Restricted Shares:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;are unlisted and not admitted to trading on any stock exchange;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;are convertible by us into ordinary shares of ABI on a one-for-one basis;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;rank equally with ordinary shares of ABI with regards to dividends and voting rights; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;have director nomination rights with respect to ABI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of this filing, we have not elected to convert our Restricted Shares into ordinary shares of ABI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our investment in ABI under the equity method of accounting because we have the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI&#x2019;s board of directors and certain ABI board committees.  Through this representation, we participate in ABI&#x2019;s policy making processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our share of ABI&#x2019;s results using a one-quarter lag because ABI&#x2019;s results are not available in time for us to record them in the concurrent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI&#x2019;s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.  We can convert our Restricted Shares to ordinary shares at our discretion.  Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our equity investment in ABI at March&#160;31, 2023 and December&#160;31, 2022 was $13.1 billion and $11.9 billion, respectively, which exceeded its carrying value of $9.2 billion and $9.0 billion by approximately 42% and 33%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in JUUL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2023, we entered into the Stock Transfer Agreement with JUUL pursuant to which, among other things, we  transferred to JUUL all of our beneficially owned JUUL equity securities.  Concurrently with and in connection with the execution of the Stock Transfer Agreement, JUUL entered into an agreement with us that provides us with a non-exclusive, irrevocable global license to certain of the JUUL Heated Tobacco IP.  In addition, all other agreements between us, on the one hand, and JUUL, on the other hand, were terminated or we were removed as parties thereto, other than certain litigation-related agreements and a license agreement relating to our non-trademark licensable intellectual property rights in the e-vapor field, which remain in force solely with respect to our e-vapor intellectual property as of or prior to March 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of transferring to JUUL all of our beneficially owned JUUL equity securities pursuant to the Stock Transfer Agreement, for the three months ended March&#160;31, 2023, we recorded a non-cash, pre-tax loss on the disposition of our JUUL equity securities of $250 million.  Additionally, we considered specific facts and circumstances around the nature of the JUUL Heated Tobacco IP and determined that the fair value of such intellectual property was not material to our consolidated financial statements as of the date of the transaction.  As a result, we did not record an asset associated with this intellectual property on our condensed consolidated balance sheet at March 31, 2023.  The primary drivers of this conclusion were (i) our rights to the JUUL Heated Tobacco IP being non-exclusive, (ii) there being no product or technology transferred to us associated with the JUUL Heated Tobacco IP and (iii) there being no connection between the JUUL Heated Tobacco IP and our current product development plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In April 2020, the FTC issued an administrative complaint challenging our investment in JUUL.  In February 2022, the administrative law judge dismissed the FTC&#x2019;s complaint.  FTC complaint counsel appealed that decision to the FTC, which appeal remains pending.  For further discussion, see Note 11. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Contingencies -&#160;Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balance of our investment in JUUL, which was classified in Level 3 of the fair value hierarchy prior to the disposition of our JUUL equity securities discussed above:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investment Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposition of JUUL equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in (income) losses from investments in equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in Cronos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we had a 41.1% ownership interest in Cronos, consisting of 156.6 million shares, which we account for under the equity method of accounting.  We report our share of Cronos&#x2019;s results using a one-quarter lag because Cronos&#x2019;s results are not available in time for us to record them in the concurrent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos&#x2019;s common shares and was classified in Level 1 of the fair value hierarchy.  At March&#160;31, 2023, the fair value of our equity method investment in Cronos was less than its carrying value by $47 million or approximately 13%.  Based on our evaluation of the duration and magnitude of the fair value decline, our evaluation of Cronos&#x2019;s financial condition (including its strong cash position) and near-term prospects, and our intent and ability to hold our investment in Cronos until recovery, we concluded that the decline in fair value of our equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our investment in Cronos, at March 31, 2023, we also owned anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain our ownership percentage.  Certain of the anti-dilution protections provide us the ability to purchase additional Cronos common shares at a per share exercise price of CAD $16.25 upon the occurrence of specified events (&#x201c;Fixed-price Preemptive Rights&#x201d;).  The Fixed-price Preemptive Rights had no value at March 31, 2023 and December 31, 2022.  Prior to December 2022, we also owned a warrant providing us the ability to purchase an &lt;/span&gt;&lt;/div&gt;additional approximate 10% of common shares of Cronos at a per share exercise price of CAD $19.00, which would have expired on March 8, 2023.  In December 2022, we irrevocably abandoned the Cronos warrant.</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQxOQ_b7b62b27-029c-4250-a1f8-fc711079c442">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JUUL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cronos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Income) losses from investments in equity securities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cronos &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments under equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JUUL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GAAP&#x201d;) and (ii) adjustments to our investment required under the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents loss as a result of the disposition of our JUUL equity securities discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents the estimated change in fair value.  Prior to the disposition of our JUUL equity securities on March 3, 2023, we accounted for our investment in JUUL as an investment in an equity security measured at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMS0yLTEtMS0yMjMxMTA_9e60740a-9c12-4f1c-8a2c-948c993d0d91"
      unitRef="usd">9211000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i407056c006d54b6ab8e43c8dd4f712d7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMS00LTEtMS0yMjMxMTA_98ee8fa4-63a9-49c1-9cd4-6fab18e8e6f0"
      unitRef="usd">8975000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i70acd0d1a18e45398127bc9cce16307f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMi0yLTEtMS0yMjMxMTA_f04a56e3-d87a-41d9-9592-01d14cca5e31"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7f105c2681d04b75b6c055147bbea3bb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMi00LTEtMS0yMjMxMTA_8eeb3907-e194-4909-8751-59fd86f939d1"
      unitRef="usd">250000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights
      contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMy0yLTEtMS0yMjMxMTA_29031785-a779-472b-b4c2-137bd234d14f"
      unitRef="usd">348000000</mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights>
    <mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights
      contextRef="ic29d9e6ebe044e90989cf465823a77f6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfMy00LTEtMS0yMjMxMTA_a6b88c9c-0ef2-432a-bccb-fc203f2f6cb7"
      unitRef="usd">375000000</mo:EquityMethodInvestmentsIncludingFixedPricePreemptiveRights>
    <us-gaap:Investments
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfNC0yLTEtMS0yMjMxMTA_0f936c27-5262-4893-8874-3fa033f2e5a6"
      unitRef="usd">9559000000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjdlOWVkZTYxYzAwZjRkNGJiMjI1NGUzZjIyZDk1NzE1L3RhYmxlcmFuZ2U6N2U5ZWRlNjFjMDBmNGQ0YmIyMjU0ZTNmMjJkOTU3MTVfNC00LTEtMS0yMjMxMTA_78868c6a-b234-43b4-8439-0a5316e6bf8c"
      unitRef="usd">9600000000</us-gaap:Investments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0e30dd02c1c94a5b81ccdba16b4c25b1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMi0xLTEtMS0yMjMxMTA_71adbe3c-f125-47a6-9a18-a954853eb4dc"
      unitRef="usd">205000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2df9ced5c50845578c7a1d3348b2c11b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMi0zLTEtMS0yMjMxMTA_f3a8630b-6612-40bd-9382-9e6e8d6729b1"
      unitRef="usd">200000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMy0xLTEtMS0yMjMxMTA_df4d1f32-7d17-46c9-b67c-dc35206a0f63"
      unitRef="usd">-35000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i37b0728e4a964ae7a16912dba9ce4741_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfMy0zLTEtMS0yMjMxMTA_b1764dbd-4eff-4b80-a4a7-d30dd03caea3"
      unitRef="usd">-66000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNC0xLTEtMS0yMjMxMTA_021d4c76-35e1-4b51-9437-f7379c700c0a"
      unitRef="usd">170000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNC0zLTEtMS0yMjMxMTA_c1b738bf-59e8-47b7-aacb-f410ceea3cc9"
      unitRef="usd">134000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNS0xLTEtMS0yMjMxMTA_b310b352-b5b8-499a-9cb1-d14573db3d07"
      unitRef="usd">-250000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i1cd8e983be5e4bf49bbb82139b8be78f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNS0zLTEtMS0yMjMxMTA_e6c87a77-9c8b-4d20-864a-87025ab41c9a"
      unitRef="usd">-100000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNi0xLTEtMS0yMjMxMTA_05cbd9bd-69d1-494d-91e5-2fc2904499dd"
      unitRef="usd">-80000000</mo:IncomeLossFromEquitySecurities>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RhYmxlOjczMzE4NGViNTkwYTQ2MWY5NGFjNmVhNWU1Y2VjMzM3L3RhYmxlcmFuZ2U6NzMzMTg0ZWI1OTBhNDYxZjk0YWM2ZWE1ZTVjZWMzMzdfNi0zLTEtMS0yMjMxMTA_7263ed30-9c75-4c8f-aa64-88251c580e23"
      unitRef="usd">34000000</mo:IncomeLossFromEquitySecurities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTExMg_6f40a18c-1d04-45fa-85fb-2dc77825a660"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <mo:EquityMethodInvestmentNumberofSharesOwnedRestricted
      contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTE1Ng_596f885e-64ba-4ca0-9d30-f8d85216fff0"
      unitRef="shares">185000000</mo:EquityMethodInvestmentNumberofSharesOwnedRestricted>
    <mo:EquityMethodInvestmentNumberofSharesOwnedCommon
      contextRef="i7af289dd4d5f439f9dc344c7e7529ba9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTIxNA_8be04448-3d45-4e0c-bdf6-221f046bdb88"
      unitRef="shares">12000000</mo:EquityMethodInvestmentNumberofSharesOwnedCommon>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNjQyMg_5ed65d12-4931-47ef-a831-159a1d2812fa">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our investment in ABI under the equity method of accounting because we have the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI&#x2019;s board of directors and certain ABI board committees.  Through this representation, we participate in ABI&#x2019;s policy making processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our share of ABI&#x2019;s results using a one-quarter lag because ABI&#x2019;s results are not available in time for us to record them in the concurrent period.&lt;/span&gt;&lt;/div&gt;The fair value of our equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI&#x2019;s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.  We can convert our Restricted Shares to ordinary shares at our discretion.  Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.The fair value of our equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos&#x2019;s common shares and was classified in Level 1 of the fair value hierarchy.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzIzNA_9b2f947f-dc6d-4d9c-8f1f-63d8e2092ff9"
      unitRef="usd">13100000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfNTE3Mw_a2ad2c96-c304-46bc-9f59-73504e0f3d8f"
      unitRef="usd">11900000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue
      contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzI0OA_8c212faa-89d7-44d5-a5a1-912b2a1daa61"
      unitRef="usd">9200000000</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue
      contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzE4NA_0c2c2a20-0974-4028-bcce-46edd68e9cac"
      unitRef="usd">9000000000</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage
      contextRef="i038f67664cef4a289bd2e7482068a8df_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzI1Nw_a8c0c355-8873-4ef0-b9f3-385525e5121b"
      unitRef="number">0.42</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage
      contextRef="ie73e09d22e2442ec9ef7697fd1e32b1a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF81OC9mcmFnOjZhYzI4MTdiN2QzNzQ4MzQ5ZTNlZTc0M2RjMGUyZGIwL3RleHRyZWdpb246NmFjMjgxN2I3ZDM3NDgzNDllM2VlNzQzZGMwZTJkYjBfMTA5OTUxMTYzNzIxMQ_7f37b1a5-5416-498a-b4c0-281d5c2d9864"
      unitRef="number">0.33</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RleHRyZWdpb246Yzc0OWUyMjJkZjY0NDBlZThmZGI4MTk3N2QzYzY3YTVfMTA5OTUxMTY0OTg3Ng_79cc64e9-1030-471b-b90f-d58723fcf7d7"
      unitRef="usd">-250000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RleHRyZWdpb246Yzc0OWUyMjJkZjY0NDBlZThmZGI4MTk3N2QzYzY3YTVfODIyMA_d9e13641-d69b-4238-aa64-553a2817965e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balance of our investment in JUUL, which was classified in Level 3 of the fair value hierarchy prior to the disposition of our JUUL equity securities discussed above:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investment Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposition of JUUL equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in (income) losses from investments in equity securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id7bf4062eea24ce4a949beb98cf77963_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfMi0yLTEtMS0yMjMxMTA_eefe1349-e118-4e2a-b7c9-5270f6799f37"
      unitRef="usd">1705000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ic849d2926e4e4725b6bfc1d0c4b15363_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfMy0yLTEtMS0yMjMxMTA_56bcf6cf-fc62-4413-9953-1ab0957d8ded"
      unitRef="usd">-1455000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ic18ca113bad9498b8bce774c190943af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNC0yLTEtMS0yMjMxMTA_31345939-e6d8-40cb-ac03-4a91e90caa78"
      unitRef="usd">250000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i917aa76b7c2948a99dfaf25b1ab4249a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNS0yLTEtMS0yMjMxMTA_979699a3-4e0e-4241-9d87-5e927038bdad"
      unitRef="usd">-250000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ic64023a55bc9457f9694dec962ce226d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82MS9mcmFnOmM3NDllMjIyZGY2NDQwZWU4ZmRiODE5NzdkM2M2N2E1L3RhYmxlOmVkMWQ1ODM1ZDMxMzQyYmFhNDc3ZTg4NWY3MDA0NjVjL3RhYmxlcmFuZ2U6ZWQxZDU4MzVkMzEzNDJiYWE0NzdlODg1ZjcwMDQ2NWNfNi0yLTEtMS0yMjMxMTA_db6cde09-64f9-4384-a4c8-cc5ee3abad23"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTY0OTI2NzQ0NjU4OA_726f984f-d854-44e2-856f-efa22f9099c4"
      unitRef="number">0.411</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <mo:EquityMethodInvestmentNumberofSharesOwnedCommon
      contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTY0OTI2NzQ0NjU4Mw_91dd9b0c-2bcc-494e-9e05-b8d14cc22c9e"
      unitRef="shares">156600000</mo:EquityMethodInvestmentNumberofSharesOwnedCommon>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue
      contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NTE1OQ_1b5d6122-2669-4718-a3a5-caf7cf99f7c8"
      unitRef="usd">-47000000</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue>
    <mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage
      contextRef="i0c2317db73d949bf97a1f0ae5666c118_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NTE3NQ_bb16e2f5-b104-4eff-9dd1-36fc2715a6e7"
      unitRef="number">-0.13</mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage>
    <mo:EquityMethodInvestmentImpairment
      contextRef="i5ed6a9c6b83e4672aa9889d6091fab17_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMTA5OTUxMTY0MTg0Nw_ae14d38f-f70d-42fe-a54c-e8a6589c736e"
      unitRef="usd">0</mo:EquityMethodInvestmentImpairment>
    <mo:EquityMethodInvestmentPricePerShareIfExercised
      contextRef="i22be6d10e72a4d068a5e2a59f3619789_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzEwMQ_ad494cf5-ff3d-4e4b-becb-2f41c05123e6"
      unitRef="cadPerShare">16.25</mo:EquityMethodInvestmentPricePerShareIfExercised>
    <mo:EquityMethodInvestmentsFixedPreemptiveRights
      contextRef="i2698ad66ea7145638fbf517179c1ee03_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzM4OA_371bb222-9d0b-4691-8386-0fdbbffb0512"
      unitRef="usd">0</mo:EquityMethodInvestmentsFixedPreemptiveRights>
    <mo:EquityMethodInvestmentsFixedPreemptiveRights
      contextRef="i22be6d10e72a4d068a5e2a59f3619789_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzM4OA_f9c19600-5b8b-4bda-87f5-12e4fd609916"
      unitRef="usd">0</mo:EquityMethodInvestmentsFixedPreemptiveRights>
    <mo:EquityMethodInvestmentPercentageOfSharesEligibleForPurchase
      contextRef="ifc3ad097e6354edca8d47d2a62d0b590_D20190301-20221130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzE3Ng_455dacdb-e9d9-4105-a253-6527a3f76d95"
      unitRef="number">0.10</mo:EquityMethodInvestmentPercentageOfSharesEligibleForPurchase>
    <mo:EquityMethodInvestmentPricePerShareIfExercised
      contextRef="i6dbdafadb4994369a437f0cb91cd5ebd_I20221130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82NC9mcmFnOjdmNTRlY2JiOTgzYTRhZDhhNGFkZDE1MDQ1NGZiYzYwL3RleHRyZWdpb246N2Y1NGVjYmI5ODNhNGFkOGE0YWRkMTUwNDU0ZmJjNjBfMzI5ODUzNDg5NzE2MA_5236a3d9-5a91-429b-88cb-a6bc4b65e453"
      unitRef="cadPerShare">19.00</mo:EquityMethodInvestmentPricePerShareIfExercised>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzA3Mg_fc667cff-8806-451f-978c-77f43dff85f6">Financial Instruments&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk.  We use various types of derivative financial instruments, including forward contracts, options and swaps.  We do not enter into or hold derivative financial instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment in ABI, whose functional currency is the Euro, exposes us to foreign currency exchange risk on the carrying value of our investment.  To manage this risk, we may designate certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, &#x201c;foreign currency contracts&#x201d;), and Euro denominated unsecured long-term notes (&#x201c;foreign currency denominated debt&#x201d;) as net investment hedges of our investment in ABI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, we had no outstanding foreign currency contracts.  When we have foreign currency contracts in effect, counterparties are domestic and international financial institutions.  Under these contracts, we are exposed to potential losses in the event of non-performance by these counterparties.  We manage our credit risk by entering into transactions with counterparties that have investment grade credit ratings, limiting the amount of exposure we have with each counterparty and monitoring the financial condition of each counterparty.  The counterparty agreements contain provisions that require us to maintain an investment grade credit rating.  In the event our credit rating falls below investment grade, counterparties to our foreign currency contracts can require us to post collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate carrying value and fair value of our total long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency denominated debt included in long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimate of the fair value of our total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Investment Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized changes in the carrying value of the foreign currency denominated debt due to changes in the Euro to U.S. dollar exchange rate in accumulated other comprehensive losses related to ABI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized pre-tax (gains) losses of our net investment hedges of $48 million and $(128) million for the three months ended March 31, 2023 and 2022, respectively, in accumulated other comprehensive losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:NumberOfForeignCurrencyDerivativesHeld
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzI5ODUzNDg4ODU0MA_5d059eaf-1374-42bc-a7ff-0d82110d8a62"
      unitRef="contract">0</us-gaap:NumberOfForeignCurrencyDerivativesHeld>
    <us-gaap:NumberOfForeignCurrencyDerivativesHeld
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzI5ODUzNDg4ODU0MA_80d97743-2ac5-44c3-b31d-316e865ff7eb"
      unitRef="contract">0</us-gaap:NumberOfForeignCurrencyDerivativesHeld>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMzA3Mw_472e0fbf-004f-4606-a8af-1df91a928c3f">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate carrying value and fair value of our total long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency denominated debt included in long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMS0xLTEtMS0yMjMxMTA_9ff5c633-a2e2-47f8-b2c9-a0ab840ab9c6"
      unitRef="usd">25387000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMS0zLTEtMS0yMjMxMTA_fb20f9db-4417-4532-8aa6-610ecb98282c"
      unitRef="usd">26680000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtFairValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMi0xLTEtMS0yMjMxMTA_dedab714-c140-4661-a6eb-f016aee07b42"
      unitRef="usd">22565000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfMi0zLTEtMS0yMjMxMTA_1222d984-9070-413e-8166-9785b95966a8"
      unitRef="usd">22928000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebt
      contextRef="i1e386c21ead541d7b2b8e375d8f79708_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNC0xLTEtMS0yMjMxMTA_1b3b1154-371d-47e0-bfba-53683f6b5f96"
      unitRef="usd">3242000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNC0zLTEtMS0yMjMxMTA_06563ec3-8db5-4b16-a3f3-d1408861a6b1"
      unitRef="usd">4540000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1e386c21ead541d7b2b8e375d8f79708_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNS0xLTEtMS0yMjMxMTA_67ba27d9-67a2-4846-8c88-c7a9df059ebf"
      unitRef="usd">2940000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i20a4c4f9e3e84900be1a9a7496505bf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RhYmxlOjMxYmIwZmZkNzc0YzQ3NjRiYWM4MWE4ZmE2YmRkZGU0L3RhYmxlcmFuZ2U6MzFiYjBmZmQ3NzRjNDc2NGJhYzgxYThmYTZiZGRkZTRfNS0zLTEtMS0yMjMxMTA_cf44d4ba-321f-4f35-bc0c-0b9f3b5b1e56"
      unitRef="usd">4165000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7e0ac77709a6467ea112cb5ce9968742_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMTA5OTUxMTYzMTMwNg_db857ca6-1e7e-4b89-b47e-1d7f169455ff"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie8891909d58c4512bd26716fe7321214_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF82Ny9mcmFnOmM3OTRhZjg0ZWFiZTQ5Mzk5ODcyNjM3YTNmYWM0NmIzL3RleHRyZWdpb246Yzc5NGFmODRlYWJlNDkzOTk4NzI2MzdhM2ZhYzQ2YjNfMTA5OTUxMTYzMTMxOQ_a2633af1-7f07-465c-97e7-81854c992834"
      unitRef="usd">128000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTYwMQ_fc12ccb2-3e8e-4cb3-b4f6-c1c2f31248ef">Benefit Plans&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost (Income)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (income) consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employer Contributions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make contributions to our pension plans to the extent that the contributions are tax deductible and pay benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service (&#x201c;IRS&#x201d;) regulations.  We made employer &lt;/span&gt;&lt;/div&gt;contributions of $7 million to our pension plans and did not make any contributions to our postretirement plans during the three months ended March 31, 2023.  Currently, we anticipate making additional employer contributions of up to approximately $25 million to our pension plans and $30 million to our postretirement plans in 2023.  However, the foregoing estimates of 2023 contributions to our pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTU4MQ_01141fe1-f152-4035-a489-ff6e53f2a806">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (income) consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy0xLTEtMS0yMjMxMTA_d0eddc83-aee6-45f9-b56b-9122a7ac4df1"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy0zLTEtMS0yMjMxMTA_db98e004-feae-46bc-8934-3bf6f635627f"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy01LTEtMS0yMjMxMTA_108a5278-277c-4482-bc81-49185d8ccd97"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMy03LTEtMS0yMjMxMTA_f564abbf-deb7-4d91-b2be-fd77dee69057"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC0xLTEtMS0yMjMxMTA_371131e8-2b15-4821-abfb-ff7df753450f"
      unitRef="usd">83000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC0zLTEtMS0yMjMxMTA_257f0c2e-b97d-4169-b31a-0a78c6c30aed"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC01LTEtMS0yMjMxMTA_3db90adf-52a5-47ed-ac81-bd41f2ab8035"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNC03LTEtMS0yMjMxMTA_961f73df-60af-471a-bda7-7a882dcb0e11"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS0xLTEtMS0yMjMxMTA_8f430eb0-3f07-4980-9e9b-b88a6c3a377b"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS0zLTEtMS0yMjMxMTA_08c51dd6-8b97-4999-9b1d-cf08bc78c2c4"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS01LTEtMS0yMjMxMTA_ea3ce58c-2b8e-47f0-84be-514773ca8c9e"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNS03LTEtMS0yMjMxMTA_85c6ebab-693c-45bd-bcb9-95d7a3d9618e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy0xLTEtMS0yMjMxMTA_7fce50dd-ecbb-454a-8542-ec3ca8547202"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy0zLTEtMS0yMjMxMTA_a2cb2faf-ed19-4c3c-88c9-ff3824f2eb85"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy01LTEtMS0yMjMxMTA_18c61043-837c-4e07-bf02-233bf25ee138"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfNy03LTEtMS0yMjMxMTA_0213292a-1f78-4d35-b514-49dd1d5add2f"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC0xLTEtMS0yMjMxMTA_1fea40af-042c-427d-963e-91f47942d6bf"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC0zLTEtMS0yMjMxMTA_fa4895b1-92b0-4f47-8f07-e0be0e952ecf"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC01LTEtMS0yMjMxMTA_4f73b736-d229-4ed3-8d94-760d66fb01ea"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfOC03LTEtMS0yMjMxMTA_5eecce27-f5eb-4c87-a628-eb23ae2e95c1"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtMS0xLTEtMjIzMTEw_12df2fb0-5c3c-43af-a7c6-c86bf543d07f"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i30cca1eca5604a78a1917a6c78b609cf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtMy0xLTEtMjIzMTEw_351061e7-b929-41ed-8c85-f1245419d0b7"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtNS0xLTEtMjIzMTEw_e88f952f-dc38-46ad-ad54-3201d5160eee"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i21e79b69e3f54ac3baaa3ec979d35fc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RhYmxlOmFhZGY3YmM1ZTU0MTQzMzE4ODU3YjAyOWY1NGE1ODAxL3RhYmxlcmFuZ2U6YWFkZjdiYzVlNTQxNDMzMTg4NTdiMDI5ZjU0YTU4MDFfMTAtNy0xLTEtMjIzMTEw_1e1f6a92-21c8-44e0-a58e-fca2391e7c06"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfNDIy_805d4bb6-1d1b-431d-82b0-5907131666ed"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id6f493aa274a41eeb69ec9eda575091c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfNDU0_027b2d2b-e16d-4844-a1c7-aee865da1b05"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="i69bda6f9d3044065b5cb45c86ee040ae_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTgxNDE5NDE4NjA4ODM_4eb18aee-2d3a-499f-9153-ac8bba1b8ec9"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="ieacd8d560cc14bb3888bf0fb293a903f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83My9mcmFnOjExZTUzMDcwZWM1ZDRhY2U4MTZmOThmMjVhYmMzMTdhL3RleHRyZWdpb246MTFlNTMwNzBlYzVkNGFjZTgxNmY5OGYyNWFiYzMxN2FfMTc1OTIxODYwNDcwMDU_b02a8cca-0b49-4add-a868-b8d0ba112ba6"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RleHRyZWdpb246NDIxMzQ2ZWFlMzUyNDE0MmI5YTQ0ZDQ4MjRkOGRiNGRfMTMw_158ffba5-5977-47af-a733-1d660df9f4fa">Earnings per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculated basic and diluted earnings per share (&#x201c;EPS&#x201d;) using the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Distributed and undistributed earnings attributable to share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,786&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RleHRyZWdpb246NDIxMzQ2ZWFlMzUyNDE0MmI5YTQ0ZDQ4MjRkOGRiNGRfMTQ2_814ffd63-64b3-4e65-b60c-586944fb8d6b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculated basic and diluted earnings per share (&#x201c;EPS&#x201d;) using the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Distributed and undistributed earnings attributable to share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,786&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMi0yLTEtMS0yMjMxMTA_f7593c4c-9993-4b52-be28-81939bd3b411"
      unitRef="usd">1787000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMi00LTEtMS0yMjMxMTA_7813e331-5579-47e7-9c1f-5935007540a4"
      unitRef="usd">1959000000</us-gaap:NetIncomeLoss>
    <mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMy0yLTEtMS0yMjMxMTA_ce09b2ab-05d5-4be7-a16e-6d9173425841"
      unitRef="usd">3000000</mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted>
    <mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfMy00LTEtMS0yMjMxMTA_c17de535-1a3f-4420-ac92-b849f1d82423"
      unitRef="usd">4000000</mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC0yLTEtMS0yMjMxMTA_05a033a0-e00e-4ac5-9f8f-f6df4ef5adcd"
      unitRef="usd">1784000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC0yLTEtMS0yMjMxMTA_526304f7-5a8c-4cba-a646-4fc48d71dcde"
      unitRef="usd">1784000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC00LTEtMS0yMjMxMTA_7c77f325-89eb-4d0c-98f6-0967a3ac4fa0"
      unitRef="usd">1955000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfNC00LTEtMS0yMjMxMTA_d2f8a42f-73c4-47c0-a319-bc0a40386217"
      unitRef="usd">1955000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC0yLTEtMS0yMjMxMTA_085072a8-6305-4355-965e-538a488bed7e"
      unitRef="shares">1786000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC0yLTEtMS0yMjMxMTA_0a745a28-2446-42ef-ac6c-cdbce0e74304"
      unitRef="shares">1786000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC00LTEtMS0yMjMxMTA_70c6e756-65d6-4b2c-899a-4f2064059154"
      unitRef="shares">1818000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83Ni9mcmFnOjQyMTM0NmVhZTM1MjQxNDJiOWE0NGQ0ODI0ZDhkYjRkL3RhYmxlOjdkZDUwOGQ1NmMwZTRkNjRhZjEwMDdlMmJmY2NhNWZkL3RhYmxlcmFuZ2U6N2RkNTA4ZDU2YzBlNGQ2NGFmMTAwN2UyYmZjY2E1ZmRfOC00LTEtMS0yMjMxMTA_ffabd24c-c955-4096-b63e-894410ef1074"
      unitRef="shares">1818000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RleHRyZWdpb246NDlkOTFlMjVhMTYwNGY1Mjg2OTk0MjdhOTgwOTZkZmRfMjA1_7cc72382-b9bf-4106-b2f9-01d83333faa5">Other Comprehensive Earnings/Losses&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings, net of deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses), net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings, net of deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses), net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Primarily reflects the impact of our designated net investment hedges related to our equity investment in ABI and our share of ABI&#x2019;s currency translation adjustments.  For further discussion of designated net investment hedges, see Note 4. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit Plans: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost/credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Amounts are included in net defined benefit plan costs.  For further details, see Note 5. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Benefit Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Amounts are included in (income) losses from investments in equity securities.  For further information, see Note 3. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RleHRyZWdpb246NDlkOTFlMjVhMTYwNGY1Mjg2OTk0MjdhOTgwOTZkZmRfMjA2_d3d05185-f853-4705-a974-e41139e02d49">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings, net of deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses), net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to net earnings, net of deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive earnings (losses), net of deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Primarily reflects the impact of our designated net investment hedges related to our equity investment in ABI and our share of ABI&#x2019;s currency translation adjustments.  For further discussion of designated net investment hedges, see Note 4. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd124c60d03f419f9b32a50e8d8ad088_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi0yLTEtMS0yMjMxMTA_369a0e1d-ba84-4237-a6b5-b8e841105ba0"
      unitRef="usd">-1436000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48147e6321604e39a0674a5c9700d5cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi00LTEtMS0yMjMxMTA_bda3e4c9-d994-4b4c-8c9d-9083b83e19ec"
      unitRef="usd">-1369000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8248ed5a8a794be4ae798af164015026_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi02LTEtMS0yMjMxMTA_a5c18f4c-a889-4026-80ec-933ce4122861"
      unitRef="usd">34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2469a4bba094953adfa2888c0f55b57_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMi04LTEtMS0yMjMxMTA_6392b0a9-ef8b-4987-b5dd-74123366bb5a"
      unitRef="usd">-2771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC0yLTEtMS0yMjMxMTA_6e248459-ccd5-465f-b96c-2ee16890ed04"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC00LTEtMS0yMjMxMTA_182c7974-20af-4fa3-95d1-6f696717a2dd"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC02LTEtMS0yMjMxMTA_f4f08e25-296e-4fc7-8f90-8cc9ee23baa8"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNC04LTEtMS0yMjMxMTA_dd753857-3690-4e74-a36a-10eb878bc7d4"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS0yLTEtMS0yMjMxMTA_1b9c815b-5930-4e51-baf5-c15751bfbc63"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS00LTEtMS0yMjMxMTA_3e900a5e-e862-4b6f-8519-b67a9875a5be"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS02LTEtMS0yMjMxMTA_177d946b-6000-456f-98c0-da0cda7d5594"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNS04LTEtMS0yMjMxMTA_3abb20b1-79d7-4cdb-8dca-f308f5e76166"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi0yLTEtMS0yMjMxMTA_cb1222ad-79ed-4d40-b723-507a8c86ef14"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi00LTEtMS0yMjMxMTA_cc9e48cc-67ed-40c5-a1f2-3e15ad81e604"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi02LTEtMS0yMjMxMTA_d5ec0cea-38f8-4ffe-a2b1-54a3581f5f13"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfNi04LTEtMS0yMjMxMTA_2f1633b7-177e-4189-b8a1-7ae771cd535a"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC0yLTEtMS0yMjMxMTA_b82c73cf-3ce1-41bb-99e1-2e4cf045ff65"
      unitRef="usd">8000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC00LTEtMS0yMjMxMTA_c7a13494-b3f1-40c0-a475-5166bec1a6ef"
      unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC02LTEtMS0yMjMxMTA_d9faebcb-3be5-4eb8-8a1a-c7ea51122eb7"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOC04LTEtMS0yMjMxMTA_3fe7b817-b798-4b56-a938-6417c5f79cf3"
      unitRef="usd">7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS0yLTEtMS0yMjMxMTA_2d8ece35-5273-4b86-a926-cbfc8e6a6b78"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS00LTEtMS0yMjMxMTA_90da4c42-b43e-401e-aeca-668ae6bb759c"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS02LTEtMS0yMjMxMTA_6002f44c-c928-406c-b889-82c1466cfcd3"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfOS04LTEtMS0yMjMxMTA_49cd67cf-0833-4a92-b539-1744e7fae83d"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtMi0xLTEtMjIzMTEw_8f038df9-11a2-424b-9979-df01a7172271"
      unitRef="usd">6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtNC0xLTEtMjIzMTEw_aecb269a-dabb-4c54-86c8-f78da89aa338"
      unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtNi0xLTEtMjIzMTEw_99996ed4-3d54-4f23-98a1-b7f19afd9118"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTAtOC0xLTEtMjIzMTEw_fc0ca9b0-b27d-4fed-a85e-3021460b0185"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f0dc52013fd4cdc82cf54d92a54b4ab_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItMi0xLTEtMjIzMTEw_9b3b7548-1076-4348-92ad-747e2fcf84ec"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ef5704929414b2aab5276dd320985a3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItNC0xLTEtMjIzMTEw_7c3664a4-b40c-4190-86d2-9964cf8bb83b"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i94ded89cd68d45d6aa8d3d943cf97dbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItNi0xLTEtMjIzMTEw_41065d40-367a-4cd9-86ba-d584eb995c76"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic36b7ae040844d2f804d1455c8538850_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTItOC0xLTEtMjIzMTEw_accb25b5-62cc-4b7e-ac72-3a27f513fa48"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae16a7ba3e464592bc4e2b2d8cc85d62_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtMi0xLTEtMjIzMTEw_cdad37fd-ec3b-4f29-9187-b404161d1221"
      unitRef="usd">-1442000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i956ac6a83c434b91ad8b518160de9170_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtNC0xLTEtMjIzMTEw_4762aecf-a3ae-4355-9010-b6d44e65ae68"
      unitRef="usd">-1381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd1c9ebd07c34c43a75cc8eb11135003_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtNi0xLTEtMjIzMTEw_e257a60e-1b8b-49df-b697-d3bd8d7276dc"
      unitRef="usd">44000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd940594473144c68357ea9c5539af8e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF83OS9mcmFnOjQ5ZDkxZTI1YTE2MDRmNTI4Njk5NDI3YTk4MDk2ZGZkL3RhYmxlOmZhOGE0YWJiYzBkNTQ0MWNhYTJlMGU2MjIwYTRiMGM1L3RhYmxlcmFuZ2U6ZmE4YTRhYmJjMGQ1NDQxY2FhMmUwZTYyMjBhNGIwYzVfMTQtOC0xLTEtMjIzMTEw_21e52cb2-0e4d-42ed-8d45-d9da13a85493"
      unitRef="usd">-2779000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53e66b45d2fd44569d4910cd6febb6c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi0yLTEtMS0yMjMxMTA_017e991a-9ec8-485d-8501-8af28faa29ab"
      unitRef="usd">-1612000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3671b5f23c94bf792e7730b318b4f31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi00LTEtMS0yMjMxMTA_d6ccb8a7-35e5-4f98-8189-e8bdf4984186"
      unitRef="usd">-1512000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bbd214e79b74f2da6764b8726a150ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi02LTEtMS0yMjMxMTA_bbc3c192-a86e-41af-8625-e01cf8ae0d21"
      unitRef="usd">68000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3e09c734e014d5ea132f83014347e58_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMi04LTEtMS0yMjMxMTA_79e1dace-c8fd-45b9-bf95-f78779e856aa"
      unitRef="usd">-3056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC0yLTEtMS0yMjMxMTA_3524274c-619f-4ea5-8a22-f3d98e243ee4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC00LTEtMS0yMjMxMTA_6521fa05-f69c-4b53-8fc1-394267f1a178"
      unitRef="usd">138000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC02LTEtMS0yMjMxMTA_c6c38da7-d7c1-4854-a475-dd507f49c557"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNC04LTEtMS0yMjMxMTA_85b7bd85-a02d-406d-a5af-577ec56c29e0"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS0yLTEtMS0yMjMxMTA_fec886c1-8843-44a1-aa49-eec0dc19fe19"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS00LTEtMS0yMjMxMTA_e8e64cca-bfb4-48df-8de6-726c6730681f"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS02LTEtMS0yMjMxMTA_b03c72c2-2a57-4fa6-aba9-0e87dfe2576b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNS04LTEtMS0yMjMxMTA_d9f1872c-d3c9-4caa-a641-98e179fbc265"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi0yLTEtMS0yMjMxMTA_bfa930a9-d45b-4f37-8693-c58c24b998e3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi00LTEtMS0yMjMxMTA_9e76b840-d76e-47b8-87bd-b9907d4d4972"
      unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi02LTEtMS0yMjMxMTA_c43647d8-1baf-4ce1-a1d4-8fd12fb95ea0"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfNi04LTEtMS0yMjMxMTA_ca2dd765-e937-4670-850f-6144d00de34e"
      unitRef="usd">107000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC0yLTEtMS0yMjMxMTA_24ae50f2-3299-40f7-8fc5-45b7e02cc185"
      unitRef="usd">-21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC00LTEtMS0yMjMxMTA_81e7087d-1505-4a45-ad0f-8263ef60bec0"
      unitRef="usd">35000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC02LTEtMS0yMjMxMTA_e065e7eb-72f1-4378-a863-6685c6a36eef"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOC04LTEtMS0yMjMxMTA_5f20096e-27ba-42f6-b4f4-6f6cd8a072a0"
      unitRef="usd">14000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS0yLTEtMS0yMjMxMTA_7bff852f-41c7-4d78-88bf-2f010cd2b61f"
      unitRef="usd">-6000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS00LTEtMS0yMjMxMTA_b6a21d68-d4fa-4a7a-911c-cd0668e05669"
      unitRef="usd">7000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS02LTEtMS0yMjMxMTA_23e921bc-ad63-4a07-bca7-5b250e9417eb"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfOS04LTEtMS0yMjMxMTA_9b04ffdf-b3c9-4104-8b26-ab186f4b5d38"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtMi0xLTEtMjIzMTEw_326beca9-748f-47eb-80cc-c471020832ef"
      unitRef="usd">-15000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtNC0xLTEtMjIzMTEw_b1ab3cae-8794-44f5-839f-5525ed671a5e"
      unitRef="usd">28000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtNi0xLTEtMjIzMTEw_dcc5cb7d-1416-465d-b2b6-f27d46323e02"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTAtOC0xLTEtMjIzMTEw_9c849461-b406-4472-95ba-6de1ca3ea401"
      unitRef="usd">13000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8663a8f0327b4f9f991b38e7c913c8e7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItMi0xLTEtMjIzMTEw_0c080c93-1461-4205-ad0b-4007d819d1e3"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic39c5d68d9a34a65b86bf58bd1e5319f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItNC0xLTEtMjIzMTEw_6b4b422c-a50c-4ee7-8dd8-8618f42182be"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe9f4486d8a3496e87d235213332f80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItNi0xLTEtMjIzMTEw_52c11498-9a46-497e-a22f-fcac1c5a323d"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iede722b699a244e0918c6683fa366e9a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTItOC0xLTEtMjIzMTEw_0b1d0aa8-b184-4c92-80e9-f08573cc312c"
      unitRef="usd">94000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i948ca0a2116f4d7a820721a03a172caa_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtMi0xLTEtMjIzMTEw_c45d92a7-8ff7-46d3-87e9-c53fb41808dc"
      unitRef="usd">-1597000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf2fc3fc500643caa6b4bcbcd6531d2a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtNC0xLTEtMjIzMTEw_30f9ae1a-1645-44af-830a-ef7e0255a9cc"
      unitRef="usd">-1434000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15be35835b9b4c7ab7cc385c16e9f766_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtNi0xLTEtMjIzMTEw_91412a4d-c211-41cf-bc96-fa35a7e42c93"
      unitRef="usd">69000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30231579ecf84ee69b1bd182cb6ef1ed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF84NS9mcmFnOjVjMWE5MmRiNzVjMDRlZDFhY2ExZWY5Y2NlYWVjZmNlL3RhYmxlOjEwM2RjNWU1YzA4YzQxNGRhYzIyYjk4NjU1NmYwZmY2L3RhYmxlcmFuZ2U6MTAzZGM1ZTVjMDhjNDE0ZGFjMjJiOTg2NTU2ZjBmZjZfMTQtOC0xLTEtMjIzMTEw_4cae8683-3c6b-4707-9909-f8839c4e5dbd"
      unitRef="usd">-2962000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RleHRyZWdpb246MTljZjg0NTA4YjdjNDM2ZDlmOTJhM2IzNmJlNTYyZjlfNDE3_08e2cb08-ca38-4687-8671-73c6bb1ff74f">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit Plans: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost/credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ABI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Amounts are included in net defined benefit plan costs.  For further details, see Note 5. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Benefit Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Amounts are included in (income) losses from investments in equity securities.  For further information, see Note 3. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i8a21466ce342442f9033dda351c1c76f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfMy0yLTEtMS0yMjMxMTA_0f2ebeb4-ccc2-48bb-b650-fe93d36b0472"
      unitRef="usd">1000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="idd2a3ee32c4c425687e4ad4ff4d1ef09_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfMy00LTEtMS0yMjMxMTA_f1f61c41-1f94-4683-97e7-d25ede8c1e93"
      unitRef="usd">31000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i9842a26a80164a39b9d29efbd4d26e1f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNC0yLTEtMS0yMjMxMTA_eb48e901-8735-4f7a-a65c-a8fd2d31c7de"
      unitRef="usd">-9000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i66ee296114304714be05372fa2564b28_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNC00LTEtMS0yMjMxMTA_d98907f2-eb96-4cbc-b568-7f7681e778dd"
      unitRef="usd">-10000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i760729c61bca480fbf703974d16ebff6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNS0yLTEtMS0yMjMxMTA_761cc41e-6d5e-41fc-85d8-f20f0e80b731"
      unitRef="usd">-8000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="iff527c2964e844a7aaf7101d9ebd98da_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNS00LTEtMS0yMjMxMTA_5d81db34-6d44-4361-a025-9f3de0766014"
      unitRef="usd">21000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31bca93a749545458ae8cdbafd27b08d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNi0yLTEtMS0yMjMxMTA_680fef79-9e70-4624-9b69-b8a00fe75b95"
      unitRef="usd">-1000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7894c01a5bf841ccac16dae6a03a17b2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfNi00LTEtMS0yMjMxMTA_f17eb1aa-acdc-4013-9a6c-7b5256a76b9f"
      unitRef="usd">35000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="ieae3d8b4d3ae4b3b8ab5e8ac275cd4b3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfOC0yLTEtMS0yMjMxMTA_bdd4d80a-6bcf-4a8a-84d8-90272c9242c5"
      unitRef="usd">7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i06b93671e6ac4c71b0ea9f09be8c806e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85MS9mcmFnOjE5Y2Y4NDUwOGI3YzQzNmQ5ZjkyYTNiMzZiZTU2MmY5L3RhYmxlOmRlNDIxZjczYmIwZTQwYmY5ZTYxM2RhMGE0YzY4Y2ExL3RhYmxlcmFuZ2U6ZGU0MjFmNzNiYjBlNDBiZjllNjEzZGEwYTRjNjhjYTFfOC00LTEtMS0yMjMxMTA_beb1052f-6936-42f6-a36c-91e22a31d209"
      unitRef="usd">14000000</us-gaap:ProfitLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0NQ_5c410682-dd1f-4c5a-b67b-9048d777d422">Segment Reporting&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating companies&#x2019; products include (i) smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; and (ii) oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix.  These products constituted our reportable segments of smokeable products and oral tobacco products at March&#160;31, 2023.  Our former financial services business, which completed the wind-down of its portfolio of finance assets in 2022, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; System heated tobacco business and Helix ROW were included in all other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our chief operating decision maker (&#x201c;CODM&#x201d;) reviews operating companies income (loss) (&#x201c;OCI&#x201d;) to evaluate the performance of, and allocate resources to, our segments.  OCI for our segments is defined as operating income before general corporate expenses and amortization of intangibles.  Interest and other debt expense, net, along with net periodic benefit income, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by our CODM.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment data were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oral tobacco products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;628&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oral tobacco products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;416&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other debt expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income, excluding service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on Cronos-related financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The comparability of OCI for our reportable segments was affected by the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"&gt;Non-Participating Manufacturer (&#x201c;NPM&#x201d;) Adjustment Items:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recorded pre-tax income for NPM adjustment items of $60 million for the three months ended March&#160;31, 2022 in our smokeable products segment.  We recorded these items as reductions to cost of sales in our condensed consolidated statement of earnings, which resulted in increased OCI in our smokeable products segment.  NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the Master Settlement Agreement (such dispute resolutions are referred to as &#x201c;NPM Adjustment Items&#x201d; and are more fully described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Cost Recovery Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Note 11. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt"&gt;Tobacco and Health and Certain Other Litigation Items:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other debt expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded the amounts shown in the table above for the smokeable products segment and general corporate expenses in marketing, administration and research costs in our condensed consolidated statements of earnings.  For further discussion, see Note 11. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzYxOQ_974ba0d5-3897-4451-9000-0d7596eab5f7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment data were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oral tobacco products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;628&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oral tobacco products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;416&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other debt expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income, excluding service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Income) losses from investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on Cronos-related financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMy0yLTEtMS0yMjMxMTA_12c7ab05-801c-4150-b4c4-831e9a274934"
      unitRef="usd">5090000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMy00LTEtMS0yMjMxMTA_d782c92f-f371-4e0b-a86b-9861cd4c5a4d"
      unitRef="usd">5265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNC0yLTEtMS0yMjMxMTA_5a295223-42d5-46bc-a929-2de33bdeebb5"
      unitRef="usd">628000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNC00LTEtMS0yMjMxMTA_718b9411-3aaf-45eb-9032-a3d99bb03312"
      unitRef="usd">613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNi0yLTEtMS0yMjMxMTA_4e9fd4e2-f76f-4c04-bfa2-d67323b272ba"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNi00LTEtMS0yMjMxMTA_53a14ef6-6b24-44ac-a2f2-be8dae396c37"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNy0yLTEtMS0yMjMxMTA_24e3fbf8-0e64-4a83-b8ed-416f810ae5ae"
      unitRef="usd">5719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfNy00LTEtMS0yMjMxMTA_0da5a1c2-86f8-44cb-9d70-2f7efdf9b177"
      unitRef="usd">5892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="ifecb17165c8841e284e60dd6e395e4ed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTAtMi0xLTEtMjIzMTEw_e85042c1-e435-48ac-8b74-7cdfd8cfdec2"
      unitRef="usd">2503000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="i009c9ec45f7c4b58aa710ce735a03140_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTAtNC0xLTEtMjIzMTEw_1001b680-dd20-4669-bb23-5e4c2be9baa5"
      unitRef="usd">2559000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="ib320b88326114d728e3d8b69afe84c7f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTEtMi0xLTEtMjIzMTEw_bf233e04-c5ee-4bcd-a4a3-3a6cefd89a78"
      unitRef="usd">416000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="i55c14255ae2a4c5981952b850c4e8453_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTEtNC0xLTEtMjIzMTEw_2ed1d223-eab7-4210-a3b5-1aa9f732672b"
      unitRef="usd">407000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="ie2950512e8be47fe9a8ae852bb0efe28_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTMtMi0xLTEtMjIzMTEw_32d54983-fe41-427c-8b75-ea13ac4404c4"
      unitRef="usd">-9000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles
      contextRef="i706f7125785a4434a70d5f5a80cac8d6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTMtNC0xLTEtMjIzMTEw_79b9934c-6bd6-4149-b85a-3cde8018eb3d"
      unitRef="usd">-5000000</mo:OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTQtMi0xLTEtMjIzMTEw_eeb46a56-4954-4735-9fe4-13aeb4b268fc"
      unitRef="usd">18000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTQtNC0xLTEtMjIzMTEw_c71160f2-5a67-45bc-8ef7-391895af39fd"
      unitRef="usd">17000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTUtMi0xLTEtMjIzMTEw_7601a227-193b-43e0-bb92-499ce5e559a8"
      unitRef="usd">135000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTUtNC0xLTEtMjIzMTEw_2cf70fec-7d76-4d23-8651-6a544bde1559"
      unitRef="usd">60000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTctMi0xLTEtMjIzMTEw_a0f9478f-a86f-45d0-9adc-e025e851e6be"
      unitRef="usd">2757000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTctNC0xLTEtMjIzMTEw_c8141991-a8d7-4aff-ac3d-0ec420cd4561"
      unitRef="usd">2884000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTgtMi0xLTEtMjIzMTEw_e7beda3a-e4f9-4c6a-8c31-675eaeb4d7f8"
      unitRef="usd">-229000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMTgtNC0xLTEtMjIzMTEw_9021d319-db36-4050-9f60-546ccba6a9d6"
      unitRef="usd">-281000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjAtMi0xLTEtMjIzMTEw_528542cc-7085-4bec-a234-f409b5d0768c"
      unitRef="usd">-31000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjAtNC0xLTEtMjIzMTEw_485bcc40-d49e-436b-bc20-ecdaef74df96"
      unitRef="usd">-46000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjEtMi0xLTEtMjIzMTEw_54e205f4-ad7e-4197-bf0f-650bc65c19be"
      unitRef="usd">-80000000</mo:IncomeLossFromEquitySecurities>
    <mo:IncomeLossFromEquitySecurities
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjEtNC0xLTEtMjIzMTEw_11035a88-c72a-4f41-9f0d-c61172369c39"
      unitRef="usd">34000000</mo:IncomeLossFromEquitySecurities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjMtMi0xLTEtMjIzMTEw_ca7ded51-bbd1-4801-b761-eb128340219c"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjMtNC0xLTEtMjIzMTEw_9be264f3-a49b-44ad-a080-f5e98026c7b8"
      unitRef="usd">-10000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjQtMi0xLTEtMjIzMTEw_ccdd2a3d-6b0a-496b-8717-67c592e39b64"
      unitRef="usd">2479000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjhlM2UzZDlkNzliNTRlYTY5MTZlMDlmYzAwYTY0NmE4L3RhYmxlcmFuZ2U6OGUzZTNkOWQ3OWI1NGVhNjkxNmUwOWZjMDBhNjQ2YThfMjQtNC0xLTEtMjIzMTEw_4edb1398-5bef-447a-8017-2eaa326bf746"
      unitRef="usd">2673000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <mo:ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0Mw_b8f02571-ecce-44b3-8707-372253f907b2">Non-Participating Manufacturer (&#x201c;NPM&#x201d;) Adjustment Items:</mo:ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMjE5OTAyMzI2MTg4Nw_1d14da01-661d-4b01-802f-cd6a9eb99b94"
      unitRef="usd">60000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <mo:ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RleHRyZWdpb246NDRiYjM0Y2Q1MTA5NGU3YWI2MDBmYjZlYTVmMjhkZTRfMzY0Nw_8de8a551-f758-42b0-a2d8-466af213f8a6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Smokeable products segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other debt expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</mo:ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="ibc4eb1d656b243898b89b6f3008cb4bf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMi0yLTEtMS0yMjMxMTA_c275848b-ee8f-44a4-9de5-ee0ea79d31b6"
      unitRef="usd">12000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="idde877d815ab4397aee17c08472bdddf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMi00LTEtMS0yMjMxMTA_689fb64c-354e-43e6-90fa-ae7636651a90"
      unitRef="usd">12000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i84ee8c9fc92344e99ab8d14573f9be5a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMy0yLTEtMS0yMjMxMTA_c45fa436-efe5-4695-9930-57e54353ab7b"
      unitRef="usd">98000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i598239b5dde34e519bcd01cb3409992e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfMy00LTEtMS0yMjMxMTA_d7080345-6a99-4936-9a78-70b7be7bcc4e"
      unitRef="usd">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i2e1290e16c10451aa1fcb7cc789b60b2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNC0yLTEtMS0yMjMxMTA_1919af48-5242-439c-8d60-8aaa10d176a7"
      unitRef="usd">1000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i70aedc832b244d9e934f496edc7227c5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNC00LTEtMS0yMjMxMTA_f0170ec3-d601-4412-ae49-1bc60813cbc9"
      unitRef="usd">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i008bb3a34d6f4ad1a419dfbe662171e3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNS0yLTEtMS0yMjMxMTA_420005d5-d2f0-4bec-8e3b-6f318262ab66"
      unitRef="usd">111000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="if3e38d13df914cd0b952143a1636ff77_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85NC9mcmFnOjQ0YmIzNGNkNTEwOTRlN2FiNjAwZmI2ZWE1ZjI4ZGU0L3RhYmxlOjJlZTE3Zjc0ZjZiZjRiYWI4NmY4YjhlOTdjYjVlZTVmL3RhYmxlcmFuZ2U6MmVlMTdmNzRmNmJmNGJhYjg2ZjhiOGU5N2NiNWVlNWZfNS00LTEtMS0yMjMxMTA_436093d3-1aaf-4939-bbf2-92bc6fcdbbdf"
      unitRef="usd">12000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzg3NA_6e782839-095c-4dce-92ee-b71dea2087b8">Debt&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Borrowings and Borrowing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, we had no short-term borrowings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the &#x201c;Credit Agreement&#x201d;), which is used for general corporate purposes and expires on August 1, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we had availability under the Credit Agreement for borrowings of up to an aggregate principal amount of $3.0 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of our long-term senior unsecured debt.  We expect interest rates on borrowings under the Credit Agreement to be based on the Term Secured Overnight Financing Rate plus a percentage based on the higher of the ratings of our long-term senior unsecured debt from Moody&#x2019;s Investors Service, Inc. and Standard&#160;&amp;amp; Poor&#x2019;s Financial Services LLC.  The applicable percentage for borrowings under the Credit Agreement at March&#160;31, 2023 was 1.0% based on our long-term senior unsecured debt ratings on that date.  The Credit Agreement does not include any other rating triggers or any provisions that could require the posting of collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement includes various covenants, one of which requires us to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis.  At March&#160;31, 2023, the ratio of Consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 10.9 to 1.0.  At March&#160;31, 2023, we were in compliance with our covenants in the Credit Agreement.  The terms &#x201c;Consolidated EBITDA&#x201d; and &#x201c;Consolidated Interest Expense,&#x201d; each as defined in the Credit Agreement, include certain adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any commercial paper issued by us and borrowings under the Credit Agreement are guaranteed by PM&#160;USA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate carrying value of our total long-term debt at March&#160;31, 2023 and December&#160;31, 2022 was $25.4 billion and $26.7 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we repaid in full our 1.000% senior unsecured Euro notes in the aggregate principal amount of $1.3 billion (&#x20ac;1.25 billion) at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, accrued interest on long-term debt of $233 million and $411 million, respectively, was included in other accrued liabilities on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a discussion of the fair value of our long-term debt and the designation of our Euro denominated senior unsecured notes as a net investment hedge of our investment in ABI, see Note 4. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODQ_26fe4c94-e9f5-4c85-82bf-02699023f907"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODQ_29f17902-49d9-4719-86a3-1891535a68ac"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzOTM5OQ_8546832a-d5f7-4f64-91c6-55fd325c2594"
      unitRef="usd">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfNjA0NzMxMzk2NDkwOA_0bfaa999-52cd-4ad9-bbe7-1c4843639923">P5Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="ia15af32ff38f4d6d8a39d7de79017b26_I20230331"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfODc1_1d0313c3-fd96-477b-9c00-07490809f171"
      unitRef="usd">3000000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i16749ccbd508483a9f1550c451780fe1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTQwMQ_fdba78f0-b77d-4b47-a832-54b6654dba86"
      unitRef="number">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mo:DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum
      contextRef="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTgzNA_707b3da5-30c8-4135-b7b7-efa78dfc837a"
      unitRef="number">4.0</mo:DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum>
    <mo:DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio
      contextRef="i61714a9ffb0644aebd57f0310d0826e9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjA2MQ_168e2870-fffd-4203-a398-94d02def2900"
      unitRef="number">10.9</mo:DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio>
    <us-gaap:LongTermDebt
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjQ3Nw_e8a579ab-a1d2-4a5f-831d-54847b0e4c2e"
      unitRef="usd">25400000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMjQ4NA_e9ae90fd-490b-4496-8c17-ed594b040cfd"
      unitRef="usd">26700000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1ca4b2ce75d43c8a23f0e7a04890b95_I20230228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTY0MDc2NA_74822d82-d21d-4736-961c-36600998cf8f"
      unitRef="number">0.01000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzMzU4MA_2faf637e-495b-4117-a1d1-3832981d9f56"
      unitRef="usd">1300000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i6a9874669ac8459496b03db680c7fa08_D20230201-20230228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMTA5OTUxMTYzMzczMA_7f713499-839a-4e8d-89fa-649114bb4b2d"
      unitRef="eur">1250000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzU1Mw_e1b0bea7-67c6-48cf-ac5b-c7e1773f790e"
      unitRef="usd">233000000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF85Ny9mcmFnOjU1MzE0YmY3ZjBmYTQyNWNiMzQ4ZjZiMTQ0ZDFkMGIwL3RleHRyZWdpb246NTUzMTRiZjdmMGZhNDI1Y2IzNDhmNmIxNDRkMWQwYjBfMzU2MA_947598e4-1aef-44fc-bf81-9ce743a90dcf"
      unitRef="usd">411000000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3MzY_d6c92825-33dd-4126-aa71-3ff928c9901b">Income Taxes&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the U.S. Government enacted legislation commonly referred to as the Inflation Reduction Act that became effective January 1, 2023.  The main provisions of the Inflation Reduction Act that impact us are: (i) a 15% corporate alternative minimum tax (&#x201c;Corporate AMT&#x201d;) and (ii) a 1% excise tax on share repurchases, which we will record in equity on our consolidated statements of stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are considered an &#x201c;applicable corporation&#x201d; for purposes of Corporate AMT.  We expect our regular federal income tax liability will generally exceed our Corporate AMT liability; however, certain unique circumstances may result in our Corporate AMT liability exceeding our regular federal income tax liability, including when tax losses are reported in a different year than book losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,479&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax rate for the three months ended March 31, 2023 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to the disposition of our former investment in JUUL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax rate for the three months ended March 31, 2022 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to a decrease in the estimated fair value of our investment in JUUL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxation in many jurisdictions.  Unrecognized tax benefits reflect the differences between tax positions we have taken or expect to take on income tax returns and the amounts recognized in the financial statements.  Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within our control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ending December&#160;31, 2023, we expect to recognize an approximate $6.5 billion ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL.  For financial statement purposes, we expect to fully reserve for the tax benefit associated with this ordinary loss by recording an unrecognized tax benefit of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $1.6 billion in 2023 on a pro-rata basis, pending the IRS&#x2019;s review of our tax position.  For the three months ended March 31, 2023, we recognized a pro-rata portion of this ordinary loss, which resulted in a tax benefit of $380 million and a reduction to our current income taxes payable.  We also recognized a $391 million increase in a long-term liability for unrecognized tax benefits related to this tax position, partially offset by an $11 million deferred federal benefit for state taxes.  There was no impact to our condensed consolidated statement of earnings for the three months ended March 31, 2023.  For further discussion of our former investment in JUUL, see Note 3. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, our total unrecognized tax benefits were $460 million.  The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at March&#160;31, 2023, was $44 million, along with $416 million affecting deferred taxes.  The amount of unrecognized tax benefit that, if recognized, would impact the effective tax rate at December 31, 2022, was $44 million, along with $25 million affecting deferred taxes.  Unrecognized tax benefits increased by $391 million from December&#160;31, 2022 due to the tax position established with respect to the character of losses from our former investment in JUUL as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the recognition of the approximate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.5 billion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ordinary loss for cash tax purposes discussed above, we expect to be subject to Corporate AMT in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions to valuation allowance charged to income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Releases to valuation allowance credited to income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.  We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized.  We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence.  In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023, we reduced the deferred tax asset and corresponding valuation allowance for the portion of our JUUL capital losses that is now part of our tax basis in the shares of a foreign subsidiary.  This outside basis difference of the foreign subsidiary is not recognized as a deferred tax asset since we do not expect the temporary difference to reverse in the foreseeable future.  The cumulative valuation allowance at March&#160;31, 2023 was primarily attributable to deferred tax assets recorded in connection with the portion of our JUUL capital losses that is now included in our tax basis in the shares of a domestic subsidiary and our investment in Cronos.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <mo:SummaryOfIncomeTaxesTableTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3Mzg_c090cef0-37e3-4f65-a033-1932224c38ff">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,479&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mo:SummaryOfIncomeTaxesTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzItMi0xLTEtMjIzMTEw_a85e861e-c931-4628-95af-7389705af53d"
      unitRef="usd">2479000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzItNC0xLTEtMjIzMTEw_3779eee1-4e10-4685-9ee2-ebe54a69b410"
      unitRef="usd">2673000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzMtMi0xLTEtMjIzMTEw_d61bdd21-06ab-450b-a79f-44866aa672e9"
      unitRef="usd">692000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzMtNC0xLTEtMjIzMTEw_8009c63d-6a63-421f-9ddf-585b9f6c9c9b"
      unitRef="usd">714000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzQtMi0xLTEtMjIzMTEw_a68fb7d0-9e37-4001-a694-ec15835313bd"
      unitRef="number">0.279</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZToxNWU2MDM4MjUxMzQ0MDBlYjFkZWNiNzQ0ZGYyNTk2MS90YWJsZXJhbmdlOjE1ZTYwMzgyNTEzNDQwMGViMWRlY2I3NDRkZjI1OTYxXzQtNC0xLTEtMjIzMTEw_ae9b90f6-5f1c-489d-aaa6-b27083cd3398"
      unitRef="number">0.267</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments
      contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDUxMDU_dd61a6cf-e74d-498d-a29b-81a8e82f5c12"
      unitRef="usd">-6500000000</mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU2MDMwMzQ_caa78592-7992-4dac-a2a4-864b8b07e6fc"
      unitRef="usd">1600000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU1OTk1Mzg_ef7b5090-8f10-4e62-889a-1d836de80367"
      unitRef="usd">-380000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDM2Mzg_6515e0ab-a7cc-436b-9c6f-a983f92184ca"
      unitRef="usd">391000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzMyOTg1MzQ5MDUwNDM_a7c31dac-6454-4248-800e-08f5110a92ee"
      unitRef="usd">-11000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5OTM_f304ad9f-201c-4919-ae81-d563406a94cb"
      unitRef="usd">460000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5NjA_a19398a1-f838-4ccd-bdbc-22f2d37b719e"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5Nzg_f5bf8e64-68e3-4a55-ac23-eb7e62c3bc7b"
      unitRef="usd">416000000</mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg4OTc_e743b31e-b837-431f-b7f0-388ca2825533"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2Mzg5MTM_8900c578-b8c9-46da-83cb-92fadc9ddb4f"
      unitRef="usd">25000000</mo:UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzEwOTk1MTE2MzkwMTU_6c8a6367-843c-4f77-a819-dff954c4fa52"
      unitRef="usd">391000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments
      contextRef="ie2f1978595a44dcbb3a13c8eaf072373_I20231231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzcxNDY4MjU2MDM2MzI_dd61a6cf-e74d-498d-a29b-81a8e82f5c12"
      unitRef="usd">-6500000000</mo:EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3NDU_58272858-2c9c-49b6-bf1c-9164ace92821">&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions to valuation allowance charged to income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Releases to valuation allowance credited to income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzEtMi0xLTEtMjIzMTEw_6d523604-790d-4503-8d85-1916ed61f9b8"
      unitRef="usd">2800000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mo:ValuationAllowanceDeferredTaxAssetIncreaseInAmount
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzItMi0xLTEtMjIzMTEw_eb20cc36-14ce-4f7b-95ce-cb32291a2ee0"
      unitRef="usd">72000000</mo:ValuationAllowanceDeferredTaxAssetIncreaseInAmount>
    <mo:ValuationAllowanceDeferredTaxAssetDecreaseInAmount
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzMtMi0xLTEtMjIzMTEw_984ed798-fc0c-41a4-a564-9648e1590426"
      unitRef="usd">4000000</mo:ValuationAllowanceDeferredTaxAssetDecreaseInAmount>
    <mo:ValuationAllowanceForeignCurrencyTranslationAdjustment
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzQtMi0xLTEtMjQ3MDg3_5e86fe7d-ce07-4e84-a2a2-224a06a5d923"
      unitRef="usd">-1000000</mo:ValuationAllowanceForeignCurrencyTranslationAdjustment>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzQtMi0xLTEtMjIzMTEw_6a2aa057-ddb7-4a40-875b-9f4c211f22e6"
      unitRef="usd">-663000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90YWJsZTo1ZTA0ZDY4YmM1ZWU0ZDI3YTA5MzllOGJiNWFiNjNmNS90YWJsZXJhbmdlOjVlMDRkNjhiYzVlZTRkMjdhMDkzOWU4YmI1YWI2M2Y1XzUtMi0xLTEtMjIzMTEw_30bd93c2-a1fd-4c78-b928-284db5d68fb2"
      unitRef="usd">2204000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDAvZnJhZzpjMGFlNWYzZTExNzk0MjJhYjZhNmUzMGNjZWVkNjczMi90ZXh0cmVnaW9uOmMwYWU1ZjNlMTE3OTQyMmFiNmE2ZTMwY2NlZWQ2NzMyXzI3Mzk_cf47b357-cc0f-42ae-9646-d4ab946b7ca8">deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.  We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized.  We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence.  In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxODE0Mjc_99285583-5d60-4232-a703-9312d07442af">Contingencies&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and certain of our subsidiaries, including PM USA and USSTC, as well as our indemnitees and investees.  Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, income tax liability, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (&#x201c;RICO&#x201d;), claims for contribution and claims of competitors, shareholders or distributors.  Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases.  An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation.  Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars.  The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome.  In certain cases, plaintiffs claim that defendants&#x2019; liability is joint and several.  In such cases, we may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment.  As a result, under certain circumstances, we may &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have to pay more than our proportionate share of any bonding- or judgment-related amounts.  Furthermore, in those cases where plaintiffs are successful, we also may be required to pay interest and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases.  This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all.  As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida&#x2019;s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well.  Such challenges may include the applicability of state bond caps in federal court.  States, including Florida, also may seek to repeal or alter bond cap statutes through legislation.  Although we cannot predict the outcome of such challenges, it is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record provisions in our condensed consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.  At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 11. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: (i)&#160;management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii)&#160;management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii)&#160;accordingly, management has not provided any amounts in our condensed consolidated financial statements for unfavorable outcomes, if any.  Litigation defense costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have achieved substantial success in managing litigation.  Nevertheless, litigation is subject to uncertainty and significant challenges remain.  It is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation.  We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts.  We have defended, and will continue to defend, vigorously against litigation challenges.  However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Judgments Paid and Provisions for Tobacco and Health (Including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Progeny Litigation) and Certain Other Litigation Items: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liability for tobacco and health and certain other litigation items at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax charges for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tobacco and health and certain other litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholder derivative lawsuits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liability for tobacco and health and certain other litigation items at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt; Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; below for a discussion of the pending settlement of the federal and state shareholder derivative lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities and other liabilities on our condensed consolidated balance sheets.  Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on our condensed consolidated statements of earnings.  Pre-tax charges for related interest costs were included in interest and other debt expense, net on our condensed consolidated statements of earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $963 million and interest totaling approximately $231 million as of March 31, 2023.  These amounts include payments for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny judgments (and related costs and fees) totaling approximately $436 million and related interest totaling approximately $60 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Security for Judgments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To obtain stays of judgments pending appeal, PM USA has posted various forms of security.  As of March 31, 2023, PM USA has posted appeal bonds totaling approximately $46 million, which have been collateralized with restricted cash and are included in assets on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview of Tobacco-Related Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Types and Number of U.S. Cases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims related to tobacco products generally fall within the following categories: (i)&#160;smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii)&#160;health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv)&#160;other tobacco-related litigation described below.  Plaintiffs&#x2019; theories of recovery and the defenses raised in tobacco-related litigation are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below lists the number of certain tobacco-related cases pending in the United States against us as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 24, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Smoking and Health Cases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health Care Cost Recovery Actions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;E-vapor Cases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Tobacco-Related Cases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes as of April 24, 2023, 19 cases filed in Illinois, 22 cases filed in New Mexico, 43 cases filed in Massachusetts and 46 non-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;cases filed in Florida.  Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;case (these &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; progeny cases are discussed below in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smoking and Health Litigation - Engle Class Action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).  Also does not include 1,390 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (&#x201c;ETS&#x201d;).  The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Broin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).  The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages.  Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Cost Recovery Litigation - Federal Government&#x2019;s Lawsuit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes as of April 24, 2023, 57 class action lawsuits, 3,746 individual lawsuits and 1467 &#x201c;third party&#x201d; lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.  The 57 class action lawsuits include 32 cases in the Northern District of California (&#x201c;Multidistrict Litigation&#x201d; or &#x201c;MDL&#x201d;) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes as of April 24, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms &#x201c;Lights&#x201d; and &#x201c;Ultra Lights&#x201d; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;International Tobacco-Related Cases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces.  See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees and Other Similar Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for a discussion of the Distribution Agreement (defined below) between Altria and Philip Morris International Inc. (&#x201c;PMI&#x201d;) that provides for indemnities for certain liabilities concerning tobacco products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tobacco-Related Cases Set for Trial: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, five &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases, four individual smoking and health cases and one e-vapor case are set for trial through June 30, 2023.  Trial dates are subject to change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trial Results: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since January 1999, excluding the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny cases (separately discussed below), verdicts have been returned in 75 tobacco-related cases in which PM USA was a defendant.  Verdicts in favor of PM USA and other defendants were returned in 47 of the 75 cases.  These 47 cases were tried in Alaska (1), California (7), Connecticut (1), Florida (10), Louisiana (1), Massachusetts (6), Mississippi (1), Missouri (4), New Hampshire (1), New Mexico (1), New Jersey (1), New York (5), Ohio (2), Pennsylvania (1), Rhode Island (1), Tennessee (2) and West Virginia (2).  One case in Massachusetts, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Main&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, where the verdict was initially returned in favor of PM USA, was reversed on appeal and remanded for a new trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the 28 non-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases in which verdicts were returned in favor of plaintiffs, 24 have reached final resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smoking and Health Liti&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;gation - Engle Progeny Trial Results&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for a discussion of verdicts in state and federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases involving PM USA as of April 24, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Smoking and Health Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs&#x2019; allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes.  Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief.  Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Progeny Litigation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized below are the non-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny smoking and health cases pending during 2023 (or recently concluded) in which a verdict was returned in favor of plaintiff and against PM USA.  Charts listing certain verdicts for plaintiffs in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny cases can be found in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smoking and Health Litigation - Engle Progeny Trial Results&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Woodley: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $5 million in compensatory damages.  There was no claim for punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mendez&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA and R.J. Reynolds Tobacco Company awarding approximately $4.5 million in compensatory damages and allocating 13% of the fault to PM USA.  After applying comparative fault, PM USA&#x2019;s portion of the compensatory damages is less than $1 million.  There was no claim for punitive damages.  The trial court denied PM USA&#x2019;s post-trial motions, and both parties appealed.  The parties subsequently reached an agreement to resolve plaintiff&#x2019;s claims.  As a result, both the appeal and cross-appeal have been dismissed and the case is concluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fontaine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $8 million in compensatory damages and $1 billion in punitive damages.  We have filed post-trial motions challenging the award and will, if necessary, appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Greene&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages.  In May 2020, the court ruled on plaintiffs&#x2019; remaining claim and trebled the compensatory damages award to approximately $30 million.  In February 2021, the trial court awarded plaintiffs attorneys&#x2019; fees and costs in the amount of approximately $2.3 million.  In July 2021, following denial of PM USA&#x2019;s post-trial motions, PM USA appealed the judgment to the Appeals Court of Massachusetts.  In September 2022, the Massachusetts Supreme Judicial Court issued an order taking jurisdiction over the appeal and heard oral arguments in January 2023.  The appeal remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Federal Government&#x2019;s Lawsuit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Cost Recovery Litigation - Federal Government&#x2019;s Lawsuit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Class Action: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2000, in the second phase of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA.  Following entry of judgment, PM USA appealed.  In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class.  Plaintiffs petitioned the Florida Supreme Court for further review.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate.  The court further declared the following Phase I findings are entitled to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;res judicata&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; effect in such individual actions brought within one year of the issuance of the mandate: (i)&#160;that smoking causes various diseases; (ii)&#160;that nicotine in cigarettes is addictive; (iii)&#160;that defendants&#x2019; cigarettes were defective and unreasonably dangerous; (iv)&#160;that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v)&#160;that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi)&#160;that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii)&#160;that all defendants sold or supplied cigarettes that were defective; and (viii)&#160;that defendants were negligent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion.  In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;res judicata&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; effect by excluding finding (v)&#160;listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants.  In February 2008, the trial court decertified the class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e Progeny Cases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deadline for filing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending.  As of April 24, 2023, approximately 551 state court cases were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pending against PM USA or Altria asserting individual claims by or on behalf of approximately 705 state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates.  The 2015 federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement resolved nearly all &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny cases pending in federal court as of the date of the agreement, and each case excluded from that agreement subsequently has been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Progeny Trial Results: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, 143 federal and state &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; decision.  Seventy-nine verdicts were returned in favor of plaintiffs, and five verdicts (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Calloway&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oshinsky-Blacker,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;McCoy, Mahfuz &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Neff&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.  In  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kaplan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;McLaughlin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the punitive damages award was vacated on appeal and remanded for a new trial.  In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sommers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the trial court entered final judgment dismissing the plaintiff&#x2019;s punitive damages claim with prejudice, and plaintiff appealed.  The Third District Court of Appeal affirmed the award and remanded for a new trial on entitlement to punitive damages and amount.  On remand, the trial court granted PM USA&#x2019;s motion for summary judgment and entered final judgment dismissing the plaintiff&#x2019;s punitive damages claim with prejudice, and plaintiff has appealed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fifty-seven verdicts were returned in favor of PM USA, of which 47 were state cases.  In addition, there have been a number of mistrials, only some of which have resulted in new trials as of April 24, 2023.  The jury in one case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Garcia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages.  Following appeals by the plaintiff and PM USA, the appellate court in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Garcia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; affirmed the compensatory damages judgment against PM USA and granted a new trial with respect to punitive damages.  The plaintiff in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Garcia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsequently filed a motion to voluntarily dismiss the punitive damages claim and to enter final judgment on the compensatory damages claim, which the court granted.  Three verdicts (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cohen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chacon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) that were returned in favor of PM USA were subsequently reversed for new trials.  Juries in two cases (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Banks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) returned zero damages verdicts in favor of PM USA.  Juries in two other cases (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Weingart&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hancock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages.  One case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pollari&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff.  Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgment in favor of the defendants.  Three cases, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gloger&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rintoul &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Caprio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duignan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs.  A post-trial appeal is pending in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duignan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The verdicts in the retrials in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gloger&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rintoul&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Caprio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) were reversed upon appeal and remanded for new trials.  Two cases, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Freeman&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Harris&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.  One case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;R. Douglas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was dismissed with prejudice following a verdict in favor of plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The charts below list the verdicts and post-trial developments in certain &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases in which verdicts were returned in favor of plaintiffs.  The first chart lists cases that are pending as of April 24, 2023 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the second chart lists cases that have concluded in the past 12 months.  Unless otherwise noted for a particular case, the jury&#x2019;s award for compensatory damages will not be reduced by any finding of plaintiff&#x2019;s comparative fault.  Further, the damages noted reflect adjustments based on post-trial or appellate rulings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References below to &#x201c;R.J. Reynolds,&#x201d; &#x201c;Lorillard&#x201d; and &#x201c;Liggett Group&#x201d; are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Currently Pending Engle Cases with Verdicts Against PM USA &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(rounded to nearest $ million)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Compensatory Damages &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Punitive Damages &lt;br/&gt;(PM USA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Post-Trial Status&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Hoffman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5 million ($3 million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeal by defendant to First District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Levine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeals by defendants and plaintiff to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Schertzer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeal by defendants to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lipp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$15 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Appeal by defendant to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Garcia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6 million ($3 million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Appeal by defendant to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Compensatory Damages &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Punitive Damages &lt;br/&gt;(PM USA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Post-Trial Status&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Duignan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pinellas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Florida Supreme Court quashed the Second District Court of Appeal&#x2019;s affirmation of  judgment against the defendants and remanded the case for reconsideration in light of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prentice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;McCall&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1&#160;million (&amp;lt;$1&#160;million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;New trial on punitive damages is set for June 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chadwell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third District Court of Appeal has ordered supplemental briefing in accordance with the decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prentice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Kaplan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;McLaughlin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Florida Supreme Court vacated the punitive damages award in accordance with the decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Sheffield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;.  The Fourth District Court of Appeals affirmed the compensatory damages award and granted a new trial on punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cooper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Blackwood&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(&amp;lt;$1&#160;million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fourth District Court of Appeal affirmed the compensatory damages award and granted a new trial on punitive damages.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PM USA&#x2019;s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Plaintiff&#x2019;s verdict following a retrial of an initial verdict in favor of plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; PM USA is not a defendant in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prentice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sheffield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which are discussed below in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle Progeny Appellate Issues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle Cases Concluded Within Past 12 Months &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(rounded to nearest $ million)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accrual Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payment Amount for Damages (if any)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Miller&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tuttle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cuddihee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Holliman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fourth quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;D. Brown&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal Court - Middle District of Florida&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Progeny Appellate Issues: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Appellate decisions in the following &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases may have wide application to other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mary Sheffield v. R.J. Reynolds Tobacco Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#x2019;s District Courts of Appeal finding that the 1999 amendments to Florida&#x2019;s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Linda Prentice v. R.J. Reynolds Tobacco Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny case against R.J. Reynolds only, the Florida Supreme Court resolved a conflict among Florida&#x2019;s District Courts of Appeal finding that in order for an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiff to prevail on fraudulent concealment and conspiracy claims, plaintiff must prove that the smoker relied to his or her detriment on a statement that concealed or omitted material information about the health risks or addictiveness of smoking.  The Florida Supreme Court declined to revisit its prior decisions giving preclusive effect to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Phase I findings, described above in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Engle Class Action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Florida Bond Statute: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny lawsuits in the aggregate and establishes individual bond caps for individual &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; progeny cases in amounts that vary depending on the number of judgments in effect at a given time.  Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;progeny cases tried in federal court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Smoking and Health Class Actions: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts.  In general, these cases have purported to be brought on behalf of residents of a particular state or states (although a few cases have purported to be nationwide in scope) and have raised addiction claims and, in many cases, claims of physical injury as well.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1)&#160;and Wisconsin (1).  See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain Other Tobacco-Related Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below for a discussion of &#x201c;Lights&#x201d; and &#x201c;Ultra Lights&#x201d; class action cases and medical monitoring class action cases pending against PM USA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario.  In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants&#x2019; cigarettes.  In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants&#x2019; cigarettes.  In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to us) seeking protection under Canada&#x2019;s Companies&#x2019; Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the United States).  The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion.  See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees and Other Similar Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Health Care Cost Recovery Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages.  Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there have been some decisions to the contrary, most judicial decisions in the United States have dismissed all or most health care cost recovery claims against cigarette manufacturers.  Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs&#x2019; claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions.  The U.S. Supreme Court has refused to consider plaintiffs&#x2019; appeals from the cases decided by five federal circuit courts of appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the cases brought in the United States, health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases),&#160;and other entities have stated that they are considering filing such actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers.  PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases.  The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed.  All of these cases have been stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with us) under the Companies&#x2019; Creditors Arrangement Act discussed above.  See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smoking and Health Litigation - Other Smoking and Health Class Actions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for a discussion of these proceedings.  See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees and Other Similar Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Settlements of Health Care Cost Recovery Litigation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 1998, PM USA and certain other tobacco product manufacturers entered into the Master Settlement Agreement (the &#x201c;MSA&#x201d;) with 46 states, the District of Columbia and certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States territories to settle asserted and unasserted health care cost recovery and other claims.  PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the &#x201c;State Settlement Agreements&#x201d;).  The State Settlement Agreements require that the original participating manufacturers or &#x201c;OPMs&#x201d; (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (&#x201c;ITG&#x201d;)) make annual payments of approximately $9.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume.  In addition, the OPMs are required to pay settling plaintiffs&#x2019; attorneys&#x2019; fees, subject to an annual cap of $500 million; these quarterly payments are expected to end in 2024.  For the three months ended March 31, 2023 and 2022, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $900 million for each period.  These amounts include PM USA&#x2019;s estimate of amounts related to NPM Adjustments discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NPM Adjustment Disputes: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &#x201c;NPM Adjustment&#x201d; is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the &#x201c;participating manufacturers&#x201d; or &#x201c;PMs&#x201d;) that applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The independent auditor (&#x201c;IA&#x201d;) appointed under the MSA has calculated that PM USA&#x2019;s share of the maximum potential NPM Adjustments for 2004-2022 is (exclusive of interest or earnings): $388 million for 2004; $181 million for 2005; $154 million for 2006; $185 million for 2007; $250 million for 2008; $211 million for 2009; $218 million for 2010; $166 million for 2011; $214 million for 2012; $224 million for 2013; $258 million for 2014; $313 million for 2015; $292 million for 2016; $285 million for 2017; $318 million for 2018; $415 million for 2019; $572 million for 2020; $675 million for 2021; and $571 million for 2022.  These maximum amounts will be substantially reduced to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments.  PM USA&#x2019;s recovery for 2004 is addressed below.  In addition, PM USA&#x2019;s recovery of such reduced amounts for all subsequent years will be dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Settlements of NPM Adjustment Disputes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Multi-State Settlement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  By the end of 2018, a total of 36 MSA states and territories had entered the multi-state settlement of NPM Adjustment disputes to which PM USA is a party.  Of these 36 states and territories, 35 entered settlement through 2022, and one state entered settlement through 2024.  In March 2022, Illinois joined the multi-state settlement, settling the NPM Adjustment disputes through 2028 and bringing the total number of states and territories that have joined the multi-state settlement to 37.  As a result, PM USA will receive approximately $80 million for 2004-2021 ($20 million of which relates to the 2019-2021 &#x201c;transition years&#x201d;).  In connection with this development for Illinois, PM USA recorded $80 million as a reduction in cost of sales in the first quarter of 2022.  Pursuant to the multi-state settlement, PM USA has received $1.15 billion since the first group of states entered the NPM Adjustment dispute settlement in 2014 and expects to receive approximately $410 million in credits to offset PM USA&#x2019;s MSA payments through 2036.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;New York Settlement.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity.  PM USA has received $435 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Montana Settlement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030.  This settlement resulted in a payment by PM USA of $4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Continuing NPM Adjustment Disputes with States That Have Not Settled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;2004 NPM Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The PMs and the nine states that have not settled the NPM Adjustment disputes participated in a multi-state arbitration of NPM Adjustment disputes for 2004.  A tenth state, Illinois, also participated in the arbitration, but joined the multi-state settlement after the arbitration panel issued its decisions described below.  Hearings for nine of the 10 states concluded by the end of 2020.  The arbitration panels issued decisions finding that three states, Missouri, New Mexico and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004.  The arbitration panels further found that the remaining seven states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004.  Washington and Missouri have challenged those determinations in their respective state courts and with the arbitration panels, and several issues remain to be resolved by the courts that may affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive.  PM USA recorded $21 million and $3 million as a reduction in cost of sales in the third quarter of 2021 and fourth quarter of 2022, respectively, for its estimate of the minimum amount of the 2004 NPM adjustment it will receive.  PM USA estimates it is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entitled to interest of approximately $23 million and $5 million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021 and fourth quarter of 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;2005-2007 NPM Adjustments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The PMs and the nine states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel.  The arbitration encompasses three years, 2005-2007, for eight of the nine states, and one year, 2005, for one state.  As of April 24, 2023, no decisions have resulted from the arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Subsequent Years.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;In July 2022, the State of Iowa filed a motion in Iowa state court against the PMs, including PM USA, claiming that the PMs wrongfully disputed the applicability of NPM Adjustments to Iowa and that all adjustment amounts to date should have been paid to Iowa rather than deposited into the disputed payments account.  A similar enforcement motion was filed by the State of New Mexico against the PMs, including PM USA, in November 2022.  PM USA has placed certain disputed NPM Adjustment amounts attributed to Iowa and New Mexico in the disputed payments account established pursuant to the terms of the MSA.  Iowa and New Mexico seek a total of approximately $133 million and $84 million, respectively, in disputed payments from all defendants combined, as well as treble and punitive damages, and other relief.  The PMs filed a cross motion to compel arbitration in the Iowa matter.  In February 2023, the Iowa state court granted the PM&#x2019;s motion, compelling arbitration.  In March 2023, Iowa withdrew its motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Disputes Under the State Settlement Agreements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds&#x2019;s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the &#x201c;ITG transferred brands&#x201d;).  PM USA filed motions to enforce the State Settlement Agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals, although further proceedings may occur based on the resolution of certain outstanding litigation between R.J. Reynolds and ITG.  In May 2022, PM USA filed a motion to compel arbitration under the MSA regarding certain positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands.  In June 2022, the matter was resolved through mutual agreement of the parties.  PM USA continues to dispute how the ITG transferred brands are treated in allocating the NPM Adjustments under the MSA and related settlements and may pursue such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018.  The Mississippi state court held a hearing in October 2021 and issued a decision in June 2022 granting the State&#x2019;s motion.  Further proceedings remain outstanding, and a final judgment has not yet been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs&#x2019; claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&amp;amp;M Brands, Inc. (&#x201c;S&amp;amp;M Brands&#x201d;), under which the states released certain claims against S&amp;amp;M Brands in exchange for receiving a portion of the funds S&amp;amp;M Brands deposited into escrow accounts in those states pursuant to the states&#x2019; escrow statutes.  In consideration for waiving its most favored nation claim, PM USA received approximately $32 million from the escrow funds paid to those MSA states under their settlement with S&amp;amp;M Brands.  These funds were received in January 2021 and were recorded in our condensed consolidated statement of earnings (losses) for the first quarter of 2021 as a reduction in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Federal Government&#x2019;s Lawsuit: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1999, the U.S. government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes.  The case ultimately proceeded only under the civil provisions of RICO.  In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in certain &#x201c;sub-schemes&#x201d; to defraud that the government had alleged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The court did not impose monetary penalties on defendants, but ordered various types of non-monetary relief, including an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including &#x201c;lights,&#x201d; &#x201c;ultra lights&#x201d; and &#x201c;low tar,&#x201d; which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand, and the issuance of &#x201c;corrective statements&#x201d; in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking &#x201c;low tar&#x201d; or &#x201c;light&#x201d; cigarettes, defendants&#x2019; manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corrective statements began appearing in newspapers and on television in the fourth quarter of 2017 and on websites in the second quarter of 2018, and the onserts began appearing in the fourth quarter of 2018.  In December 2022, the district court entered a consent order approving a settlement with respect to corrective statements on point-of-sale signage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we recorded provisions totaling approximately $28 million for the estimated costs of implementing the corrective statements on point-of-sale signage remedy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the U.S. government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes discussed above also applies to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HeatSticks,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a heated tobacco product used with the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; System.  In August 2020, we filed an opposition to the government&#x2019;s motion and, in the alternative, a motion to modify the injunction to make clear it does not apply to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The district court heard arguments on the motions in July 2022 and has not yet issued any decisions.  Regardless of the district court&#x2019;s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the U.S. Food and Drug Administration for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;E-vapor Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, we are defendants in 57 class action lawsuits relating to JUUL e-vapor products.  JUUL is an additional named defendant in each of these lawsuits.  The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices.  Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales.  The 57 class action lawsuits include 32 cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.  Three of the class action lawsuits are pending in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have been named as defendants in other lawsuits involving JUUL e-vapor products, including 3,746 individual lawsuits and 1,467 &#x201c;third party&#x201d; lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the U.S. Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of the federal individual and class action lawsuits mentioned above in the U.S. District Court for the Northern District of California for pretrial purposes.  In December 2022, JUUL reached agreements to resolve the Multidistrict Litigation through settlement.  In January 2023, the court preliminarily approved the settlement.  We are not a party to any settlements concerning the Multidistrict Litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The court has set trial dates for one case pending in the Multidistrict Litigation.  One trial in the Multidistrict Litigation is ongoing as of April 24, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim.  In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice.  Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law.  The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects.  The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020.  In January 2021, we filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021.  In June 2022, the court granted plaintiffs&#x2019; motion to certify a California state class based on state law claims against JUUL and a nationwide class based on RICO claims against Altria and other defendants.  Altria and the other defendants filed petitions with the U.S. Court of Appeals for the Ninth Circuit seeking discretionary review of the class certification order, which the court granted in October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An additional group of cases is pending in California state courts.  In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;JUUL also is named in a significant number of additional individual and class action lawsuits to which we are not currently named.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Four of the &#x201c;third party&#x201d; lawsuits noted above against us and JUUL were initiated, individually, by the attorneys general of Alaska, Hawaii, Minnesota and New Mexico alleging violations of state consumer protection and other similar laws.  We filed motions to dismiss the lawsuits.  In Alaska, Hawaii and Minnesota, the motions were denied in February 2022, May 2021 and June 2021, respectively.  Our motion to dismiss remains pending in New Mexico.  In the Alaska lawsuit, although the trial court declined to dismiss most of the plaintiff&#x2019;s claims, the trial court did dismiss plaintiff&#x2019;s public nuisance claim.  In April 2023, we agreed to settle the Minnesota lawsuit for an immaterial amount.  The trial courts in the Alaska and Hawaii lawsuits have set the trials for April 2024 and February 2024, respectively.  As of April 24, 2023, the trial court in New Mexico has not set a trial date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IQOS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, ALCS, PMI and its affiliate, Philip Morris Products S.A., in the U.S. District Court for the Eastern District of Virginia asserting claims of patent infringement based on the sale of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; System electronic device and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marlboro HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States.  Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys&#x2019; fees.  Altria and PMI were previously dismissed from the lawsuit, and plaintiffs&#x2019; claims against the other defendants have been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PM USA, ALCS and Philip Morris Products S.A. filed counterclaims against plaintiffs in the Eastern District of Virginia lawsuit alleging patent infringement by R.J. Reynolds&#x2019; e-vapor products.  In June 2022, PM USA and ALCS reached an agreement with R.J. Reynolds resulting in dismissal of their counterclaims.  In addition, ALCS filed a separate lawsuit against R.J. Reynolds in the U.S. District Court for the Middle District of North Carolina also alleging patent infringement by R.J. Reynolds&#x2019; e-vapor products.  In September 2022, a jury awarded ALCS $95 million in damages for past infringement, plus supplemental damages and interest.  In January 2023, the court ordered R.J. Reynolds to pay ALCS a 5.25% royalty on future sales of its infringing product resulting in positive net income through the expiration of the relevant patents in 2035.  R.J. Reynolds has filed a notice of appeal of the judgment.  As gains related to this lawsuit have not yet been determined to be realized or realizable in accordance with GAAP, they have not been recognized in our financial statements for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, a related patent infringement action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the U.S. International Trade Commission (&#x201c;ITC&#x201d;), but the remedies sought included a prohibition on the importation of the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; IQOS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; System electronic device, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marlboro HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and component parts into the United States and on the sale of any such products previously imported into the United States.  No damages are recoverable in the proceedings before the ITC.  In September 2021, the ITC issued a limited exclusion order barring the importation of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;System electronic device,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Marlboro HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products.  The orders became effective on November 29, 2021.  Consequently, PM USA removed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;System electronic device and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Marlboro HeatSticks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from the marketplace.  In December 2021, defendants appealed the orders to the U.S. Court of Appeals for the Federal Circuit and, in March 2023, the U.S. Court of Appeals for the Federal Circuit issued its decision affirming the ITC exclusion order in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Healthier Choices Management Corp. filed an additional unrelated patent infringement case in the U.S. District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief.  In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021.  In December 2021, the U.S. District Court denied plaintiff&#x2019;s motion to amend the complaint and plaintiff appealed this ruling to the U.S. Court of Appeals for the Federal Circuit, which reversed the district court&#x2019;s decision and remanded for further proceedings.  The U.S. Patent Office has also issued a decision that the claims of the asserted patent are not valid, and the plaintiff has appealed that ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, we entered into a stock transfer agreement with JUUL pursuant to which, among other things, we transferred to JUUL all of our beneficially owned JUUL equity securities.  See Note 3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments in Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a discussion of our disposition of our interest in JUUL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that our 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (&#x201c;Sherman Act&#x201d;) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (&#x201c;Clayton Act&#x201d;).  If the FTC&#x2019;s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party&#x2019;s board of directors or attending meetings of the other party&#x2019;s board of directors and notice to the FTC in advance of certain corporate actions, including acquisitions, mergers or certain corporate restructurings.  In February 2022, the administrative law judge dismissed the FTC&#x2019;s complaint and, also in February 2022, FTC complaint counsel appealed the administrative law judge&#x2019;s decision to the FTC.  Oral argument with respect to the appeal occurred in September 2022.  After oral argument, the FTC asked for additional briefing, which was completed in December 2022.  In March 2023, following our disposition of our interest in JUUL, we filed a motion to dismiss, or in the alternative, to stay the litigation and a motion to withdraw the matter from adjudication to discuss settlement with the FTC.  The FTC subsequently issued an order denying our request for a stay and extending to May 5, 2023 its deadline for issuance of a final decision with respect to FTC complaint counsel&#x2019;s appeal of the administrative law judge&#x2019;s decision and the remainder of the pending motions.  Altria can appeal any adverse ruling the FTC issues following its review to any U.S. Court of Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also as of April 24, 2023, 17 putative class action lawsuits have been filed against Altria and JUUL in the U.S. District Court for the Northern District of California.  The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed.  In November 2020 these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers).  The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market.  Plaintiffs seek various remedies, including treble damages, attorneys&#x2019; fees, a declaration that the agreements between Altria and JUUL are invalid and rescission of the transaction.  We filed a motion to dismiss these lawsuits in January 2021.  In August 2021, the U.S. District Court for the Northern District of California denied our motion to dismiss except with respect to plaintiffs&#x2019; claims for injunctive and equitable relief.  However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.  In January 2022, the trial court ordered that the direct-purchaser plaintiffs&#x2019; claims against JUUL be sent to arbitration pursuant to an arbitration provision in JUUL&#x2019;s online purchase agreement.  The court granted plaintiffs&#x2019; leave to replead the complaint with new direct-purchaser plaintiffs, which plaintiffs did in February 2022, substituting in four new plaintiffs.  In August 2022, the court stayed all of the cases pending any appeal to the court of appeals from the FTC&#x2019;s lawsuit against Altria and JUUL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Class Action and Shareholder Derivative Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shareholder Class Action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In October and December 2019, two purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, our former Chairman and Chief Executive Officer, and William F. Gifford, Jr., our former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the U.S. District Court for the Eastern District of New York.  In December 2019, the court consolidated the two lawsuits into a single proceeding.  The consolidated lawsuit was subsequently transferred to the U.S. District Court for the Eastern District of Virginia.  The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act.  In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit.  The claims allege false and misleading statements and omissions relating to our former investment in JUUL.  Plaintiffs seek various remedies, including damages and attorneys&#x2019; fees.  In July 2020, the defendants filed motions to dismiss plaintiffs&#x2019; claims, which the district court denied in March 2021.  In the fourth quarter of 2021, plaintiffs and defendants agreed upon a class action settlement under which, among other things, (i) all claims asserted against Altria and the other named defendants are resolved without any liability or wrongdoing attributed to them personally or to Altria and (ii) Altria will pay the class an aggregate amount of $90 million, which amount includes attorneys&#x2019; fees.  The class is defined to include persons and entities who purchased or otherwise acquired shares of Altria between October 25, 2018 through April 2, 2020, subject to certain exclusions.  The trial court granted final approval of the settlement in March 2022.  We recorded pre-tax provisions totaling $90 million in 2021 and, in January 2022, paid $90 million to plaintiffs&#x2019; escrow account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Federal and State Shareholder Derivative Lawsuits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, two purported Altria shareholders filed separate derivative lawsuits in the U.S. District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of our executives and officers.  These derivative lawsuits relate to our former investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants.  In March 2021, the U.S. District Court for the Northern District of California granted defendants&#x2019; motion to transfer both lawsuits to the U.S. District Court for the Eastern District of Virginia.  Three additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the U.S. District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws.  The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of our corporate governance and internal procedures, and attorneys&#x2019; fees.  In April 2021, the court consolidated the five cases pending in the Eastern District of Virginia into a single case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (our former Chief Growth Officer and JUUL&#x2019;s current Chief Executive Officer), certain members of our Board of Directors, JUUL, its founders and some of its current and former executives.  The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively.  The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia.  In successive orders from July 2021, September 2021 and January 2022, five of the six state derivative cases were consolidated into a single case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, plaintiffs and defendants in all the federal and state derivative cases agreed upon a settlement of these cases.  Under the terms of the settlement, among other things, we agreed to fund underage tobacco prevention and cessation programs, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which may include positive youth development programs, led by independent third-party organizations.  In 2022, we recorded pre-tax provisions totaling $27&#160;million for costs associated with the independent monitoring of our funding commitments and attorneys&#x2019; fees.  In January 2023, the federal trial court conducted a final approval hearing, at which the court sustained an objection to a provision of the settlement, but granted the parties additional time to resolve the issue.  The parties subsequently executed an amendment to the settlement agreement, and the federal trial court granted final approval of the settlement in February 2023.  No appeal was taken.  In March 2023, pursuant to the terms of the settlement agreement, plaintiffs in the state derivative cases filed motions to dismiss their lawsuits, which the state courts granted.  The settlement will become effective upon the expiration of the deadline for any appeals of the dismissal orders, which is scheduled to occur on May 1, 2023.  In the first quarter of 2023, we recorded pre-tax provisions totaling approximately $100 million related to the settlement, and in April 2023, paid $15 million to plaintiffs&#x2019; escrow account for attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Certain Other Tobacco-Related Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x201c;Lights/Ultra Lights&#x201d; Cases and Other Smoking and Health Class Actions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms &#x201c;Lights&#x201d; and/or &#x201c;Ultra Lights&#x201d; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages.  These class actions have been brought against PM USA and, in certain instances, Altria or our other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes.  Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment.  Twenty-one state courts in 23 &#x201c;Lights&#x201d; cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA.  As of April 24, 2023, two &#x201c;Lights/Ultra Lights&#x201d; class actions are pending in U.S. state courts.  Neither case is active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 24, 2023, one smoking and health case alleging personal injury or seeking court-supervised programs or an ongoing medical monitoring program on behalf of individuals exposed to environmental tobacco smoke and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court.  The case is currently inactive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UST Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time.  Plaintiffs&#x2019; allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes.  Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement.  Defenses raised in these cases have included lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations.  As of April 24, 2023, there is no such case pending against UST and/or its tobacco subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Regulation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Altria and our former subsidiaries are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the United States: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as &#x201c;Superfund&#x201d;), which can impose joint and several liability on each responsible party.  Altria and our former subsidiaries are involved in several cost recovery/contribution cases subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations.  We expect to continue to make capital and other expenditures in connection with environmental laws and regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated.  Such accruals are adjusted as new information develops or circumstances change.  Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that we may undertake in the future.  In the opinion of our management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on our condensed consolidated results of operations, capital expenditures, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees and Other Similar Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we have agreed to indemnify a limited number of third parties in the event of future litigation.  At March&#160;31, 2023, we (i) had $46 million of unused letters of credit obtained in the ordinary course of business and (ii) were contingently liable for guarantees related to our own performance, including $19 million for surety bonds recorded on our condensed consolidated balance sheet.  In addition, from time to time, we issue lines of credit to affiliated entities.  These items have not had, and are not expected to have, a significant impact on our liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of a distribution agreement between Altria and PMI (the &#x201c;Distribution Agreement&#x201d;), entered into as a result of our 2008 spin-off of our former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;part on the manufacturer.  PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI.  We do not have a related liability recorded on our condensed consolidated balance sheet at March&#160;31, 2023 as the fair value of this indemnification is insignificant.  PMI has agreed not to seek indemnification with respect to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; System patent litigation discussed above under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQOS Litigation, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;excluding the patent infringement case filed with the U.S. District Court for the Northern District of Georgia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PM USA has issued guarantees relating to our obligations under our outstanding debt securities, borrowings under our $3.0 billion Credit Agreement and amounts outstanding under our commercial paper program.  For further discussion, see Note 9. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDAxNzc_b9191f36-82b4-4f80-b6ac-e3a413a02ac2"
      unitRef="state">47</mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzcwMDY2_72cb086e-24ae-4f28-b1ae-a991ebe35a1f">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liability for tobacco and health and certain other litigation items at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax charges for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tobacco and health and certain other litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholder derivative lawsuits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liability for tobacco and health and certain other litigation items at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt; Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; below for a discussion of the pending settlement of the federal and state shareholder derivative lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below lists the number of certain tobacco-related cases pending in the United States against us as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 24, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 25, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Smoking and Health Cases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health Care Cost Recovery Actions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;E-vapor Cases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Tobacco-Related Cases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes as of April 24, 2023, 19 cases filed in Illinois, 22 cases filed in New Mexico, 43 cases filed in Massachusetts and 46 non-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;cases filed in Florida.  Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;case (these &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; progeny cases are discussed below in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smoking and Health Litigation - Engle Class Action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).  Also does not include 1,390 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (&#x201c;ETS&#x201d;).  The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Broin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).  The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages.  Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Cost Recovery Litigation - Federal Government&#x2019;s Lawsuit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes as of April 24, 2023, 57 class action lawsuits, 3,746 individual lawsuits and 1467 &#x201c;third party&#x201d; lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits.  JUUL is an additional named defendant in each of these lawsuits.  The 57 class action lawsuits include 32 cases in the Northern District of California (&#x201c;Multidistrict Litigation&#x201d; or &#x201c;MDL&#x201d;) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes as of April 24, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms &#x201c;Lights&#x201d; and &#x201c;Ultra Lights&#x201d; constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Currently Pending Engle Cases with Verdicts Against PM USA &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(rounded to nearest $ million)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Compensatory Damages &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Punitive Damages &lt;br/&gt;(PM USA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Post-Trial Status&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Hoffman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5 million ($3 million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeal by defendant to First District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Levine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeals by defendants and plaintiff to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Schertzer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Appeal by defendants to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lipp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$15 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Appeal by defendant to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Garcia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6 million ($3 million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Appeal by defendant to the Third District Court of Appeal pending.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Compensatory Damages &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Punitive Damages &lt;br/&gt;(PM USA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Post-Trial Status&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Duignan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pinellas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Florida Supreme Court quashed the Second District Court of Appeal&#x2019;s affirmation of  judgment against the defendants and remanded the case for reconsideration in light of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prentice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;McCall&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1&#160;million (&amp;lt;$1&#160;million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;New trial on punitive damages is set for June 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chadwell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third District Court of Appeal has ordered supplemental briefing in accordance with the decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prentice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Kaplan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;McLaughlin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Florida Supreme Court vacated the punitive damages award in accordance with the decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Sheffield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;.  The Fourth District Court of Appeals affirmed the compensatory damages award and granted a new trial on punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cooper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Blackwood&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Broward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(&amp;lt;$1&#160;million PM USA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fourth District Court of Appeal affirmed the compensatory damages award and granted a new trial on punitive damages.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PM USA&#x2019;s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Plaintiff&#x2019;s verdict following a retrial of an initial verdict in favor of plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; PM USA is not a defendant in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prentice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sheffield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which are discussed below in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Engle Progeny Appellate Issues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Engle Cases Concluded Within Past 12 Months &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(rounded to nearest $ million)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Plaintiff&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Verdict Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Defendant(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Court&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accrual Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payment Amount for Damages (if any)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Miller&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA and R.J. Reynolds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tuttle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;$1 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cuddihee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Holliman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Miami-Dade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fourth quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;D. Brown&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PM USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal Court - Middle District of Florida&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third quarter of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i90474c1a016f4bcab8003b2f31a36b35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzItMS0xLTEtMjIzMTEw_bf36fbdd-543f-43e9-ba48-7f862e0fd96d"
      unitRef="usd">71000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0217eb87e2e241b8ad4da3c44ced3300_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzItMy0xLTEtMjIzMTEw_584e439d-d60b-48a9-b498-1c6cd1bbf9d3"
      unitRef="usd">91000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="iefc84e48cf0c42249795f0fa77b9ea65_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzQtMS0xLTEtMjIzMTEw_cd52f2b3-0d5e-4c95-ab7c-2b50a714cd97"
      unitRef="usd">12000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="id39fde8db86346d7af0960b18bf2989e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzQtMy0xLTEtMjIzMTEw_88c5187e-cafb-4290-9410-d7b04d5f2863"
      unitRef="usd">12000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="iea367655f1904de580fbb5fccfbc7804_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMS0xLTEtMjQ2OTc4_188b95cc-92e2-4fcf-9980-d4e015d8b7bc"
      unitRef="usd">98000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="ieaacf9fe9d5240a3bd0459f2294eff52_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMy0xLTEtMjQ3MzU3_c6ff747d-b788-4a52-9f6e-66de1ddcd4cd"
      unitRef="usd">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="ic3fe928fcc4f4ef5ad3b60f07ca10cc7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMS0xLTEtMjIzMTEw_a07029b4-84bd-4b72-9b87-97c2a3fcd230"
      unitRef="usd">1000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i0b2cceb11df14f4cad29de8cb80794bd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzUtMy0xLTEtMjIzMTEw_eeb2f145-0369-4a6a-ac91-abcc6d131018"
      unitRef="usd">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzktMS0xLTEtMjIzMTEw_28be64a5-dc0d-4cdd-9cf6-9a3efb3843b1"
      unitRef="usd">11000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzktMy0xLTEtMjIzMTEw_80be75d2-9f19-4b74-a67a-789e03b6ec19"
      unitRef="usd">103000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzEwLTEtMS0xLTIyMzExMA_d48c3ceb-4383-425e-b97e-6e3c0bbb3f6a"
      unitRef="usd">171000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i17705bcff8eb49498848597476b6a197_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo4Yjc0Y2I2MTg1MmU0MDdiOWUzNTRiZTIzZTM2ZTcwNi90YWJsZXJhbmdlOjhiNzRjYjYxODUyZTQwN2I5ZTM1NGJlMjNlMzZlNzA2XzEwLTMtMS0xLTIyMzExMA_6ba38170-4275-49af-a7fd-0c1d5a9774fb"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk0MTg_9d27c864-8588-4ab0-876c-d9cab9053cb3"
      unitRef="usd">963000000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LitigationSettlementInterest
      contextRef="ieda8f0c59a1f46538b3b0c6e8f53f6d5_D20041001-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk0NTg_566b882e-2a76-4973-aa60-01a344903790"
      unitRef="usd">231000000</us-gaap:LitigationSettlementInterest>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk1OTk_e46e12ef-4419-4f59-a588-c7c8b2e2b152"
      unitRef="usd">436000000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LitigationSettlementInterest
      contextRef="i0a77c486430040b7b8e35150f7f513a9_D20041001-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk2NDc_cfb787f2-6ef0-49cc-b1fa-1acc90aae1be"
      unitRef="usd">60000000</us-gaap:LitigationSettlementInterest>
    <mo:LitigationEscrowDeposit
      contextRef="i66f2eaac69ca4a1e9412b845d82e98f9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MDk4NDY_4e71609f-66d7-4eb5-b897-7e577e612c5c"
      unitRef="usd">46000000</mo:LitigationEscrowDeposit>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i658eb60878114979945a034aa6b1706f_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtMS0xLTEtMjIzMTEw_1ca55db2-77fd-405e-982f-27ce365a8b5b"
      unitRef="claim">167</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8f59e571a0db45e8b6ec28bace62543f_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtMy0xLTEtMjIzMTEw_3aa813ea-c0eb-410c-9d7f-85caa6548d7b"
      unitRef="claim">163</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2d2aadde9431454a847f57038a8a9480_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzEtNS0xLTEtMjM4NDA5_ebc44f25-0cd4-4503-96a5-f31a21f665d7"
      unitRef="claim">162</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i264d8c165e0f471f82f66d6e65418cff_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItMS0xLTEtMjIzMTEw_4421a393-5d62-4f70-85ed-e6edfe255357"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i22a937a6e7e14fdfacea6ad40290a42f_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItMy0xLTEtMjIzMTEw_5d1f5fd8-8fdb-4efa-90bc-92dea05848c5"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i61f461a1aa5d4ee792394582b58b95ac_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzItNS0xLTEtMjM4NDEz_20e78235-dd19-46d7-8b61-ef741e280545"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtMS0xLTEtMjIzMTEw_97f22db0-491b-4ff6-9f91-d105db1ef3b0"
      unitRef="claim">5270</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i67ca21fd598f4791b318ee5cabcbed5d_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtMy0xLTEtMjIzMTEw_c095b8cb-9a99-47f3-9467-816fc579ddaf"
      unitRef="claim">3744</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iac90a0bb5f3f4b2f934b8f25141d8e55_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzMtNS0xLTEtMjM4NDE3_779c2edd-ccff-4b8d-acf5-79bec1d5dd4d"
      unitRef="claim">2150</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtMS0xLTEtMjIzMTEw_f0c77a15-c583-40ad-a415-a5c95d1ad798"
      unitRef="claim">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia0a4f7f89b7241328632d436bff2aa5f_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtMy0xLTEtMjIzMTEw_c97c3310-fd83-46af-9849-926f1c1bb0f6"
      unitRef="claim">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i01034fcbdec149c4be2d97e5b30b1d64_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MjY4Yjc4YTZlZWY0NjUzYTE5N2MzN2ExNjU2ZDFhNC90YWJsZXJhbmdlOjYyNjhiNzhhNmVlZjQ2NTNhMTk3YzM3YTE2NTZkMWE0XzQtNS0xLTEtMjM4NDIy_cea7806d-fe5a-4d67-87fa-8a8d63727361"
      unitRef="claim">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8fcf35d29f7e417fa73e1d1a62215cc3_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5MDU_1cff2ed2-bca2-43f2-9465-cb5a7f515f6a"
      unitRef="claim">19</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie745a29b163b4a30b640a432516cbc0a_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5MzQ_43237601-a7fc-47fa-bcec-e1487a3f781c"
      unitRef="claim">22</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i137abf0db81a4ec799690639f244c055_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTI5NjU_c237bbf5-8549-4826-ad95-a329421d2b30"
      unitRef="claim">43</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib42253bd8d894b90ac70f97908963886_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTMwMDI_d170c43f-42a3-4275-bc92-53ecfe8a020d"
      unitRef="claim">46</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyNumberOfCases
      contextRef="ib2d977c5bff94d44bd1a0a77dfc89b1c_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTMzNDI_4c388e58-9d48-4927-acde-582110aecf1e"
      unitRef="case">1390</mo:LossContingencyNumberOfCases>
    <mo:LossContingencyClassActionLawsuit
      contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQwNjE_e8632094-23ce-4e98-b90f-08e6dd5132ce"
      unitRef="lawsuit">57</mo:LossContingencyClassActionLawsuit>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i825d494d8ad74328a30cf05aeba68eeb_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQwODg_5084189f-9d8d-43d9-a373-6c1cd2bed9f3"
      unitRef="claim">3746</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id749f16e66d343708ca58160babcbc3f_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQxMTY_7314b1dc-0fc8-4c19-a836-39091109c16d"
      unitRef="claim">1467</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyClassActionLawsuit
      contextRef="i3e84275ff65043f2a1aa42e5f49a54cf_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQzNTQ_e8632094-23ce-4e98-b90f-08e6dd5132ce"
      unitRef="lawsuit">57</mo:LossContingencyClassActionLawsuit>
    <mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber
      contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQzODg_109baece-58b2-4c50-aada-f76c3c001309"
      unitRef="claim">32</mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber>
    <mo:LossContingencyNumberOfInactiveCases
      contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQ2OTQ_dc0b27b4-61ef-45ed-bc76-25701ee39aab"
      unitRef="case">1</mo:LossContingencyNumberOfInactiveCases>
    <mo:LossContingencyNumberOfInactiveClassActionLawsuits
      contextRef="i8e19c07da3604784b1f61734070f38d0_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTQ4MzU_282f5f5b-241d-40de-b007-bc48210353a9"
      unitRef="case">2</mo:LossContingencyNumberOfInactiveClassActionLawsuits>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i029cd62ef0e14cf7ba91174c0f57d16d_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTczNDg_0852aa5e-490f-489e-ad7a-bd357c21576a"
      unitRef="claim">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i7c1a190fb9ad430bbd01dfd78341ef13_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc0Mjk_bceb44aa-23d0-4b22-bfa8-99ef07a07d9d"
      unitRef="claim">10</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie7914aaf2c23404eaa505be9823413f4_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc0Nzg_90100d70-0b8c-4b9b-bb76-9713b27ee451"
      unitRef="claim">8</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i6905d6541f1a41eaa7e544fdf55f3804_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc1Nzk_8b7716a6-f400-47b0-af8c-b82eba88283e"
      unitRef="claim">7</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyNumberofCasesSetforTrial
      contextRef="i170c4207fac14878911ccdae6ebe6376_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5MzE_47bdbc69-2189-47e4-9ad8-e2d6f06cfe14"
      unitRef="case">5</mo:LossContingencyNumberofCasesSetforTrial>
    <mo:LossContingencyNumberofCasesSetforTrial
      contextRef="ibff416dc4d4943ef96c7732293bcfb55_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5NTY_0c1bcf4c-6570-4427-a3a5-4621ac6c48ff"
      unitRef="case">4</mo:LossContingencyNumberofCasesSetforTrial>
    <mo:LossContingencyNumberofCasesSetforTrial
      contextRef="i471e8ab3decf44de9984da88cabdc693_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTc5OTk_707ec33b-5640-4bd9-9505-e073310d8baf"
      unitRef="case">1</mo:LossContingencyNumberofCasesSetforTrial>
    <mo:LossContingencyClaimsDecided
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgyMjQ_bc7dd4d7-54ff-4f73-9240-d66530282a88"
      unitRef="case">75</mo:LossContingencyClaimsDecided>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNTA_f245b205-f97e-4618-97be-73837fff6bd3"
      unitRef="case">47</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecided
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNjE_bc7dd4d7-54ff-4f73-9240-d66530282a88"
      unitRef="case">75</mo:LossContingencyClaimsDecided>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTgzNzk_f245b205-f97e-4618-97be-73837fff6bd3"
      unitRef="case">47</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="ic56af47d5d86478d9aa935fb4c5fab66_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0MTE_95258588-f1f7-4aa8-b492-e1022e11c09b"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="ic48616efb2c747e4ad07dbc20dd6318a_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0Mjk_0c7c59e4-9083-4f10-abbe-a07289f3033e"
      unitRef="case">7</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i7915e288e3e547a89d5b90c15b002d85_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0NDg_a3d5a467-b3da-4451-bac0-b5c0a135b331"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="iaa7d7842072042029b37c8e58321a790_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0NjM_a358b936-fccd-42d1-9de9-ae5f786945ba"
      unitRef="case">10</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i9c1acd96e2d247de8e9ffbda07748403_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg0ODA_24ecd4b7-9ac0-4151-a482-765d010a9411"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MDE_947c39b9-a710-463a-ada1-4a8c89d51c92"
      unitRef="case">6</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i00334a51fb834684ac1bef68ec6e4629_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MjA_09a63479-8e0c-4842-b446-8d105dc8c87c"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="ie24403f03a804dd3a1742ecde12c32af_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1MzY_b62b07ab-4e82-4971-bf20-b21c13a4a751"
      unitRef="case">4</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="iac4943d0a50142e0a04534ccdc87f14f_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1NTc_77eda663-1c57-41d5-a26a-6f4b9575a55d"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="ifcfafebb53104f778986825aecf004e5_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMTE5ODM_cf99878e-612e-451f-9b4e-8c2472f596bd"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i0a9b420fbf06470aa983786428710658_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1NzU_8171b79a-aa00-4ec0-a274-33ee79ccbed9"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i6fca4395dd774138b948e3ba799dee3a_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg1OTE_959f3376-0034-46ba-9234-be33a2679383"
      unitRef="case">5</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="id8a13caf9c594420a4982e05e5743e96_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2MDM_9ec3bde5-7176-44d7-a069-dfae29ee97f5"
      unitRef="case">2</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="idf88f4821d864d0eb1215800a0c994a3_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2MjM_52a95a8a-4f23-4df4-a4b6-76e6d9cd420f"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i47eb567f9bbe4ee9b586eb7e4364b47d_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2NDM_ae843161-8fad-421f-b823-0a065f9c89f5"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i9cd612643df6404aa5c549ad46d4bb3f_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2NjA_6ea1e41c-b7c9-41a5-9a13-780ca5a51ee5"
      unitRef="case">2</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="ib83ad46dbea44d23905da42d1ade08e9_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2ODQ_d53accb1-535e-4ab2-96ad-e2966c364db9"
      unitRef="case">2</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyVerdictReversedNumber
      contextRef="i7a69da6cb2e54f86896141523fe42b32_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg2OTE_c8a2099e-e087-4b69-a6d6-c7b2bb7ae4c6"
      unitRef="case">1</mo:LossContingencyVerdictReversedNumber>
    <mo:LossContingencyClaimsDecidedUnfavorableNumber
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg4NDU_65e64d56-3f2a-471f-a830-0c7b8a656213"
      unitRef="case">28</mo:LossContingencyClaimsDecidedUnfavorableNumber>
    <mo:LossContingencyClaimsResolvedNumber
      contextRef="iea5829e73f1045e0979a9f058be7d748_D19990101-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MTg5Mjk_3e7fc2cb-f54e-4cc1-a1a4-9a31018e80ba"
      unitRef="case">24</mo:LossContingencyClaimsResolvedNumber>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i87ca3cff2798450a8d43bf076838e36b_I20230228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzE2NDkyNjc2NjQzNDI_552e6f4d-c185-47c8-8c6c-cff7d64dc3ae"
      unitRef="usd">5000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i87ca3cff2798450a8d43bf076838e36b_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzE2NDkyNjc2NjQzNTc_1d349b47-884f-4fd6-833b-40ea4f1a3de6"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i3d071c49dafe4c0ab73b29c76d6a6c88_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA3NDg_9e72e3e3-6e16-4179-94d9-5d953526e2e1"
      unitRef="usd">4500000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyFaultAllocationPercentage
      contextRef="ic68023ac01c34100962358f7742dc848_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA3OTE_e002b700-a467-43aa-8ec9-538cf154d1f5"
      unitRef="number">0.13</mo:LossContingencyFaultAllocationPercentage>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="ic68023ac01c34100962358f7742dc848_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA5MTI_ff628a3c-93e6-44e6-b7cc-32f090f42948"
      unitRef="usd">1000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="ic68023ac01c34100962358f7742dc848_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjA5Mjg_72b517bf-bed1-4d1b-a70a-33ecf8d16a6e"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i55d5c15b72454fe3ab6a65a94179d459_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjExOTM_0d8e49a5-f0d1-494d-a7a8-ae82fa4e3ea1"
      unitRef="usd">8000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i55d5c15b72454fe3ab6a65a94179d459_I20220930"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjEyMjU_f6a57335-75a8-476a-a9b1-508bef5bdbaa"
      unitRef="usd">1000000000</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i4caa1be6dee14b7da122d03361a0b36e_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjIyMTQ_082d8152-d252-45b0-add3-170b073f754a"
      unitRef="usd">10000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="ibce2ab3da83c4ec2b9d87386b1b038ec_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjIzNjQ_2c6c9374-8527-4ab7-9349-3aa1ef3d99c1"
      unitRef="usd">30000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="ic4312a6e41a645e78741c53abfb9b9b7_I20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjI0ODA_82fb998d-96d1-46e0-bb9e-b5fa2a3904d2"
      unitRef="usd">2300000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="id14f18627ded4c498559f94480d4c268_I20000731"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjMxNzM_6a92ff0e-8c28-48b8-9674-731b7a01bf71"
      unitRef="usd">145000000000</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i1878a54117dd41c49cbfbb12813f60f6_I20000731"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjMyMTU_59f9db7b-be2d-4a5e-b62d-f1ba6ea733d5"
      unitRef="usd">74000000000</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants
      contextRef="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjM3Nzk_72c49fa6-1a79-494f-ae90-fc9c672d51df">P1Y</mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants>
    <mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants
      contextRef="i5500f077a7c3473a827ef66ac86aa7a6_D20060701-20060731"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjM5NDg_d3d99487-0898-46f0-b051-41ec40578d7b">P1Y</mo:LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie99b75df4d1c4a3e929e255970a683a0_I20080131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU2Nzc_88ab743f-20d8-4f21-960d-c26c54733073"
      unitRef="claim">9300</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic3f5b4ed913b42fe8a04502626591600_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU3NTk_f61c6e63-a9c5-4f61-99b4-d377a4a89916"
      unitRef="claim">551</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ibe1d211aa1a14a2e8f642c7b33db6494_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjU4ODA_6e1753e7-626e-4ea3-adab-3d07746f5479"
      unitRef="plantiff">705</us-gaap:LossContingencyNumberOfPlaintiffs>
    <mo:LossContingencyClaimsDecided
      contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjYzMTE_25cabd18-62fc-425d-9257-c3a675ef136a"
      unitRef="case">143</mo:LossContingencyClaimsDecided>
    <mo:LossContingencyClaimsDecidedUnfavorableNumber
      contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY0NDU_862d1b49-fcee-4362-aa5e-9cffe012dd11"
      unitRef="case">79</mo:LossContingencyClaimsDecidedUnfavorableNumber>
    <mo:LossContingencyUnfavorableVerdictsPendingReversed
      contextRef="i170c4207fac14878911ccdae6ebe6376_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY1MDA_5e410283-4471-4aa3-bbab-598d6c36edea"
      unitRef="case">5</mo:LossContingencyUnfavorableVerdictsPendingReversed>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i19b51d165d0f46778eef2721fa2313e6_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjY5Njk_be87e32f-237b-4b96-a795-3e5cf19e0d46"
      unitRef="case">57</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i296abd7b36374cefa6b045a659376f32_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjcwMjU_5a13b0b9-c6d1-4a07-af38-bd9fff19f7f2"
      unitRef="case">47</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i12c6d88f04834b87aad507967fe72e0f_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjcxODQ_887a12e9-f501-4146-ac28-6af9c5f42958"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyVerdictReversedNumber
      contextRef="i14e9bdff03c04990be62bbba97421122_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjc4NTc_1d36f499-ae1d-4254-a437-780f4be04b50"
      unitRef="case">3</mo:LossContingencyVerdictReversedNumber>
    <mo:LossContingencyZeroDamagesVerdicts
      contextRef="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjc5ODk_0cffb315-c019-4eab-a150-d3aa32d0afbc"
      unitRef="case">2</mo:LossContingencyZeroDamagesVerdicts>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i497dcf5727db4f4c910d06dedc069b4f_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgwMjc_abb10b99-7791-45a9-b6de-6307ae3867fa"
      unitRef="usd">0</us-gaap:LossContingencyDamagesAwardedValue>
    <mo:LossContingencyZeroDamagesVerdictModified
      contextRef="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgwNzk_1c6c0949-40af-43d9-8462-49ed7a4cdf21"
      unitRef="case">2</mo:LossContingencyZeroDamagesVerdictModified>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id093ad92ec77434999f414b5e9c5764b_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgxNjA_3c429746-73a0-4ecb-b6d7-f6336c011c7b"
      unitRef="usd">0</us-gaap:LossContingencyDamagesAwardedValue>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i019cbbd7765340719c2430dc78519295_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3MjgyNDQ_d5bb71f7-cb86-475d-b7d7-8b8e73ca72d6"
      unitRef="case">1</mo:LossContingencyClaimsDecidedFavorableNumber>
    <mo:LossContingencyClaimsDecidedUnfavorableNumber
      contextRef="ia91a4fb22e6f45518c962f7f28ad376f_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg1MDA_03650793-dc39-478d-ab67-7873de642220"
      unitRef="case">3</mo:LossContingencyClaimsDecidedUnfavorableNumber>
    <mo:LossContingencyClaimsDecidedFavorableNumber
      contextRef="i300ff9979645484a96be74f4cbad94a6_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg4MjU_94b8e49e-e4e7-47cd-b7c6-3c1333407104"
      unitRef="case">2</mo:LossContingencyClaimsDecidedFavorableNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i0df68acf1505499c841787fe26736dbf_D20230424-20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Mjg5Njc_c17980d7-8587-4f5b-b3b7-d7209ae65984"
      unitRef="claim">1</us-gaap:LossContingencyClaimsDismissedNumber>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i94aba2dfe6f940fdaa35b3888c250151_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZjA2ZDYxNjgxZjU0NDUzNWFjN2ZkY2ZhNzAxMDU4MjRfNA_8b8115d0-2f98-4efc-9264-be04e09567ea"
      unitRef="usd">5000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i2dccdeba725b4dc78842d507b0a1991f_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZjA2ZDYxNjgxZjU0NDUzNWFjN2ZkY2ZhNzAxMDU4MjRfOA_98efe92f-1383-45f3-bffb-cf2f40b38bfa"
      unitRef="usd">3000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i2dccdeba725b4dc78842d507b0a1991f_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NTVlM2VhMzY3YjdmNGZkMWE3YWVmOTc5M2U2NjJhNzNfNA_df13e3ae-f71d-45cb-9580-af086663f0ad"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i033be350699e4706b3c6851d29b8b749_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzItNC0xLTEtMjIzMzkxL3RleHRyZWdpb246YTM0Nzc4Mjc5YTU0NGY5Yzk1Y2Y1NDI3M2U0NTk0OTZfNA_e105494f-e607-4bb2-a5e3-305e161199ee"
      unitRef="usd">1000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i17d488c73bb644d1bc0a479f11fbe8b4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzItNS0xLTEtMjIzMzkxL3RleHRyZWdpb246N2I4YmU5MjEzOGJjNGViMDkzMGM5NjE2ZTQwYmE1YjdfNA_0ca6b7c2-8136-4688-a497-ccba1855fac4"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i28e721d76a5f489fbcdc920d74435591_I20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzMtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246N2MyOThjODgzY2ZlNGVhNGFiYTA4ZTNjNWViMjkzMmNfNA_391a4c14-7714-43dc-b3ee-fbf5d3b19a6e"
      unitRef="usd">3000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="ief95ac0f1b534c56a693a3370c8c913f_I20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzMtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NTMyNWE4MzdkYTViNGI4NGE3MWFkOWY0MTI2YzczOTNfNA_9f606cc0-3521-4d8d-b58d-a405320e6c61"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i017bc393a586425685f5c81ac9bbd36a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzQtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MzllMzI1YjE5OTdjNDIyM2JmY2QwMzA1ZDliMWY0ZTRfNA_e664777a-eb3b-49cc-9044-dd9966ba2985"
      unitRef="usd">15000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i6191346a68624c76936656e4f4e55fbe_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzQtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MWMxNTMyYWIxZTJlNGFjM2FhNjA0NTc0ZWJhYjdjYWRfNA_562b0e2a-29d0-4a23-8e70-d64085443d68"
      unitRef="usd">28000000</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="iadd63ebeb9da4c4e80b4d08ae9800f7b_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Yzk5MzM5ZWE1MjkxNGM2ZTk5ZDQ3OTY3NWE1OWEyMjNfNA_8298bec9-6ce1-4809-a2a5-3b94f9c5da40"
      unitRef="usd">6000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i8d9ba1b77468485198eac867421125fd_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Yzk5MzM5ZWE1MjkxNGM2ZTk5ZDQ3OTY3NWE1OWEyMjNfOA_ccf9b72f-a6f0-46ba-9f69-48a2e4dd719b"
      unitRef="usd">3000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i8d9ba1b77468485198eac867421125fd_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzUtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246YWJjZGJiMTcxZTA3NDRmZWFlZWU4NDMwNWNiYmRhMzJfNA_f35d480b-00fc-42eb-a0f1-8a08387df056"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i3adaf5ea11094a4cb8c711a96d4ae229_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzYtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246ZmI1NjNkMGVlMjYwNDkyMDhmYTVhNWY5NDA4MmQ1OWFfNA_6e38f97a-70e4-4d02-aac7-c624ee4bb8cd"
      unitRef="usd">3000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="ib02c207b06774fd59c5484ff5302f756_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzYtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MmVhZTIzNjgyMDNhNDg4ODk2OWYzNzliYzdiYTNhMzhfNA_b7ec91e5-d149-4981-89af-0126425878f7"
      unitRef="usd">12000000</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="ia9461abd7dc04b78b0217e87d27ace97_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MmNmOTlkYzdmZDg5NDc0M2ExMDYzZGRiMTM2YTFmZDNfNQ_d58c7b5b-c602-4728-bcf5-ea13965b1003"
      unitRef="usd">1000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="ia9beea181cf140f9adfcebd371d4abb8_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MmNmOTlkYzdmZDg5NDc0M2ExMDYzZGRiMTM2YTFmZDNfMTA_93cf517f-8df4-4058-a0cf-cd389a7f4ee2"
      unitRef="usd">1000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="ia9beea181cf140f9adfcebd371d4abb8_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzctNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NDc4YzQ1ODA0NzZlNGJjMjlmY2VlODZmODVhYTQ2MGRfNA_19d1ea81-ec28-4565-9237-7db468a08f63"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i6d98007769944dc9b0168ff938a9dcc1_I20180930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzgtNC0xLTEtMjIzMzkxL3RleHRyZWdpb246MThiMTI5NWUzN2Q1NDdmN2IyMDlkZWUyODljNzVkZTRfNA_1c50ad53-fda6-4145-881c-69ca7d947742"
      unitRef="usd">2000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i11254f9a2eb24f83821b5815368b8e08_I20180930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzgtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246YzJmMDQzOGJjOWU1NDAwOGFlNjkwMTA3OTA4YWJmNjNfNA_ee8f9d92-8c2d-46d6-94ac-ed130a72dc7b"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i72830ce222554341a4a9785d1ab879bd_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzktNC0xLTEtMjIzMzkxL3RleHRyZWdpb246Y2JlNThkYWRlYzBjNGFkM2JkYWE1ZTM4ZDQ2ODU1OTJfNA_6cafe0a5-74ac-4484-9e11-a536b89927e6"
      unitRef="usd">2000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i700cb3ce10984b889870b8488b2700b5_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzktNS0xLTEtMjIzMzkxL3RleHRyZWdpb246NWYyMGRjZWRhOGNkNDVjMDliZTM5YmE0Nzg3YmMyZWFfNA_ed60daac-b141-451f-a468-8b111c2feed4"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="idc078b33f7684f5296fa7045d4b552eb_I20150930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTQtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOmY2ODBjMzM2NWNiNjRlYWM4ZmFlMjEwMzg3MWVlZDRjXzQ_bb7ec701-dd4a-4993-880e-be6394483d37"
      unitRef="usd">5000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyCompensatoryDamagesAwardedValue
      contextRef="i940de6589e0b4ee69091b883a32e09d1_I20150930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTQtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOmY2ODBjMzM2NWNiNjRlYWM4ZmFlMjEwMzg3MWVlZDRjXzEw_843c8c94-3b91-4a89-9480-426f14d444d8"
      unitRef="usd">1000000</mo:LossContingencyCompensatoryDamagesAwardedValue>
    <mo:LossContingencyPunitiveDamagesAwardedValue
      contextRef="i940de6589e0b4ee69091b883a32e09d1_I20150930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo1MzA2NmFkNjI0M2I0NmUwYWRmMGRkZmExMGI1YTUzMS90YWJsZXJhbmdlOjUzMDY2YWQ2MjQzYjQ2ZTBhZGYwZGRmYTEwYjVhNTMxXzEwLTUtMS0xLTIyMzM5MS90ZXh0cmVnaW9uOjI2M2IxOWZkZWRkZDQ2ZDk4ZGQzNTQ0MTYzZTBmNDk1XzQ_0af84a33-ea8f-40ba-8271-1b1889c903b4"
      unitRef="usd">0</mo:LossContingencyPunitiveDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic81bb1c5437a44efb6f55698d59aec06_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzEtNS0xLTEtMjIzMzkxL3RleHRyZWdpb246MGI3NTEzYjFhNjAyNGFiMmJiY2U0MzE2N2I5YjMyYWVfNQ_8d288b7c-ca9e-4861-b90a-8395845b6ff5"
      unitRef="usd">1000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id2f8c13313ac4e01af20b71a719f8da6_D20221001-20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzItNS0xLTEtMjIzMzkxL3RleHRyZWdpb246N2FlNzZjOThlMGIzNDVkNDkxN2VmZGQ2ZGQ2ZTRhZmFfNQ_215cbf62-631e-48e1-bf1e-3906504305d8"
      unitRef="usd">1000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i2680e01eb0d943bc86816de660361441_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzMtNS0xLTEtMjIzMzkx_566f8f3e-7dc9-4a2f-b3ed-9ae0ec10b3fa"
      unitRef="usd">2000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic7fbbab892b44cfeaa59dc1d86841818_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzQtNS0xLTEtMjIzMzkx_2245bd4f-6d65-49d2-a192-c4c8dd5a0a82"
      unitRef="usd">3000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i6234f79724d344e6bab36b0693d39350_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90YWJsZTo2MzI1Y2FjZmQ2YjM0YmM1ODc3NDc0NjVkOGUxZjQ1MS90YWJsZXJhbmdlOjYzMjVjYWNmZDZiMzRiYzU4Nzc0NzQ2NWQ4ZTFmNDUxXzUtNS0xLTEtMjIzMzkx_38382131-64a0-450d-919f-cdcb9062e6ab"
      unitRef="usd">5000000</us-gaap:LossContingencyDamagesAwardedValue>
    <mo:MaximumBondForAllDefendants
      contextRef="idd5c8372783a4bf6bc692e11c709e409_I20090630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDU3NzI_61bddecd-938f-484b-b63c-cdc9b53c018b"
      unitRef="usd">200000000</mo:MaximumBondForAllDefendants>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="id50f063bff6144ba9d1c3bae28cb30f0_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcwNTk_e3696b5d-f351-4be6-9642-806dec166c7d"
      unitRef="case">61</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i40081f1b6885464e9d63334981371279_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxMjY_fbbab39c-a8c6-4c77-9904-878e0c34e790"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i7b18f9afe75a43fca6bafec8103beadd_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxNDQ_b19f8472-fbdc-43f9-be7c-bcf6c858ab0f"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i0dd7051cbe8249a892d2558422f99b31_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxNjA_6757f074-ae06-49ad-b220-8cb921510a9c"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i0060f473b507459fa695d7f7e862b35c_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcxOTI_e9c7e324-b091-49d6-84d1-48d34f952d7b"
      unitRef="case">2</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="iff2761f6e6a84a72bf9453a2877514c2_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMDc_215ce023-1f72-441e-bf04-2375db689e21"
      unitRef="case">2</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="iec26b5b167f64b948eb60bda8d571759_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMjM_9369c00b-09f0-4a64-ba44-9ee4b7a147d0"
      unitRef="case">3</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i2140db0c9f194d7598ef7666ded56ffc_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyMzU_bbcf1baa-f408-4731-aee6-34ec33a21714"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i73f23159f88b43b1ad03568c321c2d5c_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyNDk_ae1e7fb3-7d95-4df7-bb64-a24aa1c3acda"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i601e952e30854bf9b7959748729929fb_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyNjY_917acf08-5a54-4d41-aeda-4569a3c08630"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="ib9739c01de394810956d3ca2bb685830_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyODI_bc83bb81-4724-4fd6-b0f7-8888e0e796ad"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="ifc14a32dde064ccdae95f715a64a3ec8_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDcyOTg_86c3212e-77d4-401b-8640-c67881c49907"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="icac1b63e2f934ed9a1ea24d4138a8bc9_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczMTU_bfa522f1-a2b8-4326-a1cd-3af665a616ae"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i487924c2b1964c8e814c86ad00645620_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczMjk_f3db36b9-465b-4bf9-b350-34201d7fee15"
      unitRef="case">29</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i77ddfa361b0245fc8632a21a5ab861d1_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNDc_63d5a79e-a540-4d90-909f-91aaec4a70fe"
      unitRef="case">6</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i9aeed91145b54f9e84c1ab265089eff6_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNjM_e31a6ac8-cb76-4325-b79c-19573b36d54f"
      unitRef="case">2</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="ic41867538a1a4ecaad3784d369bba1cf_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczNzU_394b77ea-9133-4152-827a-9f296622f563"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="ibd3dd41044494e7fb215da3b8dbf74b3_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDczOTE_a5aa03b1-37ba-4009-9ac7-55a64c84250a"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i8c235c89cfaf42189b0ee56ef85f0f77_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0MDU_df9590d7-2075-4abb-b567-c0309d337bf0"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i53df00b29f7f48839e6a9318937b699a_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0MjU_95abb048-6359-4733-a8e0-cd256ac9c2e6"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i44b75c2442dc43c0a7d18a54f55c6e42_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0NDQ_16d97437-99e8-4b04-b26d-1a98d9689217"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="id4697be7d479446d97c049ae8736f48f_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0NjY_f471b8dc-e7c4-4245-ac9d-9aaedf0e5722"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="i6bfde9de540b4ed0bb63aaf5d758c946_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0Nzk_d8e2f4a2-4c95-4d48-b97c-29b3e9938dd0"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <mo:LossContingencyClassNotCertifiedNumber
      contextRef="ibf123308c49642739be1ff2dfe411383_D19960501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc0OTk_b155a30e-c6fa-41b1-8b1c-916cbc454319"
      unitRef="case">1</mo:LossContingencyClassNotCertifiedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i6905d6541f1a41eaa7e544fdf55f3804_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc4MDI_8b7716a6-f400-47b0-af8c-b82eba88283e"
      unitRef="claim">7</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if79ec6e4c9a74c19997a9dca74955a22_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDc5Njc_4bc62b40-d933-426c-b96c-f72c359c01cf"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyNumberofManufacturers
      contextRef="i2e90104cb10647bb85cd65620e32994c_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg0NjA_2c78c5e0-1087-4536-8a3d-834e72c309d2"
      unitRef="manufacture">3</mo:LossContingencyNumberofManufacturers>
    <mo:LossContingencyNumberofManufacturers
      contextRef="ia6d6d211a38941ea89399fa49afe5f52_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg0OTY_97d1f6d4-7998-42d5-89e9-0edd56526603"
      unitRef="manufacture">0</mo:LossContingencyNumberofManufacturers>
    <mo:LossContingencyVerdictsUpheld
      contextRef="i2e90104cb10647bb85cd65620e32994c_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg3NTk_88463d02-0635-4b70-b9ee-d2577651cad1"
      unitRef="ruling">2</mo:LossContingencyVerdictsUpheld>
    <mo:AmountAwardedtoOtherParty
      contextRef="i93b593a0985a40cc8016f69134a44753_D20190301-20190331"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NDg4NTU_f8818d1b-089e-4dd0-b864-8f7d851d324f"
      unitRef="cad">13000000000</mo:AmountAwardedtoOtherParty>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id148113ea1ef41e0add7c35363136f03_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTA0Mjk_f1d267ef-1345-4db3-b11c-fe66428f2765"
      unitRef="claim">10</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyNumberofManufacturers
      contextRef="i75bf439c827a43829f739f2ff5266976_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTEzMTE_45cee2cd-fb45-4589-8e70-4583fa1ae59a"
      unitRef="manufacture">3</mo:LossContingencyNumberofManufacturers>
    <mo:LossContingencyNumberofStateswithSettledLitigation
      contextRef="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTE5NTA_0ff53898-e64b-43bd-b43e-bbdf41c22cd6"
      unitRef="state">46</mo:LossContingencyNumberofStateswithSettledLitigation>
    <mo:LitigationSettlementAnnualPaymentAmount
      contextRef="i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTI1NjA_e809f346-5c26-47fb-a69a-e975571fa23d"
      unitRef="usd">9400000000</mo:LitigationSettlementAnnualPaymentAmount>
    <mo:LitigationSettlementAnnualLegalFeesPayableMaximum
      contextRef="i857721e1a42b4c4895342b88f12153b0_I19981130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTI3NzM_13667492-ca24-45ef-a464-bc9a550a08d9"
      unitRef="usd">500000000</mo:LitigationSettlementAnnualLegalFeesPayableMaximum>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i0d8f32c1fb40455bb5e51678f9f29624_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzk4OTU2MDQ4NjAyNTE_03de6fd9-becf-4233-a6ba-13b1562f104a"
      unitRef="usd">900000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i94e854b8d51348db9f3ecb6573a91237_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzk4OTU2MDQ4NjAyNTE_6237c2f1-b00c-4b1c-9355-f68b0ad26ac5"
      unitRef="usd">900000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="id147ed05231e49888e6eec1a1de209d8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3MDk_a6ad4f98-1d3d-4273-80da-1e08ede15056"
      unitRef="usd">388000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="iaea3aff15c3244e099d22efd00005e87_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3MjM_2eea9012-d888-49fd-8506-f71339574d65"
      unitRef="usd">181000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i366e41742fe34ddab3a6ac544395ef0a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3Mzc_8921249b-66d1-48d2-b111-e6edfadc6f38"
      unitRef="usd">154000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i06db80a9cb864760a78eb4b727fccc60_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3NTE_8a10700d-f2fc-49fb-a70a-564795212db9"
      unitRef="usd">185000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i6a39c242a89b45ba8ba9304730ce2c3d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3NjU_50dae0b8-d17c-40c1-af14-e61fa957988b"
      unitRef="usd">250000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="id52cc241f4134704b38b12055f4d1063_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3Nzk_f34499da-85fb-4027-a06c-ad800573f1a9"
      unitRef="usd">211000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i98ab7c86e216435ab8c328cd46889009_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM3OTM_6a328e86-43e0-436c-8436-1a298c030e7a"
      unitRef="usd">218000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i88cce377b1794cafaea3109e44da8255_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MDc_3aec9cc5-e124-4381-a770-f8d979c9cb94"
      unitRef="usd">166000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i717c1ffac0354612b496c8adfb4066d4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MjE_6171f1d8-f895-4225-beb4-507d0ff47fa2"
      unitRef="usd">214000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i88aa0ae8b6904cfaa051db486ab28768_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4MzU_b51f5dfd-7196-447a-bd70-6bcbc4468c06"
      unitRef="usd">224000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i4feaea05ac4a4fb3a34ec68b4955edbb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4NDk_b5c7caaa-014a-40bf-b3b7-7180b9a81bd1"
      unitRef="usd">258000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="ia6488ac6ab1d450094cc398cf207f538_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4NjM_63bc64bf-2624-4f0e-a9a5-c3c233e1e7ac"
      unitRef="usd">313000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="ic812762e464a4962a618c514c4377af3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4Nzc_d8329049-ab7f-42a1-9217-096f35a79715"
      unitRef="usd">292000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i6b42de2c9385496eaa33ccd7de4d5f3a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM4OTE_4907ab63-a5c8-49a8-8729-6b80f85ff651"
      unitRef="usd">285000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="iafc3e2cc3c8b46a39dee066c06a6604b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MDU_4feda39c-2965-4b0c-b975-66f0098744be"
      unitRef="usd">318000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i85efb7c5447949b2a29da6afbe426465_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MTk_88f26083-a949-460a-8ae0-06a3f4effd2e"
      unitRef="usd">415000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="i0570863d6e264a92a3cae8a3dbab2b48_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5MzM_6f6e245e-7b70-4d86-80f9-32feb0bf857e"
      unitRef="usd">572000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="ibc46289ddf384a55817708ab513cdea2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTM5NTE_36d0c4ea-3770-42c0-9683-61e57fdeba09"
      unitRef="usd">675000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LitigationSettlementEstimateofPossibleGain
      contextRef="ibd2dea1c170648f5a808f3b76a33303a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU5NTI_92359c03-924a-4635-8bc2-a7d8dc8dac93"
      unitRef="usd">571000000</mo:LitigationSettlementEstimateofPossibleGain>
    <mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne
      contextRef="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ1NzU_f3279e22-fa8b-41bf-bac5-1ba1a7c89a1b"
      unitRef="state">36</mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne>
    <mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne
      contextRef="i13f79324ab2e445ab3dd114b45e1b5ef_D19980101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU5NDc_1e7d769e-27df-461b-af8f-eb09c3c9acc7"
      unitRef="state">36</mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne>
    <mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation
      contextRef="ib0a0d0e0236740f7be74ed7a98673a30_D19980101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ2NzY_c59ad48d-e6e8-4760-9d3d-5fedcedd9c92"
      unitRef="state">35</mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation>
    <mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation
      contextRef="iee8944fccf0041b29f69b6e0e45d7eab_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ3MjE_30df6b9d-df59-4cfa-8b0b-795875038c98"
      unitRef="state">1</mo:LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation>
    <mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne
      contextRef="i0c8e8c08cbe740d4a306f6bb4a27e669_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5MTA_11ae9cc3-4d03-41ef-839f-f37528b67701"
      unitRef="state">37</mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="iec5a205e894c47679bfac6bbc2c7d660_D20220301-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5NjM_dea885ec-ad86-4691-b0ed-0fcf53d2d036"
      unitRef="usd">80000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i606794f712334fc29204002ba0d6ccfe_D20220301-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTQ5ODI_c18aeb2b-a8ca-4c49-be51-91e651768b36"
      unitRef="usd">20000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i9b807a28cc05453d86e74e69ed77073d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUxMDg_c599142d-0c08-4bb2-a1e9-3e0d06c12a5c"
      unitRef="usd">80000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUyMzU_66b3c7e7-561d-485a-b068-33da8adab4f5"
      unitRef="usd">1150000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <mo:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty
      contextRef="ia387c6458a1e4b56864e914a4f653ab8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTUyNzY_0b308b21-0f10-4b17-823f-3701c95c5b24"
      unitRef="usd">410000000</mo:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="iad95738830284f1496045d0fe44e4fb8_D20150101-20151231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTU1NDE_8080f80d-1a22-4cae-b289-10572005e20a"
      unitRef="usd">435000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ibb882978d08a4cea900603cee8983240_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTU5MTQ_761ce63b-3006-4a49-a3f4-54bc9cb2a736"
      unitRef="usd">4000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <mo:LossContingencyNumberOfStatesWithConcludedHearings
      contextRef="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYwMjc_f0927ba2-a8b2-4d01-a8c7-c2121084dedf"
      unitRef="state">9</mo:LossContingencyNumberOfStatesWithConcludedHearings>
    <mo:LossContingencyNumberOfStatesWithConcludedHearings
      contextRef="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYzNDk_3a13c5e0-8d26-445a-84f1-3464ccdb852f"
      unitRef="state">9</mo:LossContingencyNumberOfStatesWithConcludedHearings>
    <mo:LossContingencyNumberOfStatesNotSettled
      contextRef="ibc05ea3950d74b6bb2b7c05dc53f411c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTYzNjA_1991d8ad-92c1-491a-b709-16c9f1775b98"
      unitRef="state">10</mo:LossContingencyNumberOfStatesNotSettled>
    <mo:LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues
      contextRef="ibcf25cd065fb4f47a44575dc187696f9_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTY0NTU_9fbef33c-9816-4ba4-a902-f9253014ce21"
      unitRef="state">3</mo:LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues>
    <mo:LossContingencyNumberOfStatesInComplianceWithEscrowStatues
      contextRef="ia95a191812c24182a1e85de4ee0e1e46_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTY2OTM_6aa58537-45ba-4ef6-a8c7-ab18bd3f1b06"
      unitRef="state">7</mo:LossContingencyNumberOfStatesInComplianceWithEscrowStatues>
    <mo:LossContingencyReductionToCostOfSales
      contextRef="i3a2a79113e7f4166b1ad0a873dc2709e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTcwOTg_66eabba0-2442-48ac-8548-14a2978f8497"
      unitRef="usd">21000000</mo:LossContingencyReductionToCostOfSales>
    <mo:LossContingencyReductionToCostOfSales
      contextRef="i1ef8738bcb2b4b82b180b4ae7bcb49c2_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTcxMDY_ac1b7532-318e-47d8-a002-272523381dab"
      unitRef="usd">3000000</mo:LossContingencyReductionToCostOfSales>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i1a538cd9271c481bbba5add236551969_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTczNTg_26f68f9d-3049-4302-8fc1-b376bedbdc8e"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i7960b6ec146940de9514bbc0a1bf4361_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTczNjY_19dae44a-8ffb-476e-9066-f42e6832efb5"
      unitRef="usd">5000000</us-gaap:LossContingencyDamagesSoughtValue>
    <mo:LossContingencyNumberOfStatesNotSettled
      contextRef="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc1NjY_db00c967-cebd-4a77-926a-5ed1691f2154"
      unitRef="state">9</mo:LossContingencyNumberOfStatesNotSettled>
    <mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod
      contextRef="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxODA4NzU_af53cc5b-597c-4994-a164-68c524c8b10e">P3Y</mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod>
    <mo:LossContingencyNumberOfStatesNotSettled
      contextRef="i459a014bfee84de18d1fafae6e906a59_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc3Njc_e2ad2fc1-d6cf-4642-807e-2de6f1bbfa1a"
      unitRef="state">8</mo:LossContingencyNumberOfStatesNotSettled>
    <mo:LossContingencyNumberOfStatesNotSettled
      contextRef="i32a0acf6d1854865a837e731f4ec9122_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc3Nzg_78b33339-8471-4d23-822a-aed05218498c"
      unitRef="state">9</mo:LossContingencyNumberOfStatesNotSettled>
    <mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod
      contextRef="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzYwNDczMTQxNzUxOTE_a269ef49-e44d-4fde-9327-ff5d7444fe23">P1Y</mo:LossContingencyNumberOfStatesNotSettledArbitrationPeriod>
    <mo:LossContingencyNumberOfStatesNotSettled
      contextRef="ife1b615ba104488fbcbfa5acfb7870b5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTc4MTQ_c4a66f21-cc38-45b4-a8c1-8d336daddc1f"
      unitRef="state">1</mo:LossContingencyNumberOfStatesNotSettled>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i86a7db94469940b0bdf76635504fc1c9_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTg3MjU_0e56234b-b9ba-4885-bc3e-5174ad80f2aa"
      unitRef="usd">133000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="iefcfe5daa12447d29a502f1354cb8786_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NTg3MzM_6025b7c3-dda9-42c2-a284-07dda31dfe34"
      unitRef="usd">84000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjE1MDE_9060b02c-b922-4c9f-b05d-de187e5f5aa6"
      unitRef="usd">32000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i41840f71688e4157a71edd78b25d1eb2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjY0ODA_67f9c3a2-d475-4c95-9dd2-013ed3edef6d"
      unitRef="usd">28000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc0MzQ_72db9cc0-7d15-4810-be7b-f433b7ff4aba"
      unitRef="claim">57</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc4MjE_5939f01d-2483-4a03-9d42-844f28c88fd4"
      unitRef="claim">57</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber
      contextRef="i4f7b74edbd44460c84d012b02edc884a_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Njc4NTU_25b21ad3-ef7a-4080-8d71-f9b871d90a27"
      unitRef="claim">32</mo:LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i16021c6cb2f8452ba899a790b0995281_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgwNDc_0e36cf11-5b5a-45a7-b093-526ce539afda"
      unitRef="claim">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i825d494d8ad74328a30cf05aeba68eeb_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgyMDI_c34366a6-8560-4f63-8acf-d746e344e54b"
      unitRef="claim">3746</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id749f16e66d343708ca58160babcbc3f_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjgyMzA_e6391883-0bc9-4d00-ac00-c6c34e73b7e2"
      unitRef="claim">1467</us-gaap:LossContingencyPendingClaimsNumber>
    <mo:LossContingencyNumberOfCasesWithSetTrialDates
      contextRef="i34fa5a79a1854ef28fd89687426e80a7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NjkwMDA_e1ec6d90-0514-42ed-953f-f79655c05d96"
      unitRef="case">1</mo:LossContingencyNumberOfCasesWithSetTrialDates>
    <mo:LossContingencyNumberOfTrialsOngoing
      contextRef="iad77b9a8d6704b7f94cdfd087b33ca00_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMTA0NDA_14f70400-4bfc-4a3d-94f1-4c1a99b2531d"
      unitRef="case">1</mo:LossContingencyNumberOfTrialsOngoing>
    <mo:NumberOfThirdPartyLawsuits
      contextRef="i05d64c409aed469ba2221a94eff7af46_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzA4NTY_d18ec8bb-5ef3-4e87-8655-a0a912b90893"
      unitRef="lawsuit">4</mo:NumberOfThirdPartyLawsuits>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i014aa6b6af9b4df1a19a1a2b7dbfb8f1_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzMwMjk_a3f95cb2-a0c6-467c-84b6-ef322d45bd21"
      unitRef="usd">95000000</us-gaap:LossContingencyDamagesAwardedValue>
    <mo:LossContingencyRoyaltyFeePercentage
      contextRef="i2439b9bbedc04392b00b5bd6ac3cc370_I20230131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzMxNzE_4d1d0f57-59bd-46f0-bc35-bf1574729c35"
      unitRef="number">0.0525</mo:LossContingencyRoyaltyFeePercentage>
    <mo:LossContingencyDamagesRecoverableValue
      contextRef="i2aaed74306e54c7498a48f427fbc3dde_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzM5ODI_c445494d-4d81-46fd-982c-b316f7edded0"
      unitRef="usd">0</mo:LossContingencyDamagesRecoverableValue>
    <mo:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i0661196cc9c54e3093e2f4c03321a3af_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzU0MzY_9849d911-2010-41bc-94be-f0ca291caddb"
      unitRef="number">0.35</mo:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <mo:LossContingencyClassActionLawsuit
      contextRef="i41dddbdee384487d9fc710339e3a0ccc_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzY5MjY_f7c0e6e5-8d57-429c-96c9-e5faca6b3735"
      unitRef="lawsuit">17</mo:LossContingencyClassActionLawsuit>
    <mo:LossContingencyNumberOfComplaints
      contextRef="iab08827c3eeb4c2ab05097b269497f30_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3NzczODk_baf21c0f-e208-4bab-987b-2f98637308c7"
      unitRef="complaint">3</mo:LossContingencyNumberOfComplaints>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i9557e21fd37641dcb6ef942359171a0b_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzg4NzY_36cf5cdd-7132-4ae0-a89f-4a8ddf812bde"
      unitRef="claim">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits
      contextRef="i71b49d8d6c6d47188f21140eb5cf4f0e_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzk5NjA_129f52a4-104b-4929-b994-75200e372ea0"
      unitRef="shareholder">2</mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits>
    <mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits
      contextRef="idb201318b1d042eb85ed1f7dff301941_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3Nzk5NjA_7fce5020-cab0-4808-98d1-7fb6f3ebe3f6"
      unitRef="shareholder">2</mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODEzNjM_ecd2a4ec-5010-464d-b552-17d74d8e14c2"
      unitRef="usd">90000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE3MDc_5af8c0a3-20d6-49c7-838e-fab3c2cccdd9"
      unitRef="usd">90000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i5822c95a3a294185ab7547237ec445a4_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE3NDY_0ef31995-62ad-40e9-901a-0b1f9477d3de"
      unitRef="usd">90000000</us-gaap:PaymentsForLegalSettlements>
    <mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits
      contextRef="i9969d54475e54393ac5135266efac3d4_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODE4NDg_2dad99a5-b88c-4131-9c98-64d3508769e8"
      unitRef="shareholder">2</mo:LossContingencyNumberOfShareholdersFilingClassActionLawsuits>
    <mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits
      contextRef="iaf4d332571e345e6b507f1fb9fb044e9_D20201001-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODI1Mjg_7c23b994-2349-40c6-9104-c5c60beb7325"
      unitRef="shareholder">3</mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits>
    <mo:LossContingencyNumberOfPendingCasesConsolidated
      contextRef="i5d69782fb04745ccb891419a687d7398_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODMyNDQ_4621d726-c6ad-4bac-955d-cce048ae1b59"
      unitRef="claim">5</mo:LossContingencyNumberOfPendingCasesConsolidated>
    <mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits
      contextRef="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODMzMTg_5ca9ff63-ab14-472c-85eb-5e15543357fc"
      unitRef="shareholder">6</mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits>
    <mo:LossContingencyNumberOfPendingCasesConsolidated
      contextRef="ida796d6b95934fcfb7672d95fd59a0a8_D20210701-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODQwMTQ_73320659-3983-4c31-84c2-c5395cd4b292"
      unitRef="contract">5</mo:LossContingencyNumberOfPendingCasesConsolidated>
    <mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits
      contextRef="i206b8d7f9a16411c9dc52f69ac0cbe30_D20200901-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODQwMjU_b56504c3-6a76-49fc-84f3-039075210cab"
      unitRef="shareholder">6</mo:LossContingencyNumberOfShareholdersFilingDerivativeLawsuits>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i0f4a22fdfe7e477ebc36bd80a51ce673_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE2NTAwMjc1_b768e143-d2ba-4b3d-9417-a5134512f554"
      unitRef="usd">27000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icd283ff376a14d0ebdf290fc219fa37b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDU3NTQ_554a3eae-75bd-4bef-b9ef-c0b1bfa650f8"
      unitRef="usd">100000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="i4f175730caa1454986f3279a4dbc1d37_D20230401-20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzMyOTg1MzUxMDUyMzc_28c8555a-d9cb-49fd-8e92-371e190c247e"
      unitRef="usd">15000000</us-gaap:LossContingencyDamagesPaidValue>
    <mo:LossContingencyStateCourtsNumber
      contextRef="ida05d85a752347c7bc48b2dd64cfe9f5_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzM4NDgyOTA5MjQ5NDM_30231c43-3acd-490a-bf6d-a8ce4b2b2a44"
      unitRef="court">21</mo:LossContingencyStateCourtsNumber>
    <mo:LossContingencyClaimsNotCertifiedNumber
      contextRef="i7e11164646c440cdb43d7579fbad7dbe_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODU5Mzc_06db7dfd-268f-4ee1-be4b-4963db9e60b5"
      unitRef="case">23</mo:LossContingencyClaimsNotCertifiedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i7e11164646c440cdb43d7579fbad7dbe_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODYxNDY_61fe8504-573f-47e1-99e3-d06d9b300bd3"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i58bffe3b3264449299e2b9f964207eda_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODYyNjk_3c248726-7c2b-4a40-bbd3-77924d32ab52"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0b0ed1328f8e4090ade76858a871504d_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODczOTk_b7e2846b-51be-4275-82c5-f1d2e0e1c7ea"
      unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i527b47537c2b4bf4a38a2dc591ed5842_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODkzMDk_8f56a5f3-776d-437a-a164-472751fd2962"
      unitRef="usd">46000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i66477b67e5d24411a9b94a8ac9d67205_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3ODk0NzY_35cfb1eb-e76b-4d35-b3f3-17d97c076f79"
      unitRef="usd">19000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib778b2cd5f1140bcad20a594e44c8b5c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDMvZnJhZzphYTljM2Y5ZmMwYTQ0NzEwOGMwNWQ0ZDYyMTg3NzNjMi90ZXh0cmVnaW9uOmFhOWMzZjlmYzBhNDQ3MTA4YzA1ZDRkNjIxODc3M2MyXzEwOTk1MTE3OTA4MDk_0ceb6f04-8676-493f-bddc-959d36bd9000"
      unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDkvZnJhZzoxMzQ4MTRhNDk2OGQ0OGY2OTA0NGM4Y2RlNGE5ZDcwZi90ZXh0cmVnaW9uOjEzNDgxNGE0OTY4ZDQ4ZjY5MDQ0YzhjZGU0YTlkNzBmXzE3OA_71fd9abb-10d2-4002-b92b-842ac85e548c">New Accounting Guidance Not Yet Adopted&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Standards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective Date for Public Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect on Financial Statements &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASU 2022-03&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i000128edea2348af9dda2888d5316af0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8xMDkvZnJhZzoxMzQ4MTRhNDk2OGQ0OGY2OTA0NGM4Y2RlNGE5ZDcwZi90ZXh0cmVnaW9uOjEzNDgxNGE0OTY4ZDQ4ZjY5MDQ0YzhjZGU0YTlkNzBmXzE4Mg_66acda69-a668-4e03-b8fe-2dd4a1045c03">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Standards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective Date for Public Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect on Financial Statements &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASU 2022-03&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.  The amendments also specify required disclosures for equity securities subject to contractual sale restrictions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;We do not expect our adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals.  See Note 11. </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtMi0xLTEtMjIzMTEw_d8175764-8543-463f-a192-2494cf5de9a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctNC0xLTEtMjIzMTEw_8cf867ff-e39a-4b6c-b265-3cce7e982cbd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTgtNC0xLTEtMjIzMTEw_974ed2ce-b3fb-4f35-80bb-492e0343c0c3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOmJkZmM0ZjgwMGM3ZDQ3ZjJiMjg0OWEyOGU0NjgzNDM5L3RhYmxlcmFuZ2U6YmRmYzRmODAwYzdkNDdmMmIyODQ5YTI4ZTQ2ODM0MzlfMTctMi0xLTEtMjIzMTEw_251fb075-7a63-46dd-a9ea-432de77dc6a1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjAy_a18bc3b4-d7b7-4405-b196-b7d04150517e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 includes $391 million of unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL, which is substantially offset by a corresponding change included in income taxes.  For further discussion, see Note 10. </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtNC0xLTEtMjIzMTEw_65a5bf98-a630-4561-ade8-4ba819eb9f1c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RhYmxlOjM1ODMzOWE1N2Q2MzRhMzc5ODhlZDBhOTEwY2VjNTEzL3RhYmxlcmFuZ2U6MzU4MzM5YTU3ZDYzNGEzNzk4OGVkMGE5MTBjZWM1MTNfMjQtMi0xLTEtMjIzMTEw_9541de35-f59b-413e-ae1c-591265ec51b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiODE5YTYxMmJmYjQwMTc4YWU0ZWVhZWFiM2JhNjQwL3NlYzpiYjgxOWE2MTJiZmI0MDE3OGFlNGVlYWVhYjNiYTY0MF8zMS9mcmFnOjU1ODhhODAzOGUzYTQyZTE5MTBmNjU1MmZhMzY2MDE2L3RleHRyZWdpb246NTU4OGE4MDM4ZTNhNDJlMTkxMGY2NTUyZmEzNjYwMTZfNjA0NzMxMzk1NDQ1OA_80aaa321-781b-4283-a4a4-5d178bd7e93e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MV%;FBWKZI]P9%-GY<E6UW5_RM),-)B3?MD;5N\&@05TV_7_Q;>>(@P$T'!G
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MC$$WJ:>]J:;U!Z8-T(/@>J?0'4R?OM5WP87&#__5CQM_U. #D9<HP.?(]_S
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M#4XO#6Q"$1Y /FEC^-W" T%E(F4)6E-.(5/KX)X#=Y(5J0FWJ7<LH65"6#W
M/;B+ '<]L @-50'LMQ[XHQZ<53WC(\I@KT$IV$B1@P<'6(>J$4/#I5\*IK^"
M%TDAF6;V2E;/<XH7>5T7^C(7P5#>M$T/C_:6Y6^F2L#>6TG!A;J0-"L/$QO&
M"4\8R< %V)]%Z8Z5/.A1]<#[(M@;X&Z;%A[O6LWY9DWA8$SKO*E*LI5STD_A
M2=A+=(O4;*C@X;:1X?%.]BC%@96G:&!]'[7?LF9QM\)9A$(\E UM7\/CC<UL
M25I'UHHVZ_5Y'$;="F>3BJ<#]1>W#0V'HP>T1ZAI:D=@L>' 2ZZL?*,]\;^>
MRKZ7M;?^MGT2CS?*&Z*@,+XNARF5M?MG4%8*E;9?/EIC$?57H;M0E4AT*G+I
M10,+U79*/-XJ;UE6F"+R_]'C]]'C;T%W3VY9.97;\O*IH)447%<7E>9K<\&]
M+J]UG>\WYN);WMY:,]6M&8XS6ZB1**,;,.E=AK E9741K09:[,N[W%IHN!F6
MKSNXO%-I!.#WC1#Z=6 F:/X=L/P74$L#!!0    (  HZFU:3 LPE+P,  # *
M   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK59=;],P%/TK5I@02+!\
M]7.TD=8"8@^#B0EX0#QXR6UC<.QBN^WV[[EVTJP?7L3#7AK;N>?TG'L=7T^V
M4OW1)8 A]Q47>AJ4QJPNPE#G)514G\L5"'RSD*JB!J=J&>J5 EHX4,7#)(H&
M8469"+*)6[M1V42N#6<";A31ZZJBZF$&7&ZG01SL%KZR96GL0IA-5G0)MV"^
MK6X4SL*6I6 5",VD( H6T^ ROIC'D06XB.\,MGIO3*R5.RG_V,E5,0TBJP@X
MY,924'QL8 Z<6R;4\;<A#=K_M,#]\8[]HS./9NZHAKGD/UAARFDP"D@!"[KF
MYJO<?H+&4-_RY9)K]TNV36P4D'RMC:P:,"JHF*B?]+Y)Q!X >?R I $DQX#>
M$X"T :3.:*W,V7I/#<TF2FZ)LM'(9@<N-PZ-;IBP9;PU"M\RQ)EL+D6!18&"
MX$A+S@IJ<')K\('5,IK(!;ZJ<(^4MG@;(!^H$DPL-7E+OMV^)Z_.7I,SP@2Y
M9IQC9?0D-"C,TH=Y(V)6BTB>$)&2:RE,J<D'%%,<XD,TU+I*=JYF22?A-57G
M)(W?D"1*4H^>^?_#DPXY:9ODU/&E3_"UV3Q-YI7(907DY^6=-@KW]"]?]FKV
MGI_=?N@7>D5SF 9(K$%M(,A>OH@'T3N?]6<B.TA$KTU$KXL]^XSG$C3;QV>T
M1@\<VAY FRP>CH:3<+-OP!,T[H_;H -A_598O[-"7TP)BN0'I=D)):^XU!KT
MZS=$@"LA'A.@%'XFK*Z>H?>@+WR&^L]9N6<B.TC0H$W0H+-R,Q"P8(:L./5_
MX36\OU>5MX.CPIV&Q'U_V8:MJF&GJLO9E4_+\%1+G!R).8T9COQB1JV84:>8
M^1KWA,@?"'[(0G-:MZGB-Q[B]4E*14&DW6@^S:/3Y$1'DCTA?L7C5O&X4_$S
M['J?E?%I^D='5DY#QCV_ESAZ[&11=_Z]/KS=*/*<,\/QD49/5!+UTR.9X5[O
MK4 MW95$8U+7PM0-JUUMKSV7KMD?K<_L=<CU]$>:^BZ%[6C)A"8<%D@9G0\Q
M;ZJ^GM03(U>NP]])@_<%-RSQ2@?*!N#[A91F-[%_T%X2LW]02P,$%     @
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MM2M<@/V^PI@^W_!W.[H7F&;_ %!+ P04    "  *.IM69O1?G'<"  #V!0
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M]K/3 M4P9EH,>PT[3I%DX88,"=FC&5::HL>5\@KVY7A?TQG8,Y#%? 7,G/P
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M8[-0 -:N?UIC-H?)3M6UF(QW/_VQ*OJG[]8@P)E#R/O4JM9\%I]L-HB5"JP
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MS:.QX-H(YWBU4-(15EE!!';M:X7HAUG! ;,'L%VI8P W'GK=!?2I.U"O[LA
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M;@E2!O$REC5!SM%6/A GK_H:U1>7SS"<"K6C;IQ;FT)*E[E.N.Z_O3:,Q)M
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MZ;7A>$EN%O*>963KBN&6PRI<6/=[(5/6&(H?\B%Q5JJD"R4E";>C-['Z.W
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M2;/G*P@-@CL?7>=DT80O,X0<MY:]\14GA]1N=YH%&V*IK=N<>Q<I@@W)<[F
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MTHK38B]P24-[W=$@ ATN/Z%CU=I?.!;*TO7%-TNZ+Z)V!O1_J<B3IN,FV-U
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M"]7^'#%>9@H7/L4JKDU'#9%5SINR-@:#4NEXE4]U''8,AMT]!FEMD ;><:/
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M&UQ)@M&#3,4DR>&.*I:V+M,U$'C%6=Z;W%N'R_.+ZR%4,?T.:73*O>%Z7>$
MW\1S;/+0N7NT=PE"H>7AJB?C U2(]Z%^M;]-SN,E:K<]7D5!@5QCG!6\A.@X
M>7D\(!NO=_'%FSI<J1;&XX(6'E>X$;.5#?B^-,#?OHB!_HY]_C]02P,$%
M  @ "CJ;5GVJ@43="0  I1L  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&ULU5E;<]NZ$?XK&!WGC#WC(^L6.W%LSSB7MC[3M)E<>AXZ?8!(2,0Q"2@
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M(X@63J-YT A%H!(G%[.GL#;(7;*X%$M9UA%,))F6 BYE*^72'#$)5)14O!/
M@8*$KP-VE9RV($Y2Y=HCES23@A04?]0'*5)]J7Q@$(4[?O_V[>_]GS+)Z/_!
M)+2>H?7S%%PL(VP YK0\D]HQ%]58:I>)$K3Y>OHGP1!HK@T6Q:/@EN9>_%D[
M[7/-E0 Y^,V0M'.C_YN$FP*39AJPBC)5,BWV5TQE IBI"BN5<K]QHB?P+N22
M^-UB#<Y)@$@.QRO!$JQ=J$+M3$QDHB\K6QOFV<J2##'3!C;5R5,1\?NH9:@$
M=1,^M*^UYJ94.A3-LEI*6(SM7X?".FQ)<,D"LG$(J#S)#$D7I0KJF$7T-0(*
M#B'<TUX82Q4^:!"]9Q:Z+5#!V;+?P@WC'H*2SKU7F:JFB/ F5X_)9FLKM:I3
M44(U<O:.(T <G/9?BFG$)1@6Q*CV$X9R$F32%U'KICZQTB@!#64I")4[J<9N
ME@!+BD0+XY+A^-03B4AZ[7!(RWI+I5E=<KO#S=PZ8]=!]H _3.FW=)S>IWPB
M(THJ>KL#EI3KF V,#X;]T]9PT($!DA*52LMO2'<9K8!2DWS$#=/G+ZF#H'!<
MTOS3,5L36FL?/XG);)2.S!WV';\\U+QIBV(Q;XKJEL8'XU>#IF@E1')MGP<7
M<%C6SD4W=HK10MY3LQ.1H_1V4\*#\>MA2Q;G6FR2$,W,?T-/6'4Z"7+M/K_X
M3>R'EET[PO82-N >R,YFA(MP.-Q\,%P+T()G ]J- 8AO"\S44: 1!@JN).5H
MT]TV5K#P#7 [W]-'DC554^F?77!33M0.NQV5-8R6_CE5[5AX4/Z'A>P@<M.N
M>]KP(;:N7Q1<QS#5%]?A05AQ3-H >^RW_8KL<3 Y;8,D#@L1;TG(_4=I0D##
M-^M$!D+2UF7>6K;H3B5M:98/126/'$PFC1! 50JCF/,'D^'I.H0C.:QU*V9R
M[3/$_BFIMR%Z](3@HY?/D'M_@6WR*J>0W\@X;E4>2,--26J@NCE$S0)R6?NB
M@=$.^--FC%DTE(,4+)?:=6;Q:(32;)H"FC!ABND68>@987B\:"LOJ]<MQC]5
MOK9X;M64Z4:3LSG:)(R/L=)V_ZQ^B.-$KJ+\@( ,T"6[0D\QJQL3JTS>5.T=
M[=T/H,/YUDSQ5I;<(/)0WW #>^X3:()X-1B(ZSQ/W0L4W-5>DC[SB*>=EJII
M2\]&Z(Y*BJO]!!">.CR@T*30X>2(4$WIN4FU(T./Y*1I;C(.AT?KVX2]7!*<
M8W5'\WNX@<\-[AZ)P]/3\8:=8%:RT$(Y;7.VT6@PH:*5*RI"VJ@=Y&-CV=0G
M:O.FG&?6[.]F=_>:L4.-_5(<_7<S.!:U)V<V%S_KL92N,1@<VK!A;^-U+._;
M E$;'\,].LC1S.]CH4XW([NG#A[(X3Y4V(K&U%+?4A?$8S=UK'SCX\G9;=OA
MZ#@KM<M'?$5!)Z?$69:$8/U-T\?\IZ6F%0"Q7?[8L/^*KW29+SC(I=0E7[Q$
M0%O&T<JH>;QU4I2V4)"J)#'+BMBJ0<]&$!E;B=7Z;N<A[C$NK7U'C^#G-3'V
M ,(LNI?F)7J5\J(+:)@'"6G65%/KSQM:)3+IW/U49K?,AI_@^)6$WV(0^\[F
MVC2R\DV*7/UX7XDT5%&='2YD$:RC>F#W EH;F%MC A>!3"XTM1BI;,1K0VJO
M5MRY/1PIDD'XEB\F#-%G, %PPSD:^$\03?UN'<A;Z>0Z"]8W.-L'F_&KVZWZ
MW>&+?*2L@%ULG-A2#2';JHK*!LAU>*YSK9T]+<TNBCTUJS&QJEA:LKJJRQB<
MN\SYH/_A+F)]FR!#<'I:!Z:[$Q[]^@I!T\6Q,>E;2SO/_J"KXK5=)/>DNW($
MO@\ZZYJ= NGAW<,[9XWU_5WW\R>=3R?H+^;\@8@NZ=# Q:\H[=OV&]1U_/2R
MWAX_8,&8J)5>E&J&HX/^V<N></&C4'P(=L$?8J8V!%OQOX62R"S:@/6919N=
M'HA!^V7NZG]02P,$%     @ "CJ;5D@4F<J/*0  %X8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C N>&ULW7UY<Q-9LN]7J>!R)^P(65BV@<;01!B[Z:8O
M-'X8IN/&B_='275DG:94I:G%0OWI7_XR\RQ5*LEF;L]$O!?3 ZB6L^3)?:M7
MZ[+Z6B^,:9)OR[RH?WRT:)K5^9,G]6QAEFD]+E>FH#OSLEJF#?VL;I_4J\JD
M&;^TS)^<'!\_>[),;?'H]2N^=EV]?E6V36X+<UTE=;M<IM7FC<G+]8^/)H_<
MA4_V=M'@PI/7KU;IK;DQS9?5=46_GOA1,KLT16W+(JG,_,='%Y/S-V=XGA_X
MNS7K.OIW@IU,R_(K?KS+?GQTC 69W,P:C)#27W?FTN0Y!J)E_$/'?.2GQ(OQ
MO]WH;WGOM)=I6IO+,O_=9LWBQT<_/$HR,T_;O/E4KG\QNI^G&&]6YC7_F:SE
MV:<GCY)96S?E4E^F%2QM(7^GWQ0.T0L_'.]XX41?..%URT2\RJNT25^_JLIU
M4N%I&@W_X*WRV[0X6^!0;IJ*[EIZKWE]61:-+6Y-,;.F?O6DH2%QX\E,7W\C
MKY_L>/TT^4 #+.KDIR(S6??])[04OYX3MYXW)WL'_)!6X^1T,DI.CD].]XQW
MZO=WRN.=[MS?<FD;PJ*F3M(B2SK[3:YL/<O+NJU,\K\OIG53$9+\GR$HR"1G
MPY. <,[K53HS/SXBRJA-=6<>O?[;?TR>';_<LX4SOX6S?:/??T3?\7KRWMRF
M>;*JRIDQ&5VNDUEY9RKZ5Y("]4Q2I?1P4LX)RYK&5 0V@@[Q #R=E%72+(CX
M&U.8++%%<I=6MFSKY$MA&[IRT] M@30Q#"*)(OFCK6R=629"NG-+C*)NDHN\
MJ6S*#\Y,U=!%3%FVX!?3VF:6QC7UB*:8Y2U/??TA^7)SP6]\N;GY?#E*TCI9
M$SGC;[QH"0676(8NP!9WIL:O<?)W766S6=%-FFB6IW99TQ8WR11;MK5LIUG0
M\<7@B5= E[-VUB2Y3:<VM\UFE+3%/+4$DRK-\!IXS S+3@GF347DR^^72Y,T
MZ;?XQ1F=2I5.L<YZ85>,H*-D!< V],H<)V)P=928Y2HO-_BW.Y*16W^:Y^86
M2[NS99XRFZ/-T2:23^GLJZ'-5\F[8IZW=/JT02& JFI73?*QNDT+^V<JQW)!
MVSKXVW_\<')R_/+3N\N/_,_)RT,_$YVFK-E.6V&G.#FY!WB6RY6A+9=87+T@
ME%F4>0;LH?<R6\M[='<,#+0U%GMGF">7!;W1SA8XQMD"R$?G5-)_%4$Z71,L
M\[KDDS+?5I@5V^L?)*Y7!*\,.)[>I39/I[G!."MZ@ YC/L?4MK&W B9; ]'^
M(-F A]I"D;#9".HT>&!5UK7E819I@VF)$&9EFV? F30CLB%<R<P=238Y0&!0
M1"GSM@%GF9'0H,DO"L:6N[+BI9& 9+R@YVK3-#D?-G;D!FC*:3J;E4>5(6#1
MX=&#)=9 6.1W(:NAPR7\)Q'*H*%1ESAN-UZ:918/$]F'-\?)5;I, 6H&H"!_
MS7C:FQ;@V)H7+ $(D18 14UD;N>6?C5X'"COB9HW/TH6Z9UR%D=F"5%"SKA'
M:\S*/$^!')_I!EB*T@D#-"==@SD5_5B2L+5TI<M51K3J6\.+7-MFP<,3:K6T
M9<(9XFZ A["T(A6RPF!N0P1L0:,1G>:2QB/*!!=SQY[0-=.0RD(HEELSEQO*
M.^J5F='F95\I,+9N"7VFAO:#&>AD\9JY2[$&(#8-B%T0+7LL&!.5]D$6$%=6
M)[.2PD'X09"N0:*3YR\#4P'*_E%:.01"*L+/-.>1F;QTV+7AE<_3F: +@?&K
M#$V;Q*$N2T;SHS 333J#5/$HN"9V22/8G DLK8CI6; N?[2EH'!E_M':RK L
MH$4EZ6IEZ$P@1/#>!@\3]R2^NB)J!XXV/ D=[N:(>%LY8Q1D?L*H3'>R6QP?
MD1/1.4U0$RC!AHG7! #::M8NZP80#SMF%-1Y>8^TZ8(%1W?^,%NQ<3LYDE7)
MW($TEF5+X!DG;]L*8,&H(X%!62O=)VMF&]%A8G0Z$%I:/6]S7I[G<)!%#F:Z
M5'J-!JCE4(G]EU5A-O[PYRS>2)@NRO9VX63D@ECI@IAN61%1YCG&-01]Y8CE
ME*'D)\(>F4\K=L^K<MD_0L_>R@J0QMHJ0C#"M6AG_&)MS%=A7X1$.91O#S@
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MK$4(9W3N<KYLO-%[=)T8N3 K.=?HM>X1[UH43@+DQ5A9SF8M4;CY-C.KQND
MYAOK^H$AF+PV(BU8A-"LOY5$$I/)N&>UGB<']C#69<#7"-I,79FL2Y8M"*S
MD?4*-#PG)&)JJTIQI]@XD+E380[QDN;K3DA#MX63)PZ.\J*##D\#7NC,2;[
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M&D4$I_Y6.F>BO!5KMVE=E\1ML3/QB'S?VL8,IAL:,0;G94[#PE7H_'_QS:L
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MT9,=$UE/3),\BNE4Q@Q67ZD66C=>#H;B@WZ6S/BTLX)?V]S-'H)TX 62U_L
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M=?[I-E\G<&R->&\#]JUV]DXOXHQ4U8M0:R ?%NZ.AWPMYWO_)%_'K'W_9!X
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MT*;[T90K#(G>/4VYY'\2&M$AX &Z/R^)RO0')EB3%<C+>_U_ 5!+ P04
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M%%RSWV:S!S\/KSO>CK9 8GL6D)+#\FCLJ0)'5IP(7L\'ZA%\)R! "A'C^(=
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M6U!V ?Y?2?2DFE@#]75Y^C=02P,$%     @ "CJ;5E;H)TE$!   @0H  !D
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M&AZ/J9IU-?!4!ZNV?LA8*4LCB]]20C+43H!^7RME]P=GH)DZ%_\"4$L#!!0
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M0\=D<^<T RTJV[9CH;%=V-<<KVF0)@#7,R'T?F 2=!=_] =02P,$%     @
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MAF#-,MJP'$6M@!,LSU$<GJ$HB&+T<#]&)V]/6W#C.OK8X7;VX$XK>3U.@,U
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M!/#YG#&YN5 OJ%;RP_\!4$L#!!0    (  HZFU9YNS9>N@4  &,D   9
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M(".D)B-[]$+-OU%I%)468-'::M=9O#?!C5ZH&3PJC:+2 BQ:6YAZ+<"S+P;
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MDENB;#2RV8;+C4.C&R;L+LZ,PEF&.)/>B4P60+[29]#D(YE5FTGD@AS,G$_
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M;"]W;W)K<VAE971S+W-H965T-30N>&ULO9EM;^(X$,>_BI5;G5JI;4@"@?8
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M%Z<-/79P(8'V:VOQ$(0&''X?Y7]02P,$%     @ "CJ;5@S7>6QJ!@  6S,
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M/*)G;H@6#:B6H)I -8EJ"M4TI;DIM$5#Z#V$_"UO0/++O=,XVCTN&7;>M7;
M,@+=*XEJ"M4TI;G)L>5 Z"\'7MV4QJQG[H<B>&^J(K\SP=5M6IK;(I\UH_4B
M3YML/12H\#CV[UKOZ*%M ZH)5).HIE!-4YH;9]MAA/C[_$.TQT"U!-4$JDE4
M4ZBF*<U-H>TQ0N\1ZF\:QVB?L=&<]]V>=,?Q[C+=\P#0G9*HIE!-4YH;'%L]
MA/[JX6KUL3*_K=IQ+.X>OQ#>&Q6T?$"U!-4$JDE44ZBF*<W-GRTSPA@?GVB/
M@6H)J@E4DZBF4$U3FIM"VV.$_G,>NN/S67L::/.C].%%R.;<W6:"/GT6[^O-
M)IP7F<?N6+OP[T;OL*%U!:I)5%.HIBG-#9NM*T)_7?'DR&WR]:TGW_@WW?NQ
M$>TW4$V@FD0UA6J:TMRXVM8D?(%/:+3U0+4$U02J2513J*8IS;V8@FT](O^9
M%CTZWHWDGNK1G<3^S?4-%:H)5).HIE!-4YH;*EMB1/X2@YK$S>)?KW"SYT!T
MB^7-IHO,/[O].]OW41/5$E03J"913:&:IC0WX+9KB4)Z=D=H18)J":H)5).H
MIE!-4YJ;PD=70O*?YM%G=D>[L_M%=W2SES9BKVW$7MR(O;H1>WFCOZ+PB&SA
M$?D+C[]M=/]D[H-+\SF;%O[AC;8HJ):@FD UB6H*U32EN1&WU4PTP8<W6M"@
M6H)J M4DJBE4TY3FIM 6-)'_;),^PSO>&=YAV!W>:-V":@+5)*HI5-.4YF;*
MUBV1OV[YVX;W95I5Z?1V59FZ_H,7W^AI*:B6H)I -8EJ"M4TI;DIMSU/A%^^
M*D+K&U1+4$V@FD0UA6J:TMP4VOHFPJYC%>U>(VD<=><W6L:@FD UB6H*U32E
MN1<7MF7,V%_&_&WS6^9%F<U2[^3V[VO?QTQ42U!-H)I$-85JFM+<?-M>:(Q?
M16N,EC>HEJ":0#6):@K5-*6Y*;3ES1B[BM9X]^),X[@SN?U;ZYTIM(I!-8EJ
M"M4TI;F9LE7,V%_%^":W^'#UU,A^UDSB]I-[@E=UW:0P7=2'#O&]:47/?T&U
M!-4$JDE44ZBF*<W-]://NQCC$QMM;% M036!:A+5%*II2G-3:!N;<;_K>/V^
M_O_>\.U>&FH4=3^@X,*_N=ZA0@L85).HIE!-4YH;*EO C/T%C&]D?]OUI_T;
M[OT(B#8[J"903:*:0C5-:6Y8;;,SQB\(-D:;%U1+4$V@FD0UA6J:TMP4VN9E
MC%T0;+Q[G:E1=PJC-0JJ"523J*9035.:&RE;HXS]-8KWA7._RUC[M]3[ 0\M
M9%!-H)I$-85JFM+<3PFTA<P$OR;8!*U-4"U!-8%J$M44JFE*<U-H:Y.)_W2:
M'F-WLGM%KDEXW'W]Z]]>[U2A-0BJ2513J*8IS4V5K4$F_AJ$.#=_LMN/3+IG
M!/IWHW?8T'X$U22J*533E.:&S?8CDV_H1YY^FO>H WGT_H>W#X'T'X3Q[U#O
M.8R6(:@F4$VBFD(U36ENB&T9,L'+D E:AJ!:@FH"U22J*533E.:F\-%'EV,?
M:C+9^W$:W3<P^+?7.U5H&X)J$M44JFE*<U-EVY#)GV]##AO0VZDLL]S,@M=?
M@JLZK4WP<[-B,6W&MFH;E$5[A=H_F-QH?8)J":H)5).HIE!-4YJ;;EN?3/#Z
M9(+6)ZB6H)I -8EJ"M4TI;DIM/7)!*M/)GOJD_'.Q7;\V^N=*K1!036):@K5
M-*6YJ;(-RN0O:5":WSH7A-^,;_]D1AL65$M03:":1#6%:IK2G/3&MF&)\88E
M1AL65$M03:":1#6%:IK2W!3:AB7&&I9X3\/2G<O^K?7.%-JOH)I$-85JFM+<
M3-E^)3[T-)--FMI^)9M7S]K2I2KR;+;^?-'K9CPWVW]>EUGS&GFY*I=%D\"]
MR=LM6Z+N92#\^]0[>6C9@FH2U12J:4ISDV?+EOC/ERU_]D-N_9OL/731.@75
M!*I)5%.HIBG-C:FM4V*\3HG1.@75$E03J"913:&:IC0WA;9.B;$Z)=Y3IW3G
M+]JEH)I -8EJ"M4TI;F1LEU*[.]2=M]9L]B&+%NT[Z^Y,W]X)E.\>]&O[ANH
M_;O1.VQHM8%J$M44JFE*<\-FJXVX[T>L[ O;GG=V><.W^YDK.Z\TT$8#U02J
M2513J*8I[2%\P^K6F#I)Z_3\=&[*&W-A\KQ-UVK1\.TKW^U/@])<MY\,_O)5
M.!CN_/QB]#(9M3\?6N;\=)G>F,NTO,D659";ZX8\^O&XR5C9G@+_]9NZ6)X-
MFE?N'XNZ+N;K+V]-.C-ENT#S^^NBJ+]^TV[@OB@_K7?[_/]02P,$%     @
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M=B)_;B/?D7R3/3;PR*7D4;:Y9G3)1#I O?_$N7S=21.43\],_P-02P,$%
M  @ "CJ;5J?EJ0OU"   5F(  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N
M>&ULM9UK;^*X H;_BL6N5C-25<@%VLZV2"VQ]Z*=HZH]>U;:U7YP$P/1Y,+8
M@>Y(^^./$R[& 5PR^VX_M$#QXR2O8R</3KA]+>4G-1>B(G_E6:'N>O.J6GSH
M]U4\%SE7E^5"%/H_TU+FO-)/Y:RO%E+PI"F49WU_,!CU<YX6O?%M\]JC'-^6
MRRI+"_$HB5KF.9=?'D16OM[UO-[VA:=T-J_J%_KCVP6?B6=1_;IXE/I9?T=)
MTEP4*BT+(L7TKG?O?6##ID#SCO^EXE7M/2;UJKR4Y:?ZR4_)76]0+Y'(1%S5
M"*[_K,1$9%E-TLOQ>0/M[>JL"^X_WM)9L_)Z95ZX$I,R^RU-JOE=[[I'$C'E
MRZQZ*E]_%)L5&M:\N,Q4\YN\;MX[Z)%XJ:HRWQ362Y"GQ?HO_VNS(?8*A/Z)
M OZF@-\JX)^J(=@4"%H%O/!$@7!3(#RWAN&FP+!=X-0ZC#8%1LVV7V^L9DM'
MO.+C6UF^$EF_6]/J!TU<36F]@=.B;EG/E=3_376Y:CPIBRHM9J*(4Z'(.UK,
M,D$F&5>*W*^SOR\2LG[Y49;ZC5_(?V7*,_(DE$Y/O2?O(E'Q-%/O;_N57J*:
MVX\WM4_6M?LG:O?(1UW_7.D*$I'8Y?MZ37:KXV]7Y\%W N\7\I+XX07Q!WY
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M:HGE!LT'.$B3?/Y5>5T^M]50!K.\2,?+QN4(QO%D\3WZN=P16PTT;4\#;=E
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MSW!5Q2L'_)PKQF0HACO:V_+V9X?:._+VEX?:=^3MKPZU=P]LOR8!FN7<KU\
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M@;('<'\II7F<V*[<_%3%OP%02P,$%     @ "CJ;5C,_.H8] @  "P4  !D
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M5"[ ^K=2FH/A.JC[_])_4$L#!!0    (  HZFU:^/<N^P@(  &$(   9
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M;?*RFT!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "CJ;5B%&FY?O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M"CJ;5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  *.IM6K*UAS08'  #?+@  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M"CJ;5KQ3*Y!L"   .R8  !@              ("!2@\  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    (  HZFU;DR>8]R0(  %4'   8
M          " @>P7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  *.IM6;%,4XI@$   :$   &               @('K&@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "CJ;5I,"S"4O P  , H
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M965T.2YX;6Q02P$"% ,4    "  *.IM6_:(&E[$,  !((0  &0
M    @('*-@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M  HZFU;3Y?GW$P<  "@3   9              " @;)#  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ "CJ;5IPK.EPW#   %2,  !D
M             ("!_$H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  *.IM6RD27_/X%   "#P  &0              @(%J5P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  HZFU8Z.OH*; ,
M (D'   9              " @9]=  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ "CJ;5M3G;.^Z @  /P8  !D              ("!
M0F$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  *.IM6
M/&VQO>0$  "-#@  &0              @($S9   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    (  HZFU81S,TF<0<  %H2   9
M      " @4YI  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ "CJ;5JB?R6%4!@  ;P\  !D              ("!]G   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  *.IM6?:J!1-T)  "E&P
M&0              @(&!=P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    (  HZFU9(%)G*CRD  !>&   9              " @96!  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ "CJ;5N[XZQ_3
M P  K0@  !D              ("!6ZL  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  *.IM6]-DA&N\*   _'@  &0
M@(%EKP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  HZ
MFU9^($LZN0(   H&   9              " @8NZ  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ "CJ;5FUH7X#<!   +@P  !D
M         ("!>[T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  *.IM66JW9>\H"   &!@  &0              @(&.P@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  HZFU9EU_;@Y0(  %8&
M   9              " @8_%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ "CJ;5G^(BPFW @  + 8  !D              ("!J\@
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  *.IM6NE*_
MPA4%   Z#P  &0              @(&9RP  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    (  HZFU96Z"=)1 0  ($*   9
M  " @>70  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M"CJ;5HVEVT!@ P  -P@  !D              ("!8-4  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  *.IM6E=P)NNH*   6'@  &0
M            @('WV   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    (  HZFU9.$GFWX0,  )$(   9              " @1CD  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "CJ;5GXA\?8$!0
MD",  !D              ("!,.@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  *.IM6H8+9YSP#  #/"@  &0              @(%K
M[0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  HZFU;'
M/YH!W0(   0(   9              " @=[P  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ "CJ;5J6>75SJ @  ;@P  !D
M     ("!\O,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  HZFU;P[-WVP 0  &D;   9              "
M@6X$ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ "CJ;
M5O(AUX!- P  $0L  !D              ("!90D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  *.IM6;\Y'!#(#  !>#   &0
M        @('I# $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   (  HZFU;N@/JU$00  )41   9              " @5(0 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ "CJ;5O[;@\H$ P  H@L
M !D              ("!FA0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  *.IM651+&F"4#  !^"0  &0              @('5%P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  HZFU;7-V3:
MD08  .<I   9              " @3$; 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ "CJ;5@2.<#=5!   W1<  !D
M ("!^2$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  *
M.IM6;%%0$]X$  #7%   &0              @(&%)@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  HZFU8MH/4!NP(  $@&   9
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M970U-"YX;6Q02P$"% ,4    "  *.IM6K97A&_<"  "_!P  &0
M    @(%[0 $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M  HZFU89Z(NL&@(  $H$   9              " @:E# 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ "CJ;5@S7>6QJ!@  6S,  !D
M             ("!^D4! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    "  *.IM6_H;?0S,,  !.J   &0              @(&;3 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  HZFU;N=(_VV@X
M ,7.   9              " @059 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ "CJ;5DNI&LNF!0  23,  !D              ("!
M%F@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  *.IM6
MI^6I"_4(  !68@  &0              @('S;0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    (  HZFU;K _X:&1(  *9W 0 9
M      " @1]W 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ "CJ;5J5>;0<Z @  ] 0  !D              ("!;XD! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  *.IM6D,'92T4*  #-<P
M&0              @('@BP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    (  HZFU:7\IMZ9 4  ) K   9              " @5R6 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ "CJ;5K?8FUY>
M&   4=T! !D              ("!]YL! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    "  *.IM6,?MZ870"  #+!0  &0
M@(&,M $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (  HZ
MFU:PTT] P@(  -4(   9              " @3>W 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ "CJ;5M"FIJDN!P  ,DP  !D
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M=#<S+GAM;%!+ 0(4 Q0    (  HZFU:E1#<_C (  ' &   9
M  " @8#4 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
M"CJ;5KT0>F)/ P  *!0   T              ( !0]<! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  *.IM6EXJ[',     3 @  "P              @ &]
MV@$ 7W)E;',O+G)E;'-02P$"% ,4    "  *.IM6*,F,$]4%   +,0  #P
M            @ &FVP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "CJ;
M5L?7<T]' @  U2L  !H              ( !J.$! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ "CJ;5A^=A6\) @  V"H  !,
M         ( !)^0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %( 4@!U
)%@  8>8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>342</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>176</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Background and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BackgroundandBasisofPresentation</Role>
      <ShortName>Background and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenues from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/RevenuesfromContractswithCustomers</Role>
      <ShortName>Revenues from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Investments in Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecurities</Role>
      <ShortName>Investments in Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BenefitPlans</Role>
      <ShortName>Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Comprehensive Earnings/Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/OtherComprehensiveEarningsLosses</Role>
      <ShortName>Other Comprehensive Earnings/Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - New Accounting Guidance Not Yet Adopted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted</Role>
      <ShortName>New Accounting Guidance Not Yet Adopted</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Background and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BackgroundandBasisofPresentationPolicies</Role>
      <ShortName>Background and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Background and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BackgroundandBasisofPresentationTables</Role>
      <ShortName>Background and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/BackgroundandBasisofPresentation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Investments in Equity Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</Role>
      <ShortName>Investments in Equity Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BenefitPlansTables</Role>
      <ShortName>Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/BenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/EarningsperShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Other Comprehensive Earnings/Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/OtherComprehensiveEarningsLossesTables</Role>
      <ShortName>Other Comprehensive Earnings/Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/OtherComprehensiveEarningsLosses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/SegmentReporting</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesTables</Role>
      <ShortName>Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/Contingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables</Role>
      <ShortName>New Accounting Guidance Not Yet Adopted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Background and Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails</Role>
      <ShortName>Background and Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/BackgroundandBasisofPresentationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails</Role>
      <ShortName>Background and Basis of Presentation (Share Repurchase Table) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/BackgroundandBasisofPresentationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails</Role>
      <ShortName>Revenues from Contracts with Customers (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/RevenuesfromContractswithCustomers</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails</Role>
      <ShortName>Investments in Equity Securities (Summary of Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails</Role>
      <ShortName>Investments in Equity Securities (Earnings in Equity Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails</Role>
      <ShortName>Investments in Equity Securities (Investment in ABI Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails</Role>
      <ShortName>Investments in Equity Securities (Investment in JUUL Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details</Role>
      <ShortName>Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails</Role>
      <ShortName>Investments in Equity Securities (Investment in Cronos Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/InvestmentsinEquitySecuritiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails</Role>
      <ShortName>Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails</Role>
      <ShortName>Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/BenefitPlansTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Benefit Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/BenefitPlansNarrativeDetails</Role>
      <ShortName>Benefit Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/BenefitPlansTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Earnings per Share (Basic and Diluted Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Basic and Diluted Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/EarningsperShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails</Role>
      <ShortName>Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/OtherComprehensiveEarningsLossesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails</Role>
      <ShortName>Other Comprehensive Earnings/Losses (Reclassifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/OtherComprehensiveEarningsLossesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Segment Reporting (Segment Data Schedule) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails</Role>
      <ShortName>Segment Reporting (Segment Data Schedule) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/SegmentReportingTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Segment Reporting (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/SegmentReportingTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails</Role>
      <ShortName>Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/SegmentReportingTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/Debt</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Income Taxes - Summary of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Contingencies (General Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesGeneralInformationDetails</Role>
      <ShortName>Contingencies (General Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails</Role>
      <ShortName>Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Contingencies (Schedule of Pending Cases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails</Role>
      <ShortName>Contingencies (Schedule of Pending Cases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails</Role>
      <ShortName>Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails</Role>
      <ShortName>Contingencies (Non-Engle Progeny Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails</Role>
      <ShortName>Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails</Role>
      <ShortName>Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Contingencies (Florida Bond Statute) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails</Role>
      <ShortName>Contingencies (Florida Bond Statute) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails</Role>
      <ShortName>Contingencies (Other Smoking and Health Class Actions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails</Role>
      <ShortName>Contingencies (Health Care Cost Recovery Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails</Role>
      <ShortName>Contingencies (NPM Adjustment Disputes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails</Role>
      <ShortName>Contingencies (Other Disputes Under the State Settlement Agreements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails</Role>
      <ShortName>Contingencies (Federal Government's Lawsuit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails</Role>
      <ShortName>Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails</Role>
      <ShortName>Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails</Role>
      <ShortName>Contingencies (Lights/Ultra Lights Cases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Contingencies (UST Litigations Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails</Role>
      <ShortName>Contingencies (UST Litigations Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails</Role>
      <ShortName>Contingencies (Guarantees and Other Similar Matters Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altria.com/role/ContingenciesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="mo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - mo-20230331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - mo-20230331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 7 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mo-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockParOrStatedValuePerShare -  mo-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="mo-20230331.htm">mo-20230331.htm</File>
    <File>exhibit101restrictedstock2.htm</File>
    <File>exhibit102performancestock.htm</File>
    <File>exhibit22q12023.htm</File>
    <File>exhibit311q12023-quarter.htm</File>
    <File>exhibit312q12023-quarter.htm</File>
    <File>exhibit321q12023-quarter.htm</File>
    <File>exhibit322q12023-quarter.htm</File>
    <File>exhibit991q12023-quarter.htm</File>
    <File>exhibit992q12023-quarter.htm</File>
    <File>mo-20230331.xsd</File>
    <File>mo-20230331_cal.xml</File>
    <File>mo-20230331_def.xml</File>
    <File>mo-20230331_lab.xml</File>
    <File>mo-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="568">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mo-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 568,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 342,
   "dts": {
    "calculationLink": {
     "local": [
      "mo-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mo-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mo-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mo-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mo-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mo-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 604,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 83,
   "keyStandard": 219,
   "memberCustom": 106,
   "memberStandard": 68,
   "nsprefix": "mo",
   "nsuri": "http://www.altria.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.altria.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Background and Basis of Presentation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.altria.com/role/BackgroundandBasisofPresentation",
     "shortName": "Background and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenues from Contracts with Customers",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.altria.com/role/RevenuesfromContractswithCustomers",
     "shortName": "Revenues from Contracts with Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Investments in Equity Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecurities",
     "shortName": "Investments in Equity Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.altria.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Benefit Plans",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.altria.com/role/BenefitPlans",
     "shortName": "Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Earnings per Share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.altria.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Comprehensive Earnings/Losses",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.altria.com/role/OtherComprehensiveEarningsLosses",
     "shortName": "Other Comprehensive Earnings/Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.altria.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.altria.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.altria.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mo:ReceivableCommercializationRightsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.altria.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - New Accounting Guidance Not Yet Adopted",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted",
     "shortName": "New Accounting Guidance Not Yet Adopted",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Background and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies",
     "shortName": "Background and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Background and Basis of Presentation (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.altria.com/role/BackgroundandBasisofPresentationTables",
     "shortName": "Background and Basis of Presentation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Investments in Equity Securities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables",
     "shortName": "Investments in Equity Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.altria.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.altria.com/role/BenefitPlansTables",
     "shortName": "Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings per Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.altria.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Other Comprehensive Earnings/Losses (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables",
     "shortName": "Other Comprehensive Earnings/Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.altria.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mo:SummaryOfIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.altria.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mo:SummaryOfIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.altria.com/role/ContingenciesTables",
     "shortName": "Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables",
     "shortName": "New Accounting Guidance Not Yet Adopted (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i87c63010612240ff9b4601af94a82301_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "mo:OwnershipPercentageInConsolidatedSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Background and Basis of Presentation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
     "shortName": "Background and Basis of Presentation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i87c63010612240ff9b4601af94a82301_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "mo:OwnershipPercentageInConsolidatedSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i8fd1800c9eeb43a08f3d8507bb997cc7_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails",
     "shortName": "Background and Basis of Presentation (Share Repurchase Table) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i31770ac6973b4c46a9b96965f34f8ec4_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails",
     "shortName": "Revenues from Contracts with Customers (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails",
     "shortName": "Investments in Equity Securities (Summary of Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i7af289dd4d5f439f9dc344c7e7529ba9_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
     "shortName": "Investments in Equity Securities (Earnings in Equity Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0e30dd02c1c94a5b81ccdba16b4c25b1_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i7af289dd4d5f439f9dc344c7e7529ba9_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
     "shortName": "Investments in Equity Securities (Investment in ABI Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i7af289dd4d5f439f9dc344c7e7529ba9_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iee8132d7c11f4ed6beae262b24846fb4_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails",
     "shortName": "Investments in Equity Securities (Investment in JUUL Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Earnings",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ic18ca113bad9498b8bce774c190943af_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
     "shortName": "Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "id7bf4062eea24ce4a949beb98cf77963_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0c2317db73d949bf97a1f0ae5666c118_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
     "shortName": "Investments in Equity Securities (Investment in Cronos Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0c2317db73d949bf97a1f0ae5666c118_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfForeignCurrencyDerivativesHeld",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfForeignCurrencyDerivativesHeld",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails",
     "shortName": "Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails",
     "shortName": "Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Benefit Plans (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.altria.com/role/BenefitPlansNarrativeDetails",
     "shortName": "Benefit Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iea34140984e94a5d9291f775b5b3d27d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Earnings per Share (Basic and Diluted Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
     "shortName": "Earnings per Share (Basic and Diluted Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails",
     "shortName": "Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ic36b7ae040844d2f804d1455c8538850_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails",
     "shortName": "Other Comprehensive Earnings/Losses (Reclassifications) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ieae3d8b4d3ae4b3b8ab5e8ac275cd4b3_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Segment Reporting (Segment Data Schedule) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails",
     "shortName": "Segment Reporting (Segment Data Schedule) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings",
     "shortName": "Condensed Consolidated Statements of Comprehensive Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Segment Reporting (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.altria.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i242ac1bb024d426f85c7c0e28cd107fa_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
     "shortName": "Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i008bb3a34d6f4ad1a419dfbe662171e3_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Debt (Narrative) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.altria.com/role/DebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Income Taxes - Summary of Income Taxes (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mo:SummaryOfIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.altria.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Contingencies (General Information) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.altria.com/role/ContingenciesGeneralInformationDetails",
     "shortName": "Contingencies (General Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
     "shortName": "Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ic3fe928fcc4f4ef5ad3b60f07ca10cc7_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Contingencies (Schedule of Pending Cases) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
     "shortName": "Contingencies (Schedule of Pending Cases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ia0a4f7f89b7241328632d436bff2aa5f_I20220425",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i22a937a6e7e14fdfacea6ad40290a42f_I20220425",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
     "shortName": "Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iea5829e73f1045e0979a9f058be7d748_D19990101-20230424",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mo:LossContingencyClaimsDecided",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0217eb87e2e241b8ad4da3c44ced3300_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i1542e02bb1e24adda3f71e99211fc9ed_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
     "shortName": "Contingencies (Non-Engle Progeny Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i87ca3cff2798450a8d43bf076838e36b_I20230228",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mo:LossContingencyCompensatoryDamagesAwardedValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i9557e21fd37641dcb6ef942359171a0b_D20220201-20220228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
     "shortName": "Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "id14f18627ded4c498559f94480d4c268_I20000731",
      "decimals": "-9",
      "lang": "en-US",
      "name": "mo:LossContingencyPunitiveDamagesAwardedValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i94aba2dfe6f940fdaa35b3888c250151_I20230131",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyCompensatoryDamagesAwardedValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
     "shortName": "Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i94aba2dfe6f940fdaa35b3888c250151_I20230131",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyCompensatoryDamagesAwardedValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "idd5c8372783a4bf6bc692e11c709e409_I20090630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:MaximumBondForAllDefendants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Contingencies (Florida Bond Statute) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
     "shortName": "Contingencies (Florida Bond Statute) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "idd5c8372783a4bf6bc692e11c709e409_I20090630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:MaximumBondForAllDefendants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i58bffe3b3264449299e2b9f964207eda_I20230424",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
     "shortName": "Contingencies (Other Smoking and Health Class Actions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "id50f063bff6144ba9d1c3bae28cb30f0_D19960501-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mo:LossContingencyClassNotCertifiedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
     "shortName": "Contingencies (Health Care Cost Recovery Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i584aaa95c26441a094e3dfe8154eed96_D19981101-19981130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mo:LossContingencyNumberofStateswithSettledLitigation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0a3154edea1f4358a6a3f9e30a8c27ce_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
     "shortName": "Contingencies (NPM Adjustment Disputes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0c8e8c08cbe740d4a306f6bb4a27e669_D20220301-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
     "shortName": "Contingencies (Other Disputes Under the State Settlement Agreements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ic4ed3c821c9f4f48827c57ad9117c320_D20210101-20210131",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "ie04ccfa6a1f247a2ba08766c593e059c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
     "shortName": "Contingencies (Federal Government's Lawsuit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i41840f71688e4157a71edd78b25d1eb2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i67ca21fd598f4791b318ee5cabcbed5d_I20220425",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
     "shortName": "Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i05d64c409aed469ba2221a94eff7af46_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mo:NumberOfThirdPartyLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iab08827c3eeb4c2ab05097b269497f30_I20201130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyNumberOfComplaints",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
     "shortName": "Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "iab08827c3eeb4c2ab05097b269497f30_I20201130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyNumberOfComplaints",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i7e11164646c440cdb43d7579fbad7dbe_I20230424",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyClaimsNotCertifiedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
     "shortName": "Contingencies (Lights/Ultra Lights Cases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i7e11164646c440cdb43d7579fbad7dbe_I20230424",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mo:LossContingencyClaimsNotCertifiedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0b0ed1328f8e4090ade76858a871504d_I20230424",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Contingencies (UST Litigations Narrative) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails",
     "shortName": "Contingencies (UST Litigations Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i0b0ed1328f8e4090ade76858a871504d_I20230424",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
     "shortName": "Contingencies (Guarantees and Other Similar Matters Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i66477b67e5d24411a9b94a8ac9d67205_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i000128edea2348af9dda2888d5316af0_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - mo-20230331.htm",
     "menuCat": "Cover",
     "order": "74",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - mo-20230331.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mo-20230331.htm",
      "contextRef": "i90474c1a016f4bcab8003b2f31a36b35_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 176,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada [Member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PUERTO RICO",
        "terseLabel": "Puerto Rico [Member]"
       }
      }
     },
     "localname": "PR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mo_ABInBevMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AB InBev [Member]",
        "label": "AB InBev [Member]",
        "terseLabel": "ABI [Member]"
       }
      }
     },
     "localname": "ABInBevMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_AccruedSettlementLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Settlement Liability, Current",
        "label": "Accrued Settlement Liability, Current",
        "terseLabel": "Settlement charges"
       }
      }
     },
     "localname": "AccruedSettlementLiabilityCurrent",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Equity Method Investments Attributable To Parent [Member]",
        "label": "Accumulated Equity Method Investments Attributable To Parent [Member]",
        "terseLabel": "ABI [Member]"
       }
      }
     },
     "localname": "AccumulatedEquityMethodInvestmentsAttributableToParentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Additional Paid In Capital, Share Based Compensation, Restricted And Deferred Stock Awards and the tax benefits associated with vestings of prior period restricted and deferred stock awards",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition and Income Tax Effect, Net",
        "terseLabel": "Stock award activity"
       }
      }
     },
     "localname": "AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_AgreementToResolveShareholderClassActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement To Resolve Shareholder Class Action",
        "label": "Agreement To Resolve Shareholder Class Action [Member]",
        "terseLabel": "Agreement To Resolve Shareholder Class Action"
       }
      }
     },
     "localname": "AgreementToResolveShareholderClassActionMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_AltriaGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altria Group",
        "label": "Altria Group [Member]",
        "terseLabel": "Altria Group [Member]"
       }
      }
     },
     "localname": "AltriaGroupMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_AmountAwardedtoOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Awarded to Other Party",
        "label": "Amount Awarded to Other Party",
        "terseLabel": "Amount awarded to other party"
       }
      }
     },
     "localname": "AmountAwardedtoOtherParty",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ArbitrationPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbitration Period",
        "label": "Arbitration Period [Axis]",
        "terseLabel": "Arbitration Period [Axis]"
       }
      }
     },
     "localname": "ArbitrationPeriodAxis",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_ArbitrationPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbitration Period [Domain]",
        "label": "Arbitration Period [Domain]",
        "terseLabel": "Arbitration Period [Domain]"
       }
      }
     },
     "localname": "ArbitrationPeriodDomain",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_BritishColumbiaSaskatchewanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "British Columbia, Saskatchewan [Member]",
        "label": "British Columbia, Saskatchewan [Member]",
        "terseLabel": "British Columbia and Saskatchewan [Member]"
       }
      }
     },
     "localname": "BritishColumbiaSaskatchewanMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CanadianTobaccoManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Tobacco Manufacturers [Member]",
        "label": "Canadian Tobacco Manufacturers [Member]",
        "terseLabel": "Canadian Tobacco Manufacturers [Member]"
       }
      }
     },
     "localname": "CanadianTobaccoManufacturersMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CashDiscountsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Discounts",
        "label": "Cash Discounts [Policy Text Block]",
        "terseLabel": "Cash Discounts"
       }
      }
     },
     "localname": "CashDiscountsPolicyTextBlock",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mo_ClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuit [Member]",
        "label": "Class Action Lawsuit [Member]",
        "terseLabel": "Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CommonStock0.3313ParValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 0.33 1/3 Par Value [Member]",
        "label": "Common Stock, 0.33 1/3 Par Value [Member]",
        "terseLabel": "Common Stock, $0.33 1/3 par value [Member]"
       }
      }
     },
     "localname": "CommonStock0.3313ParValueMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CommonStock1.700NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 1.700% Notes Due 2025 [Member]",
        "label": "Common Stock, 1.700% Notes Due 2025 [Member]",
        "terseLabel": "1.700% Notes due 2025 [Member]"
       }
      }
     },
     "localname": "CommonStock1.700NotesDue2025Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CommonStock2.200NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 2.200% Notes Due 2027 [Member]",
        "label": "Common Stock, 2.200% Notes Due 2027 [Member]",
        "terseLabel": "2.200% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "CommonStock2.200NotesDue2027Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CommonStock3.125NotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 3.125% Notes Due 2031 [Member]",
        "label": "Common Stock, 3.125% Notes Due 2031 [Member]",
        "terseLabel": "3.125% Notes due 2031 [Member]"
       }
      }
     },
     "localname": "CommonStock3.125NotesDue2031Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_CronosGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cronos Group Inc. [Member]",
        "label": "Cronos Group Inc. [Member]",
        "verboseLabel": "Cronos [Member]"
       }
      }
     },
     "localname": "CronosGroupInc.Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Consolidated EBITDA to Interest Expense Ratio",
        "label": "Debt Instrument, Consolidated EBITDA to Interest Expense Ratio",
        "terseLabel": "Debt instrument, consolidated EBITDA to interest expense ratio"
       }
      }
     },
     "localname": "DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mo_DeferredGainOnSaleOfCommercializationRightsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Gain On Sale Of Commercialization Rights, Noncurrent",
        "label": "Deferred Gain On Sale Of Commercialization Rights, Noncurrent",
        "terseLabel": "Deferred gain from the sale of IQOS System commercialization rights"
       }
      }
     },
     "localname": "DeferredGainOnSaleOfCommercializationRightsNoncurrent",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ETSSmokingandHealthCaseFlightAttendantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ETS Smoking and Health Case, Flight Attendants [Member]",
        "label": "ETS Smoking and Health Case, Flight Attendants [Member]",
        "terseLabel": "ETS Smoking and Health Case, Flight Attendants [Member]"
       }
      }
     },
     "localname": "ETSSmokingandHealthCaseFlightAttendantsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesChadwellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Chadwell [Member] [Member]",
        "label": "Engle Progeny Cases, Chadwell [Member]",
        "terseLabel": "Engle Progeny Cases, Chadwell [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesChadwellMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesCooperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Cooper [Member]",
        "label": "Engle Progeny Cases, Cooper [Member]",
        "terseLabel": "Engle Progeny Cases, Cooper [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesCooperMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesCuddiheeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Cuddihee",
        "label": "Engle Progeny Cases, Cuddihee [Member]",
        "terseLabel": "Engle Progeny Cases, Cuddihee [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesCuddiheeMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesD.BrownMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, D. Brown [Member]",
        "label": "Engle Progeny Cases, D. Brown [Member]",
        "terseLabel": "Engle Progeny Cases, D. Brown [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesD.BrownMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesDuignanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Duignan [Member]",
        "label": "Engle Progeny Cases, Duignan [Member]",
        "terseLabel": "Engle Progeny Cases, Duignan [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesDuignanMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesFreemanAndHarrisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Freeman [Member]",
        "label": "Engle Progeny Cases, Freeman And Harris [Member]",
        "terseLabel": "Engle Progeny Cases, Freeman [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesFreemanAndHarrisMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesGarciaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Garcia",
        "label": "Engle Progeny Cases, Garcia [Member]",
        "terseLabel": "Engle Progeny Cases, Garcia [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesGarciaMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesGlogerRintoulandDuignamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]",
        "label": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]",
        "terseLabel": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesGlogerRintoulandDuignamMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesHoffmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Hoffman",
        "label": "Engle Progeny Cases, Hoffman [Member]",
        "terseLabel": "Engle Progeny Cases, Hoffman [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesHoffmanMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesHollimanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Holliman [Member]",
        "label": "Engle Progeny Cases, Holliman [Member]",
        "terseLabel": "Engle Progeny Cases, Holliman [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesHollimanMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesKaplanMcLauighlinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Kaplan [Member]",
        "label": "Engle Progeny Cases, Kaplan (McLauighlin) [Member]",
        "terseLabel": "Engle Progeny Cases, Kaplan [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesKaplanMcLauighlinMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesLevineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Levine",
        "label": "Engle Progeny Cases, Levine [Member]",
        "terseLabel": "Engle Progeny Cases, Levine [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesLevineMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesLippMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Lipp",
        "label": "Engle Progeny Cases, Lipp [Member]",
        "terseLabel": "Engle Progeny Cases, Lipp [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesLippMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesMcCallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, McCall [Member]",
        "label": "Engle Progeny Cases, McCall [Member]",
        "terseLabel": "Engle Progeny Cases, McCall [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesMcCallMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases [Member]",
        "label": "Engle Progeny Cases [Member]",
        "terseLabel": "Engle Progeny Cases [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesMillerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Miller",
        "label": "Engle Progeny Cases, Miller [Member]",
        "terseLabel": "Engle Progeny Cases, Miller [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesMillerMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesPearsonDCohenCollarChaconMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member]",
        "label": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member]",
        "terseLabel": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesPearsonDCohenCollarChaconMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesPollariMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Pollari [Member]",
        "label": "Engle Progeny Cases, Pollari [Member]",
        "terseLabel": "Engle Progeny Cases, Pollari [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesPollariMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesR.DouglasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, R. Douglas [Member]",
        "label": "Engle Progeny Cases, R. Douglas [Member]",
        "terseLabel": "Engle Progeny Cases, R. Douglas [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesR.DouglasMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesReiderandBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Reider and Banks [Member]",
        "label": "Engle Progeny Cases, Reider and Banks [Member]",
        "terseLabel": "Engle Progeny Cases, Reider and Banks [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesReiderandBanksMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesSchertzerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Schertzer",
        "label": "Engle Progeny Cases, Schertzer [Member]",
        "terseLabel": "Engle Progeny Cases, Schertzer [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesSchertzerMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, State [Member]",
        "label": "Engle Progeny Cases, State [Member]",
        "terseLabel": "Engle Progeny Cases, State [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesStateMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesTuttleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Tuttle",
        "label": "Engle Progeny Cases, Tuttle [Member]",
        "terseLabel": "Engle Progeny Cases, Tuttle [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesTuttleMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EngleProgenyCasesWeingartandHancockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engle Progeny Cases, Weingart and Hancock [Member]",
        "label": "Engle Progeny Cases, Weingart and Hancock [Member]",
        "terseLabel": "Engle Progeny Cases, Weingart and Hancock [Member]"
       }
      }
     },
     "localname": "EngleProgenyCasesWeingartandHancockMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EquityContractPreemptiveRIghtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Contract, Preemptive RIghts [Member]",
        "label": "Equity Contract, Preemptive RIghts [Member]",
        "verboseLabel": "Equity Contract, Preemptive Rights [Member]"
       }
      }
     },
     "localname": "EquityContractPreemptiveRIghtsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EquityContractWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Contract, Warrant [Member]",
        "label": "Equity Contract, Warrant [Member]",
        "terseLabel": "Equity Contract, Warrant [Member]"
       }
      }
     },
     "localname": "EquityContractWarrantMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Difference Between Carrying Amount and Fair Value",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Fair Value",
        "negatedLabel": "Equity method investment, difference between carrying amount and fair value",
        "terseLabel": "Equity method investment, difference between carrying amount and fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndFairValue",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage",
        "negatedLabel": "Equity method investment, difference between carrying amount and fair value, percentage (approximately)",
        "terseLabel": "Equity method investment, difference between carrying amount and fair value, percentage (approximately)"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_EquityMethodInvestmentImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Impairment",
        "label": "Equity Method Investment, Impairment",
        "terseLabel": "Equity method investment, impairment"
       }
      }
     },
     "localname": "EquityMethodInvestmentImpairment",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_EquityMethodInvestmentNumberofSharesOwnedCommon": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Number of Shares Owned, Common",
        "label": "Equity Method Investment, Number of Shares Owned, Common",
        "terseLabel": "Number of ordinary shares owned (in shares)",
        "verboseLabel": "Number of ordinary shares owned (approximately) (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentNumberofSharesOwnedCommon",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mo_EquityMethodInvestmentNumberofSharesOwnedRestricted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Number of Shares Owned, Restricted",
        "label": "Equity Method Investment, Number of Shares Owned, Restricted",
        "terseLabel": "Number of restricted shares owned (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentNumberofSharesOwnedRestricted",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mo_EquityMethodInvestmentPercentageOfSharesEligibleForPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Percentage of Shares Eligible For Purchase",
        "label": "Equity Method Investment, Percentage of Shares Eligible For Purchase",
        "terseLabel": "Equity method investment, percentage of shares eligible for purchase (approximately)"
       }
      }
     },
     "localname": "EquityMethodInvestmentPercentageOfSharesEligibleForPurchase",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_EquityMethodInvestmentPricePerShareIfExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Price Per Share If Exercised",
        "label": "Equity Method Investment, Price Per Share If Exercised",
        "terseLabel": "Equity method investment, shares purchased, (CAD per share)"
       }
      }
     },
     "localname": "EquityMethodInvestmentPricePerShareIfExercised",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mo_EquityMethodInvestmentsFixedPreemptiveRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Fixed Preemptive Rights",
        "label": "Equity Method Investments, Fixed Preemptive Rights",
        "terseLabel": "Equity method investments, fixed preemptive rights"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFixedPreemptiveRights",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_EquityMethodInvestmentsIncludingFixedPricePreemptiveRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Including Fixed-Price Preemptive Rights",
        "label": "Equity Method Investments, Including Fixed-Price Preemptive Rights",
        "terseLabel": "Cronos"
       }
      }
     },
     "localname": "EquityMethodInvestmentsIncludingFixedPricePreemptiveRights",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Ordinary Gain (Loss), Tax Basis Of Investments",
        "label": "Equity Securities, FV-NI, Ordinary Gain (Loss), Tax Basis Of Investments",
        "negatedTerseLabel": "Equity securities, FV-NI, ordinary gain (loss), tax basis of investments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIOrdinaryGainLossTaxBasisOfInvestments",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Equity securities, ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_EuroNotes1000MaturingFebruary2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro Notes, 1.000%, Maturing February 2023",
        "label": "Euro Notes, 1.000%, Maturing February 2023 [Member]",
        "terseLabel": "Euro Notes, 1.000%, Maturing February 2023 [Member]"
       }
      }
     },
     "localname": "EuroNotes1000MaturingFebruary2023Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_EvaporLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E-vapor Litigation [Member]",
        "label": "E-vapor Litigation [Member]",
        "terseLabel": "E-vapor Litigation [Member]"
       }
      }
     },
     "localname": "EvaporLitigationMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_FederalAndStateShareholderDerivativeLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal And State Shareholder Derivative Lawsuits",
        "label": "Federal And State Shareholder Derivative Lawsuits [Member]",
        "terseLabel": "Federal And State Shareholder Derivative Lawsuits [Member]"
       }
      }
     },
     "localname": "FederalAndStateShareholderDerivativeLawsuitsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_ForeignCurrencyDenominatedDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt",
        "label": "Foreign Currency Denominated Debt [Abstract]",
        "terseLabel": "Foreign currency denominated debt included in long-term debt:"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtAbstract",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt [Member]",
        "verboseLabel": "Foreign currency denominated debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails",
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2004NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment",
        "label": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions20052007NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2005NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2006NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2007NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2008NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2009NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2010NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2011NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2012NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2013NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]",
        "label": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2014NPMAdjustmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]",
        "label": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2015NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]",
        "label": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]",
        "label": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2017NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]",
        "label": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2018NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]",
        "label": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2019NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2020 NPM Adjustments",
        "label": "Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2020NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2021NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2021 NPM Adjustments",
        "label": "Health Care Cost Recovery Actions, 2021 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2021 NPM Adjustments [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2021NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActions2022NPMAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, 2022 NPM Adjustments",
        "label": "Health Care Cost Recovery Actions, 2022 NPM Adjustments [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, 2022 NPM Adjustments"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActions2022NPMAdjustmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions [Member]",
        "label": "Health Care Cost Recovery Actions [Member]",
        "terseLabel": "Health Care Cost Recovery Actions [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActionsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActionsTransitionYears20042020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]",
        "label": "Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActionsTransitionYears20042020Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActionsTransitionYears20042021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, Transition Years 2004-2021",
        "label": "Health Care Cost Recovery Actions, Transition Years 2004-2021 [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, Transition Years 2004-2021 [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActionsTransitionYears20042021Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HealthCareCostRecoveryActionsTransitionYears20192021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Cost Recovery Actions, Transition Years 2019-2021",
        "label": "Health Care Cost Recovery Actions, Transition Years 2019-2021 [Member]",
        "terseLabel": "Health Care Cost Recovery Actions, Transition Years 2019-2021 [Member]"
       }
      }
     },
     "localname": "HealthCareCostRecoveryActionsTransitionYears20192021Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_HorizonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon",
        "label": "Horizon [Member]",
        "terseLabel": "Horizon [Member]"
       }
      }
     },
     "localname": "HorizonMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_IQOSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IQOS",
        "label": "IQOS [Member]",
        "terseLabel": "IQOS [Member]"
       }
      }
     },
     "localname": "IQOSMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_ImplementationofCorrectiveCommunicationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implementation of Corrective Communications [Member]",
        "label": "Implementation of Corrective Communications [Member]",
        "terseLabel": "Implementation of Corrective Communications [Member]"
       }
      }
     },
     "localname": "ImplementationofCorrectiveCommunicationsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_IncomeLossFromEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Securities",
        "label": "Income (Loss) from Equity Securities",
        "negatedTerseLabel": "(Income) losses from investments in equity securities",
        "negatedTotalLabel": "(Income) losses from investments in equity securities"
       }
      }
     },
     "localname": "IncomeLossFromEquitySecurities",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_IncreaseDecreaseInSettlementPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the period in Settlement payable.",
        "label": "Increase (Decrease) In Settlement Payable",
        "terseLabel": "Accrued settlement charges"
       }
      }
     },
     "localname": "IncreaseDecreaseInSettlementPayable",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_IndividualSmokingAndHealthCasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Smoking and Health Cases [Member]",
        "label": "Individual Smoking And Health Cases [Member]",
        "terseLabel": "Individual Smoking and Health Cases [Member]"
       }
      }
     },
     "localname": "IndividualSmokingAndHealthCasesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_InterestAndOtherDebtExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest And Other Debt Expense, Net [Member]",
        "label": "Interest And Other Debt Expense, Net [Member]",
        "terseLabel": "Interest and other debt expense, net [Member]"
       }
      }
     },
     "localname": "InterestAndOtherDebtExpenseNetMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_InterestExpenseRelatedToLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense Related To Litigation [Member]",
        "label": "Interest Expense Related To Litigation [Member]",
        "terseLabel": "Related Interest Costs [Member]"
       }
      }
     },
     "localname": "InterestExpenseRelatedToLitigationMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_InventoryRawMaterialsPlantMaterialNetofReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of products consisting of plant matter that is not used in the growth of plant goods",
        "label": "Inventory, Raw Materials, Plant Material, Net of Reserves",
        "terseLabel": "Leaf tobacco"
       }
      }
     },
     "localname": "InventoryRawMaterialsPlantMaterialNetofReserves",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_InvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Investments [Table]",
        "label": "Investments [Line Items]",
        "terseLabel": "Investments [Line Items]"
       }
      }
     },
     "localname": "InvestmentsLineItems",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_InvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments [Table]",
        "label": "Investments [Table]",
        "terseLabel": "Investments [Table]"
       }
      }
     },
     "localname": "InvestmentsTable",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_JTIUHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JTIUH",
        "label": "JTIUH [Member]",
        "terseLabel": "JTIUH [Member]"
       }
      }
     },
     "localname": "JTIUHMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_JUULMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JUUL [Member]",
        "label": "JUUL [Member]",
        "terseLabel": "JUUL [Member]"
       }
      }
     },
     "localname": "JUULMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_January2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2021 Share Repurchase Program",
        "label": "January 2021 Share Repurchase Program [Member]",
        "terseLabel": "January 2021 Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "January2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_January2023ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2023 Share Repurchase Program",
        "label": "January 2023 Share Repurchase Program [Member]",
        "terseLabel": "January 2023 Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "January2023ShareRepurchaseProgramMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_LightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lights [Member]",
        "label": "Lights [Member]",
        "terseLabel": "Lights [Member]"
       }
      }
     },
     "localname": "LightsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_LitigationCasesResultsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Cases Results [Member]",
        "label": "Litigation Cases Results [Member]",
        "terseLabel": "Tobacco and Health and Certain Other Litigation [Member]"
       }
      }
     },
     "localname": "LitigationCasesResultsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_LitigationEscrowDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Escrow Deposit",
        "label": "Litigation Escrow Deposit",
        "terseLabel": "Security posted for appeal of judgments"
       }
      }
     },
     "localname": "LitigationEscrowDeposit",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Amount Expected To Be Awarded from Other Party",
        "label": "Litigation Settlement, Amount Expected To Be Awarded from Other Party",
        "terseLabel": "Litigation settlement, amount expected to be awarded from other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountExpectedToBeAwardedFromOtherParty",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LitigationSettlementAnnualLegalFeesPayableMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Annual Legal Fees Payable, Maximum",
        "label": "Litigation Settlement, Annual Legal Fees Payable, Maximum",
        "terseLabel": "State settlement agreements attorney fees annual cap"
       }
      }
     },
     "localname": "LitigationSettlementAnnualLegalFeesPayableMaximum",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LitigationSettlementAnnualPaymentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Annual Payment Amount",
        "label": "Litigation Settlement, Annual Payment Amount",
        "terseLabel": "State settlement agreements annual payments"
       }
      }
     },
     "localname": "LitigationSettlementAnnualPaymentAmount",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LitigationSettlementEstimateofPossibleGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Estimate of Possible Gain",
        "label": "Litigation Settlement, Estimate of Possible Gain",
        "terseLabel": "Estimate of possible gain"
       }
      }
     },
     "localname": "LitigationSettlementEstimateofPossibleGain",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LossContingencyClaimsDecided": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Decided",
        "label": "Loss Contingency, Claims Decided",
        "terseLabel": "Number of verdicts returned"
       }
      }
     },
     "localname": "LossContingencyClaimsDecided",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClaimsDecidedFavorableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Decided Favorable, Number",
        "label": "Loss Contingency, Claims Decided Favorable, Number",
        "terseLabel": "Number of favorable verdicts"
       }
      }
     },
     "localname": "LossContingencyClaimsDecidedFavorableNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClaimsDecidedUnfavorableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Decided Unfavorable, Number",
        "label": "Loss Contingency, Claims Decided Unfavorable, Number",
        "terseLabel": "Number of unfavorable verdicts"
       }
      }
     },
     "localname": "LossContingencyClaimsDecidedUnfavorableNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClaimsNotCertifiedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Not Certified, Number",
        "label": "Loss Contingency, Claims Not Certified, Number",
        "terseLabel": "Claims not certified, number"
       }
      }
     },
     "localname": "LossContingencyClaimsNotCertifiedNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClaimsResolvedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Resolved, Number",
        "label": "Loss Contingency, Claims Resolved, Number",
        "terseLabel": "Number of claims resolved"
       }
      }
     },
     "localname": "LossContingencyClaimsResolvedNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClassActionLawsuit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Class Action Lawsuit",
        "label": "Loss Contingency, Class Action Lawsuit",
        "terseLabel": "Loss contingency, class action lawsuit"
       }
      }
     },
     "localname": "LossContingencyClassActionLawsuit",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyClassNotCertifiedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Class Not Certified, Number",
        "label": "Loss Contingency, Class Not Certified, Number",
        "terseLabel": "Class not certified"
       }
      }
     },
     "localname": "LossContingencyClassNotCertifiedNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyCompensatoryDamagesAwardedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Compensatory Damages Awarded, Value",
        "label": "Loss Contingency, Compensatory Damages Awarded, Value",
        "terseLabel": "Compensatory damages awarded"
       }
      }
     },
     "localname": "LossContingencyCompensatoryDamagesAwardedValue",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LossContingencyDamagesRecoverableValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Damages Recoverable, Value",
        "label": "Loss Contingency, Damages Recoverable, Value",
        "terseLabel": "Loss contingency, damages recoverable, value"
       }
      }
     },
     "localname": "LossContingencyDamagesRecoverableValue",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LossContingencyFaultAllocationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Fault Allocation Percentage",
        "label": "Loss Contingency, Fault Allocation Percentage",
        "terseLabel": "Loss contingency, fault allocation percentage"
       }
      }
     },
     "localname": "LossContingencyFaultAllocationPercentage",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_LossContingencyNumberOfCases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Cases",
        "label": "Loss Contingency, Number Of Cases",
        "verboseLabel": "Number of cases"
       }
      }
     },
     "localname": "LossContingencyNumberOfCases",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfCasesWithSetTrialDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Cases With Set Trial Dates",
        "label": "Loss Contingency, Number of Cases With Set Trial Dates",
        "terseLabel": "Loss contingency, number of cases with set trial dates"
       }
      }
     },
     "localname": "LossContingencyNumberOfCasesWithSetTrialDates",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfComplaints": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Complaints",
        "label": "Loss Contingency, Number Of Complaints",
        "terseLabel": "Loss contingency, number of complaints"
       }
      }
     },
     "localname": "LossContingencyNumberOfComplaints",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfInactiveCases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Inactive Cases",
        "label": "Loss Contingency, Number Of Inactive Cases",
        "terseLabel": "Loss contingency, number of inactive cases"
       }
      }
     },
     "localname": "LossContingencyNumberOfInactiveCases",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfInactiveClassActionLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Inactive Class Action Lawsuits",
        "label": "Loss Contingency, Number Of Inactive Class Action Lawsuits",
        "terseLabel": "Loss contingency, number of inactive class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfInactiveClassActionLawsuits",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfPendingCasesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Pending Cases Consolidated",
        "label": "Loss Contingency, Number Of Pending Cases Consolidated",
        "terseLabel": "Loss contingency, number of pending cases consolidated"
       }
      }
     },
     "localname": "LossContingencyNumberOfPendingCasesConsolidated",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits",
        "label": "Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits",
        "terseLabel": "Loss contingency, number of shareholders filing class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfShareholdersFilingClassActionLawsuits",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits",
        "label": "Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits",
        "terseLabel": "Loss contingency, number of shareholders filing derivative lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfShareholdersFilingDerivativeLawsuits",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States In Compliance With Escrow Statues",
        "label": "Loss Contingency, Number Of States In Compliance With Escrow Statues",
        "terseLabel": "Loss contingency, number of states in compliance with escrow statues"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesInComplianceWithEscrowStatues",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States Not In Compliance With Escrow Statues",
        "label": "Loss Contingency, Number Of States Not In Compliance With Escrow Statues",
        "terseLabel": "Loss contingency, number of states not in compliance with escrow statues"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfStatesNotSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States Not Settled",
        "label": "Loss Contingency, Number Of States Not Settled",
        "terseLabel": "Loss contingency, number of states not settled"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesNotSettled",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States Not Settled, Arbitration Period",
        "label": "Loss Contingency, Number Of States Not Settled, Arbitration Period",
        "terseLabel": "Loss contingency, number of states not settled, arbitration period"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesNotSettledArbitrationPeriod",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mo_LossContingencyNumberOfStatesWithConcludedHearings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States With Concluded Hearings",
        "label": "Loss Contingency, Number Of States With Concluded Hearings",
        "terseLabel": "Loss contingency, number of states with concluded hearings"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesWithConcludedHearings",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberOfTrialsOngoing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Trials Ongoing",
        "label": "Loss Contingency, Number Of Trials Ongoing",
        "terseLabel": "Loss contingency, number of trials ongoing"
       }
      }
     },
     "localname": "LossContingencyNumberOfTrialsOngoing",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Additional States Extended with Settled Litigation",
        "label": "Loss Contingency, Number of Additional States Extended with Settled Litigation",
        "terseLabel": "Loss contingency, number of additional states extended with settled litigation"
       }
      }
     },
     "localname": "LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofCasesSetforTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Cases Set for Trial",
        "label": "Loss Contingency, Number of Cases Set for Trial",
        "terseLabel": "Number of cases set for trial"
       }
      }
     },
     "localname": "LossContingencyNumberofCasesSetforTrial",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofManufacturers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Manufacturers",
        "label": "Loss Contingency, Number of Manufacturers",
        "terseLabel": "Number of manufacturers"
       }
      }
     },
     "localname": "LossContingencyNumberofManufacturers",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of States That Cap Bond or Require No Bond",
        "label": "Loss Contingency, Number of States That Cap Bond or Require No Bond",
        "terseLabel": "Number of states that cap bond or require no bond"
       }
      }
     },
     "localname": "LossContingencyNumberofStatesThatCapBondorRequireNoBond",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGeneralInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofStateswithSettledLitigation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of States with Settled Litigation",
        "label": "Loss Contingency, Number of States with Settled Litigation",
        "terseLabel": "Number of states with settled litigation"
       }
      }
     },
     "localname": "LossContingencyNumberofStateswithSettledLitigation",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of States with Settled Litigation, Settlement One",
        "label": "Loss Contingency, Number of States with Settled Litigation, Settlement One",
        "terseLabel": "Loss contingency, number of states with settled litigation including New York, subsequent expansion"
       }
      }
     },
     "localname": "LossContingencyNumberofStateswithSettledLitigationSettlementOne",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number",
        "label": "Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number",
        "terseLabel": "Number of pending claims, consolidated for pre-trial purposes"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants",
        "label": "Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants",
        "terseLabel": "Loss contingency, period for decertified class members to file individual actions against defendants"
       }
      }
     },
     "localname": "LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mo_LossContingencyPunitiveDamagesAwardedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Punitive Damages Awarded, Value",
        "label": "Loss Contingency, Punitive Damages Awarded, Value",
        "terseLabel": "Punitive damages awarded"
       }
      }
     },
     "localname": "LossContingencyPunitiveDamagesAwardedValue",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LossContingencyReductionToCostOfSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reduction To Cost Of Sales",
        "label": "Loss Contingency, Reduction To Cost Of Sales",
        "terseLabel": "Loss contingency, reduction to cost of sales"
       }
      }
     },
     "localname": "LossContingencyReductionToCostOfSales",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_LossContingencyRoyaltyFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Royalty Fee Percentage",
        "label": "Loss Contingency, Royalty Fee Percentage",
        "terseLabel": "Loss Contingency, Royalty Fee Percentage"
       }
      }
     },
     "localname": "LossContingencyRoyaltyFeePercentage",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_LossContingencyStateCourtsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, State Courts, Number",
        "label": "Loss Contingency, State Courts, Number",
        "terseLabel": "Number of state courts"
       }
      }
     },
     "localname": "LossContingencyStateCourtsNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyUnfavorableVerdictsPendingReversed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Unfavorable Verdicts Pending/Reversed",
        "label": "Loss Contingency, Unfavorable Verdicts Pending/Reversed",
        "terseLabel": "Number of claims with unfavorable verdicts pending/reversed"
       }
      }
     },
     "localname": "LossContingencyUnfavorableVerdictsPendingReversed",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyVerdictReversedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Verdict Reversed, Number",
        "label": "Loss Contingency, Verdict Reversed, Number",
        "terseLabel": "Number of verdicts reversed"
       }
      }
     },
     "localname": "LossContingencyVerdictReversedNumber",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyVerdictsUpheld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Verdicts Upheld",
        "label": "Loss Contingency, Verdicts Upheld",
        "terseLabel": "Number of verdicts upheld"
       }
      }
     },
     "localname": "LossContingencyVerdictsUpheld",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyZeroDamagesVerdictModified": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Zero Damages Verdict Modified",
        "label": "Loss Contingency, Zero Damages Verdict Modified",
        "terseLabel": "Zero damages verdict modified"
       }
      }
     },
     "localname": "LossContingencyZeroDamagesVerdictModified",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_LossContingencyZeroDamagesVerdicts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Zero Damages Verdicts",
        "label": "Loss Contingency, Zero Damages Verdicts",
        "terseLabel": "Zero damages verdicts"
       }
      }
     },
     "localname": "LossContingencyZeroDamagesVerdicts",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_MarketingAdministrationandResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as research and development costs and all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. Research and development costs represent the aggregate costs incurred during an accounting period to research and develop new products/technologies when the technological feasibility has not been reached. General and administrative expenses include salaries of nonsales personnel, rent, utilities, communication, etc.",
        "label": "Marketing, Administration and Research Costs",
        "terseLabel": "Marketing, administration and research costs"
       }
      }
     },
     "localname": "MarketingAdministrationandResearchCosts",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_MaximumBondForAllDefendants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Bond For All Defendants",
        "label": "Maximum Bond For All Defendants",
        "terseLabel": "Maximum bond for all defendants"
       }
      }
     },
     "localname": "MaximumBondForAllDefendants",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_NJOYHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NJOY Holdings, Inc.",
        "label": "NJOY Holdings, Inc. [Member]",
        "terseLabel": "NJOY Holdings, Inc. [Member]"
       }
      }
     },
     "localname": "NJOYHoldingsIncMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonEngleProgenyCasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Engle Progeny Cases [Member]",
        "label": "Non Engle Progeny Cases [Member]",
        "terseLabel": "Non Engle Progeny Cases [Member]"
       }
      }
     },
     "localname": "NonEngleProgenyCasesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonEngleProgenySmokingAndHealthCaseFontaineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Engle Progeny Smoking And Health Case, Fontaine",
        "label": "Non-Engle Progeny Smoking And Health Case, Fontaine [Member]",
        "terseLabel": "Non-Engle Progeny Smoking And Health Case, Fontaine [Member]"
       }
      }
     },
     "localname": "NonEngleProgenySmokingAndHealthCaseFontaineMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonEngleProgenySmokingAndHealthCaseMendezMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Engle Progeny Smoking And Health Case, Mendez",
        "label": "Non-Engle Progeny Smoking And Health Case, Mendez [Member]",
        "terseLabel": "Non-Engle Progeny Smoking And Health Case, Mendez [Member]"
       }
      }
     },
     "localname": "NonEngleProgenySmokingAndHealthCaseMendezMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonEngleProgenySmokingAndHealthCaseWoodleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Engle Progeny Smoking And Health Case, Woodley",
        "label": "Non-Engle Progeny Smoking And Health Case, Woodley [Member]",
        "terseLabel": "Non-Engle Progeny Smoking And Health Case, Woodley [Member]"
       }
      }
     },
     "localname": "NonEngleProgenySmokingAndHealthCaseWoodleyMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonEngleProgenySmokingandHealthCaseGreeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Engle Progeny Smoking and Health Case, Greene [Member]",
        "label": "Non-Engle Progeny Smoking and Health Case, Greene [Member]",
        "terseLabel": "Non-Engle Progeny Smoking and Health Case, Greene [Member]"
       }
      }
     },
     "localname": "NonEngleProgenySmokingandHealthCaseGreeneMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NonParticipatingManufacturerArbitrationPanelDecisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Participating Manufacturer Arbitration Panel Decision [Member]",
        "label": "Non-Participating Manufacturer Arbitration Panel Decision [Member]",
        "terseLabel": "Non-Participating Manufacturer Arbitration Panel Decision [Member]"
       }
      }
     },
     "localname": "NonParticipatingManufacturerArbitrationPanelDecisionMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NpmAdjustmentToCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NPM Adjustment to Cost Of Sales [Member]",
        "label": "NPM Adjustment to Cost Of Sales [Member]",
        "terseLabel": "NPM Adjustment to Cost Of Sales [Member]"
       }
      }
     },
     "localname": "NpmAdjustmentToCostOfSalesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_NumberOfThirdPartyLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Third Party Lawsuits",
        "label": "Number Of Third Party Lawsuits",
        "terseLabel": "Number of third party lawsuits"
       }
      }
     },
     "localname": "NumberOfThirdPartyLawsuits",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles",
        "label": "Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles",
        "terseLabel": "OCI"
       }
      }
     },
     "localname": "OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_OralTobaccoSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Tobacco Segment [Member]",
        "label": "Oral Tobacco Segment [Member]",
        "verboseLabel": "Oral Tobacco Segment [Member]"
       }
      }
     },
     "localname": "OralTobaccoSegmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_OtherDisputesUndertheStateSettlementAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Disputes Under the State Settlement Agreements [Member]",
        "label": "Other Disputes Under the State Settlement Agreements [Member]",
        "terseLabel": "Other Disputes Under the State Settlement Agreements [Member]"
       }
      }
     },
     "localname": "OtherDisputesUndertheStateSettlementAgreementsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_OtherInventoryRawMaterialsNetofReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Inventory, Raw Materials, Net of Reserves",
        "label": "Other Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Other raw materials"
       }
      }
     },
     "localname": "OtherInventoryRawMaterialsNetofReserves",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_OtherTabaccoRelatedCasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Tabacco-Related Cases [Member]",
        "label": "Other Tabacco-Related Cases [Member]",
        "terseLabel": "Other Tabacco-Related Cases [Member]"
       }
      }
     },
     "localname": "OtherTabaccoRelatedCasesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_OwnershipPercentageInConsolidatedSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership Percentage In Consolidated Subsidiary",
        "label": "Ownership Percentage In Consolidated Subsidiary",
        "terseLabel": "Ownership percentage in consolidated subsidiary"
       }
      }
     },
     "localname": "OwnershipPercentageInConsolidatedSubsidiary",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted",
        "negatedLabel": "Less: Distributed and undistributed earnings attributable to share-based awards"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_PendingClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Class Action Lawsuit",
        "label": "Pending Class Action Lawsuit [Member]",
        "terseLabel": "Pending Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "PendingClassActionLawsuitMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PendingIndividualLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Individual Lawsuits [Member]",
        "label": "Pending Individual Lawsuits [Member]",
        "terseLabel": "Pending Individual Lawsuits [Member]"
       }
      }
     },
     "localname": "PendingIndividualLawsuitsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Lawsuits Filed By State Or Local Governments [Member]",
        "label": "Pending Lawsuits Filed By State Or Local Governments [Member]",
        "terseLabel": "Pending Lawsuits Filed By State Or Local Governments [Member]"
       }
      }
     },
     "localname": "PendingLawsuitsFiledByStateOrLocalGovernmentsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period One",
        "label": "Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "PeriodOneMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Two",
        "label": "Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "PeriodTwoMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Philip Morris USA And R.J. Reynolds Tobacco Company",
        "label": "Philip Morris USA And R.J. Reynolds Tobacco Company [Member]",
        "terseLabel": "PM USA And R.J. Reynolds Tobacco Company [Member]"
       }
      }
     },
     "localname": "PhilipMorrisUSAAndRJReynoldsTobaccoCompanyMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PhilipMorrisUSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Philip Morris USA [Member]",
        "label": "Philip Morris USA [Member]",
        "terseLabel": "PM USA [Member]"
       }
      }
     },
     "localname": "PhilipMorrisUSAMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_PhilipMorrisUSAandAltriaGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Philip Morris USA and Altria Group [Member]",
        "label": "Philip Morris USA and Altria Group [Member]",
        "terseLabel": "Philip Morris USA and Altria Group [Member]"
       }
      }
     },
     "localname": "PhilipMorrisUSAandAltriaGroupMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_ReceivableCommercializationRightsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable, Commercialization Rights, Current",
        "label": "Receivable, Commercialization Rights, Current",
        "terseLabel": "Receivable from the sale of IQOS System commercialization rights"
       }
      }
     },
     "localname": "ReceivableCommercializationRightsCurrent",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Deferred Revenue",
        "label": "Revenue From Contract With Customer, Deferred Revenue [Policy Text Block]",
        "terseLabel": "Revenue From Contract With Customer, Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDeferredRevenuePolicyTextBlock",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mo_RevolvingCreditFacilityDueAugust2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due August 2025 [Member]",
        "label": "Revolving Credit Facility Due August 2025 [Member]",
        "terseLabel": "Revolving Credit Facility Due August 2024 [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueAugust2025Member",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Non-Participating Manufacturer Adjustment Items",
        "label": "Schedule of Non-Participating Manufacturer Adjustment Items [Table Text Block]",
        "terseLabel": "Schedule of Non-Participating Manufacturer Adjustment Items"
       }
      }
     },
     "localname": "ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mo_ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Tobacco and Health and Certain Other Litigation Items",
        "label": "Schedule of Tobacco and Health and Certain Other Litigation Items [Table Text Block]",
        "terseLabel": "Schedule of Tobacco and Health and Certain Other Litigation Items"
       }
      }
     },
     "localname": "ScheduleOfTobaccoAndHealthAndCertainOtherLitigationItemsTableTextBlock",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]",
        "label": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]",
        "terseLabel": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]"
       }
      }
     },
     "localname": "ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]",
        "label": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]",
        "terseLabel": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]"
       }
      }
     },
     "localname": "ScheduleofPretaxTobaccoandHealthLitigationChargesTable",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mo_SmokeableProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smokeable Products Segment [Member]",
        "label": "Smokeable Products Segment [Member]",
        "terseLabel": "Smokeable Products Segment [Member]"
       }
      }
     },
     "localname": "SmokeableProductsSegmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_SmokingAndHealthClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smoking and Health Class Actions and Aggregated Claims Litigation [Member]",
        "label": "Smoking And Health Class Actions [Member]",
        "terseLabel": "Smoking and Health Class Actions and Aggregated Claims Litigation [Member]"
       }
      }
     },
     "localname": "SmokingAndHealthClassActionsMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_SummaryOfIncomeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Income Taxes",
        "label": "Summary of Income Taxes [Table Text Block]",
        "terseLabel": "Summary of Income Taxes"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxesTableTextBlock",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mo_TermSecuredOvernightFinancingRateTermSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Secured Overnight Financing Rate (\"Term SOFR\")",
        "label": "Term Secured Overnight Financing Rate (\"Term SOFR\") [Member]",
        "terseLabel": "Term Secured Overnight Financing Rate (\"Term SOFR\") [Member]"
       }
      }
     },
     "localname": "TermSecuredOvernightFinancingRateTermSOFRMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_TobaccoandHealthJudgmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tobacco and Health Judgment [Member]",
        "label": "Tobacco and Health Judgment [Member]",
        "terseLabel": "Tobacco and Health Judgment [Member]"
       }
      }
     },
     "localname": "TobaccoandHealthJudgmentMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_TobaccoandHealthLitigationCasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tobacco and Health Litigation Cases [Member]",
        "label": "Tobacco and Health Litigation Cases [Member]",
        "terseLabel": "Tobacco and Health Litigation Cases [Member]"
       }
      }
     },
     "localname": "TobaccoandHealthLitigationCasesMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_USTLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UST Litigation [Member]",
        "label": "UST Litigation [Member]",
        "terseLabel": "UST Litigation [Member]"
       }
      }
     },
     "localname": "USTLitigationMember",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mo_UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits that Would Impact Deferred Tax Rate",
        "label": "Unrecognized Tax Benefits that Would Impact Deferred Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact deferred tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsthatWouldImpactDeferredTaxRate",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease In Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Decrease In Amount",
        "negatedTerseLabel": "Releases to valuation allowance credited to income tax benefit"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseInAmount",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase In Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase In Amount",
        "terseLabel": "Additions to valuation allowance charged to income tax expense"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseInAmount",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ValuationAllowanceForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Foreign Currency Translation Adjustment",
        "label": "Valuation Allowance, Foreign Currency Translation Adjustment",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ValuationAllowanceForeignCurrencyTranslationAdjustment",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mo_ValuationAllowanceRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance Rollforward [Roll Forward]",
        "label": "Valuation Allowance Rollforward [Roll Forward]",
        "terseLabel": "Valuation Allowance Rollforward [Roll Forward]"
       }
      }
     },
     "localname": "ValuationAllowanceRollforwardRollForward",
     "nsuri": "http://www.altria.com/20230331",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r225",
      "r272",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r294",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r349",
      "r351",
      "r352",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r225",
      "r272",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r294",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r349",
      "r351",
      "r352",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]",
        "verboseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r483",
      "r599",
      "r615",
      "r635",
      "r636",
      "r654",
      "r666",
      "r671",
      "r726",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r435",
      "r483",
      "r487",
      "r488",
      "r489",
      "r575",
      "r599",
      "r615",
      "r635",
      "r636",
      "r654",
      "r666",
      "r671",
      "r718",
      "r726",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r435",
      "r483",
      "r487",
      "r488",
      "r489",
      "r575",
      "r599",
      "r615",
      "r635",
      "r636",
      "r654",
      "r666",
      "r671",
      "r718",
      "r726",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r484",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r243",
      "r484",
      "r682",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r655",
      "r670",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r624",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r655",
      "r670",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r243",
      "r484",
      "r682",
      "r683",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ALASKA",
        "terseLabel": "Alaska [Member]"
       }
      }
     },
     "localname": "AK",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_AR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ARKANSAS",
        "terseLabel": "Arkansas [Member]"
       }
      }
     },
     "localname": "AR",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California [Member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "Connecticut [Member]"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_DC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DISTRICT OF COLUMBIA",
        "terseLabel": "District of Columbia [Member]"
       }
      }
     },
     "localname": "DC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DELAWARE",
        "terseLabel": "Delaware [Member]"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida [Member]"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOWA",
        "terseLabel": "Iowa [Member]"
       }
      }
     },
     "localname": "IA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Illinois [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KANSAS",
        "terseLabel": "Kansas [Member]"
       }
      }
     },
     "localname": "KS",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_LA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOUISIANA",
        "terseLabel": "Louisiana [Member]"
       }
      }
     },
     "localname": "LA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "verboseLabel": "Massachusetts [Member]"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND",
        "terseLabel": "Maryland [Member]"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MICHIGAN",
        "terseLabel": "Michigan [Member]"
       }
      }
     },
     "localname": "MI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MINNESOTA",
        "terseLabel": "Minnesota [Member]"
       }
      }
     },
     "localname": "MN",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MO": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MISSOURI",
        "terseLabel": "Missouri [Member]"
       }
      }
     },
     "localname": "MO",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MISSISSIPPI",
        "terseLabel": "Mississippi [Member]"
       }
      }
     },
     "localname": "MS",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MONTANA",
        "terseLabel": "MONTANA [Member]"
       }
      }
     },
     "localname": "MT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW HAMPSHIRE",
        "terseLabel": "New Hampshire [Member]"
       }
      }
     },
     "localname": "NH",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "New Jersey [Member]"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NM": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW MEXICO",
        "terseLabel": "New Mexico [Member]"
       }
      }
     },
     "localname": "NM",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEVADA",
        "terseLabel": "Nevada [Member]"
       }
      }
     },
     "localname": "NV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York [Member]"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OHIO",
        "terseLabel": "Ohio [Member]"
       }
      }
     },
     "localname": "OH",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OKLAHOMA",
        "terseLabel": "Oklahoma [Member]"
       }
      }
     },
     "localname": "OK",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OREGON",
        "terseLabel": "Oregon [Member]"
       }
      }
     },
     "localname": "OR",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania [Member]"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_RI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RHODE ISLAND",
        "terseLabel": "Rhode Island [Member]"
       }
      }
     },
     "localname": "RI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina [Member]"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS",
        "terseLabel": "Texas [Member]"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin [Member]"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "West Virginia [Member]"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued liabilities:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Marketing"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r29",
      "r36",
      "r124",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Benefit Plans [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r31",
      "r36",
      "r124",
      "r214",
      "r215",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior service cost/credit [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r28",
      "r36",
      "r124",
      "r214",
      "r215",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Net loss [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r84",
      "r193"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r35",
      "r36",
      "r202",
      "r610",
      "r620",
      "r623"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive losses"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r36",
      "r124",
      "r566",
      "r616",
      "r617",
      "r687",
      "r688",
      "r689",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Losses [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r27",
      "r36",
      "r124",
      "r214",
      "r215",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency Translation Adjustments and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r699",
      "r700",
      "r701",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to operating cash flows:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r268",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "All Other [Member]"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r706"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Allowance for doubtful accounts, receivables"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r56",
      "r80",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r155",
      "r169",
      "r196",
      "r222",
      "r280",
      "r286",
      "r292",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r529",
      "r533",
      "r550",
      "r669",
      "r724",
      "r725",
      "r737"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r189",
      "r205",
      "r222",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r529",
      "r533",
      "r550",
      "r669",
      "r724",
      "r725",
      "r737"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Member]",
        "terseLabel": "Assets [Member]"
       }
      }
     },
     "localname": "AssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r134",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r525",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r525",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r118",
      "r119",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Business combination, contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r58",
      "r191",
      "r638"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r52",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r150"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r222",
      "r249",
      "r250",
      "r257",
      "r259",
      "r266",
      "r267",
      "r309",
      "r341",
      "r344",
      "r345",
      "r346",
      "r352",
      "r353",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r550",
      "r637",
      "r681",
      "r695",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r161",
      "r177"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "verboseLabel": "Dividends declared (usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r699",
      "r700",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.33 1/3\u00a0per share (2,805,961,317 shares issued)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r37",
      "r209",
      "r211",
      "r217",
      "r606",
      "r612"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive earnings"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r46",
      "r216",
      "r605",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Earnings/Losses"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r389",
      "r390",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r69",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "netLabel": "General corporate expenses [Member]",
        "verboseLabel": "General corporate [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r43",
      "r600"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r221",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r370",
      "r377",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r156",
      "r157",
      "r167",
      "r225",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r562",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails",
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r152",
      "r153",
      "r354",
      "r562",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r368",
      "r549",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r18",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r225",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r562",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails",
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r94",
      "r95",
      "r96",
      "r97",
      "r151",
      "r152",
      "r153",
      "r166",
      "r225",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r562",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.",
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Debt instrument, unused borrowing capacity, amount"
       }
      }
     },
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r698",
      "r729",
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedLabel": "Deferred federal income tax benefit"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r115",
      "r509",
      "r518",
      "r519",
      "r698"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r5",
      "r105",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Accrued pension costs"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r413",
      "r451",
      "r472",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r413",
      "r452",
      "r473",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r428",
      "r438",
      "r476",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Defined benefit plan, plan assets, contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": {
     "auth_ref": [
      "r476",
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year",
        "terseLabel": "Anticipated additional employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r413",
      "r450",
      "r471",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r413",
      "r417",
      "r449",
      "r470",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r447",
      "r468",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost (income)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Amortization:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r415",
      "r448",
      "r469",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r56",
      "r275"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r731"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Loss on Cronos-related financial instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r140",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r132",
      "r135",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r132",
      "r135",
      "r139",
      "r140",
      "r143",
      "r144",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r127",
      "r129",
      "r130",
      "r132",
      "r133",
      "r138",
      "r139",
      "r141",
      "r142",
      "r144",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Per share data:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r218",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r246",
      "r249",
      "r257",
      "r258",
      "r259",
      "r263",
      "r540",
      "r541",
      "r607",
      "r613",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r218",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r249",
      "r257",
      "r258",
      "r259",
      "r263",
      "r540",
      "r541",
      "r607",
      "r613",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Losses) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r93",
      "r184",
      "r213",
      "r214",
      "r215",
      "r226",
      "r227",
      "r228",
      "r232",
      "r240",
      "r242",
      "r265",
      "r310",
      "r388",
      "r490",
      "r491",
      "r492",
      "r511",
      "r512",
      "r539",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r566",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r73",
      "r281",
      "r685"
     ],
     "calculation": {
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "verboseLabel": "ABI"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r51",
      "r75",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r197",
      "r548"
     ],
     "calculation": {
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "JUUL"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r711"
     ],
     "calculation": {
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mo_IncomeLossFromEquitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Loss on disposition of JUUL equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r71",
      "r168",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r368",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r546",
      "r572",
      "r573",
      "r574",
      "r650",
      "r651",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r368",
      "r438",
      "r443",
      "r546",
      "r572",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r368",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r572",
      "r573",
      "r574",
      "r650",
      "r651",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r379",
      "r386",
      "r537",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r647",
      "r708",
      "r709",
      "r710",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain (loss) related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General corporate expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r194",
      "r321",
      "r604",
      "r648",
      "r669",
      "r716",
      "r717"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r42",
      "r222",
      "r280",
      "r285",
      "r291",
      "r294",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r550",
      "r646",
      "r724"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Contingent liability related to performance surety bonds"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r39",
      "r154",
      "r163",
      "r182",
      "r280",
      "r285",
      "r291",
      "r294",
      "r608",
      "r646"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings before income taxes",
        "totalLabel": "Earnings before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r40",
      "r56",
      "r73",
      "r162",
      "r180",
      "r277"
     ],
     "calculation": {
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mo_IncomeLossFromEquitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Income) losses from investments under equity method of accounting",
        "negatedTerseLabel": "(Income) losses from investments in equity securities"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r500",
      "r503",
      "r508",
      "r516",
      "r520",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r224",
      "r241",
      "r242",
      "r278",
      "r498",
      "r517",
      "r521",
      "r614"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails",
      "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r494",
      "r495",
      "r503",
      "r504",
      "r507",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Cash effects of changes:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Assets and Liabilities, Net",
        "negatedLabel": "Accrued liabilities and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedTerseLabel": "Interest and other debt expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r160",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Accrued interest on long-term debt"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r77",
      "r640"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished product"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r203",
      "r639",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Inventories:"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r77",
      "r641"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r308",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments in Equity Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r707",
      "r712",
      "r714",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r707",
      "r712",
      "r714",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Investments in Equity Securities"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "totalLabel": "Investments",
        "verboseLabel": "Investments in equity securities ($0 million and $250 million at March 31, 2023 and December\u00a031, 2022, respectively, measured at fair value)"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, fair value disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r222",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r530",
      "r533",
      "r534",
      "r550",
      "r645",
      "r724",
      "r737",
      "r738"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r159",
      "r174",
      "r669",
      "r697",
      "r713",
      "r734"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r190",
      "r222",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r530",
      "r533",
      "r534",
      "r550",
      "r669",
      "r724",
      "r737",
      "r738"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit line available under the agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Loss contingency, credits to offset payments",
        "verboseLabel": "Amount ordered to be paid from other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.",
        "label": "Litigation Settlement Interest",
        "netLabel": "Litigation settlement interest expense (income)"
       }
      }
     },
     "localname": "LitigationSettlementInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r157",
      "r171",
      "r367",
      "r381",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Carrying value",
        "verboseLabel": "Carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails",
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Long-term debt, term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r87",
      "r88",
      "r336",
      "r337",
      "r338",
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r336",
      "r337",
      "r338",
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails",
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r336",
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Accrued liability for tobacco and health litigation items at end of period",
        "periodStartLabel": "Accrued liability for tobacco and health litigation items at beginning of period",
        "terseLabel": "Pre-tax charge"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Loss contingency accrual, provision"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r719",
      "r720",
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r719",
      "r720",
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Judgments paid (approximately)"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r719",
      "r720",
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r87",
      "r88",
      "r336",
      "r337",
      "r338",
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "verboseLabel": "Number of cases pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r25",
      "r158",
      "r173",
      "r222",
      "r309",
      "r341",
      "r344",
      "r345",
      "r346",
      "r352",
      "r353",
      "r550"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]",
        "terseLabel": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash Provided by (Used in) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Provided by (Used in) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Provided by (Used in) Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r57",
      "r164",
      "r181",
      "r188",
      "r207",
      "r210",
      "r215",
      "r222",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r255",
      "r280",
      "r285",
      "r291",
      "r294",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r541",
      "r550",
      "r646",
      "r724"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r256",
      "r259",
      "r280",
      "r285",
      "r291",
      "r294",
      "r646"
     ],
     "calculation": {
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Earnings for basic EPS"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r259"
     ],
     "calculation": {
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Earnings for diluted EPS"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic benefit income, excluding service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r186",
      "r229",
      "r230",
      "r233",
      "r234",
      "r243",
      "r244",
      "r245",
      "r302",
      "r303",
      "r311",
      "r312",
      "r513",
      "r514",
      "r515",
      "r538",
      "r542",
      "r543",
      "r544",
      "r551",
      "r552",
      "r553",
      "r563",
      "r564",
      "r565",
      "r567",
      "r601",
      "r602",
      "r603",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "New Accounting Guidance Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r120",
      "r388",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable, Other Payables [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfForeignCurrencyDerivativesHeld": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of foreign currency exchange rate derivatives held by the entity at the reporting date.",
        "label": "Number of Foreign Currency Derivatives Held",
        "terseLabel": "Number of foreign currency derivatives held"
       }
      }
     },
     "localname": "NumberOfForeignCurrencyDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciEquityMethodInvestmentAfterTax": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI.",
        "label": "OCI, Equity Method Investment, after Tax",
        "terseLabel": "ABI"
       }
      }
     },
     "localname": "OciEquityMethodInvestmentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r280",
      "r285",
      "r291",
      "r294",
      "r646"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing operating income (loss).",
        "label": "Operating Income (Loss) [Member]",
        "terseLabel": "Operating Income (Loss) [Member]"
       }
      }
     },
     "localname": "OperatingIncomeLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Background and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r204",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "auth_ref": [
      "r36",
      "r214",
      "r554",
      "r556",
      "r560",
      "r687"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "terseLabel": "Other comprehensive earnings (losses) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r36",
      "r38",
      "r214",
      "r554",
      "r556",
      "r560",
      "r687"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "totalLabel": "Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r34",
      "r213"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Other comprehensive (income) loss, net investment hedge, (gain) loss, before reclassification and tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r93",
      "r208",
      "r211",
      "r216",
      "r554",
      "r559",
      "r560",
      "r605",
      "r611",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive earnings (losses), net of deferred income taxes",
        "verboseLabel": "Other comprehensive earnings (losses), net of deferred income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive earnings (losses), net of deferred income taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostOfOperatingRevenue": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other costs incurred during the reporting period related to other revenue generating activities.",
        "label": "Other Cost of Operating Revenue",
        "terseLabel": "Excise taxes on products"
       }
      }
     },
     "localname": "OtherCostOfOperatingRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "verboseLabel": "Other, net (1)"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r104",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Postretirement [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r5",
      "r105",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Accrued postretirement health care costs"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r690",
      "r691"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid on common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r47",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire businesses, gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
        "label": "Payment for Pension and Other Postretirement Benefits",
        "negatedLabel": "Pension plan contributions"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r435",
      "r437",
      "r443",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r478",
      "r479",
      "r480",
      "r486",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash",
        "terseLabel": "Pension and postretirement, net"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r103",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r485",
      "r658",
      "r659",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension [Member]",
        "verboseLabel": "Pension [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r692",
      "r693"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r188",
      "r207",
      "r210",
      "r219",
      "r222",
      "r231",
      "r241",
      "r242",
      "r280",
      "r285",
      "r291",
      "r294",
      "r309",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r352",
      "r353",
      "r528",
      "r531",
      "r532",
      "r541",
      "r550",
      "r608",
      "r646",
      "r667",
      "r668",
      "r689",
      "r724"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings",
        "terseLabel": "Net earnings"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r83",
      "r192"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property, plant and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r85",
      "r176",
      "r609",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables:"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r175",
      "r183",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r36",
      "r214",
      "r554",
      "r558",
      "r560",
      "r687"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedLabel": "Amounts reclassified to net earnings"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r36",
      "r38",
      "r214",
      "r554",
      "r558",
      "r560",
      "r687"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTotalLabel": "Amounts reclassified to net earnings, net of deferred income taxes"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r34",
      "r206",
      "r213"
     ],
     "calculation": {
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Long-term debt repaid"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of senior unsecured debt"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r684",
      "r694"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash included in other current assets"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r625",
      "r686",
      "r694"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r98",
      "r172",
      "r619",
      "r623",
      "r669"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Earnings reinvested in the business"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r184",
      "r226",
      "r227",
      "r228",
      "r232",
      "r240",
      "r242",
      "r310",
      "r490",
      "r491",
      "r492",
      "r511",
      "r512",
      "r539",
      "r616",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Earnings Reinvested in the Business [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r485",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r485",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r271",
      "r272",
      "r284",
      "r289",
      "r290",
      "r296",
      "r297",
      "r300",
      "r407",
      "r408",
      "r600"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/RevenuesfromContractswithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Expected period for satisfaction of performance obligation"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails",
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r36",
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansNarrativeDetails",
      "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r76",
      "r188",
      "r222",
      "r309",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails",
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r719",
      "r721",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.",
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "terseLabel": "Schedule of Contingencies"
       }
      }
     },
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit (Income) Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Recent Accounting Guidance Not Yet Adopted"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Share Repurchase Activity"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r300",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r334",
      "r335",
      "r648",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Reporting Segment [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r280",
      "r283",
      "r288",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails",
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r1",
      "r156",
      "r170",
      "r669"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r187",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r300",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r334",
      "r335",
      "r648",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/SegmentReportingNarrativeDetails",
      "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails",
      "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r222",
      "r249",
      "r250",
      "r257",
      "r259",
      "r266",
      "r267",
      "r309",
      "r341",
      "r344",
      "r345",
      "r346",
      "r352",
      "r353",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r550",
      "r637",
      "r681",
      "r695",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r93",
      "r184",
      "r213",
      "r214",
      "r215",
      "r226",
      "r227",
      "r228",
      "r232",
      "r240",
      "r242",
      "r265",
      "r310",
      "r388",
      "r490",
      "r491",
      "r492",
      "r511",
      "r512",
      "r539",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r566",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r265",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Planned share repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r70",
      "r669",
      "r697",
      "r713",
      "r734"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity (deficit) attributable to Altria"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r120",
      "r121",
      "r125",
      "r184",
      "r185",
      "r214",
      "r226",
      "r227",
      "r228",
      "r232",
      "r240",
      "r310",
      "r388",
      "r490",
      "r491",
      "r492",
      "r511",
      "r512",
      "r539",
      "r554",
      "r555",
      "r560",
      "r566",
      "r617",
      "r618",
      "r697",
      "r713",
      "r734"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r561",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r561",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r561",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails",
      "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails",
      "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails",
      "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails",
      "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails",
      "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails",
      "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails",
      "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails",
      "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ThreatenedLitigationMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of threatened litigation against the entity.",
        "label": "Threatened Litigation [Member]",
        "terseLabel": "Threatened Litigation [Member]"
       }
      }
     },
     "localname": "ThreatenedLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r304",
      "r305",
      "r379",
      "r386",
      "r537",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r708",
      "r709",
      "r710",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "verboseLabel": "Average price per share of shares repurchased (usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r23",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Cost of Repurchased Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r6",
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Total number of shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r23",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Cost of repurchased stock (1,019,815,657 shares at March\u00a031, 2023 and 1,020,427,195 shares at December\u00a031, 2022)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r93",
      "r98",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Aggregate cost of shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails",
      "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r493",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Unrecognized tax benefits, period increase (decrease)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Reductions to valuation allowance offset to deferred tax asset (no impact to earnings)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r248",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares for diluted EPS (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r246",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares for basic EPS (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.altria.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 18
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32472-111569",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r677": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r678": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r679": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0000764180-23-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000764180-23-000060-xbrl.zip
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MS__+TFR4FE7Q.R 6"MARI6I<:J;!8:AS%(IT3O8&(%K!7IB"J%(( *6SI"=
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MLV""['P=$V2SGX13^&^4CZ-W_P502P,$%     @ "CJ;5F0HINOA%P  W:$
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M^EU_>9V">R1/:0=T9IJT(V)9Z NE;PE2!</Z3459#-,(O2[3]D2H4:1 >I[
M;W$DMX)=!CS,6\4/>8N<Q<X="8TQ"\%+<!J3O8=&F-\TD^F$*9'$, T[_13T
M0Z0LS*9#&"),+)EPN 3_ KE.8;): &;*1M:N[/-K\GX2:!#&!IU]HR OKV\2
MY[$& 3;(/7BH/LV;)L1#:"\;_N5,:A0%031#N )68YK0)5X4^H2,$MVK3$I"
MUZ.[01$>CY4HCR/_Q@[FWH[KSI6[+&O+3N8YC&N_NWRCTD_,%YZQ'(>T?O&J
MM?>G8@2&A?3H.<76_3&=-^L1^SP1H;@U)JVVV)2 6,%:45AF^>KIX/5S6+6P
MD"<<[!O>/A4\A)L3QVH,!33892<\EBFLF[^A+=UT&*4L@IO43":"^?@HX#<T
MZ]!7N=F$3YVV>6)-$5K1;AVC/<0I!V)DP@W2$QFBXSC<Z+^-OW^(T/Q WO#U
M9UPM9;ET20RN_V&G8->-Y7Q6M45U2%@9S9%.,A]&R, ?S2;2FS@N";27T )J
MH'8MUK<O]@"YFCP(\2VA<@V72+GZ=>W*8</RJ!@JRDS)-!4AVBP)^ (PQP+,
M%JOH%C!H3=,80%8'>KT@Q?.62/%<O3N)_"6R9Z@;YQ@>ASQ@5^"6PPR5Q2>=
MZQ^\W>N@^P-W"$_4?T':XR^1]O3+ZC.-19@0M*309, #C#9.X=D%44R1!\95
M:#^63,\>-'0;W?T:H7F##Z=209 6*8K ZI'P_91L>V_U55,LD6JZFGDJ$SZ4
M@4SGRZ-VG/GYJ$"=>,HP.9(&(BE[2?":0XA*1C)-G'P+C^- >GP8"!9$,&F,
M(]P&99ADBOPQN%^ >M-JHB-2C/XW8MCP=39,I"^YDB+I,G;,GC,&- ]MIW=P
MS);SR9U6GAS :1XD4?F98A+'!&<F7M/))W!@-DV$4UP6<5]$X<9JB1RCYF\0
M^W]:K#Q:&N.[W^UM.=;W D,#A' I^$DGH/E!6M\L+JU7*A\3&ZEHRKA'^6F=
M.Z>O*17K&DY$!U63Z>2*AA&F;M.4RY#NQ_AH+-C>KDG60LO"IHA'V-=<< T<
M8"*WTB9_%_58!Q4KKKWC'Z2]3=TWHUIFU/<Y;?,EUUJ(F:;G7"UVQ4YX4K*L
MI8K(M3&O>V_X>EZ+R).D+P@&3Y;&$E<B-+<P!']C.0Z,TS*Y^3@?5>[F?8'@
MEC+B0X[Y]RATS2..OK]_E)224'ZF*'%?1LJ7US>EJ^!O&?E@G\%8)VGIIW$$
MR *PL]APNY\_/%C\CS/4<FF4>[^[M^TH]XO&%[N]5WQQI]K^M:QJFTM]OCQJ
MBUKA&>V0;O7(J$P' BY,>0641X#':SYU""!PD[#P)*#^:!8*E4QD#)>!(14)
MJ>R8N)>8RN AZJXQ^^T8P25#QI&F@AXJ$7!<3ZWT2,,.ZA6W\&$2!5E:OZ55
MO=U_)ZK0]+'8&,(LOFSP$<SDD <S/D_*W2]B<2[H<_47W9>E6705(#0@E\ZM
MH3S+[?$2K4$PV#'71 WM/%P#?H\,1[.A1[)10]*O8Q:Y#+T@\V$NGE1>-DU2
M1$-)V0CDJ4F)#HXG40CH"EM/8<G'Q*G&U$P:643%1IE"=H.=0?)8'_1M$<,=
ME,$E7#O!TJR=BL/Z$VPXZMQRL1]RMD.-I%<EX65Q"R$"G):"Y3$'[:6D.BIL
MP;^#-D="IID2#:G#%A7;JK%27XESBU(>6RM&G#NQ_$M4$E*FE\N?8X-RA0DM
MNB\",8:UU\'UB%\  !.8L/>4T/3E*9^#'_F_#$!DK?0EO@H/X!IX0Y#S2%.9
M.>7YT6-@S8*B\50_@8+A"GUY40BN1"A>9^0.YT1?&<UMDB#O$N.DS)O8\5!;
M',>,H3XF!#""T]D$PGU.HV@/N^P\U U@1@%]9Z=L9,J#&E$5CCB\:%(IG@M+
M \JS&UH0SDP>)(^N?C2U5D=<!IDJ2?K!;5L\P@LP *V 7AD)06@@9)P26P,I
MVIJ*7B;_U)5EF-%#!%.,S(^4!46\<- #2S]/G ?0THJE'E4JJ@[X>, T.YJ(
M"1%,%AC]HEA;L# + IB45U:TXCYLMC( :,CX$^8",_(1.8.?E*8=!)5]S=M7
M5_-@8[F]8J[&%-(, 'O!;N8Q^(N@;/_>RZ04"#PO!9I,-VX9T8;CEG(HVDVX
M6+SC,"TQ=5XR.>#*,,D-EJ;8&-3 ""GBK[F..<ON#3ZJ*!M/:GV3!2L8[)@;
M3T;2&%[-<:\5A'*[J*GK@YJ%),X[.("R56S;QZ.8QY,)0[]]J_/Q&1CV0/>
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M+$2S=,%E-W)"XG/:!0K#<8%$HD?AQ:&B+CY&X>4.=H:"5(<JTB'@3_\JH'3
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M%#)MV>-H(VS>0V6/3>#[ZC>?^!TGMKY;/K%UKRO=,?S/"P/_X_\#4$L#!!0
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MIKWQ;#F 9WT<'IR=T&61/IM?4 ].MJC4E>E^H2%_N(7%).Z@CD^DA)(2&BL
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M_. SK@EXC=FF\:RN!!MT7>K" /_U2+[N U2R<E'X-E7P_1"8;5!6\^X)U_D
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MT5L--CNFK&!%E#X6%7Q8L<'+'Q%6=[4MO'76&+:+ C*9NC1.-"6E$I/S EK
M5K<IX^M@?/-H3#2OP>7&.&BDY\<XIN-1/]/X89V-NIFF7Z^(;B5[$6(JH5#(
M1H% ';/@"*$H%8#J,C<M8*\US)K/9DDSQ)1G^H+"P#*8=;2"G?N$4J3D5I?-
M%N.[YV.Z^S1?WWCT$22K2"LBJI3J_E6Y2)9XPJP".TDI>E%W=<VK2RMW+N^[
M\59RW>4EF8"R@#7:1QU%LN2+T<7F66PE0(H&Z_?RG>!K2E) 1XK;UUR.AQ-X
M"YH?0$07/6DCC2BN&*DQM%N2V\.C63DXZ^S9+0S?WXT(K2VJ^G4V) 24%$"J
MZ,%DKRCX$EHP?'\AO9K1.OVL9.L9]PW3[I49]<K-_H)]'"9VRXC^8C[#YF1"
MUW<2ES-3HRF#\]9X8F?..R]E3:H%J*N80-UH1-8YV>=P P5-@]O?$,4.0^QM
M+Y]BO\XB8;1M+LA_*96)%Y-83N.$_GU:<\1O:V3PIQ&-STZX:4A 1\$UL[:I
MC[W!E[*VLP/?G+5E#R*0<1)%CF#(1TM)>;;'9)4!7<YW/P%E?AAT74_*:B9E
MLP3%5UDAYLSV14LP@!Y<W1Q>>_08P,^W'98L&KL6S17W7:RBL<L0C87LD[2&
M1 $GBU?%VFS)&N["5-K)R0LQC&=+HM>"[;<T/ILG3=:,_!5 * S:H25'')#G
MPOR)%C,(%02":B>-7@<032%16P-FB1+19"!R06EVH+R*QL=@%CO:MHQ$[TXP
MRZ-031Z4,Z58(]C/4%5$H,@4"&@@M9-"M]_BR6B\_,AI15G3NH1*EFPX; 97
M]RZ6GL@DC"E2-KF5K/F-&&@*46)B2R7J&*@N$%4)&J(ORDB0V9,QK23*6Y7%
M\KC1DPQ)N(S:"G >HBQ6.@W"B:)]%JWDQEG!X '.4KWG:?MUK'\%O63_L;CB
M0W0*I%;>:I5!VUC89J)IIV?YG5AH"E<**324%#,E"2%!))6#(Q.UJ*MA02NY
M\DYDLD3.+*EHDU4HCD"Z@DZ3S!*M4M*DI)O-F1>5I8]I=#3&D^->POYY=>GT
M9/Q@Y^GU"?*6L_[K[.\-601R8%"%**V.@$PY%MA&:';5;(I)8'.1_L,A\2JJ
MO=M=(_VOYJ5JA[&('+U$H.1"L$%8'8H"2,*8-=*_ V_=S39JTHHC/8)21L?L
MLP\0.1)/'.H%%X0/5GMOUTAO#!*OHF./EN"NK2K2:ZCDDN'X-4 &B.RCUZ*H
M7!+'N#*=EZHRTCMKR%\YSW7P_!SK^"G6'_7KN@.;TRD_"GY]D<P60?/S$MQ/
MP?F5*K!/3_W.Z9F)^_:+)1C\^^+:OZO N+A1']]-3GO3+]WK_-!5;G<Y#E8F
M VN6Q^PX*/ <(*0B#%)$ZXEB6RU)K=^::]1'?G\Z[Z.;G%6P'M'YMMEZ#D*1
MEJS-&K03/J'QTHI8AW22;O"HWE71M\#<HUZ?\B]G,T]@;US+&?N/ZS#LL+:W
M1F1C$ G%10>4(_L:8$7RD(544:BZ[J.'UF9+& F?3&HZ1^4:=DV!G5 A9:NH
M")*0&(,8I'201#$N2YN;"[NOQ#=I=#J<CL\>/+R9-,*Z".W[,>>21!E$B0$S
M:!$C,UTNV7D-DHIL[Q#(,C!W][M$K:%]G3&/( &QJ*0T""!$(TRDNK ]2%V@
MN="^(NXX;M_L3\<]?#P>G9[<<(YJS>&-!;H-PN1:1E[JPLV,<T<&:D6Q,477
M=2G60+\B"O^4_/WH+=]T#G@9^K7B.)>NKA)5=YA,$KSS[!VGE)$L1;+:-7C
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M^Y[96^DA]OLWB82Z5H]>CAG"$(F-D)>I2! E8"Z)..1VDNU0C'Z-A.9S3ZL
M9W.-K1R']@$@IQ"%M+Z4H#V&G-(LU<P(:6"$_RTB>7B,^1U]52AW!/+K8<$O
M;YR+0RM@SE$4%12OO9+1>&FT]=&3\&LLK SA-05R3GDM$@=8RAC0(!$P.&\R
M>T/>A9C/(=? E6]:X/G\"^M" MWT%-D;/N[W;IR'EK0NDA,B19V(0W$/T?O@
MG8@>O(^*#T6S!D7SG:"V8H\C,(Z_M"[.<LQO5+ %G0"3(1K#AG&&/=-$&]@"
M0GHX&IW<[+B[-$LS30%$)FM\(!&!R 81)).11JU(A"S72&@^"[4*<,G+&&5B
M/\@A )5HBS$V^&P"4A+SJ21*JODV*/RA>?;OF\+D7K]__;J+JV'].4VG?<HW
M&9%=JI97':FNN(/([-2E+!*85?%):BTU)B AL2@1G40G0_$9%_@1"_R(=N/G
MX+3*=&7Q(ZZ.'[$<_"CK!<.&HL@!=$S>>FG9!%JAK020<_P(>XX?89MG^;[)
M-ISFW#NFE45077[TB@CB4S]:L&L@*+D2(T?N046 5 C1A)SJ+J>>)2S]^=2R
MBXV\&CA;X]OF,_3[O:]/:&@I@O0W[8(EE\-!5FDH+C@%6;,/9!E-VD9A@\XZ
M:"/..<@O.,BW&T%;/_TR'KU;40 QK_BK4Y!?DA.43?+:*<>!&L1B8[)!D93)
MB4 @9G4<(C35=GUM3[]'3V\G;KK*>H+7"ILX9KID=*Z3L3&BL#QC*=5+B<BA
M>=(12?D4-1^:[1YIA5D8G0:.G?Z-:/ZT%U$?)Y/-5,]KR%:JUZ*)*II:PW5E
M.Z.70Q,@A)=%1NN] 0L4LM5:0_!2.ZE<6(/F.C2UN;\&Y?>,>T3I2\!"SB#H
MDI#=GT+)<Z0>"7->@_(ZH'RXN0;E=X!2Y.R$D2F25Q"08[NLC/&@5 DA:KD&
M90/RX5_#_M;VBH%26%' Z6B$ Q,*VF"R*XZ\55&;M 9E&T#Y<+5 6??NMK)8
MLN@!G8HE@-&HO'-&0E(M >4=Q:#-!WTK04E)V6BBM*Y8B $\12MB1I^-D\ZT
M)=#Y&BAWUJ!L$2B5!)&C2*'( )E1Z*DX:^OBW\:6LC;?U].%=:#S7=&W+DI+
M=B:]CZ"CQ"RTL3YI)9/*K?$IOX:.?SU?,V5[0&F%I& 4:>$-L$,973#!@7<J
M!!5*; DH6PN:I:C<T[\FY%:",@:G0Q(RDV:'4HI@;-8)58S6&Z_;,N+R-;%U
MM]9,V1Y0EB0!M<J9A(64,C)O%B<-VKIA;O(M 65#?<KNSAJ4WP'*A$E&JTF5
MH.N.P2@)%620VJ./:56B[^[NFBG; TKV'H."I*(,S)2>O(2ZXWP63)S&JK:8
M[]:"9BDJM_O[:H'2N9P+:BNC4& * U(K5!(-1F]E7@\SM@*43U8+E &)C;:4
M8&*=&$\>DL2HK!$^4"FV):#\JM@.U^:[/:!,# WK#'N0$H$2U@VR/&1M0XPH
M4UD14.[]N@9E>T 9L\X<U@@ "$"N1"5-1AU]CL5!U"T!96M!LQR5^]=J@=(G
MI4WR(14LH*0/41 92\6;(HIS:U!>"RWK(M_O :71N0@152BN@/<ZD,6@&9S:
M11L"KD'9 J9\MF(C.@#1F:0 5$Z@DT"7I4>.>8Q)EJ MI6O-8\HT.AU.QV</
MGJW)\KOF=H$-+I++X * S<$E 1R5>Z<MLV=;8IT?FRR?KUB=KXTE4\ADH"X,
ME$6,5B,6DYWQ*4!;LD(_-B@/_GNU0!F+5%H+GR!84$Z'2+*4NG<J2*G].@!O
M RA?_O4H>RM!65R@ZC^F@ X2/T5P=55A_A*,0:7.-VUM[P[3.,R;_>FXAX_'
MH]-K;^;33!>66_]ES$\U.7XXZI\.8@^?X^0-3ED>[Y:W]LG=;W=]>1/93W>P
MOLY.CA2$%)"B%!9<C-ZD;.L@.VD5 J3FKN?^5QKP$(>8>S@\&$5,:=3%X6G!
M-#T=TW@I2&R> BQBN+^90'PMN%UO-??386^.M<%'25Q@:4 XX>^U S\YO+C3
MXNCB>[W5%U&,-MNLI$3M TA"'W0(!:'.53?%J.:BN&$^Q9*-1?M!.S[MLPR^
MA-?YD6^&:M#1!(TB>(,@4O)"VF+K+H8(X(RN"TA5J,[\X&9B=LV\-POB3Q>I
MFL/X2G[QYXC_-K_X O$)\Y_@WIN,0$G'[[GUS8#/$CQ'>(22"G.SP)Q=TD9;
M+;4M0I_[V W$^=56+3LX'A-W\_ ;%BZ[!=A=1Z'.U0C']' TF>Y3&KVE\=G5
M-.K:?NV2MHUQ)A;0(7GE$+2OHUDZ%%78&; V.-M<U*W9];9<A"7"S7A Q&"2
ML@"2K3N0SH6\-% K].8I5Z9!MNKS#\U<WJ\9A' I+^0[\DJK?"Y.7<HZL=XX
MIR1)!!4A@0]&\R?OBU32Z"C^V%E+\:IZ]F?!7&??]^R+5DF6" *,B=&0D=;Y
MPMP>K(+/%_!M(+\W1T+76$UW6?7+0'7:L,^&XQ^?8RB:4K3&:0Q2:7>^FJY<
MK*:[%N=5Q:FN+DZUO-%P"8ZR,$I+@N"])TN4),I,2H3\I^6U&RC.N]\CY&]1
MHX2 W6?=S?SZ=#(=W$B:^>Y9 0DUEB)-T@J 1 A9*2JY2MJ0=VL8+0%&9N5A
MI*TED Y4(0TY8]1H,1G@L-!0$;B&T1)@9%<>1L+FZ 6&%+T%9P4Z3Q&B4ZZD
ME*Q8PV@),'(K#R.+.B0%"GV(8"+ZB$$+<+/=19/.:Q@M 49^Y6&4C4H,(UF
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M1ON4@W(R@9<Q1C28L]+6&!EL6-N:-7J;R_DN6!$M)0DV@,@4C(3(H2O*NKV
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MT9]C0[51@].8(I4CKEX-_U^G@_C-@\$*UZ=\&(Y^]L_>_E2P$+)$.6R L3H
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M1=?G**5&L)^=B[D;!6E&T^[5#]LY34.7<6[Q./=UFAGY*%1.> @8T:GHHB;
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M%7#:0.L=0T+P*L@0-KJ4=7;@K2X?RCCR\#@RE<_#:RR"-1!@ENPJP1@PG&B
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M=9K 9G[.W]LX?3O=EZ/)NX1D>?-R<0@W(T&SX )1D6)-93" 6LZ 9H0#(EE
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MOK%ZZ,7529KAZ*VF;'3YI_K;@",5./9?C[]Y?'FCNG2-@8ZN<;A!(+GQ,MQ
M=[J&-@2\^4M__>3-SR&^@95H3F/)_*^=X?AH7-7"^C5X85UK4MW%U[U^E7!W
M+_(]7[3B_8>#XE74W&Z4$Z(@:'V.79=;E#7\Q>B,E$JMQB?YW9]X__$<_6_<
M&OV=2^7W/I.:+.L;3A?X8='WWWSW](Y9(.<>C3OZQ1OF^%[LMF=3/-OWWM>,
M#4%8>N<U)E3JH)S36$KI&$%<!_AYN]K71!"!>3.-5S+]NM\[3JZ&U(1/Y?#P
MY>D@CH?OO_HQCOG92NE/H^W9F!QZNQ\F7N\O9_O'!U];>^WDZ6;[Y^_CN]OQ
MN]^7NV]>?=_'^^3@S3O6WO[KZ,+K?=P^VMW^0EK;AU]W/_U]W([WMG&+M<[_
M/FQ]^OMH]]._7UOQ>KQV>-WKO8];='?;?M^-[TR>]?:;';)__O6\E;SHQRUV
M\.G=]W@]7GL=6B4\JSS>'^!9ZZCUH[6W]1E1+!'"!' N(:!"<J"$@@ 9B)7C
MU DK4ID%@::39#9VQ[-66YI/'IL7NRG9%&R^]ZZC# Y)"*WRWE"BH0S$20:%
M,4H):T6%S7B"S3AC<]VQ&5['9LBHXR9E#9":@*A_.3"8$R )<T)(9&A@50F<
MA>5Q?PQ\7 '38W:&V%K#ZR0/ZR"NT)QGOEDD.LW=;GC3Z[DJ3L3WOY76#S[T
M.G-67\]X/ <>GTUS9<>)1()BX$D0@"IJ@<(0 J:AL@A;Q;A/N28IF8X/:1!7
MSAGMGQ#IRUCR(%@RQ>TPA2I$ @<T-QI0%%F>=E !P1B.M(]I'VR%)70ZTKAN
MZWD%&-P]\^P_!FI$>ZP<^&*H?\1W1M0XZ??<J<T):!I&YL9E1!(*[Y[X%,?5
M_3*VQ#/(W@)DVR^G"1LGA$M/XU2@:#93ZTPD;*DFFC*<"AJGS:.US4C;FDS7
M<E*:)T37?HD6F:\M#$JF^)HQ5%)N*" .44 E9,!XH8"7 48@$9'&5;8?G)&N
MKVX+>@7XVIW.B->^*N2;?F\P2$0NE,.<.V?EJ5\UW6^KV<[@O3#P_C#- Z&R
MVDND ('6IDUN!:16 DC,9-KAUA"+E+>"X$9O<N?\.PV!HOKQR@Q%RX&B*1[I
MG#26: >B[HA0A)P'TD7C5!.'96 >,EQEXB+WYY&/" <KP# ;Z!%LZ?Y7GRS"
M]4*[X[);#H:C<X'5X;.^'_@J(MSV<IKJIE#%X][SBUG=NC*G<4K?CV<T^0,&
M&9EO@\PS(B&MHDAXB($1J9(@P00HSS6('!%&=#:2IRIF3$S'VC2((F9GX1,@
M=1DTE@4:T]NX1@J<=A@0A110& *(GT30P$@2&44">K>V2>6T75FWA;L"E&TU
MG8(7?OZB[-K>L<^.P95E>Q>[/),IWZEF_)]HFV>K?&$P/B.RCV@NK<,($ ]]
MM,IM  I*#@PTGOI@K<)P;1.OBQE5V!O$_K*#L"&05!\NF2'I82!IBEE:(;G@
M3@+,.8_,$@M@+%$@,&>B6N'1+$4)DJ2\=S*Z["A\8H["2;K\RB_82R$E<>V;
M8>%_G*2,3^M%U]]M__FIV/IUH(PW%%*8S.T(IU^-9K3MZU/'J@F O#LCF- +
MXYTF&G@:%*"6:R M08 +YG74LDX$&0&YV5O(V3^XTIPN8\92,6.*Q"F(D2-(
M@<C9$HEC$*C (6"46VLTU\KQB!D29?=@SD_6O#N?PD'IE(DIVKYESY6V,+[K
M0SD<>V*K[*&CG C%8'1RKMI<S\>I;TV=;U-[;'G<.<[UV_%4IXI%7>_^&DWX
M8*P34ZA]?Z [NV'\P452C/')R;2K]K)W?!(723>KSUL=DMR;49"%8<DHMA8(
M*!F@QEN0)AT$"I5A#@HN[=HFF5:?MZXVED\[/Q2@WF:I+X_RYJ7^N$M]JOH&
ME<Q82R%P5'E "3? 6 R!MT[[(*@+*E+E&:>A:[345X"A-=";^6QDMOY1='HI
M,U41^KWCR-"^18-VE*>^[$XJ4P^\/>U7!7:R>[-9[LWCWO.?.T\I1=FH)-*'
MBPG-"'PK!'XU@VQ1CR$+%&@GTB:X$L $& !GT%C.+%+IB*.$V;^90:.N;"^#
MQ7+ 8HJN(00)TU("*[ &-% $5(!18#E" A.N+%'1,IO>FYZ?KF6?YDHZU-*:
M3/EJ7O9[W=X 5/73KE1P*[N#8?_T>%2&*GO2:LW2KAK5V[')WZIJ>&]TV4T3
MO=O]^5FUH70Y9"B4/[P#Y[[?RWA\*SQNS2A=K(7SCB%@C$,I/T7\37 $O(E3
M3"C$2-G$EB1&^$63&5SVUSW%'>HYD"4CR*T09(K11>L.<QH(T%090*EV(,X@
M!(%Y)2'F5ABYMHFFS;^Z+> 5H'5W2L==^Y,LDV*1A?&1!OCQ+NHH@^'#%KFY
MC='=T!#R^K'#JR9Y*C%0=D_C^(U#RWO=P5^57(SNVTM2\>K'L*_C^$?;H'^V
M,_3'@W:OFUK9[W4Z53#Z*' IAZ(O3C6\FR:7E!LOB<7 0QL 1=(#R20&Q'.L
M%73&09-BT:E8A>#'>AR/R=A6;Z*:L:V1V#9%>V& . 0* 0JI ):1+!)@[  T
M4G$FM(<$)VSC"TOLF,_9/!57Y]M^[ULY2%@4E_#]Z>Y3\4/4E;I&V![' HUC
MA3+ZW@I]/TXS2R$#,L@$H$,P@'HN@>)! X^("1!YBY/;DL\H<-4@7IE=ED^.
M"6:HN"]43!&UP TC'IL(%9( ZKP?^R==E%*M/$)<KFT*M*CCT)F,U;C!JW=G
MGH)'OS.[Z2].//FQJS[7GE^6.;/J]8WK9\1%N<[):Y9!UKY,VW6!!2@00X P
MYP%50D3:YBV0GG#)D8:.N50N1<A&)]1:C1V#U83=7%:^'@9QAMVEP>[T(3IN
MB>$I%MM("2BB!&A$.2 FJDPB6<"I8CQ:5VQ1"6GS9L:B4M5NL%^.7ZU1]:WO
M%X-#W?>%TT/]?%$I:F\:DAO=F?G]\[Y_!=;0500:R?]OEU$S3/"_]*"T578^
M5W9.T_&(B4&><I&,EMH"3//?C=D=B>(\4U$WMKA8(WVN$:@+9;R]I1[A_D,2
MP<5:[/@Z<YS$BTZ^;GNT%BYH(LPT\?<T\6A&6A43:: D- !,C0641>M<:B2!
M(HAB;17FD-12 BI<S/-_W_D/DG'"F0(>:I>J5GB@HGD XG0PK(A 3-MH)FS
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M&2=A)(7*",PM$U00+H5'C'#KD(N?491QLK$XB:?S[6E"M>+ 2LH!Q8$!HT(
M'@>OO&,&A8B36*T+-9W@. -E!LJ5 \K;Y$@*D60H38W14%'%B':A.DUI86#,
M,'$S4MZ0&BE#9NT@DTY!9H"&2R>!AR8 Z@4%"LEHA5-&59Q]QT-(QVZ$F$X?
M>.MB.QDL,UBN"%AZ#RWWQ%IM"!562DBP12Q8P^(OCF6P;#Y8_FA=/Z2HK#1.
M.@4D4A10!2&0'AL0"/=!*Y6.JJ]M$K$NT0)JDV6XS'!98[B\U3EMAFBDD81A
M1&DTR(DS, BJO6$<B@<WPC,.W@X'+[)UM.(S^^0S#=0K!3DPAF- G:9 "AJ
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MD-7#DU,/"GH942,PXR)H2*V8\M!@3[TP@CB2U4-CU<-4! 8C 1J$(/!)1]!
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M.,CZ$P/[L_Y+/9IF"%4*3]J@6M;7H,"^0NG]Y_-$&_S:3!IR528-OBZ59I0
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M"2TUR,!A&!;J4#CO<FYAFL?'N1M$KGZT:7LK58AL(MEGO*D[]HW?T2]N0UN
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MY4!D;FKBS#>6/AKJ ]\S(C@Q?3U^1;D1!%^,";J.N##>"!Y$J!RMC'_AJVP
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M?6;#EE >EE#>GH*H%LG04!41Q)6)$&-<(&EB(!1CA02%P(0D6MND&U>K!#L
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M8N'.29A*%^LYQP[YN\'=*BD5=T\%>LH(U^>D$SR;-( [QR)$1L<B5;'DU#
M%B%2SE,=AREV&7K) O*PJR,+O[6<XL$YQ=FL8*PMT]A2@A*-$\1BE2(9)PII
M12,2QB*T,5W;I+-R\>K%);1I1$OHY*:)#!/"#1-IS(0!Z3).,0&-&L1.EC"\
M@(#9XL?CX<>,I D0'S,-\B4#^0LQR4,DF$B0]F82JH01@!]QO$1)1?=]AE=
M<KR_\D[+!#/7>NI]TX+&67_LS[YSSXNJ3Q?,]U(7PP(I#W<PA"R?Q'<C$^AM
M:H"V-H''1.KNFUE)+R18,Y7$B$8&NSZ1&*6,)L@F-$D5D(4*Q=HF3EJ;P&^
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M&6RH*.!BV0Q\,,^"M7[EF,E58P86#.P(1(9K).PY\K6H[G4>W,(XTJ@,;'
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M(8'UQ@H$/*]W!DK480:P:WXI8UQP70:,1(FB.'.*Q0B4'@%!KG>7;6?6 OL
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M@RS/2UO]\+$^D-5ZM6!WL:37*P*[E2BSKV'WF6'W? IVF2!8DJB0,SG.1F)
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M?'HH/DV;%YQ@*3(9,I/*9CI] _CD+ H"# MGC/!*K@BE8&W@5-' >1D2P!I
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M_MY_CYM'AS\.]CZEYL4^;GW\)CPG6&J*0B#@TGMAD9/*@4O/=5!*!4[IR*>
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M[^%E@]H36&_D^M'^0#;!8%_;SID]'ZS]=1-J &>N3^#TN]_ZABD]V1N._&L
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MIPL38H"'W& S3LUERR)YL2]C61$6X_?">4T5;9#9L'L4F@_Z%?,[?(+!Z0Z
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M6.%-1@1UBD@F,M OMB A@K+QT2E1F&<OY"+W 80%M,U6"^;/C2K.8S-HK&G
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M\;9;E>KK#6J;CV%61/<3)5[U5W*@D 9QU$E*:8R^4N2T5I7U6$M4!F%0*7/
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M3K>V+<,K1"MM!2<D3R+,M5(>_")'J"8L29SDAE>^-Z_ /=\?Y@,;G'+(11K
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M=\W,WQ[<_"3'C>S KM0*CBG#DA3\E*$_GG>07:\[A"]L3N\/=WI%+M\..3?
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MJ10&U"ZNX3(6@[<OPTH;;LG<PG;W3P^3)%Y&R9 U7@"W2. 6XS@*3"G+K39
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M=%$R)>^,*=YDGBE^J6<T]^L(XVA6\X:![F8@T@0G441.,-4,<:X(XA:<1.?
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M\T$L +@@>NG/3HTIL,>9PH"?G2[?Z/D^%"4>@^^+&7.1"2R-B5QAZ9B76I!
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MFLCP&CYN(KCKALK2-7[]L-XXDH50,Z?R!K%FR90JZE4G/*/%W*!5;B0-7[#
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ME2&$104VCI2.V("M5BQX"JHWU@I++5!8LTGHV8/Z=E06LM_-<Z;AQ.:2D$W
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MVU"$*CP5T!';Y[U6NT%Y9A/*ML"TG2K+*<;NN/LA];IGUS.UFU:>[^LXOYM
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MHHSRE%T6)25&P9>4ABGN;5DK&0^[$H2A\[%Y)C5F :Q@(NV#)OQMS(#<)!&
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M<1=DJQ.T9+ _TAF?D;WX&D?8Z>*WBH^O5Z>O07PX/!Z I=BW \?O^V#+]\/
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M!["2K^[6.EF[R%<%B(Q6<#6;O9'#,BO&Y@GT=P0NJ&8+=)N #ES!!(4BW;-
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MU7K(9*?EO)]Z(#K]O,X*;X9/S),$BU/.)Q+O9^-#H"98<@(A3];!=9/MT(!
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M\LL\3QD,4X "38D!Q01>!L:!J!@E#&-0Z>; 8JZMM&3SI"5E!.^JPT17H&R
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M5.^+V8E@^3Q1%/%D=]T,J?T1H.YK#Y)HF(#&ZPY&:=_GW.E'G% P!EX"%M3
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M[O_?7W\&IZ]_M__\/O[K_W[]PP96\O7]]U\NX+A['XZ_#)TT"5D4]1T[<?M
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MB<#2L-K_P,D;9X<6XQRXM1BO.!59)7K,H=,1MX36BIAM8^L5%S7Y?D1MGBB
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M'P9W^W;>0VOX/*LA1:@Q'Y_.C,,(/(G]M#]@XVM.^CVPHS>2\VPP.1NG]NR
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MVK<-&U-^XI<\G_/JQ3J4_T.073_2RWMO/G  )'Y#8J03ME#T8G7F3N7GGB%
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MB,,[IC-UP8 N& #6HRYH%EV!NB! %P18Z47:J^R3#R?O?JB2[3YJR1[Y'0=
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M3(^"Z)?9)GB<X+0,WBPN)2<D<2I%C;T9%W;<)0Y[C+9'C1!GV#PYC_!45<!
MM*P1W[!E@[TW^^+VK<,(\AQ;,O*<^W,(48"\5BK8V4OB:&'%2OJM?IRM-FV%
M:2W-R\.?5?@"]EHV\@L<IQBFNN50-UHD:0,'<,4G_A8EDZ3?V$?:V#N%JA'"
M#HZASI(4T9SHR(,'#&Y@A.ZNZ\R*#$T^;)H'ZQ8]8&U%T%1"[#%T?#C"!=HE
M.$LWIVYZRC/%V':#41GAS0@;"O^(ERR/?X^HZU>QPG".$9$H!,6!T9DW]>AX
M92Z3JI\_YAE-M<>7:'=:9:L-3))_TK;W9F?8KQG1D*;_=97==< 5)%DAQ^;0
MK)G,3FN59\\0Z 79[4OT&I=]2W>A%&%EW(']4]O O[S^/-C,9AW<DV!.M_;O
M(F=HEH ZE!H:M%6S.D50[R+^\*3=J_GA&I:.]ON&I0ZLI6]86J]AJ;<"[^&*
M4U23K7NKC=>6C]B&D7ISD*7.K1JN68Y-NJ;>%Y$#^*+R)*EQ+:!DX:,@AAL&
MEDP52C6%+I]%57BE1:"9F"_F3=BV74RB6[7[F$,XDZ'>/>=?DL*_RX_;?FYD
M!Q+JUP9_QL" SF S9#0VY1@[)>OJ #4K!&F3KZK7! =.%V!;8)1_I<A\*6KK
MG!63(LLY<$QL&T6MQ\'JL5\1BG25B*X>S682C9P%?X#WNQS?D:LP5U6RI#K$
MZFDX3X/EUY V[0+_/9'4&O+SS/NJ,D[_*L+ B_TM9]7>4T\MX@-BKUTX$R9]
M1BA<F9G]4$JRH+J0'U !I)+@7=A[EX)-JIK*J*5SYCH3$5-3*@VM3J(;79N(
MD.>J)Q8?I6H!,C_$RD!,SW!-N 461B4\C&?]9X$SKN5#*%#-72_@DX>^020$
M"I\A_C&B(WQ(L/X%M=:5^D9KCU1G\]F'JT^75@+J=PG&A2A[(,6P;5=#A,KJ
M3:G$^;0CS 07J>F,)3YM^/)-9K?CC%6G4ZF.H1AAM8KT>/7'P2L4;#CE.1/$
MZ=6PW_@I"MV5X!#]<.Z9YD)5")J&:D(W?P6M,1/TMDXUXRU)+[TUI-1T]NRZ
M5ZM-JJE%RF9CPTS<6*FQ19)R/9,U5H F5*'D%6E*>&BZG=KW9!&A!O; ZI[*
MB)3,'OHH%TP FLZU@=<^FZ1"30+MGBVU9+E=L)[^^I?AR?X;YQKU6],>XFXW
M3H].]-!V C>*82LEI]E3&F2K"K=&1Y$5VF@:.06F="96X)E.I':?B,ZU)<0Y
M[&0JIMAZ#N?[*O+B4MD4;L('9369WM[MJN<+-'DCJG9X:32S%\=)P:BLJGKB
M?A^GPJS/6Y^B03T"@1A]C*J B:>OV'L^\B(2G2.1WPH16[)-*A8?#I,W4179
MMG.[?!0 &[-V!PM6RR[8;C5F/Y;IA;@ >'K<B%#:4ECFC;#<$S,O#82CD724
M99$0>_ & D?(*(62*TPH@BD)#62)S*+7X"M!4RS@=5,S%$$W.\B_S^<",S-C
MB0"Z(YUMK8[T%PP^H6%TYONX=_C=7Y@XY])'K!8K=D%;,$ %HD]*95SG#<UC
M?77*1MN?^?"2Z2V;V^4D&G-TZCU1U"*JA%P8EX)C:C8D9C6;:B0L%!L43],D
M*C^!D4>;YTW*9W(YV MNFL>U5 6!2Q_ O5FZ'OYKG-S&E?XL!M)47KF1/R2T
M6&2(;V#E%UR6'H5_@@VK/[W/V6]T'@\&I"2^*$=%Y<0O*<I9XF%M867W^QZR
MS0?2$3\H!-TC]/ AW TAD\A6/)TVCDKHS1#:.;D$5&:!C><-"+3=]XK!7GPK
MP,G!22&F.^.3 &D3[WT)4$R]!],Q8"N(I$XV)3N2OQ^=7;2*-$ 0%8EX45'V
MJFVKFI*DC0T(J%"MLD[<'@Q@! IYB,&#Z;5%.K%3#V!T1<)#B#7J&=%ULQH.
MP*6#%@E"_+JZ_(P8PCY5[NYQ^ :>[GT5#8U(F9:\I@50I#IV8EF?-V$2,=@N
M=O?<2O38@#I<\&^QD.AL**ZMB7U*,M1 K;B)Z[T8I05BF3+TF/IFMC@#FK1
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MRA#2W%$F^\X(K2<2L;S2\_(TMH^:E[<K._%$U,<':S+A>7FNX$>2N^?);%2
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MVO2X5P:14J/M"42$2*"7F8RJZQ3SJ8B"%V6-4VK,YWY\@;6OKI%EI6[]4MN
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MT[C;LU1"1C&@3+I,^KFP%@9.]>(]THT@ZV 5!88>X3*"8>.JH5*7*"&?D:[
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M.-Z[BXKZ(^1F=I39VMSXHW[#>]>_=_V?PI7?F8]3&#B#XTU#S6_/UJBCACW
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M:<]"K16ZX3QL\[AI$834#&!G[IAM-]G2TN0YD,^+*A-,/VET=RW;A'2HK84
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MC/)OYG 5KKR*X;P%NE;]J>=")6UY^Z#M&AJIAIEGGZ;B\M<=TGGRTZ;>?#S
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MI']<1]R^ES3&K?-WF]6;U9_-ZG?T?S#=/B$7B%W*>;]ND-57M:7TO?W^ZR:
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M-V@Q]"P_D5:9P@)NJJM[<#U@3]T*EV]E^L7V88"'<56?KI5CI *0&04@IQR
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M6"L.YTX.3P AWX"*!\?)O8GCI@ZZIWJ=LS1+X-'QO$5_=\_4YWRVM/PQWDJ
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M11[!CV@],S7^UF'I.V.P=*OG'[]^^7#N_/KE\[?+EO/AT\6&^[T%[XL.%8E
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M#+^78-+E0[H4+5R(,N0);UF<Y=A*V9ZUD6V&UU[2)=*X]ZG]?4%=!S-^\>^
M^*\CP=\F_I:D78VOE/A/;22>YO<W*^1H_1CQW,_2.I+9UIK<@IE2)]YO7R?V
M*WG-7(WX8NS2YZW-_6L\I:0_M)KO!;XE&>RE6-+K;S&R*\"5\OVXF7QW>-2>
M(_O[G-' <Y G-CZ<""G<I5JD)U@EBDJ"QWWP1A!NNY0'#(L/":0E,"T)"E)+
MP^Z0G";X"7L!YG!>*G3:9\CV.9RC#@/NTZ58C/0DI8&CE-5Q7E8Q:'B:NX8-
MSWG7P#LDK4OO"7-?SC3$"VV$>VP'C("[44]0]1!*&9WD993"LX@7&RX)Y Y)
M9TP\Y-D$N9<>]YET@&H*I912*8O3O"S6,%8*9X<$<(X] >??N<C3[/@,A;+#
MWQ46DY#<DO0[U-&QDV*%V?U"F#AZG5V@4G;X6;[#8PA+8%@29(=Z_588DJS4
M,W5%.=== )0H2JG\E)>*A*SP8QV%J#LDIGL\AXEW@N'P7W2!GE@*5$HQO,^+
M(8*PUA@[U.DC/-7T!LJ2RL[]D.]<(-NA_KST1(?A!_2B;U<F!,K>_5BT(H':
MDN0[U,NPI1'C% NC3;>?LR2JGCXI['\S]#O4U3?X>6#+\##1^B\!<>"<](;Z
MOV-_X-"5#Z&D.OVO@:,42F&C*T"M!-6*82V!:PE@*T+>(7&I/#]WU"7Z@T8;
M32FZPOY7QY]D_1@SV+L DQ8]H*F[+0%&6$KQ%;;,>N(+X7=)>+5NHB:2TP%2
MBJVP\59YG7919&5.I":2JJ%7"JBP42]U1>VB5-(>ID8S7I%.*87"QCSCG]K%
MWL^[G)I(H()6*87"OKSHM-I%4:C\3DU$HXFE%%5AEZ_AR=I%V>6=4TUD54&K
ME$W!1U!P;^VB)%)NEF966)Y,U?^G!<]!VD>SBUV?\9PTZ?PR0F7W%WP$&91=
M['^UYZ6)4+31E)(JN 0TO3F[*$/5/OX&,2;^>,(C["/B;LD[4$!5RK2EGV#-
MZ.\0NBEY[:6;M$C:OF+Y#IB]0#PTJ+<JZ#H&2ID73_>U9!X:] E32W+=3050
M1X&U&^ M<)7B+K@L]*+-=GZ0USKT[H/E$K%7.DN5:B3IUNA*>1><(VH?8L0/
MQGRJ\%[L!<'$6^3B+]L3OIJ'4@4*GAFU"JQ]-V4_[S6A((OD1^(-SB_;3?<;
M<5!J0<'IH]:"I 04$%RM_2*@)Z&OCX]7;ZP$I2R46E 2@M),"X#M7@UJ9 0=
ME!08NHASF;(+\2MA:;FGV],&74XJI7A7XO-2*854@Y1F)-PMQ"W)WSK=:T?M
M"!XRZM&66X--F2AUHN"(:SI1A(QW?:HH.UUN)W$M)*58"UZ[BA/KO=@*G3V8
MSQF>(Q^/$6&_(3? R'.&HI]>A:4L/V\L3WT62D'KW9*Q?ERSM("G)9E(OT_,
M-OQJ-]4@'8T B4J=P,6W,DL&]:#[;F<WV+_#C%"'V%'A(>5^>&;4S,>W%59*
MM:B_RR/V_A%KZS;,T!$RAT^"O17S7U-!#6#BASK\?:\C+?WX=0A*B18<>CF)
M[OA,G@]G 7>V+>:W$7$#'SOQSW?1SXT$UQ);*=*"SZXLE$8RDS-UQ"XI=1>7
MVDV1J\)DA@ODS3'8S<A>K"<Y.AO8=K"$V@NV!8B0M)%Z_ GU4*I2P?>G%>H3
MU4S:^:)NR4H /N%4]4K10I"]ZI6)?(+M:*,<YKK=KD)5HBO5I%U$6('?;@H]
M'^H5?1XA'\7F5",Q-\!3"E8GG"S^"AA8,8>]**%SVAET2A25V,X*'KD2L>VX
M85<8)9'BTMD#G2+;IL(T^A4+T2Q@#XV9Z"!/SFI7H@9S6?E+'R^;S<#;9JI4
MA((;KFS\QGLVL3A'U9!V85B1<#,?5B6:UI/*6+(VNZE <+6YW?@NI52*LN!Z
M YB='\:I$-U4G,/ZNX9.<2TLI:0*OK-,#+ 8@^D B71T\&[+K^U)1C6 4E(E
M-^0RDEHC[KILVHI$6Q(%-]3.CXQ,Y/H7[&$&OOX994M9L482T<122JG@6<J%
MUT?05@I[-Y>E3+]\#1QI=/$[!#'MSAVC3P2>:^.BE_*&7V)<M9?PA@R5:E#P
M"N748,W?@@I("S*I@B7J4&9G)O78JPQ/-@9WV(.G_(:HJ?NP 9Y2X 7_3D[@
MZ2U$Q,"2'/:BY+=/F#T1_$QG RDAH?*4W5T_W@^B03#!TAF:Z'\[0VC;3)5*
M4? -Y90BKH-T^LI:P' _$J/_[MH2-8DG@5Y4E_2^<L=W-9F>O*'>A3=WL9A"
MQ3>OVU@@E) JX?]4GR%);$NIUY,LK(C'?GY/=Y#L&AGT-K !?^ Y:8$\"-&Y
M$\P#M^%%@$V9*.6NNF 9REPRM4*NEF!K955!<K8BUGMMX&FIR&4S+9IH/06'
M(/5L-W"PLZ%*M."DU(N"=ZI4+V(%D*RS:B!(8LM!>ASC&NS5@X]=RH0=?TX]
MF9X_\#<P#*JQE"(NN+5R(HZ@+<"V(O"]]+CTF=\OZ?=P:(6[G=2LO,$$KPVM
ME&W!$9:WY:3C/V*5WK6E9_K]5(YY) /$,,2V3; -#SENQ6;315;*NN!JR\DZ
MEBR$"<D O9C7WH3+V-!WUP/G?X,P8EWTYTI,=QN,Y5HXI4Q5CCF!;B7P5HR_
M%V,XA\;]\>@YF(DOY-,T]]CW7?E S6#.,&Y^*W<+?)2"5[GBPHD[YFM)QI;X
M+GQ]QTIX6PGSO5;P,7; D?T%YCU/=LH5>N8!\3>PO%202EFKO' 1!RMA\3=N
M14SV,N473VA%F=B".('M)TN9,&8N__OV?AM+=%,.2HFK7&P7/<G1BEBF/6A@
MHP'7_:*=[K*!^-MG8AG,2$<&.X>O"*:LY^P/(\S(DW1)1B-J@[7@+6JATJ7W
M*H_=NE)Y+4JQSSIV\C\FE8MGG?U2@OD5F2]\_BCT 85_;GB44X^G5 .5 R_$
M/)+X5OAA?Y03]<[C_4,R-EK&JS0!5 I3Y743^*G1O/.W:;-A$ %BR/,QYF(>
M"STI9$E<Q*Z1[[?.N;09"Z7 53ZXA*.<G2.W3<C4BKCND!;\?/3"/Z'5BG@S
M"M^$GSV/AG677XEO<+0% AU9TG_!_82D7U\G]%5(^76,\1UF-K1[C@\L-.4R
MT]7G@QERN?C"0TO\^4"+UB.N"^G./A^(!5=\?IDREWQ:R=N14/G/!\3COI#C
M@<4#P8?X 53W"Z/!ZO-!6)KX>'E@^;*TX[,>_,4! [A 6"X '1SI-7&, M<?
MN"X-+V(T;V<-@/G&%@X]?J6N2Y;(N\;+*6;I-H95#)NH)%.WS F8[(_&37/H
M$A%/V;)HQS<(G?FXUE"L;VP;)//MSVGA30 5NYW)@R5^Z\VI?$A,3X4KB+>M
MOM$W8HZ>8]:T@>$%ZAD50K$Q\V7"%&F2AR+A/AT3%U]Z#GDB3B#$&?KE!W,$
ME1SA&88<D/"^IEZ?;(_?UG4E_"8F4G;DKY21/ZABQ.<*=5:_Y1#E-]0/W7?.
M@$W%UBV>>47MFNJ\!J!I 5XN5^$7LCB=#2ECV(9I:4B7R\"+[Q#62[@IBGD5
MR&P1ZAM76M1\"\H/KJ*IXJ3?_Y@Y^E",T%98YOL@E?U(6+!87INJU-'2LF\T
M_D0%Q%S0>B)*S 0N5@*(*TT\5[&YT'@RT@-]HP[179D+UN&UJ ]F#4W*+)%Y
M/56,K^-WVQNK%5B=[X.3?J;>B@6G)9CY7B@=G#2R%""Y<V0J)"M.<I9XZVEO
M')OC&A[W<*:BL#%2)<S+,4RT=XW]!762E279H$?S+;]PR9R(FHXINXMRLE?*
M<"/,-^R2EMZ/"8;#,\'B@<(@%;5'\D$,31=/!763=H:_39$++UY\/K 9=DBS
M#>62>MA'[%79]H)I/Y)Z5*7,E<7-:W:%^0!)1UQ!W]SP2%.:W?:GKNLP(=:7
MZCM;0S'0YEAM5&Z"V"G34]B"!!(@V,3!VOO<')'A):1"_2X]%.Y$-S>A:Z$,
M>[1*UO6!YP7(O4.O\L,2G@"J;K$N?4?G7WDD XNFYU/V.D'/U\+PD2['&^S3
MV01SS)YJ5A]M^@9BSC7?P=.W:GUA R3MOH:;I@R-^74HM5^7C]AH[.NC<ENH
MN^-_6KR"W1-,Y73=:HJML.<8L7&<?/!R=O$BN!!>,^DVA7G3DZ&076-]G!R.
M:# 7TV9#G2S0F=?+BK4A?0%8_,RI2QRX?METC:G&,;R\)NEO(R-G$!LY@]JD
M2G)0/N 7_]RE]O?*[M@6_!LJB!]S4?95[B)HZ).JU?PZBH[J?*UW88N."N.:
M#ZFV)3J<Q#_#8@Y'<(S!JXPO \XQI'MF6(CLTE.866V@.FIQ:;N9BR?=F[NN
MRS!->ZY+EVE^*2]<BBJ/R0MVPE4;;@2LH/(3&0C8<.77@^RDG7HI^I*)9ER\
MK+#'<92AX('J'L7ITYN?,VM=U \,>5Q&7OV.$0.W_<>3_LGQ!DYO!:+Y_J@]
M(_\&SR?&=Y-%.\&^;CY-U$&9]F]'FCN((A8ARV"DQ6*#J:?U];2=D_#_B'5]
MA)9HCOEOF#G$]J^I(V-== 5;AV!8GF+T8;$"B0I A /LO9!+_I#\PAEX&(A5
MO<82T ?HZ$P>!R=%MY?7YKJ&L:M);%ZC<U9Y66VOQ7X-_]'(N%?#F&^YZH#U
M9)NGM15@YGOA(F#TAHI%Y;C?[U\C/X#%9(RG+!!C1%3\5.'.T"4WW]+<S"N7
MTB$-F,_#U55WRBXA-.L8+^RJ1X?GC#XW#5+.49D76.J]AXIMPL#W&9D&OG20
MT#O$E*$EFV&:[Y/:>6:#*>HOTL*3?O]LBT%_Y5CF^Z P-H>4KAJ'B&6)S+=*
M:?IJ;X=*20V;RZJ@M9,M!L"58YF7<"'F8_!"*@,+*@IOYVC+(4MX/";TH+<Z
MVBJ8L*GL2/72TZ$T+ZORY6_MK)9A6+?/'G8F&'K,KCOH:87U-D83E\S4FBIO
M7THLA<%0+&A>=L7HC/I&5)<WWY;"LO4-0U(RYD.$D=CD4_M[PW6O&L!\:\_A
MS6*^&%)7# Z"[A'_CGQ[@9]5=PHU",VW3K5N_52V"]YL*:R%--\CS9(WU7=%
M.ZP.] %#;G3B'3TBI&AG97GS;8G/+D<X/L-,^OX.O>:C>#*KI!;M!D>A;^@+
M34(7;H2U)N968I,5 G/\&GG!3+0U8)@EX[!=6,0&V)V(B5#-51^VZ%&L C,_
M1#1<P=\H=5S\NK%+.8=CONUW"^*2U35EC/#'^X&P0+0-32U2\RTL6%MW5%2)
MD88V6H[*?+NJ(ONALHVO X1$W0H6#R/9;Z@_C._C-W-[5].;]7[GQDVC0=99
M]8,+)=CC""*U(T?7X!DQ!SL07J5]1TX)T\F#5VGGB@4^]=J(QHFKBLJ\C*_1
M"UD&2\AR/J9LX+H::35J:3HIO<)4_P7!R7_#]2%+9%YV@_-+[QP_*7Q%V4+F
M:PUQ%]2[]X7Q>GIX?'(F3VI' 3[IGRH"L70HS;</?(J,+\@JN4%ZZ:5#RN\%
M6^(0H;?5UV*:8'0@)56IJW5$9C/,Q)2/S['_C+$G]@WL%<QE&6$KC.8Q(JQ^
M[=@"<C<G))GI5C?^LJJT>67/9U@*(*_=$][ /*B%Z*0LP[<]H1EC1I>AQMYC
M.P#G:(V=KB+K:/QYLVC8_CO("K'-^-HLHOD1\!5Y<5B1/%.:X%64' !,!X:6
M]8W7)C??TF3^N> VH\\CO**<Z-QMS97OY"A>)\Q;$.: Q^]5>6VBCL3L_O,!
MLZ6<2[ #[Q9Z$-DZ)I[H1#'+3H0!(0O<CB?URMD8QKR2UF0"4&_7-(G-M_+K
MX^.58EY)E>A ?=>SW/%FDZ2"W'Q+Z[QOW\)K=C(EYPCN3+3RX96@="JK9R8[
MQ1@]4095:^/7J\(P?>.L$*0:D+G7./]NCLJ\ZA9C]0+'(0O<-*%!GLQ\RW+:
M%87G3;!8TWA3EW,%L6F=E-L'J":T('4M\1+NM"@$J$5K7HHWJV5RMIA)3Z4X
MLU/2F6];Q?7L,$$(]N&A>YCOFU[O+M*;72I4Y\?'6XQ'+<?JG*@S2]VC-]O"
M@EF"8GAZRD10)$Z.$>'AO0;L")O[T7.2SQ=(;#>\.8=VGB-.;%%@1-R@+N)S
MRURZ&?526&ZOR$IQBE]+8GY C"G#PA0*+U[:KR/LT:789/KP7O-4,0GHT9IO
M8RHHQJ<#81\!/"3Y(@X1F\L5\9$KMS93(1]G?40J"DVP6)XY@7@Z]A3F'A*U
MANEN'KXA N^Q25?B WJYF,VP[=_@:J?,GU^1COHQP^H_/%/%X7R^F'E=2AV#
MG1R>]/O),=C)>^T#M$I*\^U;AXL^T GFU'W"Y6_)*<X]&Z*8;[?J8MB'+5XR
M*\<RWP<5]Q^CC"N;Y6^I .FD-[IHWO'-PJ3*R4U'@Q'U[C1;QKR&YKHV.J:,
M1AA4K=%I9R5Y-XU/C?#7L6B<Z$>%TZ@%D'G1IY;/X\/WF>7S3'OAK:0TW[Z2
M)\)FLS8/BV6HS+=K*,W(M4&@$%5Y8?.M*$L5?"'X+,5NA\[NQ+P"R>F_Y+*?
M*[,-5T%TU&PO39@LHWX@-9,MTY*=XRAJ! (K9 BF/)QMEH19%[.;$W76I_L-
MGLA4*7XMB7GU5[G[WF_S'DL%F/E>N$;L.P;C8> LB0>.+!1MO2%5-F+V AI4
M%[JK2=]EM4Y<>^/?;BYOF4,\00S3%EA7#^@%7'D<\L:O;7_%7J$58B<W#JJ<
M3\?;3"!5 69^F"ASK(A_[[>9LZ42K_M]\=,6^Z$<RWP?-'XOI#;U?5NTKB3(
M+]]\H?3FZXLP?]OMX6I@S.M!Q3%I^DYOPZ"< K'ABV=A&OLDTZ/>>\E*,O.B
MJS_I&43-:G=.E%!WZG&@PGNV< =DN7()6!$0!A;&U<+/0?-@,EU4PSY"D,^E
M&#$L@&^'8L$1UJJ?O@MS<7[Y,!KX-)^E&NIT+8S<9;"L[)LMH;]1'ZT"C4<_
MHK$;CUAXPMHY#Q-"WK(K:B/W"ZS2GH:]UPK*_-204_!4^$.<B"UJ6!RTI3M4
M=) Z%7N9'=MO,%UT>ZY0O1_6YMY\CMBLN.-7*V!G>NM!#)M\YZ\LC[6PSFQ%
M+NR6:.WWO6_I&-1.]Q;ZXC=/&Q?C&$T9U_"YFPZ_=9/+@C#PG,G7"7[UJ.OP
M:(,%4P_R%!E:FN.8;WM!+/^%5F+(7-M7*!##SR5-CV JZ<VWM?8AHH<%\H=H
M!9D%*),!1PS?4/C8[F&C.KR.Y<?^XHJ_V430T\"%,$1Y/4!Q,:8IBGGQE[[U
M>.?"44/T2>_AR,8XG?36MKK>CE+7VY/\ -N]0E_%HP.Y!O(J_Q# F5W#<9(E
M,C\L5 =29]L\W:H ,]\+\2.,#3/)*LG,MTPHW6)$N UC"_*,$?M5G82PGJ@3
MV07%/IBZ3]#YTK0?(UM87_[K*,"#8"X43!T:TP3!O!Q50^OC-L=I!9CY7BB^
M86PO,//_:/P:0('.?-L&MBTX.TDDR!5!4ZF2JJ>E-"C_2EOG2[%)(FQ9UV(U
M83?#",![YP480GG6\2[P?)T8:70)#[V%?I&HF.YTO2%J)^;S*(%2&.KD4XW@
MJ1J*KH:0Y1(.K:T'LLP\_3RF[(YA>6_R+F K*N:K9F'7;9 [Y4X.:QY=GVB5
MFC-/V_'W4$ZW>/^T',O\ E>\#8B?E/':"B+SK?KZ</GXJR*+2+J(^1H/D8<<
M@KS(*9D)(U"$*&M0FF\?Q(-@J()0&R>P?:Z59U]%9;Y=M0GA4\\'(0^[<"$;
M'OQ1!M*T1C3?'_D(2K!Y:" F1*&C[NL(^YA!J(6HX]JC5)+>4CM LRU\!SU7
M8[AC@#RX]8+@N*+A%%Q%;EXE'CT67@O^ SL0/(L]/",^]Q?(_T8#UX$=@NW'
M!K$H ;G$*C6@)5HW]UKY6,&O@:,Q*ZJHS(N\F 5H@9QG[+I-DP?ER,RW#*84
MR6#@NO09-&1"77=&&6QYX,]Q^&=5$_7I#0>?99/="<L]<-67,^MHS,M.%:_\
M;HNQS^58YOO@5C"39D62</8<"_7#7\1$RI [I&('*DK@*+*-PRL?2RKLD3
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M&38Y]]7L00YC7CT2U_%?GOM;,*@BI /#,X**@CS]F"T%QB:*J*U2K/7A%WO
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M-):;_'5!E\3+Z>5D,?O\<IIQY(NG/=$%D5 HID6]+[+4S!O($941/G93EG<
M<2*,;T?HNW)@N\O!>_CC=::[9%S&*Z_7U=F3A!/.B,@$W1RT:<D9T"5"&D/R
M1JB2"M<-).">Y4^$]RV(>Y?KKCO77^0\P_G\ZI^Z73%RM*CR/#(G,V>:Z\1
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M-6F'1GV:(OK4V=^PF=B:K#^,/XW)-LSS&VZ#ES#_,!*N)$EO(0. R+3PB84
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M&^;C_-]GT_E\!,) RDDSF51M!F@+@^0$"Q!3"(;NE- Z-/$8IM,3GZ9<Z"'
MO8;S<GH1QY.E!D#G9YV!4YM4T4DZIG6NVAE"')\3L4:NV*#10YW8+)DN,3&O
MO&(\02X>O-'-RQ$.@'EZLM0WKWH(AB]W_PX_7L[2!YCCV]GT; 87+R[)8)E5
M]_:+BSH.7HP$;3WH2(=C*'16&L&9CZJP:#684""!?*B;[\$5"(]#.STQZH,G
M/835MQ%@Y04E>]0JG9#E(B+3VD;F:]C#>A4<"B]D?&CZ58?V@7?!#!5NZ%LH
MVE#[V*&(+R)>:T?OBGCU965N)*C &8)/C$B2&6U#,Q3<1"<EB7GSD^9>-,<*
M*S3B]N;!TH;J/>C"VY%=><EVP=936<=#N(Y4W=&(ASN)1@<&#"TDD 6Z6'LP
M$DBFDPNDH8>:D1J=J+.)5/MVU8,+QV/U'D>0C7WHWCA& )-+F'TFMHCM"-<9
MRDB7K@F625%GJSM,+-03,W-2D^A&EDX]WEEBQ\6.D-K2C#G37BG;MM/M-4+U
M($(;K=#6999$O2UE\BQJL*SZ=PI* FD?[X6ZXV*GQOMVE.WA+EB;VDNGS7Q%
MYV516_;%$W9&&C:=<\5R!L4HYK4K111M+;8.5=P#Y;14QQ;T[M$[=A/6RHVW
M#K'N K GY?%1<,?1()NP<@?QZ,Z'@<Z-VT!S]"&9:)C(=+II2Y9Z5"$Q>GM*
MR*) %*T[_AQ)4![1)H\C)_N0OZT^^<M_O/FOOT_/:X>3VOAOW>H].!X2.N9]
MK5=8MMVPA11G9SER+53DC[?:WOKHX?6%QM2?-B1=0_6PYMU\"0(N)3:&6(=,
M1Y)8SVL+*62@O6/2!<ZQ1,5QIP#M(QEEMQ8]C>N_&RT;QBMN ;D2UEV@-,PN
MW5A^^'32#HS8QLX.5&R<$+H)B>N2#.>)Z)],=5;0#2.$9%9::Z7.(96=?#E/
M@:$/I'SVP\]]B-?V OU[#4]-)VL#,4A>:OY.E-$1#I2,?CNR"L('GY6V^M&+
M\]8CATW=[$37:0.B-+P2ZSR[G_ ,SE<S$)?RIGRRM<<+PZ@+TP"9>0.<N9*U
M$BXEL \E"3P^X'%CP=.X$+M2LF$<]GJFY96$[H)CA_MPU\F[Q[@&.Y/_SJ3=
M#K1K>'K>P:-34-()P52J\YQ1%CHH!"S/'<M+"OG!41E/@8?WW'R]L7 ?DK6]
M^-Y^&)^//_X\G<W&\]]^??%E#IR S#/94J9&^S495)%N<E9236O-7A=X?([>
MUD<?8_[Q(42>-J10X_C!^]>__?T*A?9<9\B.!1%K[R(C&"A=A_\&DQ1F3&:'
M^-#U Y\?=PZE1F,SX$LMY:\))S ;3U>1RV@2A$)286M:.$3./,^*D0*ELM,:
MK=XI'^2QXM-MBY^&SM*&M@U[:Z_JW58X?IO,/V(:ES'F+SZHQT$U-.OO!7*$
M>M'N3)KV1>'6[_J]X*1VKA0.I $$6\^PP BK81R,,T6X8F4+9]W ;'^H\G,@
MKN]#V)ZX_6HZPP37O8 \'65!.J:<P#J $5D,RI#:IY",;%,"[)2GOB.K;Z\^
MK#>A$5NV,+H#39]"0>A&DL'RENNM-O2AQ7HO$]UYIQL5HQP4VAQ52<BU-@Y<
M+4T2T= 18*I9VF7A 8I'03C#-2GY2X42:DA)I-K^AF</V:2B=BKG?QK%HUO;
MW"T)/%]/GQA)B5R)7*K_-M4F(#77CDYR%^B5S"YIO]NQ=F@SP=MPGFA]Q!Y2
M\6"+P0ZT[Z&(=*>9)#+8A,8;9C1(IF4.S*=4AWPI%PU/'$/K-^)I3HL95%!:
M<*.'A)1;&-?P7GS"&9QA1?D69TL1'\FDK//:LU*#1-J1> ,'RU!%LLQY3%*V
MGGVR*[83EYQ67.DA_^U^1T$4T8*0A7EE,^V^SDLU0;*@H_9.H1?-1^(^CQJL
M#E+1AMK/H 8KR&1=4I)L$DUGHG)DG6B>R*8H!L#51H;#%%,\32?<7MS>O09K
M'ZH/75ZS"[8_:[#VY.$^=3:',&!H(3'1<A]J\"X54KZ#URP&5"Q':U(LR435
MNF'%<ZK!ZDTV]J'[<6JP$B]>:NN8%5'7062&Q8)5R>8@DP!E-HMZ3Z8&:R_F
M[%^#M0]EA_#W77<LG(\G*X7L5TR7,WHLSG^]O+B@34W+C=\ZV-EW\$J=/7UM
M]KCAY@M@1 :'5D+2M8^LM5R3*2$+R@A.C0Y>]>"W^\:S;BC0WMJ4E65%UH8E
MWGGFT2L6E32.RRQ0QT=?Y6U/;C, ;K-OYGRD :+-,K&B#3!=/XN)4)-Y9D0P
MH)'WXX"\ V6XDZD%\[;/?.M&WQY<;IMOPJM/OXQ?7L[J4($7DUP;?ZV^&$4O
M7:S#, V8FFVB:D=VD9@$2?<Q7<$YZE[DX'%LIR 8C3G05D^Y1W:_C#1^-?X#
M\]M9G5<_0[SX6/MKOAN??2#Q!F-3M"34*;C ='&6S+[JZ\FV>*UD-"@>/>\.
M7_]YBL9P)._!J7;S<(L^2S3&,FND8MK&S +MGH2W**6BR6ZS_*OSH7$R%\:A
M=&Q8-G1[6ROOC5'&F.1H#\8[DBD"%9+U3/%BK+0)DW#[*#"#N#@;OYR=B/)4
M')BOQA.8I#&<OY[,:;WZR%4EC?#2*F%9Q4XTB<A"T9HA-US7; O7O/W8/5"&
M=EUVYNRT/85[B9G!9%YP-B?UXE><?1JGVM2U;$$[?T^/G&__T;K^;8>]].39
M;+F/XWA"FPC(G=C;D;G[U"46= HA0V9"EES/?,4"=X8,KN"52HY>=_CJ)/41
MM^R3%]1]F-J#@-Z=\$WZ#D$!QT1)B6D3$O->%":LE<)@!O"MI>P)S$X_'D\?
M';F^#T,:MU/H-)PF$;H8O6!>*%+]D7805!(,'0)$\,K'-@G=SV=Z6"L];5#>
M-+2T=QB-LPNR/T>'->#J[N.@#F')L*/#=$W]1.Z8L_0B:6,% [26B>BDRN T
M[*89/4%AZ6MT6$^RL@\GVKIZ7WS_>O(]?EJ70X  5"B8U=[3]C1G4)LB&F<T
M&"&$+8\7=]YZY),:(+87F:<-:-2X#/=ZD!E&KJ(VH@[^B4PG&5G,GF[1E)WD
ML7CZUN,9 D]SS-N!7#J0.FU?IY>SZ61:1Z%<?GP]27_Y4KDM"^=U;+OADD2&
MH,2H?6TG#,)8IQ5_/ B\]=&GP+CN-+M7UQHJ4^-'F$UJ-[>[/^DG7^/Q]?K-
MVMASOQNY&]%#Y$YXQY,G,R]Y&3@*"\'$ZHV'AW,W'E^[8\[>(_K!C7""3<&1
MG"86$0K3W"^U@<Q\5CX'L*A4ZQCY[NBZQ_5(%O"GZ7S^B@Z!^](9 (2(,5IZ
M37.HZ0R>A9PB$]Y:;3CP!*V3&'<"=H2TMG[DYFZ8L#5;!LHR^7<B8H4]4LGQ
MR"UG)9;:,R-9YK5 TJ$#3XX. V=;E^8\A.=D):49$]JJ2-L$^!KDJ'!G7 F<
M"9%)=XL + #I%)'V6XN\I?6[),P]M,;)<;PM57O($7ET_RNGGK/":%TB,S*2
M\FZ*9][KPM"0=J!$+#*V=J+OAFRHDJR!3H8>V''L+(?.GAUE,"#WDF5;'<I6
M2Z)LS@Q$*4(!A*1;.,.>D]^]3W%IY9+?AVW#>E=W0?:G2[X!5W=WLQ["DF&%
MQFFRC+.4+%E'[U *IO:3"XP7J4$+A^#<,Q66OESR/<G*/ISHTR6O0K;.\<P*
M"DN*>@ 6#6:FN"^6RP(>'_$D/6F7_%YDOL\EOP^-VKKD[_%=<FE%R85Q+31I
MVYPV!48QL#JA*SF635WB6?I[#^1==YHUKLJ\#ARD.N>+X#,C$NTH@V0A1LE<
ME)9'45Q2YE'&/=&PRH'<.I Z1W?)7_]P/*'3XA>8U5GBGP[OEM9IM7[=\7OM
M=;.0LH@8M:37*WN=!$3IDU$<C+;"Q6 >=L8_MO)@KOAL@RL$G8D0.-.N5DQ$
MKNK )6MD!MK?3HK3DW3%;W_^EY$+;\F4J]WKSG 4/;>UCPX3J29H&E L@#4L
M^^CI#"6VJM9DV!G<DW:[[2,_NY5Z=F5/6T5E.\9?+BL!IV75%JXBSN_H1[-Q
M6F >H2B*+'?"Z'2MQ3>%16D,L]F*'+26G!]:R_?@PB<G* /0?X@"T"UH5WFW
M(Q5C#J0<,.5,[=51VT0%$5C4&G,B\RR8W$Y25HM^U5)R -U[<.O?0X97,)XM
M^P?^,)Y7W^_E#$=<9U-0 L-</"-U,Y!Z;T/M&UB2$CIZWSI.O#NZDQ.EGAG4
MMN1T.\@?QJ7@#"<)O\?%[XB3EZ1;?AY/SEY<3"^7I?)?=C'R17BB1&%D(Y:*
MW1")LJJ.:%"28Q:;$]!V/G[V@'%R4C0X;QJ.>SH4.]S ?D-QXYJK H3=):"K
M&%*@77C-!$\H$76V\5!5Z"! ?\I:.WXU'-6Q9\1,!QN5BY$)-%@'.7$6%:EZ
M/@%X)YVP9J=:GZ\AWMWE&NR!'<>.=W^IU%P+__>?OWSZ]S'."-F'SS_A)SQ?
M!DF\RPECD2RZ0+>[#99T1.,8<*,,*HLRM,Y4W W9$X]I[R42F^T VK.FAU+6
M+]!^7C9NQ=L*XA>\5T[D7<#V5/Z_%] CU??WP/'[A*HW=AU=QKC5!@MJIFQ]
MYPHF%HM#EG(PW'*;,NXTPNQYR=9C%?E/3;3VX5*?(O5Z\O&2](1* 7$5I\H>
MBI8A,NDB*7].>18EIR^%DUD9$0/ZO@3H+ISA5?4>&7F?R'3DPE,JP+<Z6:%$
M8 XRU)%0AL4:ZC0 0FHO<A0[I:=_O8F ARA-@[)MV-K\79#]F0C8@*N[)W<=
MPI)A$P&3""DBV;?&U?8E0@46:M&Q<"@!<^%RMWCV$Q26OA(!>Y*5?3C19R*@
MMK6$@W0Y)70=HX&>@8F%*9Y-"0*\W6'P\M--!-R+S/<E NY#HZ.W=[^9.U.S
MK 9,4=JZW' Y2H_O=B-)*1MN'$>9@@1ZRWD(40:E(EB+P2O</4EIZ]*#92DI
M =:'X%@N*)DVJ?8ORIJ1<JQT=/3#TMJT'3I+Z9YZ0R^-\^ -4RI=%:"!"5AG
MK<OBDS!^L[/(UUOTN8^4[%7TN0\3>J@*WM%\B!%\CF0YE B$+7H@@U1I@JJP
MU(&5'@9/Y7NJ49$NHM(#.XX=%>FL0X*OY2*D.\B:1J.Y]<S'0J^)%-Y88:(U
M.QW07Z_QOY>XM#+^]V';L';<+LC^-/X;<'5W@^X0E@Q<.BJ+,,(8%D"1)6NR
M8.!,8"FCC8@*TF[1VB<H+'T9_SW)RCZ<Z*\JR18R96G5G#-G.B.PP*-AJ%)0
MW)(&9Q^W_)]H5=)>!-Y>E;0'=8YN\U?<U[^PG)DZ+F/,L(J=J'Y,_UU7[=<#
M<-#>-QP!0H4:JT(2&J-M%J!M01\A:%3.9O^P(V!7!(U'P'%K0]:N5MHETHB2
M8R&2HHXZ*&%%<$[S1U_?/@SV+]&[%_,Y+N97T<+\9O*N4FPVGIQ]#_/Q_+?)
M-,YQ]JFJ=\LX'_UX.DGC\S%4^7@)Y^GR?/GIN^GY^:OI['>8Y5&D[8GL@'8"
M@ND@D0YD7?5 * A>!SJ9^PK"]K"?)S!;: \QNC=.>VQ.]^!5V!;M_L=X\>'.
M9N:W=W-[ZTO"K#*6E04,@4P6]+42N880(,7$4/K$+8\E-6_EWWH/1\PY.+J$
M[9#5,IAX#)1+=>!^UG[!U9 Y)/5LW5M3C#+GW-!&F5195[T,6:@I'+P(VJ83
MRLDADK#:[^S/5^,IBU(/16K-#P"9M,M2<Q:%J::F3BQH\*P$;LAD,2*YUEG[
M_=X/AZJX*X<? @!J:UC4L=8@!L5\\I850-"U53,8O8]Z>]P!@0<H65V)<FRG
M^984TZ6D+.VCI7.E^-K7FW.F'!G6VK@ZE+T@2\&X(KB-!GO3B#;!/(7A,WMQ
M]_ZJ@ Y4[E.QZ'1-W=S5E8MGEWWU73/0>$]'+R_H(CJ]V(:-^/Z<Y-K1]@2J
MQ+*AVU_+G!GM+#&!/,L@0_*IMYJJ9R'/NY<T/ =QWH?=/8CQIB]S[?TF6NE4
MZ"HRRM6N7IZ!*YI9G34OD4?0?3=3/WJ9PU$Y_4C^S0%L>DK%$"F@S58:AH"V
MYM0&%FM6I4@^>]1 ZK#:1;Q.*!^BE4(X*&\&GD:X [(_DQX:<'6/+/8#6#)P
MQ4/TP=BDF8A6,*VC9U$9PV2)"EPLCMZO9RHLO4TC[$E6]N!$;TD/PA1=-&E^
M1M4)-B ="V!J)5G066H3==I0;)Y/TL->!-Z:]+ /=8Z>]' S_W[5_'? 4H=[
M%ARNV&&7'6]F.0CG19*8E"]:E3K^&M IQ:7C/.>X>[G#/8NW37 PDF,0Q3&,
M)C'M@V.1!\EJSI43( 2:<I0$A]T;<YJ@+4KNZM3"R+1 P6(RCF5AO2U)@MMT
M8I]BW]06##Z\.>H^/#A2<]2KMHM1R>PE9N:7$2W)0\TS#'08.P^<VYCMH?WF
MGD"[RY92T#-QA^AZND^S.PLYR"@4R]EQI@-'%@M]*0PZ:YT-"(\K+<^H$>$@
MHM(7 QK:Q(V[UTFEA<NFL!Q3J75:=!):[ED=F!HXO0,%?#]B=.QN@T]!H!HP
M98@&J6]GXU3Q+4_0U^7'/PCJ>(YYI#4=EUYY5DRM"8OT(<KL6,DZ6^&M,>+0
M7I7WK7EB M*$M$,T,YV_&O^!^>T,\>)CU>_?C<\^+.8C(2)D[@,3@HQ,K9.C
M*U1:EI5&'8V,6AW:CGO[BB?&_P9D;=A4]'XQ_7(XO;G2HWX\'Y^-XSF^FL[>
M7L[2!YCCR&5(-E344=3&"BFQZF5@B92I(J5W9G.HYN['P2X 3DPVVA/]KJC8
MYJ+R^N(C76GULY'V*1,T06)K/9UA1;.@.%1ER<AD3)8Q'2@/UZN<&-,/)-]=
MSKJ6F7<"'*DAM#%:D@SFK,AF0@(5(D\I<I62>=P,?2J9=P?RJQ-1GDKFW0\X
M&W]:.NA>3^:T8'WFN_'\GRLG?_2.9^T9YY%N'>"%!1,L?69]R<8 F(V!V)U=
M4P_A>0KAUKUX/.V)UCWD>%QC>TF"-H.T>$]_>1TT>!1;3VET#^$Z3BI<.R[>
M*QZ-6#"TF!0.QN9DR"8IBFXEJ!A%9DFY**7(NJC6GNSAQ>.1S++C2,<^E._#
M<;F&=,-N>5WMEG5O-&]MSJ2-RCI64YM"\ (*^M('+Y.T8><A*0^O-'PF6#NV
M;"J"#6G:1\AB#>\?-< W65RALE%Q3D+.K(N<C ]O&:C@F0 N"18G6W57BV_K
M J?(X,,IV#A+IE-"2/:BH.6:V>0)M]:$.V7#@O,J1%'GQN5=#O\33]<[1'\<
ME#?#INOM@NS/=+T&7-T]!>L0E@R;KN>R"@4X05)1K.;%>27H,^=\)"U*)K^3
M6?H$A:6O=+V>9&4?3K35.[=/<O?!R%1+D@O))].*E"*P2K-<HI).!*%W<$MM
M??232N+;B^S3AC0;(I_OU7@"DS2&\VL#JD'2WDY/[9R9MS_VC?2[&#4/W*D4
M5=(%(4(N-G*(KDY%CSC::87V+L'YNLK^VFN*SF53-5Z5.)+<F,R"3U6,$+C2
M:$A5'< Y>!=95Q_'*C_H37DUG>'X;/+R<E8#]I^O%Y__'<_I"M3*80VQ* R&
MZ2* -#G49(6!X"84ITOK7K&[(3NFC=1,8C;='STPI8>&0&\6'W#V<GKQ<88?
MZI5>"4*' U8Z_(*+Z\OZ[YC/<$VA[['0KMYANNH*EI;582\F^3W\,8I.6P[9
M,J.1B&:$8CX(9,*C]\D%4+FU4ZW]+DY2)(_,[%Z]NUN(]OWGNH_QY.P=KGK!
MU!S:[S^O]OSK A;+P-1/TW15VWB?)_2J;(VK&L543$#M9))1L:@*6<329P#G
M@HD[5?>UNCV:[FZH;MT#"/D3%8EG$3YUWA0=DB6]7-J:B2$9!)59=D8* *S;
M.N'PZ5,7H7VBL_NP<NBPVR[8_HS.[LW%?>)OA[!@:#$)/"<R)5.=U^#HC; U
M8.0LLT:7(+7SRI=G+QY=HK.]2<<^E&_K);MC+4VF%^,)':KY!XSKB%,V6:/U
MAL58")[-FH&L#L*L [<:%8@-0W:+TVR7E9Y8\&XOMDS[HVD/=NC^5^YJA&^P
M4EH16/VWEL&1X5QGF 4=M<8< W>M.V\>AO1/569O5:8Q^WOHEKD%UGJ6^ [
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MJ8E3CWRY-^X^8.[SG1!N;QG-]Z[4>Y[R;GO<[&XD@T-A3$B":[0B1)FSJG%
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MN9=*!B85D/UHN620G6%D-=#N5.UYVSH$_B3CD0/*Q5X!RGWX,U@T:A=07WN
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M 8V](A\OK@=EO9]6@'3&PCFNKT*70A*.1[I1E:TM*!4+GJ!I7L@J3UF4N)%
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MRQ9&=Z!I0_?Q"M%JX,6;LO)^_XR+#]5SL;["[GX7L<;DEO)NA8A.)&!JZ<\
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M0$?/YFCT)E6174TP/"27HS-07$I5_CP 2F; \%!;$2-CHM-!V;'K0P\)>1I
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M12$5/3HWN.,@[V Z0[6#OV-OJ#[8[?VH]NW5I[SX\'G^7S="D'_+]+<_O;C
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MI("#=AM<1"=8"2IN+2$]J;RT=K/\('@/)B]MK3ZS+\47\E[E1>W-4<A[;41
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M9-?FSJ,KGDBAJ0G>Y7AL^O;X^G2U_!_YE@_7Z?N,E[>_/VHLLA'.Q)PC!L[
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M\@TF\*) KQ%'CM?:<BK()\@QZG/^<'U#X<=Z3GDU^J +/:11S(L:+2%P%HP
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M0QQ@S7*$)Y FF, DBR(:)XK)&+FPW+[IN1'8QX,=N1LE'<"5JHA&B!$H]>(
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M9^&57@+-C:F/U&%I]'*LR'(![AH%>Y<&Z3>^G<0_^:A-:RV:"('M@#F5#+D
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MGR=Q0C,>0UD7G0]-8AU,-4=)S5<!QR+,G+)XG>AG;DRU%Q/4<@(C:*]3EE/
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MTF42-CL>;R[6$O<LC-L)<23#,%51!L-8&9>[-(&8)!2&49+PE# NA5, E4^
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MRJE=WM^6@CINHBZ :L>,PZ$:F>MZH.1,7>T@>"*C"YU,2B_MBKXFC(ZG^U'
M%UF6C=>,4Q[9?ED7VXW<YE6)HE_D2JI\6[S_ZU$_)JNBG71YJ^I??-9JTN)^
M$4FE:$H)U/200D0";;U)%L LRS"7&0]X9.6@YU.HN=%+K5-I$#R^4*A,$.G&
M,5Y&S8Z1IAZ+D?FK.0S5)=!+C<!>)5"K '[::V52@=>__/D*U*KY8SV?0'OB
M2"\B3<JH/D%\S;]>V^['UA;)QNNK6Q+&B4JC#'(N&419$D&,0@XSDX,19RIE
M*G7SF[3NVV6V3^,NV97 _U,5M>)V^N4^)G:$.PK.8^^ ;V\^@NOM=I.SW;:\
M>]NNP1>Z\9L=H3="GNC0OM]).<\9CM?$YMY /_8ZT^[G];91P%=A'B"B34B2
MH1"B@'%(XH!"0H.0T)@&&94N=F17AW.S$<]QTSZG^]\KDG+CID[$[2C))XYC
MG^V?J\Q2AX(9F4<Z;;-%R!,3=78W*0'9*O^:=ZS?<W:Y-/> I0?9]7*Y_F'.
MQM]))3<;*;[3OZ[U/-J^D]R4B-3=7C^8\[5%3%28DE! E0F39R1.(=:$ Q.]
MD\649)PEW"V:VET(JWDT?83U5[F4I6><7M2?]DH!NM<*:"5$;FPK_?>\FG%;
M^A=@E4EL[8S88]#:Z6N\,9C*D6F/]4'Z*["7'V@%0*F!^5VE@^8[4&DQ)NC6
M7J'C@C^1I^@8@^#B0-H?Q(M.I3V:G,K1M+^V#>?3 8WT#UK^OJ%Z'3.]?I6/
MZXU>4#A)8BXES!*10"1%  EF% 9*1$)1AD5@E0>LK9.Y&;"'L-RCH*"2U#UL
M^030=K+W!=/(G-X#H5Z!RY<@&!2Y?-+HY*'+E]0Z%[M\\5GW2?Y)8[[\<K]>
MR:H>ZX*I+&,\"Z&,D\3L5(V_BB009R+0UB+FF%E=D9YK?&Z3NI0/E +698;M
M)_,)<-V3> @<HU]^6B/A-&DOJ=QKLIXT-MDDO:1&<W)>?*;G@;A9S??A2G&&
MJ* RA K%>@M'0P0IC21D24(BGDB6!4ZEAYJ-SVU25K+U/;)NHF9Y*MT3B[$/
MGBUA<#]C/J.OKV/D9M/3GA2?4>KD,/C<,SVK1NX#Y8\9@Q81CB4.F( 9%Q%$
M"D60!$) G!)"@B1.>!0LMMV9TEKZ<)JJ$R1'.Z:&J Y''.M G@%12<YE8A(B
M!2R#*,DDI I3B%BH(I9D4283QR*;PV"<J)RF=R#MN&\@."-3X!&5%Z?='HMA
M7E;?5]G+,SU,6^#RLHHGI2Q;'NU'D[JA\C#B>"CQ<?6D]R_KC<G3IYAFRT!1
MF'(<0Q0Q!K'2YDU&.0HI-@G0TOVYM-U<;^VOQQ'TR+.^(9S;A&_'U6[J#\=J
MLLR1U>'C3WM)?S;^YC;8.?.!%2:>F*&]KTDYPDKMUVQA]Y+W<)LOZV7.GZO_
M'B][DUC$4182B' :5)E&2(Q#&&<8!SAC0E(GOVY7 >:VAWH51O-2 V_!,^?'
MPHY^QD1X9$9J!?<*5(*#/^O_GSH$IA6]\<-=SG<_E]"65G <PEC:VW&^U'^_
MNEM*W<.=7#V7R42^2+HIUJMW-^M[N;I9+Y=T<W-/M?[UR0:C!&&D]T52<&)N
M8#!D*<]@0$2*D>(XM4L*TJ/ON5%=*3^H%:CRW.@Y6.EP!=Z!4HTK4"ER!2I5
MW/,).0]1.PV.#/S(##A7S*WO[\?$?J+;^V%CX#<55%\X+][C.S<XU2U^7TT;
M=_B]F^@9"7DH<V,R_^W*>N>++(M5$G $<4K+^P0.:1Q&,!5A1$G,648#ISC(
M,YW,;:%HE%6JA.R52.8LG'8F[U"0QKX"=,7'/?JQ!0!?L8_GNI@V\K%%R9.X
MQ[9GO5>,1><*82:ABG 21)!$6#-!$'%(*$T@94D0$W, ']GFZ.S3_]Q(PJY.
M)AJ]:.G9L>HT*<<>@9$9:-;@>ZL8.W009E4QUGTP?%:,;8.R=\78LXW.I6)L
MF\8.%6-;FW%>>*XYW^RD^":WVV6=6IJR?)EOGV]V&Q,IMT@2H9)(,JA4IB"2
M2$$L(@9QA(.$<"$BNZ*(-IW-;4DY2@KX/=W<.12ZZ@:V<TGP"M?(_%_+"AJ(
M':35.]A*7H_@65.Z5Q GXN]A8+JPM#4Z%RFYNX6I^-=:EP;9VK_3]Q9=TU3^
M\$7_9RT,GQ>?UUL3 ,!-//*^F'2&642(9M@LYA!%00JIB!%,D&*4!PR%A+KL
MZ&TZG1O3UC*#2NBKTFPIRM1Q!\%[II.V&@+;>W>_P(Y^_>X!TQX7\?8@>;N/
MM^ARXFMY>Q!.;^<=WNV1._;=^T6<A#B-: P3:4X.(B4@DRF&*8LEIVD4T<0J
MG67=WMS(Y)U<TA]F\],C<ZQ&IYT,>N@\\CQ_]_[3]3^OO[[WE#?VJ%O?O+&Z
MA>GRQA[%?9$WMO'K?DOWK^NU^)$OEXN 8YKH.0)Y%D@]63(]66+&H9DEDF%&
MD60NR_.^X;G-FKU<;LOK 2:[);2/\B-/GTZ]G9? UTIZ6N8.S4ZZE+U6YO5R
M=?)W=Q>*5\5Z_YEO[]>[[5=)1;Y\?B?UQ_^0K\SB=\BF?OMCI6?$??ZH5TEN
M-F1W<I%H>YD$ 8=)AD.(&)60$$&A"@0)$4HB0;FM8X47B>8VP=^_KG5^!=9[
MJ<'C06S[.WX_X]9Y#C+]:(S,.">%OT&M$JAU DVEP+$$Q!4X* :^O-F V;MJ
M3#YP4SEP3#2 3HX<7L&^[-[AIYO)G#Z\HM)T!?';<)]]W,T"ITB;IC* ^H?$
M%!@SOH11>4 ?RC +A,)6V1SJ]N:V8+W+B^TFYUN3X_1FO=P]L'[50#12-GLZ
M)_W'WM-]_/;]Z\>;[^#V [BY_?3'[[]XJPMRU+/W_NYFROW=S>O9]_K7PWUV
MO_[MW7IWMZ3[Z&.E1$(S&D))L( (!P&D&1%0<IJD.&-$1E8^5A9]S6W.G?5-
M_/HW4 OMP1/T-=C=]I]'",>V["9'K[_?[  4W])/U@7-08ZP%_"Q=WQ]W<";
M.;I>T*3-L?72*WX]VX[)</[#.-)J/9%&-=Q_VEPFF&495)D)*)>9-FPBD9IL
MT4)PS%'(;5FXOQ1SXV<+WYY&$J=2(6 T,I]KZ-G?JGWX.GE]FD$9F?'_WQD/
M/UYPWL9E/KYPE\=G?$\X*SC[^<.U-ST+KS@K[6U]X^P:<U[ OO%[*79+>:N^
MK\O*X=<K4<EA"F+)S9;FJS)%]M$C_.-6/E1U<(ZAM:$,B,JB5&_53;E.R<TM
M4I9"E014!7%"$;=* ^5-HKDM;'NMS&:_UJNLAU)/X+)D7:5;72VA$?10JF?-
MH9Y&M'-]FWZ<1E[K!@]1797+*K!ZI%&S7@6G'[V)5L3Q)IK+JN@7WHLKI*=N
MIEHM_:+26#D]-]PS+^+!;;WXOC:K]XKG2_E9;H]9B[ZO]?;S7N]$GW(AQ2_/
M?Q12?%P=TAN9I?ZI/&^_9L5V0_EV@2G3 ZY22*F)IX^C"-*0*\A$K+>/*>9Q
ME#GE5QQ!R+FMM0T=37K\S5Y+4_,-R+JVA_G+^I#&R]2) FJY_E'\FV-:QS$&
MW<[9Y*V'<N3E^-4H'A0$6L-714;TGXV>8*\H8,_@)Z,KR%<_@V.RMJ.^X,^]
MQC[S5XXX(+[R8(XAXK3Y-$<$^20OYYA]]4Y<IWO^3O^J:]S5-? 65$:,H4"O
M#C'3ZP1-L?XI4S#)DC"2%"4B=BH'>J&?N5%]"7Q97%*M-XU"*#WRUIV%-<UB
M$8=9 C6"%*)$(4B08# @* UY@+&2D7,FP-[ 3IP#L%]5F2Y([18W#]_?R.M3
MC8^I1G(H6UI+Z3$1: <._E+^G>UEZF1_;:J>2?/7^KCS4=C-^N'!Y#O0.X'P
M;UD0F+I8Q;N=U&@E]2$S#S(414D*%4FIR4X20)QQ!E.5"1DAQ8/0BF6M>IL;
MUY9B_G]E1;<"B)T$1E3W,WX+F#O/GOR"-S)15,*"4MHK\ +%=V.B:'T6Y!?-
MB<YYO*#J<J1CC]+%XQJ+)J8ZBK'7IG',XO"2H\??9KOX)N_,9_.K7-]MZ.-]
MSNFR#E^,<2HYCR74IFT&44P5)#S"$*>13).04Y59A:BT]C(WMFU*Z!@;VHYF
M.[EZPVAD4G6#Q]Z%T$;]-J-+-] PN/2_&LZ%K6U/XW)HH][!$='JX7[;V-?%
MX8K3^G$+DN PB3.L=UP!->74%339WR"2"2:$J#!1T>*QC"/]MJ6;K=W^RZ)G
ME\_\=?_C??&_T&59^9-N]7[L+E^94TQSR?$LJ65Q*!?P QZE0493&"JE3-0^
M@50IKFW>)) H"27)1 W^^Y7EUG<4Z/>]3P*\7 D#>=6S?]#MML:>81R9J$_+
M=A97X$R!3W];9@=\/&V?;7J<="OM ,'K;;7+JSWOR;C>(.R6Y@A+=Y:OI*BW
M[E_TAU,<SUP_R^T7/<\VW^3F*>>E3\Q-6?6XWM_()!8LH0P&E(80H8SKS7BH
MK42J*(Z2&"?8[6K,CUQS,R1+64%1"0NXEO;O5?'HOH7,/ V?Y277](,R]KW6
M42-0JP1JG4"I5"-IW55YV56-8*T9N-YN-SG;;4M7D^T:?*$;O^GM1H+>UPV6
M)ZFFO;3R"^7)/97GYH?9](>#V7VVJ5P6NN<%5B@CB")( V*L>"P@3K(()CQD
M<23U5IY9)72U[&]N/'PPA/K?4G4A[&8_>L!M*MNQ<=?2$+9D1_]V8P<NGFW&
M2[V]B;W8H?HE6['KM2%7W2;_=)F[[N =D\84<YD0&".LMZ94$.,2)6#,52HC
M&<91[&3W7>AG;OQ1SX&#G#8N+$ZXNES,#D)KFHM9)Z!ZWLM>A,'KO>QI+V]P
M+WM1U?/WLI<?[VM<;/(GO0U]DA]7NL'RAJGXE>8KXX3SR_-O4MSEJ[NO<EEN
M54T:@K+^ 0V$BK( PPPC;LH1<4BB,((DBV*%.$$A=LINU4^,N5%)+29HRMFK
MYD3/4;&U4\;&>F0BZ@-S#ZME"$K>C)E>0DQLXPP!ZM3T&=3:L!W6!ZG?H<M+
M'E9A@C%A,H1$A1(BH3#$$8T@CVBJ$D$92:F;TYI=QU93;U(?ML,&0E6"-_9>
M_9S:+$? ;2/F =6)]V.UQ& :'S@WG#SOSSHZ?9-MFAT0EW9KEF_WHZBO\DFN
M=O*+W*CUYL'<%MRR91UR\TX6?),_FA]OU??\01/D@JE$)B(+-3E%>C,7<PYI
MDFH#30F9LB 4+"0N!IIC_W.SS,Q8<',R7%TQEE[-A1:^4+0, ZYO'_>Z@?5!
M.3<><QTF.T(;$?R1F:V6W-0I/()[%/X*-,0O(PM+!?Q17$_D/'&=:^^3DEY/
M:%ZS7]]F^L8"BC)6GRZ_T%Q\7-W0QWQ+E_LBN1F/1*HDI#AD$&52_T0S4^1,
ML8CPA(D@= OJ:^EM;A1W%!88:6&^ K6\?2\D6[&VO&;TA>#8EX<#P.L1SV8!
MBK? M+:^)HXPLU#[-%3,YJ5^9%([('V[EW+[R8R:H:S*F3-B$8^,7Y8,20*1
M3$/(.(DAY2HDJ8RR#%F5K^KN:FXTLO?**D4%>UE[5E%I0=B./_S@-C)Y](7,
MF3BZT?#$&BT=34H9W0J_Y@N+-]S(0LA\\:X.O?B0%UP34;F%^*!_5RR(HB+A
M',,,8>-+*P7$:89AS'C&8JYB'%H586KM96X4L1<45)+6E8) *:L=/[2#VDX-
MWJ :^U"G#TK6E&"%0DNF7OU^103ZA^/\;V]UDJEOI=A^UML][!RQ:,Z:;]8K
M$V@N5_SY9DGSA^*K_C:63U)\WI7V;X0DH3$GIH*ZMA"0Y@ L6  SJF(AN;8=
MN%42;;ONYD8!E51FQ\Y+:<&F%M<ZT,X&XW8B\(_<R(Q@I 4-<:] )3#82WP%
M*IF]@F@=KN@9S(GB%8>#ZA*LZ(#1Q6A%FS:F"E=TT*<1K^CR5M_C[BJ'OQ0F
M#<AGK4==P54)EA&%,YC)((0HSH@VN)B D5 L8#&5G#DY*5WJ:&Z$>Y2SRJF4
MK_AR)TJO1[ N\ZW1,JK ];CZ LRVY]+#P1O] /J FY%1D\%!2I^GS.TX>#M.
MOM#-Q.?&[<J>'A!W/-^/(8R3]:TR9<2*ZY6H/:^+;^NE6!A""!$.81PS<_C+
M)20TX) J3EG**,)$NG#$Y:[FQA)EJF)ME!5TZ>H#W8*G'1GX06ED.M@#5(I9
M)JW<"PJ,I/XHH1L-3Z30TM&DM-"M\&MBL'BC'S7\4^9W]YIOKI_DAM[)RB"Y
M5>_RY4[_]ML]U5_4[6Y;;/7XFTO8."490PS#()3$\$4"2<PII%(JIK*4".QT
M;>38_]Q(9"\^I)7\H"@E+N_,1:4#>/_E&_A)FQ[5GR[[I'@9'SO^&1'UD4EI
M+SFH10?'W74E-FC(?05JC?QQ54_D/!&8:^^3LEI/:%Y37=]FAOIT?\I7LDS(
MNT",:X8+$X@#$6F.BV.(:1#HX0B"*,6I"C.G"ZTS?<R-QXXB@C^-D%4:ZMZ>
MV$<L[?AH($)CGTX[@C/ ?_I$?>_.T<<>WLCS^43%RV[-IX\Z'T]79]S??ZQK
M5XQ4())@O=4)LLC4<R3F3 3%D(>41S(0#"=6]LMITW.;TO4=BI;/^HCT-5B=
M9\H#(!AYSAZU=\]K]QH&ZU/A 7!,= )L\5&X'/%>4/CB<>[KYZ<ZNKT@9^.8
M]M(3'M*+/&XDSVL?O\>E+-.8K,3UPWJSS?^K_/V7C<D"OWTVH?);_3=3^?;1
M? T+H4*:9D0;()G4=$6BP*14QC#$3&"IL>614[RZ+\'F1G:?9%$ VLAJ(1K:
M#<@M,F3L[$R?MQB1D;GW97:1HT[&@[G6JCQ.:NIU!?::79492+97Y2,']49*
M*>(!\#%RB@P1Z^V2BG@ LS6KB(_V>U0!__AID44\25B$8<!PF?POA)3JGQBB
ME,0RI)C;9?^LVIL;>WY<ZH;7N6OQW#TZ[4370^>1^>GCIT\?/]]^_.:IVO=1
MM[[5OG4+TU7[/HK[HMIWX]?];)Y7%]V?Z7:WD;4#:Q8& 8F(29>A+1B$ @YQ
M8&:20"I-$ KCT.G4N*6ON<VM4Y^+2MJ>7L)M*-L9')ZP&WF.]H?-V2"P ,33
M&M_6TZ3+MH7*KU=BFU?<*W\^K/\E31(YO7"+'=\6=:[?>N.=$92E,DEAG,@4
MHE1FD&BJ@ &/B H#&J?2RF.XLZ>YD<9!6K 7%]3RNI]F=&#<><;C#[F1*6-"
MT.Q+7'H#;ZK2E0- ="I.:07,Y:*3[:]/5DS22HMFD4B[%YR)]//CPS'%XO=U
MY2[PS7BV[+_8#(4RH65FVDCO8)C)S)%F,"1(9#*C(E*VY]Y=?<V-3#]_^;V1
MSK0LU&<\6VX5*(5V)X=.L#LYU2>$([/J].A9DZM/%">BU\%HNG"L+3X76;:S
M@:EXUE:3!M-:O^)CMYO+XM/ARCN*8A:G$89QF&4019IJRZJ(G!$:2!D($5G5
MH>_N:FY,^VK35M8X_=37FZ %X3X;W;ZX3;O/M89LX"[W'!JC;')?=/2&>]QS
M"K=O<<^^X6R8O5_=E<:>;O'YAA:RN-D)D=]+62]V-$ XHT$,*>;F@D\S!D8I
MAFF,6(IH$L4ILK3+.KJ:&UF4XH):7E *? 7V(KN;%5U =]ID'N$;F3,F1L[:
M'O.(X$3F6"N27FPP2TPNFF!=[T]E@5GJT3# ;-_H9W]]X_=2[);R5GV6/ZXY
M7^]*WM;]K?2/O$S[:USE;^[U>,OBXZKY3*[9_5%;@M_E7]M?M(+_6@0)ST2@
M$ Q29LK[B5C;;&$(!4O")(LD)MCJI'$<\>9&W5\E-[N7H\S@UUTNRKP>G]=;
M\!]2_TVL']L<KZ<85#LS\>V&:N1EHC$\WXRS--V( OSQ*.A6EKX5E4(F*++Q
MY$$E\.?W\AC0: 9*U3P:H^-@[LF ]2S<I$;O.,"^-I1'ZJ7?2F!\/+;/WR3?
M;<JB#Q^>/N<W5=BD%J$1IXMX'!&:I#!1,88H)0ED,18P5 %)XU"@,.$N'&_;
M\=S8^]__^..3&R];0VS'N&, -[;)78H,CC)?@0__@)\_^J-$5U \D9UUMY/2
MF"L8KPG*^7WG??WMABZ_KQG5Q/;R:C"*TA!ADW0A,(6B,QE &H848LREE(1$
MJ8@73W+#UA9;^DN]N,R,9E_C31 C*:A%[7_M>A'5SMV[#Z1&YI"1(;+>ION
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M_E7E"+*2=5KX1PVQ&<5[NKDSR'UM'XN-21U>E FW7GP+U5_S*AI,O[C;E)_
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MPY1&+-!4D;H5,[G0D\L7/HU?W_4OEF[M71C:S7P/N(QM(56E72H1P2@%-#I
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M/QOB(>U=R*(H4YHH9(8S;>2P -),"DBY"-(H$T0*I\PG-IW.[6BZ\@#B+SR
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MT)FZ[-0_DK3+\D4_AODP?WPL*_9:7L[$U@[6'4WTCE<2A 449D>,4DDAHXA
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MB.1QCBC#5MZ5W5V-C>0:<4$E;V,5@$9B]QG=A7,G[P5$KV<&'!8X:U(,".!
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MD3Z@[9F;+.(&P1^]^':X@C5,A. ;>6.X@N$8"Q@J!+K)7_1-/AD;;/:P\0[
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MQ-H]([$[:J$2#SOT/&Q^87=(#M((>S3AX6U[\VU2D#117 I8L"H3<"(@5:B
MN42%YK"HR)"]M^W-M[$QT<U"/CB7)%MCT\X;'AKW?<KU[=/?;JX#>=AN-?/U
ML-4M#.=ANQ7WE8?MSH\]ZFP^+\RD^UPN.9W^2]+%IYGXJ!>U"<4XR3DGD&&D
MEWIEO-/U+(*4)"1*(Q$A875"TM;)V&92(R>H!05&4O#)[#VTK Z5.$]!VC[7
M0@'5\P3TPLBM5F<'"'YE.T\U.EP%SPZU7A7S['K69R'\QR0A(D.%S"!E20)1
MQJN\U!+F*6(HSB.%D57>UZ:]L4W?FS^G]/O\T2OD1*-CLQ0ZZ=SW4OB/+Y>_
MWGP-%6ZRU<U[,?S'D(OA/XXOAO_PG".;O(FR2;9A+K8O?]!R6ANG>G?W.)_M
M1H)]+*?/>O<W$:*05!$"I9(%1$DN(<FC"*J,""ZS/(K3U"4TU%D"IWDX0*SH
M)[J85>=M:KX HI81?+J]<\R>ZCP0=GO@7N'M><J;S>XZ'4]3EF>M@-D3URJ\
MBLJ] (T6 5.P^@(8*B^K<__#)FOUA><@@ZMW0W[,MYZVMW)1'4^NIQ4A.24Y
MB6%"N>:WG.J--,+*6 UQ@E*."V:U$^CH9VS61",6D&LV>Y(+L*RN*]Z5,_"\
M%-N?. :YGT+:CL "X-<S36T6 "UB?</3 PUUP!"(;$[U,BBE=*BZ3QQ=CWNG
M&-1C7&H*NEPNY<J4U_GTDT^?3<GQO\WGXJ]R.IU$(B4JI3&,,9<0%=H,8BB*
M(>:8) (IK/<8DQ]RP>8.F08[NW7Y]'<[[]$VKVX$RHWLYDY2"^^7:+ ;=COB
M" UESRRR%1=<-N@9^^?=1F:P%CI@(A\7C,)E)NSN<N@LA=8@',E8:/^NLZ/8
MW>/\3U,)8R9^E72Z^O[!!*-=<G,WNJ[MF<=QQ'(LM*5B(K_RQ.362)EF)$F3
M!,>X4%9>OE:]C<UH:22NW!EJF4$E-&BDKGYQ^?"PJ&/0S"_+QR7X4J[*A]HS
MU#G9LL60M--3<*![YJ4UQI>G,.X#0FOOH[!0#N0O-,!GZ^*N8X_A20<;BR:&
M<HFQUV;'B<7A)3]S\C,M%U5H2+U,?)5T^;R0XL9$^CTO3)+LJL3W;[,Y,Q4<
MS=;W:O;TO#+>,#->3LO:5YE.N7'",,XS.]X0:28+1!2%/,(91"*-(4M%!'-,
MBURQ&#/JY*?2I[!C6T*,KG6XU$5C=X&UOF!>Q<;6&H-*Y0NPJS2HM :OU;X
M.XJ?Y1#3ZS=C9T./Y4OH>8T;QT?@;+T/,3J!K/Y>11UTMS $Z/N[C$'Z=*^.
M]2ITIDIR46<K4S3#>8YABO4?".<%+ A2D,LHS057>KN2V5;'.M[%V!:1U^%G
ME9A.J<I:P.RXI@T"4<_LZH&.4[VL=@#.J)=UHN'!ZF6U*[9;+ZOC2>>#AW4A
MAJ8$PS=9>?[>S[=;D'4!38RB+(DPS*7*3&;""%)",I@HGF*6%(0GMI%EMGV.
M;?(W@F[+0'Z8NQ?1=,&\\WRA#R3[/_VLP6MD!FM4[^=G'==8@VI]XM 'N .=
M.X0"V>5PP16NDT<,U@T-==#@JMG.<8/SJV>G>6]<["8YI2(ND(!YC"1$&8LA
MY2B#O,"21(C@6$:>B=V;+L;FGE.G<N>-'^=T*Z]WIO8UEG9;Z/,0ZIEV=X33
M6]9:O%YRL>^I'C[[^KJ#M\JWOJ=@2X;U_2?/S>MU_6RHXD95E]^-B\QGW=?L
MX:-<E#\TG?S0)M!?R^=RM9SP(N.%R"146<2TO19+6!2\@!2EK)"IIEQJE4GZ
M/#'&9L(=9@";5=J84*OECCY 50H!L=$(3!N5?%-9.8U>I^4WT)CTS4H'2:YJ
M1<"- KNJ@%H7L%4&?!ER.'S3C?4U+&^6@RS<\)R1FLP'5=M\94YMOU$2,Q_]
M3V<V\VHM@ ^Z_EOM/7%K2A_-9Z]C)J_GLX444CZ:?^I_&,[6:!FQUC;UA.<"
M8U04D'.LESBL]!)']6(G>4ZTY9O'1""7V["PXHUMZ3,^1FN?SS,\UL\?-CMK
M^NT&H^<U[\#7_0)LU .-?@=1X:]4!*]UW)Q']>0*'PS\/OSDSQ?N[9SH@P';
MZF$?KA?/')?&9;2^SEKOIU.24IYF!)(H11 AGD&69#DL4AHK+$P4GQ-Q'W8Q
M-O*M_6;79Q.UTZQC"LE#&.V(]#QP>B;#&I>U&VSP<XG3NH?*MWC8P;#)$T\J
M>) )\?23?O/ZM]FB3N#S7U+<TY]-,<OE!(LLBC*:PUQ$.40,YY#1/-)_% GB
M/*+"+@5A1S]CF^&[8KY*V^4VS4^A:C?7 V#5\X1_!9-);O.^"R;G2=\!0J"9
M?ZJ70:=_AZK['-#UN&=\754Y\LXXJ%3'GLT]6\1CE9.(0\6+2"_RF:: 6*90
MR(1G,4XD(KE3>-W1;L9& TV5V*V8CC>9':#:T<#Y4/7, AXHN<?1M8(0*HSN
M>"?#1M&U*GH01-?^]+EW%/]'+N9-KOS?Y4*4?/5U+DI52C&)6):D0F:09'D"
MD10)+$BF8$32A% 4Y5F1^-U(G.YT;/1@)-T4'?E1RPH>&V%]C[);,'>]1PB#
MY."W!A6LZ_H8C>#@:W^P^MX'A('WS4[__6 ^XZ2_&R_;<_V6EM[H%+];M]-G
M]A;O.A/YI]G#5-XNYKJ#EP]T:6J=E/I%.A/OZ>S/M0&228Y0FB&((B6T52<R
M2-,DAYF01&!:R"C%EB1NU>'8"+P2&C12@TILD]+9"%X%<U6BNWNOV8'?R>;!
M(>W;#GQ+-*U)/#BJ Q%X('1=^-L)JI/<;=?*4+SMI-,.9[N]%_00[OX[7?US
M_CP55X_ZVUC5*;7+'R:]]C>3L5$6VA1/"P$CQG.(J"DSGTH*"4L*A;."Y,)I
M;^XGQMBX_>01'EAI1<!?1A-05JI4R?GE6I_JX85U,LTS!^^LH\" 0_)6)X7U
M:%1*@%H+L%&C>O!;D)2=88#L][2Q2X@Q'$9: F5Y5FG;FA^=5CXPW^23_H:_
M:\8VY+V@CU5X%B&1'A2*88+S""*58L@2AF!11"CF4O^0.85>G^YJ;+18ES+9
MB@H:69T"WRP0MN.U,+CUS%V^D#F34S<:@0BHI:-!2:9;X7TBL7C#_=!S$[YQ
M)U>K:54N[G(V>S;54%ZJ?SS.GV>KB<0J8SB*M9U5F+HBB=XMY[F"^@/BB4P9
MBXE58F+[+D=''J::'EAN1 ;T82&;HHRT$A\\U?([>/):HM]]^!D>T[Z//K?!
M6UN1+T M-&BD!K78P?&T/_4,C^M09YXA\'4Z\'2#ZO1QIV4[@QUVNNFU>]3I
M^.897FFO*AMM/>;>2S4W2P8WN8%*5?)*FN;'VM"<B(SDC/,8XLADQB9(VX)1
M1HT?<J2DDEF4.;FXG"/,V B_\71[53-JDVKVW51K))>_Z)VU$1\L]M7R\(GS
M'40[<W.HH>EYW6BIY+5V0FZ&Y$"=S6^T1H$]\\[$-:0/GZ\HPWO[G0G:4;_
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MV*8!>-Z*NJ[NZ)#6W E\YT4@&*3#KP%-2H!:=K C?&=R@/,P]EX!@F']=@N
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M1Y%2>AHI+"$BB38&1<1A))&*4A;G*;&*J/;L?VRSL-8!&"6 T0*LU0"-'A?
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M#*AT!0@JT@"8=2F7NJ"32F]F2@HQ]-55D^O.[=YC5[-%M4 %V(]>=@Z@LO;
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M-TOU_O2\D573;0Y*&NSIO?F71BJ2/)8YCL-88)I0CC,I$YS*C!#):)*)H>]
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M(_3T_+ZJK>IW ^MT/?1;;;IAXT->+B<KE_%*7-^N[X"+-TPI3^& +F1V'4)
M5L YY1"Y<E[<P=2..M,GE^GY254G4&DNW@&8GW7FX"%QC<@V,XF2(L:HL1:1
MV'5/EHR>*V-%G1W:2:KF(8IZ?A_1J0EJJ(M!^$NOQE_'*4_37<>/9!2"TI%D
M5*HUE6178Y! SA\+5D4;1.O\WP.D]%O_U=HW:B'O 9BD'="W*#17BL)+K)E,
M35+Q*!P(PYGT@9F06C\X/]+T=%83UCR*/TW*0\@6;N4AMK+>.7C#,T?0@3-0
MIF:]$YW"/'H=(Q<EW'U'TS3E<^#U0F?58%UF?8Z4]C .I<W"=8#M1?Z(?VP)
MJM9T<)9]*C*!IY,<5!"97#=B2,82 A?.\=3\<'J<I'X+MYH?4@WE/X##BM@9
M3W/Z,4_IB^6[/%W4DK,)3K?9VKJ24QB16(2D%!W%R)"X*\2G%Y+S+&1I7O5^
M&(7]%FYU +:NM#, [*WBA3JE<)Z7X_DJ'+W#\(.<1B>,XH77-O#$'QW\-98P
MQ*F7V9,4PMT.&FWBNJ.H[;=FK#4FSZ2U?M-05U;^KSB>OIU^P$E^6Q[H.K+%
MG^2EMH8NH/5J  XF<)Y)X%KGPG+F,=Q)G^](31VU=,^59:TP=A;)#\7R[=XC
M5G'M6#3 ?7UB9VA[D,M@(<I"VX/GPEWKET,/4]-S&5HGINMTL0\ 0%M,C$0@
MA48L%+,P11(AJE%85SOCL&P]\PQ;^V1;R_=<A-9A6N$@P0X@GU"MY'A=:5E[
M[\VF]1HH3V-E17N>D ):X.CK7/E@R3,,]&U,P>2@DR^/C0$XJN/AP^3TFP3O
MO!JIE2(&D6]8#<3X/)N03A;U\4CM<[PI]'Y7'RF1S);+^3A<+FO*]N.LVE3B
MF.B@3_RTFOR6%S?W"R1-H:L+:$VIK;8LIT"Y. C&6*S/$'QNG=UJRT&_*??.
ML=NCN@=PK&[-@%FW*%7H?4%R*:.H@\?0!W(+2@8K9(JQ>$XA=P=V<YN&OCL.
M]X>''6;U:.4, %PO4EKM4]JQ.$YOIB_QRYC._BVV1L5GB:%69T3,Y'%@'5TF
M!$0?ZC>!!]?:.CY-5=^UPX,!8&,%#@"2[_,2:^;F)YQ/25J+6T^3RSB.ER--
MC/C &$34M8H_Z#JNA %)RBB148GF7;J>IJIO!W(PD&RLP$%XG%L\K +V.L5O
MGC_7Y/?7O+YV^7FVZ6'V$?\8.4R<)<6@<!%K>0"%[I8<'V.=3HJVHPZM:WP.
M)+%OGW$P<.U2M8/ [L=YQL7E_-N6EV)2=L%+!*M9K:B*%H+@"J+,N@A&?Y-;
MA][WJ>BW]F- "#Q108>#S*]!-LV?*NH["LE'0IGH'/%0D-4$5:KM9),$K;5R
M61O)7.M79O>IZ+=@9$ @.U%! \@E_C*>SN8K$:[%0IN$AV!<K'7 $I11M5L2
MV62-Z!W&9*1M759REX9^ZT@&!*^3E#. J*.-*$=6.U$L(NTA55LBAT!<9V)=
M29-5DB;PUD65;2COMT9E0$#N 0@#L*W;5U;3M..L,,J$')0 ;HVL_) T18F0
MI&0R)&Y9\R%G3]'4M_]XQO?C)ZND&<3./'7QW4H7G_-R''%RFYDV(QAO+W"6
M>8R/\'3.X8PRJV*\CQ"R8:!X(",9%9*9\EBT,THU+U<[QW#&QD=)T"0*%RS(
MNK643)[D%3UPY;@K,@0;6O?;[N%NL-_AD(<@L>.[P4/4/0"O=:N1U6L<SU>Y
M@U?C19S,%I?S/#(BQJQM]8/H#%+U89LK%.H9<D>4#%XJU]H;?9RBOL'8'U8>
M[D!VJN(& ,.MVR8ZW-[.5[L^K9AZE^<?/I-V1B47J7000!*K&:T4 #6Y0D5G
MP[.BG8]=5/L\0=:?ZA[Q%$"V5N&P4+FB?_%FL;C,:92EC42P@VR9K!W_.*#7
M#)Q%XZRQQ>O6><D'2/E371DV0M_1JAH XFXE\C<\K=@9^<*442X"17\!E)&<
M8D#:/\6()),L.C2?[OP@,7^JF[]34-=&7<UPUWUH?>V-+V;EZG:^45"]\Z.[
M"J>?YJ-1(+V^_KU>[J:-I"G"HC4@?:FOND.N$0N#9.K5"9,I-A^E\@ IIU?;
M?,W3R_R:]FDM"JX?^??Q\O/+R\62EIM?-U"NS2_I_U*] <<LLK<Q 9.U>H-)
M!*<47S7-P,@MTZRU,3N"S+[G>)Z.G/N%-=WJ:A#5"K5'U-NRFMI6TYYY_G4<
M\^(#'1@C[XIVGFR]]]*3_\D0?&("6":;S.M;F=1Z4,C#U/0][K,]O!I)?@!^
MV*:.I[+S]DN>8WWKL-D\(Z6\X\IP\(*32UG]RA#)80@RTEZ(T@G1R8RTW>3T
M/=FS/8I:R7X ,%H-9GHWGY7Q<I2MUL(&<@$3"E#12/#*<B"K:C2/9&59Z_3%
MUO)]#^EL#Y-C9=OC7>G%;'3=R?!%NJCS19?SE1)PFNIP4:+J\ZK%X8BCI4,V
M&7 ^D[VL4R0QZURKN5!KP[)-3\\MWW.QOD=RML-&1P(>@"6YMH0W]:0C&Y5
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M=L4^#=[$TUU94I@SGW^C$VK5YWX44HQ<U^EA1=;8F@(G-#F#R:%HDY+/7'0
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M+H8UAN(EQ>51AMKVNW@(09&KHI34T0?/Y!,':C-:^GTWV!T:SZ:?83IN6]T
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M/+!3Z%B=7-;!%*_'?^3T;CZ.^=T\YXLOM:SP_?C39]I,J$T,AK90]-:#*M:
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M!-02T*B8;4FAW#W!FMY>]'%E=:3>3Y=?W[<76Y=NL<[B)H9!\T@R2"C AR#
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MYBN,L5YZ%R&%6E2>G  G<@ >G.5":&%PP&WI=G7'SHB8E=$05*C7=%Z"B\Y
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M3K6_$-EC8N.B[GP^67LM=7#*_KRHCSC_/DE8KP(NI4W)>2E)7$:!0L$A*)-
MU6:9E4<^-6_3MG5"8S\<-@? 3H@=JHU.[=KO4X(N+I8739>V,.UD,I!J6U9E
MC8&8N854R'_PUBAU@GJB;3,:^[WQ_/ Z6!]=FJ[?_O4-TS76NY^;^?3=TFE=
M-6N]S"2>VK@43$RZUDLE"%Y%"-4GL=PI<X(N:_O/;^R7S/,CKY&N1B6L?7YU
M3U^MWW71]#XF9AUH9FRMXT.@#19!9A.4QQ02LI.C<?L<QZ%1'A.1#776I76\
M^#J;7T_^9ZG#=Z66)BUJ;1(N+FTF;[CZ%)GK#,KQ MZ55%^/Z4R(%H-L3TBU
M]_1Z<_I:XF0G*-LHK5,K^7!Q[TFF\WO^[BN:Y.2:-KE&KDF4TM3R.-K:$%DA
MKR0KI1,WEDE_9G ^/=/>O,<1<=I E9T&,$\+]5(7;8(E8185:EML:R!$(:IL
M41CGDDBM[P?WG=LXA/7]'>2#='3X 3Z[#E?G2&DYG@9XZZ<U3D Y"^WOD P
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M8IG;X@T7,;=N,C=PBN/&QJ>WA8V5U"R3ZQP8W&RSD ,JQCED\H]K4V8&SO
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M;0[#PZ79+RA^;CRC>2E.4@!DB_<$=D5@EU8#D]QX'9)1>SQ&M6_T,T;3EA/
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M1"M.@$^2 P\N<V^TSKH,1\-@9J3FJ5UGP</!DNP,$:M*]XU/Q!(K/@8'9LE
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MG!,1X\5*\GI3"@LN9JR]31'0RUK]/!0>T68A6@?*C)I@\QBAJ^@71\=X-E*
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M;6%N8V5S=&]C:RYH=&U02P$"% ,4    "  *.IM6!=]HO^L#  !Z+   $P
M            @ %E+P  97AH:6)I=#(R<3$R,#(S+FAT;5!+ 0(4 Q0    (
M  HZFU;^*V%U:@@  $,L   <              "  8$S  !E>&AI8FET,S$Q
M<3$R,#(S+7%U87)T97(N:'1M4$L! A0#%     @ "CJ;5D[\V9A="   52T
M !P              ( !)3P  &5X:&EB:70S,3)Q,3(P,C,M<75A<G1E<BYH
M=&U02P$"% ,4    "  *.IM65"PD0RT$   F$0  '               @ &\
M1   97AH:6)I=#,R,7$Q,C R,RUQ=6%R=&5R+FAT;5!+ 0(4 Q0    (  HZ
MFU8H'C?9- 0  +<1   <              "  2-)  !E>&AI8FET,S(R<3$R
M,#(S+7%U87)T97(N:'1M4$L! A0#%     @ "CJ;5K)DE%M%%   (\,  !P
M             ( !D4T  &5X:&EB:70Y.3%Q,3(P,C,M<75A<G1E<BYH=&U0
M2P$"% ,4    "  *.IM6U&T"1 @$  #Y'0  '               @ $08@
M97AH:6)I=#DY,G$Q,C R,RUQ=6%R=&5R+FAT;5!+ 0(4 Q0    (  HZFU:0
M2/AOE_<" ':]'@ /              "  5)F  !M;RTR,#(S,#,S,2YH=&U0
M2P$"% ,4    "  *.IM6V]+M$XL<  !B20$ #P              @ $67@,
M;6\M,C R,S S,S$N>'-D4$L! A0#%     @ "CJ;5NCY*7Q['   61(! !,
M             ( !SGH# &UO+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4
M"  *.IM6?])"5_.E  "?)0< $P              @ %ZEP, ;6\M,C R,S S
M,S%?9&5F+GAM;%!+ 0(4 Q0    (  HZFU9Z5^P@A1D! *NO"P 3
M      "  9X]! !M;RTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ "CJ;
M5CY0HYYXSP  KS() !,              ( !5%<% &UO+3(P,C,P,S,Q7W!R
;92YX;6Q02P4&      \ #P 3!   _28&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
